Effective Health Care Program

Comparative Effectiveness Review
Number 96

Primary Care Management of Abnormal Uterine Bleeding

AHRQ
Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Comparative Effectiveness Review

Number 96

Primary Care Management of Abnormal Uterine Bleeding

Prepared for:
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2007-10065-I

Prepared by:
Vanderbilt Evidence-based Practice Center
Nashville, TN

Investigators:
Katherine E. Hartmann, M.D., Ph.D.
Rebecca N. Jerome, M.L.I.S., M.P.H.
Mary Louise Lindegren, M.D.
Shannon A. Potter, M.L.I.S.
Tracy C. Shields, M.S.I.S.
Tanya S. Surawicz, M.P.H.
Jeffrey C. Andrews, M.D.

AHRQ Publication No. 13-EHC025-EF
March 2013

This report is based on research conducted by the Vanderbilt Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10065 I). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, to inform the development of clinical practice guidelines, other quality enhancement tools, methodologic guidance for systematic review, or to inform reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EffectiveHealthCare@ahrq.hhs.gov.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation: Hartmann KE, Jerome RN, Lindegren ML, Potter SA, Shields TC, Surawicz TS, Andrews JC. Primary Care Management of Abnormal Uterine Bleeding. Comparative Effectiveness Review No. 96. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065 I.) AHRQ Publication No. 13-EHC025-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2013. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm.

AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an e-mail list to learn about new program products and opportunities for input.

We welcome comments on this systematic review. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director
Evidence-based Practice Program
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Shilpa Amin, M.D., M.Bsc., FAAFP
Task Order Officer
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Acknowledgments

We are indebted to an exceptional group of colleagues who made this report possible. Each step of a systematic review draws on the skills and attention of an entire team. The authors gratefully acknowledge the following individuals for their contributions to this project:

Dr. Mamata Raj was instrumental in extracting data and completing tables. Dedicated staff members Ms. Kathy Lee, Ms. Sanura Latham, and Mr. Ross Brown assisted with formatting, data entry, and article retrieval. Ms. J. Nikki McKoy and Ms. Nila Sathe provided guidance on logistics of the review process and organization of the report. Dr. Melissa McPheeters offered key input and feedback on the protocol, conceptual framework for the report, and methodological issues.

Key Informants

Janet R. Albers, M.D.
SIU Center for Family Medicine
Springfield, IL

Barbara S. Apgar, M.D.
University of Michigan
Ann Arbor, MI

Marc A. Fritz, M.D.
UNC Fertility Preservation Program
Chapel Hill, NC

Kristen A. Matteson, M.D., M.P.H.
Women and Infants' Hospital
Providence, RI

Malcolm G. Munro, M.D.
University of California, Los Angeles
Los Angeles, CA

Technical Expert Panel

In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives are sought. Divergent and conflicted opinions are common and perceived as health scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design and/or methodologic approaches do not necessarily represent the views of individual technical and content experts.

Andrea S. Lukes, M.D.
Duke University
Durham, NC

Kristen A. Matteson, M.D., M.P.H.
Women and Infants' Hospital
Providence, RI

Malcolm G. Munro, M.D.
University of California, Los Angeles
Los Angeles, CA

Anita L. Nelson, M.D.
University of California, Los Angeles
Los Angeles, CA

Peer Reviewers

Peer reviewer comments on a preliminary draft of this report were considered by the EPC in preparation of this final report. Synthesis of the scientific literature presented here does not necessarily represent the views of individual reviewers.

Jeffrey Jensen, M.D., M.P.H.
Oregon Health & Science University
Portland, OR

Annekathryn Goodman, M.D.
Gillette Center for Women's Cancer
Boston, MA

Jonathan Klein, M.D., M.P.H.
University of Rochester
Rochester, NY

Patricia Langenberg, M.A., Ph.D.
University of Maryland, Baltimore
Baltimore, MD

Anita Nelson, M.D.
University of California, Los Angeles
Los Angeles, CA

Lee A. Learman, M.D., Ph.D.
Indiana University
Indianapolis, IN

Malcolm Munro, M.D.
University of California, Los Angeles
Los Angeles, CA

Primary Care Management of Abnormal Uterine Bleeding

Structured Abstract

Objective. The Vanderbilt Evidence-based practice Center systematically reviewed evidence about interventions for symptomatic abnormal uterine bleeding (AUB), both irregular and cyclic. We focused on interventions that are suitable for use in primary care practice including medical, behavioral, and complementary and alternative medicine approaches.

Data sources. We searched MEDLINE®, CINAHL®, and Embase for randomized controlled trials (RCTs) published in English from January 1980 to June 2012 in women with symptomatic AUB. We also searched regulatory data and scientific publications for data about harms.

Review methods. Using dual review with a priori criteria, we excluded 1,734 publications because they did not address a Key Question, were not an eligible study design, or did not apply to the primary care treatment of AUB.

Results. Thirty-nine RCTs (6 good quality, 10 fair quality, and 23 poor quality) evaluated 12 distinct interventions. These included 7 studies of the levonorgestrel-releasing intrauterine system (LNG-IUS), 13 of nonsteroidal anti-inflammatory drugs (NSAIDs), 6 of tranexamic acid (TXA), and 5 of combined oral contraceptive pills (COCs). The majority of studies made direct comparisons to other drugs. Ten studies enrolled women with irregular uterine bleeding; the remainder focused on women with heavy cyclic bleeding. Among women with irregular menses, metformin, metformin with exenatide, and a tricyclic oral contraceptive improved menstrual regularity. Among women with heavy, cyclic menstrual bleeding all seven studies of LNG-IUS favored the intrauterine system in comparisons that included NSAIDs, COCs, progestogens and usual care. Reduction in menstrual blood loss ranged from 70 to 87 percent less bleeding than baseline. NSAIDs reduced bleeding in six of six studies when compared with placebo or progestogens. The degree of improvement was highly variable for individual women. TXA was more effective than progestogens and NSAIDs in three of four studies, and COCs provided benefit compared with placebo in two studies. Harms were rare and trials underpowered to assess harms for all interventions. For most interventions, surveillance studies of longer-term risks were not done in comparable populations.

Conclusions. Two interventions for irregular bleeding (metformin, COCs) and four for heavy cyclic bleeding (LNG-IUS, NSAIDs, TXA) have low or moderate strength of evidence for effectiveness, while COCs have high strength of evidence. Several common interventions (including diet and exercise and acupuncture) lack sufficient evidence. Across interventions, data are sparse to evaluate long-term improvements and risk of harms.
Limitations include a predominance of small, short trials lacking standard terminology and diagnostic criteria for identifying and including women with AUB. Tools for collecting outcome data are crude (e.g., collection of sanitary products to measure blood loss) and may contribute to a high rate of attrition. Emphasis on biologic outcomes may neglect the importance of patient-reported outcomes that assess whether symptoms are considered resolved by women themselves.

Contents

Tables

Figures

Appendixes

Executive Summary

Background

Abnormal uterine bleeding (AUB) is among the most common gynecologic complaints of reproductive-age women in ambulatory care settings. It is estimated to affect 11 to 13 percent of reproductive-age women at any given time. Prevalence increases with age, reaching 24 percent in women aged 36 to 40.[1,2] Women generally present for care because the amount, timing, or other characteristics of the bleeding have changed from their individual norm. Population norms for menstrual bleeding, as established by 5th and 95th percentiles, are:[3-7]

- Frequency of menses within a 24- to 38-day window
- Regularity (i.e., cycle-to-cycle variation) within 2 to 20 days
- Duration of flow from 4 to 8 days
- Blood loss volume from 5 to 80 ml

Symptoms outside this normal range, or different from normal for the individual, can become problematic and deserve evaluation because they can warn of underlying conditions. Common problems include worry about the cause, embarrassment if the bleeding includes flooding-type bleeding with saturation of clothing, missed work and responsibilities, limitations of social activities and exercise, decreases or changes in sexual activity, and frustration with costs of sanitary protection. Collectively, the effects of troublesome bleeding reduce quality of life and drive desire for information about causes and treatment options.[1,8]

There is not a clear consensus on the clinical evaluation of a patient presenting with abnormal bleeding. Recommendations suggest that initial evaluation confirm the source and timing of bleeding, and exclude certain architectural etiologies (e.g., fibroids, polyps), cancer and precancerous changes in the cervix or uterus, coagulation defects, and systemic disease. The 2011 International Federation of Gynecology and Obstetrics (FIGO) classification recommends a structured history followed by uterine evaluation.[9] In the research setting, the alkaline hematin method is the preferred technique for direct measurement of total menstrual blood loss (MBL). The pictorial blood loss assessment chart is a semi-quantitative tool for uniform reporting of bleeding as represented by the degree of saturation of sanitary pads and tampons. Diagnostic tools and evaluation strategies are not within the scope of this review;[10,11] however, the review captures the operational definitions used by researchers and addresses applicability of the findings to contemporary practice.

Terminology

Nomenclature to classify AUB has evolved steadily over the past several decades.[12] Early classifications relied primarily on bleeding characteristics, using terms like menorrhagia (i.e., abnormally long or heavy menses) and metrorrhagia (i.e., bleeding at irregular intervals). These terms were often linked with timing and amount to infer whether or not regular and predictable ovulation was occurring. These terms are generally applied without formal documentation of ovulatory status. Furthermore, previously applied terms like “dysfunctional uterine bleeding” also carried a variable element of recognition that the label was a diagnosis of exclusion.[12] The resulting challenge was that practitioners and researchers applied different exclusions before selecting interventions or enrolling patients. Over time, these differences in terminology and use of operational definitions resulted in inconsistent application of diagnostic terms.[4,12-14]

Recent international consensus recommendations, formally adopted by FIGO in 2010 and published in 2011, more consistently align terminology by creating two major groupings (i.e., discrete structural vs. nonstructural) for causes of bleeding.[9,15,16] The FIGO classification includes nine categories of abnormal bleeding arranged according to the acronym PALM-COEIN:[9,15] four have objective visual criteria detected by imaging, biopsy, or pathology (i.e., PALM: **p**olyps; **a**denomyosis; **l**eiomyomata; and **m**alignancy and hyperplasia) while another five are not directly related to structural abnormalities (i.e., COEIN: **c**oagulopathy; **o**vulatory dysfunction; **e**ndometrial; **i**atrogenic; and **n**ot yet classified).

If we map the intended focus of this comparative effectiveness review to the FIGO classification, we are addressing the COEIN groups that are characterized as "ovulatory dysfunction" (AUB-O), "endometrial hemostatic dysfunction" (AUB-E), and "not yet classified" (AUB-N) abnormal bleeding. However it is crucial to note that direct measures of ovulation are not employed in most available literature and endometrial samples for classification are even rarer, except when used to rule out malignancy. Indeed much remains to be explained about the pathophysiology of the very common and problematic complaint of unpredictable and/or heavy bleeding. In summary, the relevant population for this review includes nonpregnant women from menarche to menopause who have had abnormal bleeding (scant or heavy) for 3 months or longer that is not attributed to structural abnormalities, coagulation defects, systemic illnesses, or medications.

While some reviews further subdivide women experiencing AUB into age groups,[17] such as those near menarche and in the perimenopausal timeframe, we plan to retain an emphasis on categorization. Women across the reproductive lifespan can have abnormal bleeding that arises from ovulatory dysfunction or endometrial processes.[18] While the underlying causes may vary, for instance from lack of consistent regulation of the hypothalamic-pituitary-ovarian axis in teens near the onset of menses, and from lack of ovarian reserve in perimenopausal women, the treatment options overlap.[19] We will report when research was done with an age-restricted population but will otherwise cover all the relevant literature regardless of reproductive age or reproductive history of participants.

Therapies

In a recently published research article examining the practice patterns for medical treatment of AUB, authors reported that practicing obstetrician-gynecologists most frequently selected oral contraceptives for the treatment of both irregular and abnormal cyclic menstrual bleeding and lacked an overall awareness of current evidence on effectiveness of treatment options for AUB.[20]

Current recommendations for medical management of irregular and abnormal cyclic uterine bleeding include levonorgestrel-releasing intrauterine system (LNG-IUS), nonsteroidal anti-inflammatory drugs (NSAIDs), antifibrinolytics, combined oral contraceptives (COCs), and progestogens.[21-26] Surgical intervention is usually reserved for women with persistent bleeding that does not respond to medical therapy or for women who have finished childbearing and do not wish to indefinitely continue medical therapy.[2,21]

Scope and Key Questions

The relevant population for this review includes nonpregnant women from menarche to menopause who have had AUB for 3 months or longer, that is not attributed to structural abnormalities, coagulation defects, systemic illnesses, or medications. This review evaluates the interventions and direct comparisons among treatments that are often used and promoted as first-

line choices, with the goal of clearly describing their effectiveness and potential harms for use in primary care settings. We explicitly defined eligibility criteria using a PICOTS (population, intervention, comparator[s], outcome, timing, and setting) structure (Table A).

Table A. PICOTS

PICOTS Element	Description
Population:	Nonpregnant women from menarche to menopause who have had abnormal bleeding for 3 months or longer whose bleeding is not caused by structural abnormalities, coagulation defects systemic disease, cancer, or medication. Two specific subtypes of abnormal bleeding will be the focus: • *Irregular uterine bleeding:* problem bleeding (frequent or infrequent) of 3 months or greater duration, excluding regular cyclic/menstrual patterns of bleeding, fibroids, polyps, adenomyosis, cancers, medication side effects, coagulation defects, and related systemic disease. • *Abnormal cyclic uterine bleeding*: problem bleeding of 3 months or greater duration, excluding irregular and unpredictable patterns of bleeding, fibroids, polyps, adenomyosis, cancers, medication side effects, coagulation defects, and related systemic disease.
Interventions:[a]	• Medical therapies o Nonsteroidal anti-inflammatory drugs o Antifibrinolytics o Oral hormone treatments (e.g., oral contraceptives, progestogens) o Levonorgestrel-releasing intrauterine system o Vaginal ring contraceptive device • Behavioral strategies (e.g., stress reduction, weight reduction, exercise) • Complementary and alternative medicine therapies (e.g., acupuncture, herbal medicine)
Comparator:	Direct comparison among interventions listed above or comparison to placebo.
Outcomes:	• Bleeding profile (e.g., amount, frequency, duration, pattern, symptom bother, hematocrit) • Quality of life including both general and bleeding specific measures • Pain related to bleeding • Sexual function as reported by sexual function measures, general measures of sexual activity, frequency and satisfaction • Patient satisfaction with outcomes and acceptability of treatment • Fertility • Time to conception • Additional interventions including concurrent and consecutive surgical and nonsurgical treatments • Harms[b] (e.g., thromboembolic events, emotional side effects, weight gain, short- and long-term harms)
Timing:	Interventions initiated after symptoms present most months for 3 months or longer.
Setting:	Any clinical care setting.

PICOTS = population, intervention, comparator, outcome, timing, and setting
[a]Excluding surgical interventions and procedures such as endometrial ablation.
[b]Includes treatment-related adverse events (e.g., drug side effects); does not include consequences related to the failure to adequately treat the symptom.

Key Questions

Key Question 1A

What is the evidence for the effectiveness of medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with irregular uterine bleeding?

Key Question 1B

What is the evidence for the effectiveness of medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with abnormal cyclic uterine bleeding?

Key Question 2

What are the harms, including adverse events, associated with medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) in women with irregular uterine bleeding or abnormal cyclic uterine bleeding?

Analytic Framework

We developed the analytic framework (Figure 1 of full report) based on clinical expertise of Key Informants and refined it with input from a Technical Expert Panel. The analytic framework illustrates the population, interventions, outcomes, and adverse effects that guided the literature search, study eligibility, screening, and synthesis.

Methods

Literature Search

For Key Question (KQ) 1, we searched MEDLINE®, CINAHL®, and Embase. Search results were limited to papers published in English, and published in or after 1980. Search strategies used a combination of subject headings (i.e., controlled vocabulary) and keywords (Appendix A of full report). We also searched the reference lists of included publications and recent systematic reviews related to management of AUB. For KQ2, we expanded our search of primary literature to include standard drug package inserts, and structured a separate literature search to identify publications that conducted surveillance for harms in large datasets (Appendix A of full report).

Inclusion and Exclusion Criteria

We predefined inclusion and exclusion criteria related to the study population, intervention, comparators, outcomes, timing, and setting in order to assess the eligibility of the search results. Eligible studies had to explicitly define and describe the study population, interventions, and outcomes. We included randomized controlled trials (RCTs) of interventions for women with irregular or abnormal cyclic uterine bleeding. We excluded studies of women with AUB caused by coagulation defects, systemic disease, structural abnormalities, cancer, or medication side-effects. For KQ1A we included studies of women with polycystic ovarian syndrome (PCOS) if the patient baseline and outcome data included information on cycle regularity. We excluded studies of women with infertility if the primary treatment goal was conception. Harms data to address KQ2 was captured from the included RCTs for KQ1, reports based on pharmacoepidemiological databases, large observational studies, large case-controlled studies, and postmarketing surveillance data.

Study Selection

We developed screening forms to assess eligibility for inclusion in the review for KQ1 and KQ2. We revised the forms following testing by the team. We conducted screening in two phases: abstract and full-text screening. Publications were promoted to full-text review when one reviewer indicated that the publication met all inclusion criteria or when the title and abstract did not provide adequate information to make a determination. Two reviewers independently reviewed each publication at the full-text screening phase. Discordant classifications were resolved in team meetings including senior investigators.

Data Extraction

Two reviewers independently extracted relevant data from all included publications using a predefined evidence table shell. A senior investigator reviewed the evidence tables for accuracy and completeness. The final evidence tables are provided in Appendix J of the full report.

Quality (Risk of Bias) Assessment

We assessed quality of RCTs using the Cochrane Collaboration Risk of Bias Tool,[27] which evaluates domains including sequence generation, allocation concealment, blinding, outcome data reporting, and reporting bias. Two independent reviewers assessed risk of bias as low, high, or unclear for each domain. We used a preestablished threshold of criteria to rate the quality of each study based on the risk of bias assessment as good, fair, or poor. Discordant assessments were resolved in team meetings including senior investigators. A summary of all component items and overall risk of bias/quality score for each included study is provided in Appendix I of the full report.

Data Synthesis

We provide a systematic narrative synthesis of the available data from original research studies of acceptable quality for nonsurgical treatment of AUB. We present individual study data grouped by KQ and then intervention. Detailed study information is provided in evidence tables included in Appendix J of the full report.

A meta-analysis was not feasible for this review. Few studies had comparable treatment doses, interval, or duration of followup. Among those that did, the ability to aggregate data is limited by differences in outcomes measures which included measures of blood loss from sanitary product collection, and self-report using scoring systems including standardized pictorial systems. For regularity of bleeding no two measures of outcome were the same.

Strength of the Body of Evidence

For KQ1, we used explicit criteria to grade the overall strength of the evidence (e.g., low, moderate, high, and insufficient) on each intervention. We used established concepts of the quantity of evidence (e.g., numbers of studies, aggregate ending-sample sizes), the quality of evidence (i.e., from the quality ratings of individual articles), directness of the outcomes for informing the KQs, and the coherence or consistency of findings across similar and dissimilar studies and in comparison to known or theoretically sound principles of clinical or behavioral research and practice. For KQ2, we did not rate of strength of evidence because a fully inclusive

assessment of harms could not be completed for each of the 12 interventions that have been widely studied in populations that lack direct applicability to this report.

Applicability

We assessed applicability of the results from the literature to the population of women with abnormal cyclic and irregular uterine bleeding. Using the PICOTS framework, we identified factors that may limit the applicability of individual research studies. We summarized the applicability of the body of evidence and described key elements from the PICOTS framework that characterize the applicability of the identified studies.

Results

For KQ1, we identified 1,775 titles and abstracts for screening; 219 publications were identified as potentially eligible for inclusion and were promoted for full-text review. We identified 41 publications from 39 unique studies that met criteria for inclusion. Ten studies included in the review addressed KQ1A; 31 publications representing 29 studies addressed KQ1B. We conducted a separate search and screening process for KQ2. We identified 2,730 titles and abstracts for screening. Of these, 788 references were promoted for full text review. Using predefined criteria, we found 25 publications about harms that were eligible for inclusion. We obtained package inserts for each KQ1 included drug intervention.

Description of Included Studies (KQ1)

Thirty-nine included studies evaluated NSAIDs (13 studies),[28-40] the LNG-IUS (7 studies),[28,41-46] tranexamic acid (TXA; 7 studies),[29,34,40,47-50] COCs (6 studies),[31,41,43,51-53] contraceptive vaginal ring (1 study),[54] metformin (4 studies),[55-58] progestogens (1 study),[59] cabergoline (1 study),[60] lifestyle/behavioral changes (2 studies),[61,62] acupuncture (2 studies),[61,63] and patient decision aids (3 studies)[64-66] using at least one comparator or placebo arm. The total number of interventions addressed is greater than the number of studies because of direct comparisons between one or more interventions within single studies. Study duration was typically 6 months or less. Four of the studies addressing KQ1B included a followup of 1 to 2 years.

KQ1A. Management of Irregular Uterine Bleeding

Ten RCTs addressed restoring menstrual regularity in those with irregular uterine bleeding. Three were conducted in the United States,[51,57,62] two in Italy,[56,60] two in Turkey,[58,59] and one each in China,[63] Sweden,[61] and the United Kingdom.[55] The studies ranged in size from 23 to 201 participants and examined the efficacy of metformin (4 studies),[55-58] progestogen (1 study),[59] triphasic birth control pills (1 study),[51] cabergoline (1 study),[60] diet and exercise (1 study),[62] and acupuncture (2 studies).[61,63] The majority compared treatment to placebo or sham intervention; three included comparisons of effectiveness of two interventions. Two studies were classified as good quality,[51,60] two studies as fair quality,[55,63] and six studies as poor quality.[56-59,61,62]

Metformin and Exenatide

Metformin was an active treatment arm in four RCTs conducted among women with PCOS. Two RCTs compared metformin outcomes to a placebo group,[55,56] one compared metformin to N-acetyl-cysteine,[58] and one three-armed study compared metformin only, exenatide only, and

both.[57] In each case, compared with baseline or placebo, metformin was effective for improving the regularity of bleeding over a number of months.[55,56,58] Combination therapy improved cycle frequency better than metformin or exenatide alone in 60 women with PCOS.[57]

Progestogens

Vaginal micronized progesterone and oral dydrogesterone were studied in a single trial among women clinically classified as having dysfunctional uterine bleeding.[59] Both routes of administration improved cycle regularity with 92 percent and 85 percent of participants, respectively, achieving cycle length of less than 35 days and no intermenstrual bleeding by the third cycle of use. Effects were statistically comparable, but the trial was not powered to show equivalence or noninferiority.

COCs

A triphasic oral contraceptive was also studied in a single RCT among women with irregular uterine bleeding.[51] This trial included women with both short and long intervals between bleeding episodes and with both heavy and normal amounts of bleeding. The outcomes are provided by the authors in aggregate and not presented by initial bleeding characteristics. Overall, 68 percent of women taking the COC achieved excellent or good cycle control as assessed by the study investigators compared with 26 percent of those receiving a placebo.

Cabergoline

In a very preliminary investigation of cabergoline,[60] a drug indicated for the treatment of prolactinoma, treatment over 6 months was associated with return of regular menses in three of eight women compared with none of six receiving placebo. Women in the study had PCOS and normal prolactin levels.

Behavioral and Lifestyle Interventions

Among adolescents with PCOS, both a low-fat, calorie-restricted diet and a carbohydrate-restricted diet in conjunction with 30 minutes of aerobic activity 3 days a week resulted in more regular menses among those who lost weight.[62] This single small study did not present outcomes by the diet group to which participants were randomized. Presumably there was not a clear difference, meaning there is no evidence for which dietary approach to choose. A single trial of acupuncture in 84 women[61] also included an exercise control group at the same intensity as the diet and exercise trial. This group experienced a meaningful improvement in their menstrual frequency (42% increase from baseline calculated by study investigators) that was comparable to acupuncture at 32 weeks. We did not find evidence comparing diet to exercise directly.

Complementary and Alternative Medicine

Two studies of acupuncture with different underlying hypotheses and different methods (conventional acupuncture and low-frequency electroacupuncture) found benefit for a specific style of acupuncture when compared with no intervention or alternate placement of acupuncture needles.[61,63] By 32 weeks in the trial of electroacupuncture for PCOS,[61] women who received 14 acupuncture treatments over 16 weeks had a 121 percent improvement in cycle regularity while those who exercised only had a 42 percent improvement. Both were statistically comparable in this small trial. Both acupuncture and exercise were superior to no treatment. In the trial of two differing placements of needles every other day for 3 cycles,[63] women who received treatment

for “mind tranquilizing and menstruation promotion” had greater improvements (no treatment failures among 21 women) compared with those receiving traditional placement (n=16) for “delayed menses” among whom 19 percent did not have improvements.

KQ1B. Management of Abnormal Cyclic Bleeding

We identified 31 publications representing 29 studies addressing nonsurgical interventions for the management of abnormal cyclic uterine bleeding. The interventions evaluated in the studies included the LNG-IUS (7 studies),[28,41-46] NSAIDs (13 studies),[28-40] TXA (7 studies),[29,34,40,47-50] COCs (5 studies),[31,41,43,52,53] and contraceptive vaginal ring (1 study).[54] We also identified three studies that evaluated decision aids for the management of AUB.[65-67] Included studies described nonsurgical interventions and compared these interventions to another intervention (17 studies),[28,29,31,33,34,37,38,40-45,48,49,54,58,67] placebo (9 studies),[30,32,35,36,39,47,50,52,53] or usual care (4 studies)[46,64-66] Studies were conducted in 16 countries (United States, Canada, the United Kingdom, Australia, Finland, the Netherlands, Sweden, Czech Republic, Germany, Hungary, Poland, Ukraine, Turkey, India, Egypt, and Brazil). Of the 29 included studies, 4 studies were assessed as good quality,[35,47,52,53] 8 as fair quality,[30,38,39,42,45,49,50,54] and 17 as poor quality.[28,29,31-34,36,37,40,41,43,44,46,48,64-66]

LNG-IUS

LNG-IUS was an effective intervention for reduction of abnormal cyclic uterine bleeding in all seven of the identified studies.[28,41-46] Five studies that measured menstrual blood loss (MBL) directly from collected sanitary materials documented 70 to 87 percent reductions in bleeding when comparing treated women with their baseline.[28,41-43,45] When measured, 80 percent or more of women who were enrolled because they met criteria for heavy menses achieved normal total blood loss. These improvements were significantly greater than changes in comparison groups treated with NSAIDs, COCs, progestogens, and usual care. Evidence suggests the LNG-IUS effectively reduces self-reported symptom severity and duration of bleeding. A single study among women scheduled for hysterectomy found that LNG-IUS users were more likely to cancel their surgery compared with women in the usual care group.[46]

NSAIDs

In 13 studies, NSAIDs including mefenamic acid, naproxen, meclofenamate, and flurbiprofen given at the onset of menses for up to 5 days reduced MBL when compared with baseline.[28-40] NSAIDs are effective when compared with placebo.[35,39,68] Overall, 6 of 13 studies provided statistical comparisons to baseline only. Evidence is equivocal, one trial each, showing NSAIDs are similar in effectiveness or superior to oral norethisterone.[33,37] When measured, specific NSAIDs have been shown to reduce blood loss by 20 to 59 percent.[28-31,33-35,38-40,68] While NSAIDs can significantly reduce MBL, they did not consistently reduce bleeding to levels considered clinically normal (i.e., less than 80 ml) in all patients. There was considerable variability in response, with some patients experiencing an increase in blood loss during treatment. Studies evaluated treatment durations from one to six menstrual cycles. There were no differences in MBL reductions between NSAIDs and oral norethisterone or COCs. There were also no differences seen between individual types of NSAIDs, specifically mefenamic acid and naproxen. The most recent study found similar reductions in patient-reported assessments of bleeding severity when NSAIDs plus TXA was compared with TXA alone.[40]

TXA

All seven RCTs including TXA treatment demonstrated effectiveness for improving heavy bleeding.[29,34,40,47-50] TXA at a dose of 1.95 to 4.5 grams per day for 4 to 5 days from the onset of bleeding led to a clinically significant reduction in MBL, ranging from a 26 to 54 percent decrease in studies lasting up to a year. Both biologic and self-reported symptoms of bleeding severity were improved. In comparison to progestogens (norethisterone and medroxyprogesterone acetate), COCs, and NSAIDs, TXA provided greater reduction in MBL, however not all trials presented statistical analysis for head-to-head comparisons. No head-to-head comparisons of TXA versus LNG-IUS were identified.

COCs

Five RCTs included groups treated with COCs.[31,41,43,52,53] Measured reduction in bleeding was from 43 to 69 percent with complete normalization of total volume of bleeding achieved in 30 to 44 percent of women. One crossover comparison to mefenamic acid in 24 participants found both to be effective but lacked power to determine if either treatment was superior.[31] Two placebo-controlled studies found COCs effective for reducing menstrual bleeding and days of bleeding.[52,53] In the two head-to-head comparisons between COCs and LNG-IUS,[41,43] reductions in heavy menstrual bleeding were documented in both treatment groups. Women with a LNG-IUS had greater benefit.

Contraceptive Vaginal Ring

A single RCT compared the efficacy of the contraceptive vaginal ring with norethisterone in 95 women with abnormal cyclic uterine bleeding. The treatments were equally effective, reducing the patient-reported bleeding score by 67 percent in the contraceptive vaginal ring group and by 70 percent in the norethisterone group.[54]

Decision Aids

Three studies investigated decisions aids to assist women seeking treatment for heavy cyclic bleeding in making informed decisions about care.[64-66] Their findings suggest these tools do increase patient knowledge and enhance satisfaction with care. Overall, decision aids did not result in choices that influence disease symptoms in directly measurable ways. One study found fewer women who received the decision aid ultimately choose surgical referral and hysterectomy.[65] However this treatment choice cannot necessarily be linked to improvement in bleeding symptoms.

KQ 2. Harms of Interventions for Management of Abnormal Bleeding

Capturing useful information about potential harms of treatment for reproductive-age women that is specifically applicable to interventions for abnormal bleeding is a challenge because many agents have multiple indications and harms are often not well-studied in reproductive-age women. A wide range of interventions are used to treat abnormal bleeding. Twelve interventions relevant to the primary care setting were identified for this report. In this section we have restricted brief summaries to medications only (behavioral and lifestyle interventions, acupuncture, and decision support tools, each with little potential for serious harm, are discussed in the full report). We summarized harms and present findings in this order:

- Addressing the clinical trials included in this review.
- Compiling the key content of package inserts.
- Searching for surveillance studies that aimed to examine risk of harm in large populations of individuals (i.e., 1,600 or more) for specific interventions.
- Providing information from existing contemporary reviews and guidance on harms for common medications with broad indications.

We have grouped the interventions together, presenting those for abnormal irregular uterine bleeding first, followed by those for abnormal cyclic uterine bleeding. In instances in which the agent was used for both conditions the information is presented only once.

Metformin and Exenatide

In the included trials, metformin is associated with increased gastrointestinal (GI) symptoms including abdominal pain, nausea, and diarrhea.[55-57] This is compatible with the package insert.[69] Severe harms of metformin detected in larger studies, typically among older adults with type 2 diabetes, include lactic acidosis, serious hypoglycemia (most often in combination with other agents) and liver failure. Incidence of such serious harms is below 1 in 10,000 and may be as low as 1 per 100,000 person-years of exposure.[70]

Exenatide is typically used as a second agent when adequate glycemic control is not achieved with a single diabetes treatment. Its harm profile is uninformed by the literature in this review which included only one study with 40 women treated.[57] The package insert suggests hypoglycemia is the most serious side effect,[71] and large scale surveillance studies have not confirmed initial concerns that pancreatitis was more common among those treated.[72,73] Reviews including data about harms identify metformin as a first-line agent of choice for diabetes management, and concur that both agents are associated with excess GI complaints.[74-76]

Progesterone

Route of progestogen administration was compared in one comparative effectiveness trial for women with irregular menses.[59] In the remaining studies, progestogens were included as the comparator arms (in each case hypothesizing and documenting the superiority of the agent under study) or within COCs.[33,37,42,44,45,48,49] The progesterone-releasing intrauterine system is separately reviewed below.

Progestogens, like depot medroxyprogesterone acetate (DMPA), and vaginal micronized progesterone gel are associated with increased complaints of weight gain, fluid retention, abdominal pain, nausea, change of mood, and change in appetite. Many of these were documented in the included studies which were typically under-powered or made comparisons to other active agents, making comparisons of risk of side effects less informative. Among the most common complaints associated with progestogens is irregular bleeding. Package inserts also note potential dangers of exposure to high doses in pregnancy.[77]

A surveillance study has linked DMPA to increased future rate of fractures (though analyses were not controlled for key confounders like smoking and body mass index),[78] while another large study showed recovery of normal bone density within 2 to 3 years of ceasing use.[79] Some data suggest use of progestogens is associated with increased risk of deep venous thrombosis, though other research restricted to those using particular drugs for the indication of heavy menses demonstrates that women with heavy menses have higher risk of deep vein thrombosis regardless of the intervention they use suggesting some degree of confounding by the indication

for which the drug is given.[80] Reviews and meta-analyses confirm common side effects, including progestogens being a cause of irregular bleeding.[81]

COCs

Primary care providers and many women are aware of the most serious risks of COCs and the more common side-effects including edema, nausea, breast tenderness, skin changes, and GI symptoms. The studies in this review reported harms profiles for common symptoms similar to package insert documents.[82-85] Certain risks like that for venous thromboembolism, myocardial infarction, cerebral hemorrhage, hypertension, gallbladder disease, and benign liver tumors are also well documented. Patients and clinicians should be alerted to factors that increase risk of complications such as cigarette smoking, advancing age (with 35 often used as a threshold), and predisposition to thrombotic events. Two recent systematic reviews have reiterated increased risk for deep venous thrombosis with a suggestion that risk is lowest in those COCs containing levonorgestrel or norgestimate as the progestogens.[6,86]

Cabergoline

The sole study of cabergoline in this review was exploratory with 14 women with PCOS and 15 normal controls.[60] When used for treatment of prolactinoma, this drug is associated with nausea, headache, dizziness, lack of energy, and constipation. Cochrane reviews on three different conditions found no difference in overall risk of harms for cabergoline compared with placebo,[87,88] however a review of use for Parkinson's patients revealed increased valvular heart disease on echocardiogram with few symptomatic individuals.[89,90] The applicability of this data to young women with irregular menses is very limited.

LNG-IUS

Participants in the included trial of use of the LNG-IUS for abnormal cyclic uterine bleeding had few serious complications. Common side effects include changes in bleeding pattern including spotting and complete absence of menses. Abdominal pain/bloating, headache, depressed or altered mood, heavy bleeding, breast tenderness, and intrauterine device expulsion are expected to occur in approximately 5 percent or more of women using this treatment, as reflected in package inserts.[91,92] Surveillance studies provide good estimates from large registries of users. Difficult insertions occur in 3 to 4 percent of women, with painful insertion occurring in about 1 percent.[93,94] Risk of uterine perforation is between 0.9 and 2.6 per 1,000 users and the majority are not recognized at the time of insertion.[94-97] Nulliparous status and noncontraceptive indications do not appear to influence risk of perforation. Hair loss, that is known to be reversible in many but not all patients, occurs in about 1.8 per 1,000 users.[95] The LNG-IUS is not associated with increased risk of deep vein thrombosis in more than 8 million person-years of observation.[98-100] Systematic reviews match package insert and surveillance data also noting that expulsion occurs in 5 to 16 percent of women.[81,84,101,102]

Contraceptive Vaginal Ring

In the single trial of the contraceptive vaginal ring included in this review, the incidence of nausea, headache, and breast tenderness was comparable in both treatment groups during three cycles of treatment. The contraceptive vaginal ring users were less likely to report breakthrough bleeding than women taking norethisterone. Local events, including vaginal discomfort, vaginitis, foreign body sensation and coital problems were reported more frequently in ring-

users, but no one discontinued treatment due to adverse events. Product materials note that the contraceptive vaginal ring is contraindicated in cigarette smokers over age 35 due to increased risk of venous thromboembolism. A 15-year cohort study that included over 38,000 person-years of contraceptive vaginal ring use reported an elevated adjusted relative risk of 2.5 (95% CI, 1.4 to 4.4) for thrombotic stroke and 2.1 (95% CI, 0.7 to 6.5) for myocardial infarction compared with women (over 9 million person-years) who had not used hormonal contraception.[98] Systematic reviews have noted that the risk of venous thromboembolism for the contraceptive vaginal ring was elevated and similar to COCs.[103]

NSAIDs

NSAIDs are generally dosed intermittently in young women with problem bleeding. This makes detection of harms challenging. Complaints commonly reported in trials included: abdominal pain, nausea, gastritis, and light headedness or dizziness. Less common events included rashes and itching. These agents include a boxed warning on the product labels about cardiovascular and GI risks.[104-106] Upper gastrointestinal bleeding occurs in approximately 1 percent of patients treated for 3 to 6 months and at higher rates with longer use.[105-107] However, the majority of use assessed in this way is chronic, daily use. Product materials note that short term use is not without risk but do not provide risk estimates. Other common side effects include edema, abdominal pain, constipation, nausea, vomiting, heart burn, headache, nervousness, and conflicting central nervous system complaints like anxiety and tremor as well as malaise and somnolence. A pooled analysis of trials found mild neurologic and GI adverse events were more common in those treated than among placebo users.[108] The available reviews note additional investigation is required to clarify potential cardiovascular risks.[109,110]

TXA

Within studies in our review similar numbers of participants withdrew from TXA treatment arms as from placebo and comparison groups.[47,48] Side effect profiles were similar across those treated and untreated with the agent who remained in trials. The Food and Drug Administration has examined concerns about changes in QT-interval changes on electrocardiograms, but overall the number of subjects included in trials was considered to be low for evaluating harms and drug safety.[111] The updated prescription label now includes headache, nasal and sinus symptoms, back pain, and abdominal pain as occurring in more than 10 percent of those taking the drug.[112] Joint pain, muscle cramps and spasms, migraine, anemia, and fatigue occur in more than 5 percent of users. Post-marketing reports have identified thrombosis, allergic reactions including anaphylaxis, and visual disturbances.[112] This led to contraindications similar to those for COCs recommending that women with any history of thrombotic disease, risk for thrombotic disease, who smoke, are over age 35, or who concomitantly use tissue plasminogen activator, avoid the drug. Several reviews have examined harms and concluded that GI effects are most common and no thrombotic events were identified in 10 study populations.[113-116] It is important to note that overall these trials are small and large-scale surveillance data over time will likely be required for definitive answers.

Discussion

Summary of Strength of Evidence and Findings

The strength of evidence tables (Table B and Table C) summarize the total number of studies and within those studies the number of women who received the specific intervention. The tables also provide the assessment of the risk of bias, consistency of findings across trials, directness of the evidence that treatment improves the symptom, and precision of the estimates provided by the literature.

Overall the evidence to answer KQs about the management of AUB did not reach standards for high strength of evidence for any intervention from the literature relevant to treatment of women with irregular uterine bleeding (Table B). COCs, as represented in a single good quality placebo controlled trial with 201 participants, documented effectiveness.[51] The treatment effect was large with improvement in bleeding patterns reported for more than 80 percent of women taking COC compared with 45 percent for the placebo group. Combined, these factors provided moderate evidence of benefit. Use of metformin is supported by low strength of evidence predominantly related to small trials of somewhat limited quality. For the remainder of the interventions investigated for management of irregular uterine bleeding, there is insufficient evidence that follows from single and/or lower quality studies.

Table B. Strength of evidence for improving menstrual regularity (KQ1A)

Intervention Quality: Studies (Subjects Assigned to Intervention)	Risk of Bias	Consistency	Directness	Precision	Overall Strength of Evidence[a]	Findings Comparisons
Progestogen[b] Poor: 1(69)[59]	High	NA	Direct	Imprecise	Insufficient	Not analyzed by arm
COC[c] Good: 1(101)[51]	Low	NA	Direct	Precise	Moderate	Cycle control improved:[d] 87% COC vs. PBO, p<0.001[51]
Metformin[e] Poor: 3(81)[56-58] Fair: 1(45)[55]	Medium	NA	Direct	Imprecise	Low	Delay to first ovulation:[f] 24 days MET vs. PBO, p=0.02[55]
Exenatide[g] Poor: 1(20)[57]	High	NA	Direct	Imprecise	Insufficient	Small, poor quality trial
Cabergoline[h] Good: 1(8)[60]	Low	NA	Direct	Imprecise	Insufficient	Cycle control improved:[i] 100% CBG vs. PBO, p=NR[60]
Diet[j] Poor: 1(24)[62]	High	NA	Direct	Imprecise	Insufficient	Not analyzed by arm

Table B. Strength of evidence for improving menstrual regularity (KQ1A) (continued)

Intervention Quality: Studies (Subjects Assigned to Intervention)	Risk of Bias	Consistency	Directness	Precision	Overall Strength of Evidence[a]	Findings Comparisons
Exercise[k] Poor: 1(34)[61]	High	NA	Direct	Imprecise	Insufficient	Not analyzed by arm
Acupuncture[l] Poor: 1(33)[61] Fair: 1(23)[63]	High	NA	Direct	Imprecise	Insufficient	Menstrual regulation:[m] 86% MP-ACU > R-ACU, p<0.05[63]

CBG = cabergoline; COC = combined oral contraceptive; MET = metformin; MR-ACU = menstruation-promoting acupuncture; NR = not reported; PBO = placebo; R-ACU = routine acupuncture

[a]Overall strength of evidence assessment based on good and fair quality studies only.

[b]Oral dydrogesterone (n=35) vs. 8% vaginal micronized progesterone (n=34).

[c]Triphasic norgestimate-ethinyl estradiol vs. placebo (n=100).

[d]Subject assessment.

[e]Poor quality studies: metformin vs. N-acetyl cysteine (n=50), exenatide (n=20), or placebo (n=12); Fair quality study: metformin vs. placebo (n=47).

[f]Mean days to ovulation.

[g]Compared with metformin (n=20) or metformin plus exenatide (n=20).

[h]Compared with placebo (n=6).

[i]Menstrual cyclicity restoration in oligomenorrhea or spontaneous menses in amenorrhea.

[j]Low-fat diet (n=12) vs. low-carbohydrate diet (n=12).

[k]Compared with acupuncture (n=33) or no intervention (n=17).

[l]Poor quality study: acupuncture vs. exercise (n=34) or no intervention (n=17); Fair quality study: mind tranquilizing acupuncture vs. routine acupuncture (n=17).

[m]Patients cured or markedly relieved.

For management of heavy cyclic bleeding, the literature was more robust (Table C). COCs are supported by high strength of evidence for the purpose of decreasing MBL. The LNG-IUS, various NSAIDs, and TXA are also effective for reducing the amount of measured menstrual bleeding and are each supported by moderate strength of evidence. In head-to-head comparisons with statistically significant differences, the LNG-IUS has one trial showing superiority to NSAIDs,[28] two showing superiority to COCs,[41,43] and two showing superiority to progestogens.[42,44,45] COCs were equivalent in one trial compared with an NSAID.[31] TXA was also superior to NSAIDs,[29,34] and when combined with an NSAID was superior to TXA alone.[40] Most of these interventions have been shown to have additional positive effects, typically including shorter duration of bleeding and improvement in symptoms when participants used standardized scoring systems to report treatment response.

Table C. Strength of evidence for improving heavy menstrual bleeding (KQ1B)

Intervention Quality: Studies (Subjects Assigned to Intervention)	Risk of Bias	Consistency	Directness	Precision	Overall Strength of Evidence[a]	Findings[b] Comparisons
LNG-IUS Poor: 5(173)[28,41,43,44,46] Fair: 2(104)[42,45]	Medium	Consistent	Direct	Precise	Moderate	71% and 94% reduction in MBL in 2 head-to-head studies LNG-IUS > MPA, p<0.001[42] LNG-IUS vs. NOR, p=NS[45]
NSAID Poor: 9(192)[28,29,31-34,36,37,40] Fair: 3(129)[30,38,39,68] Good: 1(32)[35]	Medium	Consistent	Direct	Imprecise	Moderate	28% to 49% reduction in MBL in 3 placebo controlled trials; 46% and 47% reduction in MBL in 1 head-to-head study (2 NSAID arms) MFA vs. PBO, p=NR[30] p<0.001[39,35] MFA vs. NPX, p=NS[38]
TXA Poor: 4(202)[29,34,40,48] Fair: 2(260)[49,50] Good: 1(123)[47]	Medium	Consistent	Direct	Precise	Moderate	26% and 40% reduction in MBL in 2 placebo controlled trials; 45% reduction in MBL in 1 head-to-head study TXA vs. PBO, p<0.001[50,47] TXA > NOR, p<0.001[49]
COC[c] Poor: 3(90)[31,41,43] Good: 2(269)[52,53]	Low	Consistent	Direct	Precise	High	64% and 69% reduction in MBL in 2 placebo controlled trials COC vs. PBO, p<0.001[52,53]
Progestogen[d] Poor: 1(50)[48] Fair: 4(173)[42,45,49,54]	Medium	Inconsistent	Direct	Imprecise	Insufficient	20% increase to 87% reduction in MBL in 4 head-to-head studies MPA < LNG-IUS, p<0.001[42] NOR < LNG-IUS, p=NS[45] NOR < TXA, p<0.0001[49] NOR vs. CVR, p=NS[54e]
CVR Fair: 1(48)[54]	Medium	NA	Direct	Imprecise	Insufficient	67% reduction in MBL[e] in 1 head-to-head study CVR vs. NOR, p=NS[54]

COC = combined oral contraceptive; CVR = contraceptive vaginal ring; LNG-IUS = levonorgestrel-releasing intrauterine system; MBL = menstrual blood loss; MCF = meclofenamate; MFA = mefenamic acid; MPA = medroxyprogesterone; NA = not applicable; NOR = norethisterone; NPX = naproxen; NR = not reported; NS = not significant; NSAID = nonsteroidal anti-inflammatory drug; PBO = placebo; TXA = tranexamic acid

[a]Overall strength of evidence assessment based on good and fair quality studies only.

[b]Change in menstrual blood loss from baseline measured by the alkaline hematin method (unless otherwise noted) from good and fair quality studies.

[c]Ethinyl estradiol and levonorgestrel (n=71) or norethindrone and ethinyl estradiol (n=19) or estradiol valerate and dienogest (n=269).

[d]Medroxyprogesterone (n=177) or oral norethisterone (n=113) or depot medroxyprogesterone (n=44).

[e]Percent change in menstrual blood loss measured by the pictorial blood loss assessment chart.

Applicability

Applicability describes the extent to which results observed in published studies from this review are likely to reflect the expected outcomes when an intervention is applied to broader populations in real-world conditions. Studies for this review were intended to provide information to inform primary care management of irregular or cyclic AUB. In shaping the methods for this review, we engineered the report so that the included research is applicable to primary care of women with these complaints in the United States. Because we narrowed our focus to symptomatic women of reproductive age with chronic complaints of abnormal bleeding, this comes at the cost of fewer studies being addressed. However, it assures that studies included were explicitly designed to examine the effectiveness of the treatments for improving the outcomes of interest in the populations of interest. Applicability of the findings is therefore high.

For each intervention, it is important to note the following provisions. The results of this review apply for women:

- Who are reproductive age and state they have an irregular pattern of menstrual bleeding or heavy cyclic menstrual bleeding;
- Without abnormal findings on pelvic exam or on ultrasound report (fibroids, polyps);
- Without an intrauterine device in place, and who are not pregnant or lactating;
- Who are healthy, and without renal impairment, hepatic impairment, intestinal disease, thyroid disease, abnormal cervical cytology, noncyclic bleeding, history or presence of significant medical problems (e.g., thromboembolic disease, coagulopathy, subarachnoid hemorrhage, endocrine disorders, or eye disease);
- For whom any additional clinically determined diagnostic and screening tests have been completed to rule out other causes of abnormal bleeding;
- Does not have any of the contraindications found in the Food and Drug Administration sources discussed in the main document and do not have risks of drug-drug interactions if they take multiple prescription medications.

This review was not designed to guide evaluation of women with abnormal bleeding, rather to address what treatments have evidence of effectiveness once the diagnosis is established and primary care management is to be initiated.

Overall applicability was high. However, often women who are in trials do not reflect the full range of those with abnormal bleeding seen in primary care. Study participants were more likely to be normal weight, nonsmokers, with few, if any concomitant conditions. The interventions (except in the case of specific comparators as noted) are available in the same doses and formulation in the United States. Outcomes such as measured blood loss, self-reported symptom severity and days of bleeding are of direct relevance to women with abnormal bleeding. Our findings are sparse for outcomes which can be considered essential for a condition like AUB that is defined by symptoms. Important outcomes include satisfaction with response to treatment, definitive assessments of whether or not the women considered their complaint resolved, and whether they wished to continue the same treatment or add additional treatments. Followup in general was brief, so the findings may not apply well to management of a chronic condition like abnormal bleeding. This makes assessments of harms challenging since use of interventions over extended periods may have different risk profiles from short timeframes like one to six cycles.

Research Gaps

Recent improvements in unifying nomenclature and formalizing consensus definitions for the clinical groupings of bleeding abnormalities[9] will likely continue to have a positive influence on the ability to properly interpret the findings of individual studies, to identify groups of studies with comparable methods, and to aggregate results. An array of methodologic recommendations and specific research needs are detailed in the full report. Common themes included the need for larger, better controlled RCTs, with combinations of biological and patient-reported outcomes and that evaluate outcomes over longer periods of time, at least past 1 year. Populations need to become more representative of those seeking care (teens, heavier women, those with common comorbidities like diabetes) and need to directly address common clinical interventions like COCs and progestogens that are represented in the literature by a surprisingly small number of older studies, given how ubiquitous their application is in clinical care. No studies examine trajectories through care, mapping sequential treatment options or costs of care based on the initial treatment strategy assigned. No studies examined combining effective treatments, especially in women who had improvements but did not reach satisfactory control of bleeding or cycle regularity. Overall trial designs should begin to shift towards effectiveness from efficacy, moving beyond the level of proof of concept that is required for drug and device approval to a deeper level that can better inform care, cost considerations and policy.

Conclusions

Women who have problematic irregular or heavy cyclic menstrual bleeding have a number of treatment options available that are supported by systematic review of the research literature. These include high strength of evidence that COCs can improve menstrual regularity for women with irregular bleeding patterns. Metformin is supported by moderate strength of evidence for improving cycle regularity especially among women with PCOS. This provides both a contraceptive and a noncontraceptive option for irregular menses. Other interventions like progestogens are associated with statistically and clinically meaningful improvements from baseline patterns, however the overall evidence is insufficient from well-designed, larger studies with ability to directly compare treatment arms rather than only pre-post measures within groups.

Multiple interventions for heavy cyclic bleeding are supported by evidence that they reduce MBL. These include strong evidence that COCs are effective and moderate strength of evidence that the LNG-IUS, NSAIDs, and TXA reduce bleeding relative to baseline, decrease total volume of bleeding when comparisons are made across treatment groups, and when measured, decrease days of bleeding per cycle. In direct comparisons, LNG-IUS is superior to NSAIDs. TXA is superior to NSAIDs and TXA combined with an NSAID was superior to TXA alone. Results from COC and NSAID comparisons suggest comparable effectiveness. Not all women will benefit from these interventions. Across agents data are sparse to evaluate long-term improvements and risk of harms.

Limitations include a predominance of small, short trials lacking standard terminology and diagnostic criteria for identifying and including women with AUB. Tools for collecting outcome data are crude (collection of sanitary products) and may contribute to a high rate of attrition. Biologic outcomes, like measured blood loss and hemoglobin or hematocrit levels, may neglect the importance of patient-reported outcomes that assess whether symptoms are considered resolved by women themselves. Nevertheless, the variety of effective options suggests many women can achieve symptom relief and have available choices that address both symptoms and

contraceptive or fertility desires, as well as potentially improving other symptoms like menstrual cramping.

References

1. Liu Z, Doan QV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007 May-Jun;10(3):183-94. PMID: 17532811.
2. Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Bio 2010 Oct;152(2):133-7. PMID: 20688424.
3. Belsey EM, Pinol AP. Menstrual bleeding patterns in untreated women. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1997 Feb;55(2):57-65. PMID: 9071513.
4. Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
5. Hallberg L, Hogdahl AM, Nilsson L, et al. Menstrual blood loss—a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45(3):320-51. PMID: 5922481.
6. Manzoli L, De Vito C, Marzuillo C, et al. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 2012 Mar 1;35(3):191-205. PMID: 22283630.
7. Treloar AE, Boynton RE, Behn BG, et al. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967 Jan-Mar;12(1 Pt 2):77-126. PMID: 5419031.
8. Matteson KA, Clark MA. Questioning our questions: do frequently asked questions adequately cover the aspects of women's lives most affected by abnormal uterine bleeding? Opinions of women with abnormal uterine bleeding participating in focus group discussions. Women Health 2010 Mar;50(2):195-211. PMID: 20437305.
9. Munro MG, Critchley HO, Broder MS, et al.; FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011 Apr;113(1):3-13. PMID: 21345435.
10. Doubilet PM. Diagnosis of abnormal uterine bleeding with imaging. Menopause 2011 Apr;18(4):421-4. PMID: 21701427.
11. Bradley LD. Diagnosis of abnormal uterine bleeding with biopsy or hysteroscopy. Menopause 2011 Apr;18(4):425-33. PMID: 21701428.
12. Woolcock JG, Critchley HO, Munro MG, et al. Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertil Steril 2008;90(6):2269-80. PMID: 18258230.
13. Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007 Mar;87(3):466-76. PMID: 17362717.
14. Rahn DD, Abed H, Sung VW, et al.; Society of Gynecologic Surgeons Systematic Review Group. Systematic review highlights difficulty interpreting diverse clinical outcomes in abnormal uterine bleeding trials. J Clin Epidemiol 2011 Mar;64(3):293-300. PMID: 20705427.
15. Munro MG, Critchley HO, Fraser IS; FIGO Working Group on Menstrual Disorders. The FIGO classification of causes of abnormal uterine bleeding. Int J Gynaecol Obstet 2011 Apr;113(1):1-2. PMID: 21316671.
16. Fraser IS, Critchley HO, Munro MG, et al. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod 2007 Mar;22(3):635-43. PMID: 17204526.

17. Hale GE, Zhao X, Hughes CL, et al. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the staging of reproductive aging workshop (STRAW) staging system. J Clin Endocrinol Metab 2007 August 1, 2007;92(8):3060-7. PMID: 17550960.

18. Heller DS. Pathologic basis for abnormal uterine bleeding with organic uterine pathologies. Menopause 2011 Apr;18(4):412-5. PMID: 21701425.

19. Albers JR, Hull SK, Wesley RM. Abnormal uterine bleeding. Am Fam Physician 2004 Apr 15;69(8):1915-26. PMID: 15117012.

20. Matteson KA, Anderson BL, Pinto SB, et al. Practice patterns and attitudes about treating abnormal uterine bleeding: a national survey of obstetricians and gynecologists. Am J Obstet Gynecol 2011 May 14. PMID: 21737060.

21. Ely JW, Kennedy CM, Clark EC, et al. Abnormal uterine bleeding: a management algorithm. J Am Board Fam Med 2006 Nov-Dec;19(6):590-602. PMID: 17090792.

22. National Collaborating Centre for Women's and Children's Health. Heavy Menstrual Bleeding. NICE Clinical Guideline CG44. London: Institute for Health and Clinical Excellence; 2007.

23. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 14: management of anovulatory bleeding. Int J Gynaecol Obstet 2001 Mar;72(3):263-71. PMID: 11296797.

24. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 59: clinical management guidelines for obstetricians-gynecologists: intrauterine device. Obstet Gynecol 2005 Jan;105(1):223-32. PMID: 15625179.

25. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010 Jan;115(1):206-18. PMID: 20027071.

26. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 121: long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2011 Jul;118(1):184-96. PMID: 21691183.

27. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing the risk of bias in included studies. In: Higgins JP, Green S, eds. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2011.

28. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 2005 Aug;112(8):1121-5. PMID: 16045528.

29. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996 Sep 7;313(7057):579-82. PMID: 8806245.

30. van Eijkeren MA, Christiaens GC, Geuze HJ, et al. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol 1992 May;166(5):1419-28. PMID: 1595797.

31. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991 Feb;31(1):66-70. PMID: 1872778.

32. Grover V, Usha R, Gupta U, et al. Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. Asia Oceania J Obstet Gynaecol 1990 Sep;16(3):255-9. PMID: 2088249.

33. Cameron IT, Haining R, Lumsden MA, et al. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol 1990 Jul;76(1):85-8. PMID: 2359570.

34. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand 1988;67(7):645-8. PMID: 3073625.

35. Vargyas JM, Campeau JD, Mishell DR, Jr. Treatment of menorrhagia with meclofenamate sodium. Am J Obstet Gynecol 1987 Oct;157(4 Pt 1):944-50. PMID: 3314521.

36. Tsang BK, Domingo MT, Spence JE, et al. Endometrial prostaglandins and menorrhagia: influence of a prostaglandin synthetase inhibitor in vivo. Can J Physiol Pharmacol 1987 Oct;65(10):2081-4. PMID: 3123043.

37. Cameron IT, Leask R, Kelly RW, et al. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 1987 Jul;34(1):99-110. PMID: 3685399.

38. Hall P, Maclachlan N, Thorn N, et al. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol 1987 Jun;94(6):554-8. PMID: 3304401.

39. Fraser IS, Pearse C, Shearman RP, et al. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet Gynecol 1981 Nov;58(5):543-51. PMID: 7029369.

40. Najam R, Agarwal D, Tyagi R, et al. Comparison of traneximic acid with a combination of traneximic acid and mefenamic acid in reducing menstrual blood loss in ovulatory dysfunctional uterine bleeding (DUB). Journal of Clinical and Diagnostic Research 2010;4(5):3020-5.

41. Shaaban MM, Zakherah MS, El-Nashar SA, et al. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 2011 Jan;83(1):48-54. PMID: 21134503.

42. Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010 Sep;116(3):625-32. PMID: 20733445.

43. Endrikat J, Shapiro H, Lukkari-Lax E, et al. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 2009 Apr;31(4):340-7. PMID: 19497153.

44. Kucuk T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol 2008;35(1):57-60. PMID: 18390083.

45. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998 Jun;105(6):592-8. PMID: 9647148.

46. Lahteenmaki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998 Apr 11;316(7138):1122-6. PMID: 9552948.

47. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010 Oct;116(4):865-75. PMID: 20859150.

48. Kriplani A, Kulshrestha V, Agarwal N, et al. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006 Oct;26(7):673-8. PMID: 17071438.

49. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995 May;102(5):401-6. PMID: 7612535.

50. Freeman EW, Lukes A, VanDrie D, et al. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol 2011 Oct;205(4):319 e1-7. PMID: 21777897.

51. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000 Dec;96(6):913-20. PMID: 11084177.

52. Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: A randomized, double-blind Phase III trial. Hum Reprod 2011;26(10):2698-708. PMID: 21784734.

53. Jensen JT, Parke S, Mellinger U, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: A randomized controlled trial. Obstet Gynecol 2011;117(4):777-87. PMID: 21422847.

54. Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 2012 Mar;85(3):246-52. PMID: 22067765.

55. Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002 Feb;87(2):569-74. PMID: 11836287.

56. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000 Jan;85(1):139-46. PMID: 10634377.

57. Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93(7):2670-8. PMID: 18460557.

58. Oner G, Muderris, II. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011 Nov;159(1):127-31. PMID: 21831508.

59. Karakus S, Kiran G, Ciralik H. Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial. Aust N Z J Obstet Gynaecol 2009 Dec;49(6):685-8. PMID: 20070724.

60. Paoletti AM, Cagnacci A, Depan GF, et al. The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 1996;66(4):527-32. PMID: 8816612.

61. Jedel E, Labrie F, Oden A, et al. Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab 2011 Jan;300(1):E37-45. PMID: 20943753.

62. Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2011;24(3):161-5. PMID: 21419674.

63. Cai XM, Wu J. The mind-tranquilizing and menstruation-regulating method for acupuncture treatment of delayed menstrual cycle—a clinical controlled study. J Tradit Chin Med 2009 Mar;29(1):35-8. PMID: 19514186.

64. Vuorma S, Rissanen P, Aalto AM, et al. Impact of patient information booklet on treatment decision—a randomized trial among women with heavy menstruation. Health Expect 2003 Dec;6(4):290-7. PMID: 15040791.

65. Kennedy AD, Sculpher MJ, Coulter A, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA 2002 Dec 4;288(21):2701-8. PMID: 12460093.

66. Protheroe J, Bower P, Chew-Graham C, et al. Effectiveness of a computerized decision aid in primary care on decision making and quality of life in menorrhagia: Results of the MENTIP randomized controlled trial. Medical Decision Making 2007;27(5):575-84. PMID: 17898242.

67. Vuorma S, Teperi J, Aalto AM, et al. A randomized trial among women with heavy menstruation— impact of a decision aid on treatment outcomes and costs. Health Expect 2004 Dec;7(4):327-37. PMID: 15544685.

68. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 1984 Aug 1;149(7):788-93. PMID: 6380294.

69. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.

70. Chan KA, Truman A, Gurwitz JH, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 2003 Mar 24;163(6):728-34. PMID: 12639207.

71. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2011.

72. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011 Jun;13(6):559-66. PMID: 21320263.

73. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009 Apr;25(4):1019-27. PMID: 19278373.

74. LeBlanc E, O'Connor E, Whitlock EP, et al. Screening for and Management of Obesity and Overweight in Adults. Evidence Report No. 89. AHRQ Publication No. 11-05159-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; Oct 2011.

75. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011(10):CD006423. PMID: 21975753.

76. Waugh N, Cummins E, Royle P, et al. Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement). London: National Institute for Health and Clinical Excellence; 2009.

77. Aktun H, Moroy P, Cakmak P, et al. Depo-Provera: use of a long-acting progestin injectable contraceptive in Turkish women. Contraception 2005 Jul;72(1):24-7. PMID: 15964288.

78. Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 2008 Dec;78(6):459-64. PMID: 19014791.

79. Rosenberg L, Zhang Y, Constant D, et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception 2007 Dec;76(6):425-31. PMID: 18061699.

80. Sundstrom A, Seaman H, Kieler H, et al. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009 Jan;116(1):91-7. PMID: 19016686.

81. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005(4):CD002126. PMID: 16235297.

82. Loestrin 1/20 [package insert]. Pomona, NY: Duramed Pharmaceuticals, Inc.; 2009.

83. Nordette [package insert]. Sellersville, PA: Teva Pharmaceuticals USA, Inc.; 2010.

84. Ortho Tri-Cyclen [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2010.

85. Natazia [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2012.

86. Martinez F, Ramirez I, Perez-Campos E, et al. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care 2012 Feb;17(1):7-29. PMID: 22239262.

87. Tang H, Hunter T, Hu Y, et al. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2012(2):CD008605. PMID: 22336848.

88. Scholz H, Trenkwalder C, Kohnen R, et al. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 2011(3):CD006009. PMID: 21412893.

89. Bogazzi F, Manetti L, Raffaelli V, et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 2008 Dec;31(12):1119-23. PMID: 19246980.

90. Rasmussen VG, Ostergaard K, Dupont E, et al. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. Mov Disord 2011 Apr;26(5):801-6. PMID: 21671508.

91. Mirena [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2009.

92. FDA. Statistics filing memorandum for a supplemental NDA (Mirena).FDA; 2009. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM245687.pdf. Accessed April 13, 2012.

93. Harrison-Woolrych M, Zhou L, Coulter D. Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand. N Z Med J 2003 Aug 8;116(1179):U538. PMID: 14513085.

94. Zhou L, Harrison-Woolrych M, Coulter DM. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena). Pharmacoepidemiol Drug Saf 2003 Jul-Aug;12(5):371-7. PMID: 12899110.

95. Paterson H, Clifton J, Miller D, et al. Hair loss with use of the levonorgestrel intrauterine device. Contraception 2007 Oct;76(4):306-9. PMID: 17900442.

96. van Grootheest K, Sachs B, Harrison-Woolrych M, et al. Uterine perforation with the levonorgestrel-releasing intrauterine device: analysis of reports from four national pharmacovigilance centres. Drug Saf 2011 Jan 1;34(1):83-8. PMID: 21142273.

97. Van Houdenhoven K, van Kaam KJ, van Grootheest AC, et al. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception 2006 Mar;73(3):257-60. PMID: 16472566.

98. Lidegaard O, Lokkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012 Jun 14;366(24):2257-66. PMID: 22693997.

99. Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423. PMID: 22027398.

100. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010 Nov;30(11):2297-300. PMID: 20798377.

101. French R, Van Vliet H, Cowan F, et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev 2004(3):CD001776. PMID: 15266453.

102. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006(2):CD003855. PMID: 16625593.

103. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol 2012 Aug;24(4):235-40. PMID: 22729096.

104. Lucas PJ, Baird J, Arai L, et al. Worked examples of alternative methods for the synthesis of qualitative and quantitative research in systematic reviews. BMC Med Res Methodol 2007;7:4. PMID: 17224044.

105. Meclofenamate sodium [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc.; 2006.

106. Naprosyn [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2010.

107. Flurbiprofen tablet [package insert]. Detroit, MI: Caraco Pharmaceutical Laboratories, Inc.; 2007.

108. Marjoribanks J, Proctor M, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010(1):CD001751. PMID: 20091521.

109. Garcia Rodriguez LA, Gonzalez-Perez A, Bueno H, et al. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One 2011;6(2):e16780. PMID: 21347435.

110. Salvo F, Fourrier-Reglat A, Bazin F, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011 Jun;89(6):855-66. PMID: 21471964.

111. FDA. New Drug Application: 22-430 (Tranexamic Acid) Summary Review.Center for Drug Evaluation and Research; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022430s000sumr.pdf. Accessed April 13, 2012.

112. Lysteda [package insert]. Parsippany, NJ: Ferring Pharmaceutical; 2011.

113. Alshryda S, Sarda P, Sukeik M, et al. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br 2011 Dec;93(12):1577-85. PMID: 22161917.

114. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000(4):CD000249. PMID: 11034679.

115. Naoulou B, Tsai MC. Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: A systematic review. Acta Obstet Gynecol Scand 2012 May;91(5):529-37. PMID: 22229782.

116. Sukeik M, Alshryda S, Haddad FS, et al. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011 Jan;93(1):39-46. PMID: 21196541.

Introduction

Background

Condition

Abnormal uterine bleeding (AUB) is among the most common of gynecologic complaints from reproductive-age women in ambulatory care settings—of similar frequency to the number seeking care for urinary tract infections and vaginitis. In the general population, AUB is estimated to affect 11 to 13 percent of reproductive-age women. The prevalence of AUB increases with age, reaching 24 percent in women aged 36 to 40.[1,2] In addition to gynecologists, all primary care practitioners including pediatricians, family physicians, advanced practice nurses, and internists, will encounter the need to evaluate, treat, or refer women with bleeding-related symptoms.[3] Women generally present because the amount, timing, or other characteristics of the bleeding have changed from their individual norm.

Population norms for menstrual bleeding, as established by 5th and 95th percentiles, are:[4-7]

- Frequency of menses within a 24 to 38 day window
- Regularity (cycle-to-cycle variation) within 2 to 20 days
- Duration of flow from 4 to 8 days
- Volume of blood loss from 5 to 80 ml

Symptoms outside this range or different from normal for the individual can become problematic and deserve evaluation because they can warn of underlying conditions. Common problems include worry about the cause, embarrassment if the bleeding includes flooding-type bleeding with saturation of clothing, missed work and responsibilities, limitations of social activities and exercise, decreases or changes in sexual activity, and frustration with costs of sanitary protection.[1,8] Collectively, the effects of troublesome bleeding reduce quality of life and drive desire for information about causes and treatment options.[1,8]

There is not a clear consensus on the clinical evaluation of a patient presenting with abnormal bleeding. Recommendations suggest that initial evaluation confirm the source and timing of bleeding, and exclude certain architectural etiologies, cancer, coagulation defects, and systemic disease. The 2011 International Federation of Gynecology and Obstetrics (FIGO) classification recommends a structured history followed by uterine evaluation.[9] In the research setting, the alkaline hematin method is the preferred technique for direct measurement of total menstrual blood loss (MBL). The pictorial blood loss assessment chart is a semi-quantitative tool for uniform reporting of bleeding as represented by the degree of saturation of sanitary pads and tampons. Diagnostic tools and evaluation strategies are not within the scope of this review;[10,11] however, the review captures the operational definitions used by researchers and addresses applicability of the findings to contemporary practice.

Terminology

Nomenclature to classify symptomatic problem bleeding has evolved steadily over the past several decades.[12] Early classifications primarily used characteristics of the bleeding to group women. Terms like menorrhagia (abnormally long or heavy menses) and metrorrhagia (bleeding at irregular intervals) were often linked with timing (short or long intervals) and amount (heavy or light) to infer whether or not regular and predictable ovulation was occurring and further assign likely ovulatory or anovulatory status. These terms are generally applied without formal

documentation of ovulatory status. Furthermore, previously applied terms like "dysfunctional uterine bleeding" also carried a variable element of recognition that the label was a diagnosis of exclusion.[12] The resulting challenge was that practitioners and researchers applied different exclusions before selecting interventions or enrolling patients. Over time, differences in terminology choice and in operational definitions have resulted in wide inconsistencies in application of diagnostic terms.[4,12-14]

Recent international consensus recommendations, formally adopted by FIGO in 2010 and published in 2011, more consistently align terminology by creating two major groupings (i.e., discrete structural vs. nonstructural) for causes of bleeding.[9,15,16] The FIGO classification includes nine categories of abnormal bleeding arranged according to the acronym PALM-COEIN:[9,16] four have objective visual criteria detected by imaging, biopsy, or pathology (i.e., PALM: **p**olyps; **a**denomyosis; **l**eiomyomata; and **m**alignancy and hyperplasia) while another five are not directly related to structural abnormalities (i.e., COEIN: **c**oagulopathy; **o**vulatory dysfunction; **e**ndometrial; **i**atrogenic; and **n**ot yet classified).

If we map the intended focus of this comparative effectiveness review (CER) to the FIGO classification, we are addressing the COEIN groups that are characterized as "ovulatory dysfunction" (AUB-O), "endometrial hemostatic dysfunction" (AUB-E), and "not yet classified" (AUB-N) abnormal bleeding. However it is crucial to note that direct measures of ovulation are not employed in most available literature and endometrial samples for classification are even more rare, except when used to rule out malignancy. Indeed much remains to be explained about the pathophysiology of the very common and problematic complaint of unpredictable and/or heavy bleeding. In summary, the relevant population for this review includes nonpregnant women from menarche to menopause who have had abnormal bleeding (scant or heavy) for 3 months or longer that is not attributed to structural abnormalities, coagulation defects, systemic illnesses, or medications.

While some reviews further subdivide women experiencing AUB into age groups,[17] such as those near menarche and in the perimenopausal timeframe, we plan to retain an emphasis on categorization. Women across the reproductive lifespan can have abnormal bleeding that arises from ovulatory dysfunction or endometrial processes.[18] While the underlying causes may vary, for instance from lack of consistent regulation of the hypothalamic-pituitary-ovarian axis in teens near the onset of menses, and from lack of ovarian reserve in perimenopausal women, the treatment options overlap.[3] We will report when research was done with an age-restricted population but will otherwise cover all the relevant literature regardless of reproductive age or reproductive history of participants.

Therapies

Current guidelines from professional societies including the American Congress of Obstetricians and Gynecologists,[19-22] the American Academy of Family Physicians,[23] and the National Institute for Clinical Excellence[24] recommend medical therapy, including the levonorgestrel-releasing intrauterine system (LNG-IUS), nonsteroidal anti-inflammatory drugs (NSAIDs), antifibrinolytics, combined oral contraceptives (COCs), and progestogens, as the first-line treatment for irregular uterine bleeding and abnormal cyclic bleeding.

In a recently published research article,[25] Matteson and colleagues examined the practice patterns and attitudes from a U.S. sample of obstetricians and gynecologists regarding the medical treatment of women with AUB. The authors reported that practicing obstetrician-gynecologists most frequently selected COCs for the treatment of both irregular and abnormal

cyclic menstrual bleeding and that participants lacked an overall awareness of current evidence on effectiveness of common treatment options for AUB.[25] However, another recent publication[26] reported that, that in conflict with recommendations, uterine-preserving surgical procedures were the most common first-line treatment for women with heavy menstrual bleeding within a large cohort from a national claims database of large employers.

Primary Care Treatment Options

Pharmacologic therapies to treat AUB in the ambulatory setting include estrogens, progestogens, combination (estrogen and progestogen) hormonal formulations, NSAIDs, antifibrinolytics, and progesterone-releasing intrauterine devices (IUDs). Medical interventions are generally considered first-line treatment.[27,28] Surgical intervention is usually reserved for women with persistent bleeding that does not respond to medical therapy or for women who have finished childbearing and do not wish to continue medical therapy indefinitely.[2,23]

LNG-IUS

A pooled analysis of data from five randomized controlled trials (RCTs) reported that the LNG-IUS provided clinically and statistically significant sustained reductions in MBL.[29] Locally released progesterone from the IUD reduces growth of the uterine lining, minimizing the tissue available to be shed during menstruation. IUDs are used as contraception by approximately 5 percent of women in the United States.[30] Based on large-scale claims data, use of the LNG-IUS increased 19-fold between 2002 and 2008 to 7.7 per 1000 women, becoming the most commonly used IUD in the United States.[31]

NSAIDs

NSAIDs are commonly used to treat AUB (more recently termed AUB-E) because of the role of prostaglandins in the pathogenesis of heavy menstrual bleeding. Higher levels of prostaglandin E2 have been observed in the endometria of women with heavy menstrual bleeding.[32] Additional evidence points to an abnormal ratio of specific prostaglandins as a contributing factor to problems with hemostasis.[32] NSAIDs act to reduce prostaglandin synthesis by inhibiting the enzyme cyclo-oxygenase and therefore reducing endometrial prostaglandin levels leading to decreased potential for vasodilation and angiogenesis.[33] Based on a limited number of small studies, a 2007 Cochrane Review[34] found that NSAIDs were superior to placebo but less effective than tranexamic acid and LNG-IUS at reducing MBL.

TXA

TXA is an antifibrinolytic that slows the breakdown of fibrin in blood clots. By decreasing the degradation of physiologic blood clots, blood flow from uterine vessels sealed by the clot is decreased. Since it is not a hormonal agent and does not have contraceptive effects it may be useful for women who desire a pregnancy or for whom hormonal treatment is contraindicated. TXA appears to be well-tolerated and cost-effective, reducing blood loss considerably and improving health related quality of life for women with menorrhagia.[35]

COCs

COCs are commonly used to manage abnormal bleeding associated with ovulation since they work in part by superimposing an organized cycle and discourage thick growth of the uterine lining. The American Congress of Obstetrics and Gynecologists 2010 Practice Bulletin for

noncontraceptive uses of hormonal contraceptives recommends COCs as a reasonable choice to regulate and reduce menstrual bleeding, based on good and consistent scientific evidence.[21] However, according to a 2009 Cochrane systematic review,[36] there is insufficient evidence to establish the effectiveness of the oral contraceptive pill compared with other medical therapies, placebo, or no therapy for the treatment of heavy menstrual bleeding.[36] In a clinical review for diagnosis and management of AUB,[37] authors assert that COCs are likely beneficial for treatment of anovulatory (i.e., acyclic) AUB but there is lack of good quality data to support their use in abnormal cyclic bleeding.[37] The COC is also known to cause abnormal bleeding patterns, with breakthrough bleeding reported as one of the most common reasons for discontinuation of COC use.[38] Additional data are needed on the number needed to treat and the number needed to harm for adverse effects.

Progestogens

During a normal cycle, the natural rise and fall of progesterone, which is produced by the ovary after ovulation, has multiple biological effects on the endometrium. These include "organization" that results in the coordinated withdrawal bleeding observed as the menses after progesterone levels fall. Cyclic administration of progestogens in women with AUB is intended to mimic natural production of progesterone in the luteal phase and then withdrawal, by providing the agent for a number of days, typically 10 to 14, after which bleeding occurs. Other methods of administration of progestogen, such as by long acting injection or oral contraceptive pills that contain only a progestogen, exploit a different biologic property of progestogens. When continuously administered, progestogens encourage endometrial quiescence and reduce growth of the endometrium. In women with AUB, these effects can modulate problematic symptoms by fostering endometrial stability and a relatively thin endometrium resulting in less bleeding. The American Congress of Obstetrics and Gynecologists practice bulletins on management of anovulatory bleeding and noncontraceptive uses of hormonal contraceptives note that progestogens are an appropriate first-line choice for medical management of irregular bleeding that results from lack of regular, predictable ovulation.[19,21]

Behavioral and Lifestyle Interventions

Diet and physical activity interventions have been proposed for irregular menstrual bleeding because irregular menses often indicate irregular or absent ovulation. Obesity and metabolic syndrome, including polycystic ovarian syndrome (PCOS), are associated with increased risk of anovulatory cycles. Trials that have achieved modest weight loss in infertile patients have restored regular ovulatory function in a majority of women with obesity-related subfertility.[39] Both aerobic and strength training as well as weight loss may improve blood sugar profiles and reduce relative or frank insulin resistance, which are intermediates to restoring regular menses in some women.

Complementary and Alternative Medicine

Initial literature scans suggested that there is an extremely limited body of literature on trials of complementary and alternative medicine for AUB. Complementary and alternative medicine based therapies are included as interventions of interest due to their increasing popularity among patients and growing interest to clinicians.[40]

Scope and Key Questions

Scope of the Review

The relevant population for this review includes nonpregnant women from menarche to menopause who have had AUB for 3 months or longer, that is not attributed to structural abnormalities, coagulation defects, systemic illnesses, or medications.

The literature reflects various management options for women with AUB with conflicting recommendations/summaries. Interventions of interest for this review include medical, complementary and alternative medicine, and behavioral/lifestyle interventions. This review does not consider surgical interventions for AUB, as surgical management is adequately covered by other groups conducting systematic reviews.

This review is focused on the evidence available to inform selection of nonsurgical options to treat AUB with an emphasis on interventions that are accessible to and within the scope of usual practice for primary care practitioners in a clinical care setting. This means that while we *did not* restrict literature review to studies conducted only in primary care settings, we did restrict the review to include only those interventions that could be deployed in primary care. We address abnormal bleeding that is chronic in nature, meaning the symptom has persisted for the majority of the prior 3 months, and is of two primary and common types: (1) irregular in timing (i.e., acyclic); and (2) abnormal though cyclic. We explicitly defined eligibility criteria using a PICOTS (population, intervention, comparator(s), outcome, timing, and setting) structure (Table 1).

Table 1. PICOTS

PICOTS Element	Description
Population:	Nonpregnant women from menarche to menopause who have had abnormal bleeding for 3 months or longer whose bleeding is not caused by structural abnormalities, coagulation defects, systemic disease, cancer, or medication. Two specific subtypes of abnormal bleeding will be the focus: • *Irregular uterine bleeding:* problem bleeding (frequent or infrequent) of 3 months or greater duration, excluding regular cyclic/menstrual patterns of bleeding, fibroids, polyps, adenomyosis, cancers, medication side effects, coagulation defects, and related systemic disease. • *Abnormal cyclic uterine bleeding*: problem bleeding of 3 months or greater duration, excluding irregular and unpredictable patterns of bleeding, fibroids, polyps, adenomyosis, cancers, medication side effects, coagulation defects, and related systemic disease.

Interventions:[a]	• Medical therapies
	  o Nonsteroidal anti-inflammatory drugs
	  o Antifibrinolytics
	  o Oral hormone treatments (e.g., oral contraceptives, progestogens)
	  o Levonorgestrel-releasing intrauterine system
	  o Vaginal ring contraceptive device
	• Behavioral strategies (e.g., stress reduction, weight reduction, exercise)
	• Complementary and alternative medicine therapies (e.g., acupuncture, herbal medicine)

Comparator:	Direct comparison among interventions listed above or comparison to placebo.

Table 1. PICOTS (continued)

PICOTS Element	Description
Outcomes:	• Bleeding profile (e.g., amount, frequency, duration, pattern, symptom bother, hematocrit) • Quality of life including both general and bleeding specific measures • Pain related to bleeding • Sexual function as reported by sexual function measures, general measures of sexual activity, frequency and satisfaction • Patient satisfaction with outcomes and acceptability of treatment • Fertility • Time to conception • Additional interventions including concurrent and consecutive surgical and nonsurgical treatments • Harms[b] (e.g., thromboembolic events, emotional side effects, weight gain, short- and long-term harms)
Timing:	Interventions initiated after symptoms present most months for 3 months or longer.
Setting:	Any clinical care setting.

PICOTS = population, intervention, comparator, outcome, timing, and setting
[a]Excluding surgical interventions and procedures such as endometrial ablation.
[b]Includes treatment-related adverse events (e.g., drug side effects); does not include consequences related to the failure to adequately treat the symptom.

Key Questions

Key Question 1A (KQ1A)

What is the evidence for the effectiveness of medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with irregular uterine bleeding?

Key Question 1B (KQ1B)

What is the evidence for the effectiveness of medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with abnormal cyclic uterine bleeding?

Key Question 2 (KQ2)

What are the harms, including adverse events, associated with medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) in women with irregular uterine bleeding or abnormal cyclic uterine bleeding?

Analytic Framework

We developed the analytic framework (Figure 1) drawn from clinical expertise of Key Informants and refined it with input from a Technical Expert Panel (TEP). The analytic framework illustrates the population, interventions, outcomes, and adverse effects that guided the literature search, study eligibility, screening, and synthesis.

Figure 1. Analytic framework



CAM = complementary and alternative medicine
Note: Numbers in circles represent Key Questions.

Organization of This Report

The Methods chapter describes our processes including our search strategies, inclusion and exclusion criteria, approach to review of abstract and full publications, methods for extraction of data into evidence tables, and compiling evidence. We also describe our approach to grading the quality of the literature and assessing the strength of the evidence.

The Results Chapter presents the findings of the literature search and review of the evidence by Key Question (KQ). When there are distinct populations in which the interventions have been studied such as enrollment based on differing criteria, we discuss related data together. Within KQs we present summary information in the order: devices, medications, lifestyle and behavior interventions, and complementary and alternative medicine. Within a category such as medication, we organize the results from greater number of studies to fewer, and presented the results of placebo controlled trials before direct comparisons.

The final section discusses the results and enlarges on the methodologic considerations relevant to each KQ. We also outline the current state of the literature and needs for future research on management of AUB. We include a list of abbreviations and acronyms at the end of the report followed by appendixes to provide further detail on our methods and the studies assessed. The appendices are as follows:

- Appendix A Literature Search Strategies
- Appendix B Abstract Review Form (KQ1)
- Appendix C Abstract Review Form (KQ2)
- Appendix D Full-Text Review Form (KQ1)
- Appendix E Full-Text Review Form (KQ2)
- Appendix F Cochrane Risk of Bias Tool
- Appendix G Cochrane Risk of Bias Criteria
- Appendix H Thresholds for Quality Assessment
- Appendix I Risk of Bias and Quality Score for Individual Studies
- Appendix J Evidence Table
- Appendix K Reasons for Exclusion (KQ1)

Methods

The methods for this comparative effectiveness review (CER) follow those suggested in the Agency for Healthcare Research and Quality (AHRQ) Methods Guide for Effectiveness and Comparative Effectiveness Reviews.[41] The main sections in this chapter reflect the elements of the protocol established for the CER; certain methods map to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.[42]

Topic Refinement and Review Protocol

The topic for this report was nominated by a health care professional using the Effective Health Care Web site (http://effectivehealthcare.ahrq.gov/). Working from the nomination, we drafted the initial Key Questions (KQs) and analytic framework and sought input from Key Informants representing family medicine, generalist and subspecialty obstetrics and gynecology, and midwifery. Key Informants uniformly stressed the importance of terminology and of establishing clear and distinct categories of women for whom the review is intended to apply and suggested framing the review from the vantage point of a primary care provider or specialist who is at the earliest stage of management of abnormal uterine bleeding (AUB), which is typically nonsurgical management. KQs were refined to reflect the feedback from Key Informants and address gaps in existing evidence reviews and knowledge base about management of AUB.

After review from AHRQ, the KQs and analytic framework were posted online for public comment. We received no comments during the public posting phase. We prepared final KQs and resubmitted them to AHRQ for review. We identified Technical Experts on the topic to provide assistance during the project. The Technical Expert Panel (TEP) included individuals with expertise in bleeding abnormalities, nomenclature and classification of AUB, and lead authors of ongoing reviews of surgical interventions. The TEP included five members serving as technical or clinical experts. To ensure robust, scientifically relevant work, we called on the TEP to review and provide comments as our work progressed. TEP members participated in conference calls and discussions through e-mail to:

- Refine the analytic framework and KQs;
- Discuss the preliminary assessment of the literature, including inclusion/exclusion criteria;
- Provide input on the information and domains included in evidence tables;

Literature Search Strategy

Search Strategy

Databases

We searched the following databases: MEDLINE® (PubMed interface), the Cumulative Index of Nursing and Allied Health Literature (CINAHL®), and Embase. All search results were limited to English language. Searches were further restricted from 1980 forward in order to ensure literature was relevant to current secular trends in practice as well as available treatment strategies. We carried out hand searches of the reference lists of recent systematic reviews related to management of AUB and the reference lists of included publications. Searches were executed between September 2011 and June 2012.

Search Terms

Each search strategy used a combination of subject headings (i.e., controlled vocabulary) and keywords appropriate for each database (Appendix A). The search strategies included terms related to AUB, along with drug and therapy terms relevant to the topic and focus of Key Question 1A (KQ1A) and Key Question 1B (KQ1B). For Key Question 2 (KQ2), we conducted a second, separate search in MEDLINE (PubMed interface), using controlled vocabulary and keywords focusing on adverse effects and harms associated with those drugs and treatments from our KQ1A and KQ1B included studies. We also employed a combination of subject headings and keywords to narrow retrieval to desired study types; for KQ1A and KQ1B, this included terms related to randomized controlled trials (RCTs), and for KQ2, terms geared toward also retrieving cohort and postmarketing surveillance studies.

Supplementary Information for KQ2

To further assess KQ2, we searched Internet resources to identify current research and regulatory information related to adverse effects and harms specific to those drugs and therapies from KQ1A and KQ1B included publications, with the term harm referring to any negative psychological, physical, or health system consequence associated with the intervention being studied. These searches were executed between January and March 2012. The Scientific Resource Center invited manufacturers of drugs from our included studies to provide Scientific Information Packets.

For each included intervention, we conducted searches of the Food and Drug Administration (FDA) database of approved drugs (Drugs@FDA) and DailyMed to locate the most recent label information, determine the approval date, ascertain therapeutically equivalent drugs, and find other relevant information related to harms. For those drugs no longer marketed or unavailable in the United States, label information (including indications and usage, and harms) was also retrieved from the regulatory agencies of other countries where the drug is approved (e.g., HealthCanada's Drug Product Database), drug information databases (e.g., Micromedex® and LexiComp®), and manufacturer or pharmaceutical company Web sites. Additionally, we searched the FDA's safety information and adverse reporting Web site (MedWatch) to verify the most recent changes to label information were included in our harms data.

To supplement the harms data extracted from package inserts and relevant studies, we adapted our primary PubMed search strategy to identify systematic reviews and meta analyses examining the therapeutic agents identified in our analysis of the literature for KQ1, limiting to items published since 2005.

To ascertain current and ongoing research, we searched clinicaltrials.gov with topic keywords (e.g., “abnormal uterine bleeding”, “menorrhagia”, “heavy menstrual bleeding”), looked at both recruiting and completed studies, and again focused on those drugs and therapies from KQ1A and KQ1B included publications.

Inclusion and Exclusion Criteria

To be considered for inclusion, studies had to explicitly define and describe the study population, the interventions, and outcomes.

For this CER, the population of interest included women with symptomatic cyclic or irregular uterine bleeding (Table 2). We excluded studies of women with AUB caused by coagulation defects, systemic disease (e.g., thyroid disease), structural abnormalities (e.g.,

fibroids, polyps), cancer, or medication side effects. Studies that included patients with AUB of mixed or ill-defined etiologies were reviewed for evaluable data from patients meeting the description of the population of interest. For KQ1A we included studies of women with polycystic ovarian syndrome (PCOS) if the patient baseline and outcome data included information on cycle regularity. We excluded studies of women with infertility if the primary treatment goal was conception.

Table 2. Definitions of eligible patient populations

Patient group	Description
Irregular uterine bleeding	Problem bleeding (frequent or infrequent) of 3 months or greater duration, excluding regular cyclic/menstrual patterns of bleeding, fibroids, polyps, adenomyosis, cancers, medication side effects, coagulation defects, and related systemic disease.
Abnormal cyclic uterine bleeding	Problem bleeding of 3 months or greater duration, excluding irregular and unpredictable patterns of bleeding, fibroids, polyps, adenomyosis, cancers, medication side effects, coagulation defects, and related systemic disease.

To be considered for inclusion, clinical research studies had to evaluate a nonsurgical intervention. For KQ1 and KQ2 we included data from controlled clinical trials (e.g., RCTs) designed to evaluate an intervention or treatment strategy for individuals from the population of interest. For KQ2, we also included data from uncontrolled observational studies, namely high-quality, large cohort studies, postmarketing surveillance studies, and registries/databases, with a population of 1,600 or more patients or records to capture information on adverse events or other harms.[43] We determined that a minimum sample size of 1,600 was needed in order to reliably detect harms with an estimated prevalence of 1 percent. We did not specify a minimal population size for KQ1. Several factors, including varying prevalence of cyclic and irregular patterns of bleeding and the large number of interventions under consideration for this review, make it difficult to reliably establish a minimum sample size for evaluating treatment effectiveness.

To balance resources and focus on literature of most immediate relevance to primary care practice in the United States, we excluded papers that were not published in English.[44]

Study Selection

We developed individual abstract and full-text screening forms for KQ1 and KQ2 (Appendixes B, C, D and E). We revised the forms following testing by the team. The forms were adapted for use in the Web-based systematic review product, DistillerSR (Evidence Partners, Ottawa, Canada).

We conducted screening in two phases: abstract and full-text screening. Publications were promoted to full-text review when one reviewer indicated that the publication met all inclusion criteria or when the title and abstract did not provide adequate information to make a determination. Two reviewers independently reviewed each publication at the full-text screening phase. Discordant classifications were resolved in team meetings including senior investigators.

Quality (Risk of Bias) Assessment of Individual Studies

Two senior team members independently assessed quality of the included studies; disagreements were resolved through discussion or third party adjudication as needed. We recorded quality assessments in tables, summarizing each study.

We used the Methods Guide for Effectiveness and Comparative Effectiveness Reviews[41] and the Cochrane Risk of Bias Tool[45] (Appendix F), an existing tool with established validity and

reliability, to assess methodological quality of included studies. This tool includes criteria for judging risk of bias for specific elements from five fundamental domains: sequence generation, allocation concealment, blinding, outcome data, and selective reporting (Appendix G) in RCTs. From these domains an overall assessment of risk of bias was calculated based on prespecified thresholds for modified quality assessment criteria from the Cochrane Risk of Bias (RoB) Tool (Appendix H). The overall risk of bias assessment was then expressed as one of three final study quality ratings: studies assessed as having a high risk of bias were categorized as "poor" quality studies; studies having a medium risk of bias were categorized as "fair" quality studies; and studies assessed as low risk of bias were categorized as "good" quality studies.

We assessed quality for the included studies that addressed KQ1 only. For KQ2, we sought evidence from varied sources; it was not possible to systematically assess the quality of the evidence related to harms. A summary of all component items and overall risk of bias/quality score for each included study is provided in Appendix I.

Data Extraction

We created uniform evidence tables to extract data and facilitate data synthesis. We collected those data related to population characteristics, type of abnormal bleeding, intervention characteristics, and outcomes including harms.

We evaluated the ability to capture data across publications about candidate effect modifiers and confounders of treatment response and uniformly extracted information about candidates including age, body mass index, parity, and smoking status. When available we also collected current and prior contraception, perimenopausal status, fibroid status, and comorbidities including diabetes and PCOS. The final evidence tables are provided in Appendix J.

Data Synthesis

A meta-analysis was not feasible for this review. Few studies had comparable treatment doses, interval, length of treatment, or duration of followup. Among those that did, the ability to aggregate data was limited by differences in outcomes measures which included measures of blood loss from sanitary product collection, and self-report using scoring systems including standardized pictorial systems.

For regularity of bleeding no two measures of outcome were the same. We provide a narrative synthesis of the available data from original research studies of acceptable quality for nonsurgical treatment of AUB.[46] We group findings and summary tables by KQ, intervention, and outcomes.

Strength of the Body of Evidence

The strength of evidence evaluation is stipulated in the Methods Guide for Effectiveness and Comparative Effectiveness Reviews.[41,47] The guide emphasizes the following four major domains: risk of bias (low, medium, high); consistency (inconsistency not present, inconsistency present, unknown or not applicable); directness (direct, indirect); and precision (precise, imprecise) of the evidence. Risk of bias was derived from the quality assessment of the individual studies that addressed the KQ and specific outcomes under consideration.

We used explicit criteria for rating the overall strength of the evidence on each intervention into qualitative categories (e.g., low, moderate, high, and insufficient). We used established concepts of the quantity of evidence (e.g., numbers of studies, aggregate ending-sample sizes),

the quality of evidence (i.e., from the quality ratings on individual articles), directness of the outcomes for informing the KQs, and the coherence or consistency of findings across similar and dissimilar studies and in comparison to known or theoretically sound ideas of clinical or behavioral knowledge. For this CER, overall strength of evidence for each intervention was made based upon a qualitative consideration of the assessment for each domain.

We assessed the overall strength of evidence rating based on the assessments for the individual domains for cycle regularity (KQ1A) and menstrual blood loss (MBL) reduction KQ1B. Data from studies that were considered to be fair or good quality were included in the assessments. Poor quality studies were identified but not included in the assessment of strength of evidence. For KQ2, we did not rate of strength of evidence because a fully inclusive assessment of harms could not be completed for each of the 12 interventions that have been widely studied in populations that lack direct applicability to this report.

The overall strength of evidence was graded as "high", "moderate", "low", or "insufficient" (Table 3).[47] When no studies were available for an outcome or comparison of interest, or if the available evidence was weak (i.e. from studies with high risk of bias) we graded the evidence as insufficient.

Two senior investigators independently graded the body of evidence and final assignment was reviewed with the project team. We achieved alignment through group discussion with careful attention to application of consistent standards across each area item being graded.

Table 3. Strength of evidence grades and definitions

Grade	Definition
High	We are very confident that the estimate of effect lies close to the true effect for this outcome. The body of evidence has few or no deficiencies. We believe that the findings are stable.
Moderate	We are moderately confident that the estimate of effect lies close to the true effect for this outcome. The body of evidence has some deficiencies. We believe that the findings are likely to be stable, but some doubt remains.
Low	We have limited confidence that the estimate of effect lies close to the true effect for this outcome. The body of evidence has major or numerous deficiencies (or both). We believe that additional evidence is needed before concluding either that the findings are stable or that the estimate of effect is close to the true effect.
Insufficient	We have no evidence, we are unable to estimate an effect, or we have no confidence in the estimate of effect for this outcome. No evidence is available or the body of evidence has unacceptable deficiencies, precluding judgment.

Applicability

We assessed applicability of the results gathered from the literature to the population of women with abnormal cyclic and irregular uterine bleeding according to EPC methods guidance.[48] Assessments of applicability were done to account for any factors limiting the ability to apply interventions to other populations or other settings, such as inadequate description of the intervention or failure to report followup data.

Using the patient, intervention, comparator, outcome, timing, and setting (PICOTS) framework, we identified factors that may limit the applicability of individual research studies. We summarized the applicability of the body of evidence and described key elements from the PICOTS framework that characterize the applicability of a body of studies.

Peer Review and Public Commentary

Experts in reproductive endocrinology and primary care treatment of women were invited to provide external peer review. The draft report was posted for 4 weeks to elicit public comment. We addressed all reviewer comments by revising the text as appropriate. Responses to peer and public review comments will be listed in the disposition of comments report. This report will be available on the AHRQ Web site 3 months after the posting of this final CER.

Results

Introduction

This chapter presents the results of the systematic review of the literature on primary care management of abnormal uterine bleeding (AUB). We present findings for Key Question 1 (KQ1) beginning with an overview of the content of the literature as a whole, followed by results and detailed analysis organized first by studies addressing irregular uterine bleeding (KQ1A) and then by studies addressing abnormal cyclic uterine bleeding (KQ1B). When there are distinct populations in which the interventions have been studied such as enrollment based on differing criteria, we discuss related data together. Within KQs we present summary information in the order: devices, medications, lifestyle and behavioral interventions, and complementary and alternative medicine. Within a category such as medication, we organize the results from greater number of studies to fewer, and presented the results of placebo controlled trials before direct comparisons. These analyses are followed by review of the studies and supplemental information addressing KQ2, which pertains to harms associated with the interventions identified for KQ1.

Studies also are described in summary tables, generally organized to present particular common outcomes, like change in volume of bleeding, in a single summary in the relevant section of text. Details on quality assessment and individual components of the quality scoring for individual studies can be found in Appendix I. Information about the overall strength of evidence supporting the effectiveness of specific interventions (or lack of utility) is summarized by related outcomes in the Discussion.

Results of Literature Searches

Searches identified 1,775 titles and abstracts for screening for KQ1. From this broad screening, we reviewed the publication abstracts and identified 219 publications as potentially eligible for inclusion. Following a review of the full text, we identified 39 studies described in 41 publications that met the predetermined criteria for inclusion. Publications from 10 studies addressed KQ1A. Thirty-one publications from 29 studies addressed KQ1B. Overall 6 of these studies were rated as good quality, 10 as fair, and 23 as poor with regard to risk of bias in the findings. Details of the scoring of individual publications are included in Appendix I.

We conducted a separate search and screening process for KQ2. We identified 2,730 titles and abstracts for screening. Of these, 788 references were promoted for full-text review. Using predefined criteria, we found 25 publications that were eligible for inclusion. We received 4 of 17 requested industry packets and obtained package inserts for each KQ1 included drug intervention. See Figures 2 (KQ1) and 3 (KQ2) for a diagram of literature search and screening.

The complete list of excluded papers and exclusion reasons is provided in Appendix K for KQ1 and in Appendix L for KQ2.

Figure 2. Flow diagram of literature search and screening (KQ1)



KQ = Key Question; RCT = randomized controlled trial
[a]After duplicates removed.
[b]Total does not equal number excluded as publications could be excluded for multiple reasons.

Figure 3. Flow diagram of literature search and screening (KQ2)



KQ1 = Key Question 1; LNG-IUS = levonorgestrel-releasing intrauterine system; TXA = tranexamic acid; CVR = contraceptive vaginal ring

[a]Total does not equal number excluded as publications could be excluded for multiple reasons.

[b]Numbers do not tally as papers could include data on harms for more than one intervention.

Description of Included Studies

Included studies evaluated 12 different interventions including: levonorgestrel-releasing intrauterine system (LNG-IUS), nonsteroidal anti-inflammatory drugs (NSAIDs), combined oral contraceptives (COCs), tranexamic acid (TXA), contraceptive vaginal ring, metformin, exenatide, progestogens, cabergoline, lifestyle/behavioral changes, acupuncture, and decision aids using at least one comparator or placebo arm. Table 4 includes a complete list of the medications from the included studies. Twenty-one studies were head-to-head comparisons and 14 of the included studies established intervention efficacy by comparison to placebo. Four studies compared the intervention to usual or existing care. The majority of studies (29 studies reported in 31 publications) included in this review recruited women with complaints of abnormal cyclic uterine bleeding (KQ1B). Ten of the included studies targeted women with irregular uterine bleeding (KQ1A). Fourteen studies (36 percent) included some measure of patient reported outcome. Sixteen studies (41 percent) included some measure of symptom resolution or normalization.

The duration of the studies included in this review was generally short. Studies addressing KQ1A had a duration of 6 months or less with most (7/10) lasting 3 to 4 months. For KQ1B, study duration ranged from 2 cycles to 2 years. The majority of the studies (22/29) evaluating an intervention for abnormal cyclic bleeding lasted 6 months or less. Two studies that compared the effectiveness of LNG-IUS with COC lasted for 1 year. Of the two studies on the use of decision aids, one included a 1-year followup and the other included a 2-year followup.

We did not identify publications that explicitly focused on reducing heavy menstrual blood loss (MBL) in the context of irregular menses, especially menses with extended intervals between episodes of bleeding. The publications included for KQ1A are focused exclusively on irregular bleeding patterns, most often oligomenorrhea (fewer cycles than normal across months). Studies that met the criteria for inclusion for KQ1A evaluated progestogens (1 study),[49] COCs (1 study),[50] metformin (4 studies),[51-53,54] exenatide (1 study),[53] cabergoline (1 study),[55] diet (1 study),[56] and exercise (1 study),[57] and acupuncture (2 studies).[57,58] These total to more than 10 since several were direct comparisons. Two studies were good quality,[50,55] 2 were fair quality,[51,58] and 6 were poor quality.[49,52-54,56,57]

For KQ1B, most of the included studies evaluated LNG-IUS (7 studies),[59-65] NSAIDs (13 studies)[63,66-77] or TXA (7 studies).[66,71,77-81] We identified 5 studies[59,61,68,82,83] that evaluated the use of COCs for the management of AUB and 1 study of the contraceptive vaginal ring.[84] We found 3 studies[85-87] that evaluated decision aids for the management of AUB. Included studies evaluated the effect of these interventions on MBL, quality of life, menstrual cycle patterns, and other clinical and functional outcomes. Among the most common outcome metrics was change in MBL expressed as a percent. This was typically reported as a comparison of post-treatment blood loss to baseline. The alkaline hematin method and the pictorial blood loss assessment chart score were used to measure MBL. The alkaline hematin method, the current gold standard for estimating MBL, requires women to collect their used feminine hygiene products; consequently, it is rarely used outside of a research setting.[88,89] The pictorial blood loss assessment chart score is a practical, semi quantitative method of estimating MBL, in which women indicate the type of product used and the degree of saturation using a chart for guiding classification.[90-92]

For KQ2, we identified 23 publications reporting on harms of the included interventions. We also reviewed and summarized harms reported in the randomized controlled trials (RCTs) from KQ1 and from the package inserts for all products and prescription interventions included in KQ1.

Table 4. Medications from studies included in the CER

Medication	Brand Name
Levonorgestrel-releasing intrauterine system	Mirena®
Contraceptive vaginal ring	NuvaRing®
Antifibrinolytic Agents	
Tranexamic acid, oral	Lysteda®
Combined Oral Contraceptives, Oral	
Estradiol valerate and dienogest, oral	Natazia®
Ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg), oral	Nordette®, Altavera®, Levora®, Marlissa®, Portia® 28
Ethinyl estradiol (0.20 mg) and norethindrone acetate (1.0 mg), oral	Loestrin® 21 1/20, Junel® 1/20, Microgestin® 1/20, Minestrin® 1/20
Norgestimate ethinyl estradiol (triphasic), oral	Ortho Tri-Cyclen®, Tri-Sprintec®, Tri-Previfem®, MonoNessa®, Ortho Tri-Cyclen® Lo, Ortho-Cyclen®, Sprintec®, TriNessa®
Progestogens	
Dydrogesterone, oral	Gynorest® International brand names: Dabroston, Dufaston, Duphaston®, Terolut
Medroxyprogesterone acetate, injectable suspension	Depo-Provera® CI, Depo-subQ Provera 104
Medroxyprogesterone acetate, oral	Provera®
Norethisterone/norethindrone, oral	Aygestin®
Progesterone, vaginal gel	Crinone®
Nonsteroidal Anti-Inflammatory Drugs	
Flurbiprofen, oral	Ansaid®
Meclofenamate	Meclomen®
Mefenamic acid, oral	Ponstel®
Naproxen sodium, oral	Naprosyn®, Anaprox® DS, Anaprox®, Naprosyn® Suspension, EC-Naprosyn®, Various OTC brands
Other	
Cabergoline, oral	Dostinex®
Exenatide, injection	Byetta®
Ethamsylate, etamsylate	International brand names: Altodor, Dicinone, Dicynene, Dicynone, Eselin®, Ethamsyl, Hemo 141, Hemoced, Impedil
Metformin hydrochloride, oral	Glucophage®, Glucophage XR®, Fortamet®, Glumetza®

KQ1A. Management of Irregular Uterine Bleeding

Description of Included Studies

As noted in the description of the overall literature yield for this review, we did not identify publications that explicitly focused on mitigating the heaviness of irregular uterine bleeding. Symptoms like gushing or soaking type bleeding commonly occur in the context of irregular menses, especially menses with extended intervals between episodes of bleeding. The publications available to be included for this KQ focused on improving the regularity of bleeding and enrolled participants with bleeding categorized by the research teams as "dysfunctional uterine bleeding" or irregular bleeding with oligomenorrhea (i.e., fewer cycles than normal).

Studies were included whether or not participants reported menorrhagia (heavy bleeding) as long as the authors reported on the use of the intervention to improve cycle regularity. We did

not review the literature on infertility or subfertility resulting from absent or infrequent ovulation, even when it included cycle regularity data. Interventions for fertility treatment in this group, like clomiphene, are distinct from those for symptom management used in primary care settings. Likewise research populations of infertile women likely lack comparability to the broader population of women whose primary complaint is irregular cycles and may include women with subfertility who are seeking treatment for problem bleeding.

Overall 10 studies addressed restoring menstrual regularity in those with irregular uterine bleeding. Three were conducted in the United States,[50,53,56] two in Italy,[52,55] two in Turkey,[49,54] and one each in China,[58] Sweden,[57] and the United Kingdom.[51] The studies ranged in size from 23 to 201 participants and examined the efficacy of metformin (4 studies),[51-54] acupuncture (2 studies),[57,58] diet and exercise (1 study),[56] cabergoline (1 study),[55] progestogen (1 study),[49] and triphasic birth control pills (1 study).[50] Two studies were classified as good quality,[50,55] two as fair quality,[51,58] and six as poor quality[49,52-54,56,57] with respect to risk of bias in the assessment of effectiveness of the intervention of improving cycle regularity. Details of quality scoring for individual publications are included in Appendix I.

Overall these 10 studies, that included women with irregular uterine bleeding, offer incomplete evidence that medications, possibly diet and exercise, and potentially acupuncture may offer some benefit for establishing more predictable menstrual bleeding patterns. They provide no direct evidence about the ability to reduce the heaviness of bleeding or the symptoms and bother associated with intermittent heavy bleeding because quantity of bleeding and patient-reported outcomes other than timing of bleeding were not among the outcomes for these trials.

Key Points

- Metformin improves regularity of menstrual bleeding in women with polycystic ovarian syndrome (PCOS) when evaluated over months. When combined with exenatide, a newer injectable drug typically used for type 2 diabetes, the effect is greater than either metformin or exenatide alone over 6 months of followup in a single study of 60 women.
- In a very preliminary investigation of cabergoline, a drug typically used for elevated prolactin, three of eight women with PCOS and normal prolactin levels resumed regular cycles while none did in the six-person placebo group.
- Both oral dydrogesterone and vaginal micronized progesterone gel administered on a cyclic schedule had comparable influence on normalizing timing of menses.
- Triphasic norgestimate-ethinyl estradiol birth control pills provided excellent or good control of bleeding abnormalities in 68 percent of those taking active pills compared with 26 percent of those receiving placebo.
- In adolescents both a low-fat, calorie-restricted diet or a carbohydrate-restricted diet along with 30 minutes of anaerobic exercise 3 days a week resulted in more regular menses if the individual lost weight.
- Acupuncture improved cycle regularity in two trials, one in which both acupuncture and exercise (30 minutes 3 days each week) resulted in improvements by 32 weeks compared with placebo. In this study acupuncture provided more rapid relief by 16 weeks than exercise. Another poorly-described study found more individuals “cured” using needle placement specific for mind tranquilizing and menstruation promotion compared with those for delayed menses.
- In summary a number of available interventions appropriate for use in primary care settings have preliminary evidence of effectiveness for increasing the regularity of

menses. Only metformin consistently demonstrated benefit across studies and each of these studies enrolled women with oligomenorrhea and PCOS.
- Overall, literature is absent to inform choice of any of these modalities over another.

Detailed Synthesis

Medical Therapies

Seven studies, two conducted in the United States, two in Italy, two in Turkey, and one in the United Kingdom examined medical therapies to improve menstrual interval.[49-55] Five included women who met detailed criteria for PCOS[51-55] and two included women classified as having dysfunctional uterine bleeding by clinical criteria that are not tightly operationalized but include extended intervals between cycles.[49,50] We first present the findings for the RCTs that enrolled women with irregular uterine bleeding and then the data from PCOS trials.

Medical Therapies for Irregular Uterine Bleeding

Two studies, one comparing a triphasic oral contraceptive with placebo and one comparing vaginal micronized progesterone (8% gel) with oral dydrogesterone, evaluated medical therapy in women with irregular uterine bleeding (Table 5).

Table 5. Primary outcomes of medical interventions for irregular uterine bleeding

Author, Year Country Quality	Comparison Groups (n)	Key Cycle Control Outcomes
Davis et al., 2000[50] United States Good	**G1:** Triphasic norgestimate-ethinyl estradiol oral contraceptive (101) **G2:** Placebo (100)	• Study population included women with oligomenorrhea, menorrhagia, menometrorrhagia, and polymenorrhea. • Investigators classified resolution of bleeding abnormalities from diaries as excellent or good in 41.2% and 26.8% of those receiving intervention and 10.5% and 15.8% of those on placebo (p<0.001). • Women's self-assessments were similar to the investigators' and indicated better outcomes in those receiving the oral contraceptive (p<0.001).
Karakus et al., 2009[49] Turkey Poor	**G1:** Vaginal micronized progesterone, 90 mg every other night for 10 days (34) **G2:** Oral dydrogesterone, 10 mg daily for 10 days (35)	• Both groups achieved comparable regularity of bleeding patterns in the 3 treated cycles observed: 92.6%, 88.9%, and 92.6% in the vaginal group, and 81.5%, 88.9%, and 85.2% in oral group (p>0.5). • Satisfaction with intervention was comparable between groups (p=0.5).

Triphasic Oral Contraceptives

Oral contraceptives over-ride the hypothalamic-pituitary-ovarian axis coordination of ovarian sex steroid production. By providing exogenous estrogen and progestogen, oral contraceptives are intended to regulate cycle control pharmacologically. A single RCT[50] evaluated a triphasic norgestimate-ethinyl estradiol preparation compared with placebo among women classified as having dysfunctional uterine bleeding. Triphasic oral contraceptives have three distinct levels of progestogen (norgestimate in this study) and estrogen (ethinyl estradiol) over the course of the 21 days of active pills in a typical 28 day oral contraceptive pill pack, compared with monophasic pills which have the same hormone level provided across all 21 days of active pills.

The researchers randomized 201 women at a 1:1 ratio to receive either the study drug or placebo for three 28-day cycles. Data from 192 patients were included in the outcome analyses.

The study enrolled participants with a variety of menstrual concerns including heavy periods, frequent periods, irregular and heavy periods, and rare episodes of bleeding. Investigators did not systematically evaluate for the presence of disorders of hemostasis. The data are provided in aggregate for all participants regardless of their bleeding pattern or primary symptom. The study drug regimen included 0.18 mg norgestimate and 0.035 mg ethinyl estradiol for days 1 to 7, 0.215 mg norgestimate and 0.035 mg ethinyl estradiol for days 8 to 14, 0.25 mg norgestimate and 0.035 mg ethinyl estradiol for days 15 to 21, and inactive tablets for days 22 to 28. The primary efficacy outcomes included the investigator and the subject's overall assessment of improvement in AUB symptoms.

Both the investigator assessments and subject assessments of symptom improvement indicated significant ($p<0.001$) improvement in cycle control in the study drug group compared with the placebo group. The investigator assessed some level of subject improvement (fair, good, or excellent) in 81.4 percent of triphasic norgestimate ethinyl estradiol-treated patients as compared with 35.8 percent of placebo-treated patients; the proportions of subject-rated improvement were similar to investigator ratings. Among several quality of life measures assessed, improvement over baseline was only observed in physical functioning in the triphasic norgestimate ethinyl estradiol-treated patients compared with their placebo-treated counterparts.

This good quality, multicenter, industry-sponsored trial was conducted in the United States and appears to have been conducted to expand the indication for a particular brand name to include cycle control for women with dysfunctional uterine bleeding. The trial was published in 2000 and was the only study identified that included women with problem bleeding from irregular and closely spaced or rare menses.

Progestogens

Prior to menses without ovulation the sequence of biologic events that includes a rise in progesterone and then a precipitous drop does not occur. This is because the literal site of ovulation, the corpus luteum, is responsible for production of progesterone. In the absence of conception, the corpus luteum involutes and ceases production. This rise and fall in progesterone has multiple biological effects on the endometrium which include "organization" that results in a coordinated withdrawal bleed, the menses, after progesterone levels fall. Administration of a progestogen is intended therapeutically to mimic natural production of progesterone and then withdrawal.

A single RCT sought to compare the efficacy of oral dydrogesterone, 10 mg twice daily for 10 days starting on cycle day 15, compared with vaginal micronized progesterone (8 percent gel) applied every other evening from cycle days 17 to 27. Both groups had improvements in cycle regularity compared with their baseline (p value not provided).[49] Regular bleeding patterns were observed in more than 89 percent of the three treated cycles in the vaginal administration group, and more than 82 percent of the oral group. Improvement in bleeding patterns was comparable for both groups ($p>0.5$). Satisfaction with the intervention was also comparable across groups.

Medical Therapies for PCOS

Three medical therapies (metformin, exenatide, and cabergoline) were evaluated in five trials that enrolled women with PCOS (Table 6). We present the findings from the study of cabergoline followed by findings from four studies that evaluated metformin or exenatide. In summary, each of the studies of medical therapies reported findings that favor the medical intervention for establishing more predictable cycles in women with PCOS. No medication was effective for all participants though several exceeded 80 percent of those on active therapy

achieving improvements in cycle regularity. The number and size of studies is small and overall the quality is fair to poor with one small pilot study of good quality design and implementation but limited by lack of statistical power.

Table 6. Primary outcomes of medical interventions for irregular uterine bleeding in women with PCOS

Author, Year Country Quality	Comparison Groups (n)	Key Cycle Control Outcomes
Paoletti et al., 1995[55] Italy Good	**G1:** Cabergoline, 0.5 mg each week (8) **G2:** Placebo (6)	3 of 8 women receiving cabergoline resumed regular cycles. 5 of 8 had onset of menses within 32 to 37 days of treatment initiation. Among women receiving placebo 3 had no menses and 3 had menstrual cycles that were widely separated in time. (No statistical comparisons are provided.)
Fleming et al., 2002[51] United Kingdom Fair	**G1:** Metformin, 850 mg twice a day (45) **G2:** Placebo (47)	Mean time to first ovulation was shorter with metformin (23.6 days) than placebo (41.8 days) (p=0.02). Total ovulation events where higher among women receiving metformin over 16 weeks (p=0.59). Pregnancy rate not different among those who desired to conceive (4 of 23 in G1 and 1 of 19 in G2).
Oner and Muderriss 2011[54] Turkey Poor	**G1:** Metformin, 500 mg 3 times a day (50) **G2:** N-acetyl-cysteine, 600 mg 3 times a day (50)	Menstrual regularity improved significantly (p≤0.05) from baseline in G1 (from 17% to 47%) and G2 (from 29% to 53%). There was no significant difference in improvement from baseline between G1 and G2.
Elkind-Hirsch et al., 2008[53] United States Poor	**G1:** Exenatide, 10 mcg twice a day (20) **G2:** Metformin, 500 mg twice a day (20) **G3:** Both (20)	The combination of exenatide and metformin was superior to either medication alone for improving menstrual frequency. Women taking both had 80% of menses predicted for a normal pattern, compared with 57% (G1) and 49% (G2).
Moghetti et al., 2000[52] Italy Poor	**G1:** Metformin, 500 mg twice a day (11)[a] **G2:** Placebo (12)[a]	Study enrolled women with fewer than 6 menses per year and followed for 26 weeks. "Menstrual frequency" improved with metformin compared with placebo (p=0.002).

[a]total n=23; exact group size not specified.

Cabergoline

Cabergoline is a dopamine agonist used in treatment of pituitary adenomas, which are benign hormone producing growths in the pituitary often producing elevated prolactin levels. Mechanism of effectiveness for restoring cycles in PCOS may include amplifying dopamine neurotransmitter actions in the central nervous system resulting in hypoprolactinemia and lower levels of hormone signals that increase androgen production by the ovary.[55]

One good quality RCT[55] conducted in Italy evaluated cabergoline for improving menstrual cyclicity. In this preliminary study of 14 women, authors compared time to onset of menses and regularity of cycle in women treated with cabergoline (0.5 mg per week) with women receiving placebo. No statistical comparisons are reported, only the summary that five of the eight women receiving cabergoline had menses with three of them resuming regular cycles over 4 months. All women taking placebo had either no cycles (n=3) or widely spaced cycles (n=3).

Metformin and Exenatide

Metformin, the most common choice for initial type 2 diabetes management, reduces liver glucose production and increases uptake and use of glucose in other tissues throughout the body. Because relative insulin resistance is one of the manifestations of PCOS, metformin is believed

to disrupt this part of the syndrome by improving insulin response. Exenatide, a newer agent for treatment of type 2 diabetes introduced in 2005, is administered by subcutaneous injection. This drug promotes increased insulin release in response to blood glucose and it dampens glucagon activity. Glucagon is the natural hormone which promotes glucose release from storage in the liver. It is often administered as a second agent to improve glycemic control in those with type 2 diabetes. As metformin, it may improve the relative insulin resistance seen in PCOS.

One British[51] and one Italian[52] RCT evaluated metformin compared with placebo for improving menstrual cycle regularity among women with PCOS defined by rare or absent menstrual cycles, and hyperandrogenic chronic anovulation. The larger trial in the United Kingdom enrolled 82 women and randomly assigned them to an 850 mg dose twice a day. As with typical administration the dose was initiated at a lower level and increased over a week to reduce risk of gastrointestinal distress. Over the course of 16 weeks those on metformin ovulated sooner, an average of 18.2 days earlier (p=0.02), than those receiving placebo. Those on metformin also had a higher total number of ovulatory events (p=0.059). The Italian study (n=23), used a metformin dose of 500 mg 3 times a day (also after a ramp up) and reported "menstrual frequency" improved (p=0.002), without additional definitions of the outcome.

A poor quality trial (n=100)[54] in Turkey compared metformin (500 mg 3 times a day) to N-acetyl-cysteine (600 mg 3 times a day) for improving menstrual regularity in women with PCOS. Menstrual regularity improved significantly ($p \leq 0.05$) from baseline in both groups with no significant difference in improvement between groups.

A third trial in the United States compared three arms with 20 participants in each: metformin (500 mg twice each day), exenatide (10 mcg twice a day), and both.[53] Participants were followed for 6 months. The primary outcome for this trial was the proportion of menses achieved over time compared with what would be a predicted normal pattern. For instance a woman predicted to have six menses over 6.5 months would have a menstrual index of 50 percent if she in fact had only three menses over that time. Women taking metformin had 57 percent of expected menstrual bleeds and those on placebo had 49 percent. Those taking both metformin and exenatide had 80 percent of the predicted normal number of menses which was a significant advantage in effectiveness.

Behavioral Interventions

A single, poor quality study in teens with PCOS in the United States (n=24), attempted to examine the influence of diet and exercise on restoration of normal menses (Table 7).[56]

Table 7. Primary outcomes of behavioral interventions for irregular uterine bleeding in women with PCOS

Author, Year Country Quality	Comparison Groups (n)	Key Cycle Control Outcomes
Ornstein et al., 2011[56] United States Poor	**G1:** Hypocaloric low-fat diet (12) **G2:** Carbohydrate restriction without caloric or fat targets (12)	Both groups were asked to complete 30 minutes of aerobic exercise 3 times per week. Both lost similar amounts of weight over 12 weeks. Menstrual patterns are not reported by group. Amount of weight loss correlated with menstrual regularity.

Diet and Exercise

The rationale for examining the effects of diet and exercise is based on similar effects to the diabetes medications studied. Exercise improves glucose utilization and insulin sensitivity.

Likewise diet, with even modest weight loss, can improve insulin response. The study advised girls in both intervention groups to spend 30 minutes in aerobic activity 3 times each week. One arm was instructed in how to keep a hypocaloric diet, consisting of less than 40 grams per day of fat. The other group was instructed in how to follow a low-carbohydrate (i.e., no more than 20 grams per day) diet without specific calorie targets or fat restriction. Among the 16 who completed the study, both groups lost comparable amounts of weight over 12 weeks, an average of 6.5 percent of bodyweight. The authors did not report menstrual patterns by diet treatment group; they report only that degree of weight loss correlated with menstrual regularity ($r= -0.2$, $p=0.001$).[56]

Complementary and Alternative Medicine

Two trials, one of fair quality[58] and another of poor quality,[57] report on use of acupuncture for menstrual regularity among women with oligomenorrhea from PCOS and dysfunctional uterine bleeding, respectively (Table 8).

Table 8. Primary outcomes of acupuncture for irregular uterine bleeding

Author, Year Country Population Quality	Comparison Groups (n)	Key Cycle Control Outcomes
Cai and Wu, 2009[58] China Dysfunctional uterine bleeding Fair	**G1:** Acupuncture at points for mind tranquilizing and menstruation promotion (23) **G2:** Routine acupuncture points for delayed menses (17)	Based on self-reported scores, 67% of G1 were classified as cured compared with 19% of G2 over 3 cycles. 25% of G1 classified as markedly relieved compared with 19% of G2. There were no failures in G1 and 19% in G2 ($p<0.05$).
Jedel et al., 2011[57] Sweden PCOS Poor	**G1:** Low-frequency electroacupuncture (33) **G2:** Brisk exercise at least 30 minutes 3 days per week (34) **G3:** No active intervention (17)	Electroacupuncture achieved greater improvement in regularity (+146% from baseline) compared with G2 (58% improvement) and G3 (17% worsening). All comparisons $p<0.05$ at 16 weeks. By 32 weeks, electroacupuncture (+121% increase in cycle regularity) and exercise (+42%) were comparable and both superior to no intervention (−17%).

PCOS = polycystic ovarian syndrome

Acupuncture

The smaller study (n=40)[58] inadequately describes inclusion criteria specifying only that women were clinically diagnosed with dysfunctional uterine bleeding, and likewise operationalizes outcomes loosely by classifying participants as "cured" or not without providing a definition of what characteristics of the menstrual pattern or bleeding constituted a cure. The intervention of interest to the investigators was acupuncture for mind tranquilizing and menstruation promotion compared with a more conventional selection of needle sites used for delayed menses. Over three cycles more women were classified as cured using the mind-tranquilizing and menstruation promoting method (67% vs.19%); more women classified symptoms as markedly relieved, and there were no failures in the intervention compared with the usual approach arm (19%,, $p<0.05$).

The larger, poor quality study done in Sweden (n=84)[57] randomized participants to low-frequency electroacupuncture for a total of 14 treatments, brisk exercise 30 minutes 3 times each week, or no active intervention. At 16 weeks electroacupuncture achieved greater improvement in menstrual regularity, defined as a ratio of the number of observed versus expected cycles.

Women began the study with a ratio of 0.28 menses per expected cycle and improved in the electroacupuncture group to 0.69 menses per expected cycle a 146-percent increase in cycle regularity when compared with either exercise (58% improvement) or no active intervention (17% worsening) at 16 weeks. By 32 weeks, electroacupuncture (121% increase in cycle regularity) and exercise (42% increase in cycle regularity) were comparable and both superior to no intervention (17% decrease in cycle regularity).

KQ1B. Management of Abnormal Cyclic Bleeding

Description of Included Studies

We identified 31 publications representing 29 studies addressing primary care interventions for the management of abnormal cyclic uterine bleeding. Most of the studies that qualified for inclusion evaluated the LNG-IUS (7 studies),[59-65] NSAIDs (13 studies),[63,66-77] or TXA (7 studies).[66,71,77-81] We identified five studies[59,61,68,82,83] that evaluated use of COCs for the management of AUB and one study of the contraceptive vaginal ring.[84] We found three studies[85-87] that evaluated decision aids for the management of AUB. The total number of interventions addressed is greater than the number of studies because of direct comparisons between one or more interventions within single studies. Included studies described interventions appropriate for primary care and compared these interventions to another intervention (16 studies), placebo (9 studies), or usual care (4 studies). The results are summarized below and details for each study are presented in the Evidence Table (Appendix J).

Levonorgestrel-Releasing Intrauterine System (Mirena®)

Key Points

- LNG-IUS is associated with a clinically significant reduction in MBL ranging from 70 to 87 percent in studies lasting up to 1 year. However, there are no controlled longer-term followup studies.
- In comparison to progestogens, combined hormonal pills, and NSAIDs, LNG-IUS provided greater reduction in MBL.
- No head-to-head comparisons of LNG-IUS versus TXA were assessed. An indirect comparison of the percentage reduction and volume reduction in MBL suggests that LNG-IUS has a greater effect than TXA.

Detailed Synthesis

The LNG-IUS is an intrauterine, long-term, progestogen-only method of contraception licensed for 5 years of use. The system must be inserted and removed by a qualified practitioner, including primary care providers. The LNG-IUS has a T-shaped plastic frame with a rate-limiting membrane on the vertical stem that releases a daily dose of 20 micrograms of levonorgestrel into the endometrial space. The effects of the LNG-IUS are local and hormonal, including prevention of endometrial proliferation. The LNG-IUS is also licensed for the management of idiopathic menorrhagia or heavy menstrual bleeding.

Seven RCTs of LNG-IUS were included (Table 9).[59-65] The number of study participants ranged from 39 to 165. The total number of women assigned to LNG-IUS was 275; study endpoint outcome measures were reported for 255.

Criteria for participation varied among the studies. Three trials assessed MBL using the alkaline hematin method for study entry and required that women have a mean MBL of 80 ml or more for at least one[63,64] or two [60] cycles prior to randomization. One study required that study participants report a pictorial blood loss assessment chart score greater than 100 for two consecutive cycles. For one trial, the inclusion criterion was self-defined as “heavy menstrual bleeding", although mean MBL and pictorial blood loss assessment scores were reported at baseline.[59] For one trial the inclusion criterion was intention to undergo hysterectomy for AUB not due to a fibroid greater than 3 cm.[65] In one trial, the authors did not adequately describe the inclusion criteria, although organic causes were excluded.[62] Baseline median and mean MBL values differed among the studies.

The target intervention was the same for all seven trials: LNG-IUS (52 mg levonorgestrel, initial release rate 20 mcg per 24 hours). The comparator differed among the 7 trials. Two trials compared LNG-IUS to a COC, including continuous daily ethinyl estradiol (30 mcg)/levonorgestrel (150 mcg)[59] and cyclic monthly norethindrone acetate (1 mg)/ethinyl estradiol (20 mcg) for days 1 to 21.[61] Three trials compared LNG-IUS with a progestogen: single intramuscular injection of depot medroxyprogesterone acetate (DMPA) on the first day of the cycle,[62] oral tablet of medroxyprogesterone acetate (MPA; 5 mg) daily starting on the first day of the cycle,[62] oral MPA (10 mg) daily for 10 days each cycle starting on cycle day 16,[60] and norethisterone (5 mg) 3 times daily from cycle day 5 to 26 for three cycles.[64] One trial compared LNG-IUS with oral mefenamic acid (500 mg) 3 times daily for first 4 days of each cycle.[63] One trial assigned the patients in the control group to continue their preexisting medical treatment for excessive uterine bleeding or symptoms of dysmenorrhea, or both.[65]

The primary outcome of six of the LNG-IUS studies was change in blood loss. The alkaline hematin method was used to measure MBL in four trials.[59,60,63,64] One of these four reported both mean and median MBL.[60] Two studies only reported median MBL[63,64] and one study only reported mean MBL.[59] Two trials used the pictorial blood loss assessment score for the primary outcome measure.[61,62] Two trials used the pictorial blood loss assessment chart as a secondary outcome measure.[59,63] One study reported the proportion of women who cancelled their prior decision to undergo hysterectomy as the primary outcome measure.[65]

The timing of the summative outcome measure reporting varied among the trials. One trial reported after one menstrual cycle.[64] Three trials reported after three menstrual cycles.[60,63,64] Four trials reported after six menstrual cycles.[60,62,63,65] Two trials reported after 12 months.[59,61]

The setting varied: one trial was conducted in three countries (Brazil, Canada, and the United States);[60] two trials were conducted in the United Kingdom;[63,64] the remainder of studies were conducted in Egypt,[59] Canada,[61] Turkey,[62] and Finland.[65] Two studies were assessed as fair quality,[60,64] and five were of poor quality related to inadequate allocation concealment, lack of blinding of participants and assessors, and selective outcome reporting.[59,61-63,65] Details of quality scoring for individual publications are included in Appendix I.

Table 9. Primary outcomes of LNG-IUS for abnormal cyclic uterine bleeding

Author, Year Country Quality	Comparison Groups (n)	Key Outcomes
Kaunitz et al., 2010[60] United States, Canada, Brazil Fair	**G1:** LNG-IUS (82) **G2:** MPA,10 mg daily for 10 days of each cycle (83)	• Median reduction in MBL (alkaline hematin) was −128.7 ml in G1 compared with −17.8 ml in G2 after 6 cycles (p<0.001). • Higher proportion of women with successful treatment (defined as MBL<80 ml and 50% or greater reduction in MBL from baseline) in G1 (84.8%) compared with G2 (22.2%) (p<0.001).
Irvine et al., 1998[64] United Kingdom Fair	**G1:** LNG-IUS (22) **G2:** Norethisterone, 5 mg 3 times daily on cycle day 5 to 26 (22)	• MBL decreased significantly in both groups after 3 cycles (94% reduction for G1 and 87% reduction for G2). • More women in G1 (76%) wished to continue treatment after 3 months as compared with G2 (22%).
Shaaban et al., 2011[59] Egypt Poor	**G1:** LNG-IUS (56) **G2:** Low-dose COC, 30 mcg ethinyl estradiol and 150 mcg levonorgestrel (56)	• MBL assessed by alkaline hematin method significantly (p<0.001) decreased in both groups from baseline. • Greater reduction in MBL measured by alkaline hematin method at 12 months in G1 (87.4 ± 11.3%) compared with G2 (34.9 ± 76.9%) (p=0.01). • PBLAC scores decreased more in G1 (86.6 ± 17.0%) compared with G2 (2.5 ± 93.2%) at 12 months (p<0.001). • Women in G1 had significant improvements in ferritin and hemoglobin at 12 months. • Fewer bleeding days per year in G1 (34.5 ± 12.0) compared with G2 (65.1 ± 15.3) (p<0.001).
Endrikat et al., 2009[61] Canada Poor	**G1:** LNG-IUS (20) **G2:** COC, 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (19)	• PBLAC score decreased significantly (p<0.001) in both groups at 12 months. • The MBL median score decreased more in G1 (from 228 to 13, −83% mean change) compared with G2 (from 290 to 72, mean change −68%) (p=0.002). • Proportion of women with successful treatment (defined as MBL score<100 at 12 months) higher in G1 (80%) compared with G2 (37%) (p<0.009). • Mean hemoglobin levels increased in both groups from baseline (p<0.001).
Kucuk and Ertan, 2008[62] Turkey Poor	**G1:** LNG-IUS (44) **G2:** DMPA, single shot (44) **G3:** MPA, 5 mg daily (44)	• More women in G1 (86%) with successful treatment compared with G2 (75%) or G3 (68%). • PBLAC scores, days of menstrual bleeding, and hemoglobin improved in all 3 groups from baseline. • Mean MBL scores at 6 months were lower in G1 (77) compared with G2 (146) and G3 (154) (p<0.01).

Table 9. Primary outcomes of LNG-IUS for abnormal cyclic uterine bleeding (continued)

Author, Year Country Quality	Comparison Groups (n)	Key Outcomes
Reid and Virtanen-Kari, 2005[63] United Kingdom Poor	**G1:** LNG-IUS (25) **G2:** Mefenamic acid, 500 mg 3 times per day for first 4 days of cycle (26)	• MBL significantly reduced in both groups from baseline. • After 6 months median MBL was 5 ml in G1 compared with 100 ml in G2 (p<0.001).
Lahteenmaki et al., 1998[65] Finland Poor	**G1:** LNG-IUS (28) **G2:** Usual care (28)	• Proportion of women cancelling hysterectomy was 64% in G1 vs. 14.3% in G2 (p<0.001).

COC = combined oral contraceptive; DMPA = depot medroxyprogesterone; LNG-IUS = levonorgestrel-releasing intrauterine system; MBL = menstrual blood loss; MPA = medroxyprogesterone; PBLAC = pictorial blood loss assessment chart

Description of Results

Outcome Measures

All but one of the LNG-IUS studies reported MBL using the alkaline hematin method or pictorial blood loss assessment score as the primary outcome. Four trials[59,60,63,64] used the alkaline hematin method to measure MBL and four trials used the pictorial blood loss assessment chart to estimate blood loss.[59,61-63] Two studies also reported treatment success as an outcome, defined as MBL less than 80 ml[60] or pictorial blood assessment score less than 100.[61] One trial reported the proportion of women who cancelled their prior decision to undergo hysterectomy as the primary outcome measure.[65] Other outcome measures reported in the studies of LNG-IUS included total bleeding and spotting days, hemoglobin, ferritin, treatment failure, and menorrhagia severity score.

Menstrual Blood Loss

Reduction Expressed as a Percent

Three studies reported the percent reduction in MBL from baseline (Table 10). A fair quality multicenter trial with 165 participants compared LNG-IUS with oral MPA administered during the luteal phase of the cycle and reported a mean reduction in MBL of 71 percent (SD ± 88%) in the LNG-IUS group compared with 22 percent (SD ± 36%) in the MPA group at the 6-month interval (p<0.001).[60] In a small fair quality RCT conducted in the United Kingdom,[64] the change in MBL was comparable between groups after 3 months of treatment with a 94-percent reduction in MBL for LNG-IUS users and an 87-percent reduction in MBL among women taking norethisterone.

A trial conducted in Egypt with 112 participants compared LNG-IUS with continuous combined ethinyl estradiol (30 mcg) and levonorgestrel (150 mcg; continuous COC) and reported an 87-percent (SD ± 12%) reduction in mean MBL in the LNG-IUS group compared with a 35-percent (SD ± 77%) reduction in the COC group at the 12-month interval (p=0.013).[59]

Table 10. Percent change in blood loss from baseline in studies of LNG-IUS

Author, Year	Comparator	LNG-IUS Group	Comparator Group	LNG-IUS vs. Comparator
Kaunitz et al., 2010[60]	MPA[a]	−70.8	−21.5	p<0.001
Irvine et al., 1998[64]	Norethisterone[b]	−94.0	−87.0	p=NS
Shaaban et al., 2011[59]	COC, continuous[c]	−87.4	−34.9	p=0.013

COC = combined oral contraceptive; MPA = medroxyprogesterone
[a]Oral medroxyprogesterone acetate (10 mg) once daily for 10 consecutive days starting on day 16 in each cycle.
[b]5 mg 3 times daily from day 5 to 26 of the cycle over three cycles.
[c]Ethinyl estradiol (30 mcg) and levonorgestrel (150 mcg).

Reduction Expressed as a Volume

Four studies reported the absolute reduction in MBL from baseline (Table 11). The multicenter trial with 165 participants reported a statistically significant (p<0.001) reduction in median MBL after six menstrual cycles with LNG-IUS (128.8 ml) compared with those receiving MPA (17.8 ml).[60]

The United Kingdom trial with 44 participants and 3 months duration reported similar reductions (p=NS) in median MBL for the LNG-IUS group (104 ml) and the norethisterone group (94 ml).[64]

The trial conducted in Egypt with 112 participants that compared LNG-IUS with continuous COC reported a statistically significant (p<0.001) reduction in mean MBL after 12 menstrual cycles with LNG-IUS (255.6 ml) compared with those receiving COC (156.1 ml).[59] A trial conducted in the United Kingdom with 51 participants that compared continuous LNG-IUS with mefenamic acid for the first 4 days of each cycle reported a statistically significant (p<0.001) difference in reduction in median MBL after six menstrual cycles with LNG-IUS (117 ml) compared with those receiving mefenamic acid (21 ml).[63] The same study reported a statistically significant reduction in median pictorial blood loss assessment chart score: a 215 point reduction after six cycles with LNG-IUS compared with a 74-point reduction with mefenamic acid (p<0.001).[63]

Table 11. Change in blood loss volume from baseline in studies of LNG-IUS

Author, Year	Comparator	LNG-IUS Group	Comparator Group	LNG-IUS vs. Comparator
Kaunitz et al., 2010[60]	MPA	−128.8 ml	−17.8 ml	p<0.001
Irvine et al., 1998[64]	Norethisterone	−104.0 ml	−94.0 ml	p=NS
Shaaban et al., 2011[59]	COC, continuous	−255.6 ml	−156.1 ml	p<0.001
Reid and Virtanen−Kari, 2005[63]	Mefenamic acid	−117.0 ml	−21.0 ml	p<0.001

COC = combined oral contraceptive; MPA = medroxyprogesterone
[a]Oral medroxyprogesterone acetate (10 mg) once daily for 10 consecutive days starting on day 16 in each cycle.
[b]5 mg 3 times daily from day 5 to 26 of the cycle over three cycles.
[c]Ethinyl estradiol (30 mcg) and levonorgestrel (150 mcg).

Pictorial Blood Loss Assessment Chart Score

Four studies reported change in pictorial blood loss assessment chart score from baseline. A poor quality Canadian trial with 39 participants compared LNG-IUS with 20 mcg ethinyl estradiol and 1 mg norethindrone acetate (cyclic COC) and reported an 83-percent reduction in the mean pictorial blood loss assessment chart score in the LNG-IUS group (median scores

declined from 228 to 12) compared with a 68-percent reduction in the cyclic COC group (median scores declined from 290 to 72) at 12 months.[61]

Another poor quality Turkish study of 132 women compared LNG-IUS use with either a single intramuscular injection of DMPA or with daily oral MPA. After 6 menstrual cycles, the LNG-IUS users had a mean score reduction of 210 compared with a reduction of 138 in the DMPA group ($p<0.01$), and a 76-point reduction in the MPA group ($p<0.01$). No significant difference was reported in the reductions in the pictorial blood loss assessment chart score between DMPA and MPA.[62]

The pictorial blood loss assessment was used in two trials that also measured MBL using the alkaline hematin method. One study reported a reduction in the mean pictorial blood loss assessment chart score of 90 percent (SD ± 12%) in the LNG-IUS group at the 6-month interval compared with a reduction of 42 percent (SD ± 54%) in the COC group.[59] At 12 months, the mean scores declined by 275 (87%) for LNG-IUS users compared with only 51 (3%) for the women taking COCs.[59] In another study, the change in median pictorial blood assessment scores from baseline was significantly greater ($p<0.001$) in the LNG-IUS group from 240 (range, 91 to 545) to 25 (range, 0 to 401) compared with the mefenamic acid group from 233 (range, 77 to 469) to 159 (range, 50 to 307) after six cycles of treatment. [63]

Treatment Success

Three studies reported the percent of women with successful treatment; however the definition of success differed among the trials. The fair quality multicenter trial with 165 participants that compared LNG-IUS with oral MPA reported a 85 percent (67/79) success rate in the LNG-IUS group at the 6-month interval, compared with a 22 percent (18/81) success rate in the MPA group ($p<0.001$).[60] Treatment success was defined as MBL less than 80 ml at the end of study and 50 percent or greater reduction in MBL from baseline.[60]

The poor quality Canadian trial with 39 participants that compared LNG-IUS with cyclic COC reported a treatment success of 80 percent (16/20) in the LNG-IUS group at the 12-month interval compared with 37 percent (7/19) in the cyclic COC group ($p<0.009$).[61] Treatment success was defined as a pictorial blood loss assessment chart score less than 100 at 12 months.[61]

The poor quality Turkish study that compared LNG-IUS with DMPA injection or oral MPA use reported treatment success rates of 86 percent, 75 percent, and 68 percent, respectively.[62] The criterion for determining treatment response was a pictorial assessment bleeding score less than 185 and stabilization or increase in hemoglobin levels.[62]

Total Bleeding Days and Total Spotting Days

The trial conducted in Egypt with 112 participants that compared LNG-IUS with continuous COC did not report baseline days of bleeding or spotting. The study did report that the endpoint number of bleeding days, adjusted for 1-year duration was 34.5 ± 12.0 for the LNG-IUS group and 65.1 ± 15.3 for the continuous COC group ($p<0.001$). The study also reported that the endpoint number of spotting days, adjusted for 1-year duration, was not different between the two groups.[59]

The trial conducted in Turkey with 132 participants that compared LNG-IUS with either a single intramuscular injection of DMPA or with daily oral MPA reported a statistically significant decrease in mean bleeding days after six menstrual cycles with all three interventions. No significant difference was reported in the decrease in bleeding days between LNG-IUS and DMPA and MPA.[62]

Hemoglobin

The trial conducted in Turkey with 132 participants that compared LNG-IUS with either a single intramuscular injection of DMPA or with daily oral MPA reported a statistically significant increase in hemoglobin after six menstrual cycles with all three interventions. The mean hemoglobin score was increased by 0.8 g/dl in the LNG-IUS group compared with 0.5 g/dl with DMPA ($p<0.05$) and compared with 0.6 g/dL with MPA ($p<0.05$). No significant difference was reported in the increase in hemoglobin between DMPA and MPA.[62]

The trial conducted in Egypt with 112 participants that compared LNG-IUS with continuous COC reported a statistically significant ($p<0.001$) increase in hemoglobin for the LNG-IUS group (1.2 g/dl) compared with the continuous COC group (−0.4 g/dl).[59] The United Kingdom trial with 44 participants reported no significant differences in hemoglobin changes over 3 months.[64] The Canadian trial with 39 participants that compared LNG-IUS with cyclic COC reported no significant differences in hemoglobin changes.[61]

Ferritin

The trial conducted in Egypt with 112 participants that compared LNG-IUS with continuous COC reported a statistically significant ($p<0.001$) increase in ferritin for the LNG-IUS group (56.7 mcg/dl) compared with the continuous COC group (−34.3 mcg/dl).[59] The United Kingdom trial with 44 participants and 3 months duration reported no significant differences in ferritin changes.[64]

Treatment Failure

The trial conducted in Egypt with 112 participants that compared LNG-IUS with continuous COC defined treatment failure as initiation of an alternative medical treatment or need for surgery or expulsion of the LNG-IUS. The trial reported a statistically significant ($p=0.007$) lower failure rate for the LNG-IUS group compared with the continuous COC group (hazard ratio= 0.30; 95% CI, 0.14 to 0.73).[59]

Proportion of Women Who Cancelled Hysterectomy

An open randomized multicenter study conducted in Finland with 56 women aged 33 to 49 scheduled to undergo hysterectomy for treatment of excessive uterine bleeding reported that 64 percent (95% CI, 44 to 81%) of women in the LNG-IUS group compared with 14 percent (95% CI, 4 to 33%) of women in the control group (continued current medical treatment) had cancelled their decision to undergo hysterectomy after 6 months ($p<0.001$).[65]

Head-to-Head Comparisons

LNG-IUS Versus COC

Both the trial that compared LNG-IUS to continuous COC (daily 30 mcg of ethinyl estradiol and 150 mcg levonorgestrel)[59] and the trial that compared LNG-IUS to cyclic COC (1 mg norethindrone acetate and 20 mcg ethinyl estradiol for days 1 to 21)[61] found that LNG-IUS was superior to COC for blood loss reduction expressed as a percent (83 to 90% reduction in mean pictorial blood loss assessment chart score for LNG-IUS compared with 42 to 68% for COC). One trial reported superiority of LNG-IUS for blood loss expressed as volume, total bleeding days, treatment failure, hemoglobin, and ferritin level.[59] One of the trials reported superiority of LNG-IUS for achieving blood loss below the definition of heavy menstrual bleeding.[61]

LNG-IUS Versus Progestogens

The only outcome measure used by all three trials that compared progestogens to LNG-IUS was MBL reduction by volume.[60,62,64] Two trials reported that LNG-IUS significantly reduced MBL compared with progestogens, including oral MPA (10 mg daily for 10 days starting on cycle day 16[60] or 5 mg daily starting on cycle day 1[62]) and DMPA (single injection of on cycle day 1).[62] A third trial reported no significant difference between LNG-IUS and norethisterone (5 mg 3 times daily from cycle day 5 to cycle day 26 for three cycles) for reducing MBL.[64] The trials used different progestogen formulations and different measures of blood loss.[60,62,64] One of the trials comparing LNG-IUS to oral MPA reported significantly greater treatment success, reduction in blood loss as a percentage, and women achieving blood loss less than the definition of heavy menstrual bleeding in the LNG-IUS group.[60]

LNG-IUS Versus Mefenamic Acid

A single trial reported significantly greater reduction in MBL for LNG-IUS (117 ml) compared with mefenamic acid (500 mg 3 times daily for first 4 days of cycle; 21 ml).[63]

Prevention of Hysterectomy

A single poor quality trial reported significantly more ($p<0.001$) women cancelled their decision to undergo hysterectomy in the LNG-IUS group (64%; 95% CI, 44 to 81%) compared with women who continued current medical treatment (14%; 95% CI, 4 to 33%).[65]

Contraceptive Vaginal Ring

Key Points

- A single RCT reported that the contraceptive vaginal ring was as effective as norethisterone for improving bleeding.
- More women who were randomized to the vaginal ring were satisfied with treatment compared with women randomized to norethisterone.
- More women in the vaginal ring group elected to continue treatment than in the oral medication group.

Detailed Synthesis

We identified a single RCT of fair quality that compared the efficacy of the contraceptive vaginal ring to norethisterone in 95 women with abnormal cyclic uterine bleeding (Table 12). The study was conducted in Egypt among women with a pictorial blood loss assessment chart score over 185. The primary outcome measure was MBL after three cycles of treatment assessed using the pictorial blood loss assessment chart score. Other outcome measures included duration of menses, hemoglobin, ferritin, and quality of life.

The treatments were equally effective, reducing the patient-reported bleeding score by 67 percent in the contraceptive vaginal ring group and by 70 percent in the norethisterone group.[84]

Table 12. Primary outcomes of contraceptive vaginal ring for abnormal cyclic uterine bleeding

Author, Year Country Quality	Comparison Groups (n)	Key Outcomes
Abu Hashim et al., 2012[84] Egypt Fair	**G1:** Contraceptive vaginal ring, 15 mcg of ethinyl estradiol and 120 mcg etonogestrel inserted between day 1 and 5 of cycle and used for 3 weeks/cycle (48) **G2:** Norethisterone acetate tablets,5 mg 3 times daily on days 5 to 26 (47)	• Mean PBLAC score declined significantly (p<0.001) from baseline after 3 cycles for G1 (from 288 to 90) and G2 (from 302 to 92). • Mean hemoglobin levels increased from baseline for both G1 (p=0.02) and G2 (p=0.03). • Duration of menses was significantly shorter (p<0.001) for both G1 and G2. • More women in G1 (71%) than in G2 (42.5%) were satisfied with treatment. • More women in G1 (77%) than in G2 (25.5%) elected to continue treatment.

PBLAC = pictorial blood loss assessment chart; MBL = menstrual blood loss

Nonsteroidal Anti-Inflammatory Drugs

Key Points

- The most commonly studied NSAID was mefenamic acid; other NSAIDs included naproxen, meclofenamate, and flurbiprofen.
- Overall, NSAIDs demonstrated significant reductions in MBL (20 to 49 percent) compared with baseline and were significantly more effective than placebo, but many women still have objective menorrhagia after treatment. Variability in treatment response with NSAIDs is considerable, including some individuals with increases in MBL with treatment.
- Comparing individual NSAIDs, there were no significant differences found in reductions of MBL between mefenamic acid and naproxen.
- In one RCT, LNG-IUS was significantly more effective at reducing MBL compared with mefenamic acid.
- In two trials, TXA had significantly greater reductions in MBL compared with either flurbiprofen or mefenamic acid.
- There were no significant differences between NSAIDs and either norethisterone, low-dose COC, ethamsylate, or an older progesterone-impregnated intrauterine coil in 5 trials.
- Studies were mostly of short duration with most lasting from 2 to 3 cycles.
- No studies examined quality of life, sexual function, fertility, or time to conception as an outcome. Quality of life needs further attention since most women will be offered treatment based on complaints/perception rather than objective measurement.
- NSAIDs are also effective against menstrual-related abdominal pain and cramping.

Detailed Synthesis

We identified 13 unique studies from 14 publications that examined the use of NSAIDs for abnormal cyclic uterine bleeding (Table 13). Seven were parallel group RCTs[63,66,67,69,70,74,77] and six were randomized, crossover trials.[68,71-73,75,76] Trials were conducted in seven different countries: Australia,[68,76] Canada,[73] India,[69,77] the Netherlands,[67] Sweden,[71] United Kingdom,[63,66,70,74,75] and the United States.[72] The number of participants in each trial ranged from 19 to 110 with crossover trials ranging from 14 to 69. One study was assessed as good quality,[72]

three were assessed as fair quality,[67,75,76] and nine were assessed as poor quality.[63,66,68-71,73,74,77] Details of quality scoring for individual publications are included in Appendix I.

Studies used different inclusion criteria for defining menorrhagia. Six trials used the objective alkaline hematin method with MBL more than 80 ml as criteria for inclusion.[63,66,67,70,71,75] Two trials used the alkaline hematin method with MBL more than 50 to 60 ml,[72,74] one study used a combination of subjective and objective assessments of MBL more than 80 ml,[73] and four trials used either subjective criteria or did not define heavy menstrual bleeding for inclusion into the trial.[68,69,76,77] Some studies required women to have regular cycles.[63,67,68,72,73,77] Most studies excluded populations who had underlying disease or intrauterine device (IUD) use. One study[76] included patients with IUD (n=6), fibroids (n=2), Von Willebrand disease (n=1) and reported changes in MBL separately for women with ovulatory menorrhagia from those with underlying disease. Another study also included patients with IUDs (n=7) in the eligible patient population.[72] Patients ranged in age from 14 to 51 years of age.

The target intervention differed among the 13 studies. For each NSAID, dose and duration did not vary greatly. The most commonly studied NSAID, mefenamic acid, was used in 11 trials.[63,66-70,73-77] The usual dose of mefenamic acid was 500 mg 3 times a day starting at the onset of menses for duration of 5 days or until cessation of menses. One study initiated mefenamic acid 5 days prior to onset of menses through cessation.[67] Another trial used a slightly different regimen with 500 mg at onset of menses followed by 250 mg every 6 hours for 3 to 5 days.[73] One study included mefenamic acid at 250 mg 3 times a day from onset menses for 5 days in conjunction with TXA 500 mg 3 times a day for the same 5-day period.[77] One trial studied meclofenamate at a dose of 100 mg 3 times a day from onset of menses for duration of 6 days or until cessation of menses.[72] Naproxen was studied in two trials with initial loading doses of 500 to 550 mg then 250 to 275 mg every 6 hours for 5 days or until 24 hours after cessation of heavy bleeding.[68,75] Flurbiprofen was studied in one trial at a dose of 100 mg twice a day from onset of menses for duration of 5 days.[71]

The comparator differed among the 13 studies. Mefenamic acid was compared with placebo in four studies, two RCTs[67,69] and two crossover trials.[73,76] One crossover trial compared meclofenamate to placebo.[72] Two crossover trials compared mefenamic acid to naproxen[68,75] for two cycles. One of these crossover trials also used low-dose COC with 30 mcg ethinyl estradiol and 150 mcg levonorgestrel given daily for 21 days for two cycles.[68] Two RCTs used norethisterone 5 mg twice daily from day 19 to 26 of the cycle[70] or days 15 to 25 of the cycle[74] for two cycles. Two RCTs used progesterone-releasing intrauterine systems, including the LNG-IUS that releases 20 mcg of levonorgestrel per day for six cycles[63] and an older progesterone-impregnated intrauterine coil that releases 65 mcg of progesterone daily for two cycles.[74] One RCT compared mefenamic acid (500 mg every 8 hours) with TXA (1 gram every 6 hours) and ethamsylate (500 mg every 6 hours) for the first 5 days of menses for three cycles.[66] One crossover trial compared flurbiprofen (100 mg twice a day for 5 days) with 1.5 grams of TXA (3 times a day for the first 3 days of menses and 1 gram on days 4 to 5) for two cycles.[71] One RCT compared a combination of mefenamic acid (250 mg per day) and TXA (500 mg 3 times a day) to TXA alone from day 1 to 5 of menses for three cycles.[77]

Duration of treatment ranged from one[67] to six[63] menstrual cycles, with the majority consisting of two[68,70-76] to three[66,69,77] cycles.

The primary outcome for most studies (11/13) was MBL measured with the alkaline hematin method.[63,66-68,70-76] Seven studies reported mean MBL[66-68,71-73,76] and four studies reported median MBL.[63,70,74,75] One small, placebo-controlled crossover trial[73] measured MBL but only

reported the proportion of women who experienced reductions in MBL during the treatment cycles. One trial used the pictorial blood loss assessment chart score[77] as the primary outcome measure for blood loss and a second trial of NSAIDS used the pictorial blood loss assessment chart as a secondary outcome measure.[63] One trial reported the percentage of patients relieved of menorrhagia,[69] however the method of measurement was not provided. Other outcomes studied included duration of bleeding,[66,69,70,72,75,76] number of pads/tampons used,[66,69,72,75] and total menstrual fluid loss.[63] One trial examined patient satisfaction.[66] No studies examined quality of life, sexual function, fertility, or time to conception as an outcome.

Table 13. Primary outcomes of NSAIDs for abnormal cyclic uterine bleeding

Author, Year Country Quality	Comparison Groups (n)	Key Outcomes
Vargyas et al., 1987[72] United States Good	**G1[a]:** Meclofenamate, 100 mg 3 times daily for 2 cycles followed by placebo for 2 cycles (15) **G2:** Placebo for 2 cycles, followed by meclofenamate for 2 cycles (17)	• Mean MBL during meclofenamate cycles (69.0 ± 6.3 ml) was significantly less than baseline (141.6 ± 15.9 ml) and during placebo cycles (135.6 ± 11.3 ml) (p<0.0001). • Mean number of bleeding days was shorter during meclofenamate cycles (4.8 ± 0.2) than during placebo cycles (5.4 ± 0.18) (p<0.0003). • Median hemoglobin, hematocrit, and serum ferritin levels did not change during the study.
Van Elijkeren et al., 1992[67] Netherlands Fair	**G1:** Mefenamic acid, 500 mg 3 times daily (6) **G2:** Placebo (5)	• Mean MBL decreased 40% in G1 from baseline mean 108 ml to 65 ml (p=0.01) compared with increase in G2 from 151 ml to 189 ml (p=0.46). • Patients were scheduled for hysterectomy.
Hall et al., 1987[75] United Kingdom Fair	**G1:** Mefenamic acid 500 mg every 8 hrs. in phase 1 and naproxen in phase 2 (19)[a] **G2:** Naproxen 550 mg loading dose followed by 275 mg every 6 hrs. in phase 1 followed by mefenamic acid in phase 2 (19)[a]	• Treatment with mefenamic acid and naproxen reduced bleeding by average of 47 and 46% respectively.
Fraser et al., 1981, 1984[76,93] Australia Fair	**G1:** Mefenamic acid, 500 mg 3 times daily for 2 cycles followed by placebo for 2 cycles (38)[a] **G2:** Placebo for 2 cycles followed by mefenamic acid (31)[a]	• Mefenamic acid significantly reduced mean MBL (28%) compared with placebo (p<0.001). • Reductions were greater (30%) among women with MBL >80 ml at baseline (p<0.001). • Only 30 out of 69 women had measured blood loss >80 ml during placebo cycles.
Najam et al., 2010[77] India Poor	**G1:** TXA, 500 mg and mefenamic acid, 250 mg 3 times daily (55) **G2:** TXA, 500 mg 3 times daily (55)	• The mean PBLAC score in G1 declined from 246 to 100 at 6 months (p<0.01) and in G2 from 250 to 125 (p=NS). • Hemoglobin levels significantly increased in both groups, from 8.6 to 12.3 in G1 (p=0.016) and from 9.5 to 12.0 in G2 (p=0.04).
Reid and Virtanen-Kari, 2005[63] United Kingdom Poor	**G1:** LNG-IUS (25) **G2:** Mefenamic acid 500 mg 3 times daily for first 4 days of cycle (26)	• MBL significantly reduced in both groups from baseline but after 6 months median MBL was 5 ml in G1 compared with 100 ml in G2 (p<0.001).

Table 13. Primary outcomes of NSAIDs for abnormal cyclic uterine bleeding (continued)

Author, Year Country Quality	Comparison Groups (n)	Key Outcomes
Bonnar and Sheppard, 1996[66] Ireland Poor	**G1:** Mefenamic acid, 500 mg (25) **G2:** TXA, 1 g (27) **G3:** Ethamsylate, 500 mg (29)	• TXA reduced MBL by 54% (mean decreased from 164 ml to 75 ml) and mefenamic acid reduced MBL by 20% (from 186 ml to 148 ml). Ethamsylate did not reduce MBL. • Mean MBL for women in G1 remained >80 ml after 3 treatment cycles (148 ml; range, 138 to 168 ml). • 77% in G2 and 74% in G1 wished to continue treatment. • Improvement in dysmenorrheal was reported by 19% in G1, 13% in G2 and 4% in G3.
Fraser and McCarron, 1991[68] Australia Poor	**G1:** Mefenamic acid, 500 mg every 6 to 8 hrs. for 2 cycles; naproxen, 500 mg at onset followed by 250 mg every 6 to 8 hrs. for 2 cycles (15)[a] **G2:** Mefenamic acid, 500 mg every 6 to 8 hrs. for 2 cycles; low-dose COC (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) for 2 cycles (15)[a]	• Mefenamic acid reduced MBL by 38% in G2 (p=0.002) and by 20% in G1 (p=0.198). • Women treated with low-dose COC had 43% reduction in MBL (p<0.001). • Naproxen resulted in a 12% reduction in MBL (p=0.079).
Grover et al., 1990[69] India Poor	**G1:** Mefenamic acid, 500 mg, every 8 hours (40)[a] **G2:** Placebo (40)[a]	• 86% of women in G1 reported relief of menorrhagia compared with 20% in G2 (p<0.001). • Mean bleeding days in G1 reduced from 9.7 ± 3.1 to 4.1 ± 0.6.
Cameron et al., 1990[70] Scotland Poor	**G1:** Mefenamic acid, 500 mg 3 times daily (17) **G2:** Norethisterone, 5 mg twice daily (15)	• Median blood loss was significantly reduced in both groups from 123 ml to 81 ml in G1 (p<0.001) and from 109 ml to 92 in G2 (p<0.002). • Median percentage reduction in blood loss was 24% for G1 and 20% for G2 (p>0.1). • 52% of women in G1 and 67% in G2 still had menorrhagia after 2 months of treatment.
Andersch et al., 1988[71] Sweden Poor	**G1:** Flurbiprofen, 100 mg twice daily for 2 cycles followed by TXA for 2 cycles (15)[a] **G2:** TXA, 1.5 g 3 times daily on days 1 to 3 and 1 g twice daily on days 4 to 5 for 2 cycles followed by flurbiprofen for 2 cycles (15)[a]	• Both treatments significantly reduced MBL (p<0.01). • Reduction in MBL was 53% with TXA compared with 24% for flurbiprofen (p<0.01). • Mean MBL reduced to 155 ± 33 ml with TXA and 223 ± 44 ml for flurbiprofen (baseline MBL was 295 ± 52 ml). • Hemoglobin did not change with either treatment.

Table 13. Primary outcomes of NSAIDs for abnormal cyclic uterine bleeding (continued)

Author, Year Country Quality	Comparison Groups (n)	Key Outcomes
Tsang et al., 1987[73] Canada Poor	**G1:** Mefenamic acid, 500 mg at onset followed by 250 mg every 6 hrs. for 3 to 5 days for 2 cycles followed by placebo (14)[a] **G2:** Placebo for 2 cycles followed by mefenamic acid for 2 cycles (14)[a]	• 8/10 women experienced reduction in MBL while taking mefenamic acid compared with placebo (p<0.05).
Cameron et al., 1987[74] United Kingdom Poor	**G1:** Mefenamic acid, 500 mg 3 times daily (8) **G2:** Norethisterone, 5 mg twice daily (8) **G3:** Progesterone-impregnated intrauterine coil releasing 65 mcg daily (8)	• Median MBL reduced in G1 from 68 to 47 ml (p=0.05) and in G3 from 71 to 45 ml (p<0.05). • Median MBL was unchanged in G2 (94 to 110 ml).

COC = combined oral contraceptive; LNG-IUS = levonorgestrel-releasing intrauterine system; MBL = menstrual blood loss; NS = not significant; PBLAC = pictorial blood assessment chart; TXA = tranexamic acid
[a]Crossover study.

Description of Results

Outcome Measures

All studies of NSAIDs examined bleeding outcomes. Eleven studies used the alkaline hematin method for an objective measure of MBL. Two trials used the pictorial blood loss assessment chart to assess blood loss.[63,77] One study[69] reported relief of menorrhagia for which methods were not provided.

Although we aimed to collect data on measures of quality of life, sexual function, fertility and time to conception, none of the 13 clinical trials reported on these outcomes. One study reported patient satisfaction based on participants' wish to continue treatment at the end of the study.[66]

MBL

Reduction Expressed as a Percent

Four trials of fair to good quality reported statistically significant reductions in MBL compared with baseline, ranging from 40 to 49 percent among those who received one to two treatment cycles of NSAIDs, including mefenamic acid, naproxen, or meclofenamate (Table 14).[67,72,75,76]

A good quality crossover trial conducted in the United States,[72] randomized 32 women with MBL more than 60 ml to meclofenamate or placebo for 2 treatment cycles. Seven (21%) participants were using an IUD. Significantly (p<0.0001) greater reductions in MBL were reported among those receiving meclofenamate (48.9 ± 3.7%) compared with those receiving placebo (9.2 ± 5.3%). During treatment, the change in MBL associated with meclofenamate ranged from −42 ± 3 percent in cycle 1 to −56 ± 8 percent in cycle 3.

A small, fair quality, RCT conducted in the Netherlands,[67] randomized women scheduled for a hysterectomy due to subjective menorrhagia to either mefenamic acid 500 mg (n=6) or placebo

(n=5) 3 times daily starting 5 days before expected menses to cessation of bleeding for 1 treatment cycle. Eligible participants had regular cycles, no IUD, and MBL more than 80 ml. Those receiving mefenamic acid had greater reductions (40%, p=0.01) in mean MBL from baseline compared with placebo where a nonsignificant increase (25%) in MBL was reported,

A randomized, double-blind crossover fair quality trial conducted in the United Kingdom[75] compared naproxen (550 mg at onset of menses then 275 mg every 6 to 8 hours for 5 days) to mefenamic acid among 38 women with MBL more than 80 ml for 2 treatment cycles. Patients with pelvic inflammation, fibroids, or other local disease were excluded. There were no significant differences in mean MBL reduction between the two groups receiving mefenamic acid (46% and 47%) and the two groups receiving naproxen (44% and 48%). Reductions in MBL compared with baseline were statistically significant (p<0.001) in both the groups receiving mefenamic acid and naproxen.

One crossover RCT of fair quality conducted in Australia and published in two papers[76,93] randomized 85 women with menorrhagia to mefenamic acid or placebo for two cycles. Overall there was a 28-percent reduction in mean MBL among those who received mefenamic acid compared with those who received placebo (p<0.001). There was a 30-percent reduction (p<0.001) in blood loss among those with MBL more than 80 ml at baseline (n=30) but a 28-percent increase in blood loss among those with MBL more than 35 ml at baseline (n=14).

Six poor quality trials also reported significantly reduced MBL compared with baseline levels (Table 14). One poor quality RCT conducted in the United Kingdom[63] compared 51 participants randomized to either mefenamic acid or to LNG-IUS. Both LNG-IUS and mefenamic acid significantly (p<0.005) reduced MBL compared with baseline; however, the study reported a greater reduction in median MBL among those treated with LNG-IUS (95%) compared with those receiving mefenamic acid (23%) after six cycles of treatment.

One RCT[66] conducted in Ireland randomized women to either TXA (n=27), mefenamic acid (n=25), or ethamsylate (n=29) for three cycles. The study reported a 54-percent reduction in mean MBL from baseline for those receiving TXA (p<0.001), a 20-percent reduction for those receiving mefenamic acid (p<0.001), and no reduction for those receiving ethamsylate.

A small crossover trial[71] conducted in Sweden compared TXA to flurbiprofen for two treatment cycles. A greater reduction in mean MBL from baseline was reported among those receiving TXA (53%) compared with those receiving flurbiprofen (24%).

One RCT conducted in the United Kingdom[70] examined the efficacy of mefenamic acid compared with norethisterone among 32 participants with MBL more than 80 ml for 2 cycles. Median percent change in blood loss volume was not significantly different between mefenamic acid (−24%; range, 5 to −83%) and norethisterone (−20%; range, 2 to −53%). Median MBL with treatment was 81 ml (range, 22 to 193 ml) for those receiving mefenamic acid and 92 ml (range, 43 to 189 ml) for those receiving norethisterone. One patient treated with mefenamic acid had an increase in blood loss.

One crossover trial[68] conducted in Australia examined the efficacy of mefenamic acid compared with low-dose COC (30 mcg ethinyl estradiol and 150 mcg levonorgestrel given daily for 21 days) in one group and mefenamic acid compared with naproxen in another group, each for two cycles among women with a clinical history of menorrhagia. There was no significant difference in reduction of mean MBL between those receiving mefenamic acid (38%) and those receiving low-dose COC (43%) or between those receiving mefenamic acid (20%) and those receiving naproxen (12%).

Table 14. Percent change in blood loss from baseline in studies of NSAIDs

Author, Year	NSAID	Comparator	NSAID Group	Comparator Group	NSAID vs. Comparator Group
Vargyas et al., 1987[72]	Meclofenamate	Placebo	−48.9	−9.2	p<0.0001
Van Elijkeren et al., 1992[67]	Mefenamic acid	Placebo	−40.0	NR	NR
Hall et al., 1987[75]	Mefenamic acid	Naproxen	−47.0	−46.0	NS
Fraser et al., 1981, 1984[76,93]	Mefenamic acid	Placebo	NR	NR	p<0.001
Reid and Virtanen-Kari,2005[63]	Mefenamic acid	LNG-IUS	−23.0	−95.0	p<0.001
Bonnar and Sheppard,1996[66]	Mefenamic acid	TXA	−20.0	−54.0	p<0.05
Bonnar and Sheppard,1996[66]	Mefenamic acid	Ethamsylate	−20.0	0	p<0.001
Fraser and McCarron, 1991[68]	Mefenamic acid	Naproxen	−20.0	−12.0	NS
Fraser and McCarron, 1991[68]	Mefenamic acid	COC[a]	−38.0	−43.0	NS
Cameron et al., 1990[70]	Mefenamic acid	Norethisterone	−24.0	−20.0	NS
Andersch et al., 1988[71]	Flurbiprofen	TXA	−24.0	−53.0	p<0.01

COC = combined oral contraceptive; LNG-IUS = levonorgestrel-releasing intrauterine system; TXA = tranexamic acid; NS = nonsignificant

[a]30 mcg ethinyl estradiol and 150 mcg levonorgestrel.

Reduction Expressed as a Volume

In four trials of fair to good quality,[67,72,75,76] treatment with meclofenamate, mefenamic acid or naproxen reduced MBL compared with baseline (Table 15). Mean or median MBL after treatment ranged from 65 to 77 ml. Mefenamic acid and naproxen were comparable in effectiveness.[75]

A good quality crossover trial conducted in the United States randomized 32 women to meclofenamate or placebo for 2 cycles. There was a significantly greater reduction in mean MBL from baseline with meclofenamate (72.6 ml) compared with placebo (6.0 ml).[72]

A small fair quality RCT conducted in the Netherlands randomized women scheduled for a hysterectomy due to subjective menorrhagia to mefenamic acid (n=6) or placebo (n=5). There was a significant reduction in mean MBL from baseline in the treatment group (43 ml, p=0.01) compared with a 38-ml increase in MBL in the placebo group.[67]

A fair quality crossover trial conducted in the United Kingdom compared naproxen to mefenamic acid among 38 women with MBL more than 80 ml for 2 treatment cycles. Median reductions in blood volume from baseline for mefenamic acid ranged from 54 ml to 61 ml (p<0.001) and the reduction for naproxen ranged from 52 to 62 ml (p<0.001) over 2 treatment cycles. There were no significant differences in reductions in MBL between mefenamic acid and naproxen.[75]

A fair quality crossover RCT conducted in Australia reported greater reductions in mean MBL among those receiving mefenamic acid (18.8 ml) for 2 treatment cycles compared with those receiving placebo. Among the women with MBL more than 80 ml at baseline (n=30), there was a significant ($p<0.001$) reduction in mean MBL (33.6 ml) among those receiving mefenamic acid compared with those receiving placebo.[76]

Six poor quality studies reported similar findings; NSAIDS significantly reduced MBL compared with baseline (Table 15). In a poor quality RCT conducted in the United Kingdom with 51 women,[63] MBL was reduced by 21 ml in those receiving mefenamic acid compared with baseline; however, the women in the LNG-IUS group reported significantly greater reductions in blood loss volume (117 ml, $p<0.001$) from baseline.

In an RCT conducted in Ireland,[66] 81 women were randomized to either TXA (n=27), mefenamic acid (n=25), or ethamsylate (n=29) for three cycles. Compared with baseline, those receiving TXA had an 89 ml reduction in MBL, those receiving mefenamic acid reported a 43 ml reduction, and those receiving ethamsylate reported an increase in MBL of 8 ml. Those receiving TXA had a 46 ml greater reduction in MBL compared with those receiving mefenamic acid ($p<0.05$) and those receiving mefenamic acid had a 51 ml greater reduction in MBL compared with those receiving ethamsylate; however, mean MBL (148 ml; range, 138 to 168 ml) after 3 cycles of treatment with mefenamic acid remained more than 80 ml.

In a crossover trial conducted in Australia, [68] there were no differences in absolute reductions in MBL volume between mefenamic acid and low-dose COC (30 mcg ethinyl estradiol and 150 mcg levonorgestrel given daily for 21 days) or between mefenamic acid compared with naproxen. Reductions in blood loss volume compared with baseline were reported for both those receiving mefenamic acid (38.1 ml, $p=0.002$) and those receiving COC (43.2 ml, $p<0.001$). In the other group, there were nonsignificant reductions in MBL from baseline for mefenamic acid (26 ml) and naproxen (15.5 ml).

In one RCT conducted in the United Kingdom,[70] median MBL was reduced after 2 cycles of mefenamic acid from 123 ml (range, 86 to 237 ml) to 81 ml (range, 22 to 193 ml), a reduction of 42 ml ($p<0.001$) and was significantly reduced with norethisterone from 109 ml (range, 81 to 236 ml) to 92 ml (range, 43 to 189 ml), a reduction of 17 ml ($p<0.002$), but there was no significant difference in reductions between mefenamic acid and norethisterone.

A small crossover trial[71] conducted in Sweden that compared TXA with flurbiprofen for two treatment cycles, reported significantly ($p<0.01$) greater reductions in mean MBL from baseline for TXA (140 ml, $p<0.01$) compared with the change in MBL from baseline for flurbiprofen (72 ml, $p<0.01$).

In another small RCT conducted in the United Kingdom,[74] median MBL was significantly reduced after two cycles of treatment with mefenamic acid (n=6), 38 ml reduction (median 47 ml; range, 39 to 210 ml) from baseline (85 ml; range, 68 to 169 ml), $p=0.05$, and was significantly reduced with a progesterone-impregnated intrauterine coil (n=7), 19 ml reduction (median 45 ml; range, 31 to 77 ml) from baseline (median 64 ml; range, 56 to 164 ml, $p<0.05$). However, there was no significant reduction in median MBL after two cycles of norethisterone (21 ml; median 110 ml; range, 18 to 187 ml).

Table 15. Change in blood loss volume from baseline in studies of NSAIDs

Author, Year	NSAID	Comparator	NSAID Group	Comparator Group	NSAID vs. Comparator Group
Vargyas et al., 1987[72]	Meclofenamate	Placebo	-72.6	-6.0	p<0.0001
Van Elijkeren et al., 1992[67]	Mefenamic acid	Placebo	-43.0	+38.0	NR
Hall et al., 1987[75]	Mefenamic acid	Naproxen	-57.5	-57.0	p=NS
Fraser et al., 1981, 1984[76]	Mefenamic acid	Placebo	NR	NR	p<0.001
Reid and Virtanen-Kari,2005[63]	Mefenamic acid	LNG-IUS	-21.0	-117.0	p<0.001
Bonnar and Sheppard,1996[66]	Mefenamic acid	TXA	-43.0	-89.0	p<0.05
Bonnar and Sheppard,1996[66]	Mefenamic acid	Ethamsylate	-43.0	+8.0	p<0.05
Fraser and McCarron, 1991[68]	Mefenamic acid	Naproxen	-26.0	-15.5	p=NS
Fraser and McCarron, 1991[68]	Mefenamic acid	COC[a]	-38.1	-43.2	p=NS
Cameron et al., 1990[70]	Mefenamic acid	Norethisterone	-42.0	-17.0	p=NS
Andersch et al., 1988[71]	Flurbiprofen	TXA	-72.0	-140.0	p<0.01
Cameron et al., 1987[74]	Mefenamic acid	Norethisterone	-38.0	-21.0	NR
Cameron et al., 1987[74]	Mefenamic acid	Progesterone-impregnated intrauterine coil	-38.0	-19.0	NR

COC = combined oral contraceptive; LNG-IUS = levonorgestrel-releasing intrauterine system; NSAID = nonsteroidal anti-inflammatory drug; NR = not reported; NS = nonsignificant

[a]Ethinyl estradiol (30 mcg)/levonorgestrel (150 mcg).

Pictorial Blood Loss Assessment Chart Score

One poor quality RCT conducted in India[77] randomized 110 women with menorrhagia to a combination of TXA and mefenamic acid or TXA alone for three treatment cycles. The pictorial blood loss assessment chart score was lowered by 146 points (59%, p<0.01) from baseline in those receiving mefenamic acid plus TXA and by 125 points (50%, p=NS) from baseline in those receiving TXA alone. In a poor quality RCT conducted in the United Kingdom,[63] women receiving mefenamic acid reported a 74-point reduction (p<0.001) in the median pictorial blood loss assessment chart score from baseline.

Relief of Menorrhagia

Improvement in the subjective relief of menorrhagia with NSAIDs was reported in two trials.[66,69] One RCT conducted in India[69] randomized 80 women with subjectively defined, cyclic, heavy bleeding to either mefenamic acid or placebo for three cycles. Relief of menorrhagia was significantly greater among those receiving mefenamic acid (86%) compared with those receiving placebo (20%). Another trial[66] reported that most women (57%) who

received mefenamic acid thought their blood loss was less after three treatment cycles compared with baseline. A small, placebo-controlled crossover trial conducted in Canada[73] randomized women to 2 cycles each of mefenamic acid and placebo and reported that 8 of the 10 women who competed the study experienced reductions in MBL during the mefenamic acid cycles compared with their placebo cycles ($p<0.05$).

Duration of Bleeding and Total Menstrual Fluid Loss

Duration of bleeding (in days) was reported in six trials of NSAIDs.[66,69,70,72,75,76] In two trials, one fair and one good quality, the duration of menstrual blood flow was shorter among those receiving either meclofenamate[72] or mefenamic acid[76] compared with placebo. Another fair quality study reported that both mefenamic acid and naproxen reduced the mean number of bleeding days.[75]

Two poor quality RCTs reported a significantly shorter duration of bleeding during mefenamic treatment cycles compared with pretreatment cycles,[69,70] but there was no change with norethisterone.[70] In one poor quality, three-arm trial[66] of mefenamic acid, TXA, and ethamsylate, there was no difference in duration of menstrual bleeding between treatment arms. In one poor quality study,[63] total menstrual fluid loss was significantly less at cycle 3 and cycle 6 compared with baseline among women receiving mefenamic acid.

Hemoglobin

In two trials,[71,72] hemoglobin concentrations did not increase during treatment with NSAIDs. In a good quality, crossover trial conducted in the United States, the median hemoglobin, hematocrit, and ferritin levels were unchanged compared with baseline.[72] In a crossover trial conducted in Sweden,[71] hemoglobin concentration during control cycles was no different from hemoglobin concentration during treatment. In the RCT in India,[77] mean hemoglobin increased significantly in the group receiving combined mefenamic acid and TXA (12.3 g/dl) and in the group receiving TXA alone (12.0 g/dl).

Head-to-Head Comparisons

Mefenamic Acid Versus Naproxen

Two crossover trials compared mefenamic acid to naproxen.[68,75] There were no differences in reduction of MBL between mefenamic acid and naproxen.

One fair quality crossover trial[75] conducted in the United Kingdom compared naproxen to mefenamic acid among 38 women with MBL more than 80 ml for 2 treatment cycles. Primary outcomes were mean MBL using the alkaline hematin method. Both mefenamic acid and naproxen reduced median MBL by 46 to 47 percent and 44 to 48 percent, respectively, compared with baseline. The median reductions in MBL volume from baseline for mefenamic acid ranged from 54 ml to 61 ml ($p<0.001$); the reduction for naproxen ranged from 52 to 62 ml ($p<0.001$) over two treatment cycles. There were no differences in reductions in MBL between mefenamic acid and naproxen.

One poor quality crossover trial[68] conducted in Australia randomized 30 women with a clinical history of menorrhagia to either mefenamic acid or naproxen for 2 cycles. The same dose of mefenamic acid was compared with oral contraceptives in a second group (see section below). The primary outcome was MBL measured by the alkaline hematin method. Mefenamic acid reduced mean MBL by 20 percent compared with baseline (p=NS). Naproxen reduced mean

MBL by 12 percent compared with baseline (p=NS) with no significant differences in reductions between mefenamic acid and naproxen. Despite these reductions, the majority of women receiving NSAIDs still had objective menorrhagia after treatment. There was considerable variability in response to both NSAIDs, with some women experiencing increases in MBL during treatment with NSAIDs.

Mefenamic Acid Versus Progesterone-Releasing Intrauterine Systems

Two poor quality RCTs conducted in the United Kingdom examined the efficacy of mefenamic acid compared with progesterone-releasing intrauterine systems. One studied the continuous LNG-IUS,[63] and the other studied an older progesterone-impregnated intrauterine coil that releases 65 mcg of progesterone daily.[74] Both trials used objective measures of MBL (alkaline hematin method) for inclusion criteria, but with slightly different volumes (more than 80 ml[63] and more than 50 ml[74]) to assess MBL outcomes.

One RCT with 51 participants[63] reported a statistically significant greater reduction in median MBL from baseline in the women with LNG-IUS (117 ml) compared with the women receiving mefenamic acid (21 ml) after six cycles of treatment. Significantly greater ($p<0.001$) reductions in the median pictorial blood loss assessment chart score and total menstrual fluid loss were also reported with LNG-IUS compared with mefenamic acid. Despite significant reductions with mefenamic acid, most patients still had objective MBL more than 80 ml.

One small RCT[74] reported reductions in median MBL after two cycles of treatment with both mefenamic acid (n=6), with a reduction of 21 ml (median 47 ml; range, 39 to 210 ml) from baseline (85 ml; range, 68 to 169 ml; p=0.05), and with the progesterone-impregnated intrauterine coil (n=7) with a reduction of 19 ml (median 45 ml; range, 31 to 77 ml) from baseline (median 64 ml; range, 56 to 164 ml; $p<0.05$). No statistics for head-to-head comparisons were reported.

NSAIDs Versus TXA

Two poor quality trials compared NSAIDs with TXA.[66,71] Both trials reported that women receiving TXA had significantly greater reductions in mean MBL compared with either mefenamic acid or flurbiprofen over three cycles.

One RCT[66] conducted in Ireland, randomized 81 women with MBL more than 80 ml to either TXA (n=27), mefenamic acid (n=25), or ethamsylate (n=29) for three cycles. There was a significant reduction in mean MBL from baseline over three treatment cycles for two of three treatment arms: 54 percent ($p<0.001$) for TXA and 20 percent ($p<0.001$) for mefenamic acid. The absolute change in MBL compared with baseline was −89 ml with TXA, −43 ml with mefenamic acid, and +8 ml with ethamsylate.

One small randomized crossover trial[71] conducted in Sweden compared TXA to flurbiprofen in 15 women with MBL more than 80 ml. The trial reported a statistically significant reduction in mean MBL (53%) in the group receiving TXA (53%) compared with the group receiving flurbiprofen (24%). Absolute reductions in blood loss volume from baseline were greater for TXA (140 ml) compared with flurbiprofen (72 ml).

TXA Plus Mefenamic Acid Versus TXA Alone

One poor quality RCT conducted in India[77] randomized 110 women with menorrhagia (not objectively defined) to a combination of TXA and mefenamic acid or to TXA alone. After three treatment cycles, the pictorial blood loss assessment chart score was reduced in those receiving

mefenamic acid plus TXA (59%, p<0.01) and in those receiving TXA alone (50%, p=NS). No statistics for head-to-head comparisons were reported.

Mefenamic Acid Versus Norethisterone

Two poor quality RCTs conducted in the United Kingdom examined the efficacy of mefenamic acid compared with norethisterone. [70,74] Both trials examined the same dose and duration of mefenamic acid (500 mg 3 times daily on cycle days 1 to 5) and the same dose of norethisterone (5 mg twice per day) but given during slightly different cycle days, (days 19 to 26[70] vs. days 15 to 25[74]). Both trials used the alkaline method for MBL measurement for inclusion (50 to 80 ml) and outcome criteria.

One RCT[70] reported no difference in reductions of median MBL among those receiving 2 treatment cycles of mefenamic acid (n=17) compared with those receiving norethisterone (n=15). With either treatment, the majority of women still had MBL more than 80 ml. In the other small RCT,[74] no statistics for head-to-head comparisons were reported. Compared with baseline, median MBL was reduced after treatment with mefenamic acid (n=6) by 38 ml and by 21 ml (p=NS) among those receiving norethisterone (n=6). Median MBL with treatment was 47 ml (range, 39 to 210 ml) with mefenamic acid and 110 ml (range, 24 to 222 ml) with norethisterone.

Mefenamic Acid Versus Low-Dose COC

One poor quality crossover trial[68] conducted in Australia examined the efficacy of mefenamic acid compared with low-dose COC with 30 mcg ethinyl estradiol and 150 mcg levonorgestrel given daily for 21 days among 30 women with a clinical history of menorrhagia. There were no differences between mefenamic acid and COC in reductions in mean MBL (38% vs. 43%) or absolute reductions in MBL volume (38 ml vs. 43 ml).

Tranexamic Acid

Key Points

- Women taking TXA at a dose of 1.95 to 4.5 grams per day for 4 to 5 days from the onset of bleeding experienced a clinically significant reduction in MBL, ranging from 26 percent to 54 percent in studies lasting up to 1 year. However, there are no long-term followup studies.
- In comparison to progestogens, combined hormonal pills, and NSAIDs, TXA appeared to provide greater reduction in MBL. No head-to-head comparisons of TXA versus LNG-IUS were assessed.
- The number of reports of side-effects and adverse effects was generally not significantly different between TXA and the comparator.
- Although no thromboembolic events were reported in any of the included TXA studies, there are concerns about the possible increased risk of thromboembolic events in particular women. The Food and Drug Administration (FDA) has issued precautions and contra-indications.

Detailed Synthesis

TXA is a competitive inhibitor of plasminogen activation, thereby acting as an antifibrinolytic agent. TXA does not appear to affect platelet numbers or aggregation but acts to reduce the breakdown of fibrin in a preformed clot. Because menstrual bleeding involves

liquefaction of clotted blood from the spiral endometrial arterioles, a reduction in this process is the putative mechanism of reduced menstrual bleeding.

Seven RCTs of TXA were identified (Table 16).[66,71,77-81] One study compared TXA alone to TXA plus mefenamic acid, and is discussed in the NSAIDs section above.[77] For the six other studies of TXA, study population ranged from 15[71] to 304.[81] The total number of women randomized to TXA was 475. The total number of women assigned to TXA for whom study endpoint outcome measures were collected, including intention to treat missing data protocols, was 460.

For five of the trials, the bleeding criterion for study entry was a mean MBL (assessed using the alkaline hematin method) of at least 80 ml for two or three cycles prior to randomization.[66,71,78,80,81] A sixth trial used the pictorial blood loss assessment chart score greater than 100 to enroll participants.[79] The mean MBL at baseline was similar for four of the trials (range, 153 to 186 ml).[66,78,80,81] The mean MBL at baseline was 295 ml for one trial.[71]

The intervention dosage differed among the six trials. The TXA administration protocols for each menstrual cycle were: 1.95 grams per day or 3.9 grams per day for up to 5 days,[81] 2 grams per day for 5 days,[79] 3.9 grams per day for up to 5 days,[78] 4 grams per day for 4 days,[80] 4 grams per day for 5 days,[66] 4.5 grams per day for 3 days and then 2 grams per day for 2 days.[71]

Two of the studies were placebo-controlled.[78,81]The comparator differed across the other four trials and included: oral MPA for 20 days,[79] oral norethisterone for 7 days,[80] mefenamic acid for 5 days,[66] ethamsylate for 5 days,[66] and flurbiprofen for 5 days.[71]

The primary outcome of the trials was change in blood loss (absolute volume or percent) or change in pictorial blood loss assessment chart score. The alkaline hematin method was used to assess MBL in five trials.[66,71,78,80,81] The absolute change in mean blood loss from baseline and percent change were reported in five studies.[66,71,78,80,81] Three of these four reported mean MBL,[71,78,80] and three reported median MBL.[66,78,80] One trial used the pictorial blood loss assessment chart, which is a validated chart that helps participants more uniformly report bleeding as represented by the degree of saturation of sanitary pads and tampons, for the outcome measure.[79]

The timing of the summative outcome measure reporting varied among the trials. Two trials reported after two menstrual cycles.[71,80] Two trials reported after three menstrual cycles.[66,81] Two trials reported after six menstrual cycles.[78,79]

The setting varied: two trials were conducted in the United States,[78,81] three in Europe,[66,71,80] and one in India.[79] Overall one study was assessed as good quality,[78] two were fair quality,[80,81] and three were poor quality.[66,71,79] Details of quality scoring for individual publications are included in Appendix I.

Table 16. Primary outcomes of TXA for abnormal cyclic uterine bleeding

Author, Year Country Quality	Comparison Groups (n)	Key Outcomes
Lukes et al., 2010[78] United States Good	**G1:** TXA 1.3 g 3 times daily up to 5 days per cycle (123) **G2:** Placebo (73)	• Mean reduction in MBL measured by the alkaline hematin method after 6 cycles was greater in G1 compared with G2 (p<0.001). • Proportion of women with at least 50 ml reduction in MBL was 56% in G1 and 19% in G2 (p<0.0001). • Women in G1 reported improvements in quality of life (measured by the Menorrhagia Impact Score) compared with G2 (p<0.01).
Freeman et al., 2011[81] Fair	**G1:** TXA 3.9 g per day for up to 5 days of menstrual bleeding (118) **G2:** TXA 1.95 g per day for up to 5 days of menstrual bleeding (117) **G3:** Placebo (69)	• Mean MBL was significantly reduced during treatment compared with baseline for G1 (26%) and for G2 (39%). • The reduction in mean MBL was significantly greater in the group receiving the higher TXA dose (G2).
Preston et al., 1995[80] United Kingdom Fair	**G1:** TXA 1 g 4 times daily for 4 days (25) **G2:** Norethisterone 5 mg twice a day on days 19 to 26 (21)	• Mean reduction in MBL from baseline was 45% for G1 (p<0.0001); mean MBL increased in G2 (p=NS). • Fourteen (56%) women in G1 and 2 (9.5%) women in G2 achieved MBL<80 ml.
Kriplani et al., 2006[79] India Poor	**G1:** TXA 500 mg 4 times daily for 5 days (50) **G2:** MPA 10 mg twice daily days 5 to 25 (50)	• Both groups had significant (p<0.005) reductions in PBLAC scores after 3 months and mean reduction in blood loss was 60.3% in G1 and 57.7% in G2. • Hemoglobin levels rose in both groups (p<0.05 for both). • Three women in G1 (6.1%) and 13 (28.9%) in G2 did not respond to treatment (p=0.003).
Bonnar and Shepard, 1996[66] Ireland Poor	**G1:** TXA 1 g every 6 hrs. (27) **G2:** Ethamsylate 500 mg every 6 hrs. (29) **G3:** Mefenamic acid 500 mg every 8 hrs. (25)	• Women in G1 had blood loss reduction of 54% compared with 20% for women in G3. • No reduction in blood loss for G2.
Andersch et al., 1988[71] Sweden Poor	**G1:** TXA for 2 cycles followed by flurbiprofen for 2 cycles (15)[a] **G2:** Flurbiprofen for 2 cycles followed by TXA for 2 cycles (15)[a]	• MBL was significantly reduced during treatment with flurbiprofen and TXA. • MBL was significantly (p<0.01) lower during treatment with TXA compared with flurbiprofen.

MBL = menstrual blood loss; PBLAC = pictorial blood assessment chart
[a]Crossover study.

Description of Results

Outcome Measures

The alkaline hematin method for MBL was used as an outcome measure in 5 of the TXA trials.[66,71,78,80,81] One poor quality trial used the pictorial blood loss assessment chart to assess blood loss, with menorrhagia defined by a pictorial blood loss assessment chart score of 100 or greater.[79] Other outcome measures included hemoglobin level, treatment success, and quality of life.

MBL

Reduction Expressed as a Percent

In five studies (one good quality, two fair quality, and two poor quality), TXA was associated with significant reductions in MBL ranging from 26 to 54 percent (Table 17). A good quality placebo-controlled trial reported a statistically significant ($p<0.001$) reduction in mean MBL among women in the modified intent-to-treat population receiving TXA (40%) compared with those receiving placebo (8%) for six menstrual cycles. The attributable reduction for TXA was 32 percent ($p<0.001$).[78] The other placebo-controlled trial of fair quality reported significant reductions in mean MBL for women receiving 3.9 or 1.95 grams per day of TXA (39% and 26%, respectively) compared with a reduction in MBL of 2 percent for women taking placebo ($p<0.001$).[81]

The trial that compared TXA with norethisterone reported a statistically significant reduction in mean MBL among women receiving TXA for two treatment cycles compared with those receiving norethisterone: 45-percent reduction (95% CI, 23% increase to 93% reduction; $p<0.0001$ vs. baseline) compared with a 20-percent increase (95% CI, 114% increase to 62% reduction; $p=0.26$ vs. baseline).[80]

A trial that compared TXA with ethamsylate and with mefenamic acid reported that over three treatment cycles the mean reduction in MBL from baseline for the group receiving TXA was 54 percent ($p<0.001$). For the mefenamic acid group the mean reduction in MBL from baseline was 20 percent ($p<0.001$). There was no change in MBL for the ethamsylate group.[66]

A small, poor quality, crossover trial (n=15) that compared TXA with flurbiprofen reported that over two treatment cycles the mean reduction in MBL from baseline for TXA was 53 percent ($p<0.01$) compared with 24 percent for flurbiprofen ($p<0.01$).[71]

Table 17. Percent change in blood loss from baseline in studies of TXA

Author, Year	Comparator	TXA Group	Comparator Group	TXA vs. Comparator Group
Lukes et al., 2010[78]	Placebo	-40.4	-8.2	p<0.001
Freeman et al., 2011[81]	Placebo	-38.6 (high dose) -26.1 (low dose)	-1.9	p<0.0001
Preston et al., 1995[80]	Norethisterone	-45.0	+20.0	p<0.0001
Bonnar and Shepard, 1996[66]	Mefenamic acid	-54.0	-20.0	p<0.05
Bonnar and Shepard, 1996[66]	Ethamsylate	-54.0	Increased	p<0.0001
Andersch et al., 1988[71]	Flurbiprofen	-53.0	-24.0	p<0.01

MPA = medroxyprogesterone; NS = nonsignificant; NR = not reported

Reduction Expressed as a Volume

In five studies (one good quality, two fair quality, and two poor quality) TXA was associated with significant reductions in MBL ranging from 47 to 140 ml (Table 18). Both placebo-controlled trials reported a statistically significant reduction in mean MBL for women treated with TXA.[78,81] Among women in the modified intent-to-treat population receiving TXA for six menstrual cycles, one study reported a reduction in MBL of 69.6 ml compared with a reduction

of 12.6 ml in the placebo group; the attributable reduction for TXA was 57 ml (p<0.001). The calculated least-squares mean reduction in MBL in the modified intent-to-treat population receiving TXA (66.3 ml) was greater compared with those receiving placebo (17.8 ml); the attributable reduction for TXA was 48.5 ml (p<0.001).[78] The effect size for TXA (standardized observed effect) was 0.67 based upon the modified intention to treat analysis and the standard deviation. The effect size was 0.49 based upon the least squares mean change analysis and the standard deviation.[78] The effect size for TXA compared with placebo is large.

In the larger fair quality study that compared high-dose (3.9 g/day) and low-dose (1.95 g/day) TXA to placebo, the mean reduction from baseline for the intent-to-treat population was 65.3 ml and 46.5 ml, respectively, while the placebo group had a small insignificant decline of 3.0 ml. The low-dose group did not meet the authors predetermined threshold of at least 50 ml per cycle reduction in MBL from baseline, but both groups treated with TXA did achieve a reduction in MBL from baseline that exceeded the threshold determined by authors to be meaningful to women (36 ml/cycle).[81]

A small fair quality trial that compared TXA with norethisterone reported a statistically significant reduction in mean MBL occurred among women receiving TXA for two treatment cycles compared with those receiving norethisterone: 79 ml reduction (95% CI, 62 to 108 ml reduction) compared with 34 ml increase (95% CI, −2 to 64 ml reduction).[80]

A trial that compared TXA with ethamsylate and with mefenamic acid reported that the pretreatment MBL in the TXA group ranged from 143 to 178 ml, and over three treatment cycles the mean MBL was 72 to 77 ml, a mean reduction in MBL of 89 ml (range, 24 to 214 ml, p<0.001). For the ethamsylate group, the pretreatment MBL ranged from 157 to 185 ml, and over three treatment cycles the mean MBL was 161 to 185 ml, a mean increase of 8 ml (range, 280 to 103 ml). For the mefenamic acid group, the pretreatment MBL ranged from 159 to 199 ml, and over three treatment cycles the mean MBL was 138 to 168 ml, a mean reduction in MBL of 43 ml (range, 82 to 179 ml; p<0.001).[66] Head-to-head comparisons of the results of treatment on absolute changes in blood loss showed that TXA reduced the mean loss by 97 ml more than with ethamsylate (95% CI, 54 to 140 ml, p<0.001) and by 56 ml more than with mefenamic acid (95% CI, 2 to 90 ml, p<0.05).[66]

A small crossover trial that compared TXA with flurbiprofen reported that over two treatment cycles the mean reduction in MBL from baseline for TXA was 140 ml (SD ± 33 ml, p<0.01), compared with 72 ml (SD ± 44 ml, p<0.01) for flurbiprofen.[71]

Table 18. Change in blood loss volume from baseline in studies of TXA

Author, Year	Comparator	TXA Group	Comparator Group	TXA vs. Comparator Group
Lukes et al., 2010[78]	Placebo	−69.6 ml	−12.6 ml	p<0.001
Freeman et al., 2011[81]	Placebo	-65.3 ml (high-dose) -46.5 ml (low-dose)	-3.0 ml	p<0.0001
Preston et al., 1995[80]	Norethisterone	−79.0 ml	+34.0 ml	p<0.0001
Bonnar and Shepard, 1996[66]	Mefenamic acid	−89.0 ml	−43.0 ml	p<0.05
Bonnar and Shepard, 1996[66]	Ethamsylate	−89.0 ml	+8.0 ml	p<0.001
Andersch et al., 1988[71]	Flurbiprofen	−140.0 ml	−72.0 ml	p<0.01

NR = not reported

Pictorial Blood Loss Assessment Chart Score

One poor quality trial that used the pictorial blood loss assessment chart score as the blood loss measure, compared TXA with oral MPA and reported a significant ($p<0.005$) reduction in the pictorial blood loss assessment chart score over three treatment cycles from baseline for both TXA (60.3%) and MPA (57.7%).[79]

Hemoglobin

Four studies[71,78-80] reported changes in hemoglobin level. In the good quality study, mean hemoglobin levels were unchanged from baseline for women taking TXA (0.02 ± 1.10 g/dL) while the placebo group had a statistically significant increase (0.34 ± 0.66 g/dL) that was not considered clinically significant.[78] The post treatment hemoglobin levels were similar (estimated difference 0.2 g/dl, 95% CI, −0.5 to 0.9) in the TXA (12.9 g/dl) and norethisterone groups (12.6 g/dl).[80] Hemoglobin levels rose significantly from baseline for women taking TXA ($p=0.0003$) and women taking MPA ($p=0.02$).[79] The small crossover trial did not find differences in mean hemoglobin during the control cycles (127.4 ± 3.7 g/l) compared with either TXA (126.2 ± 3.0 g/l) or flurbiprofen (127.2 ± 3.4 g/l) cycles.[71]

Treatment Success

One placebo-controlled trial reported a statistically significant difference ($p<0.001$) for achieving a MBL below 80 ml (standard definition of heavy menstrual bleeding) in the modified intent-to-treat population between women receiving TXA (43%) compared with those receiving placebo (17%) for six menstrual cycles.[78] This same study reported that 69 percent of cycles in the TXA group achieved a predetermined MBL reduction of at least 36 ml, representing a blood loss reduction considered meaningful to women.[78] In the three-arm placebo controlled study, women receiving the higher (3.9 g/day) and lower (1.95 g/d) dose of TXA achieved a reduction in MBL from baseline that was perceived as meaningful to participants; however, only participants receiving the higher dose of TXA (3.9 g/day) achieved a mean reduction in MBL that exceeded 50 ml per cycle.[81]

Quality of Life

One placebo-controlled trial reported a statistically significant ($p<0.001$) difference in social or leisure activities, and in physical activity, favoring TXA.[78] Women taking TXA has significant improvements in quality of life as assessed by the Menorrhagia Impact Questionnaire.[81]

Head-to-Head Comparisons

TXA Versus Norethisterone and MPA

The trial that compared TXA with norethisterone reported a statistically significant ($p<0.0001$) reduction in mean MBL for women receiving TXA for two treatment cycles compared with no reduction for women receiving norethisterone.[80] Expressed as percentage, the change in MBL for TXA was a 45-percent reduction (95% CI, 23% increase to 93% reduction; $p<0.0001$ vs. baseline) compared with an increase of 20 percent (95% CI, 114% increase to 62% reduction; $p=0.26$ vs. baseline) for norethisterone; expressed as a measure of volume, there was a reduction in MBL of 79 ml (95% CI, 62 to 108 ml reduction) for TXA compared with an increase of 34 ml (95% CI, −2 to 64 ml reduction) for noresthisterone.[80]

In a trial that compared TXA with oral MPA, both groups experienced significant reductions in MBL compared with baseline; the effect of these interventions was comparable (p=0.78). [79]

TXA Versus Mefenamic Acid, Ethamsylate, and Flurbiprofen,

TXA reduced the mean blood loss by 97 ml more than with ethamsylate (95% CI, 140 to 54, p<0.001) and by 46 ml more than with mefenamic acid (95% CI, 90 to 2 ml, p<0.05).[66] The trial that compared TXA with flurbiprofen reported that the reduction in MBL during treatment with TXA was significantly (p<0.01) greater than the reduction reported during treatment with flurbiprofen.[71]

Combined Oral Contraceptives

Key Points

- In two medium-sized RCTs, treatment of affected women with estradiol valerate and dienogest led to improvement in a range of AUB symptoms, including both overall complete response and effects on relevant laboratory values (e.g., hemoglobin, ferritin).
- In one small RCT and one small randomized crossover study of combination therapy with ethinyl estradiol and levonorgestrel and one small RCT assessing therapy with ethinyl estradiol and norethindrone acetate, COC treatment was associated with significant reductions in MBL as compared with baseline.

Detailed Synthesis

We identified five RCTs that explored the effects of therapy with COCs on the incidence and severity of abnormal cyclic uterine bleeding including two studies examining estradiol valerate and dienogest,[82,83] two studies examining ethinyl estradiol plus levonorgestrel,[59,68] and one study examining the combination of norethindrone acetate and ethinyl estradiol (Table 19).[61] All five studies were industry-sponsored.[59,61,68,82,83] Three were multicenter RCTs, involving Australia and Europe,[82] the United States and Canada,[83] and Canada,[61] and two were academic single center studies, one conducted in Egypt[59] and one conducted in Australia.[68] Two of the studies included seven 28-day cycles of therapy with the primary response rate determined after 90 days of therapy,[82,83] while one examined outcomes after 6 months[68] and two assessed outcomes after 12 months.[59,61] Two studies employed a placebo comparison group,[82,83] two compared COCs to LNG-IUS,[59,61] and one included a randomized crossover comparison of a COC to mefenamic acid.[68]

Table 19. Primary outcomes of COCs for abnormal cyclic uterine bleeding

Author, Year Country Quality	Comparison Groups (n)	Key Outcomes
Fraser et al., 2011[82] United States, Canada Good	**G1:** Estradiol valerate and dienogest (149) **G2:** Placebo (82)	• Full resolution of qualifying abnormal menstrual symptoms during the first 90 days of treatment observed in 40.7% of G1, as compared with 1.6% of G2 (p<0.0001). • Mean reduction in MBL was 69% in G1 vs. 5.8% in G2 and there were significant reductions in days of bleeding (p=0.0186), and number of sanitary protection items used (p<0.0001) observed in G1 vs. G2. • G1 participants had significant improvements vs. baseline in hemoglobin, hematocrit, and ferritin values; no similar change in G2.
Jensen et al., 2011[83] Australia, Europe Good	**G1:** Estradiol valerate and dienogest (120) **G2:** Placebo (70)	• Full resolution of qualifying abnormal menstrual symptoms during the first 90 days of treatment observed in 43.8% of G1 vs. 4.2% of G2 (p<0.001). • Mean reduction in MBL was 353 ml (64.2%) in G1 vs. 130 ml (18.7%) in G2 (p<0.001). • G1 participants had significant improvements vs. baseline in hemoglobin, hematocrit, and ferritin values; no similar change in G2.
Shaaban et al., 2011[59] Egypt Poor	**G1:** LNG-IUS (56) **G2:** Ethinyl estradiol and levonorgestrel (56)	• G2 associated with significant reduction in MBL at 12 months vs. baseline from 274.3 ± 142.6 ml to 118.2 ± 75.0 ml (p<0.001). • Reduction in MBL at 12 months was significantly greater in the G1 vs. G2. • Significant improvements in patient assessment of overall health noted in G1 and G2.
Endrikat et al., 2009[61] Canada Poor	**G1:** LNG-IUS (20) **G2:** Ethinyl estradiol and norethindrone acetate (19)	• G1 and G2 experienced a significant decreased in MBL at 12 months compared with baseline. Mean decrease of 68% in MBL for G2 (p<0.001). • Median MBL in G2 decreased from 290 ml at baseline to 72 ml at 12 months.
Fraser et al., 1991[68] Australia Poor	**G1:** Mefenamic acid (12)[a] **G2:** Ethinyl estradiol and levonorgestrel (12)[a]	• Significant reduction in mean MBL observed during the COC treatment cycles (43%) as compared with baseline. (p<0.001). • At least 20% reduction in MBL as compared with the preceding baseline cycles was observed in 10/12 patients during mefenamic acid treatment and 9/12 during COC treatment.

LNG-IUS = levonorgestrel-releasing intrauterine system; MBL = menstrual blood loss; COC = combined oral contraceptive
[a]Crossover study.

All studies assessed measures related to changes in MBL, including use of the alkaline hematin method[59,68,82,83] and the pictorial blood loss assessment chart.[59,61] Other outcomes included number of sanitary items used, a composite outcome of menstrual bleeding-related factors,[82,83] and related hematologic parameters (i.e., hematocrit, hemoglobin, and/or serum ferritin).[59,61,82,83] One study also assessed potential impact on health-related quality of life[15] and one described effects on a menorrhagia symptom severity score.[61] None of the studies assessed any potential effect modifiers.

Among the five studies of COC therapy, two were good quality[82,83] and three were poor quality.[59,61,68] Details of quality scoring for individual publications are included in Appendix I.

Description of Results

Estradiol Valerate and Dienogest

Two multicenter RCTs with the same industry sponsor assessed the utility of estradiol valerate and dienogest in treatment of women with AUB, defined as prolonged, frequent, and/or heavy bleeding. The first RCT[82] was conducted in Australia and Europe and comprised 231 women, randomized at a 2:1 ratio after a 90-day run-in period to receive estradiol valerate and dienogest for seven 28-day cycles. The study drug regimen included estradiol valerate 3 mg on days 1 to 2, estradiol valerate 2 mg and dienogest 2 mg on days 3 to 7, estradiol valerate 2 mg and dienogest 3 mg on days 8 to 24, estradiol valerate 2 mg on days 25 to 26, and placebo on days 27 to 28. Complete response, defined as full resolution of qualifying abnormal menstrual symptoms during the first 90 days of treatment as compared with the 90-day run-in phase, was observed in 29.5 percent of the estradiol valerate and dienogest group, as compared with 1.2 percent of the placebo-treated patients ($p<0.0001$). Treatment with estradiol valerate and dienogest was also associated with significant reductions in volume of MBL ($p<0.0001$), days of bleeding ($p=0.02$), and number of sanitary protection items used ($p<0.0001$) as compared with the placebo group. The estradiol valerate and dienogest-treated patients also experienced significant improvements versus baseline in hemoglobin, hematocrit, and ferritin values; similar improvements were not observed in the placebo-treated group.

The second RCT[83] was conducted at centers in the United States and Canada, employing the same dose and randomization schema and including 190 women with AUB. Complete response, defined as full resolution of qualifying abnormal menstrual symptoms during the first 90 days of treatment as compared with the 90-day run-in phase, was observed in a significantly greater proportion of the estradiol valerate and dienogest group (35/80, 44%) as compared with the placebo group (2/48, 4%, $p<0.001$). The mean reduction in MBL was also greater in the estradiol valerate and dienogest (−353 ml or −64% vs. loss during run-in phase) when compared with the placebo group (−130 ml or −19% vs. observed run-in loss, $p<0.001$). Individuals in the estradiol valerate and dienogest group also experienced significant improvements in hemoglobin, hematocrit, and ferritin values as compared with the run-in phase, while similar improvements were not observed in the placebo group.

Ethinyl Estradiol and Levonorgestrel

Two randomized controlled trials assessed the utility of an ethinyl estradiol (30 mcg) and levonorgestrel (150 mcg) combination in women with menorrhagia.[59,68] One of these trials was a single center RCT involving 112 women with idiopathic menorrhagia randomized to LNG-IUS (n=56) or ethinyl estradiol/levonorgestrel (n=56) for 12 months.[59] Efficacy data from the LNG-IUS arm of the study is discussed further in the LNG-IUS section of this report. In this trial, the COC regimen was associated with a significant reduction in MBL as assessed by the alkaline hematin method at 12 months as compared with baseline, from 274.3 ± 142.6 ml to 118.2 ± 75.0 ml ($p<0.001$); however, the overall reduction in MBL was significantly greater in the LNG-IUS group as compared with the COC group. Significant improvements in patient assessment of overall health and reduction in physically ill days were noted in both treatment groups.

The other trial assessing the use of ethinyl estradiol and levonorgestrel was a crossover study in women with menorrhagia, with one arm comparing outcomes of 12 women treated sequentially with mefenamic acid (500 mg every 12 hours from first sign of menses until 24 hours after usual duration of heavy bleeding) and COCs for two cycles each in random order,

with a two-cycle washout period between treatment cycles.[68] Additional efficacy details for mefenamic acid and for another treatment arm in this study involving naproxen are further discussed in the NSAIDs section of this report. A significant ($p<0.001$) reduction in mean MBL as measured by the alkaline hematin method was observed during the COC treatment cycles as compared with baseline (43%); the reduction in mean MBL during the mefenamic acid treatment period was not significantly different than the COC treatment period. A response of at least 20 percent reduction in MBL as compared with the preceding baseline cycles was observed in 10 of 12 patients during mefenamic acid treatment and in 9 of 12 during COC treatment. One patient responded to COCs but not to mefenamic acid, and two patients exhibited a response to mefenamic acid but not to the COC regimen.

Ethinyl Estradiol and Norethindrone Acetate

One multicenter randomized controlled trial compared the combination of ethinyl estradiol (20 mcg) and norethindrone acetate (1 mg) to use of a levonorgestrel-releasing intrauterine system (LNG-IUS) over 12 months in 39 women with idiopathic menorrhagia.[61] Efficacy data from the LNG-IUS arm of the study is also discussed further in the levonorgestrel-releasing intrauterine system section of this report. The LNG-IUS arm included 17 women and the COC arm included 12. Both arms experienced a significant ($p<0.001$) decrease in MBL at 12 months as compared with baseline, with a decrease from a median MBL of 290 ml at baseline to a median of 72 ml at 12 months observed in the COC group (mean decrease 68%). The decrease in MBL, however, was significantly greater in the LNG-IUS group versus the COC group ($p=0.002$). Treatment success, defined as MBL less than 100 at 12 months, was observed in a significantly ($p<0.009$) greater proportion of the LNG-IUS participants (80%) as compared with the COC group (37%). Menorrhagia symptom severity scores were also significantly lower in the LNG-IUS group at 6 months as compared with the COC group ($p=0.05$). No significant changes in hemoglobin concentration were observed in either group during the study.

Use of Decision Aids in Treatment of Menorrhagia

Key Points

- Three RCTs evaluated decision aids to assist patients with menorrhagia. All were of poor quality due to lack of blinding of participants and care providers.
- Improvements in general health status, the primary outcome for 2 studies, were not associated with decision aids. One study reported lower use of hysterectomy among women who had an interview prior to their consultation while another study did not show differences in hysterectomy rates after 1 year. Two studies did not report differences in treatment outcomes after 6 months or 1 year.

Detailed Synthesis

Decision aids are interventions to inform patients of their treatment options when more than one option exists. A recent Cochrane review of RCTs of decision aid[94] found that decision aids are beneficial in increasing patient knowledge of treatment options, help to clarify benefits and harms associated with therapeutic choices, and increase patient participation in decision selection. They have been shown to reduce elective surgery and have no apparent adverse effects on patient outcomes or satisfaction.[94]

We identified three RCTs with four publications[85-87,95] about medical decision aids in women with menorrhagia (Table 20). All of the studies used a written decision aid booklet; one study evaluated a computerized decision aid in conjunction with the pamphlet and one study also mailed participants a videotape and conducted an interview prior to clinical appointment. Diagnosis of menorrhagia was determined from medical records and not quantified in any of the studies. Length of followup ranged from 6 months to 2 years. Two studies were conducted in the United Kingdom[86,87] and one was conducted in Finland.[85] These studies were all of poor quality.

The largest study (n=894), conducted in England, randomized women to receive booklet and videotape with interview, materials without interview, or standard practice groups.[86] General health status improved significantly and menorrhagia severity decreased in all three groups. Treatment rates were similar in all groups after 2 years. Women in the interview group had a lower rate of hysterectomy and reported greater satisfaction with treatment results. A medium sized Finnish study evaluated the effectiveness of a mailed information booklet on treatment outcomes and general health status after 1 year.[85,95] More women who received the decision aid were less likely to receive newer treatment methods including minor surgery or LNG-IUS (16% vs. 26%, p=0.03). Most of the measured health outcome scores improved after 1 year for both groups with no significant difference in patient satisfaction, knowledge, anxiety or sexual satisfaction.

A small English study[87] conducted from 2003 to 2005 evaluated a computerized decision aid in conjunction with a patient leaflet. Women in the intervention group had significantly less decisional conflict at 2 weeks and higher knowledge scores at 6 months. There were no significant group differences in anxiety or treatments received after 6 months.

Although decision aids do help to increase patient knowledge, there are some methodological limitations in these studies, including low participation rates, large number of drop outs, and lack of blinding. The diagnosis of menorrhagia was not quantified and no effect modifiers were examined in any of these studies. Information on harms was not reported in any of the decision aid studies.

Table 20. Primary outcomes of decision aids for abnormal cyclic uterine bleeding

Author, Year Country Quality	Comparison Groups (n)	Outcomes	Results
Protheroe et al., 2007[87] United Kingdom Poor	**G1:** Computerized decision aid and information leaflet (74) **G2:** Information leaflet only (72)	**Primary:** total score on Decisional Conflict Scale **Secondary:** anxiety, quality of life, knowledge, treatment preferences	• Decisional conflict was significantly reduced in G1 vs. G2 (adjusted difference 16.6 95% CI, 21.5 to 11.6, p<0.001). • Anxiety declined slightly for both groups (p=NS). • Quality of life and knowledge scores improved in both groups but more in G1 as compared with G2.
Vuorma et al., 2004[85,95] Finland Poor	**G1:** Information booklet (184) **G2:** Usual care (179)	**Primary:** Planned treatment at 3 months and actual treatment at 1 year General health status measured by RAND -36 **Secondary:** knowledge of treatment methods, satisfaction with communication anxiety and sexuality	• Fewer women in G1 received newer treatments (minor surgery or LNG-IUS) (p=0.03); hysterectomy rates were similar in both groups. • Most health status measures improved for both groups. • At 3 months 18% of women in G1 and 8% in G2 had received prescription for oral medication (p=0.007). • There were no differences between groups in anxiety, satisfaction, knowledge or sexual satisfaction.
Kennedy et al., 2002[86] United Kingdom Poor	**G1:** Interview and information booklet (300) **G2:** Information booklet only (296) **G3:** No intervention (298)	**Primary:** general health status measured using SF-36 **Secondary:** treatments received during followup, severity of menorrhagia, patient satisfaction	• Health status measures improved for all 3 groups. Treatment rate (81%) during study was similar for all 3 groups (p=0.17) but women in G1 were less likely to have a hysterectomy (OR 0.60 95% CI, 0.38 to 0.96). • G1 were more satisfied in taking part in treatment decision and with results compared with G3.

CI = confidence interval; OR = odds ratio; NS = nonsignificant

KQ2. Harms of Interventions for Management of Abnormal Bleeding

Description of Included Studies and Sources of Information

Capturing useful information about potential harms of treatment for reproductive-age women that is specifically applicable to interventions for abnormal bleeding is a challenge. A wide range of interventions are used to treat abnormal bleeding. Twelve interventions relevant to the primary care setting were identified for this report. They range from medications that are exceptionally familiar to providers such as NSAIDs to potentially less familiar or newer medications like exenatide (an injectable diabetes agent). Interventions also include those with widespread use and many indications, like oral contraceptive pills or acupuncture, as well as those specifically for the indication of abnormal bleeding like TXA.

To pare down the scope of the material, we took a four step approach to structuring this KQ about harms.

- Summarizing harms detected within clinical trials included in this review. This has limitations since many of the studies are small, with a range in size of 14 to 894 and a median total study population of 80. Thus they are not well-suited to detecting events that are rare but may be serious or affect a specific subgroup of women.
- Compiling the key content of FDA documents and package inserts for specific products addressed in this review. This however lacks specificity as many of these products have multiple indications and the concerns may not be as applicable to the population of women with AUB or to the dose and duration of use for treating AUB. Furthermore symptoms and harms are reported in these documents that may not be statistically, meaningfully different between the active agent and the placebo.
- Searching for surveillance studies that aimed to examine risk of harm in large populations of individuals (i.e., 1600 or more) using the specific intervention. This last step was done using a separate search described in greater detail in methods. We restricted summarizing results from harms surveillance studies to: metformin, exenatide, progestogens, cabergoline, LNG-IUS, contraceptive vaginal ring, and TXA.
- Providing information about existing contemporary reviews and guidance on harms for common medications with broad indications. Like the second approach it is important to note that these extant literature reviews reflects varied indications and populations that may not be directly applicable to use for AUB.

The organization of this chapter includes evidence about harms from these sources in the following order:

- Harms identified in randomized trials included in this review.
- Harms flagged in FDA package inserts and regulatory proceedings.
- Harms investigated in large surveillance studies of metformin, exenatide, relevant progestogens, cabergoline, LNG-IUS, contraceptive vaginal ring, and TXA.
- Contemporary reviews that include review of harms.

We present this summary of harms in the same order of KQs and intervention methods as the results for our KQs. Interventions for irregular uterine bleeding are present before those for abnormal cyclic uterine bleeding.

Key Points for Harms of Reviewed Treatments

- Metformin is associated with increased risk of gastrointestinal symptoms like diarrhea and abdominal pain. Symptoms can be reduced by slowly increasing the dose. Severe harms including lactic acidosis, serious hypoglycemia, and liver failure, studied among populations of adult diabetics, occur at incidence rates below 1 in 10,000 and may be as low as 1 in 100,000 person-years of exposure.
- Progestogens are associated with a number of common side effects of hormonal preparations including weight gain, fluid retention, abdominal pain, nausea, change in mood, and change in appetite. Abnormal uterine bleeding is itself a common side effect of progestogen only interventions.
- COCs have commonly recognized side effects that include edema, breast tenderness, nausea, headache, and skin changes. Known contraindications, including advancing age, smoking, and high risk of thrombosis, apply when considering use of COCs for irregular

bleeding. Selected COC formulations may have lower risk of deep vein thrombosis than others.

- Cabergoline has few known distinct harms; however, data is inadequate to assess risk in young women without elevated prolactin.
- LNG-IUS has few serious harms after insertion. Irregular bleeding, especially early after insertion is the most commonly reported side effect. Painful insertion occurs in roughly 1 of 100 procedures; 3.2 of 100 insertions are technically difficult, and uterine perforation occurs in 0.9 to 2.6 cases per 1,000. The LNG-IUS is not associated with increased deep vein thrombosis risk.
- NSAIDs have common harms that include abdominal pain, nausea, gastritis, and lightheadedness/dizziness. Gastrointestinal bleeding is a serious side effect related to total dose and duration of use; however, even short-term use can increase risk. The risk of gastrointestinal bleeding from low-dose, intermittent NSAID use is poorly characterized.
- TXA use is associated with headache, nasal and sinus symptoms, back pain, and abdominal pain in more than 10 percent of those taking the drug. Joint pain, muscle cramps, migraine, anemia and fatigue occur in more than 5 percent. Rare events are less well characterized and may include thrombosis, anaphylaxis, and visual disturbances. TXA is contraindicated in those with higher risk of thrombosis.
- Contraceptive vaginal ring has similar side effects to COCs including breast tenderness, nausea and headache. Ring users also experience local problems including leucorrhea, vaginitis, and ring-related events including expulsion, foreign body sensation, and coital problems. The contraceptive vaginal ring is not recommended for use in cigarette smokers over age 35.
- Other than COCs, progestogens, and the LNG-IUS, the available data may not apply well to populations of young women using these treatments.

Detailed Synthesis

Harms Related to Metformin

Information about Metformin from Included Trials

Metformin was investigated in two placebo controlled trials[51,52] and in two arms of a three-arm trial in which two arms included metformin:[53] one metformin alone and another with combined oral metformin and exenatide weekly injections. Doses used in these studies, after an initial 1 week dose ramp up were 850 mg twice a day,[51] 500 mg 3 times daily,[52] and 1,000 mg twice daily.[53] Combined, the three RCTs, with four total metformin arms, administered the drug to only 77 women, 20 of whom were also receiving another agent.[51-53] This provides insufficient power to detect events that occur at the level of 1 to 5 percent or lower that are typically of concern for harms. It also provides insufficient power to conclude that specific symptoms were statistically more common among those treated than among the 33 women who received placebo in two studies.[51,52] Women receiving metformin did report gastrointestinal symptoms, including diarrhea, abdominal pain, and nausea at higher absolute numbers than those in the placebo or exenatide only groups,[52,53] and the study reporting withdrawals[51] documented 3 times as many women on the active drug withdrew from the trial for side effects (15/45 vs. 5/47; $p<0.05$).

Information About Metformin From FDA Documents and Package Inserts

Increased gastrointestinal complaints are consistent with the documented side effects listed in the package insert for metformin which include: diarrhea, nausea/vomiting, flatulence, indigestion, and abdominal discomfort as events that are the most common and expected to occur in more than 5 percent of those who initiate the drug.[96] Of note, it is recommended that the dose be increased gradually over 1 week or more precisely because these effects are common and can be reduced by gradual introduction of the drug. The most serious known side effect of metformin is lactic acidosis which occurs when lactate accumulates in the blood and decreases blood pH. The package insert includes a boxed warning for this concerning effect.[96] Little is known about how common lactic acidosis might be among reproductive-age women, with PCOS and not type 2 diabetes, similar to those in the study or for whom the intervention might be considered as part of primary care management of irregular uterine bleeding.

Information About Metformin From Large Datasets

Our literature search aimed at identifying publications designed to investigate harms, required more than 1,600 exposed individuals, or for case-control analyses, case identification consistent with a base population of more than 1,600. We identified four publications focused on metformin harms.[97-100]

The Toxic Exposure Surveillance System database of the American Association for Poison Control Centers provided data from 1996 through 2000 for accidental and intentional over ingestion and unintentional misuse of metformin for 4,072 cases.[97] Fifty-nine percent were women and the majority was adults. Children under 12 had few serious side effects and no deaths. Among adults, harms were evenly distributed across ages with a trend for more serious outcomes in the elderly. In all groups lactic acidosis was rare (1.6%) and hypoglycemia at 2.8 percent was more common that previously reported. Given all individuals had unintended or higher than therapeutic doses, they also observed elevated creatinine levels, an increased anion gap, hypotension, and coma among those hospitalized.

The first publication focused on harms of intended use was published in 2003 to assess incidence of serious acute liver injuries in patients on hypoglycemic agents.[98] The population comprised the 171,264 members of five health maintenance organizations receiving oral diabetes medications. They identified 35 cases of acute liver failure, not known to be attributable to another cause. Incidence per 1,000 person-years of use was not statistically meaningfully different by medication used, after adjusting for other comorbidities and confounders. Overall occurrence was roughly 1 case per 10,000 person-years in this population of all adult diabetics.[98]

In 2008, an analysis using the U.K. General Practice Research Database undertook an analysis of the risk of lactic acidosis and hypoglycemia among 50,048 type 2 diabetics using oral medications.[99] The average age of patients included in the analysis was 60.7 ± 11.7 and 54.8 percent were women. They determined the incidence rate of lactic acidosis was 3.3 per 100,000 person-years among metformin users and 4.8 per 100,000 person-years among those on sulfonyl ureas. The adjusted odds ratios for both lactic acidosis and severe hypoglycemic episodes were significantly higher for those on sulfonyl ureas than metformin with a more than 2-fold elevation in risk. However this analysis also did not include individuals taking metformin for indications other than diabetes.

A retrospective cohort of more than 44,169 diabetic patients in a prepaid health plan followed for an average of 4.2 years evaluated use of endoscopy.[100] The exposure of interest was defined by prescription of specific diabetes medications and the outcome of interest was lower

gastrointestinal tract endoscopy including flexible sigmoidoscopy and colonoscopy. The analysis was undertaken in part out of concern that therapy with metformin, with attendant risk of gastrointestinal side effects, could increase use of lower tract endoscopy. Forty-seven percent of participants were women with an average age of 66. The authors found that rates of endoscopy were higher among all groups of diabetics on medications, including those using insulin. Taking into account the precision of the estimates, there was no evidence that metformin led to excess use compared with other medications either in the window immediately after initiation or with chronic use. Overall, the higher use of endoscopy may simply reflect greater screening and prevention vigilance among these patients with a chronic disease. No comparison is offered to rates among diabetics controlled with diet and exercise alone.

Information About Metformin From Systematic Reviews

Estimates for withdrawals related to inability to tolerate the drug in included trials are consistent with the meta-estimate in a recent systematic evidence review on management of obesity. The AHRQ Screening and Management of Obesity in Adults[101] evidence review reported a risk ratio of 3.92 (95% CI, 1.23 to 12.57) for withdrawals in metformin-treated groups compared with placebo in trials aimed at weight loss and not diabetes management.[101] The report likewise found excess complaints of gastrointestinal symptoms but was not able to quantify risk and noted that evidence about harms is insufficient to inform care.[101]

Similar to the surveillance data, a Cochrane pooled analysis of comparative data from 347 trials found an upper limit of 4.3 cases of lactic acidosis per 100,000 patient-years among metformin-treated diabetic patients.[102] The analysis indicated no significant difference in mean treatment levels or net change from baseline for lactate for metformin users as compared with users of other therapies represented in the included trials.[103] This review also notes that the only evidence for lactic acidosis associated with metformin use is based on approximately 330 cases reported in the literature.[102] The 2011 AHRQ comparative effectiveness review (CER) Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update[104] included 140 trials with a meta-analysis. Across all data sources in their review, the reviewers concluded there was high grade evidence that metformin alone and in combination with other diabetes medications was associated with greater occurrence of gastrointestinal side effects than with other agents alone or in combinations that did not include metformin. Nonetheless the overall safety profile and effectiveness of metformin led to the conclusion that metformin was the first-line agent for initial management of type 2 diabetes. The authors take care to point out that even among trials for a chronic condition like type 2 diabetes, longer term surveillance for harms does not exceed 2 years. As in diabetes, women with abnormal bleeding might wish to consider chronic treatment and the literature to assess safety of continued use for any indication is scant.

Within a number of reviews of oral diabetes agents[105,106] metformin is typically found to have a favorable safety profile when compared with other medications and is often noted to be first-line therapy in part for this reason. Relative safety in the context of other options for treating diabetes is not directly applicable to use for improving menstrual cycle regularity, however there are no physiologic reasons to expect that younger individuals without diabetes would experience greater risk.

Harms Related to Exenatide

Information About Exenatide From the Included Trial

A single RCT in this review investigated exenatide, finding that alone it was less effective than metformin, but that when combined the results were superior to either agent alone for improving cycle regularity in women with PCOS.[53] Exenatide is injected weekly and is generally administered as a second agent among those with diabetes that is insufficiently controlled on a single agent. The trial included in this review allocated women with PCOS to three groups: 1,000 mg of metformin twice daily, exenatide 10 mcg per day, or both.[53] Nausea, diarrhea, and bloating were more common in the arms taking metformin. No harm was more common in the exenatide group except injection site pain or bruising which was de facto restricted to groups using exenatide. Comparisons across groups of 20 are underpowered to detect differential harms across groups or to detect more rare and potentially serious harms.

Information About Exenatide From FDA Documents and Package Insert

The package insert for exenatide notes that hypoglycemia is a common adverse effect but does not specify what proportion of those prescribed the drug might experience low blood sugar.[107] Events that occurred in 2 percent or more of new users of exenatide when added to a regimen with metformin or a sulfonyl urea include: nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, asthenia which is a lack of strength or energy, gastroesophageal reflux, and increased sweating. Postmarketing experience includes reports of: injection-site reactions; generalized pruritus and/or urticaria; macular or papular rash; angioedema; anaphylactic reaction; increased international normalized ratio with concomitant warfarin use sometimes associated with bleeding; nausea, vomiting, and/or diarrhea resulting in dehydration; abdominal distension; abdominal pain; eructation; constipation; flatulence; acute pancreatitis; hemorrhagic and necrotizing pancreatitis sometimes resulting in death; dysgeusia; somnolence; altered renal function, including increased serum creatinine; renal impairment; worsened chronic renal failure or acute renal failure (sometimes requiring hemodialysis); kidney transplant and kidney transplant dysfunction; and alopecia (Byetta Package Insert, 2011).[107]

Information About Exenatide From Large Datasets

Surveillance studies have all focused on acute pancreatitis which is suspected of being a rare but important side effect. Two analyses in large patient pools did not identify an association,[108,109] while a third publication with data from the FDA post marketing surveillance database did see increased risk for both exenatide and another drug with similar but not identical mechanism, sitagliptin.[110]

The two claims-based analyses relied on large databases of health plan enrollees: The Ingenix Research Datamart[108] and the Normative Health Information database.[109] The first examined 27,966 individuals who began exenatide and 16,276 who started sitagliptin.[108] During 1 year of followup, acute pancreatitis occurred in 0.13 percent of those on exenatide and 0.12 percent of those on sitagliptin. In adjusted models, relative to comparison cohorts within the health plan the relative risk of acute pancreatitis was 1.0 for both groups with confidence bounds from 0.6 to 1.7 and 0.5 to 2.0 respectively. The second analysis included 25,719 new users of exenatide compare to 234,536 new users of other diabetes medications.[109] The groups differed in important ways including more obesity and concomitant diabetes medications among those using exenatide. In adjusted models to control for these and other factors, there was no increase in use

for current or recent use but an elevation in risk for past use. This was compared with a matched case-control analysis that found no association for any category of current, recent, or past use. This is compatible with those with past use having unknown additional comorbidity or discontinuing use because of other serious health events. The authors conclude overall there was not increased risk of pancreatitis among those taking exenatide.

The FDA surveillance data compared adverse events for exenatide to those for other drugs in the database.[110] They found the odds of being on exenatide were more than 10-fold higher than the control drug for pancreatitis. Pancreatic cancer was almost 3-fold higher. The sole control for confounding was the use of those on other drugs in the registry as a comparator. The authors note that the FDA data is limited by incomplete data and reporting bias; notably they lack information about obesity and individual behaviors such as alcohol use and the risk models are not adjusted for these confounders.

Information About Exenatide From Systematic Reviews

Systematic reviews of diabetes medications (including the AHRQ report above on obesity treatment[101]), a detailed CER conducted by the United Kingdom's National Health Service, and a Cochrane analysis including exenatide, reveal gastrointestinal issues, particularly nausea and vomiting, and hypoglycemia as the most commonly observed side effects observed in those initiating therapy with this agent.[101,111,112]

Harms Related to Progestogens

Information About Progestogens From Included Trials

A single RCT included in this review investigated progestogen use for improving cycle regularity.[49] The two agents used in this comparative effectiveness trial were 20 mg of oral dydrogesterone, each day for 10 days, or 90 mg of micronized progesterone gel vaginally every other day for 10 days. The authors' intent was to demonstrate that both oral and vaginal administration improved cycle control which was the case compared with baseline. However power calculations did not indicate the equivalence band desired and the overall study was small (n=69). They report the only adverse events experienced were in the micronized vaginal progesterone gel group and included one episode each of groin pain, ovarian cyst, and 5-kg weight gain. These events were too rare given the small study size to meaningfully assert comparability or excess of harms between groups. Six patients in each treatment group withdrew from the study (reasons not given), suggesting there was not a large discrepancy in willingness to stay on study drug.

Eight studies of treatments for abnormal cyclic bleeding (KQ1B) included a progestogen as a comparator. MPA was a comparator in three studies,[60,62,79] one of which included DMPA as a third comparison arm.[62] Five studies compared LNG-IUS, TXA, an NSAID, or the contraceptive vaginal ring to norethisterone[64,70,74,80,84] and one of these studies also included a third arm using the progesterone-impregnated intrauterine coil as a comparator.[74] Harms reported with this class of drug include: breakthrough bleeding; spotting; change in menstrual flow; amenorrhea; headache; nervousness; dizziness; edema; increases or decreases in weight; change in cervical secretions; cholestatic jaundice, breast tenderness and galactorrhea; skin sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash; acne, alopecia and hirsutism; rash (allergic) with and without pruritus; anaphylactoid reactions and anaphylaxis; depression; pyrexia; fatigue; insomnia; nausea; and somnolence.[113-116] Most studies reviewed were small and

did not systematically compare adverse events across interventions groups. In all but one case, progestogens were a comparator that was hypothesized and found to perform less well than the intervention under study. The one exception was a direct comparison of two routes of delivery discussed above.[49] We consider COCs and the LNG-IUS in their own section.

Information About Progestogens From FDA Documents and Package Inserts

We have summarized information for progestogen only methods included in this review. The label for Crinone, the progesterone vaginal gel, reports adverse events seen in the three clinical studies for secondary amenorrhea in women taking either 4-percent or 8-percent strength Crinone along with estrogen and occurring in 5 percent or more of women.[114] These are given as: abdominal pain (5% in patients taking 4% strength, 9% in patients taking 8% strength, respectively); appetite increased (5%, 8%); bloating (13%, 12%); cramps not otherwise specified (19%, 26%); fatigue (21%, 22%); headache (19%, 15%); nausea (8%, 6%); back pain (8%, 3%); myalgia (8%, 0%); depression (19%, 15%); emotional lability (23%, 22%); sleep disorder (18%, 18%); vaginal discharge (11%, 3%); upper respiratory tract infection (5%, 8%); and pruritus in genital area (2%, 6%).[114] The package insert for vaginal progesterone gel includes a warning that "physicians should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular disorders, pulmonary embolism, and retinal thrombosis)."[114]

This profile of complaints is similar among smaller groups of women who receive the drug as part of treatment for infertility care. One of the specific agents studied among women with irregular menses, dydrogesterone, is not available in the United States. This compound has been associated with risk of onset of acute porphyria. Porphyria is a genetic condition in which individuals have a range of severities of defects in the enzyme pathways that produce heme. The insert advises prescribing only for compelling reasons. Our review team does not find evidence that other progestogens are associated with acute onset of porphyria symptoms.

The DMPA label[115] includes a warning to women who may become pregnant while using the drug or find themselves exposed to the drug during the first 4 months of pregnancy regarding the risk of hypospadias; the risk of hypospadias, usually 5 to 8 per 1,000 male births in the general population, may be approximately doubled with exposure to these drugs.[115] Additionally, there have been undesirable effects at the site of injection, such as residual lump, change in skin color, or sterile abscess.[115]

Information about Progestogens from Large Datasets

The specific compounds used for irregular uterine bleeding or abnormal cycle bleeding were not addressed in large surveillance studies or in systematic review that compiled information about harms separate from their inclusion in COCs with the exception of DMPA and norethindrone in progestin-only pills.

As noted, we did not attempt to review the surveillance literature related to harms of oral contraceptives or specific progestogens in COCs. We did however seek large scale primary studies related to harms of progestogen-only formulations such as DMPA. Four studies, one conducted in Europe, one in Turkey, and two in Africa, described harms associated with DMPA.[117-120] A single cross-cutting study of contraceptive risks included norethindrone-alone pills.[121]

A Danish case-control study that included 64,548 women with fractures indicated an association with DMPA use (OR=1.44; 95% CI, 1.01 to 2.06); this however was not adequately controlled for factors that may confound the relationship, such as the potentially increased use of

DMPA among smokers or those with lower body mass index which are both also associated with fracture risk.[118] A study in South Africa evaluated bone density in 3,487 black, reproductive-age women using injectable progestogens as contraception and reported decreased bone density by measurement of heel bone density; this effect was reversible within 2 to 3 years of discontinuing the injected progestogen across age categories of users.[119] These findings are compatible with data from smaller studies which they review well in their publication.

DMPA has been associated in observational studies with deep venous thrombosis.[117] However, other work comparing those who use medications for menorrhagia has documented increased risk among women who use TXA, mefenamic acid, and norethisterone, suggesting that the increased risk of thrombosis may be an example of confounding by indication. Such confounding suggests that the reason for which the medication is administered itself increases risk of the adverse outcomes.[122] In a comprehensive study of 9,262 DMPA users in Turkey conducted between 1996 and 2004, deep vein thrombosis was not observed.[120] The most common adverse effects reported were menstrual disturbances (80%), weight gain (10%), bloating, breast pain, headache, mood change, and sexual difficulties (each reported by more than 1%). More than one-third of women discontinued the method with the most common reasons for discontinuing other than desiring to conceive being irregular menses and side effects.

A 2012 publication about hormonal contraceptive methods and risk of thrombotic stroke and myocardial infarction, estimated risk based on person-years of exposure to specific contraceptive methods in a cohort of 15 years duration.[121] In a total of 85,874 women-years of observation, norethindrone progestin-only pills were not statistically significantly associated with increased risk of either stroke or myocardial infarction.

Information About Progestogens From Systematic Reviews

A Cochrane review examining the use of progestogens for the treatment of heavy menstrual bleeding found that progestogens had a generally better side effect profile than danazol, with lower incidence of side effects such as headache, weight gain, and skin changes; however, breast changes were relatively more common in the progestogens group.[123] In the context of evaluating progestogen-only pills for contraception, another Cochrane review found inter-cycle bleeding and cycle irregularity to be some of the most common reasons for treatment discontinuation represented in included trials.[124]

Harms Related to COCs

Information About COCs From Included Trials

Our review included six RCTs examining COC use in women with abnormal uterine bleeding.[50, 59, 61, 68, 82, 83] Due to the low power of these three medium sized RCTs and three small RCTs for detecting adverse events, reports of potential harms in these publications are largely limited to descriptive text rather than quantitative comparisons.

Among women with irregular menses only (KQ1A), one study treated patients with COCs. Davis and colleagues[50] assessed a triphasic pill in which the estrogen was ethinyl estradiol and the progestogen was norgestimate. Their trial randomly assigned 201 women to the oral contraceptive arm or a placebo. Authors do not provide detailed description of adverse events, noting that the incidence was low and comparable between the two groups. Four women in the COC group and three in the placebo group discontinued use after adverse events. Sixteen percent

of those on active drug and 19 percent of those receiving placebo withdrew prior to completion of the trial.

Two trials assessing the use of estradiol valerate and dienogest in women with abnormal cyclic uterine bleeding (KQ1B) each found that 9 to 10 percent of women discontinued therapy with the COC regimen due to side effects.[82,83] The type and incidence of adverse effects noted in these two studies of estradiol valerate and dienogest are similar to those noted in the package insert for this combination.[125]

The trial examining therapy with ethinyl estradiol and norethindrone acetate reported that five women discontinued the study due to adverse events (approximately 25%), noting that the most comment events included intermenstrual bleeding, menstrual disorder, and headache.[61] The two studies involving use of ethinyl estradiol and levonorgestrel did not describe potential harms associated with treatment failure, other than noting the incidence of treatment failure.[59,68]

Information About COCs From FDA Documents and Package Inserts

The package inserts are similar for all combined estrogen and progestogen oral contraceptive pills. The warning for combined pills notes:

> Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptive (COC) use. This risk increases with age particularly in women over 35 years of age and with the number of cigarettes smoked. For this reason, COC's should not be used by women who are over 35 years of age and smoke.[126-128]

Other serious harms associated with COCs include thrombophlebitis and venous thrombosis with and without embolism, arterial thromboembolism, pulmonary embolism, myocardial infarction, cerebral hemorrhage, cerebral thrombosis, hypertension, gallbladder disease and benign liver tumors. A complete listing of package insert adverse events for this and other oral contraceptives reviewed in this report is included in Appendix N. Package inserts do not generally include information about the expected population incidence of these harms.

The majority of primary care providers and many women are aware of the most serious risks of COCs and of more common side effects such as edema, nausea, vomiting, skin changes, and gastrointestinal symptoms. Among more common side effects are also changes in cycle characteristics themselves including spotting/breakthrough bleeding, lack of menses, and change in characteristics of menstrual flow.

Adverse events for specific COCs studied for heavy menstrual bleeding in this review include Nordette-28® (0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel). The package insert reports based on data from case control studies, the relative risk for superficial venous thrombosis is three times higher in users of the COC compared with nonusers; the risk of deep vein thrombosis or pulmonary embolism is 4 to 11 times higher, and 1.5 to 6 times higher in women predisposed to venous thromboembolic disease.[127] The incidence of deep vein thrombosis and pulmonary embolism for users of low-dose (i.e., less than 0.05 mg ethinyl estradiol) COCs is up to 4 per 10,000 woman-years compared with 0.5 to 3 per 10,000 woman-years for nonusers, although this risk is less than the risk associated with pregnancy (6 per 10,000 woman-years).[127] A large postmarketing study noted that the Nordette label information reports a relative risk of thrombotic strokes ranging from 3 for normotensive users to 14 in women with severe hypertension. The relative risk of hemorrhagic stroke is reported to be 1.2 for

nonsmokers using oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension.[127]

Label information on estradiol valerate and dienogest (Natazia®) reports two cases of myocardial infarction and two cases of rupture ovarian cyst from clinical trials, along with known serious risk of other cardiovascular events, vascular events, and liver disease (the estimated attributable risk of liver adenomas is 3.3 cases per 100,000 COC users).[125] In clinical studies of the drug, 11.4 percent of women discontinued treatment due to an adverse reaction, most commonly: menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding; 2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying; 1.2%); acne (1.1%), headache (including migraines; 1.1%), and weight increased (0.7%).[125]

Postmarketing reports with Natazia include: venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke); hypertension; gallbladder disease; hepatitis; hypersensitivity; fluid retention; hypertriglyceridemia; dizziness; chloasma; angioedema; erythema nodosum; erythema multiforme; vulvovaginal candidiasis; and gastrointestinal symptoms.[125]

Information About COCs From Large Datasets

More than a hundred publications about harms (and preventive effects) of COCs are available and full review was beyond the scope of this review. The systematic reviews featured below include contemporary pills formulations and their harms.

Information About COCs From Systematic Reviews

Two recent systematic reviews have identified significant increased risk of deep venous thrombosis among users of oral contraceptives, though the size of risk varied significantly among different COC regimens and appeared lowest for agents containing levonorgestrel or norgestimate.[129,130] One Cochrane review has evaluated the potential association between COC use and weight gain, finding insufficient evidence to make conclusions and noting the likelihood that there is no large association between COCs and increased weight during therapy.[131] Other Cochrane reviews have assessed the relative efficacy and safety of various oral contraceptive regimens; these reviews note variability in the type and incidence of adverse events among included studies and comment that adverse event reporting among these studies was generally of lower quality than expected, recommending better tracking of side effects in future studies as well as systematic capture of patient reasons for treatment discontinuation.[132-135] One of these reviews found that the incidence of discontinuation due to side effects was lower in triphasic-treated patients as compared with their monophasic-treated counterparts.[134] The one Cochrane review assessing the use of COCs in the setting of heavy menstrual bleeding identified only one small crossover trial, which did not include description of adverse events.[36]

Harms Related to Cabergoline

Information About Cabergoline From Included Trials

A single exploratory study, with 29 participants among whom 14 had PCOS and 15 were normal controls, randomly assigned 16 women to cabergoline and 13 to placebo for 4 months.[55] The authors did not report adverse events and all women completed the trial.

Information About Cabergoline From Package Insert

The package insert for this drug intended to treat elevated prolactin levels provides data about the risk of side effects in comparison to placebo in a 4-week study and compared with bromocriptine which is another medication for prolactinoma treatment.[136] In Table 21 we summarize the incidence of cabergoline side effects that occurred in more than 5 percent of those on the drug, as well as 4 week experience of side effects among individuals on placebo. We did not identify large dataset analyses aimed at surveillance for harms.

Table 21. Side effects reported in cabergoline trials

Side Effect (% participants experiencing)	Placebo at 4 Weeks	Cabergoline at 4 Weeks	Cabergoline at 8 weeks
Nausea	20	27	29
Headache	25	26	26
Dizziness	5	15	17
Asthenia	10	9	6
Constipation	0	10	7
Abdominal pain	5	5	5
Somnolence	5	5	2
Fatigue	0	7	5
Depression	5	3	3
Hot flashes	5	1	3
Dyspepsia	0	2	5

Information About Cabergoline From Large Datasets

One harms surveillance study using the U.S. Adverse Event Reporting System Database [137]and two analyses done with data from the UK General Practice Research Database [138,139] have linked drugs typically used to treat Parkinson's disease, including cabergoline, to risk of harms. Comparing cabergoline, an ergot derived drug, to nonergot derived drugs, or no medication, these descriptive studies report new cardiac valve regurgitation occurred almost 5 times more often among those receiving cabergoline in the UK case control study[137] and more than 100-fold more often in the United States adverse events registry.[137] The latter publication followed the former which may have raised awareness and amplified reporting. The research team using United States data also reported increased odds of other forms of noncardiac fibrotic reaction in the pleura, retroperitoneal spaces, and lungs. Most recently, cabergoline in the UK database was link with doubling of heart failure risk.[139] Notably these populations are substantially older and highly likely to have a specific comorbidity (Parkinson's) which may also modify risk and which makes estimation of risk in other groups infeasible. No direct surveillance data is available to inform estimation of risk in reproductive-age women.

Information About Cabergoline From Systematic Reviews

Several systematic reviews have explored the safety and efficacy of cabergoline for treatment of a range of conditions. Two Cochrane reviews on ovarian hyperstimulation syndrome and restless leg syndrome, respectively, each assessed a small pool of available trials, finding no significant difference in overall incidence of adverse events between cabergoline and comparators.[140,141] A meta-analysis of dopamine receptor agonist use among individuals with Parkinson's disease found a relative risk of 6.38 (95% CI, 3.17 to 12.81) for moderate to severe valvular regurgitation[142]; a similar analysis of cabergoline use in hyperprolactinemia also found a significant increase in risk of valve regurgitation, though this echocardiographic finding in this

patient population was clinically asymptomatic in all patients and participants were certain to be older and more frail than women who would use the treatment for irregular uterine bleeding.[143]

Harms Related to Lifestyle and Behavioral Interventions

Information Across Sources for Diet and Exercise

The single RCT of diet and exercise intervention was conducted in teens with irregular menses and did not identify adverse effects.[56] One acupuncture trial included 34 women randomized to a walking regimen who reported no adverse events or injuries.[57] However it is important not to assume that lifestyle and behavioral interventions such as diet and exercise are without risks. The U.S. Preventive Services Task Force report on Screening and Management of Obesity in Adults[101] provides a clear and succinct description of the potential harms stating:

> Possible harms that could accrue from [these] interventions include bone loss and increased fracture risk, injuries from increased physical activity, decreased self-esteem from being labeled as obese or failure to lose weight, use of extreme or unhealthy dietary approaches, and weight cycling.[101]

Harms Related to Acupuncture

Information Across Sources for Acupuncture

One study of acupuncture, that compared two strategies for selecting placemen of needles, did not discuss harms or withdrawals.[58] The other RCT reports only local redness or hematomas occurring in 10 percent of those receiving acupuncture in 14 sessions over 16 weeks.[57] Two of 33 women in the acupuncture group reported other side effects which were dizziness and nausea, while the exercise and no intervention control group did not report any events.

A number of Cochrane reviews have explored the use of acupuncture for treatment of a variety of women's health issues, ranging from dysmenorrhea to endometriosis-related pain to induction of labor; across the board, these reviews found that potential harms of acupuncture have not been well studied and are often omitted from trial reports completely, noting that investigation of possible adverse effects is an important consideration for future research involving this therapeutic approach.[144-147]

Harms Related to LNG-IUS

Information About LNG-IUS From Included Trials

One trial did not provide any information about harms or adverse effects.[59] Two trials stated that there were no serious adverse effects related to either treatment.[64,65] In one trial with 39 participants, one participant discontinued LNG-IUS therapy (5%) and five participants discontinued cyclic COC (26%).[61] One trial reported side effects in a table without comparative statistics.[63]

One trial (n=165) reported that no deaths or drug-related serious adverse events occurred during the study.[60] Six participants in the LNG-IUS group (7%) and two in the oral MPA group (2%) discontinued treatment because of adverse events.[60] The LNG-IUS was expelled in four participants (5%); two other participants had the LNG-IUS removed due to adverse effects.[60] No uterine perforations or pregnancies were observed during the study.[60] Other treatment-emergent

adverse events reported during the study and occurring in at least 5 percent of women in any treatment group were reported in a table without comparative statistics.

One trial reported 242 adverse events among 51 participants, with 158 in the LNG-IUS group and 84 in the mefenamic acid group.[63] The LNG-IUS was expelled in two participants (8%); one of these had chlamydial endometritis.[63]

Information About LNG-IUS From FDA Documents and Package Insert

In October 2009, the prescription label for the LNG-IUS available in the United States was updated though a process with the FDA.[148] This revision was made for the new indication: treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception as their method of contraception.[149]

According to the package insert, the most common (i.e., more than 10 percent) adverse reactions reported in clinical trials of LNG-IUS are: uterine/vaginal bleeding alterations (51.9%), amenorrhea (23.9%), intermenstrual bleeding and spotting (23.4%), abdominal /pelvic pain (12.8%), and ovarian cysts (12%).[148] The data provided reflect the experience with the use of Mirena brand LNG-IUS in the adequate and well-controlled studies for contraception (n=2,339) and heavy menstrual bleeding (n=80). For the treatment of heavy menstrual bleeding indication (n=80), the subjects included women aged 26 to 50 with confirmed heavy bleeding and exposed for a median of 183 treatment days of Mirena (range, 7 to 295 days).

The adverse reactions seen across the two indications overlapped, and are reported using the frequencies from the contraception studies. The less common (i.e., between 5% and 9% of users) adverse reactions are: headache/migraine (7.7%), acne (7.2%), depressed/altered mood (6.4%), menorrhagia (6.3%), breast tenderness/pain (4.9%), vaginal discharge (4.9%), and IUD expulsion (4.9%). Other relevant adverse reactions occurring in fewer than 5 percent of subjects include nausea, nervousness, vulvovaginitis, dysmenorrhea, back pain, weight increase, decreased libido, cervicitis/Papanicolaou smear normal/class II, hypertension, dyspareunia, anemia, alopecia, skin disorders including eczema, pruritus, rash and urticaria, abdominal distention, hirsutism, and edema.[148,150]

Information About the LNG-IUS From Large Datasets

Large scale surveillance for harms provides important information to patients to assure informed decisions about risks. This data includes information about complications with insertion. In the New Zealand monitoring system which includes 3,519 insertions, difficult insertions occurred in 3.6 percent of procedures and were not well predicted by nulliparous status of noncontraceptive use of the IUD. Pain on insertion occurred for 1 percent of patients and 0.5 percent of attempts to insert could not be completed.[151,152] Uterine perforation rates in three large datasets ranged from 0.9 to 2.6 cases per 1,000.[151,153,154] Authors of each of these studies, as well as those of another report from four national pharmacovigilance centers in Europe confirm, that perforations may not consistently be associated with painful insertions and that only a small portion (less than 10%) are recognized at the time of the insertion.[155]

In surveillance data, the LNG-IUS in not associated with increased risk of deep vein thrombosis,[117] including in more than 8 million women-years of observation among Danish women.[156] The anecdotally reported complaint of hair loss is supported by a single study in New Zealand by surveying women in the national registry. They found five cases of alopecia (two recovered, one not, and two still unknown) and estimated incidence to be 1.8 per 1,000 users.[153]

A 2012 publication about hormonal contraceptive methods and risk of thrombotic stroke and myocardial infarction, estimated risk based on person-years of exposure to specific contraceptive methods in a cohort of 15 years duration.[121] In a total of 184,875 women-years of observation, the LNG-IUS was not statistically significantly associated with increased risk of myocardial infarction, and appeared, relative to women not using hormonal methods, to offer protection from stroke (RR=0.73; 95% CI, 0.54 to 0.98).

Information About the LNG-IUS From Systematic Reviews

Systematic reviews report adverse events similar to those noted in the package insert,[148] with weight gain, bloating, acne, nausea and breast pain as the most commonly observed side effects. These systematic reviews also comment on the risk of spontaneous device expulsion, reporting an incidence of 5 to 16 percent.[157-159]

Harms Related to Contraceptive Vaginal Ring

Information About Contraceptive Vaginal Ring From Included Trials

The vaginal ring was used in a single study in this review as a treatment for heavy menstrual bleeding and was found to be similar in effectiveness to oral norethisterone.[84] The contraceptive vaginal ring provides a steady release of 15 mcg of ethinyl estradiol and 120 mcg of etonogestrel daily and is used vaginally for 3 weeks per cycle and then removed for 1 week. Following three cycles of treatment, this study reported that the incidence of nausea, headache, and breast tenderness was comparable in both treatment groups. The contraceptive vaginal ring users were less likely to report breakthrough bleeding than the women taking norethisterone. No ring expulsions were reported. Local events, including vaginal discomfort, vaginitis, foreign body sensation and coital problems were reported more frequently in ring-users, but no one discontinued treatment due to adverse events.

Information About Contraceptive Vaginal Ring From FDA Documents and Package Insert

The package insert lists the most common harms reported by 5 to 14 percent of women in clinical trials including vaginitis, headache, upper respiratory infection, vaginal secretion, sinusitis, nausea, and weight gain.[160] The adverse events leading to discontinuation of treatment in 1 to 2.5 percent of women include device-related events (e.g., foreign body sensation, coital problems, and expulsion), vaginal symptoms, headache, emotional lability, and weight gain. The package insert also warns against use of the vaginal contraceptive ring in cigarette-smokers over age 35.

Information About Contraceptive Vaginal Ring From Large Data Sets

We identified three studies reporting data on harms from large studies of contraceptive vaginal ring users.[121,161,162] A 15-year Danish cohort study that included over 38,000 person-years of vaginal ring use reported an elevated adjusted relative risk of 2.5 (95% CI, 1.4 to 4.4) for thrombotic stroke and 2.1 (95% CI, 0.7 to 6.5) for myocardial infarction compared with women (over 9 million person-years) who had not used hormonal contraception.[121] In an observational study of over 2,500 Swiss women, 20 percent (n=539) of contraceptive vaginal ring users reported 753 adverse events. The most common harms were changes in menstrual bleeding pattern (2.3%), vaginal discomfort (2.2%), leucorrhea (2.1%), mood disorders (2.0%)

and headache (1.9%).[161] This profile is similar to data from a German open label study of the acceptability of the contraceptive vaginal ring in which 431 of 5,823 (7.4%) of women discontinued use for side effects over six cycles of use. In the full cohort, 9.9% of women experienced symptoms classified as adverse events with the most common being bleeding pattern, headache (including migraine),and acne.[162] The research team reports 19 women (<0.3%) has serious adverse events each of which was an isolated event, other than dizziness which was reported by two women.

Information About Contraceptive Vaginal Ring From Systematic Reviews

A recently published review of the contraceptive vaginal ring summarized adverse events from three large trials.[163] The number of women using the contraceptive vaginal ring in these three studies ranged from 499 to 2,322. Over one half of the women (58 to 66%) reported at least one adverse event and 29 to 38 percent of these were possibly related to the contraceptive. The most frequent complaints were headache (5.8 to 7.2%), ring-related (4.4 to 6.8%), vaginitis (3.9 to 5.6%), leucorrhea (3.2 to 4.8%), and nausea (0.8 to 3.2%). Between 11 and 14 percent of women discontinued use of the contraceptive vaginal ring due to adverse events. Two women in one study had deep vein thrombosis. Hypertension was reported in four women (0.8%) in a single study. A study that investigated the effects of the device on lipid profiles reported increases in triglycerides and sex hormone binding globulin levels but total cholesterol was unchanged.

Another systematic review of COCs and bone health included one small cohort study of contraceptive vaginal ring users, noting no change in bone mineral density from baseline for the vaginal ring users compared with an increase in bone density among the control group of nonhormone users.[164] A recently published systematic review examining thrombotic risks of oral contraceptives included data from studies of the contraceptive vaginal ring.[165] The risk of venous thromboembolism for the contraceptive vaginal ring was elevated and similar to COCs containing ethinyl estradiol and gestodene (5.6-fold increase) or desogestrel (7.3-fold increase) or ethinyl estradiol and drospirenone (6.3-fold increase).[165]

Harms Related to NSAIDs

Information About NSAIDs From Included Trials

Three trials did not provide any information about harms or adverse effects.[68,73,74] Two trials reported there were no serious side effects.[75,77] Another trial reported treatment discontinuation among one person receiving mefenamic acid and one person receiving norethisterone after the third cycle.[70] A table of adverse events was presented in this study with no comparative statistics, though abdominal pain was reported in 18 percent and 20 percent of both mefenamic acid and norethisterone groups.

In one trial,[63] there were 242 adverse events noted with 158 in the LNG-IUS group and 84 in the mefenamic acid group. There were two significant adverse events in this study, one with hypertension in a patient with a history of hypertension, and one with chlamydia endometriosis resulting in LNG-IUS expulsion. Of note, a smaller proportion of patients reported abdominal pain with mefenamic acid (7.7%) compared with LNG-IUS (32.0%), though significance was not reported in the table of adverse events.

In another trial,[66] a total of 18 patients stopped treatment including three of 23 taking mefenamic acid due to poor efficacy or an unwanted event such as nausea, headache, and dizziness.

One trial[77] reported nausea and gastrointestinal disturbances in nine (16.4%) and eight (14.5%) and leg cramps in seven (12.7%) and 12 (21.8%) cases among those receiving TXA and TXA with mefenamic acid, respectively.

One small crossover trial reported no treatment discontinuations,[71] however, patients receiving TXA reported nausea, dizziness, numbness, restless legs, and headache. Vomiting and difficulty swallowing was reported by three women in the TXA group. Patients receiving flurbiprofen reported tiredness, stomach pains, and nausea.

In one trial,[67] one person discontinued mefenamic acid due to severe skin rash and itching and in another trial,[69] one person on mefenamic acid complained of gastritis. In another trial,[72] one patient had epigastric distress and four patients had nausea and vomiting on meclofenamate. However, the severity of dysmenorrhea ($p<0.006$), backache ($p<0.02$), and headache ($p<0.002$) were significantly less for patients taking meclofenamate than placebo. There was no difference in nausea or vomiting.

One trial[75] reported any side effects in 18 patients taking naproxen and in 15 patients taking mefenamic acid. Thirteen patients taking naproxen experienced gastrointestinal symptoms (i.e., nausea, diarrhea, abdominal discomfort, and anorexia) compared with six taking mefenamic acid. Central nervous system symptoms (i.e., light headedness, dizziness, tiredness, and headache) were reported by patients receiving mefenamic acid (n=6) and naproxen (n=5).

One trial[76] reported no significant differences in nausea, depression, breast symptoms, and other symptoms between mefenamic acid and placebo. However there was significant reductions in abdominal pain ($p<0.001$), headache ($p<0.001$), and diarrhea ($p<0.008$) among those taking mefenamic acid compared with placebo.

Information About NSAIDs From FDA Documents and Package Inserts

As a class, NSAIDs carry a risk of serious harms from cardiovascular thrombotic events, myocardial infarction, stroke, renal effects, and hepatic effects, along with gastrointestinal ulceration, bleeding and perforation. All drugs in this class have a boxed warning for cardiovascular and gastrointestinal risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1 percent of patients treated for 3 to 6 months, and in about 2 to 4 percent of patients treated for 1 year, with trends continuing with longer duration of continuous use.[166-168] Labels note that even short-term therapy is not without risk with this drug class.

In general, NSAIDs have been commonly associated with harms including edema, abdominal pain, constipation, diarrhea, dyspepsia/heartburn, elevated liver enzymes, flatulence, gastrointestinal bleeding, nausea, vomiting, body weight changes, headache, nervousness and other manifestations of central nervous system stimulation (e.g., anxiety, insomnia, increased reflexes, tremor), symptoms associated with central nervous system inhibition (e.g., amnesia, asthenia, depression, malaise, somnolence), rash, changes in vision, dizziness/vertigo, tinnitus, and signs and symptoms suggesting urinary tract infection.

More harms information on specific drugs is limited in the package inserts, for many of the reasons given in the above discussion. In controlled studies of meclofenamate, approximately 4 percent of the patients had diarrhea severe enough to require discontinuation of the drug.[167] See Appendix M for more complete information from individual package inserts.

Information About NSAIDs From Systematic Reviews

A pooled analysis of trials in a systematic review of NSAIDs for the treatment of dysmenorrhea found that mild neurological and gastrointestinal adverse events reported at significantly greater frequency by those receiving NSAIDs as compared with those receiving placebo.[169] Another recent review underscores the risk of various gastrointestinal complaints and notes that the cardiovascular effects of the traditional NSAIDs are poorly understood and warrant further research;[103] an increased risk of nonfatal myocardial infarction was also observed in a recent systematic review and meta-analysis.[170]

Harms Related to TXA

Information About TXA From Included Trials

Within studies included in our review, similar numbers of participants withdrew from TXA and placebo or other treatment groups.[78,79] No thrombotic events were reported in the participants treated with TXA and no deaths occurred during the study. Serious adverse events reported in the TXA groups of trials included allergic reactions, headaches, and other symptoms such as tachycardia, acute bronchitis, hypoglycemia, and posttraumatic stress disorder, the latter judged to be unrelated to study treatment. There was no significant difference in the percentage of side effects reported, comparing TXA to placebo. In particular, the frequency of gastrointestinal-related adverse events was similar between groups. In another trial,[66] a total of 18 patients stopped treatment including four of 26 taking TXA due to poor efficacy or an unwanted event such as nausea, headache, and dizziness. One included trial had no withdrawals or side effects reported,[71] another reported no serious adverse effects.[80]

Information about TXA from FDA Documents and Package Insert

The companies, Xanodyne Pharmaceuticals and Ferring Pharmaceuticals, that manufacture TXA (Lysteda®) received FDA approval after submitting research findings and other data in 2009. The manufacturer conducted two placebo-controlled randomized trials; the second of which has been published.[78] The first trial randomized 304 women and compared two doses of TXA (1,950 mg and 3,900 mg daily for up to 5 days during each menstrual period) versus placebo over three cycles.[171] The data provided to the FDA for safety included these two pragmatic cluster RCTs and two uncontrolled phase three trials, and a single QT-interval phase two study. In total, these five studies described 12,169 treatment cycles, but among them only 234 women received the current recommended therapeutic dose of the medication.[172] Overall, the nature and number of adverse events did not raise any significant safety concerns. There were no venous thromboembolic events in subjects taking TXA. There were no adverse effects on vision or ocular safety concerns. There was no effect on the QT-interval. No drug-drug interactions studies were conducted. The total number of subjects in clinical trials who received TXA was considered low for evaluation of harms and drug safety.

The FDA also reviewed evidence from a database for a different formulation of TXA that included 40 cases of possible venous thromboembolism over 5 years (none in the United States), with 40 percent of these events occurring with intravenous use of the drug, and for indications other than heavy menstrual bleeding.[171] The review utilized by the FDA also documented associated instances of retinal venous and arterial occlusion and ligneous conjunctivitis.[171]

In April 2011, the prescription label and package insert for the formulation of TXA available in the United States was updated.[171] According to the current label, the most common adverse

reactions reported in clinical trials of TXA were headache (50.4%), nasal and sinus symptoms (25.4%), back pain (20.7%), abdominal pain (19.8%), musculoskeletal pain (11.2%), arthralgia (6.9%), muscle cramps and spasms (6.5%), migraine (6%), anemia (5.6%), and fatigue (5.2%); comparative statistics between active drug and placebo were not provided.[171]

Information About TXA From Large Data Sets

We identified a single large surveillance study using the General Practice Database from the United Kingdom.[122] The case-control analysis of deep vein thrombosis reported increased odds of TXA use among cases (OR=3.20; 95% CI, 0.65 to 15.78) and note lack of precision of the estimates based on sparse use of the medication. This report, examining drugs used for heavy menstrual bleeding, found that all common treatments for menorrhagia were associated with deep vein thrombosis risk and raised the question of confounding by indication, meaning that characteristics of the women being treated (abnormal bleeding patterns) rather than the drugs themselves might be the causal component.[122]

Based on United States and worldwide postmarketing reports, the following have been reported in patients receiving TXA for various indications: nausea, vomiting, and diarrhea; allergic skin reactions; anaphylactic shock and anaphylactoid reactions; impaired color vision and other visual disturbances; dizziness; and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery and vein obstruction).[171] There postmarketing reports of venous and arterial thrombotic events included women who had used TXA concomitantly with combined hormonal contraceptives.

In consideration of the information reviewed, the FDA issued contra-indications and precautions for TXA use, advising clinicians not to prescribe TXA to women known to have the following conditions: active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis); a history of thrombosis or thromboembolism, including retinal vein or artery occlusion; an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy). Four precautions are noted: (1) concomitant therapy with tissue plasminogen activators may decrease the efficacy of both medications; (2) the risk of venous thromboembolism and arterial thromboses may increase further when hormonal contraceptives are administered with TXA, of particular concern in women who are obese or smoke cigarettes, especially smokers over 35 years of age; (3) TXA is not recommended for women taking either Factor IX complex concentrates or anti-inhibitor coagulant concentrates because the risk of thrombosis may be increased; (4) patients should be instructed to report visual and ocular symptoms promptly and the medication should be stopped pending a complete ophthalmic evaluation, including dilated retinal examination, to exclude the possibility of retinal venous or arterial occlusion.[171]

Information About TXA From Systematic Reviews

A 2012 review of the efficacy of TXA in treating heavy menstrual bleeding is compatible with this review, finding mild to moderate adverse effects reported in included studies.[173] Gastrointestinal effects were most common, and there were no reports of thromboembolic events in the 10 studies evaluated.[173] A Cochrane review conducted a combined analysis of the efficacy and safety of TXA and ethamsylate as antifibrinolytics used to treat heavy menstrual bleeding; emphasizing the short duration of the included studies, they comment that no increase in adverse events was observed with use of these agents.[174] Two systematic reviews of TXA use in orthopedic surgery recently found no increased risk of thrombotic events in their pooled data

analyses.[175,176] It is important to note that the trials included in these reviews are similar to those in this review in that they are underpowered to detect rare but important harms.

Harms Related to Decision Aids

There are no harms associated with using decision aids other than time invested by patient and clinician if the decision aid does not effectively inform patients about important care options.

Summary

Pharmaceutical agents, procedures and devices, and even diet and exercise have potential complications. While contraceptive methods have typically been well-characterized in the broadly applicable population of reproductive-age women, there may be characteristics associated with abnormal bleeding that modify the risk profile of these interventions when restricted to women with indications related to AUB. Women and their care providers will need to weigh individual risk profiles, desire for contraception, and treatment strategies in order to balance symptom management with minimization of risk, especially when choosing medications that are less well-studied in this population, such as those used for diabetes management.

Discussion

Key Findings

State of the Literature

We identified 1,775 nonduplicate publications through the search process, with 219 proceeding to full-text review (Figure 2). We included 41 publications that reported on 39 separate randomized controlled trials (RCTs) and 12 types of interventions. These studies evaluated the levonorgestrel-releasing intrauterine system (LNG-IUS; 7 studies),[59-65] the contraceptive vaginal ring (1 study),[84] nonsteroidal anti-inflammatory drugs (NSAIDs; 13 studies),[67-70,72-76] tranexamic acid (TXA; 7 studies),[66,71,77-81] combined oral contraceptives (COCs; 6 studies),[50,59,61,68,82,83] metformin (4 studies),[51-54] exenatide (1 study),[53]progestogens (1 study),[49] cabergoline (1 study),[55] acupuncture (2 studies),[57,58] lifestyle/behavioral changes (1 study),[56] and patient decision aids (3 studies)[86,87,177] using at least one comparator or placebo arm.

A number of these studies compared the intervention of primary interest to a progestogen, such as medroxyprogesterone (MPA).[49,60,62,64,70,74,79,80] These studies were not considered important contributions to evidence about the effectiveness of progestogens for treatment since in each case the hypothesis was that the progestogen would be inferior or equivalent to the intervention being studied. Though we report the outcomes for progestogen comparisons to other interventions we have not separately summarized the effectiveness of progestogens. One trial evaluated two routes of progestogen and was treated as a study evaluating progestogen for symptom management.[49]

The quality of the included studies tended to be fair (10 studies)[51,58,60,64,67,75,76,80,81,84] or poor (23 studies).[49,52-54,56,57,59,61-63,65,66,68-71,73,74,77,79,86,87,177] In part, this followed from the difficulty of blinding participants to intervention status. For instance, no LNG-IUS studies included sham insertion or a sham LNG-IUS string placement in the endocervical canal along with placebo medication in both groups, though this would be required to achieve complete masking of intervention groups. Likewise it can be challenging to mask outcome assessors to group status when women and providers assess outcomes. An unmasked participant is counted in the scoring as an unmasked assessor when the outcome is self-reported or self-collected. While this is rigorous and appropriate in the evaluation of risk of bias in RCTs, it may be an inappropriately strict criterion to apply for studies in which menstrual products are collected for measurement of blood loss or in which biological markers such as hemoglobin or hematocrit levels are also assessed. Understanding this context can inform interpretation of the literature.

Effectiveness of Interventions for Abnormal Bleeding

Key Question 1A (KQ1A). Management of Irregular Uterine Bleeding

A number of available interventions suitable for use in primary care have preliminary evidence of effectiveness for improving the regularity of menses. Only metformin has demonstrated effectiveness in more than one RCT with a total of 175 women with polycystic ovaries participating in each of three studies. One study suggests adding exenatide to metformin treatment can enhance effectiveness. No head-to-head comparison trials are available to inform choices among medication types for management of irregular uterine bleeding.

Progestogens

Vaginal micronized progesterone (8% gel) and oral dydrogesterone were studied in a single trial among women clinically classified as having dysfunctional uterine bleeding.[49] In this RCT, both vaginal and oral administration improved cycle regularity with 92 percent and 85 percent of participants, respectively, achieving regular bleeding by the third cycle of use. Effects were comparable, but the trial was not powered to show equivalence or noninferiority.

COCs

A triphasic oral contraceptive was also studied in a single RCT among women with irregular uterine bleeding.[50] This trial included women with both short and long intervals between bleeding episodes and with both heavy and normal amounts of bleeding. The outcomes are provided in aggregate and not presented by initial bleeding characteristics. Overall, 68 percent of women taking the COC achieved excellent or good cycle control compared with 26 percent of those receiving a placebo.

Metformin and Exenatide

Metformin was an active treatment arm in four RCTs conducted among women with polycystic ovarian syndrome (PCOS), two comparing outcomes to a placebo group,[51,52] one comparing metformin with N-acetyl-cysteine,[54] and one comparing metformin only, exenatide only, and both.[53] In each case, metformin was effective for improving the regularity of bleeding over a number of months compared with baseline or placebo. When combined with exenatide the effect was greater than either alone in the study of 60 women with PCOS that compared all three approaches.[53]

Cabergoline

In a very preliminary investigation of this drug indicated for treatment of prolactinomas, cabergoline was associated with return of regular menses in three of eight women in the treated group compared with none of the six receiving placebo.[55] All women in the study had PCOS and normal prolactin levels.

Behavioral and Lifestyle Interventions

Among adolescents with PCOS, both a low-fat, calorie-restricted diet and a carbohydrate-restricted diet in conjunction with 30 minutes of aerobic activity 3 days a week resulted in more regular menses among those who lost weight.[56] This single small study did not present outcomes by the diet group to which participants were randomized. Presumably, there was not a clear difference, meaning there is no evidence to guide choice of dietary intervention. A single trial of acupuncture also included an exercise control group at the same intensity as the diet and exercise trial.[57] This group experienced a 42-percent improvement in regularity of menses. We did not find evidence comparing diet to exercise directly.

Complementary and Alternative Medicine

Two studies of acupuncture with different underlying hypotheses and different methods (conventional acupuncture and low-frequency electroacupuncture) found benefit for a specific style of acupuncture when compared with no intervention or alternate placement of acupuncture needles.[57,58] By 32 weeks in the trial of electroacupuncture for PCOS, women who received acupuncture had a 121-percent improvement in cycle regularity while those who exercised only

had a 42-percent improvement which was statistically comparable in this small trial.[57] Both acupuncture and exercise were superior to placebo in this trial. In the trial of two differing placements of needles, women who received treatment for "mind tranquilizing and menstruation promotion" had greater improvements (no treatment failures among 21 women) compared with those receiving traditional placement (n=16) for "delayed menses" among whom 19 percent did not have improvements.[58]

KQ1B. Management of Abnormal Cyclic Bleeding

The LNG-IUS, various NSAIDs, TXA, and COCs are effective for reducing the amount of menstrual bleeding and in some instances have been shown to have additional benefits. Each category of intervention is described below.

LNG-IUS

All seven studies of the LNG-IUS demonstrated that the intervention effectively reduced heavy menstrual bleeding.[59-65] Evidence suggests the device reduces the volume and duration of bleeding, improves iron status, and is an acceptable alternative to hysterectomy for some women. In direct comparisons, the LNG-IUS was superior to COCs and NSAIDs at reducing menstrual blood loss (MBL). We did not find any studies that compared the LNG-IUS to TXA.

Our analysis of LNG-IUS is consistent with prior systematic reviews. A 2001 systematic review of five RCTs reported mean MBL reductions were between 71 and 96 percent.[178] A 2005 systematic review identified 10 RCTs comparing LNG-IUS with surgery or pharmaceutical treatments.[157] The odds ratio for the proportion unwilling to continue with treatment was 0.27 (95% CI, 0.10 to 0.67) in favor of LNG-IUS. The odds ratio for proportion of women satisfied with treatment was 2.13 (95% CI, 0.62 to 7.33).[157]

Contraceptive Vaginal Ring

One study investigated the contraceptive vaginal ring finding that it was similar in effectiveness to norethisterone when taken orally three times a day for 21 days of each cycle. Overall more women were satisfied with the contraceptive vaginal ring and chose to continue use compared with women taking oral norethisterone.

NSAIDs

In a total of 13 studies, NSAIDs including mefenamic acid, naproxen, meclofenamate, and flurbiprofen, given at the onset of menses for up to 5 days reduce MBL by 20 to 49 percent.[63,66-77] Studies have evaluated use over one to six menstrual cycles. Our analysis of NSAIDs is consistent with a prior 2007 systematic review; NSAIDs were more effective than placebo at reducing bleeding, but less effective than TXA or LNG-IUS.[34] There were no differences in reductions between NSAIDs and oral progestogens, COC, and an older progesterone-impregnated intrauterine system (Progestasert®). There were no differences seen between individual types of NSAIDs, specifically mefenamic acid and naproxen. The most recent study found similar reductions in pictorial blood loss assessment chart scores when NSAIDs were combined with TXA compared with TXA alone. NSAIDs reduce MBL, but do not consistently reduce MBL to clinically meaningful levels (i.e., less than 80 ml) in all patients. There was considerable variability in response. Some patients had an increase in blood loss during treatment. NSAIDs do not regulate the pattern of menstruation nor provide contraception. NSAIDs do provide relief of dysmenorrhea. Therefore, for patients who desire both reduced

MBL and relief from dysmenorrhea, but not contraception, and who do not have contraindications, NSAIDs can be considered for up to five days during menses.

TXA

All seven RCTs of TXA demonstrate effectiveness of improving heavy bleeding.[66,71,77-81] TXA at a dose of 1.95 to 4.5 grams per day for 4 to 5 days from onset of bleeding meaningfully reduces MBL by 40 to 60 percent in studies lasting up to 1 year. Both biologic and self-reported symptoms of bleeding severity are improved. Our analysis of TXA is consistent with prior systematic reviews of another formulation of TXA. A 1995 systematic review pooled results from seven trials and found a reduction in MBL of 46.7 percent (95% CI, 47.9% to 51.6%) with TXA.[179] A 2004 systematic review and meta-analysis of two RCTs of TXA versus placebo reported a mean MBL difference of −93.96 ml (95% CI, −151.43 ml to −36.49 ml) in favor of TXA treatment.[174]

COCs

Though the volume of RCT literature examining use of COCs in women with abnormal uterine bleeding (AUB) is somewhat small relative to the frequency with which these agents are used as a first-line therapy in women presenting with AUB symptoms, our analysis indicates these agents are associated with decreases in AUB among treated women. All five RCTs of COCs for the indication of heavy cyclic menstrual bleeding found benefit for reducing volume of menstrual bleeding. [59,61,68,82,83] Two studies also identified improvements in related laboratory values such as hematocrit and ferritin, [82,83] and one study also found significant improvement in patient rating of overall health.[59] These findings are consistent with the 2010 American Congress of Obstetrics and Gynecology recommendations, which note that combined hormonal contraceptives are a "reasonable option for initial management of menorrhagia."[21] In the two head-to-head comparisons between COCs and LNG-IUS,[59,61] reductions in heavy menstrual bleeding were documented in both treatment groups, with a somewhat greater benefit for LNG-IUS users.

Decision Aids

Three studies investigated decisions aids to assist women seeking treatment for heavy cyclic bleeding in making informed decisions about care.[86,87,177] The study results suggest that decision aids increase patient knowledge and enhance satisfaction with care but do not affect disease symptoms in directly measureable ways. One study found fewer women who received the decision aid ultimately chose surgical referral and hysterectomy.[86] However this decision cannot be linked to improvement in bleeding symptoms. Since there are no known harms associated with using decision aids, they may help patients evaluate treatment options and feel secure in their choices.

Applicability

Applicability describes the extent to which results observed in published studies from this this review are likely to reflect the expected outcomes when an intervention is applied to broader populations in real-world conditions. Studies for this review were intended to provide information to inform primary care management of AUB, whether irregular or cyclic. In shaping the methods for this review, we have engineered the report so that the included research is applicable to primary care of women in the United States. Our stricter criteria, narrowing

findings to only symptomatic populations of reproductive-age women with chronic complaints of abnormal bleeding, comes at the cost of fewer studies being addressed. However, it assures that those studies that are included were explicitly designed to examine the effectiveness of the treatments for improving the outcomes of interest in the populations of interest. Applicability of the findings is therefore high.

For each intervention, it is important to note the following provisions. The results of this review apply for women:

- Who are reproductive age and state they have an irregular pattern of menstrual bleeding or heavy cyclic menstrual bleeding.
- Without abnormal findings on pelvic exam or on ultrasound report (fibroids, polyps).
- Without an intrauterine device (IUD) in place, and who are not pregnant or lactating,
- Who are healthy, and without renal impairment, hepatic impairment, intestinal disease, thyroid disease, abnormal cervical cytology, noncyclic bleeding, history or presence of significant medical problems (e.g., thromboembolic disease, coagulopathy, subarachnoid hemorrhage, endocrine disorders, or eye disease).
- For whom any additional clinically determined diagnostic and screening tests have be completed to rule out these and other causes of abnormal bleeding.
- Does not have any of the contraindications found in the Food and Drug Administration sources discussed in the main document and do not have risks of drug-drug interactions if they take multiple prescription medications.

Our review was not designed to guide evaluation of women with abnormal bleeding, rather to address what treatments have evidence of effectiveness once the diagnosis is established and primary care management is to be initiated.

Applicability of Literature About Interventions for Irregular Uterine Bleeding (KQ1A)

The literature about management of irregular uterine bleeding applies to women in primary care settings in the United States. Ten RCTs, three conducted in the United States, two in Italy, two in Turkey, and one each in China, Sweden, and the United Kingdom provide evidence about seven types of intervention. Enrolled populations were narrowly defined and had either a clinical diagnosis of irregular uterine bleeding, or met research criteria for PCOS. As a result the findings are strictly applicable only to these groups of women. We describe the agents study within the two populations in which the research was conducted.

Use for Irregular Uterine Bleeding (KQ1A)

Progestogens

The study comparing vaginal micronized progesterone (8% gel) with oral dydrogesterone for a 10-day time period is applicable to primary care in the United States, as both routes are used in standard care in the United States to provide progesterone in order to organize a withdrawal bleed that will typically occur within days of completing the progestogen. The oral agent in this trial, dydrogesterone, is not available in the United States. This study is therefore a surrogate for oral versus vaginal administration of similar progestogen formulations such as MPA that are widely used in the United States for this purpose; however it does not provide direct evidence to support use of other agents. The outcome of interest for this review was regularity of bleeding after treatment which was provided for three menstrual cycles. Both groups had improvement

however applicability for chronic use is unclear as no long-term followup of symptom control is available. Progesterone is often used in management of specific causes of abnormal bleeding such as PCOS however this study does not directly apply because the population was not addressed in this study. Progesterone can be used by women who wish to conceive.

COCs

The single study, conducted in the United States, is directly applicable to primary care in the United States. The study population of 201 women is representative of the spectrum of complaints that may accompany chronic irregular uterine bleeding including menses that are widely separated in time whether light, normal, or heavy with regard to heaviness of bleeding, and includes women with closely space and unpredictable bleeding also without restriction on heaviness of bleeding. The intervention is a common version of triphasic COC (Ortho Tri-Cyclen®) that provides direct evidence for its effectiveness and indirect evidence for other triphasic pills with similar dosing profiles. The evidence is less direct but likely applicable to monophasic pills of similar estrogen and progestogen content. It does not apply to progestogen-only formulations or to pills with estrogen doses lower than 0.035 mcg as used in this study. Comparison to placebo provides definitive evidence of benefit but does not provide information about how COCs compare to other strategies that might be used such as LNG-IUS or progestogens. The outcomes included those that are a priority of women seeking treatment for uterine bleeding and included cycle regularity, incidence of excessive bleeding, and overall rating of symptom improvement.[50] Harms and contraindications, as discussed in KQ2, are well-known to care providers and often to women themselves, and COCs are not applicable as a long-term strategy for women who wish to conceive.

Management of PCOS (KQ1A)

Metformin and Exenatide

The four trials that investigated use of metformin are applicable to care in the United States and were conducted in the United States, Turkey, Italy, and the United Kingdom. The study in the United States compared metformin, to exenatide or both. These studies enrolled women with PCOS and fewer than expected normal menses. They investigated doses of metformin that are available in the United States (500 mg and 850 mg, administered by mouth twice daily). None of the studies used an extended-release form which is now available so evidence related to that formulation is indirect. The outcome of interest for this review was menstrual frequency which was improved compared with placebo in 2 trials. One head-to-head comparison was metformin compared with exenatide or both. Both were superior to either alone for cycle control. Another trial compared metformin to N-acetyl-cysteine. The most common side effect which is gastrointestinal symptoms was identified in these studies and thus would be expected to apply to this typically younger group of women who do not have diabetes. Metformin can be used by women who wish to conceive and is safe for use in pregnancy. Based on other literature, it may enhance fertility. Little is known about exenatide and fertility and safety in pregnancy, however it does not have contraceptive effects.

Diet and Exercise

The applicability of the single trial of diet and exercise is limited. It enrolled 24 adolescents with PCOS, 16 of whom completed the study and evaluated a low-fat, calorie-restricted diet or a carbohydrate-restricted diet along with 30 minutes of anaerobic exercise 3 days a week. The trial

did not provide an intention to treat analysis, comparing arms but did report that weight loss in either group improved cycle regularity. Behavioral changes can be applied in many populations and would be expected to have benefits. Thus evidence is insufficient to advise which dietary pattern is superior. Another arm of a single study found exercise 30 minutes each day, 3 days a week, was more effective than no intervention and as effective as acupuncture in improving cycle regularity.

Acupuncture

Two trials, one conducted in Sweden and one in China, assessed acupuncture. Depending on the availability and the skill of acupuncturists available in communities, this intervention may not be broadly applicable in the United States. Both tradition acupuncture and electroacupuncture improved cycle regularity but this was assessed in essentially unblended trials. The outcomes examined were relevant to patient symptoms however were very poorly-described in one study in which the investigators applied categories like "cured" without clear definitions. Overall, literature is absent to inform choice of any of these modalities over another.

Applicability of Literature to Management of Abnormal Cyclic Bleeding (KQ1B)

Twenty-nine studies contributed evidence about interventions for management of abnormal cyclic bleeding focused predominantly on effectiveness for reducing the amount of bleeding among women with heavy menstrual bleeding. Overall these RCTs are applicable to primary care in the United States. Five were conducted in the United States (including two multi-country trials), eight studies were conducted in the United Kingdom, four studies were conducted in Canada (including two multicenter studies), three studies were conducted in Australia (including one multicenter trial), and two each were conducted in Finland, Egypt, and India. A single study was conducted in each of the following countries: Netherlands, Sweden, and Turkey.

LNG-IUS

Overall, the study findings for LNG-IUS from this review apply to women in the primary care settings in the United States. One trial was conducted in three countries (United States, Canada, and Brazil), two trials were conducted in the United Kingdom, and the others were conducted in Egypt, Canada, Turkey, and Finland. The settings are not substantially different from a primary care setting in the United States. However, a limitation is that adolescent women and women with obesity were not included in the RCTs populations, so direct applicability to their care is lacking. Enrolled populations met our inclusion criteria and like others used direct measures of volume of bleeding that would be replaced in clinical care with patient self-report.

The LNG-IUS is available in the United States. The intervention dosage was the same for all seven trials and is that currently marketed (52 mg levonorgestrel, initial release rate 20 mcg per 24 hours). The LNG-IUS must be inserted by a provider. The details of the insertion procedure must be understood and practiced to safely provide this treatment in a primary care setting. The comparator differed among the seven trials; two trials compared LNG-IUS to a COC, three trials compared LNG-IUS to a progestogen (oral or intramuscular route), one trial used an NSAID as a comparator, and one trial assigned the patients in the control group to continue with their existing medical treatment for excessive uterine bleeding or symptoms of dysmenorrhea, or both. None of the trials compared LNG-IUS with TXA.

The primary outcome of the trials was change in blood loss which directly addresses the primary symptom for which women typically seek treatment. One study used the proportion of women who cancelled their prior decision to undergo hysterectomy as the primary outcome measure. Timing of assessment of outcome varied among the trials: one trial reported after 1 menstrual cycle, three trials reported after 3 menstrual cycles, four trials reported after 6 menstrual cycles, and two trials reported after 12 months. The latter are more informative for a device intended to be in place for 5 years.

Contraceptive Vaginal Ring

The contraceptive vaginal ring is available in the United States, and the group of women enrolled in the only study available is comparable in symptom profile to those in other studies in this CER. MBL reduction between the contraceptive vaginal ring users and the comparison group receiving norethisterone 3 times daily was similar. Women in the contraceptive vaginal ring group were more satisfied with treatment, however, it is important to note that comparison of the ring to an agent dosed 3 times each day may not be applicable to typical practice patterns in the United States when selecting a progestogen to prescribe for AUB.

NSAIDs

The 13 RCTs examining NSAIDs and included in this review are applicable to United States populations. The studies were conducted in seven countries including Australia (2 studies), Canada (1 study), India (2 studies), the Netherlands (1 study), Sweden (1 study), the United Kingdom (5 studies), and the United States (1 study). In some trials, women were excluded who were on hormonal medications, had menorrhagia related to an IUD, or who were taking NSAIDs or steroids. Therefore, results of these studies are applicable to women with no contraindications to NSAIDs including underlying hepatic, renal, or thyroid disease, stomach ulcers, or asthma, and no drug sensitivity.

The specific NSAID administered to participants varied and included mefenamic acid (11 trials), naproxen (2 trials), flurbiprofen (1 trial), and meclofenamate (1 trial). One trial evaluated mefenamic acid in conjunction with TXA. For each NSAID, dose and duration did not vary greatly, with usually up to 5 days duration of use. The most commonly used dose of mefenamic acid was 500 mg 3 times a day starting at the onset of menses. One trial initiated mefenamic acid 5 days prior to onset of menses through cessation of bleeding. Another trial used 500 mg at onset of menses followed by 250 mg every 6 hours for 3 to 5 days. Mefenamic acid at a dose of 250 mg 3 times a day from onset menses for 5 days was used when combined with TXA in one trial. Naproxen was evaluated with initial loading doses of 500 to 550 mg then 250 to 275 mg every 6 hours for 5 days or until 24 hours after cessation of heavy bleeding. Meclofenamate was studied at a dose of 100 mg 3 times a day from onset of menses for duration of 6 days or until cessation. Flurbiprofen was studied at a dose of 100 mg twice a day from onset of menses for duration of 5 days. Each of these doses is available for prescription in the United States. Notably, the literature lacks RCTs about ibuprofen which is likely the most common prescription and over-the-counter NSAID used for heavy bleeding and dysmenorrhea.

Outcomes for the trials in this review included documentation of objective blood loss. This is not applicable in routine clinical care and subjective assessment of MBL is nearly always used as the criteria for initiating and determining success with NSAIDs. NSAIDs are also effective in reducing dysmenorrhea, and therefore patients with both heavy cyclic menstrual bleeding and dysmenorrhea or headaches may desire NSAIDs.

TXA

The literature about TXA for management of abnormal cyclic bleeding applies well to women in primary care settings in the United States. Two trials were conducted in the United States, three were conducted in Europe, and one took place in India. Enrolled populations met inclusion criteria and reviewed studies implemented exclusion of participants as described in the methods for this review. Because women with comorbidities are systematically excluded from these trials, we must note the studies apply to healthy women with heavy cyclic menstrual bleeding. While studies quantified the amount of bleeding at baseline, this is typically not feasible in clinical populations and the patient's statement that menstrual bleeding is heavy would be more likely to be used as a criterion for consideration of this therapy.

The formulation of TXA (Lysteda®) used in the included studies is the same that is currently available in the United States. The intervention dosage differed among the five trials but was in the range of 1.95 to 4.5 grams per day for 4 to 5 days. Treatments compared with TXA in these trials did not include LNG-IUS or COC regimens. This modestly limits applicability since these would be among the usual interventions considered in real-world clinical settings.

The primary outcome of the TXA trials was change in blood loss which is typically the most pertinent symptom for women. The timing of assessments of outcomes varied among the trials but was generally short: two trials reported after two menstrual cycles, four trials reported after three menstrual cycles, one trial reported after six menstrual cycles. No trials reported outcomes for use of TXA for 1 year or more of therapy. This limits understanding of applicability for long-term use of this agent. Reporting of adverse events was not adequate for an assessment of harms and in the context of short followup in trials, this prevents consideration of risks.

COCs

The findings of this review are applicable to women visiting a primary care setting for management of heavy, cyclic uterine bleeding. The included RCTs were conducted in the United States (1 study), Canada (2 studies), Australia (1 study), multiple sites in Europe (1 study), and Egypt (1 study) in outpatient clinical care settings. Known contraindications to use of COCs and abnormal findings during diagnostic work-up (e.g., fibroids or other endometrial pathology) were commonly employed as exclusion criteria in the identified studies and these diagnostic exclusions are applicable in the general primary care setting as well. Study participants were all older than 18, and had normal range body weights so no evidence directly informs symptom management or safety in younger adolescents or obese patients. COCs were compared with placebo in three studies and with LNG-IUS in two studies. Both participants in the COC group and LNG-IUS had improvements from baseline, but the LNG-IUS was superior to COC. In comparison to mefenamic acid, COCs were superior. The outcomes assessed were those of high relevance to patients and included MBL, blood counts and iron reserves, and participant and clinician assessment of symptoms.

Decision Aids

Use of decision aids is increasingly common and promoted in U.S. health care settings especially in clinical contexts in which patient preference plays a strong role in selection of the treatment and prioritization of outcomes. Three studies of decision aids are included in this review. Two were conducted in the United Kingdom and one in Finland. They are somewhat applicable to care in the United States but may not directly apply given differences in payment structures for care and prescriptions as well as potential differences in clinical care norms. All

three studies used information booklets mailed to patients prior to their appointments and one added a computerized decision tool. The studies assessed outcomes like general health status, quality of life, and decisional conflict, as well as secondary outcomes like anxiety. Study populations included women older than 30 and 35 respectively in the two that reported, so findings do not generalize to younger women. None found benefit which may or may not reflect how similar approaches would be received in a U.S. health care context or across a broader age span of women.

Final Comments on Applicability

Overall applicability of this literature to providing care was high. However, often women who are in trials do not reflect the full range of those with abnormal bleeding seen in primary care and, as we have noted, groupings of participants do not correspond directly to newer classifications of sub-types of AUB.[9] Study participants were more likely to be normal weight, nonsmokers, with few, if any concomitant conditions. The interventions (except in the case of specific comparators as noted) are available in the same doses and formulation in the United States. Outcomes such as measured blood loss, self-reported symptom severity and days of bleeding are of direct relevance to women with abnormal bleeding. Our findings are sparse for outcomes which can be considered essential for a condition like AUB that are defined by symptoms. Important outcomes include satisfaction with response to treatment, definitive assessments of whether or not the women considered their complaint resolved, and whether they wished to continue the same treatment or add additional treatments. Followup in general was brief, so they findings may not apply well to management of a chronic condition like abnormal bleedings. This makes findings about assessments of harms challenging since use of interventions over extended periods may have different risk profiles from short timeframes like one to six cycles.

Summary of Strength of Evidence and Findings

Overall the evidence to answer KQs about the management of AUB, did not reach standards for high strength of evidence for any intervention. This was particularly true in the literature relevant to treatment of women with irregular uterine bleeding. Combined oral contraceptives, as represented in a single good quality placebo controlled trial with a total of 201 participants, documented effectiveness. The treatment effect was large with improvement in bleeding patterns reported for more than 80 percent of women taking COC compared with 45 percent for the placebo group. Combined, these factors provided moderate evidence of benefit. Use of metformin is supported by low strength of evidence predominantly related to small trials with somewhat limited quality. For the remainder of the interventions investigated for management of irregular uterine bleeding, there is insufficient evidence that follows from single or lower quality studies, or both.

The strength of evidence tables (Table 22 and Table 23) that follow summarize the total number of studies and within those studies the number of women who received the specific intervention. The tables also provide the assessment of the risk of bias, consistency of findings across trials, directness of the evidence that treatment improves the symptom, and precision of the estimated provided by the literature. The complete scoring is found in the Appendix J. For KQ1B, risk of bias associated with blinding of patients, personnel and outcome assessment was most likely to compromise overall assessment of study quality. For KQ1A, risk of bias

associated with blinding of patients and personnel and incomplete outcome data was most likely to compromise overall study quality.

Table 22. Strength of evidence for improving menstrual regularity (KQ1A)

Intervention Quality: Studies (Subjects Assigned to Intervention)	Risk of Bias	Consistency	Directness	Precision	Overall Strength of Evidence[a]	Findings Comparisons
Progestogen[b] Poor: 1(69)[49]	High	NA	Direct	Imprecise	Insufficient	Not analyzed by arm
COC[c] Good: 1(101)[50]	Low	NA	Direct	Precise	Moderate	Cycle control improved:[d] 87% COC vs. PBO, p<0.001[50]
Metformin[e] Poor: 3(81)[52,53,54] Fair: 1(45)[51]	Medium	NA	Direct	Imprecise	Low	Delay to first ovulation:[f] 24 days MET vs. PBO, p=0.02[51]
Exenatide[g] Poor: 1(20)[53]	High	NA	Direct	Imprecise	Insufficient	Small, poor quality trial
Cabergoline[h] Good: 1(8)[55]	Low	NA	Direct	Imprecise	Insufficient	Cycle control improved:[i] 100% CBG vs. PBO, p=NR[55]
Diet[j] Poor: 1(24)[56]	High	NA	Direct	Imprecise	Insufficient	Not analyzed by arm
Exercise[k] Poor: 1(34)[57]	High	NA	Direct	Imprecise	Insufficient	Not analyzed by arm
Acupuncture[l] Poor: 1(33)[57] Fair: 1(23)[58]	High	NA	Direct	Imprecise	Insufficient	Menstrual regulation:[m] 86% MP-ACU > R-ACU, p<0.05[58]

CBG = cabergoline; COC = combined oral contraceptive; MET = metformin; MR-ACU = menstruation-promoting acupuncture; NR = not reported; PBO = placebo; R-ACU = routine acupuncture

[a]Overall strength of evidence assessment based on good and fair quality studies only.

[b]Oral dydrogesterone (n=35) vs. 8% vaginal micronized progesterone (n=34).

[c]Triphasic norgestimate-ethinyl estradiol vs. placebo (n=100).

[d]Subject assessment.

[e]Poor quality studies: metformin vs. N-acetyl cysteine (n=50), exenatide (n=20), or placebo (n=12); Fair quality study: metformin vs. placebo (n=47).

[f]Mean days to ovulation.

[g]Compared with metformin (n=20) or metformin plus exenatide (n=20).

[h]Compared with placebo (n=6).

[i]Menstrual cyclicity restoration in oligomenorrhea or spontaneous menses in amenorrhea.

[j]Low-fat diet (n=12) vs. low-carbohydrate diet (n=12).

[k]Compared with acupuncture (n=33) or no intervention (n=17).

[l]Poor quality study: acupuncture vs. exercise (n=34) or no intervention (n=17); Fair quality study: mind tranquilizing acupuncture vs. routine acupuncture (n=17).

[m]Patients cured or markedly relieved.

For management of heavy cyclic bleeding the literature was more robust. Combined oral contraceptives are supported by high strength of evidence for the purpose of decreasing MBL. The LNG-IUS, various NSAIDs, and TXA are also effective for reducing the amount of measured menstrual bleeding and are each supported by moderate strength of evidence. Of note, in head-to-head comparisons with statistically significant differences, the LNG-IUS has one trial each showing superiority to NSAIDs, two showing superiority to COCs, and two showing

superiority to progestogens. COCs were superior in one trial compared with an NSAID. TXA was also superior to an NSAID, and when combined with an NSAID was superior to TXA alone. Most of these interventions have been shown to have additional positive effects, typically including shorter duration of bleeding and improvement is symptoms when participants used standardized scoring systems to report on treatment response.

Table 23. Strength of evidence for improving heavy menstrual bleeding (KQ1B)

Intervention Quality: Studies (Subjects Assigned to Intervention)	Risk of Bias	Consistency	Directness	Precision	Overall Strength of Evidence[a]	Findings[b] Comparisons
LNG-IUS Poor: 5(173)[59,61-63,65] Fair: 2(104)[60,64]	Medium	Consistent	Direct	Precise	Moderate	71% and 94% reduction in MBL in 2 head-to-head studies LNG-IUS > MPA, p<0.001[60] LNG-IUS vs. NOR, p=NS[64]
NSAID Poor: 9(192)[63,66,68-71,73,74,77] Fair: 3(113)[67,75,76,93] Good: 1(32)[72]	Medium	Consistent	Direct	Imprecise	Moderate	28% to 49% reduction in MBL in 3 placebo controlled trials; 46% and 47% reduction in MBL in 1 head-to-head study (2 NSAID arms) MFA vs. PBO, p=NR[67] p<0.001[76,72] MFA vs. NPX, p=NS[75]
TXA Poor: 4(202)[66,71,77,79] Fair: 2(260)[80,81] Good: 1(123)[78]	Medium	Consistent	Direct	Precise	Moderate	26% and 40% reduction in MBL in 2 placebo controlled trials; 45% reduction in MBL in 1 head-to-head study TXA vs. PBO, p<0.001[81,78] TXA > NOR, p<0.001[80]
COC[c] Poor: 3(90)[59,61,68] Good: 2(269)[82,83]	Low	Consistent	Direct	Precise	High	64% and 69% reduction in MBL in 2 placebo controlled trials COC vs. PBO, p<0.001[83,82]

Table 23. Strength of evidence for improving heavy menstrual bleeding (KQ1B) (continued)

Intervention Quality: Studies (Subjects Assigned to Intervention)	Risk of Bias	Consistency	Directness	Precision	Overall Strength of Evidence[a]	Findings[b] Comparisons
Progestogen[d] Poor: 4(161)[79,62,70,74] Fair: 4(173)[60,64,80,84]	Medium	Inconsistent	Direct	Imprecise	Insufficient	20% increase to 87% reduction in MBL in 4 head-to-head studies MPA < LNG-IUS, p<0.001[60] NOR < LNG-IUS, p=NS[64] NOR < TXA, p<0.0001[80] NOR vs. CVR, p=NS[84e]
CVR Fair: 1(48)[84]	Medium	NA	Direct	Imprecise	Insufficient	67% reduction in MBL[e] in 1 head-to-head study CVR vs. NOR, p=NS[84]

COC = combined oral contraceptive; CVR = contraceptive vaginal ring; LNG-IUS = levonorgestrel-releasing intrauterine system; MBL = menstrual blood loss; MCF = meclofenamate; MFA = mefenamic acid; MPA = medroxyprogesterone; NA = not applicable; NOR = norethisterone; NPX = naproxen; NR = not reported; NS = not significant; NSAID = nonsteroidal anti-inflammatory drug; PBO = placebo; TXA = tranexamic acid

[a]Overall strength of evidence assessment based on good and fair quality studies only.

[b]Change in menstrual blood loss from baseline measured by the alkaline hematin method (unless otherwise noted) from good and fair quality studies.

[c]thinyl estradiol and levonorgestrel (n=71) or norethindrone and ethinyl estradiol (n=19) or estradiol valerate and dienogest (n=269).

[d]Medroxyprogesterone (n=177) or oral norethisterone (n=113) or depot medroxyprogesterone (n=44).

[e]Percent change in menstrual blood loss measured by the pictorial blood loss assessment chart.

Implications for Clinical and Policy Decisionmaking

This review highlights the variety of options that can be effective for management of abnormal bleeding. We hope it serves to encourage care providers and women to consider the full range of potentially helpful interventions. This review may help to underscore the fact that contraceptive options like LNG-IUS and COCs are a proven option, while widening consideration to include agents like metformin for women with PCOS and TXA for those with heavy bleeding. Clinicians may be also be alerted to the some of the constraints of the literature for these specific populations and proceed with more information to guide decisions and to discuss likely side effects and potential harms.

Since these conditions are not typically life-threatening but are chronic, problematic, and can be embarrassing and costly in terms of lost productivity, the primary health system and policy challenge is to recognize that failure to address AUB is unnecessarily diminishing women's quality of life and function.[1,8] Cost differences are unlikely to drive choices among many of these interventions, though initial costs of long term treatments like the IUS can be disincentives if up-front or maintenance costs to the patient are high.[180-183] Likewise for newer drugs, like TXA, decisions about eligibility and copays could influence uptake and continued utilization of an effective medication. All the interventions described, with the exception of exenatide, cabergoline, and acupuncture, are likely to be covered by most payors for these indications. For the treatments noted that have not yet proven effectiveness in large well-conducted studies this will need to be addressed with high quality research before policy decisions can be recommended.

Limitations of This CER

In this review we focused tightly on primary care interventions for two specific patterns of abnormal bleeding (irregular and cyclic). While this approach was identified by our team, Key Informants, and the Technical Expert Panel (TEP) as an area of the literature that would benefit from evidence synthesis, our focus does prevent comparison to second line therapies that may be used by subspecialists for women who have failed primary care treatment and prevents examination of how these medications fare when compared with surgical options. The latter category of study is fairly small, and for broader perspective, there are a number of reviews within the last 5 to 10 years that provide more sweeping information about these interventions. For the reader's convenience, Appendix M lists these reviews and related practice guidelines and summarizes the conclusions that are relevant to the focus of this review.

Existing literature cannot uniformly be related to more recent updates in classification of AUB that have potential to drive greater uniformity in research and greater thoroughness in clinical evaluation. At present the inclusion and exclusion criteria of trials, the operational definitions of the condition under study and the level of screening of participants to document conformity with the FIGO 2011 classifications is lacking. As a result this literature synthesis is constrained to groupings that are less specific. Nonetheless we have organized the findings into groupings that are clinically recognized presentations and this evidence does apply for the scenarios described.

We restricted this review to publications in English. Based on review of abstracts (generally available in English) and on the expertise of our team and TEP, we do not feel that this biases the review for assessment of the LNG-IUS and medications because few studies were omitted, and larger, higher quality trials are typically published in the English language literature. The sole domain that may be fundamentally under-represented because of this strategy is complementary and alternative medicine which includes interventions such as herbal remedies, acupuncture, and massage therapy. We also restricted interventions to those that had been studied in randomized trials. This limits the degree of context that we can provide from observational studies about factors such as predictors of treatment success or effect modifiers. However, it is uncommon for observational studies to meet criteria sufficient to influence the assessment of strength of evidence when there are trials available, so this restriction is unlikely to have influenced the overall findings of this review.

Limitations of the Evidence Base

Throughout the report we endeavored to point out limitations specific to the included populations, comparisons, and quality of the literature. Recent improvements in unifying nomenclature and formalizing consensus definitions for the clinical groupings of bleeding abnormalities[9] will likely continue to have a positive influence on the ability to properly interpret the findings of individual studies, to identify groups of studies with comparable methods and to aggregate results. Though we did not systematically review literature about pathophysiology, normative patterns for bleeding, natural history of AUB subtypes, or health systems influences, we comment here beyond the need for specific trials in order to encompass other forms of research that could enhance the design and conduct of effectiveness studies as well as filling important gaps in knowledge that hinder research.

Methodologic Limitations

Recurring methodologic recommendations include a need for:

- Larger RCTs, appropriately powered for direct head-to-head comparisons of treatment options in which loss of participants is minimized and intention-to-treat analyses are uniformly conducted.
- Detailed attention to operational criteria for defining the bleeding pattern under study and for methods used to define inclusion and exclusion. Conformity with FIGO PALM-COIEN sub-types may be desirable.
- Study of the validity and reproducibility of classification of women presenting with problem irregular and cyclic bleeding using the PALM-COIEN groupings or other approaches is needed to understand the diagnostic properties of clinical classification systems.
- Clear and definitive operational definitions of outcomes that include, indeed prioritize, patient-reported, condition-specific quality of life and satisfaction measures over durations of time compatible with treatment of a chronic condition. This should include assessments of whether the woman herself considers her bleeding problem resolved.
- Study populations that match the characteristics of those who present with AUB in primary care settings. This includes teens, perimenopausal women, heavier women, and women with common comorbidities such as diabetes and hypertension.
- More effective mechanisms of masking participants, researchers, and providers to intervention status. This may include need to develop sham procedures to mimic IUD insertion and to provide a sham "string" to confirm placement should a patient or provider check status. (Of note the IUD is effective without a string and string-less insertion is also an option for research where placement can be confirmed by ultrasound.)
- Studies designed to assess treatment trajectory and cost. Such studies could randomize women to distinct treatment pathways and track the rate of conversion from one treatment to another for inadequate symptom control or sequence addition of measures, so that the effectiveness of combining multiple intervention methods can be assessed.
- An overall shift towards effectiveness from efficacy, moving beyond the level of proof of concept that is required for drug and device approval to a deeper level that can better inform care, cost considerations, and policy.

Ongoing Research

We identified four ongoing studies that may add to our understanding of the relative safety and efficacy of different regimens for treatment of AUB (additional details provided in Appendix P). Two currently funded trials are exploring the effect of a pretreatment regimen, one employing misoprostol and one using norethindrone acetate, on short and long term bleeding outcomes among women undergoing placement of an LNG-IUS for treatment of heavy menstrual bleeding. A large postmarketing surveillance study of the Mirena® LNG-IUS is also underway in Kazakhstan, with a planned enrollment of 1,700 participants, potentially contributing additional safety information to this body of literature. The utility and safety of new investigational agent, a selective progesterone receptor modulator (CDB-2914) that has shown promise for reducing bleeding in studies involving women with fibroids, is also currently being assessed in a study involving women with AUB.

Future Research Needs

While the number of informative studies that could be designed is likely limitless, we list examples, grouped by indication and intervention, of types of studies that could resolve current and pressing gaps in knowledge.

Irregular Uterine Bleeding

- Development of a body of literature that examines benefits of exercise and weight loss focused on improving bleeding patterns in women with irregular bleeding that results from failed, mistimed, or poor-quality ovulation.
- Continued investigation of the role that insulin sensitizing and glycemic control agents like metformin and exenatide have on improving irregular bleeding patterns.
- Carefully controlled trials of complementary and alternative medicine interventions like acupuncture for improving menstrual regularity.
- RCTs specifically designed to assess both the heaviness and the interval of bleeding in women with irregular bleeding, which could include approaches shown to have benefit for heavy cyclic bleeding.

Abnormal Cyclic Uterine Bleeding

- Investigate the epidemiology and natural history of heavy menstrual bleeding in representative primary care populations in order to better understand the boundaries of what constitutes normal bleeding patterns and to document the trajectory of AUB. This would for instance, contribute data about what factors predict severity and whether a proportion of cases are self-limited.
- Determine whether harms reported to be associated with treatments for heavy bleeding result because a causal contributor to the heavy bleeding is also related to the harm. For instance abnormalities in coagulation may enhance risk of DVT and be associated with heavy menses. Analyses for such confounding by indication may better assess risk of harms and predictors of response.
- Across specific interventions, additional research and analysis is needed to determine which individuals are most likely to respond to which interventions. This could develop from personalized medicine approaches, from better understanding of the mechanisms underpinning AUB, or from predictive modeling in large datasets.
- Assess the acceptability and cost-effectiveness of various treatments in the primary care setting in the United States including LNG-IUS, NSAID, COCs and TXA.
- Determine the most valid and accurate indirect measures of MBL that can be used in primary care settings and that correlate with objective direct measures.

Progesterone Containing IUDs Including the LNG-IUS

- Establish a registry of LNG-IUS users in the United States for extended followup of potential harms and preventive effects (e.g., reduced risk of endometrial cancer, anemia).
- Extend postmarketing surveillance to assure safety when used in teens and nulliparous patients.
- Examine costs in light of whether the treatment simultaneously resolves bleeding complaints and provides contraception.

NSAIDs

- Directly compare classes of NSAIDs including commonly available over-the-counter preparations.
- Conduct long-term effectiveness studies to determine if treatment effects are durable or wane over time.
- Model the costs of treatment with varied NSAID dosing strategies.
- Determine if "pre-loading" in the days before onset of menses significantly reduces menstrual bleeding alone and in combination with NSAIDs after onset of menstrual bleeding.

COCs

- Conduct direct comparisons of COCs with other AUB management strategies to better understand the relative merits of treatment options.
- Examine costs in light of whether the treatment simultaneously treats complaints and provides contraception.

TXA

- Establish a registry of TXA users and exploit existing large payer datasets to examine long-term followup for both effectiveness beyond 6 months and incidence of rare/uncommon adverse effects.

Conclusions

Women who have problematic irregular or heavy cyclic menstrual bleeding have a number of treatment options available that are supported by systematic review of the research literature. These include high strength of evidence that COCs can improve menstrual regularity for women with irregular bleeding patterns. Metformin is supported by moderate strength of evidence for improving cycle regularity especially among women with PCOS. This provides both a contraceptive and a noncontraceptive option for irregular menses. Other interventions like progestogens are associated with statistically and clinically meaningful improvements from baseline patterns, however the overall evidence is insufficient from well-designed, larger studies with ability to directly compare treatment arms rather than only pre-post measures within groups.

Multiple interventions for heavy cyclic bleeding are supported by evidence that they reduce MBL. These include strong evidence that COCs are effective and moderate strength of evidence that LNG-IUS, NSAIDs, and TXA reduce bleeding relative to baseline, decrease total volume of bleeding when comparisons are made across treatment groups, and when measured, decrease days of bleeding. In direct comparisons, LNG-IUS is superior to NSAIDs. TXA is superior to NSAIDs and TXA combined with an NSAID was superior to TXA alone. Results from COC and NSAID comparisons suggest comparable effectiveness. Not all women who are treated with any of these interventions that can be effective will improve. Across agents data are sparse to evaluate long-term improvements and risk of harms.

Limitations include a predominance of small, short trials lacking standard terminology and diagnostic criteria for identifying and including women with AUB. Tools for collecting outcome data are crude (collection of sanitary products) and may contribute to a high rate of attrition. Biologic outcomes, like measured blood loss and hemoglobin or hematocrit levels, may neglect the importance of patient-reported outcomes that assess whether symptoms are considered

resolved by women themselves. Nevertheless, the variety of effective options suggests many women can achieve symptom relief and will have available to them choices that address both symptoms and contraceptive or fertility desires, as well as potentially improving other symptoms like menstrual cramping.

References

1. Liu Z, Doan QV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007 May-Jun;10(3):183-94. PMID: 17532811.
2. Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Bio 2010 Oct;152(2):133-7. PMID: 20688424.
3. Albers JR, Hull SK, Wesley RM. Abnormal uterine bleeding. Am Fam Physician 2004 Apr 15;69(8):1915-26. PMID: 15117012.
4. Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
5. Hallberg L, Hogdahl AM, Nilsson L, et al. Menstrual blood loss—a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45(3):320-51. PMID: 5922481.
6. Treloar AE, Boynton RE, Behn BG, et al. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967 Jan-Mar;12(1 Pt 2):77-126. PMID: 5419031.
7. Belsey EM, Pinol AP. Menstrual bleeding patterns in untreated women. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1997 Feb;55(2):57-65. PMID: 9071513.
8. Matteson KA, Clark MA. Questioning our questions: do frequently asked questions adequately cover the aspects of women's lives most affected by abnormal uterine bleeding? Opinions of women with abnormal uterine bleeding participating in focus group discussions. Women Health 2010 Mar;50(2):195-211. PMID: 20437305.
9. Munro MG, Critchley HO, Broder MS, et al.; FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011 Apr;113(1):3-13. PMID: 21345435.
10. Bradley LD. Diagnosis of abnormal uterine bleeding with biopsy or hysteroscopy. Menopause 2011 Apr;18(4):425-33. PMID: 21701428.
11. Doubilet PM. Diagnosis of abnormal uterine bleeding with imaging. Menopause 2011 Apr;18(4):421-4. PMID: 21701427.
12. Woolcock JG, Critchley HO, Munro MG, et al. Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertil Steril 2008;90(6):2269-80. PMID: 18258230.
13. Rahn DD, Abed H, Sung VW, et al.; Society of Gynecologic Surgeons Systematic Review Group. Systematic review highlights difficulty interpreting diverse clinical outcomes in abnormal uterine bleeding trials. J Clin Epidemiol 2011 Mar;64(3):293-300. PMID: 20705427.
14. Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007 Mar;87(3):466-76. PMID: 17362717.
15. Fraser IS, Critchley HO, Munro MG, et al. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod 2007 Mar;22(3):635-43. PMID: 17204526.
16. Munro MG, Critchley HO, Fraser IS; FIGO Working Group on Menstrual Disorders. The FIGO classification of causes of abnormal uterine bleeding. Int J Gynaecol Obstet 2011 Apr;113(1):1-2. PMID: 21316671.

17. Hale GE, Zhao X, Hughes CL, et al. Endocrine Features of Menstrual Cycles in Middle and Late Reproductive Age and the Menopausal Transition Classified According to the Staging of Reproductive Aging Workshop (STRAW) Staging System. J Clin Endocrinol Metab 2007 August 1, 2007;92(8):3060-7. PMID: 17550960.

18. Heller DS. Pathologic basis for abnormal uterine bleeding with organic uterine pathologies. Menopause 2011 Apr;18(4):412-5. PMID: 21701425.

19. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 14: management of anovulatory bleeding. Int J Gynaecol Obstet 2001 Mar;72(3):263-71. PMID: 11296797.

20. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 59: clinical management guidelines for obstetricians-gynecologists: intrauterine device. Obstet Gynecol 2005 Jan;105(1):223-32. PMID: 15625179.

21. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010 Jan;115(1):206-18. PMID: 20027071.

22. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 121: long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2011 Jul;118(1):184-96. PMID: 21691183.

23. Ely JW, Kennedy CM, Clark EC, et al. Abnormal uterine bleeding: a management algorithm. J Am Board Fam Med 2006 Nov-Dec;19(6):590-602. PMID: 17090792.

24. National Collaborating Centre for Women's and Children's Health. Heavy Menstrual Bleeding. NICE Clinical Guideline CG44. London: Institute for Health and Clinical Excellence; 2007.

25. Matteson KA, Anderson BL, Pinto SB, et al. Practice patterns and attitudes about treating abnormal uterine bleeding: a national survey of obstetricians and gynecologists. Am J Obstet Gynecol 2011 May 14PMID: 21737060.

26. Jensen JT, Lefebvre P, Laliberte F, et al. Cost Burden and Treatment Patterns Associated with Management of Heavy Menstrual Bleeding. J Womens Health (Larchmt) 2012 Feb 23PMID: 22360696.

27. Samuel NC, Justin Clark T. Future research into abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol 2007;21(6):1023-40. PMID: 17584533.

28. Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol 2011 Mar;117(3):705-19. PMID: 21343774.

29. Endrikat J, Vilos G, Muysers C, et al. The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia. Arch Gynecol Obstet 2011 Apr 8PMID: 21475963.

30. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23 2010 Aug(29):1-44. PMID: 20939159.

31. Xu X, Macaluso M, Ouyang L, et al. Revival of the intrauterine device: increased insertions among US women with employer-sponsored insurance, 2002-2008. Contraception 2012 Feb;85(2):155-9. PMID: 22067778.

32. Smith SK, Abel MH, Kelly RW, et al. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol 1981 Apr;88(4):434-42. PMID: 7225303.

33. Pinkerton JV. Pharmacological therapy for abnormal uterine bleeding. Menopause 2011 Apr;18(4):453-61. PMID: 21701432.

34. Lethaby A, Augood C, Duckitt K, et al. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007(4):CD000400. PMID: 17943741.

35. Lumsden MA, Wedisinghe L. Tranexamic acid therapy for heavy menstrual bleeding. Expert Opin Pharmacother 2011 Sep;12(13):2089-95. PMID: 21767224.

36. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev 2009(4):CD000154. PMID: 19821266.

37. Telner DE, Jakubovicz D. Approach to diagnosis and management of abnormal uterine bleeding. Can Fam Physician 2007 Jan;53(1):58-64. PMID: 17872610.

38. Kiley J, Hammond C. Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol 2007 Dec;50(4):868-77. PMID: 17982329.

39. Norman RJ, Noakes M, Wu R, et al. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004 May-Jun;10(3):267-80. PMID: 15140873.

40. Livdans-Forret AB, Harvey PJ, Larkin-Thier SM. Menorrhagia: a synopsis of management focusing on herbal and nutritional supplements, and chiropractic. J Can Chiropr Assoc 2007 Dec;51(4):235-46. PMID: 18060009.

41. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2011. www.effectivehealthcare.ahrq.gov.

42. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009 Oct;62(10):e1-34. PMID: 19631507.

43. Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol 2010 May;63(5):502-12. PMID: 18823754.

44. Avoiding bias in selecting studies. AHRQ Draft Manuscript: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; June 23 2011. www.effectivehealthcare.ahrq.gov.

45. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. PMID: 22008217.

46. Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol 2011 Nov;64(11):1187-97. PMID: 21477993.

47. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010 May;63(5):513-23. PMID: 19595577.

48. Atkins D, Chang SM, Gartlehner G, et al. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol 2011 Nov;64(11):1198-207. PMID: 21463926.

49. Karakus S, Kiran G, Ciralik H. Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial. Aust N Z J Obstet Gynaecol 2009 Dec;49(6):685-8. PMID: 20070724.

50. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000 Dec;96(6):913-20. PMID: 11084177.

51. Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002 Feb;87(2):569-74. PMID: 11836287.

52. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000 Jan;85(1):139-46. PMID: 10634377.

53. Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93(7):2670-8. PMID: 18460557.

54. Oner G, Muderris, II. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011 Nov;159(1):127-31. PMID: 21831508.

55. Paoletti AM, Cagnacci A, Depan GF, et al. The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 1996;66(4):527-32. PMID: 8816612.

56. Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2011;24(3):161-5. PMID: 21419674.

57. Jedel E, Labrie F, Oden A, et al. Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab 2011 Jan;300(1):E37-45. PMID: 20943753.

58. Cai XM, Wu J. The mind-tranquilizing and menstruation-regulating method for acupuncture treatment of delayed menstrual cycle—a clinical controlled study. J Tradit Chin Med 2009 Mar;29(1):35-8. PMID: 19514186.

59. Shaaban MM, Zakherah MS, El-Nashar SA, et al. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 2011 Jan;83(1):48-54. PMID: 21134503.

60. Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010 Sep;116(3):625-32. PMID: 20733445.

61. Endrikat J, Shapiro H, Lukkari-Lax E, et al. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 2009 Apr;31(4):340-7. PMID: 19497153.

62. Kucuk T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol 2008;35(1):57-60. PMID: 18390083.

63. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 2005 Aug;112(8):1121-5. PMID: 16045528.

64. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998 Jun;105(6):592-8. PMID: 9647148.

65. Lahteenmaki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998 Apr 11;316(7138):1122-6. PMID: 9552948.

66. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996 Sep 7;313(7057):579-82. PMID: 8806245.

67. van Eijkeren MA, Christiaens GC, Geuze HJ, et al. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol 1992 May;166(5):1419-28. PMID: 1595797.

68. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991 Feb;31(1):66-70. PMID: 1872778.

69. Grover V, Usha R, Gupta U, et al. Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. Asia Oceania J Obstet Gynaecol 1990 Sep;16(3):255-9. PMID: 2088249.

70. Cameron IT, Haining R, Lumsden MA, et al. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol 1990 Jul;76(1):85-8. PMID: 2359570.

71. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand 1988;67(7):645-8. PMID: 3073625.

72. Vargyas JM, Campeau JD, Mishell DR, Jr. Treatment of menorrhagia with meclofenamate sodium. Am J Obstet Gynecol 1987 Oct;157(4 Pt 1):944-50. PMID: 3314521.

73. Tsang BK, Domingo MT, Spence JE, et al. Endometrial prostaglandins and menorrhagia: influence of a prostaglandin synthetase inhibitor in vivo. Can J Physiol Pharmacol 1987 Oct;65(10):2081-4. PMID: 3123043.

74. Cameron IT, Leask R, Kelly RW, et al. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 1987 Jul;34(1):99-110. PMID: 3685399.

75. Hall P, Maclachlan N, Thorn N, et al. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol 1987 Jun;94(6):554-8. PMID: 3304401.

76. Fraser IS, Pearse C, Shearman RP, et al. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet Gynecol 1981 Nov;58(5):543-51. PMID: 7029369.

77. Najam R, Agarwal D, Tyagi R, et al. Comparison of traneximic acid with a combination of traneximic acid and mefenamic acid in reducing menstrual blood loss in ovulatory dysfunctional uterine bleeding (DUB). Journal of Clinical and Diagnostic Research 2010;4(5):3020-5.

78. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010 Oct;116(4):865-75. PMID: 20859150.

79. Kriplani A, Kulshrestha V, Agarwal N, et al. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006 Oct;26(7):673-8. PMID: 17071438.

80. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995 May;102(5):401-6. PMID: 7612535.

81. Freeman EW, Lukes A, VanDrie D, et al. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol 2011 Oct;205(4):319 e1-7. PMID: 21777897.

82. Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: A randomized, double-blind Phase III trial. Human Reproduction 2011;26(10):2698-708. PMID: 21784734.

83. Jensen JT, Parke S, Mellinger U, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: A randomized controlled trial. Obstetrics and Gynecology 2011;117(4):777-87. PMID: 21422847.

84. Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 2012 Mar;85(3):246-52. PMID: 22067765.

85. Vuorma S, Rissanen P, Aalto AM, et al. Impact of patient information booklet on treatment decision—a randomized trial among women with heavy menstruation. Health Expect 2003 Dec;6(4):290-7. PMID: 15040791.

86. Kennedy AD, Sculpher MJ, Coulter A, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA 2002 Dec 4;288(21):2701-8. PMID: 12460093.

87. Protheroe J, Bower P, Chew-Graham C, et al. Effectiveness of a computerized decision aid in primary care on decision making and quality of life in menorrhagia: results of the MENTIP randomized controlled trial. Medical Decision Making 2007;27(5):575-84. PMID: 17898242.

88. Shaw ST, Jr., Aaronson DE, Moyer DL. Quantitation of menstrual blood loss—further evaluation of the alkaline hematin method. Contraception 1972 Jun;5(6):497-513. PMID: 4650663.

89. Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest 1964;16:244-8. PMID: 14161862.

90. Zakherah MS, Sayed GH, El-Nashar SA, et al. Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecol Obstet Invest 2011;71(4):281-4. PMID: 21228538.

91. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995 Jun;85(6):977-82. PMID: 7770270.

92. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990 Aug;97(8):734-9. PMID: 2400752.

93. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 1984 Aug 1;149(7):788-93. PMID: 6380294.

94. Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011(10):CD001431. PMID: 21975733.

95. Gemzell-Danielsson K, Inki P, Boubli L, et al. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)—a multicentre prospective study. Hum Reprod 2010 Feb;25(2):354-9. PMID: 19955104.

96. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.

97. Spiller HA, Quadrani DA. Toxic effects from metformin exposure. Ann Pharmacother 2004 May;38(5):776-80. PMID: 15031415.

98. Chan KA, Truman A, Gurwitz JH, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 2003 Mar 24;163(6):728-34. PMID: 12639207.

99. Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008 Nov;31(11):2086-91. PMID: 18782901.

100. Lewis JD, Capra AM, Achacoso NS, et al. Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiol Drug Saf 2007 Nov;16(11):1195-202. PMID: 17603822.

101. LeBlanc E, O'Connor E, Whitlock EP, et al. Screening for and Management of Obesity and Overweight in Adults. Evidence Report No. 89. AHRQ Publication No. 11-05159-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; Oct 2011.

102. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010(1):CD002967. PMID: 20091535.

103. Salvo F, Fourrier-Reglat A, Bazin F, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011 Jun;89(6):855-66. PMID: 21471964.

104. Bennett WL, Wilson LM, Bolen S, et al. Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update. AHRQ Publication No. 11-EHC038-EF. Rockville, MD: Agency for Healthcare Research and Quality; Mar 2011.

105. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005(3):CD002966. PMID: 16034881.

106. Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012 Feb 7;156(3):218-31. PMID: 22312141.

107. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2011.

108. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009 Apr;25(4):1019-27. PMID: 19278373.

109. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011 Jun;13(6):559-66. PMID: 21320263.

110. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011 Jul;141(1):150-6. PMID: 21334333.

111. Waugh N, Cummins E, Royle P, et al. Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement). London: National Institute for Health and Clinical Excellence.; 2009.

112. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011(10):CD006423. PMID: 21975753.

113. Aygestin [package insert]. Sellersville, PA: Teva Women's Health, Inc.; 2010.

114. Crinone [package insert]. Livingston, NJ: Columbia Laboratories, Inc.; 2009.

115. Depo-Provera CI [package insert]. New York, NY: Pharmacia & Upjohn Company; 2011.

116. Provera [package insert]. New York, NY: Pharmacia and Upjohn Company; 2009.

117. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010 Nov;30(11):2297-300. PMID: 20798377.

118. Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 2008 Dec;78(6):459-64. PMID: 19014791.

119. Rosenberg L, Zhang Y, Constant D, et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception 2007 Dec;76(6):425-31. PMID: 18061699.

120. Aktun H, Moroy P, Cakmak P, et al. Depo-Provera: use of a long-acting progestin injectable contraceptive in Turkish women. Contraception 2005 Jul;72(1):24-7. PMID: 15964288.

121. Lidegaard O, Lokkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012 Jun 14;366(24):2257-66. PMID: 22693997.

122. Sundstrom A, Seaman H, Kieler H, et al. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009 Jan;116(1):91-7. PMID: 19016686.

123. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008(1):CD001016. PMID: 18253983.

124. Grimes DA, Lopez LM, O'Brien PA, et al. Progestin-only pills for contraception. Cochrane Database Syst Rev 2010(1):CD007541. PMID: 20091638.

125. Natazia [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2012.

126. Loestrin 1/20 [package insert]. Pomona, NY: Duramed Pharmaceuticals, Inc.; 2009.

127. Nordette [package insert]. Sellersville, PA: Teva Pharmaceuticals USA, Inc.; 2010.

128. Ortho Tri-Cyclen [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2010.

129. Manzoli L, De Vito C, Marzuillo C, et al. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 2012 Mar 1;35(3):191-205. PMID: 22283630.

130. Martinez F, Ramirez I, Perez-Campos E, et al. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care 2012 Feb;17(1):7-29. PMID: 22239262.

131. Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011(9):CD003987. PMID: 21901687.

132. Lawrie TA, Helmerhorst FM, Maitra NK, et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011(5):CD004861. PMID: 21563141.

133. Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005(3):CD004695. PMID: 16034942.

134. Van Vliet HA, Grimes DA, Helmerhorst FM, et al. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006(3):CD003283. PMID: 16856002.

135. Van Vliet HA, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2011(11):CD003553. PMID: 22071807.

136. Cabergoline [package insert]. Sellersville, PA: Teva Pharmaceuticals 2011.

137. Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord 2009 Jan 15;24(1):129-33. PMID: 19170199.

138. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007 Jan 4;356(1):29-38. PMID: 17202453.

139. Renoux C, Dell'Aniello S, Brophy JM, et al. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf 2012 Jan;21(1):34-41. PMID: 22109939.

140. Tang H, Hunter T, Hu Y, et al. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2012(2):CD008605. PMID: 22336848.

141. Scholz H, Trenkwalder C, Kohnen R, et al. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 2011(3):CD006009. PMID: 21412893.

142. Rasmussen VG, Ostergaard K, Dupont E, et al. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. Mov Disord 2011 Apr;26(5):801-6. PMID: 21671508.

143. Bogazzi F, Manetti L, Raffaelli V, et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 2008 Dec;31(12):1119-23. PMID: 19246980.

144. Smith CA, Zhu X, He L, et al. Acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev 2011(1):CD007854. PMID: 21249697.

145. Zhu X, Hamilton KD, McNicol ED. Acupuncture for pain in endometriosis. Cochrane Database Syst Rev 2011(9):CD007864. PMID: 21901713.

146. Cheong YC, Hung Yu Ng E, Ledger WL. Acupuncture and assisted conception. Cochrane Database Syst Rev 2008(4):CD006920. PMID: 18843737.

147. Smith CA, Crowther CA. Acupuncture for induction of labour. Cochrane Database Syst Rev 2004(1):CD002962. PMID: 14973999.

148. Mirena [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2009.

149. FDA. FDA approves additional use for IUD Mirena to treat heavy menstrual bleeding in IUD users [Internet]. 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm184747.htm. Accessed May 11, 2012.

150. FDA. Statistics filing memorandum for a supplemental NDA (Mirena).FDA; 2009. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM245687.pdf.

151. Zhou L, Harrison-Woolrych M, Coulter DM. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena). Pharmacoepidemiol Drug Saf 2003 Jul-Aug;12(5):371-7. PMID: 12899110.

152. Harrison-Woolrych M, Zhou L, Coulter D. Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand. N Z Med J 2003 Aug 8;116(1179):U538. PMID: 14513085.

153. Paterson H, Clifton J, Miller D, et al. Hair loss with use of the levonorgestrel intrauterine device. Contraception 2007 Oct;76(4):306-9. PMID: 17900442.

154. Van Houdenhoven K, van Kaam KJ, van Grootheest AC, et al. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception 2006 Mar;73(3):257-60. PMID: 16472566.

155. van Grootheest K, Sachs B, Harrison-Woolrych M, et al. Uterine perforation with the levonorgestrel-releasing intrauterine device: analysis of reports from four national pharmacovigilance centres. Drug Saf 2011 Jan 1;34(1):83-8. PMID: 21142273.

156. Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423. PMID: 22027398.

157. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005(4):CD002126. PMID: 16235297.

158. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006(2):CD003855. PMID: 16625593.

159. French R, Van Vliet H, Cowan F, et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev 2004(3):CD001776. PMID: 15266453.

160. NuvaRing [package insert]. Whitehouse Station, NJ: Merck & Co.; 2012.

161. Merki-Feld GS, Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care 2007 Sep;12(3):240-7. PMID: 17763262.

162. Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany. Eur J Contracept Reprod Health Care 2008 Mar;13(1):31-8. PMID: 17853162.

163. Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception 2010 Nov;82(5):418-27. PMID: 20933115.

164. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception 2006 May;73(5):445-69. PMID: 16627030.

165. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol 2012 Aug;24(4):235-40. PMID: 22729096.

166. Flurbiprofen tablet [package insert]. Detroit, MI: Caraco Pharmaceutical Laboratories, Inc.; 2007.

167. Meclofenamate sodium [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc.; 2006.

168. Naprosyn [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2010.

169. Marjoribanks J, Proctor M, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010(1):CD001751. PMID: 20091521.

170. Garcia Rodriguez LA, Gonzalez-Perez A, Bueno H, et al. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One 2011;6(2):e16780. PMID: 21347435.

171. Lysteda [package insert]. Parsippany, NJ: Ferring Pharmaceutical; 2011.

172. FDA. New Drug Application: 22-430 (Tranexamic Acid) Summary Review.Center for Drug Evaluation and Research; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022430s000sumr.pdf.

173. Naoulou B, Tsai MC. Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: A systematic review. Acta Obstet Gynecol Scand 2012 May;91(5):529-37. PMID: 22229782.

174. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000(4):CD000249. PMID: 11034679.

175. Sukeik M, Alshryda S, Haddad FS, et al. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011 Jan;93(1):39-46. PMID: 21196541.

176. Alshryda S, Sarda P, Sukeik M, et al. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br 2011 Dec;93(12):1577-85. PMID: 22161917.

177. Vuorma S, Teperi J, Aalto AM, et al. A randomized trial among women with heavy menstruation — impact of a decision aid on treatment outcomes and costs. Health Expect 2004 Dec;7(4):327-37. PMID: 15544685.

178. Stewart A, Cummins C, Gold L, et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG 2001 Jan;108(1):74-86. PMID: 11213008.

179. Coulter A, Kelland J, Peto V, et al. Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 1995 Summer;11(3):456-71. PMID: 7591547.

180. Stern D, Reissman D. Specialty pharmacy cost management strategies of private health care payers. J Manag Care Pharm 2006 Nov-Dec;12(9):736-44. PMID: 17249906.

181. Kim YA, Rascati KL, Prasla K, et al. Retrospective evaluation of the impact of copayment increases for specialty medications on adherence and persistence in an integrated health maintenance organization system. Clin Ther 2011 May;33(5):598-607. PMID: 21665044.

182. Hartung DM, Carlson MJ, Kraemer DF, et al. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population. Med Care 2008 Jun;46(6):565-72. PMID: 18520310.

183. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011 Jun 20;29(18):2534-42. PMID: 21606426.

Abbreviations and Acronyms

ARHQ	Agency for Healthcare Research and Quality
CER	Comparative Effectiveness Review
CINAHL	Cumulative Index to Nursing and Allied Health Literature
COC	Combined oral contraceptive
g	Gram
GnRH	Gonadotropin-releasing Hormone
HRQoL-4	Health related quality of life survey-based questionnaire
IM	Intramuscular
IUD	Intrauterine device
kg	Kilogram
KQ	Key Questions
LHRH	Luteinizing Hormone-releasing Hormone
LNG-IUS	Levonorgestrel-releasing intrauterine system
MBL	Menstrual blood loss
mcg	Microgram
MeSH	Medical Subject Heading
mg	Milligram
MIQ	Menorrhagia Impact Questionnaire
mmol	Millimolar
MPA	Medroxyprogesterone acetate
N	Number
NS	Non-significant
NSAID	Nonsteroidal anti-inflammatory drug
OR	Odds ratio
PBLAC	Pictorial Blood Loss Assessment Chart
PCOS	Polycystic ovary syndrome
PICOTS	Population, Interventions, Comparators, Outcomes, Timing, Settings
RCT	Randomized Controlled Trials
RR	Relative Risk
SOE	Strength of Evidence
TEP	Technical Expert Panel
TXA	Tranexamic acid

Appendix A. Literature Search Strategies

Table A1: KQ1 search strategy and results from PubMed (pubmed.gov interface)

Terms		Results
#1	uterine hemorrhage[mh:noexp] OR metrorrhagia[mh] OR menstruation disturbances[mh:noexp] OR menorrhagia[mh] OR oligomenorrhea[mh] OR menorrhagia[tiab] OR metrorrhagia[tiab] OR menometrorrhagia[tiab] OR polymenorrhea[tiab] OR oligomenorrhea[tiab] OR hypermenorrhea[tiab] OR dysfunctional uterine bleeding[tiab] OR excessive uterine bleeding[tiab] OR abnormal uterine bleeding[tiab] OR irregular uterine bleeding[tiab] OR ((ovulation dysfunction[tiab] OR ovulatory dysfunction[tiab]) AND (bleeding[tiab] OR hemorrhage[tiab] OR haemorrhage[tiab])) OR ((anovulation[mh] OR anovulation[tiab] OR anovulatory[tiab]) AND (hemorrhage[tiab] OR haemorrhage[tiab] OR bleeding[tiab]))	20,586
#2	therapy[sh:noexp] OR drug therapy[mh] OR drug therapy[sh] OR contraceptives, oral[mh] OR contraceptive agents, female[pa] OR progestins[mh] OR progestins[pa] OR contraceptive devices, female[mh:noexp] OR intrauterine devices[mh] OR anti-inflammatory agents, non-steroidal[mh] OR anti-inflammatory agents, non-steroidal[pa] OR antifibrinolytic agents[mh] OR antifibrinolytic agents[pa] OR complementary therapies[mh] OR cam[sb] OR diet therapy[mh] OR diet therapy[sh] OR exercise therapy[mh] OR psychotherapy[mh]	3,994,137
#3	#1 AND #2 AND english[la] AND humans[mh] AND 1980:2012[dp]	4,846
#4	#3 AND editorial[pt]	30
#5	#3 AND letter[pt]	190
#6	#3 AND comment[pt]	100
#7	#3 AND case reports[pt]	872
#8	#3 AND review[pt]	1,078
#9	#3 AND news[pt]	11
#10	#3 AND newspaper article[pt]	5
#11	#3 AND historical article[pt]	12
#12	#3 AND clinical conference[pt]	7
#13	#3 AND practice guideline[pt]	23
#14	#3 AND meta-analysis[pt]	43
#15	#3 AND congresses[pt]	6
#16	#3 AND consensus development conference[pt]	11
#17	#3 AND retracted publication[pt]	3
#18	#3 AND jsubsetk	21
#19	#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18	2,090*
#20	#3 NOT #19	2,756
#21	#20 AND (random allocation[mh] OR double-blind method[mh] OR single-blind method[mh] OR randomized controlled trial[pt] OR controlled clinical trial[pt] OR clinical trial[pt] OR clinical trial[tiab] OR random[tiab] OR randomized[tiab] OR randomised[tiab] OR randomly[tiab] OR assigned[tiab] OR allocated[tiab] OR control[tiab] OR controlled[tiab] OR controls[tiab])	1,374

Key: [dp] publication date; jsubsetk consumer health subset; [la] language; [mh] medical subject heading; [pa] pharmacological action; [pt] publication type; [sb] subset search; [sh] subheading; [tiab] keyword in title or abstract.
* Note: numbers may not tally as some articles are excluded in more than one category.

Table A2: KQ1 search strategy and results from CINAHL (EBSCOhost interface)

Terms		Results
#1	(MH "Uterine Hemorrhage") OR (MH "Metrorrhagia") OR (MH "Menorrhagia") OR (MH "Menstruation Disorders") OR menorrhagia OR metrorrhagia OR menometrorrhagia OR polymenorrhea OR oligomenorrhea OR hypermenorrhea OR dysfunctional uterine bleeding OR excessive uterine bleeding OR abnormal uterine bleeding OR irregular uterine bleeding OR ovulation dysfunction OR ovulatory dysfunction OR ((anovulation OR anovulatory OR cyclic OR cyclical) AND (hemorrhage OR haemorrhage OR bleeding))	1,933
#2	(MH "Therapeutics") OR therapeutic OR therapeutics OR therapy OR therapies OR treatment OR treatments OR management OR (MH "Drug Therapy+") OR drug therapy OR (MH "Contraceptives, Oral+") OR oral contraceptive OR oral contraceptives OR (MH "Intrauterine Devices") OR intrauterine device OR intrauterine devices OR intrauterine system OR intrauterine systems OR IUD OR IUS OR vaginal ring OR (MH "Progestational Hormones+") OR progestin OR progestins OR progestogen OR progestogens OR (MH "Antiinflammatory Agents, Non-Steroidal+") OR non-steroidal anti-inflammatory OR nonsteroidal anti-inflammatory OR non-steroidal antiinflammatory OR nonsteroidal antiinflammatory OR NSAID OR NSAIDs OR (MH "Antifibrinolytic Agents") OR antifibrinolytic OR anti-fibrinolytic OR antifibrinolytics OR anti-fibrinolytics OR tranexamic acid OR aminocaproic acid OR (MH "Natural and Biologically Based Therapies+") OR (MH "Acupuncture+") OR (MH "Alternative Therapies") OR alternative medicine OR complementary medicine OR herbal medicine OR chinese medicine OR acupuncture OR phytotherapy OR (MH "Life Style Changes") OR (MH "Exercise+") OR (MH "Therapeutic Exercise+") OR exercise OR (MH "Weight Loss") OR weight loss OR (MH "Stress Management") OR stress reduction	888,917
#3	#1 AND #2	1,267
#4	#3 AND limiters: English language; Human	376
#5	#3 AND limiters: English language; Human; Exclude MEDLINE records	33

Table A3: KQ1 search strategy and results from EMBASE (OVID interface)

Terms		Results
#1	exp uterus bleeding/ OR menstruation disorder/ OR exp "menorrhagia and metrorrhagia"/ OR (uterine hemorrhage OR metrorrhagia OR menorrhagia OR menometrorrhagia OR polymenorrhea OR oligomenorrhea OR hypermenorrhea OR dysfunctional uterine bleeding OR excessive uterine bleeding OR abnormal uterine bleeding OR irregular uterine bleeding OR ((ovulation dysfunction OR ovulatory dysfunction) AND (bleeding OR hemorrhage OR hemorrhage)) OR ((anovulation OR anovulation OR anovulatory) AND (hemorrhage OR haemorrhage OR bleeding))).mp	27,343
#2	exp oral contraceptive agent/ OR exp intrauterine contraceptive device/ OR exp vagina ring/ OR exp gestagen/ OR exp nonsteroid antiinflammatory agent/ OR exp antifibrinolytic agent/ OR exp alternative medicine/ OR exp traditional medicine/ OR exp acupuncture/ OR exp diet therapy/ OR exp weight reduction/ OR exp stress management/ OR exp relaxation training/	929,093
#3	1 AND 2, limited to human and English language and 1980-2012	6,055
#4	3 AND review.pt	1,823
#5	3 AND conference paper.pt	273
#6	3 AND conference abstract.pt	84
#7	3 AND editorial.pt	96
#8	3 AND letter.pt	213
#9	3 AND note.pt	138
#10	3 AND short survey.pt	148
#11	3 AND case report/	641
#12	3 AND practice guideline/	184
#13	3 AND systematic review/	158
#14	3 AND meta analysis/	138
#15	4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14	3,365*
#16	3 NOT 15	2,690
#17	16 AND (exp clinical trial/ OR exp controlled clinical trial/) AND (exp randomization/ OR randomized controlled trial/ OR (random OR randomly OR randomized OR randomised).mp)	573**

Key: / subject term; exp explode term; .mp keyword, subject term, or substance term; .pt publication type.
* Note: numbers may not tally as some articles are excluded in more than one category.
**After removal of 213 citations duplicated in PubMed, 360 unique citations retained for review

Table A4: KQ2 search strategy and results from PubMed (pubmed.gov interface)

Search terms		Search results
#1	levonorgestrel/ae[mh] OR intrauterine devices, medicated/ae[mh] OR norethindrone/ae[mh] OR ethinyl estradiol/ae[mh] OR medroxyprogesterone acetate/ae[mh] OR mefenamic acid/ae[mh] OR norgestrel/ae[mh] OR genistein/ae[mh] OR dydrogesterone/ae[mh] OR tranexamic acid/ae[mh] OR ethamsylate/ae[mh] OR flurbiprofen/ae[mh] OR naproxen/ae[mh] OR indomethacin/ae[mh] OR metformin/ae[mh] OR progesterone/ae[mh:noexp] OR contraceptives, oral, combined/ae[mh:noexp] OR anti-inflammatory agents, non-steroidal/ae[mh:noexp] OR ((ferric carboxymaltose[supplementary concept] OR ferrous sulfate[supplementary concept] OR exenatide[supplementary concept] OR norgestimate, ethinyl estradiol drug combination[supplementary concept] OR estradiol Valerate, dienogest drug combination[nm] OR dienogest[nm]) AND ae[sh])	23,134
#2	cohort studies[mh] OR product surveillance, postmarketing[mh] OR clinical trial, phase IV[pt] OR databases, factual[mh] OR adverse drug reaction reporting systems[mh] OR case control studies[mh] OR cohort[tiab]	1,373,280
#3	#1 AND #2 AND eng[la] AND humans[mh] AND 1980:2012[dp]	3,142
#4	#3 AND review[pt]	218
#5	#3 AND case reports[pt]	138
#6	#3 AND letter[pt]	124
#7	#3 AND comment[pt]	84
#8	#3 AND meta-analysis[pt]	51
#9	#3 AND practice guideline[pt]	2
#10	#3 AND editorial[pt]	22
#11	#3 AND biography[pt]	1
#12	#3 AND congresses[pt]	2
#13	#3 AND consensus development conference[pt]	2
#14	#3 AND historical article[pt]	2
#15	#3 AND in vitro[pt]	4
#16	#3 AND news[pt]	6
#17	#3 AND retracted publication[pt]	2
#18	#3 NOT (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17)	2,611

Key: [tiab] title/abstract word; [mh] MeSH heading; [mh:noexp] MeSH heading not exploded to narrower terms; [la] language; [pt] publication type

Table A5: KQ2 search strategy and results from PubMed (pubmed.gov interface) for update

Search terms		Search results
#1	intrauterine devices, medicated/ae[mh] OR medroxyprogesterone acetate/ae[mh] OR dydrogesterone/ae[mh] OR tranexamic acid/ae[mh] OR ethamsylate/ae[mh] OR metformin/ae[mh] OR progesterone/ae[mh:noexp] OR ((exenatide[supplementary concept] OR cabergoline[supplementary concept) AND ae[sh])	4,055*
#2	cohort studies[mh] OR product surveillance, postmarketing[mh] OR clinical trial, phase IV[pt] OR databases, factual[mh] OR adverse drug reaction reporting systems[mh] OR case control studies[mh] OR cohort[tiab]	1,410,620
#3	#1 AND #2 AND eng[la] AND humans[mh] AND 1980:2012[dp]	672
#4	#3 AND review[pt]	35
#5	#3 AND case reports[pt]	25
#6	#3 AND letter[pt]	26
#7	#3 AND comment[pt]	16
#8	#3 AND meta-analysis[pt]	6
#9	#3 AND practice guideline[pt]	2
#10	#3 AND editorial[pt]	4
#11	#3 AND biography[pt]	0
#12	#3 AND congresses[pt]	0
#13	#3 AND consensus development conference[pt]	0
#14	#3 AND historical article[pt]	2
#15	#3 AND in vitro[pt]	1
#16	#3 AND news[pt]	0
#17	#3 AND retracted publication[pt]	0
#18	#3 NOT (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17)	576**

Key: [tiab] title/abstract word; [mh] MeSH heading; [mh:noexp] MeSH heading not exploded to narrower terms; [la] language; [pt] publication type

* Search Strategy for literature update for KQ2 was revised to include on only the interventions identified for KQ1

** Includes 78 new items added with June 2012 update

Appendix B. Abstract Review Form (KQ1)

First Author, Year: _____

Endnote Reference ID #: _____ Abstractor Initials: __ __ __

KQ1A: What is the evidence for the effectiveness of medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with irregular uterine bleeding?

KQ1B: What is the evidence for the effectiveness of medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with abnormal cyclic uterine bleeding?

	Primary Inclusion/Exclusion Criteria			
X-1	1. Paper reports original research (i.e., paper is not a review, editorial, commentary, letter to editor, etc.).	Yes	No	Cannot Determine
X-2	2. Paper published in English language.	Yes	No	Cannot Determine
X-3	3. Eligible study design: randomized controlled trial.	Yes	No	Cannot Determine
	4. Study compares at least two nonsurgical intervention(s) among women with chronic problem bleeding (i.e., abnormal uterine bleeding, menorrhagia, menometrorrhagia, metrorrhagia, uterine hemorrhage, anovulatory bleeding, oligomenorrhea, dysfunctional uterine bleeding).	Yes	No	Cannot Determine
	If "no", check one or more of the following reasons for exclusion:			
X-4	□ Study is basic science, anatomy, imaging, prevalence, physiology, diagnostic, biomarker, or biological mechanism study only.			
X-9	□ Contraceptive efficacy or effectiveness study.			
X-6	□ Study population consists exclusively of women whose bleeding is caused by: structural abnormality (e.g., fibroids, polyps, adenomyosis); cancer; medication side effect; endometrial hyperplasia; or systemic disease (e.g., thyroid disease, coagulopathy).			
X-7	□ Study population consists of post-menopausal women.			
X-8	□ Study evaluates surgical or invasive intervention(s) only or surgical or invasive intervention is the only comparator.			
X-5	□ Other (e.g., intervention unlikely to be used in the primary care setting; intervention not approved for use in the U.S.; bleeding related to pregnancy; acute/emergent bleeding, etc.)			

Retain for:

□ Background/Discussion □ Review of references □ Harms data □ Other_____

COMMENTS:

Appendix C. Abstract Review Form (KQ2)

First Author, Year: _____

Endnote Reference ID #: _____ Abstractor Initials: __ __ __

KQ2. What are the harms, including adverse events, associated with medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) in women with irregular uterine bleeding or abnormal cyclic uterine bleeding?

	Primary Inclusion/Exclusion Criteria			
X-1	1. Paper reports original research (i.e., paper is not a review, editorial, commentary, letter to editor, etc.).	Yes	No	Cannot Determine
X-2	2. Paper reports data from a population* of 1600 or more. **overall population or number of records in the database*	Yes	No	Cannot Determine
X-3	3. An objective of the paper is the reporting of harms data.	Yes	No	Cannot Determine
X-4	4. Paper reports harms data for one or more of the selected interventions addressed in KQ1. (*listed below)* Harms data is associated with one or more selected interventions from KQ1: □ LNG-IUS (Mirena®) □ Progestogen □ Tranexamic acid (Lysteda®) □ Other (i.e., cabergoline, exenatide, ethamsylate, metformin)	Yes	No	Cannot Determine

Retain for:

□ Background/Discussion □ Review of references □ Other_____

COMMENTS:

Appendix D. Full-Text Review Form (KQ1)

First Author, Year: _____

Endnote Reference ID #: _____ Abstractor Initials: __ __ __

KQ1A: What is the evidence for the effectiveness of medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with irregular uterine bleeding?

KQ1B: What is the evidence for the effectiveness of medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with abnormal cyclic uterine bleeding?

	Primary Inclusion/Exclusion Criteria		
X-1	1. Paper reports original research (i.e., paper is not a review, editorial, commentary, letter to editor, etc.)	Yes	No
X-2	2. Eligible study design: randomized controlled trial	Yes	No
	3. Study reports baseline and outcome data for a study population with ≥80 percent women in the target population or reports baseline and outcome data for a subset of women in the target population.	Yes	No
	If "no", classify exclusion as related to one or more of the reasons below:		
X-6	□ Study population >20 percent women whose bleeding is caused by: structural abnormality (e.g., fibroids, polyps, adenomyosis); cancer; medication side effect; endometrial hyperplasia; or systemic disease (e.g., thyroid disease, coagulopathy).		
X-7	□ Study population consists of post-menopausal women.		
X-10	□ Study does not report baseline and outcome data for a study population with ≥80 percent women in the target population or a subset of women in the target population.		
	4. Study informs a key question.	Yes	No
	If "no", classify exclusion as related to one or more of the reasons below:		
X-4	□ Study is basic science, anatomy, imaging, prevalence, physiology, diagnostic, biomarker, or biological mechanism study only		
X-9	□ Study evaluates contraceptive efficacy or effectiveness only		
X-8	□ Study evaluates surgical or invasive intervention(s) only or surgical or invasive intervention is the only comparator		
X-5	□ Other (e.g., intervention unlikely to be used in the primary care setting; intervention not approved for use in the U.S.; bleeding related to pregnancy; acute/emergent bleeding, etc.).		
	If "yes", check one or both KQs below:		
	□ KQ1A: Effectiveness of a medical, behavioral or complementary and alternative medicine (CAM) intervention (e.g. hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with irregular abnormal bleeding		
	□ KQ1B: Effectiveness of a medical, behavioral or complementary and alternative medicine (CAM) intervention (e.g. hormonal treatment, weight loss, or acupuncture) for improving short and long-term outcomes in women with abnormal cyclic bleeding		
	□ Unclear/ discuss		

Retain for:

□ Background/Discussion □ Review of references □ Harms data □ Other_____

COMMENTS:

Appendix E. Full-Text Review Form (KQ2)

First Author, Year: _____

Endnote Reference ID #: _____ Abstractor Initials: __ __ __

KQ2. What are the harms, including adverse events, associated with medical, behavioral, and complementary and alternative medicine interventions (e.g., hormonal treatment, weight loss, or acupuncture) in women with irregular uterine bleeding or abnormal cyclic uterine bleeding?

	Primary Inclusion/Exclusion Criteria		
X-1	1. Paper reports original research (i.e., paper is not a review, editorial, commentary, letter to editor, etc.).	Yes	No
X-2	2. Paper reports data from a population of 1600 or more. **overall population or number of records in the database*	Yes	No
X-4	3. Paper reports harms from one or more of the selected interventions included in KQ1. *If "yes", specify below*. □ LNG-IUS (Mirena®) □ Progestogen including: • depot or oral medroxyprogesterone • norethisterone/ norethindrone • oral dydrogesterone • vaginal progesterone • progesterone coil □ Tranexamic acid (Lysteda®) □ Other including: • cabergoline • ethamsylate • exenatide • metformin	Yes	No
	4. Study addresses KQ2. *If "no", classify exclusion as related to one or more of the reasons below.*	Yes	No
X-3	□ Reporting of harms is from a general population or reporting of harms is not an objective of the paper/study.		
X-5	□ Study is basic science, anatomy, imaging, prevalence, physiology, diagnostic, biomarker, or biological mechanism study only.		
X-6	□ Study of men only.		
X-7	□ Study population consists of post-menopausal women or a population aged over 65 years.		
X-8	□ Other		

Retain for:

□ Background/Discussion □ Review of references □ Other_____

COMMENTS:

Appendix F. Cochrane Risk of Bias Tool

Use the modified Cochrane Collaboration tool to assess risk of bias for randomized controlled trials. Bias is assessed as a judgment (high, low, or unclear) for individual elements from five domains (selection, performance, attrition, reporting, and other).

AUB KQ1 Risk of Bias Assessment (Reference ID #)

Domain	Description	High Risk of Bias	Low Risk of Bias	Unclear Risk of Bias	Reviewer Assessment	Reviewer Comments
Selection bias ***Random sequence generation***	Described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups	Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence	Random sequence generation method should produce comparable groups	Not described in sufficient detail	**High** **Low** **Unclear**	
Selection bias ***Allocation concealment***	Described the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen before or during enrollment	Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment	Intervention allocations likely could not have been foreseen in before or during enrollment	Not described in sufficient detail	**High** **Low** **Unclear**	
Reporting bias ***Selective reporting***	Stated how the possibility of selective outcome reporting was examined by the authors and what was found	Reporting bias due to selective outcome reporting	Selective outcome reporting bias not detected	Insufficient information to permit judgment†	**High** **Low** **Unclear**	
Other bias ***Other sources of bias***	Any important concerns about bias not addressed above*	Bias due to problems not covered elsewhere in the table	No other bias detected	There may be a risk of bias, but there is either insufficient information to assess whether an important risk of bias exists or insufficient rationale or evidence that an identified problem will introduce bias	**High** **Low** **Unclear**	

* If particular questions/entries were pre-specified in the study's protocol, responses should be provided for each question/entry.
† It is likely that the majority of studies will fall into this category.
Assess each main or class of outcomes for each of the following. Indicate the specific outcome.

AUB KQ1 Risk of Bias Assessment (Reference ID #)

Outcome:

Domain	Description	High Risk of Bias	Low Risk of Bias	Unclear Risk of Bias	Reviewer Assessment	Reviewer Comments
Performance bias ***Blinding (participants and personnel)***	Described all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provided any information relating to whether the intended blinding was effective.	Performance bias due to knowledge of the allocated interventions by participants and personnel during the study.	Blinding was likely effective.	Not described in sufficient detail	**High** **Low** **Unclear**	
Detection bias ***Blinding (outcome assessment)***	Described all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Provided any information relating to whether the intended blinding was effective.	Detection bias due to knowledge of the allocated interventions by outcome assessors.	Blinding was likely effective.	Not described in sufficient detail	**High** **Low** **Unclear**	
Attrition bias ***Incomplete outcome data***	Described the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. Stated whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported.	Attrition bias due to amount, nature or handling of incomplete outcome data.	Handling of incomplete outcome data was complete and unlikely to have produced bias	Insufficient reporting of attrition/exclusions to permit judgment (e.g., number randomized not stated, no reasons for missing data provided)	**High** **Low** **Unclear**	

Appendix G. Cochrane Risk of Bias Criteria

Criteria for judging risk of bias using the Cochrane Collaboration Risk of Bias Tool[a]

Bias	Judgment	Criteria
RANDOM SEQUENCE GENERATION Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence.	'Low risk' of bias.	The investigators describe a random component in the sequence generation process such as: • Referring to a random number table; • Using a computer random number generator; • Coin tossing; • Shuffling cards or envelopes; • Throwing dice; • Drawing of lots; • Minimization*. *Minimization may be implemented without a random element, and this is considered to be equivalent to being random.
	'High risk' of bias.	The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some systematic, non-random approach, for example: • Sequence generated by odd or even date of birth; • Sequence generated by some rule based on date (or day) of admission; • Sequence generated by some rule based on hospital or clinic record number. Other non-random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgement or some method of non-random categorization of participants, for example: • Allocation by judgement of the clinician; • Allocation by preference of the participant; • Allocation based on the results of a laboratory test or a series of tests; • Allocation by availability of the intervention.
	'Unclear risk' of bias.	Insufficient information about the sequence generation process to permit judgement of 'Low risk' or 'High risk'.
ALLOCATION CONCEALMENT Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.	'Low risk' of bias.	Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: • Central allocation (including telephone, web-based and pharmacy-controlled randomization); • Sequentially numbered drug containers of identical appearance; • Sequentially numbered, opaque, sealed envelopes.
	'High risk' of bias.	Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: • Using an open random allocation schedule (e.g. a list of random numbers); • Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or not sequentially numbered); • Alternation or rotation; • Date of birth; • Case record number; • Any other explicitly unconcealed procedure.
	'Unclear risk' of bias.	Insufficient information to permit judgement of 'Low risk' or 'High risk'. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement – for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
SELECTIVE REPORTING Reporting bias due to selective outcome reporting.	'Low risk' of bias.	Any of the following: • The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; • The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).

Bias	Judgment	Criteria
	'High risk' of bias.	Any one of the following: • Not all of the study's pre-specified primary outcomes have been reported; • One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; • One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); • One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; • The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
	'Unclear risk' of bias.	Insufficient information to permit judgement of 'Low risk' or 'High risk'. It is likely that the majority of studies will fall into this category.
OTHER BIAS Bias due to problems not covered elsewhere in the table.	'Low risk' of bias.	The study appears to be free of other sources of bias.
	'High risk' of bias.	There is at least one important risk of bias. For example, the study: • Had a potential source of bias related to the specific study design used; or • Has been claimed to have been fraudulent; or • Had some other problem.
	'Unclear risk' of bias.	There may be a risk of bias, but there is either: • Insufficient information to assess whether an important risk of bias exists; or • Insufficient rationale or evidence that an identified problem will introduce bias.
BLINDING OF PARTICIPANTS AND PERSONNEL Performance bias due to knowledge of the allocated interventions by participants and personnel during the study.	'Low risk' of bias.	Any one of the following: • No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; • Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
	'High risk' of bias.	Any one of the following: • No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; • Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.
	'Unclear risk' of bias.	Any one of the following: • Insufficient information to permit judgment of 'Low risk' or 'High risk'; • The study did not address this outcome.
BLINDING OF OUTCOME ASSESSMENT Detection bias due to knowledge of the allocated interventions by outcome assessors.	'Low risk' of bias.	Any one of the following: • No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; • Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.
	'High risk' of bias.	Any one of the following: • No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; • Blinding of outcome assessment, but likely that the blinding could have been broken and the outcome measurement is likely to be influenced by lack of blinding.
	'Unclear risk' of bias.	Any one of the following: • Insufficient information to permit judgment of 'Low risk' or 'High risk'; • The study did not address this outcome.

Bias	Judgment	Criteria
INCOMPLETE OUTCOME DATA Attrition bias due to amount, nature or handling of incomplete outcome data.	'Low risk' of bias.	Any one of the following: • No missing outcome data; • Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); • Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; • For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; • Missing data have been imputed using appropriate methods.
	'High risk' of bias.	Any one of the following: • Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; • For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; • 'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomization; • Potentially inappropriate application of simple imputation.
	'Unclear risk' of bias.	Any one of the following: • Insufficient reporting of attrition/exclusions to permit judgement of 'Low risk' or 'High risk' (e.g. number randomized not stated, no reasons for missing data provided); • The study did not address this outcome.

Note: [a] Adapted from the Cochrane Collaboration Risk of Bias Tool. See Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing the risk of bias in included studies. In: Higgins JP, Green S, eds. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2011.

Appendix H. Thresholds for Quality Assessment

Quality assessment thresholds for *Cochrane Risk of Bias (RoB) Tool***:** There are three categories for describing the quality of studies: "Good", "Fair", and "Poor". In order to assign a study to a category, we need to establish the threshold between good and fair quality studies and between fair and poor quality studies. Cochrane Collaboration uses strict criteria for the quality ratings.

Cochrane Collaboration criteria for quality ratings:

- *A good quality study must meet all criteria (Low RoB).*
- *A fair quality study does not meet, or it is not clear that it meets, at least one criterion, but it has no known important limitation that could invalidate its results (Moderate RoB).*
- *A poor quality study has important limitations and/or at least one criterion is not met (High RoB).*

Modifications of criteria for quality ratings:

- *If all criteria are rated as "low" = Low RoB =* ***Good Quality***
- *If one criterion is rated as "high" or 1-2 criteria are "unclear", and the assessment is that this was* ***unlikely*** *to have biased the outcome, and there is no known important limitation that could invalidate the results = Low RoB =* ***Good Quality***
    - *Example: not blinded, but blinding was not possible and based upon design and outcomes, it is unlikely that the lack of blinding could have affected the outcome measure or other factor that would introduce bias*
- *If one criterion is rated as "high" or 1-2 criteria are "unclear", and the assessment is that this was* ***likely*** *to have biased the outcome, and there is no known important limitation that could invalidate the results = Moderate RoB =* ***Fair Quality***
    - *Could be* ***poor****, if the factors were considered to combine to important limitations*
- *If one criterion is rated as "high" and 3 are "unclear = Moderate RoB =* ***Fair Quality***
    - *Could be* ***poor****, if the factors were considered to combine to important limitations*
- *If two criteria are rated as "high", and all other criteria are 'low', and the assessment that this was* ***unlikely*** *to have biased the outcome, and there are no known important limitations that could invalidate the results = Moderate RoB =* ***Fair Quality***
- *If two criteria are rated as "high", and all other criteria are 'low', and the assessment that this was* ***likely*** *to have biased the outcome, and there are important limitations that could invalidate the results = High RoB =* ***Poor Quality***
- *If three or more criteria are rated as "high" = High RoB =* ***Poor Quality***
- *If four or more criteria are rated as "unclear"= High RoB =* ***Poor Quality***

Low RoB criteria	High RoB criteria	Unclear RoB criteria	Rating
7	0	0	Good
5-6	0-1	0-2	Good or Fair
3-5	0-2	0-3	Fair or Poor
0-4	2-7	0-7	Poor
0-3	0-7	4-7	Poor

Appendix I. Risk of Bias and Quality Score for Individual Studies

Author, Year	Random Sequence Generation	Allocation Concealment	Selective Reporting	Blinding (patients and personnel)	Blinding (outcome assessment)	Incomplete Outcome Data	Other Bias	Quality Score
Abu Hashim et al., 2012[1]	+	+	+	-	-	+	+	Fair
Andersch et al., 1988[2]	?	?	?	?	?	+	+	Poor
Bonnar and Sheppard, 1996[3]	+	?	?	-	-	+	+	Poor
Cai and Wu, 2009[4]	+	+	+	?	?	+	+	Fair
Cameron et al., 1987[5]	?	?	?	-	-	?	?	Poor
Cameron et al., 1990[6]	?	?	+	?	?	+	+	Poor
Davis et al., 2000[7]	+	+	+	+	+	+	+	Good
Elkind-Hirsch et al., 2008[8]	+	?	+	-	-	-	+	Poor
Endrikat et al., 2009[9]	+	-	+	-	?	+	-	Poor
Fleming et al., 2002[10]	+	+	+	+	+	-	+	Fair
Fraser and McCarron, 1991[11]	?	?	+	-	-	-	+	Poor
Fraser et al., 1981[12]; 1984[13]	?	?	+	+	+	+	+	Fair
Fraser et al., 2011[14]	+	+	?	+	+	+	+	Good
Freeman et al., 2011[15]	?	?	+	+	?	+	+	Fair
Grover et al., 1990[16]	?	?	?	?	?	?	-	Poor
Hall et al., 1987[17]	+	+	+	+	+	-	+	Fair
Irvine et al., 1998[18]	+	+	?	?	-	+	+	Fair
Jedel et al., 2011[19]	+	+	+	-	?	-	+	Poor
Jensen et al., 2011[20]	+	+	?	+	+	+	+	Good
Karakus et al., 2009[21]	+	-	?	-	?	-	?	Poor
Kaunitz et al., 2010[22]	+	+	+	-	?	+	+	Fair
Kennedy et al., 2002[23]	+	+	+	-	-	-	+	Poor
Kriplani et al., 2006[24]	+	?	?	-	-	-	+	Poor
Kucuk and Ertan, 2008[25]	-	-	?	?	?	+	+	Poor
Lahteenmaki et al., 1998[26]	+	+	?	?	-	+	+	Poor
Lukes et al., 2010[27]	+	+	+	+	+	+	+	Good
Moghetti et al., 2000[28]	?	?	?	+	+	?	+	Poor

Author, Year	Random Sequence Generation	Allocation Concealment	Selective Reporting	Blinding (patients and personnel)	Blinding (outcome assessment)	Incomplete Outcome Data	Other Bias	Quality Score
Najam et al., 2010[29]	+	?	?	-	-	+	+	Poor
Oner and Muderris, 2011[30]	?	?	+	?	?	-	?	Poor
Ornstein et al., 2011[31]	?	?	+	-	?	-	-	Poor
Paoletti et al., 1996[32]	+	?	+	+	+	+	+	Good
Preston et al., 1995[33]	+	+	?	+	+	-	+	Fair
Protheroe et al., 2007[34]	+	+	?	-	-	+	?	Poor
Reid and Vitaren-Kari, 2005[35]	+	+	?	-	-	+	+	Poor
Shabaan etal., 2011[36]	+	-	+	-	?	+	-	Poor
Tsang et al., 1987[37]	?	?	+	+	+	-	+	Poor
van Eijkeren et al., 1992[38]	+	+	+	+	+	-	+	Fair
Vargyas et al., 1987[39]	+	+	+	+	+	+	+	Good
Vuorma et al., 2004[40, 41]	+	+	+	-	-	+	+	Poor
Totals								
	+	27	19	23	14	13	24	31	
	?	11	16	16	8	13	3	4	
	-	1	4	0	17	13	12	4	

Notes: Low risk of bias: +; High risk of bias: -; Unclear risk of bias: ?

References

1. Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception. 2012 Mar;85(3):246-52. PMID 22067765.

2. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand. 1988;67(7):645-8. PMID 3073625.

3. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996 Sep 7;313(7057):579-82. PMID 8806245.

4. Cai XM, Wu J. The mind-tranquilizing and menstruation-regulating method for acupuncture treatment of delayed menstrual cycle--a clinical controlled study. J Tradit Chin Med. 2009 Mar;29(1):35-8. PMID 19514186.

5. Cameron IT, Leask R, Kelly RW, et al. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins. 1987 Jul;34(1):99-110. PMID 3685399.

6. Cameron IT, Haining R, Lumsden MA, et al. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol. 1990 Jul;76(1):85-8. PMID 2359570.

7. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000 Dec;96(6):913-20. PMID 11084177.

8. Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2008;93(7):2670-8. PMID 18460557.

9. Endrikat J, Shapiro H, Lukkari-Lax E, et al. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can. 2009 Apr;31(4):340-7. PMID 19497153.

10. Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002 Feb;87(2):569-74. PMID 11836287.

11. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991 Feb;31(1):66-70. PMID 1872778.

12. Fraser IS, Pearse C, Shearman RP, et al. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet Gynecol. 1981 Nov;58(5):543-51. PMID 7029369.

13. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol. 1984 Aug 1;149(7):788-93. PMID 6380294.

14. Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: A randomized, double-blind Phase III trial. Human Reproduction. 2011;26(10):2698-708. PMID 21784734.

15. Freeman EW, Lukes A, VanDrie D, et al. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol. 2011 Oct;205(4):319 e1-7. PMID 21777897.

16. Grover V, Usha R, Gupta U, et al. Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. Asia Oceania J Obstet Gynaecol. 1990 Sep;16(3):255-9. PMID 2088249.

17. Hall P, Maclachlan N, Thorn N, et al. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol. 1987 Jun;94(6):554-8. PMID 3304401.

18. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol. 1998 Jun;105(6):592-8. PMID 9647148.

19. Jedel E, Labrie F, Oden A, et al. Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E37-45. PMID 20943753.

20. Jensen JT, Parke S, Mellinger U, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: A randomized controlled trial. Obstetrics and Gynecology. 2011;117(4):777-87. PMID 21422847.

21. Karakus S, Kiran G, Ciralik H. Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial. Aust N Z J Obstet Gynaecol. 2009 Dec;49(6):685-8. PMID 20070724.

22. Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Sep;116(3):625-32. PMID 20733445.

23. Kennedy AD, Sculpher MJ, Coulter A, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA. 2002 Dec 4;288(21):2701-8. PMID 12460093.

24. Kriplani A, Kulshrestha V, Agarwal N, et al. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol. 2006 Oct;26(7):673-8. PMID 17071438.

25. Kucuk T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol. 2008;35(1):57-60. PMID 18390083.

26. Lahteenmaki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ. 1998 Apr 11;316(7138):1122-6. PMID 9552948.

27. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Oct;116(4):865-75. PMID 20859150.

28. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000 Jan;85(1):139-46. PMID 10634377.

29. Najam R, Agarwal D, Tyagi R, et al. Comparison of traneximic acid with a combination of traneximic acid and mefenamic acid in reducing menstrual blood loss in ovulatory dysfunctional uterine bleeding (DUB). Journal of Clinical and Diagnostic Research. 2010;4(5):3020-5.

30. Oner G, Muderris, II. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):127-31. PMID 21831508.

31. Ornstein RM, Copperman NM, Jacobson MS. Effect of Weight Loss on Menstrual Function in Adolescents with Polycystic Ovary Syndrome. Journal of Pediatric and Adolescent Gynecology. 2011;24(3):161-5. PMID 21419674.

32. Paoletti AM, Cagnacci A, Depan GF, et al. The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. Fertility and Sterility. 1996;66(4):527-32. PMID 8816612.

33. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995 May;102(5):401-6. PMID 7612535.

34. Protheroe J, Bower P, Chew-Graham C, et al. Effectiveness of a computerized decision aid in primary care on decision making and quality of life in menorrhagia: Results of the MENTIP randomized controlled trial. Medical Decision Making. 2007;27(5):575-84. PMID 17898242.

35. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG. 2005 Aug;112(8):1121-5. PMID 16045528.

36. Shaaban MM, Zakherah MS, El-Nashar SA, et al. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011 Jan;83(1):48-54. PMID 21134503.

37. Tsang BK, Domingo MT, Spence JE, et al. Endometrial prostaglandins and menorrhagia: influence of a prostaglandin synthetase inhibitor in vivo. Can J Physiol Pharmacol. 1987 Oct;65(10):2081-4. PMID 3123043.

38. van Eijkeren MA, Christiaens GC, Geuze HJ, et al. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol. 1992 May;166(5):1419-28. PMID 1595797.

39. Vargyas JM, Campeau JD, Mishell DR, Jr. Treatment of menorrhagia with meclofenamate sodium. Am J Obstet Gynecol. 1987 Oct;157(4 Pt 1):944-50. PMID 3314521.

40. Vuorma S, Teperi J, Aalto AM, et al. A randomized trial among women with heavy menstruation -- impact of a decision aid on treatment outcomes and costs. Health Expect. 2004 Dec;7(4):327-37. PMID 15544685.

41. Vuorma S, Rissanen P, Aalto AM, et al. Impact of patient information booklet on treatment decision--a randomized trial among women with heavy menstruation. Health Expect. 2003 Dec;6(4):290-7. PMID 15040791.

Appendix J. Evidence Table

AUB KQ1 Evidence Table (Reference ID #121)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Cai and Wu, 2009 **Country:** China **Enrollment period:** November 2004 to October 2005 **Intervention setting:** Outpatient **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** Patients	**Intervention:** Mind tranquilizing and menstruation promoting method. Acupoints: Shenting (GV24), bilateral Siguan and bilateral Sanyinjiao (SP6). Shenting was transversely punctured and Siguan and Sanyinjiao were needled perpendicularly. **Comparator:** Routine acupuncture method for treating delayed menstrual cycle of the liver-*qi* stagnation type. Acupoints: bilateral Xingjian (LR2), Ligou (LR 5), Xuehai (Sp 10), Diji (SP8) and Zigong (EX-CA1) all perpendicularly punctured. Both groups used No. 32 filiform needles manipulated with the even method. After arrival of *qi* needles retained for 30 minutes and manipulated every 10 minutes. Treatment given every other day, with 2 day interval in the weekend for 3 menstrual cycles.	**Inclusion criteria:** • Delayed menstrual cycle (TCM diagnosis of dysfunctional uterine bleeding of the ovulatory type) with menstrual cycles lasting 36 to 50 days **Exclusion criteria:** Organic pathologic changes **N at enrollment:** **G1:** 23 **G2:** 17 **N at followup:** **G1:** 21 **G2:** 16 **Age, range in years:** **G1+G2:** (18, 42) **BMI:** NR **Parity:** NR **Race/ethnicity:** NR	NR	Therapeutic effect on disease condition, n (%): Cured[a]: **G1:** 16 (76.19) **G2:** 1 (6.25) Markedly relieved[b]: **G1:** 3 (14.29) **G2:** 5 (31.25) Improved[c]: **G1:** 2 (9.52) **G2:** 9 (56.25) Failed[d]: **G1:** 0 (0) **G2:** 1 (6.25) **G1 vs. G2:** p<0.05 Therapeutic effects for regulating menstruation, n (%): Cured: **G1:** 14 (66.67) **G2:** 3 (18.75) Markedly relieved: **G1:** 4 (19.05) **G2:** 4 (25.00) Improved: **G1:** 3 (14.29) **G2:** 6 (37.50) Failed: **G1:** 0 (0) **G2:** 3 (18.75) **G1 vs. G2:** p<0.05 Therapeutic effects on symptoms, n (%): Cured:	**Overall quality:** Fair **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: Unclear Blinding outcome assessment: Unclear Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
	Groups: **G1:** Mind tranquilizing and menstruation promoting acupuncture **G2:** Routine acupuncture **Followup:** 3 cycles			**G1:** 11 (52.38) **G2:** 2 (12.5) Markedly relieved: **G1:** 9 (42.86) **G2:** 5 (31.25) Improved: **G1:** 1 (4.76) **G2:** 8 (50.0) Failed: **G1:** 0 (0) **G2:** 1 (6.25) **G1 vs. G2:** p<0.05 **Bleeding:** NR **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** **G1:** 4/5 **G2:** 1/1 **Time to conception:** NR **Additional interventions:** NR	

Table Notes: [a] Disappearance of all symptoms and integral score decreased by ≥90%; [b] Disappearance of most of the symptoms, and the integral score decreased by ≥70%, but <90%; [c] Improved: Alleviation of the symptoms and the integral score decreased by ≥30%, but <79%; [d] No obvious improvement in the symptoms and the integral score decreased by <30%.

AUB KQ1 Evidence Table (Reference ID #631)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Davis et al., 2000 **Country:** United States **Enrollment period:** May 1997 to October 1998 **Intervention setting:** 16 sites **Funding:** Ortho-McNeil Pharmaceutical Corporation **Author industry relationship disclosures:** 5/5 **Study Design:** RCT **Blinding:** Patients, investigators	**Intervention:** Days 1-7: 0.180 mg norgestimate/0.035 mg ethinyl estradiol; Days 8-14: 0.215 mg norgestimate/0.035 mg ethinyl estradiol; Days 15-21: 0.250 mg norgestimate/0.035 mg ethinyl estradiol; Days 22-28: inactive tablets **Comparator:** Days 1-28: placebo tablets **Groups:** **G1:** Triphasic norgestimate/ethinyl estradiol **G2:** Placebo **Followup:** 3 28-day treatment cycles (84 days)	**Inclusion criteria:** • Aged 15 to 50 years Good general health Not pregnant or nursing At least 2-month history of menorrhagic, menometrorrhagic, oligomenorrheic or polymenorrheic dysfunctional uterine bleeding not attributed to systemic disease or structural pathology **Exclusion criteria:** History of endometrial ablation and undergone dilation and curettage within 90 days before screening visit **N at enrollment:** **G1:** 101 **G2:** 100 (ITT) **G1:** 97 **G2:** 95 **N at followup:** **G1:** 60 **G2:** 64 **Age, mean years ± SD:** **G1:** 29.8 ± 8.9 **G2:** 29.3 ± 8.1 **BMI:** NR	**Bleeding:** Duration of abnormal uterine bleeding, mean months ± SD: **G1:** 77.4 ± 73.5 **G2:** 68.3 ± 71.2 Duration of abnormal uterine bleeding, median months: **G1:** 67.6 **G2:** 40.5 Bleeding pattern history,[a] n (%): Metrorrhagia: **G1:** 23 (23.7) **G2:** 26 (27.4) Menometrorrhagia: **G1:** 29 (29.9) **G2:** 33 (34.7) Oligomenorrhea: **G1:** 54 (55.7) **G2:** 54 (56.8) Polymenorrhea: **G1:** 20 (20.6) **G2:** 20 (21.1) Hemoglobin, mean g/dl ± SD: **G1:** 12.7 ± 1.2 **G2:** 12.85 ± 1.1 **Quality of life:** SF-36 score,[b] mean:[c] Physical functioning: **G1:** 88.60 **G2:** 88.71 Role functioning/physical:	Investigator-rated overall assessment of symptom resolution, %: Excellent: **G1:** 41.2 **G2:** 10.5 Good: **G1:** 26.8 **G2:** 15.8 Fair: **G1:** 13.4 **G2:** 9.5 No change: **G1:** 10.3 **G2:** 46.3 Worse: **G1:** 2.1 **G2:** 2.1 Unable to evaluate: **G1:** 6.2 **G2:** 15.8 **G1 vs. G2:** p<0.001 Subject-rated assessment of symptom improvement, %: Much improved: **G1:** 49.5 **G2:** 19.8 Improved: **G1:** 23.7 **G2:** 19.8 Slightly improved: **G1:** 14.0 **G2:** 5.8 No change: **G1:** 8.6 **G2:** 47.7 Worse:	**Overall quality:** Good **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		Weight, mean pounds ± SD: **G1:** 173.4 ± 55.9 **G2:** 171.1 ± 48.5 **Race, n (%):** White: **G1:** 73 (75.3) **G2:** 66 (69.5) Black: **G1:** 16 (16.5) **G2:** 22 (23.2) Asian: **G1:** 4 (4.1) **G2:** 1 (1.1) Other: **G1:** 4 (4.1) **G2:** 6 (6.3)	**G1:** 87.10 **G2:** 89.12 Bodily pain: **G1:** 70.99 **G2:** 74.81 General health: **G1:** 75.00 **G2:** 77.36 Vitality: **G1:** 57.04 **G2:** 60.06 Social functioning: **G1:** 84.01 **G2:** 85.15 Role functioning/ emotional: **G1:** 78.85 **G2:** 82.75 Mental health: **G1:** 72.52 **G2:** 75.29 Reported health transition: **G1:** 41.13 **G2:** 43.24 Sexual functioning: **G1:** 19.27 **G2:** 17.35	**G1:** 2.2 **G2:** 3.5 Don't know: **G1:** 2.2 **G2:** 3.5 **G1 vs. G2:** p<0.001 **Quality of life:** SF-36[b] score,[c] mean change from baseline ± SD:[d] Physical functioning: **G1:** 4.19 ± 16.83 **G2:** 0.47 ± 13.35 **G1 vs. G2:** p<0.001 Role functioning/physical: **G1:** 1.61 ± 24.59 **G2:** 1.18 ± 30.11 **G1 vs. G2:** p=0.160 Bodily pain: **G1:** 4.45 ± 22.58 **G2:** 0.15 ± 20.77 **G1 vs. G2:** p=0.896 General health: **G1:** 1.58 ± 15.02 **G2:** 1.12 ± 11.29 **G1 vs. G2:** p=0.265 Vitality: **G1:** 6.18 ± 17.70 **G2:** 3.94 ± 17.22 **G1 vs. G2:** p=0.410 Social functioning: **G1:** 0.40 ± 20.06 **G2:** -1.76 ± 21.58 **G1 vs. G2:** p=0.735 Role functioning/emotional: **G1:** 6.09 ± 30.67 **G2:** 2.75 ± 29.64 **G1 vs. G2:** p=0.694 Mental health: **G1:** 4.52 ± 14.03	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				G2: 1.65 ± 17.12 **G1 vs. G2:** p=0.935 Reported health transition: **G1:** -4.03 ± 28.62 **G2:** -4.41 ± 21.88 **G1 vs. G2:** p=0.109 Sexual functioning: **G1:** -2.51 ± 22.75 **G2:** -0.10 ± 26.05 **G1 vs. G2:** p=0.404 **Patient satisfaction:** **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events:** Discontinued study prematurely, n (%): **G1:** 16 (15.8) **G2:** 19 (19) Discontinued due to adverse events, n: **G1:** 4 **G2:** 3	

Table Notes: Blood loss estimated from PBLAC Higham et al.; [a] Subjects could have more than one category of bleeding pattern history; [b] Medical Outcome Study, 36-item short-form health survey plus five items from the full set on sexual functioning; [c] Quality of life scores transformed to a 0-100 scale with a higher score indicating better quality of life, except for reported health transition and sexual functioning, for which a higher score indicates a lower quality; [d] Significance is computed using analysis of covariance with adjustment for baseline score, study centers, and interaction terms.

AUB KQ1 Evidence Table (Reference ID #1431)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)[a]	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Elkind-Hirsch et al., 2008 **Country:** United States **Enrollment period:** August 2006 to June 2007 **Intervention setting:** Outpatient clinics **Funding:** Amylin Pharmaceuticals, Inc/Eli Lilly Corp **Author industry relationship disclosures:** 2/5 **Study Design:** RCT **Blinding:** None	**Intervention:** Exenatide 5 µg by subcutaneous injection twice a day and increased to 10 µg twice per day after 1 month. **Comparator:** Metformin 500 mg for two weeks and gradually increased to 1000 mg twice a day; Combination: metformin 500 mg for two weeks and gradually increased to 1000 mg twice a day plus exenatide 5 µg by subcutaneous injection twice a day and increased to 10 µg twice per day after 1 month. All groups received treatment for 24 weeks. **Groups:** **G1:** Exenatide **G2:** Metformin **G3:** Combination metformin and exenatide **Followup:** 24 weeks	**Inclusion criteria:** Aged 18 to 40 years Polycystic ovary syndrome Overweight/obese (BMI >27) Menstrual disorders (fewer than six menstruations in 12 months) One of the following two criteria: either clinical and/or biochemical hyperandrogenism (excluding secondary causes) and/or polycystic ovaries **Exclusion criteria:** Diabetics Smokers Those who used injectable hormonal contraceptive within 6 months Those taking sex hormones, drugs that affect gastrointestinal motility or carbohydrate metabolism, or lipid-lowering and/or anti-obesity drugs within 3 months of the study **N at enrollment:** **G1:** 20 **G2:** 20 **G3:** 20 **N at followup:** **G1:** 14	**Bleeding:** Cycle changes measured by menstrual frequency index,[b] mean ± SD: **G1:** 0.22 ± 0.04 **G2:** 0.21 ± 0.04 **G3**: 0.29 ± 0.04 Absolute weight, mean kg ± SD: **G1:** 110.5 ± 6 **G2:** 113.4 ± 7 **G3:** 112 ± 8 Abdominal girth, mean cm ± SD: **G1:** 120.4 ± 4.5 **G2:** 123.4 ± 4.3 **G3:** 122 ± 4.4 BMI, mean kg/m^2 ± SD: **G1:** 40.3 ± 2 **G2:** 43.3 ± 2 **G3:** 40.9 ± 2	**Bleeding:** Cycle changes measured by menstrual frequency index,[b] mean ± SD: **G1:** 0.57 ± 0.08 **G2:** 0.49 ± 0.08 **G3:** 0.83 ± 0.08 **G1+G2+G3 vs. BL:** p=0.0001 **G3 vs. G1:** p=0.091 **G3 vs. G2:** p=0.018 Ovulatory rate,%: **G1:** 50 **G2:** 29 **G3:** 86 **G3 vs. G1:** p<0.001 **G3 vs. G2**: p<0.001 **Weight changes:** Weight loss, mean kg ± SD: **G1:** 3.2 ± 0.1 **G2:** 1.6 ± 0.2 **G3:** 6 ± 0.5 **G1+G2+G3 vs. BL:** p=0.001 **G1 vs. G2:** p=0.019 **G3 vs. G2:** p=0.003 Abdominal girth, mean ± SD: **G1:** 119.6 ± 4.3 **G2:** 123.9 ± 4.4 **G3:** 116 ± 4.3 **G1+G2+G3 vs. BL:** p=0.047 **G3 vs. G2:** p=0.04	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: Unclear Selective reporting: Low Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: High Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)[a]	Outcome Measure(s)	Overall Quality Risk of Bias
		G2: 14 **G3:** 14 **Age, mean years ± SD:** **G1:** 28.2 ± 1.1 **G2:** 27.7 ± 1.3 **G3:** 32.1 ± 0.7 **G1 vs. G2 vs. G3:** p=NS **BMI, mean kg/m^2 ± SD:** **G1:** 39.9 ± 1.5 **G2:** 41.3 ± 1.8 **G3:** 41.2 ± 1.7 **G1 vs. G2 vs. G3:** p=NS **Parity:** NR **Race, n (%):** Caucasian: **G1+G2+G3:** 40 (67) African-American: **G1+G2+G3:** 20 (33)		BMI, mean kg/m^2 ± SD: **G1:** 39.3 ± 2 **G2:** 42.3 ± 2 **G3:** 39.2 ± 2 **G1+G2+G3 vs. BL:** p<0.0001 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events, n (%):** Nausea: **G1:** 3 (15) **G2:** 4 (20) **G3:** 9 (45) Diarrhea: **G1:** 0 **G2:** 6 (30) **G3:** 2 (20) Bloating: **G1:** 0 **G2:** 2 (10)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)[a]	Outcome Measure(s)	Overall Quality Risk of Bias
				G3: 1 (5) Vomiting: **G1:** 1 (5) **G2:** 1 (5) **G3:** 2 (10) Cramping (gastrointestinal): **G1:** 1 (5) **G2:** 0 **G3:** 0 Headache: **G1:** 1 (5) **G2:** 0 **G3:** 0 Indigestion/heartburn: **G1:** 0 **G2:** 0 **G3:** 2 (10) Stomachache: **G1:** 0 **G2:** 1 (5) **G3:** 0 Constipation: **G1:** 0 **G2:** 1 (5) **G3:** 1 (5) Fatigue: **G1:** 0 **G2:** 2 (10) **G3:** 1 (5) Dizzy: **G1:** 0 **G2:** 0 **G3:** 2 (10) Injection site pain/bruise: **G1:** 1 (5) **G2:** NA **G3:** 2 (10) Pregnancy: **G1:** 1 (5) **G2:** 2 (10)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)[a]	Outcome Measure(s)	Overall Quality Risk of Bias
				G3: 1 (5) Menstrual cramps: **G1:** 0 **G2:** 1 (5) **G3:** 0 Dysfunctional menstrual bleeding: **G1:** 1 (5) **G2:** 1 (5) **G3:** 0 Acne: **G1:** 0 **G2:** 0 **G3:** 1 (5) Migraines: **G1:** 0 **G2:** 1 (5) **G3:** 0 Hot flashes: **G1:** 0 **G2:** 1 (5) **G3:** 0	

Table Notes: [a] Baseline measures for the subset of subjects who competed the trial (n=14 in each group); [b] Cycle event rate (normalized to 12 per 52 weeks)

AUB KQ1 Evidence Table (Reference ID #564)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Fleming et al., 2002 **Country:** United Kingdom **Enrollment period:** NR **Intervention setting:** NR **Funding:** Sponsored by the Scottish Office **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** Patients, investigators	**Intervention:** Metformin 850 mg once per day for first week, then 850 mg twice daily for 15 more weeks **Comparator:** Placebo **Groups:** **G1:** Metformin **G2:** Placebo **Followup:** 16 weeks	**Inclusion criteria:** • Aged <35 years • Oligomenorrhea (cycle length ≥41 days; <8 cycles per year) or amenorrhea and PCOS **Exclusion criteria:** Significant hyperprolactinemia Abnormal thyroid function tests Congenital adrenal hyperplasia **N at enrollment:** **G1:** 45 **G2:** 47 **N at followup:** **G1:** 26 **G2:** 39 **Age, mean years (95% CI):** **G1:** 28.6 (26.9 to 30.3) **G2:** 29.2 (27.5 to 30.7) **BMI, mean kg/m^2:** **G1:** 34.2 **G2:** 35.0	**Menstrual cycle:** Menses per year, mean (95% CI): **G1:** 4.6 (3.5, 5.6) **G2:** 4.0 (3.1, 4.9) **Reproductive hormones:** Day 1 estradiol, mean pmol/liter (95% CI): **G1:** 142 (123, 161) **G2:** 164 (110, 217) Day 1 testosterone, mean nmol/l (95% CI): **G1:** 3.1 (2.4, 3.8) **G2:** 3.8 (3.4, 4.5)	**Menstrual cycle:** Observation weeks, n: **G1:** 345 **G2:** 503 Luteal weeks, n (luteal ratio %): **G1:** 78 (23) **G2:** 66 (13) **G1 vs. G2:** p<0.001 Luteal phase with Pmax <7 ng/ml, n (%): **G1:** 2 (8) **G2:** 5 (13) **G1 vs. G2:** p=NS Time to first ovulation, mean days (95% CI): **G1:** 23.6 (17, 30) **G2:** 41.8 (28, 56) **G1 vs. G2:** p=0.02 **Reproductive hormones:** Day 8 estradiol, mean pmol/l (95% CI): **G1:** 226 (150, 302) **G2:** 183 (127, 240) **G1 vs. BL:** p<0.03 **G2 vs. BL:** p=NS Day 8 testosterone, mean nmol/l (95% CI): **G1:** 3.5 (2.8, 4.2) **G2:** 4.2 (3.5, 4.9) **G1 vs. BL:** p=NS **G2 vs. BL:** p=NS **Metabolic parameters:**	**Overall quality:** Fair **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: High Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				BMI at week 14, mean kg/m^2: **G1:** 34.6 **G2:** 35.6 **G1 vs. BL:** p=0.03 **G2 vs. BL:** p=0.04 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** Pregnancies during study: **G1:** 5 **G2:** 3 Pregnancies in patients who declared wish to conceive: **G1:** 4/23 **G2:** 1/19 **G1 vs. G2:** p=0.23 **Additional interventions:** NR	

AUB KQ1 Evidence Table (Reference ID #25)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Jedel et al., 2011 **Country:** Sweden **Enrollment period:** November 2005 to January 2008 **Intervention setting:** Sahlgrenska University Hospital **Funding:** Grants from the Osher center for Integrative medicine, Swedish Medical Research Council, Novo Nordisk Foundation, Wilhelm and Martina Lundgren's Science fund, Haljmar Svensson Foundation, Tore Nilson Foundation, Ake Wiberg Foundation, Alderbert Research Foundation, Ekhaga Foundation and the Swedish Federal Government **Author industry relationship disclosures:** None **Study Design:**	**Intervention(s):** Low frequency electro-acupuncture[a]: Western medical acupuncture given twice weekly for 2 weeks, once a week for 6 weeks and once every other week for 8 weeks (total 14 treatments over 16 weeks) **Comparator(s):** Physical exercise: 16 weeks of regular exercise including brisk walking, cycling, or any other aerobic exercise at pace faster than normal walking that could be sustained for at least 30 min at least 3 days per week. No active intervention. **Groups:**[b] **G1:** Acupuncture **G2:** Exercise **G3:** No intervention **Followup:** 12 week observation followed by 16 weeks of intervention followed by 16 weeks followup (44 week study)	**Inclusion criteria:** • Ultrasound verified polycystic ovaries with ≥12 follicles 2 to 9 mm and/or ovarian volume ≥10 ml in one or both ovaries together with either oligomenorrhea, amenorrhea, and/or clinical signs of hyperandrogenism (hirsutism or acne) **Exclusion criteria:** Aged ≥38 years Any pharmacological treatment within 12 weeks or breast feeding within 24 weeks of study entry Cardiovascular disease, diabetes mellitus, or endocrine or neoplastic causes of hyperandrogenemia including androgen secreting tumors, Cushing's syndrome, congenital adrenal hyperplasia and hyperprolactinemia **N at enrollment:** **G1:** 33 **G2:** 34 **G3:** 17 **N at followup:** 12 week observation period:	**Bleeding:** Menstrual frequency, mean days per month ± SD: **G1:** 0.28 ± 0.28 **G2:** 0.26 ± 0.33 **G3:** 0.23 ± 0.28	**Bleeding:** Change in menstrual frequency at week 16 from baseline, mean days per month ± SD (% change): **G1:** 0.41 ± 0.33 (146) **G2:** 0.14 ± 0.33 (58) **G3:** -0.04 ± 0.007 (-17) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p=NS **G3 vs. BL:** p=NS Change in menstrual frequency at week 32 from baseline, mean days per month ± SD (% change): **G1:** 0.33 ± 0.37 (121) **G2:** 0.11 ± 0.36 (42) **G3:** -0.04 ± 0.07 (-17) **G1 vs. BL:** p=0.003 **G2 vs. BL:** p=NS **G3 vs. BL:** p=NS **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment:: Low Selective reporting: Low Blinding patients/personnel: High Blinding outcome assessment: Unclear Incomplete outcome reporting: High Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
RCT **Blinding:** None		**G1:** 29 **G2:** 30 **G3:** 15 16 week treatment period: **G1:** 24 **G2:** 22 **G3:** 13 16 week followup: **G1:** 21 **G2:** 18 **G3:** 11 **Age, mean years ± SD:** **G1**: 29.7 ± 4.3 **G2**: 30.2 ± 4.7 **G3**: 30.1 ± 4.2 **BMI, mean kg/m^2 ± SD:** **G1:** 29.1 ± 8.83 **G2:** 27.7 ± 6.44 **G3:** 26.8 ± 5.56 **BMI ≥30, n (%):** **G1:** 11/29 (38) **G2:** 11/30 (37) **G3:** 4/15 (27) **Parity:** NR **Race/ethnicity:** NR		**Additional interventions:** NR **Adverse events:**[c] Isolated redness and subsequent hematomas, n: **G1:** 3 **G2:** 0 **G3:** 0 Dizziness, n: **G1:** 1 **G2:** 0 **G3:** 0 Nausea, n: **G1:** 1 **G2:** 0 **G3:** 0	

Notes: [a] Details about needle placement given in text on pg E38; [b] All three groups of women received oral information about the benefits of regular physical exercise and were instructed to complete an exercise diary during weeks 1-32 of the study; [c] No long-term adverse events in G1 and no short-term or long-term adverse events in G2 and G3.

AUB KQ1 Evidence Table (Reference ID #76)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Karakus et al., 2009 **Country:** Turkey **Enrollment period:** August 2004 to April 2005 **Intervention setting:** Outpatient clinic **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** None	**Intervention:** Vaginal micronized progesterone (8% gel) 90 mg, every other evening from menstrual cycle day 17 to 27 **Comparator:** Dydrogesterone 10 mg orally twice daily for 10 days starting on cycle day 15 **Groups:** **G1:** Vaginal progesterone **G2:** Oral progesterone **Followup:** 3 cycles	**Inclusion criteria:** • Aged 35 to 45 years • No menopausal symptoms • Did not take hormone therapy • Diagnosed with dysfunctional uterine bleeding • No contraindication for progesterone or progestins • Endometrial thickness >5 mm by transvaginal ultrasound **Exclusion criteria:** Taking anticoagulants or antiprostaglandins Prefer hormonal contraceptive methods Known intolerance to progesterone or progestins **N at enrollment:** **G1:** 34 **G2:** 35 **N at followup:** **G1:** 27 **G2:** 27 **Age, mean years ± SD:** **G1:** 39.1 ± 3.6 **G2:** 39.6 ± 3.0 **BMI, mean kg/m^2 ± SD:**	Secretory endometrium in endometrial sample, n (%): **G1:** 8 (29.6) **G2:** 6 (22.2) **G1 vs. G2:** p=0.412	**Bleeding:** Irregular bleeding pattern,[a] n (%): First cycle: **G1:** 2 (7.4) **G2:** 5 (18.5) **G1 vs. G2:** p=0.42 Second cycle: **G1:** 3 (11.1) **G2:** 3 (11.1) **G1 vs. G2:** p=1.0 Third cycle: **G1:** 2 (7.4) **G2:** 4 (14.8) **G1 vs. G2:** p=0.67 Secretory endometrium in endometrial sample, n (%): **G1:** 24 (88.9) **G2:** 22 (81.5) **G1 vs. G2:** p=0.732 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** Self-reported patient satisfaction with treatment, n (%): **G1:** 23 (85) **G2:** 21 (78) **G1 vs. G2:** p=0.491 **Fertility:**	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: High Selective reporting: Unclear Blinding patients/personnel: High Blinding outcome assessment: Unclear Incomplete outcome reporting: High Other: Unclear

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G1: 29.2 ± 5.4 **G2:** 30.3 ± 3.7 **G1 vs. G2:** p=0.371 **Gravidity, mean ± SD:** **G1:** 4.4 ± 2.1 **G2:** 4.8 ± 2.3 **G1 vs. G2:** p=0.584 **Parity, mean ± SD:** **G1:** 3.0 ± 1.4 **G2:** 3.6 ± 2.2 **G1 vs. G2:** p=0.209 **Race/ethnicity:** NR		NR **Time to conception:** NR **Additional interventions:** See comment[b] **Adverse events, n:** Groin pain: **G1:** 1 **G2:** 0 5-kg weight gain: **G1:** 1 **G2:** 0 Ovarian cyst: **G2:** 1 **G2:** 0	

Table Notes: [a] Regular bleeding: cycle length less than 35 days and no intermenstrual bleeding; [b] Oral estrogen added for n=1 in G2 because of 45-day menstrual delay.

AUB KQ1 Evidence Table (Reference ID #700)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Moghetti et al., 2000 **Country:** Italy **Enrollment period:** NR **Intervention setting:** Hospital clinic **Funding:** Grants from Italian Ministry of Higher Education and Scientific Research, and Regione de Veneto **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** Patients, investigators	**Intervention:** Oral metformin 500 mg once daily for first week; 500 mg twice a day for a second week; 500 mg three times a day for 24 weeks **Comparator:** Placebo **Groups:** **G1:** Metformin **G2:** Placebo **Followup:** 26 weeks	**Inclusion criteria:** Women aged 18 to 35 years • Polycystic ovary syndrome[a] Normal glucose tolerance Referred for menstrual abnormalities with or without hirsutism **Exclusion criteria:** See inclusion criteria **N at enrollment[b]:** **G1+G2:** 23 **N at followup:** **G1+G2:** 23 **Age, mean years ± SD:** **G1:** 23.9 ± 1.2 **G2:** 21.4 ± 1.4 **BMI, mean kg/m^2 ± SD:** **G1:** 27.1 ± 1.5 **G2:** 32.6 ± 1.1 **G1 vs. G2:** p<0.05 **Parity:** NR **Race/ethnicity:** NR	**Bleeding:** Severe oligomenorrhea (6 or fewer menses per year), n (%): **G1+G2:** 20 (87) Less severe menstrual irregularities, n (%): **G1+G2:** 3 (13) Androstenedione, mean nmol/l ± SD: **G1:** 12.5 ± 1.5 **G2:** 10.3 ± 0.7 Free testosterone, mean pmol/l ± SD: **G1:** 11.6 ± 1.8 **G2:** 10.7 ± 1.4	**Bleeding:** Menstrual frequency improvement, median (IQR):[c] **G1:** NR **G2:** NR **G1 vs. G2:** p=0.002[d] Menstrual pattern improved: **G1:** 5 **G2:** 0 Androstenedione, mean nmol/l ± SD: **G1:** 13.6 ± 2.1 **G2:** 10.7 ± 1.0 **G1 vs. G2:** p=0.74 Free testosterone, mean pmol/l ± SD: **G1:** 8.7 ± 1.5 **G2:** 10.4 ± 1.7 **G1 vs. G2:** p=0.04 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR	**Overall quality:** Poor **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Unclear Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: Unclear Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Additional interventions: NR	

Table Notes: [a] PCOS diagnosed by presence of hyperandrogenic chronic anovulation, after exclusion of Cushing's syndrome, late onset 21-hydroxylase deficiency, thyroid dysfunction, hyperprolactinemia or androgen secreting tumors; [b] The authors do not report how many subjects were randomized to treatment and placebo; [c] Results only displayed graphically in Figure 1 (pg. 142); [d] After controlling for baseline BMI and androstenedione.

AUB KQ1 Evidence Table (Reference ID #1777)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Oner and Muderris, 2011 **Country:** Turkey **Enrollment period:** March 2008 to April 2009 **Intervention setting:** University gynecologic endocrinology clinic **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** NR	**Intervention:** 1.5 g/day metformin (500 mg 3 times per day) **Comparator:** 1.8 g/day N-acetyl-cysteine (600 mg 3 times per day) **Groups:** **G1:** Metformin **G2:** N-acetyl-cysteine **Followup:** 24 weeks	**Inclusion criteria:** PCOS[a] with hirsutism and menstrual irregularity **Exclusion criteria:** Congenital adrenal hyperplasia, Cushing's syndrome or androgen secreting tumors, thyroid disease, hyperprolactinemia Diabetes mellitus or impaired glucose tolerance Use of drugs known to affect carbohydrate metabolism within 3 months preceding the study **N at enrollment:** **G1:** 50 **G2:** 50 **N at followup:** **G1:** 30 **G2:** 45 **Age, mean years ± SD:** **G1:** 22.6 ± 4.8 **G2:** 23.7 ± 4.4 **BMI, mean kg/m^2 ± SD:** **G1:** 24.3 ± 6.2 **G2:** 23.0 ± 4.6 **Parity:** NR **Race/ethnicity:**	**Menstrual cycle:** Regular, n (%): **G1:** 5 (17) **G2:** 13 (29) **G1 vs. G2:** p=NS Irregular, n (%): **G1:** 25 (83) **G2:** 32 (71) **G1 vs. G2:** p=NS	**Menstrual cycle:** Regular, n (%): **G1:** 14 (47) **G2:** 24 (53) **G1 vs. G2:** p=NS Irregular, n (%): **G1:** 16 (53) **G2:** 21 (47) **G1 vs. G2:** p=NS Restoration of menstrual regularity, n (%): **G1:** 9 (36) **G2:** 11 (34) **G1 vs. G2:** p=NS **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse Events:**	**Overall quality:** Poor **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Low Blinding patients/personnel: Unclear Blinding outcome assessment: Unclear Incomplete outcome reporting: High Other: Unclear

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		NR		Discontinued due to gastrointestinal side effects, n (%): **G1:** 2 (4) **G2:** NR	

Table Notes: [a] PCOS defined as presence of at least two of following three criteria: (1) oligo- or anovulation, (2) clinical and/or chemical signs of hyperandrogenism and/or (3) polycystic ovaries.

AUB KQ1 Evidence Table (Reference ID #1363)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Ornstein et al., 2011 **Country:** United States **Enrollment period:** NR **Intervention setting:** Hospital **Funding:** Long Island Jewish Medical Center Small Grants **Author industry relationship disclosures:** None **Study Design:** RCT **Blinding:** None	**Intervention:** Hypocaloric low fat diet **Comparator:** Carbohydrate restriction without caloric or fat targets **Groups:** **G1:** Low fat diet **G2:** Low carbohydrate diet **Followup:** 12 weeks	**Inclusion criteria:** Aged 12 to 22 years Postmenarche ≥2 years Diagnosed with PCOS BMI 85th percentile **Exclusion criteria:** Use of medications known to cause menstrual dysfunction or to affect insulin secretion or action Endocrinopathies including non-classic 21-hydroxylase deficiency, thyroid dysfunction, Cushing's syndrome, hyperprolactinemia, and diabetes mellitus Androgen-producing tumors Renal or hepatic disease Pregnancy **N at enrollment:** **G1:** 12 **G2:** 12 **N at followup:** **G1:** 7 **G2:** 9 Age, mean ± SD years: **G1+G2:** 15.8 ± 2.2 **BMI:** NR **Parity:** NR	Cycle changes, mean ± SD: **G1+G2:** 0.6 ± 0.6 Weight, mean kg ± SD: **G1+G2:** 95.1 ± 18.6 Waist circumference, mean cm ± SD: **G1+G2:** 103.3 ± 12.3 BMI, kg/m^2 ± SD: **G1+G2:** 35.7 ± 6	Cycle changes, mean ± SD: **G1+G2:** 1.6 ± 1.3, **G1+G2 vs. BL:** p=0.003 Weight , mean kg ± SD: **G1+G2:** 89 ± 18 **G1+G2 vs. BL:** p<0.0001 Waist circumference, mean cm ± SD: **G1+G2:** 97.6 ± 13 **G1+G2 vs. BL:** p=0.01 BMI, kg/m^2 ± SD: **G1+G2:** 32.9 ± 5.8 **G1+G2 vs. BL:** p<0.0001 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse Events:** NR	**Overall quality:** Poor **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Low Blinding patients/ personnel: High Blinding outcome assessment: Unclear Incomplete outcome reporting: High Other: High

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		Race/ethnicity, n (%): White (non Latina): **G1+G2:** 8 (50) Latina: **G1+G2:** 3 (19) Black: **G1+G2:** 2 (13) South Asian: **G1+G2:** 2 (13) Asian: **G1+G2:** 1 (6)			

AUB KQ1 Evidence Table (Reference ID #1675)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Paoletti et al., 1996 **Country:** Italy **Enrollment period:** NR **Intervention setting:** Clinic **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** Subjects, investigators	**Intervention:** Cabergoline, one 0.5 mg tablet every week for ≥4 months **Comparator:** Placebo **Groups:** **G1:** Cabergoline **G2:** Placebo **Ga:** Polycystic ovary syndrome **Gb:** Control **Followup:** 4 cycles	**Inclusion criteria:** • Aged 20 to 28 years • Lean polycystic ovary syndrome: persistent amenorrhea or oligomenorrhea of perimenarchal onset • Controls were healthy women with: regular menstrual cycles **Exclusion criteria:** See inclusion criteria **N at enrollment:** **G1a:** 8 **G1b:** 8 **G2a:** 6 **G2b:** 7 **N at followup:** **G1a:** 8 **G1b:** 8 **G2a:** 6 **G2b:** 7 **Age, years mean ± SD:** **Ga:** 22 ± 3 **Gb:** 23 ± 2 **BMI, mean kg/m^2 ± SD:** **Ga:** 22.9 ± 0.29 **Gb:** 22.7 ± 0.38 **Parity:** NR **Race/ethnicity:** NR	**Menstrual cycle:** Oligomenorrhea, n: **G1a:** 3/8 **G2a:** 3/6 Amenorrhea, n: **G1a:** 5/8 **G2a:** 3/6	**Menstrual cycle:** Regular cycles,[a] n: **G1a:** 3/8 **G2a:** 0/6 Spontaneous menses within 32 to 37 days from onset of treatment, n: **G1a:** 5/8 **G2a:** 0/6 Persistent oligomenorrhea, n: **G2a:** 3/6 Persistent amenorrhea, n: **G2a:** 3/6 **Quality of life:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR	**Overall quality:** Good **Risk of bias:** Randomization: Low Allocation concealment: Unclear Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: Low Other: Low

Table Notes: [a] 28-day intervals.

AUB KQ1 Evidence Table (Reference ID #1783)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Abu Hashim et al., 2011 **Country:** Egypt **Enrollment period:** July 2008 to September 2010 **Intervention setting:** University outpatient clinic and private practice **Funding:** None. NuvaRing provided by Organon Egypt and sanitary pads by Proctor and Gamble, Cairo, Egypt **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** Outcome assessors (laboratory and statistical)	**Intervention:** Nuvaring, 15 mcg of ethinyl estradiol and 120 mcg of etonogestrel; inserted between days 1-5 of cycle for three weeks followed by one week ring free. **Comparator:** Norethisterone acetate tablets 5 mg three times daily from days 5-26 of cycle for three cycles **Groups:** **G1:** Vaginal ring **G2:** Norethisterone **Followup:** 3 months	**Inclusion criteria:** Heavy menstrual bleeding (mean PBAC score >185 for two control cycles) Parous women desiring contraception Age 20-35 Good general health with regular menstrual cycle and evidence of ovulation Normal pelvic exam with uterus < 10 cm No pathology identified in pelvic ultrasound, normal histology on endometrial biopsy, negative cervical smear No contraindication to either contraceptive vaginal ring or norethisterone **Exclusion criteria:** Pregnancy BMI >30 kg/m^2 Smokers Current IUD use AUB not fully investigated Hormone therapy or any medication that might affect MBL within previous three months Used injectable hormones for contraception	**Bleeding:** PBAC, mean score ± SD: **G1:** 287.8 ± 77.4 **G2:** 302.4 ± 84.6 Cycle length, mean days ± SD: **G1:** 26.9 ± 3.7 **G2:** 27.2 ± 4.4 Menses duration, mean days ± SD: **G1:** 8.8 ± 2.7 **G2:** 8.4 ± 2.6 Hemoglobin, g/dL ± SD: **G1:** 10.5 ± 1.3 **G2:** 10.7 ± 1.2 Ferritin (mcg/dL) **G1:** 18.4 ± 3.3 **G2:** 17.1 ± 2.9 **Quality of life:** Self-rated health ≥ very good, n (%): **G1:** 2 (4.1) **G2:** 2 (4.2) Feeling physically unwell, mean number of days ± SD: **G1:** 7.4 ± 1.8 **G2:** 7.5 ± 2.1 Feeling mentally unwell, mean number of days ± SD: **G1:** 5.8 ± 1.7 **G2:** 6.2 ± 1.6 No regular activity, mean	**Bleeding:** PBAC, mean score ± SD: **G1:** 90.2 ± 24.4 **G2:** 92.3 ± 26.7 **G1 vs. G2:** p=NS **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 PBAC score reduction from baseline, (%): **G1:** 68.6 **G2:** 69.5 **G1 vs. G2:** p=NS Menses duration, mean days ± SD: **G1:** 5.3 ± 1.2 **G2:** 5.5 ± 1.1 **G1 vs. G2:** p=NS **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 Hemoglobin, g/dL ± SD: **G1:** 11.3 ± 1.2 **G2:** 11.4 ± 1.1 **G1 vs. G2:** p=NS **G1 vs. BL:** p=0.02 **G2 vs. BL:** p=0.03 Ferritin (mcg/dL) **G1:** 36.7 ± 6.2 **G2:** 35.1 ± 5.7 **G1 vs. G2:** p=NS **G1 vs. BL:** p=0.01 **G2 vs. BL:** p=0.01 **Quality of life:** Self-rated health ≥ very good, n (%):	**Overall quality:** Fair **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		previous 12 months Use of drugs that interfere with contraceptive hormone metabolism Previous endometrial resection/ablation and other pathology Heavy menstrual bleeding of endocrine or systemic origin **N at enrollment:** **G1:** 48 **G2:** 47 **N at followup:** **G1:** 48 **G2:** 47 **Age, mean years ± SD:** **G1:** 27.8 ± 4.9 **G2:** 28.2 ± 4.4 **BMI, mean kg/m^2 ± SD:** **G1:** 24.8 ± 3.8 **G2:** 25.4 ± 3.2 **Parity, n (%):** 1 **G1:** 5 (10.4) **G2:** 6 (12.8) 2 **G1:** 14 (29.2) **G2:** 10 (21.3) ≥ 3 **G1:** 29 (60.4) **G2:** 31 (65.9) NR **Race/ethnicity:**	number lost days ± SD: **G1:** 6.4 ± 2.1 **G2:** 6.3 ± 2.3	**G1:** 17 (35.4) **G2:** 14 (29.7) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 Feeling physically unwell, mean number of days ± SD: **G1:** 3.3 ± 1.1 **G2:** 3.5 ± 1.3 **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 Feeling mentally unwell, mean number of days ± SD: **G1:** 4.7 ± 1.2 **G2:** 5.1 ± 1.3 **G1 vs. BL:** p=NS **G2 vs. BL:** p=NS No regular activity, mean number of lost days ± SD: **G1:** 1.7 ± 1.2 **G2:** 2.6 ± 1.4 **G1 vs. BL:** p=0.002 **G2 vs. BL:** p=0.03 **Pain:** NR **Sexual function:** NR **Patient satisfaction:** Very satisfied/satisfied, n (%): **G1:** 34 (70.8) **G2:** 20 (42.5) **G1 vs. G2:** p=0.003 Uncertain/dissatisfied, n	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		NR		(%): **G1:** 14 (33.4) **G2:** 27 (57.5) **G1 vs. G2:** p=0.003 Continued treatment, n (%): **G1:** 37 (77) **G2:** 12 (25.5) **G1 vs. G2:** p=0.001 Discontinued treatment, n (%): **G1:** 11 (23) **G2:** 35 (74.5) **G1 vs. G2:** p=0.001 **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse Events:** Nausea, n (%): **G1:** 1 (2) **G2:** 2 (4.2) **G1 vs. G2:** p=NS Headache, n (%): **G1:** 3 (6.25) **G2:** 2 (4.2) **G1 vs. G2:** p=NS Breast tenderness, n (%): **G1:** 2 (4.2) **G2:** 3 (6.4) **G1 vs. G2:** p=NS Breakthrough bleeding/spotting, n (%): **G1:** 2 (4.2) **G2:** 6 (12.8) **G1 vs. G2:** p=0.02	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Leukorrhea, n (%): **G1:** 5 (10.4) **G2:** 1 (2.1) **G1 vs. G2:** p=0.01 Vaginal discomfort, n (%): **G1:** 2 (4.2) **G2:** NA **G1 vs. G2:** p=0.003 Vaginitis, n (%): **G1:** 4 (8.3) **G2:** 1 (2.1) **G1 vs. G2:** p=0.03 Ring-related events, n (%): **G1:** 3 (6.25) **G2:** NA p=0.002	

AUB KQ1 Evidence Table (Reference ID #1170)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Andersch et al., 1988 **Country:** Sweden **Enrollment period:** NR **Intervention setting:** NR **Funding:** University of Goteborg and The Goteborg Medical Society **Author industry relationship disclosures:** NR **Study Design:** RCT (crossover) **Blinding:** NR	**Intervention:** Flurbiprofen 100 mg, 2 times per day on days 1-5 for cycles 3 and 4 followed by tranexamic acid for cycles 5 and 6 **Comparator:** Oral tranexamic acid 1.5 g, 3 times per day on days 1-3; 1 g twice daily on days 4 and 5 for cycles 3 and 4 followed by flurbiprofen for cycles 5 and 6 **Groups:** **G1:** Flurbiprofen first then tranexamic acid **G2:** Tranexamic acid first then flurbiprofen **Ga:** Flurbiprofen **Gb:** Tranexamic acid **Followup:** 6 months[a]	**Inclusion criteria:** • Idiopathic menorrhagia MBL >80 ml during 2 periods No history or evidence of pelvic pathology **Exclusion criteria:** Menorrhagia caused by uterine myomata Menorrhagia caused by intrauterine device Use of oral contraceptives or intrauterine device Pregnancy in previous 6 months **N at enrollment:** **G1+G2:** 15 **N at followup:** **G1+G2:** 15 **Age, mean years (range):** **G1+G2:** 40.5 (34, 49) **BMI:** NR **Parity, mean (range):** **G1+G2:** 1.7 (0, 3) **Race/ethnicity:** NR	**Bleeding:** MBL measured using the alkaline hematin method, mean ml (SE) (range): **G1+G2:** 295 (52) (81, 701) Hemoglobin, mean g/l (SE): **G1+G2:** 127.4 (3.7)	**Bleeding:** MBL measured using the alkaline hematin method, mean ml (SE) (range): **Ga:** 223 (44) (50, 636) **Gb:** 155 (33) (36, 511) MBL change from baseline, %, p-value: **Ga:** -24, p<0.01 **Gb:** -53, p< 0.01 **Ga vs. Gb:** p<0.01 Hemoglobin, mean g/l (SE), p value: **Ga:** 127.1 (3.4), p=ns **Gb:** 126.2 (3.0), p=ns **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NA **Additional interventions:** NR **Adverse events[b]:**	**Overall quality:** Poor **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Unclear Blinding patients/personnel: Unclear Blinding outcome assessment: Unclear Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Patient complained of side effects which they attributed to medication, n: **Ga:** 7 **Gb:** 4 Vomiting and difficulty swallowing, n: **Ga:** NR **Gb:** 3	

Table Notes: [a] Cycles 1 and 2 Control –no treatment followed by 4 treatment cycles (cross over after 4th cycle); [b] "Treatment with tranexamic acid caused nausea, dizziness, numbness, “restless legs”, headache and in 3 women vomiting and difficulty swallowing. Flurbiprofen caused tiredness, stomach pains and nausea. No patient discontinued therapy due to side effects."

AUB KQ1 Evidence Table (Reference ID #871)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Bonnar and Sheppard, 1996 **Country**: Ireland **Enrollment period**: NR **Intervention setting**: University department of OB-GYN **Funding**: Health Research Board of Ireland and Pharmacia, Sweden **Author industry relationship disclosures:** None **Study Design:** RCT **Blinding**: None	**Intervention/ Comparator:** Tranexamic acid 1 g six hourly; mefenamic acid 500 mg eight hourly; ethamsylate 500 mg six hourly All treatments taken for five days from day 1 of bleeding for three cycles **Groups:** **G1:** Tranexamic acid **G2:** Mefenamic acid **G3:** Ethamsylate **Followup:** 3 cycles	**Inclusion criteria:** • Aged 35 to 46 years • Complaint of regular heavy menstrual bleeding Mean menstrual loss >80 ml measured over three consecutive menstrual periods before treatment **Exclusion criteria:** Organic causes of menorrhagia excluded by hysteroscopy, endometrial biopsy, cervical smear test 3 to 12 months before enrollment History of renal or hepatic impairment Previous thromboembolic disease Inflammatory bowel disease Peptic or intestinal ulceration Coagulation or fibrinolytic disorders **N at enrollment:** **G1:** 27 **G2:** 25 **G3:** 29 **N at followup:** **G1:** 26	**Bleeding:** MBL measured by alkaline hematin method during 3 cycles pretreatment, mean ml: **G1:** 164 **G2:** 186 **G3:** 170 MBL duration, mean days ± SD: **G1:** 5.5 ± 1.4 **G2:** 5.8 ± 1.3 **G3:** 5.7 ± 1.1 Sanitary towels, mean ± SD: **G1:** 23 ± 7.0 **G2:** 25 ± 7.0 **G3:** 25 ± 9.0	**Bleeding:** MBL measured by alkaline hematin method during 3 treatment cycles, mean ml: **G1:** 75 **G2:** 148 **G3:** 175 MBL change, n (%): Less: **G1:** 18 (69) **G2:** 13 (57) **G3:** 12 (44) Same: **G1:** 4 (15) **G2:** 5 (22) **G3:** 5 (19) Greater: **G1:** 4 (15) **G2:** 4 (17) **G3:** 8 (30) Dysmenorrhea change, n (%): Better: **G1:** 5 (19) **G2:** 3 (13) **G3:** 1 (4) Same: **G1:** 14 (54) **G2:** 11 (48) **G3:** 19 (70) Worse: **G1:** 7 (27) **G2:** 8 (35) **G3:** 4 (15) MBL duration, mean	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: Unclear Selective reporting: Unclear Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G2: 23 **G3:** 27 **Age, mean years ± SD:** **G1:** 40 ± 5 **G2:** 38 ± 8 **G3:** 37 ± 8 **BMI:** NR **Height, mean cm ± SD:** **G1:** 160 ± 6 **G2:** 161 ± 6 **G3:** 164 ± 7 **Weight, mean kg ± SD:** **G1:** 66 ± 10 **G2:** 66 ± 12 **G3:** 64 ± 9 **Parity:** NR **Race/ethnicity:** NR		days ± SD: **G1:** 4.9 ± 1.8 **G2:** 5.3 ± 1.3 **G3:** 5.7 ± 2.0 Sanitary towels, mean ± SD, p value: **G1:** 20 ± 6.0, p<0.01 **G2:** 23 ± 9.0, p<0.05 **G3:** 25 ± 9.0 **G1 vs. BL:** p<0.01 **G2 vs. BL:** p<0.05 **G3 vs. BL:** p=NS **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** Wish to continue treatment at end of study, n (%): **G1:** 20 (77) **G2:** 17 (74) **G3:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Adverse events: Withdrawal,[a] n: **G1:** 4 **G2:** 3 **G3:** 11 Withdrawal due to unwanted event such as nausea, headache or dizziness, n: **G1:** 3 **G2:** 1 **G3:** 4	

Table Notes: [a] Reasons for withdrawal: poor efficacy (G3: n=5; G2: n=1); unwanted event such as nausea, headache and dizziness (G1: n=3; G2: n=1; G3: n=4).

AUB KQ1 Evidence Table (Reference ID #1116)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Cameron et al., 1990 **Country:** United Kingdom **Enrollment period:** NR **Intervention setting:** Outpatient department **Funding:** Parke-Davis Research Laboratories, Eastleigh, UK **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** NR	**Intervention:** Mefenamic acid, 500 mg three times daily on days 1-5 of menses **Comparator:** Norethisterone, 5 mg twice daily on cycle days 19-26 **Groups:** **G1:** Mefenamic acid **G2:** Norethisterone 2 control cycles Cycle 1 Cycle 2 2 treatment cycles Cycle 3 Cycle 4	**Inclusion criteria:** Heavy menstruation defined by average MBL >80 ml per cycle **Exclusion criteria:** Organic disease Receiving medical treatment for menorrhagia **N at enrollment:** **G1:** 17 **G2:** 15 **N at followup:** **G1:** 17 **G2:**15 **Age, median years (range):** **G1:** 40 (27, 48) **G2:** 40 (21, 51) **BMI:** NR **Height, median cm (range):** **G1:** 163 (154, 177) **G2:** 163 (150, 181) **Weight, median kg (range):** **G1:** 67 (52, 92) **G2:** 65 (48, 102) **Parity:** NR	**Bleeding:** MBL measured by alkaline hematin method, median ml (range): **G1:** 123 (86, 237) **G2:** 109 (81, 236) Duration at cycle 1, median days (range): **G1:** 7 (5, 8) **G2:** 7 (5, 10) Duration at cycle 2, median days (range): **G1:** 6 (4, 9) **G2:** 6 (4, 9) Cycle length at cycle 1, median days (range): **G1:** 28 (21, 35) **G2:** 28 (21, 35) Cycle length at cycle 2, median days (range): **G1:** 27 (21, 33) **G2:** 29 (21, 31**)**	**Bleeding:** MBL measured by alkaline hematin method, median ml (range): **G1:** 81 (22, 193) **G2:** 92 (43, 189) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.002 MBL change, median % (range): **G1:** -24 (-83, 5) **G2:** -20 (-53, 2) **G1 vs. G2:** p>0.1 Duration at cycle 3, median days (range): **G1:** 6 (5, 9) **G2:** 6 (4, 8) Duration at cycle 4, median days (range): **G1:** 5 (3, 8) **G2:** 6 (4, 8) **G1 vs. BL:** p<0.01 **G2 vs. BL:** p=NS Cycle length at cycle 3, median days (range): **G1:** 27 (25, 37) **G2:** 29 (28, 32) Cycle length at cycle 4, median days (range): **G1:** 28 (25, 32) **G2:** 29 (26, 35) **G1 vs. BL:** p=NS **G2 vs. BL:** p=NS **Quality of life:**	**Overall quality:** Poor **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Low Blinding patients/personnel: Unclear Blinding outcome assessment: Unclear Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		Race/ethnicity: NR		NR **Pain, n (%):** Abdominal pain: **G1:** 3 (18) **G2:** 3 (20) Headache: **G1:** 4 (24) **G2:** 5 (33) **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events, n (%):** Any side effect: **G1:** 10 (59) **G2:** 9 (60) Nausea: **G1:** 2 (12) **G2:** 1 (7) Other[a]: **G1:** 2 (12) **G2:** 1 (7)	

Table Notes: [a] Not including abdominal pain or headache.

AUB KQ1 Evidence Table (Reference ID #1184)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Cameron et al., 1987 **Country:** United Kingdom **Enrollment period:** NR **Intervention setting:** Hospital **Funding:** Birthright research grant, Royal College of Obstetricians and Gynaecologists **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** NR	**Intervention:** Mefenamic acid 500 mg three times per day for the first five days of cycle; **Comparator:** Norethisterone 5 mg two times per day on cycle days 15 to 25; Progesterone-impregnated coil releasing 65 mcg progesterone daily Two control cycles, two treatment cycles **Groups[a]:** **G1:** Mefenamic acid **G2:** Norethisterone **G3:** Progesterone-impregnated coil **Followup:** 4 months	**Inclusion criteria:** Mean MBL >50 ml **Exclusion criteria:** See inclusion criteria **N at enrollment:** **G1:** 8 **G2:** 8 **G3:** 8 **N at followup:** **G1:** 6 **G2:** 7 **G3:** 6 **Age, median years (range):** **G1:** 40 (33, 48) **G2:** 39 (35, 46) **G3:** 40 (29, 42) **BMI:** NR **Weight, median kg (range):** **G1:** 64 (50, 70) **G2:** 64 (52, 73) **G3:** 70 (54, 89) **Height, median cm (range):** **G1:** 162 (149, 164) **G2:** 164 (152, 169) **G3:** 162 (145, 164) **Parity, median (range):** **G1:** 4 (2, 4)	**Bleeding:** MBL measured by alkaline hematin method, median ml (range): **G1:** 68 (61, 169) **G2:** 94 (55, 312) **G3:** 71 (56, 164) MBL measured by alkaline hematin method, followup group, median ml (range): **G1:** 85 (68, 169) **G2:** 131 (55, 259) **G3:** 64 (56, 164) Number of bleeding days, median (range): **G1:** 5 (4, 7) **G2:** 6 (4, 7) **G3:** 5 (4, 6) Cycle length, median days (range): **G1:** 28 (23, 38) **G2:** 28 (24, 30) **G3:** 26 (23, 30) Endometrial prostaglandin, median pg/mg (range): **G1:** 412 (256, 9506) **G2:** 770 (152, 2251) **G3:** 842 (265, 1630)	**Bleeding:** MBL measured by alkaline hematin method, median ml (range): **G1:** 47 (39, 210) **G2:** 110 (24, 222) **G3:** 45 (31, 77) **G1 vs. BL:** p=0.05 **G2 vs. BL:** p=NS **G3 vs. BL:** p<0.05 Number of bleeding days: No difference vs. baseline[b] Endometrial prostaglandin, median pg/mg (range): **G1:** 546 (412, 3434) **G2:** 985 (55, 1987) **G3:** 273 (178, 832) **G1 vs. BL:** p=NS **G2 vs. BL:** p=NS **G3 vs. BL:** p=0.05 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR	**Overall quality:** Poor **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Unclear Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: Unclear Other: Unclear

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G2: 4 (1, 4) **G3:** 2 (2, 4) **Race/ethnicity:** NR		**Additional interventions:** NR **Adverse events:** NR	

Table Notes: [a] Does not include a treatment group randomized to danazol (n=6); [b] Baseline refers to control cycles.

AUB KQ1 Evidence Table (Reference ID #123)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Endrikat et al., 2009 **Country:** Canada **Enrollment period:** NR **Intervention setting:** 9 centers **Funding:** Bayer Schering Pharma AG, Berlin, Germany **Author industry relationship disclosures:** 5/6 **Study Design:** RCT **Blinding:** Open-label	**Intervention:** LNG-IUS 52 mg levonorgestrel released up to 20 µg per 24 hours inserted within 7 days of start of last menstrual period for 12 months **Comparator:** One tablet daily for 12 months of COC containing 1 mg norethindrone acetate and 20 µg ethinyl estradiol for days 1-21 and placebo tablet for days 22-28 **Groups:** **G1:** LNG-IUS **G2:** COC **Followup:** 12 months	**Inclusion criteria:** Aged ≥30 years Healthy • Diagnosis of idiopathic menorrhagia assessed by MBL score ≥100 on PBLAC for two consecutive cycles Normal or only slightly enlarged uterus **Exclusion criteria:** Contraindications for LNG-IUS and COC use Metabolic and endocrine diseases Diagnostically unclassified genital bleeding History of liver or vascular disease Concomitant use of medications that could influence study objective, including: sex steroids; tranexamic acid; NSAIDs; platelet aggregation inhibitors; anticoagulants; and drugs known to induce or inhibit liver enzymes Intramural or subserous fibroids of mean diameter ≥4 cm or submucous fibroids Adenomyosis or endometrial abnormalities (e.g., polyps or hyperplasia) Perimenopausal **N at enrollment:** **G1:** 20 **G2:** 19	**Bleeding:** MBL measured by PBLAC score, median: **G1:** 228 **G2:** 290 Hemoglobin,[a] mean g/L: **G1:** 126 **G2:** 125	**Bleeding:** MBL measured by PBLAC score at 12 months, median: **G1:** 13 **G2:** 72 **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.002 MBL measured by PBLAC score at 12 months, estimate for median difference (95% CI): **G1 vs. G2:** -62 (-89, -18) MBL measured by PBLAC score at 12 months, mean % change: **G1:** -83 **G2:** -68 Treatment success,[b] n (%): **G1:** 16/20 (80.0) **G2:** 7/19 (36.8) **G1 vs. G2:** p<0.009 Hemoglobin at 12 months, mean g/L: **G1:** 134 **G2:** 136 Hemoglobin at 12 months, baseline-adjusted mean g/L change: **G1:** +8.6 **G2:** +9.6 **G1 vs. G2:** p=0.711	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: High Selective reporting: Low Blinding patients/personnel: High Blinding outcome assessment: Unclear Incomplete outcome reporting: Low Other: High

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		N at followup: **G1:** 17 **G2:** 12 **Time since start of menorrhagia, mean years ± SD:** **G1:** 10.0 ± 8.23 **G2:** 6.1 ± 4.4 **Age, mean years ± SD:** **G1:** 41.8 ± 4.3 **G2:** 42.4 ± 4.4 **BMI, mean kg/m^2 ± SD** **G1:** 24.3 ± 1.9 **G2:** 22.6 ± 2.3 **Births, n (%)** 0: **G1:** 3 (15.0) **G2:** 3 (15.8) 1: **G1:** 6 (30.0) **G2:** 4 (21.1) 2: **G1:** 6 (30.0) **G2:** 10 (52.6) ≥3: **G1:** 5 (25.0) **G2:** 2 (10.5) **Race/ethnicity:** NR		Hemoglobin, estimate for mean difference (95% CI): **G1 vs. G2:** -0.99 (-6.43, 4.45) **Quality of life:** Menorrhagia severity score[c]: 6 months: **G1:** NR **G2:** NR **G1 vs. G2:** p=0.045 12 months: **G1:** NR **G2:** NR **G1 vs. G2:** p=NS Menorrhagia severity score, estimated mean % difference at 6 months (95% CI): **G1 vs. G2:** -6.37[d] (-12.61, -0.14) **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Adverse events: Discontinued study (reasons were intermenstrual bleeding, menstrual disorder, and headache), n: **G1:** 1 **G2:** 5	

Table Notes: [a] Hemoglobin analyzed in the sub-population who had not used iron supplements during the study. Results were similar to whole study population (data not shown); [b] Treatment success defined as MBL score < 100 at 12 months; treatment failure recorded if MBL score ≥ 100 or if treatment was discontinued; [c] Assessed by condition specific questionnaire (see: Ruta et al.) but scores only displayed graphically; [d] Menorrhagia severity scores significantly lower (better quality of life) in G1 compared to G2 at 6 months.

AUB KQ1 Evidence Table (Reference ID #1349)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Fraser et al., 2011 **Country:** Australia, Europe **Enrollment period:** February 2006 to May 2008 **Intervention setting:** 34 centers **Funding:** Bayer Health Care Pharmaceuticals **Author industry relationship disclosures:** 7/7 **Study Design:** RCT **Blinding:** Patients, investigators	**Intervention:** Estradiol valerate/ dienogest, oral 7 consecutive treatment cycles of 28 days each (estradiol valerate 3 mg on days 1-2, estradiol valerate 2 mg /dienogest 2 mg on days 3-7, estradiol valerate 2 mg/ dienogest 3 mgs on days 8-24, estradiol valerate 1 mg on days 25-26, placebo on days 27-28) **Comparator:** Placebo **Groups:** **G1:** Estradiol valerate/dienogest **G2:** Placebo **Followup:** 8 months	**Inclusion criteria[a]:** Aged 18 or older Heavy menstrual bleeding Two or more menstrual bleeding episodes with a MBL of >80 ml, prolonged menstrual bleeding (≥8 days) and/or frequent menstrual bleeding (>5 episodes with a minimum of 20 bleeding days overall) during the 90 day run-in phase Willing to use barrier method of contraception Normal endometrial biopsy result or mild, simple endometrial hyperplasia 6 months prior to study entry **Exclusion criteria:** Abnormal transvaginal ultrasound Abnormal lab values which were clinically significant History of endometrial ablation Dilatation and curettage 2 months preceding the study Bleeding due to organic pathology determined during 90 day run-in phase including chronic endometriosis, adenomyosis, endometriosis, endometrial polyps,	**Bleeding:** MBL measured by the alkaline hematin method, mean ml ± SD: **G1:** 639.4 + 513.5 **G2:** 645.1 + 391.2 Bleeding and spotting days, 90-day run-in phase, mean: **G1:** 23.0 **G2:** 21.0 Bleeding only days, 90-day run-in phase, mean ± SD: **G1:** 17.3 ± 6.7 **G2:** 16.6 ± 6.7 Spotting only days, 90-day run-in phase, mean ± SD: **G1:** 5.7 ± 5.6 **G2:** 4.4 ± 5.1 Bleeding episodes, 90-day run-in phase, mean ± SD: **G1:** 3.5 ± 0.6 **G2:** 3.4 ± 0.7 Sanitary protection items, 90-day run-in phase, mean ± SD: **G1:** 81.6 ± 32.7 **G2:** 82.0 ± 39.3 Hemoglobin, mean g/dl ± SD: **G1:** 12.1 ± 1.2 **G2:** 12.1 ± 1.4 Hematocrit, mean % ± SD: **G1:** 39.7 ± 3.7 **G2:** 39.8 ± 4.2	**Bleeding:** MBL measured by the alkaline hematin method, mean ml ± SD: **G1:** 175.8 ± 200.8 **G2:** 553.6 + 308.0 MBL measured by the alkaline hematin method, mean change[d] ml ± SD: **G1:** -485 ± 409.6 **G2:** -93.2 ± 268.0 **G1 vs. G2:** p<0.0001 MBL < 80 ml for each episode, n (%): **G1:** 86/136 (63.2) **G2:** 11/76 (14.5) Bleeding and spotting days, 90-day efficacy phase, mean: **G1:** 21.3 **G2:** 19.1 Bleeding and spotting days, mean change[d]: **G1:** -1.6 **G2:** -1.9 Bleeding only days, 90-day efficacy phase, mean ± SD: **G1:** 13.7 ± 7.0 **G2:** 14.9 ± 5.7 Bleeding only days, mean change[d] ± SD: **G1:** -3.7 ± 8.4 **G2:** -2.1 ± 7.2	**Overall quality:** Good **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Unclear Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		leiomyomas or uterine malignancy Unwilling to discontinue tranexamic acid or NSAIDs during menses BMI >32 kg/m^2 Women aged 35 or older who smoked more than 10 cigarettes per day (or any number of cigarettes in Australia and the UK) Contraindications to the use of combined oral contraceptives **N at enrollment:** **G1:** 149 **G2:** 82 **N at followup:** **G1:** 109 **G2:** 62 **Age, mean years ± SD:** **G1:** 39.5 ± 6.6 **G2:** 38.5 ± 7.5 **BMI, mean kg/m^2 ± SD:** **G1:** 24.6 ± 3.5 **G2:** 25.7 ± 3.0 **Weight, mean kg ± SD:** **G1:** 69.8 ± 11.8 **G2:** 71.6 ± 10.2 **Parity:** NR **Race/ethnicity, n (%):** Caucasian: **G1:** 144 (96.6)	Ferritin, mean ng/ml ± SD: **G1:** 13.6 ± 13.6 **G2:** 13.9 ± 14.5	**G1 vs. G2:** p=0.0186 Spotting only days, 90-day efficacy phase, mean ± SD: **G1:** 7.6 ± 7.8 **G2:** 4.2 ± 5.5 Spotting only days, mean change[d] ± SD: **G1:** 2.1 ± 8.2 **G2:** -0.2 ± 6.0 Bleeding episodes, 90-day efficacy phase, mean ± SD: **G1:** 3.1 ± 0.9 **G2:** 3.1 ± 0.6 Bleeding episodes, mean change[d] ± SD: **G1:** -0.4 ± 1.1 **G2:** -0.4 ± 0.7 **G1 vs. G2**: p=0.5095 Sanitary protection items, 90-day efficacy phase, mean ± SD: **G1:** 43.3 ± 31.7 **G2:** 64.8 ± 26.3 Sanitary protection items, mean change[d] ± SD: **G1:** -38.4 ± 30.0 **G2:** -16.5 ± 32.2 **G1 vs. G2**: p<0.0001 Reduction in MBL volume, mean % (median): **G1:** 69.4 (79.2) **G2:** 5.8 (7.4)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G2: 80 (97.6) Black: **G1:** 1 (0.7) **G2:** 0 (0) Asian: **G1:** 2 (1.3) **G2:** 1 (1.2) Other: **G1:** 2 (1.3) **G2:** 1 (1.2) **Bleeding symptoms,[b] n (%):** Prolonged bleeding: **G1:** 20 (13.4) **G2:** 10 (12.2) Frequent bleeding: **G1:** 0 **G2:** 0 Heavy bleeding: **G1:** 136 (91.3) **G2:** 76 (92.7)		**G1 vs. G2:** p<0.0001 ≥20% reduction in MBL,%: **G1:** 94 **G2:** 40 ≥50% reduction in MBL,%: **G1:** 84 **G2:** 12 ≥80% reduction in MBL,%: **G1:** 50 **G2:** 0 Hemoglobin, adjusted change from baseline, mean g/dl: **G1:** +0.70 **G2:** +0.05 **G1 vs. G2:** p<0.0001 Hematocrit, adjusted change from baseline, mean %: **G1:** +1.5 **G2:** -0.05 **G1 vs. G2**: p<0.0049 Ferritin, adjusted change from baseline, mean ng/ml: **G1:** +8.6 **G2:** +0.4 **G1 vs. G2**: p<0.0017 Patient reported improvement in bleeding symptoms, %: **G1:** 77.9 **G2:** 45.1 **G1 vs. G2:** p<0.0001	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Responder status,[c] n (%): Complete: **G1:** 44 (29.5) **G2:** 1 (1.2) Partial or non-responder[e]: **G1:** 64 (43.0) **G2:** 61 (74.4) Missing data: **G1:** 41 (27.5) **G2:** 20 (24.4) Complete response rate (excluding patients with missing data), % (95% CI): **G1:** 40.7 (31.4, 50.6) **G2:** 1.6 (0.0, 8.7) **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** Concomitant use of iron, n (%): **G1:** 28/149 (18.8) **G2:** 27/82 (32.9)	

Table Notes: See #1365 Jensen et al same study protocol used in United States and Canada; [a] Use of medications to relieve women of heavy menstrual bleeding (sex steroids, NSAIDS, tranexamic acid) was not allowed during study period; [b] Some women presented with multiple symptoms. [c] Complete response to treatment defined as composite of following components: no bleeding episodes lasting more than 7 days, no more than 4 bleeding episodes overall, no bleeding episodes with blood loss volume ≥80 ml, no more than one bleeding episode increase from baseline, no more than 24 days of bleeding overall and no increase from baseline in total number of bleeding days. In addition patients recruited because of presence of prolonged bleeding were required to demonstrate a decrease of at least 2 days in maximum duration of a bleeding cycle. Patients recruited because of heavy bleeding, the blood loss volume had to <80 ml and had to represent a decrease of at least 50% relative to average blood loss volume per episode during the study recruitment phase; [d] Change from 90 day run-in phase to 90-day efficacy phase; [e] Detail on criteria not achieved in partial or non-responders presented in Table 2 of manuscript (pg. 2702).

AUB KQ1 Evidence Table (Reference ID #1103)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Fraser et al., 1991 **Country:** Australia **Enrollment period:** NR **Intervention setting:** NR **Funding:** Parke-Davis Company Sydney, Australia **Author industry relationship disclosures:** NR **Study Design:** RCT (cross-over) **Blinding:** None	**Intervention[a]:** Mefenamic acid, 500 mg every 6-8 hours from first sign of menses until 24 hours after usual duration of heavy bleeding for a maximum of 5 days; Naproxen, 500 mg at first onset of menses followed by 250 mg every 6-8 hours until 24 hours after usual duration of heavy bleeding for a maximum of 5 days **Comparator:** Mefenamic acid, 500 mg every 6-8 hours from first sign of menses until 24 hours after usual duration of heavy bleeding for a maximum of 5 days; Low dose combined oral contraceptive (ethinyl estradiol 30 µg and levonorgestrel 150 µg) daily for 21 out of 28 days **Groups[b]:** **G1:** Cycles 1 and 2: no treatment Cycles 3 and 4: mefenamic acid or naproxen Cycles 5 and 6: no treatment Cycles 7 and 8: mefenamic acid or naproxen **G2:** Cycles 1 and 2: no treatment Cycles 3 and 4: mefenamic	**Inclusion criteria:** • Menorrhagia Regular periods Ovulating No hormonal therapy in the previous 3 months **Exclusion criteria:** Menorrhagia due to pelvic causes Menorrhagia due to systemic causes **N at enrollment:** **G1:** 15 **G2:** 15 **N at followup:** **G1:** 14 **G2:** 12 **Age:** NR **BMI:** NR **Parity:** NR **Race/ethnicity:** NR	**Bleeding:** MBL measured by alkaline hematin method in cycles 1 and 2, mean ml ± SD: **G1:** 131.1 ± 80.8 **G2:** 101.0 ± 52.5	**Bleeding:** MBL measured by alkaline hematin method during 2 mefenamic acid treatment cycles, mean ml ± SD: **G1:** 105.1 ± 88.6 **G2:** 62.9 ± 27.7 MBL % change from baseline during 2 mefenamic acid treatment cycles: **G1:** -20 **G2:** -38 **G1 vs. BL:** p=0.198 **G2 vs. BL:** p=0.002 MBL during 2 no treatment cycles 5 and 6, mean ml ± SD: **G1:** 131.9 ± 71.6 **G2:** 90.9 ± 61.3 MBL during 2 treatment cycles (G1: naproxen; G2: COC), mean ml ± SD: **Gb:** 115.6 ± 113.0 **Gc:** 57.8 ± 34.8 MBL % change from baseline during 2 treatment cycles (G1: naproxen; G2: COC): **Gb:** -12 **Gc:** -43 **Gb vs. BL:** p=0.079 **Gc vs. BL:** p<0.001	**Overall quality:** Poor **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Low Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: High Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
	acid or combined monophasic oral contraceptive Cycles 5 and 6: no treatment Cycles 7 and 8: mefenamic acid or combined monophasic oral contraceptive **Ga:** Mefenamic acid **Gb:** Naproxen **Gc:** Combined oral contraceptive **Followup:** 8 cycles			MBL reduction during 2 treatment cycles with mefenamic acid compared to 2 treatment cycles with naproxen and COC: **Gb vs. Ga:** p=0.129 **Gc vs. Ga:** p=0.079 Clinically significant[c] reduction in MBL during 2 mefenamic acid treatment cycles, n (%): **G1:** 8/14 (57) **G2:** 10/12 (83) Clinically significant[c] reduction in MBL during 2 treatment cycles, n (%): **Gb:** 9/14 (64) **Gc:** 9/12 (75) **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Additional interventions: NR	

Table Notes: [a] A third group, not included in this review, received mefenamic acid and danazol (n=15); [b] The order of treatment within each group was randomized; [c] Objective reduction of 20% between the mean of first two cycles and mean of each 2 treatment cycles.

AUB KQ1 Evidence Table (Reference ID #1304, #1255)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Fraser et al., 1981 Fraser et al., 1984[a] **Country:** Australia **Enrollment period:** NR **Intervention setting:** NR **Funding:** Park-Davis and Co Australian National Health and Medical Research council **Author industry relationship disclosures:** NR **Study Design:** RCT (crossover) **Blinding:** Patients, clinicians	**Intervention:** Mefenamic acid 500mg, 3 times/day, onset to end of menses for 2 cycles followed by placebo for 2 cycles **Comparator:** Placebo for two cycles followed by mefenamic acid for 2 cycles **Groups:** **G1:** Mefenamic acid first then placebo **G2:** Placebo first then mefenamic acid **Ga:** Mefenamic acid **Gb:** Placebo **Followup:** 4 cycles	**Inclusion criteria:** Menorrhagia **Exclusion criteria:** See inclusion criteria **N at enrollment[a]:** **G1+G2:** 85 **N at followup:** **G1:** 38 **G2:** 31 **Age years, mean ± SD:** **G1+G2**: 33 ± 6.9 **BMI:** NR **Parity:** NR **Race/ethnicity:** NR	**Bleeding:** Menorrhagia duration, mean years ± SD: **G1+G2:** 11.2 ± 9.4 Dysmenorrhea duration, mean years ± SD: **G1+G2:** 11.6 ± 8.5 Bleeding days per cycle, mean ± SD: **G1+G2:** 3.3 ± 1.8 Pain, days per cycle, mean ± SD: **G1:** 3.1 ± 1.9 **G2:** 3.1 ± 1.7	**Bleeding:** MBL measured by alkaline hematin method, mean ml (SE): All patients (n=69): **Ga:** 48.1 (4.4) **Gb:** 66.9 (4.7) **Ga vs. Gb:** p<0.001 True menorrhagia (n=30): **Ga:** 77.2 (8.7) **Gb:** 110 (5.9) **Ga vs. Gb:** p<0.001 MBL <80 ml (n=39): **Ga:** 36.9 (3.4) **Gb:** 45.8 (2.6) **Ga vs. Gb:** p<0.025 MBL <35 ml (n=14): **Ga:** 31.6 (7.9) **Gb:** 24.7 (1.4) **Ga vs. Gb:** p=NS MBL measured by alkaline hematin method, mean ml (SE): **G1a:** 55.2 (4.9) **G1b:** 69.4 (5.5) **G2a:** 63.7 (4.7) **G2b:** 39.8 (4.2) **G1a vs. G1b:** p<0.05 **G2a vs. G2b:** p<0.001 **G1a vs. G2a:** p<0.02 **G1b vs. G2b:** p<0.4 Bleeding days per cycle, mean (SE): **Ga:** 4.9 (0.14) **Gb:** 5.3 (0.14) **Ga vs. Gb:** p<0.003 **Pain:**	**Overall quality:** Fair **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: High/Low Other: **Low**

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Abdominal pain, days per cycle, mean (SE): **Ga:** 1.5 (0.13) **Gb:** 2.1 (0.15) **Ga vs. Gb:** p<0.001 Headache, days per cycle, mean (SE): **Ga:** 0.8 (0.14) **Gb:** 1.6 (0.16) **Ga vs. Gb:** p<0.001 Nausea, days per cycle, mean (SE): **Ga:** 0.6 (0.09) **Gb:** 0.7 (0.10) **Ga vs. Gb:** p=NS Diarrhea, days per cycle, mean (SE): **Ga:** 0.22 (0.06) **Gb:** 0.45 (0.09) **Ga vs. Gb:** p<0.008 Depression, days per cycle, mean ± SD: **Ga:** 0.8 (0.15) **Gb:** 1.1 (0.14) **Ga vs. Gb:** p=NS Breast symptoms, days per cycle, mean (SE): **Ga:** 0.9 (0.13) **Gb:** 1.1 (0.18) **Ga vs. Gb:** p=NS **Quality of life:** NR **Patient satisfaction:** NR	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Fertility: NR **Time to conception:** NR **Additional interventions:** NR	

Table Notes: [a] Intrauterine device (n=6), fibroids (n=2), and Von Willebrand's disease (n=1); [b] Comparison of patients' subjective assessment of menstrual blood loss (60/69 87%) provided perception data accurate enough for analysis.

AUB KQ1 Evidence Table (Reference ID #1767)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Freeman et al., 2011 **Country:** United States **Enrollment period:** December 2006 to May 2008 **Intervention setting:** 63 participating study sites **Funding:** Ferring Pharmaceuticals, Inc **Author industry relationship disclosures:** 5/6 **Study Design:** RCT **Blinding:** Patients, investigators	**Intervention:** 3.9 g/day tranexamic acid (1.3 g 3 times daily) for up to 5 consecutive days **Comparator:** 1.95 g/day tranexamic acid (0.65 g 3 times a day) for up to 5 consecutive days Placebo **Groups:** **G1:** Tranexamic acid (3.9 g) **G2:** Tranexamic acid (1.95 g) **G3:** Placebo **Followup:** 3 cycles	**Inclusion criteria:** Aged 18-49 Average MBL during two pretreatment cycles ≥80 No abnormal findings at cervical cytology screening **Exclusion criteria:** History or presence of clinically significant disease History of bilateral oophorectomy or hysterectomy Pregnant, breastfeeding or planning pregnancy during the study Women with fibroids requiring surgical management **N at enrollment:** **G1:** 118 **G2:** 117 **G3:** 69 **N at followup:** **G1:** 112 **G2:** 115 **G3:** 67 **Age, mean years (range):** **G1:** 39.2 (20-50) **G2:** 40.2 (20-49) **G3:** 38.9 (19-48)	**Bleeding:** MBL measured by alkaline hematin method, mean mL/cycle: **G1:** 169.0 **G2:** 178.0 **G3:** 153.6 Duration, mean years ± SD: **G1:** 11.9 ± 8.9 **G2:** 12.1 ± 9.4 **G3:** 10.0 ± 8.4	**Bleeding:** MBL mean reduction from baseline, mL/cycle: **G1:** 65.3 **G2:** 46.5 **G3:** 3.0 **G1 vs. BL:** p<0.0001 **G2 vs. BL:** p<0.0001 **G3 vs. BL:** p=NS **G1 vs. G3:** p<0.0001 **G2 vs. G3:** p<0.0001 MBL % reduction from baseline: **G1:** 38.6 **G2:** 26.1 **G3:** 1.9 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR	**Overall quality:** Fair **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Unclear Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		BMI: NR **Parity:** NR **Race/ethnicity, n (%):** White: **G1:** 77 (67.0) **G2:** 76 (66.1) **G3:** 43 (64.2) Black: **G1:** 34 (29.6) **G2:** 31 (27.0) **G3:** 22 (32.8) Asian: **G1:** 0 **G2:** 3 (2.6) **G3:** 0 Native American: **G1:** 1 (0.9) **G2:** 0 **G3:** 0 Pacific Islander: **G1:** 0 **G2:** 1 (0.9) **G3:** 0 Other: **G1:** 3 (2.6) **G2:** 4 (3.5) **G3:** 2 (3.0)		**Adverse Events, n (%):** At least 1 adverse event: **G1:** 97 (84.4) **G2:** 104 (90.4) **G3:** 56 (83.6) Viral upper respiratory infection: **G1:** 8 (7.0) **G2:** 12 (10.4) **G3:** 3 (4.5) Fatigue: **G1:** 4 (3.5) **G2:** 13 (11.3) **G3:** 3 (4.5) Musculoskeletal pain: **G1:** 6 (5.2) **G2:** 10 (8.7) **G3:** 2 (3.0) Arthralgia: **G1:** 5 (4.4) **G2:** 7 (6.1) **G3:** 1 (1.5) Myalgia: **G1:** 6 (5.2) **G2:** 5 (4.4) **G3:** 0 Nasal congestion: **G1:** 3 (2.6) **G2:** 8 (7.0) **G3:** 0 Sinusitis: **G1:** 3 (2.6) **G2:** 7 (6.1) **G3:** 1 (1.5) Multiple allergies: **G1:** 4 (3.5) **G2:** 6 (5.2) **G3:** 0 Throat irritation: **G1:** 0 **G2:** 7 (6.1)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				G3: 2 (3.0) Anemia: **G1:** 1 (0.9) **G2:** 6 (5.2) **G3:** 1 (1.5) Nausea: **G1:** 1 (0.9) **G2:** 1 (0.9) **G3:** 1 (1.5) Diarrhea/upper abdominal pain: **G1:** 0 **G2:** 1 (0.9) **G3:** 0 Lenticular opacity: **G1:** 1 (0.9) **G2:** 0 **G3:** 0 Blurred vision: **G1:** 1 (0.9) **G2:** 0 **G3:** 1 (1.5) Withdrawal from study for AEs not treatment related[a]: **G1:** 1 (0.9) **G2:** 3 (2.6) **G3:** 1 (1.5) Serious AE's not considered related to treatment[b]: **G1:** 1 (0.9) **G2:** 1 (0.9) **G3:** 0	

Table Notes:[a] mild myalgia (1 subject in G1); moderate anemia, moderate menorrhagia, severe anemia (1 subject each in G2) moderate headache (1 subject in G3); [b]1 subject in G1 experienced severe dyspepsia, gastritis, and chest pain and 1 subject in G2 experienced severe ovarian torsion on day 56 of study

AUB KQ1 Evidence Table (Reference ID #1114)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Grover et al., 1990 **Country:** India **Enrollment period:** January 1987 to October 1989 **Intervention setting:** Hospital **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** Patients, clinicians	**Intervention:** Mefenamic acid 500 mg 8 hourly from first day of cycle for 5 days or cessation of menses **Comparator:** Placebo tablets 3 times per day from first day of menses for 5 days **Groups:** **G1:** Mefenamic acid **G2:** Placebo **Followup:** 3 cycles	**Inclusion criteria:** Aged 19-50 years Cyclical menorrhagia defined subjectively Normal cervical cytology and secretory endometrium **Exclusion criteria:** History of drug sensitivity, thyroid, hepatic or renal disease **N at enrollment:** **G1:** 40 **G2:** 40 **N at followup:** **G1:** 40 **G2:** 40 **Age, mean years ± SD:** **G1:** 35.8 ± 7.5 **G2:** 35 ± 6.4 **BMI:** NR **Parity 2-4, %:** **G1+G2:** 80 **Race/ethnicity:** NR **Contraception,[a] laparo-scopic or post partum tubal ligation, %:** **G1:** 43 **G2:** 42	**Bleeding:** Menorrhagia duration, mean months ± SD: **G1:** 36 ± 2.5 **G2:** 32 ± 2.4 Bleeding days per cycle, mean ± SD: **G1:** 9.7 ± 3.1 **G2:** 8.8 ± 3.5 Amount of bleeding (measured subjectively by pads changed per day), mean ± SD: **G1:** 15.2 ± 3.1 **G2:** 14.7± 3.1	**Bleeding:** Relief of menorrhagia, %: **G1:** 86 **G2:** 20 **G1 vs. G2:** p<0.001 Bleeding days per cycle, mean ± SD: **G1:** 4.1 ± 0.6[c] **G2:** NR Amount of bleeding (measured subjectively by pads changed per day), mean ± SD: **G1:** 6.5 ± 0.02 **G2:** NR **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** Hysterectomy, n (%): **G1:** 2/40 (5)	**Overall quality:** Poor **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Unclear Blinding patients/personnel: Unclear Blinding outcome assessment: Unclear Incomplete outcome reporting: Unclear Other: High

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		No previous treatment, %: **G1+G2:** 73 **Previous hormonal therapy,[b] %:** **G1+G2:** 27		**G2:** NR **Adverse events:** Gastritis, n (%): **G1:** 1 (2.5) **G2:** 0	

Table Notes: [a] No study patient was using an intrauterine device or hormonal contraception; [b] Combination pills or medroxyprogesterone acetate tablets 10 mg daily; [c] Authors state this is significant reduction from before treatment.

AUB KQ1 Evidence Table (Reference ID #1190)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Hall et al., 1987 **Country:** United Kingdom **Enrollment period:** NR **Intervention setting:** Outpatient clinics **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT (crossover) **Blinding:** Patients, clinicians	**Intervention:** Naproxen loading dose 550 mg followed by 275 mg every 6 hours for 5 days **Comparator:** Mefenamic acid 500 mg every 8 hours **Groups:** **G1:** Naproxen in phase 1 and mefenamic acid in phase 2 **G2:** Mefenamic acid in phase 1 and naproxen sodium in phase 2 **Ga:** Naproxen **Gb:** Mefenamic acid **Followup:** 6 cycles	**Inclusion criteria:** • Aged 18 years through menopause Dysfunctional uterine bleeding MBL of >80ml confirmed in 2 initial control cycles **Exclusion criteria:** Pelvic inflammation Uterine fibroids Local disease Gross cyclic irregularities Taking NSAIDs, steroids Drug sensitivity Disorder requiring medical care Poor clinic attendance **N at enrollment[a]:** **G1:** 19 **G2:** 19 **N at follow-up:** **G1:** 17 **G2:** 16 **Age, mean years ± SD:** **G1:** 40.5 ± 3.6 **G2:** 38.1 ± 4.7 **BMI:** NR **Parity:** NR **Race/ethnicity:** NR	**Bleeding** MBL measured using the alkaline hematin method, median ml (range): **G1:** 118.5 (68, 186) **G2:** 129.3 (58, 369) **G1 vs. G2:** p=0.92 Bleeding days per cycle, mean ± SD: **G1:** 8.0 ± 2.8 **G2:** 6.6 ± 1.5 Hemoglobin, mean g/dl ± SD: **G1:** 13.0 ± 1.0 **G2:** 12.1 ± 1.70 **G1 vs. G2:** p=0.06 Serum iron, mean µmol/l ± SD: **G1:** 14.3 ± 5.96 **G2:** 11.8 ± 7.95 Tampons used, mean: **G1:** 31 **G2:** 32	**Bleeding** MBL measured using the alkaline hematin method (with slight modification to accommodate bulky material at phase 1), median ml (range): **G1:** 67.0 (15, 151) **G2:** 68.0 (22, 381) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.84 MBL at treatment phase 2, **G1**: 64.5 (22-135) **G2**: 67.3 (18-357) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.69 Bleeding days per cycle, mean, p value: **G1a:** 6.4 **G1b:** 5.9 **G2a:** 5.9 **G2b:** 6.0 **G1a vs. BL:** p=0.01 **G1b vs. BL:** p=0.01 **G2a vs. BL:** p=0.004 **G2b vs. BL:** p=0.03 Tampons used, mean: **G1a:** 23 **G1b:** 23 **G2a:** 25 **G2b:** 25 **G1a vs. BL:** p=0.003 **G1b vs. BL:** p=0.005 **G2a vs. BL:** p=0.003 **G2b vs. BL:** p=0.017	**Overall quality:** Fair **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: High Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		Menorrhagia duration, mean number of months ± SD: **G1:** 55.8 ± 53.0 **G2:** 45.0 ± 41.4		**Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events, n:** Any side effects: **Ga:** 18 **Gb:** 15 Gastrointestinal[b]: **Ga:** 13 **Gb:** 6 Central nervous system symptoms[c]: **Ga:** 5 **Gb:** 6 Other[d]: **Ga:** NR **Gb:** NR	

Table Notes: [a] 50 patients at baseline, 9 withdrew before treatment, 1 withdrew in first treatment phase, 5 had <80 cc mbl, so 35 analyzed; [b] Included nausea, diarrhea, abdominal discomfort and anorexia; [c] Complaints of light headedness, dizziness, tiredness and headache; [d] A small number of patients in each treatment group noted weight increase, limb pain, pelvic discomfort, and post menstrual discharge.

AUB KQ1 Evidence Table (Reference ID #789)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Irvine et al., 1998 **Country:** United Kingdom **Enrollment period:** NR **Intervention setting:** Clinic **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** None	**Intervention:** Levonorgestrel-releasing intrauterine system inserted within the first seven days of menses **Comparator:** Norethisterone, 5 mg three times daily from cycle day 5 to 26 for three cycles **Groups:** **G1:** LNG-IUS **G2:** Norethisterone **Followup:** 3 months	**Inclusion criteria:** • Aged 18 to 45 years • Parous • Good general health with a regular menstrual cycle • Normal pelvic examination with a sound measurement of the uterus of <10 cm • Negative cervical cytology • Measured menstrual blood loss >80 ml **Exclusion criteria:** Treated with steroid hormones or anticoagulants during the previous three months • Used injectable hormones for contraception during the previous 12 months **N at enrollment:** **G1:** 22 **G2:** 22 **N at followup:** **G1:** 20 **G2:** 16 **Age, median years (range):** **G1**: 38.5 (31, 45) **G2**: 39 (30, 45)	**Bleeding:** MBL measured using alkaline haematin method, median ml (range): **G1:** 105 (82, 780) **G2:** 120 (82, 336) Hemoglobin, median g/dL (range): **G1:** 12.8 (11.7, 13.8) **G2:** 13.1 (11.1, 15.5) Serum ferritin, median ng/l (range): **G1:** 19 (4, 49) **G2:** 14 (<1, 53) Reported intermenstrual bleeding, n (%): **G1:** 11/22 (50) **G2:** 8/22 (36) Mood swings, n (%): **G1:** 19/22 (86) **G2:** 20/22 (91) Breast tenderness, n (%): **G1:** 19/22 (86) **G2:** 16/22 (73) Periods interfered with daily life, n (%): **G1:** 20/22 (91) **G2:** 18/22 (82)	**Bleeding:** MBL measured using alkaline haematin method, median ml (range): Cycle 1: **G1:** 16 (0, 62) **G2:** 46 (0, 213) Cycle 3: **G1:** 6 (0, 284) **G2:** 20 (4, 137) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 MBL measured using alkaline haematin method, median reduction ml (range): Cycle 1: **G1:** 92 (63, 718) **G2:** 75 (-96, 225) Cycle 3: **G1:** 104 (-108, 73) **G2:** 94 (56, 209) **G1 vs. G2:** p=0.56 Hemoglobin/serum ferritin: **G1:** NR **G2:** NR **G1 vs. BL:** p=NS **G2 vs. BL:** p=NS Reported intermenstrual bleeding, n (%) **G1:** 10/19 (53) **G2:** 2/12 (17) Mood swings at 3 months, n (%): **G1:** 12/19 (63) **G2:** 7/12 (58)	**Overall quality:** Fair **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Unclear Blinding patients/personnel: Unclear Blinding outcome assessment: High Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		Height, median cm (range): **G1:** 158.5 (152, 170) **G2:** 159.5 (147, 178) **Weight, median kg (range):** **G1:** 69.9 (52.1, 116.0) **G2:** 71.4 (46.4, 96.6) **Parity, median (range):** **G1:** 2 (1, 5) **G2:** 2 (1, 5) **Race/ethnicity:** NR		**G1 vs. BL:** p=0.038 **G2 vs. BL:** p=0.038 **G1 vs. G2:** p=NS Breast tenderness at 3 months, n (%): **G1:** 14/19 (74) **G2:** 2/12 (17) **G1 vs. BL:** p=0.0003 **G2 vs. BL:** p=0.0003 **G1 vs. G2**: p=0.0008 Periods interfered with daily life at 3 months, n (%): **G1:** 6/19 (32) **G2:** 2/12 (17) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2**: p=NR Well or very well satisfied with treatment, n (%): **G1:** 14/22 (64) **G2:** 8/18 (44) Moderately or poorly satisfied with treatment, n (%): **G1:** 8/22 (36) **G2:** 10/18 (56) Continuation with the treatment, n (%): **G1:** 17/22 (77) **G2:** 4/18 (22) **Adverse events, n:** Withdrawal from study: **G1:** 2 **G2:** 6 Unacceptable drug related side effects:	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				G1: 1 **G2:** 2 Perceived treatment failure: **G1:** 0 **G2:** 2 Prolonged amenorrhea: **G1:** 0 **G2:** 1 LNG-IUS expulsion: **G1:** 1 **G2:** NA Default from final visit: **G1:** 0 **G2:** 1 Serious adverse events: **G1:** 0 **G2:** 0	

AUB KQ1 Evidence Table (Reference ID #1365[a])

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Jensen et al., 2011 **Country:** United States, Canada **Enrollment period:** December 2005 to May 2008 **Intervention setting:** 47 centers **Funding:** Bayer HealthCare Pharmaceuticals **Author industry relationship disclosures:** 5/5 **Study Design:** RCT **Blinding:** Patients, clinicians	**Intervention:** Estradiol valerate 3 mg on days 1–2; estradiol valerate 2 mg/dienogest 2 mg on days 3–7; estradiol valerate 2 mg/dienogest 3 mg on days 8–24; estradiol valerate 1 mg on days 25–26; placebo on days 27–28. **Comparator:** Placebo **Groups:** **G1:** Estradiol valerate/dienogest **G2:** Placebo **Followup:** 30 days	**Inclusion criteria:** • Aged 18 or older • Heavy menstrual bleeding (at least two bleeding episodes with a measured volume of ≥ 80 ml), prolonged menstrual bleeding (at least two bleeding episodes each lasting ≥ 8 days), frequent bleeding (> 5 bleeding episodes with a min of 20 bleeding days overall) or combination of any above criteria confirmed by use of electronic diaries and hemoglobin extraction from sanitary products • Women > 40 years had to have follicle-stimulating hormone level <40 miu/mL • Normal endometrial biopsy or mild simple endometrial hyperplasia 6 months before study entry • Willing to use a barrier method of contraception and to use (and collect) all sanitary protection items (pads and tampons) **Exclusion criteria:** Abnormal transvaginal	**Bleeding:** MBL measured by the alkaline hematin method, mean ml ± SD: **G1:** 518 ± 382 **G2:** 618 ± 432 Bleeding and spotting days, 90-day run-in phase, mean ± SD: **G1:** 25.1 ± 10.5 **G2:** 24.7 ± 9.7 Bleeding only days, 90-day run-in phase, mean ± SD: **G1:** 18.6 ± 7.5 **G2:** 17.9 ± 6.5 Spotting only days, 90-day run-in phase, mean ± SD: **G1:** 6.5 ± 6.0 **G2:** 6.8 ± 6.2 Bleeding episodes, 90-day run-in phase, mean ± SD: **G1:** 3.5 ± 0.8 **G2:** 3.5 ± 0.8 Sanitary protection items, 90-day run-in phase, mean ± SD: **G1:** 90 ± 42 **G2:** 96 ± 45 Hemoglobin, mean g/dl ± SD: **G1:** 12.2 ± 1.3 **G2:** 12.0 ± 1.4 Hematocrit, mean % ± SD: **G1:** 37.3 ± 3.6 **G2:** 37.0 ± 3.8	**Bleeding:** MBL measured by the alkaline hematin method, mean ml ± SD: **G1:** 196 ± 267 **G2:** 444 ± 306 MBL measured by the alkaline hematin method, mean change[e] ml ± SD: **G1:** -353 ± 309 **G2:** -130 ± 338 **G1 vs. G2:** p<0.001 Reduction in MBL volume, mean % (median %): **G1:** 64.2 (70.6) **G2:** 7.8 (18.7) **G1 vs. G2:** p<0.001 ≥20% reduction in MBL,%: **G1:** 91 **G2:** 51 ≥50% reduction in MBL,%: **G1:** 80 **G2:** 17 ≥80% reduction in MBL,%: **G1:** 45 **G2:** 5 Increase in MBL volume during treatment, %: **G1:** 5 **G2:** 20 MBL <80 ml for each episode, n (%): **G1:** 51/91 (56)	**Overall quality:** Good **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Unclear Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		ultrasonogram defined as the presence of uterine pathology, (e.g., fibroids or polyps whose size or location would be associated with heavy menstrual bleeding) Clinically significant abnormal values for any laboratory examination undergone in the 2 months before the study Endometrial ablation or dilatation and curettage Organic pathology including von Willebrand disease, chronic endometritis, adenomyosis, endometriosis, endometrial polyps, significant leiomyomas, or uterine malignancy Use of agents intended for the treatment of symptoms of abnormal uterine bleeding (e.g., tranexamic acid, nonsteroidal anti-inflammatory drugs, and sex steroids) BMI >32 kg/m^2 Smoking more than 10 cigarettes per day (in women older than 35	Ferritin, mean ng/ml ± SD: **G1:** 23.2 ± 35.1 **G2:** 21.2 ± 18.6	**G2:** 16/60 (26.7) Bleeding and spotting days, 90-day efficacy phase, mean ± SD: **G1:** 23.5 ± 13.1 **G2:** 22.9 ± 10.2 Bleeding and spotting days, mean change[e] ± SD: **G1:** -1.1 ± 14.0 **G2:** -2.3 ± 6.7 Bleeding only days, 90-day efficacy phase, mean ± SD: **G1:** 15.3 ± 9.6 **G2:** 16.0 ± 6.1 Bleeding only days, mean change[e] ± SD: **G1:** -2.8 ± 10.8 **G2:** -2.2 ± 4.6 **G1 vs. G2:** p=0.024 Spotting only days, 90-day efficacy phase, mean ± SD: **G1:** 8.2 ± 8.4 **G2:** 6.9 ± 6.7 Spotting only days, mean change[e] ± SD: **G1:** +1.7 ± 8.2 **G2:** -0.2 ± 4.9 Bleeding episodes, 90-day efficacy phase, mean ± SD: **G1:** 3.0 ± 1.2 **G2:** 3.2 ± 0.7 Bleeding episodes, mean change[e] ± SD:	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		years) Contraindications for the use of COCs **N at enrollment:** **G1:** 120 **G2:** 70 **N at followup:** **G1:** 84 **G2:** 51 **Age, mean years ± SD:** **G1:** 36.9 ± 7.5 **G2:** 37.0 ± 6.7 **BMI, mean kg/m^2 ± SD:** **G1:** 26.3 ± 3.6 **G2:** 25.8 ± 3.6 **Weight, mean kg ± SD:** **G1:** 71.3 ± 11.1 **G2:** 69.5 ± 11.8 **Parity:** NR **Race/ethnicity, n (%):** White: **G1:** 71(59.2) **G2:** 46(65.7) Black: **G1:** 38(31.7) **G2:**14(20.0) Hispanic: **G1:** 8(6.7) **G2:** 6(8.6) **Bleeding symptoms,[bc] n (%):** Prolonged bleeding:		**G1:** -0.5 ± 1.5 **G2:** -0.30 ± 0.9 **G1 vs. G2**: p=0.080 Sanitary protection items, 90-day efficacy phase, mean ± SD: **G1:** 51 ± 49 **G2:** 69 ± 29 Sanitary protection items, mean change[e] ± SD: **G1:** -44 ± 41 **G2:** -21 ± 43 **G1 vs. G2:** p<0.001 Hemoglobin, adjusted change from baseline, mean g/dl: **G1:** +0.6 **G2:** +0.1 **G1 vs. G2:** p=0.0004 Hematocrit, adjusted change from baseline, %: **G1:** +1.4 **G2:** -0.05 **G1 vs. G2:** p=0.001 Ferritin, adjusted change from baseline, mean ng/ml: **G1:** +2.9 **G2:** -0.4 **G1 vs. G2:** p=0.011 Patient reported improvement in bleeding symptoms, %: **G1:** 81.2 **G2:** 38.3 **G1 vs. G2:** p<0.001 Responder status[c] (ITT), n	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G1: 26 (21.7) **G2:** 12 (17.1) Frequent bleeding: **G1:** 4 (3.3) **G2:** 2 (2.9) Heavy bleeding: **G1:** 91 (75.8) **G2:** 60 (85.7)		(%): Complete: **G1:** 35 (29.2) **G2:** 2 (2.9) **G1 vs. G2:** p<0.001 Partial or non-responder[d]: **G1:** 45 (37.5) **G2:** 46 (65.7) Missing data: **G1:** 40 (33.3) **G2:** 22 (31.4) Complete response rate (evaluable participants excluding missing data), n (%): **G1:** 35/80 (43.8) **G2:** 2/48 (4.2) **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events:**	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Any adverse event, n (%): **G1:** 80/119 (67.2) **G2:** 36/66 (54.5) Discontinued treatment due to adverse events, n (%): **G1:** 11 (9.2) **G2:** 4 (6.1) Serious adverse event,[f] n: **G1:** 1 **G2:** 1 Adverse event, n (%): Acne: **G1:** 6 (5.0) **G2:** 0 Anemia: **G1:** 2 (1.7) **G2:** 4 (6.1) Anxiety: **G1:** 1 (0.8) **G2:** 3 (4.5) Arthralgia: **G1:** 0 **G2:** 3 (4.5) Back pain: **G1:** 3 (2.5) **G2:** 3 (4.5) Breast pain: **G1:** 5 (4.2) **G2:** 0 Breast tenderness: **G1:** 4 (3.4) **G2:** 1 (1.5) Bronchitis: **G1:** 3 (2.5) **G2:** 2 (3.0) Cervical dysplasia: **G1:** 3 (2.5) **G2:** 2 (3.0)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Chest pain: **G1:** 1 (0.8) **G2:** 2 (3.0) Depression: **G1:** 3 (2.5) **G2:** 1 (1.5) Diarrhea: **G1:** 3 (2.5) **G2:** 2 (3.0) Dizziness: **G1:** 0 **G2:** 2 (3.0) Dysmenorrhea: **G1:** 3 (2.5) **G2:** 2 (3.0) Dyspepsia: **G1:** 3 (2.5) **G2:** 0 Fatigue: **G1:** 4 (3.4) **G2:** 3 (4.5) Gastroenteritis: **G1:** 3 (2.5) **G2:** 0 Headache: **G1:** 5 (4.2) **G2:** 9 (13.6) Hypertension: **G1:** 2 (1.7) **G2:** 2 (3.0) Hypoesthesia: **G1:** 1 (0.8) **G2:** 2 (3.0) Influenza: **G1:** 3 (2.5) **G2:** 0 Insomnia: **G1:** 1 (0.8) **G2:** 2 (3.0) Metrorrhagia: **G1:** 6 (5.0)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				G2: 0 Migraine: **G1:** 3 (2.5) **G2:** 0 Nasopharyngitis: **G1:** 9 (7.6) **G2:** 6 (9.1) Nausea: **G1:** 6 (5.0) **G2:** 5 (7.6) Sinusitis: **G1:** 4 (3.4) **G2:** 1 (1.5) Tension headache: **G1:** 4 (3.4) **G2:** 0 Upper respiratory tract infection: **G1:** 4 (3.4) **G2:** 1 (1.5) Vaginal infection: **G1:** 3 (2.5) **G2:** 0 Vaginitis bacterial: **G1:** 6 (5.0) **G2:** 4 (6.1) Vomiting: **G1:** 2 (1.7) **G2:** 2 (3.0) Vulvovaginal mycotic infection: **G1:** 4 (3.4) **G2:** 3 (4.5) Weight increase: **G1:** 7 (5.9) **G2:** 0	

Table Notes: [a] See #1349 Fraser et al; same study protocol used in Australia and Europe; [b] Some participants presented with multiple symptoms; [c] Complete response to treatment defined as composite of following components: no bleeding episodes lasting more than 7 days, no more than 4 bleeding episodes overall, no bleeding episodes with blood loss volume ≥80 ml, no more than one bleeding episode increase from baseline, no more than 24 days of bleeding overall and no increase from baseline in total number of bleeding days. In addition patients recruited because of presence of prolonged bleeding were required to demonstrate a decrease of at least 2 days in maximum duration of a bleeding cycle. Patients recruited because of heavy bleeding, the blood loss volume for each episode had to <80 ml and had to represent a decrease of at least 50% from the average of the qualifying bleeding episodes (ie episodes with blood loss volume ≥ 80 mL during the run-in phase); [d] Detail on criteria not achieved in partial or non-responders presented in Table

2 of manuscript (pg. 781); [e] Change from 90-day run-in to 90-day efficacy phase* compared with change from baseline with placebo; [f] Serious treatment emergent adverse events in treatment group a myocardial infarction and in placebo group hospitalization for a suicide attempt.

AUB KQ1 Evidence Table (Reference ID #32)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality and Risk of Bias
Author: Kaunitz et al., 2010 **Country**: United States, Canada, Brazil **Enrollment period**: July 2006 to June 2008 **Intervention setting**: 55 centers **Funding**: Bayer Schering Pharma AG **Author industry relationship disclosures**: 4/6 **Study Design**: RCT **Blinding**: None	**Intervention:** Levonorgestrel-releasing intrauterine system (LNG-IUS) placed within 7 days of onset of menstruation (in case of initial placement failure, only one attempt at replacement could be made) **Comparator:** Oral medroxyprogesterone 10 mg one daily for 10 days each cycle starting on cycle day 16 **Groups:** **G1:** LNG-IUS **G2:** Medroxyprogesterone **Followup:** Cycle 3 and cycle 6; 6 months	**Inclusion criteria:** • Aged ≥18 years • Parous • Idiopathic heavy MBL (≥80 ml per cycle) confirmed in at least two screening menstrual cycles before randomization Desiring intrauterine contraception and willing to use barrier contraception if required **Exclusion criteria:** Changes in menstrual regularity, hot flushes, sleeping disorders or changes in mood within 3 months preceding study Breastfeeding Congenital or acquired uterine abnormality including fibroids if they distorted the uterine cavity or cervical canal History of organic causes of AUB (e.g., endometriosis, adenomyosis, endometrial polyps)[a] Use of LNG-IUS or copper IUD during 30 days before the study History of vascular or coagulation disorders Concomitant use of medication or presence of underlying	**Bleeding:** MBL measured using the alkaline hematin method, median ml (range): **G1:** 148.0 (68.3, 431.4) **G2:** 154.2 (63.4, 456.0) Cycle length, mean days ± SD: **G1:** 27.2 ± 3.4 **G2:** 27.3 ± 2.3	**Bleeding:** MBL measured using the alkaline hematin method at mid-study, median ml (range): **G1:** 30.3 (0, 317.5) **G2:** 136.2 (0, 404.8) MBL at end of study, median ml (range): **G1:** 7.1 (0, 1435.6) **G2:** 121.5 (0, 437.7) MBL change from baseline, mean ml (95% CI): Mid-study: **G1:** -108.3 (-125.4, -91.2) **G2:** -21.2 (-38.1, -4.3) End of study: **G1:** -114.7 (-144.2, -85.1) **G2:** -39.0 (-68.2, -9.8) MBL change from baseline, median ml (range): Mid-Study: **G1:** -115.1 (-405.8, 54.4) **G2:** -3.2 (-270.9, 146.7) **G1 vs. G2:** p<0.001 End of study: **G1:** -128.8 (-393.6, 1242.2) **G2:** -17.8 (-271.5, 78.6) **G1 vs. G2:** p<0.001	**Overall quality:** Fair **Risk of Bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: High Blinding outcome assessment: Unclear Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality and Risk of Bias
		disease/condition known to affect metabolism or pharmacokinetics of study medication BMI >35 kg/m^2 **N at enrollment:** **G1:** 82 **G2:** 83 **N at followup:** **G1:** 73 **G2:** 72 **Age, mean years ± SD:** **G1:** 38.3 ± 5.2 **G2:** 39.3 ± 5.4 **BMI, mean kg/m^2 ± SD:** **G1:** 27.2 ± 3.9 **G2:** 27.4 ± 4.6 **Parous, %:** **G1+G2:** 100 **Births, mean number (range):** **G1:** 2.5 (1, 5) **G2:** 2.6 (1, 7) **Race/ethnicity, n (%):** White: **G1:** 56 (68.3) **G2:** 62 (74.7) Black: **G1:** 17 (20.7) **G2:** 13 (15.7) Hispanic: **G1:** 6 (7.3) **G2:** 6 (7.2) Asian:		MBL % change from baseline, mean ± SD: Mid-study: **G1:** -61.7 ± 41.8 **G2:** -11.1 ± 42.5 **G1 vs. G2:** p<0.001 End of study: **G1:** -70.8 ± 88.3 **G2:** -21.5 ± 35.8 **G1 vs. G2:** p<0.001 MBL % change from baseline, median (range): Mid-study: **G1:** -83.2 (-100.0, 44.3) **G2:** -2.2 (-100.0, 231.5) End of study: **G1:** -95.4 (-100.0, 642.3) **G2:** -13.1 (-100.0, 51.1) Proportion in which treatment was successful,[b] n (%) **G1:** 67/79 (84.8) **G2:** 18/81 (22.2) **G1 vs. G2:** p<0.001 **Quality of life:** NR **Pain:** NR **Sexual function:** NR	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality and Risk of Bias
		G1: 2 (2.4) **G2:** 1 (1.2) Other: **G1:** 1 (1.2) **G2:** 1 (1.2)		**Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events:** Deaths or serious adverse events, n: **G1:** 0 **G2:** 0 Withdrawal from study, n: **G1:** 4 **G2:** 2 Expulsion of LNG-IUS,[c] n: Full: **G1:** 2 **G1:** NA Partial: **G1:** 2 **G2:** NA Drug related adverse events, n (%): **G1+G2:** 69 (42.6) Headache: **G1:** 13 (16.3) **G2:** 9 (11.0) Ovarian cyst:	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality and Risk of Bias
				G1: 10 (12.5) **G2:** 2 (2.4) Vaginitis, bacterial: **G1:** 9 (11.3) **G2:** 3 (3.7) Urinary tract infection: **G1:** 6 (7.5) **G2:** 3 (3.7) Acne: **G1:** 5 (6.3) **G2:** 5 (6.1) Hypertension: **G1:** 5 (6.3) **G2:** 1 (1.2) Sinusitis: **G1:** 5 (6.3) **G2:** 3 (3.7) Upper respiratory tract infection: **G1:** 5 (6.3) **G2:** 1 (1.2) Breast tenderness: **G1:** 4 (5.0) **G2:** 3 (3.7) Fatigue: **G1:** 4 (5.0) **G2:** 2 (2.4) Pelvic pain: **G1:** 4 (5.0) **G2:** 2 92.4) Increased weight: **G1:** 4 (5.0) **G2:** 5 (6.1) Lower abdominal pain: **G1:** 3 (3.8) **G2:** 5 (6.1)	

Table Notes: [a] Three or more subserous or intramural fibroids with a total volume of less than 5 cm^3 were acceptable; [b] Treatment success defined as MBL <80 ml at end of study and 50% or greater reduction in MBL from baseline. [c] One woman experienced heavy bleeding after expulsion of the system.

AUB KQ1 Evidence Table (Reference ID #493)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Kennedy et al., 2002 **Country:** England (UK) **Enrollment period:** October 1996 to February 1998 **Intervention setting:** 6 hospitals **Funding:** Grant from UK National Health Service **Author industry relationship disclosures:** None **Study Design:** RCT **Blinding:** None (not possible)	**Intervention:** Interview group received booklet and videotape at their home 6 weeks before consultation and had an interview immediately before consultation Information group received booklet and videotape at their home 6 weeks before consultation **Comparator:** Standard practice control group received no intervention **Groups:** **G1:** Interview plus information **G2:** Information only **G3:** Control **Followup:** 2 years (questionnaires sent at 6,12, and 24 months post consultation)	**Inclusion criteria:** • Referred from primary to secondary care with uncomplicated menorrhagia if referral related to new episode of menorrhagia • Deemed nonurgent by their consultant **Exclusion criteria:** See inclusion criteria **N at enrollment:** (Randomized) **G1:** 300 **G2:** 296 **G3:** 298 (Returned baseline questionnaire) **G1:** 298 **G2:** 293 **G3:** 294 **N at followup:** **G1:** 215 **G2:** 206 **G3:** 204 **Age, mean years ± SD:** **G1:** 41 ± 6.9 **G2:** 40 ± 7.2 **G3:** 40 ± 7.0 **Age leaving full-time education, n (%):** ≤16: **G1:** 171 (57.0) **G2:** 171 (57.8) **G3:** 172 (57.7)	Knowledge of available treatments,[a] mean ± SD: **G1:** 65 ± 23.2 **G2:** 66 ± 21.2 **G3:** 68 ± 21.0 Menorrhagia severity,[b] mean ± SD: **G1:** 48 ± 14.8 **G2:** 47 ± 13.8 **G3:** 47 ± 14.8 Treatment preference held, n (%): **G1:** 139 (47.6) **G2:** 117 (41.1) **G3:** 130 (45.6)	Clinicians perception of consultation length “longer than usual”, %: **G1:** 28.5 **G2:** 16.9 **G3:** 18.9 Health status measured by SF-36 score,[c] role physical dimension: **G1:** NR **G2:** NR **G3:** NR **G1 vs. G2:** p=NS **G1 vs. G3:** p=0.04 **G2 vs. G3:** p=NS **Bleeding:** NR **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** Self reported opportunity to take part in treatment decision making, OR (95% CI): **G1 vs. G3:** 1.49 (1.11, 2.01) **G2 vs. G3:** 1.24 (0.91, 1.69) **G1 vs. G2:** p=NS **G1 vs. G3:** p=0.008 **G2 vs. G3:** p=NS	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: High Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		17-18: **G1:** 69 (23.0) **G2:** 74 (25.0) **G3:** 73 (24.5) ≥ 19: **G1:** 50 (16.7) **G2:** 44 (14.9) **G3:** 44 (14.8) Unknown: **G1:** 10 (3.3) **G2:** 7 (2.4) **G3:** 9 (3.0) **Menorrhagia duration, n (%):** Less than 1 year: **G1:** 63 (21.2) **G2:** 73 (25.0) **G3:** 64 (21.8) 1-2 years: **G1:** 58 (19.5) **G2:** 64 (21.9) **G3:** 67 (22.9) 2-3 years: **G1:** 48 (16.2) **G2:** 40 (13.7) **G3:** 45 (15.4) More than 3 years: **G1:** 128 (43.1) **G2:** 115 (39.4) **G3:** 117 (39.9) **Previous treatment, n (%):** Hormonal drugs: **G1:** 84 (32.7) **G2:** 91 (36.1) **G3:** 99 (40.1) Non-hormonal drugs: **G1:** 96 (37.4) **G2:** 108 (42.9) **G3:** 103 (41.7)		Self reported rating of overall results of treatment, OR (95% CI): **G1 vs. G3:** 1.44 (1.03, 2.01) **G2 vs. G3**: 1.16 (0.85, 1.60) **G1 vs. G2:** p=NS **G1 vs. G3:** p=0.03 **G2 vs. G3**: p=NS **Fertility:** NR **Time to conception:** NR **Additional interventions (during 2 year followup):** Underwent at least one treatment,[d] n (%): **G1:** 212 (83.8) **G2:** 204 (78.9) **G3:** 196 (80.3) Hysterectomy, n (%): **G1:** 81 (38.2) **G2:** 98 (48.0) **G3:** 94 (48.0) OR (95% CI): **G1 vs. G3:** 0.60 (0.38, 0.96) **G2 vs. G3:** 1.16 (0.73, 1.85) **G1 vs. G2:** p=NS **G1 vs. G3:** p=0.04 **G2 vs. G3:** p=NS Endometrial destruction, n (%): **G1:** 25 (11.8) **G2:** 15 (7.4)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		Oral contraceptive pill: **G1:** 61 (23.7) **G2:** 55 (21.8) **G3:** 58 (23.5) Dilation and curettage: **G1:** 55 (21.4) **G2:** 64 (25.4) **G3:** 55 (22.3) **Ever had any surgery, n (%):** **G1:** 248 (84.9) **G2:** 236 (83.1) **G3:** 238 (83.2)	**G3:** 16 (8.2) OR (95% CI): **G1 vs. G3:** 0.88 (0.33, 2.30) **G2 vs. G3:** 0.51 (0.18, 1.42) Drug therapy, n (%): **G1:** 145 (68.4) **G2:** 138 (67.6) **G3:** 119 (60.7) OR (95% CI): **G1 vs. G3:** 1.48 (0.93, 2.36) **G2 vs. G3:** 1.40 (0.87, 2.25) Other treatment, n (%): **G1:** 43 (20.3) **G2:** 39 (19.1) **G3:** 36 (18.4) OR (95% CI): **G1 vs. G3:** 1.14 (0.68, 1.89) **G2 vs. G3:** 0.99 (0.59, 1.67) Underwent or waiting for hysterectomy, n (%): **G1:** 82 (38.7) **G2:** 101 (49.3) **G3:** 101 (51.5) OR (95% CI): **G1 vs. G3:** 0.53 (0.35, 0.83) **G2 vs. G3:** 1.03 (0.67, 1.60)	

Table Notes: [a] Scored 0-2 for knowledge of 7 treatment options, then transformed to a 0-100 scale; [b] Assessed using a menorrhagia outcome scale; [c] Adjusted mean health status scores only displayed graphically in figure 2 (pg. 2704), no other dimensions showed a significant difference between groups; [d] Women may have received more than 1 treatment.

AUB KQ1 Evidence Table (Reference ID #267)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Kriplani et al., 2006 **Country:** India **Enrollment period:** November 2002 to November 2004 **Intervention setting:** Hospital/clinic single site **Funding:** Indian Council of Medical Research **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** None	**Intervention:** Tranexamic acid 500 mg four times daily for five days starting on cycle day one **Comparator:** Medroxyprogesterone acetate 10 mg twice daily from cycle day 5 to 25 for 3 months **Groups:** **G1:** Tranexamic acid **G2:** Medroxyprogesterone **Followup:** 6 months	**Inclusion criteria:** • Menorrhagia (PBLAC score >100) **Exclusion criteria:** Fibroids, adenomyosis, endometriosis, atypia on endometrial histopathology Thyroid disease Hormone therapy in previous 3 months **N at enrollment:** **G1:** 50 **G2:** 50 **N at followup:** **G1:** 49 **G2:** 45 Duration of menorrhagia, mean months: **G1:** 26 **G2:** 24 **Age, mean years ± SD (range):** **G1:** 36.43 ± 8.25 (15, 50) **G2:** 36.67 ± 7.54 (19, 49) **Parity, mean (range)** **G1:** 3.06 ± 1.38 (0, 8) **G2:** 2.84 ± 1.26 (0, 6) **Courses completed:** 1: **G1:** 48 **G2:** 45 2:	**Bleeding:** MBL, measured by PBLAC score, mean: **G1:** 356.94 **G2:** 370.24 Duration of bleeding, mean days: **G1:** 7.08 **G2:** 8.36 Cycle length, mean days: **G1:** 26.9 **G2:** 26.6 Hemoglobin, mean g%: **G1:** 10.71 **G2:** 10.83 Endometrial thickness, mean mm: **G1:** 7.40 **G2:** 7.46	**Bleeding:** MBL, measured by PBLAC score, mean: Month one: **G1:** 149.17 **G2:** 167.93 Month two: **G1:** 138.92 **G2:** 179.51 Month three: **G1**: 141.64 **G2**: 156.67 Month six: **G1**: 239.6 **G2**: 242.6 PBLAC score, % change: Month one: **G1:** -58.2 **G2:** -54.6 Month two: **G1:** -61.0 **G2:** -51.5 Month three: **G1:** -60.3 **G2:** -57.7 Month six: **G1:** -32.0 **G2:** -35.3 PBLAC score < 100 at month three, n (%): **G1:** 19 (38.8) **G2:** 15 (33.3) Hemoglobin at month three, mean g%: **G1:** 11.2 **G2:** 11.4	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: Unclear Selective reporting: Unclear Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: High Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G1: 48 **G2:** 41 3: **G1:** 47 **G2:** 33 **Race/ethnicity:** NR		**G1 vs. BL:** p=0.003 **G2 vs. BL:** p=0.019 Lack of response to treatment, n (%): **G1:** 3 (6.1) **G2:** 13 (28.9) **G1 vs. G2:** p=0.003 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** Liked treatment well or very well, %: **G1:** 78.7 **G2:** 69.7 Elected to continue treatment, %: **G1:** 63.8 **G2:** 48.5 **Fertility:** NR **Time to conception:** NR **Additional interventions:** Hysterectomy during 6 month study period, n (%): **G1:** 2 (4)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				G2: 8 (17.8) **G1 vs. G2:** p=0.002 Hysterectomy at one year after stopping study, n: **G1:** 8/30 **G2:** 1/25	

Table Notes: No additional medication allowed during study period. Iron supplementation was given only when hemoglobin level was < 8 g%.

AUB KQ1 Evidence Table (Reference ID #189)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Kucuk et al., 2008 **Country:** Turkey **Enrollment period:** August 2005 to May 2006 **Intervention setting:** Single center **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** None	**Intervention:** LNG-IUS(Mirena) on cycle day 2 or 3 **Comparators:** Single shot of depot medroxyprogesterone acetate on first day of cycle Medroxyprogesterone acetate 5 mg tablet every day starting on first day of cycle **Groups:** **G1:** LNG-IUS **G2:** Depot medroxy-progesterone **G3:** Medroxyproges-terone **Followup:** 6 months	**Inclusion criteria:** • Menorrhagia[a] Perimenopausal[b] Smoker **Exclusion criteria:** Organic pathology Occasional smokers Irregular bleeding but non-menorrhagic **N at enrollment:** **G1:** 44 **G2:** 44 **G3:** 44 **N at followup:** **G1:** 44 **G2:** 44 **G3:** 44 **Age, mean years ± SD:** **G1:** 42.8 ± 1.1 **G2:** 43.1 ± 1.6 **G3:** 42.6 ± 1.9 **BMI, mean kg/m^2 ± SD:** **G1:** 29.1 ± 3.3 **G2:** 27.1 ± 4.4 **G3:** 26.4 ± 3.9 **Parity, mean ± SD:** **G1:** 1.9 ± 0.3 **G2:** 1.8 ± 0.4 **G3:** 1.9 ± 0.6 **Smoker, %:** **G1:** 100 **G2:** 100 **G3**: 100	**Bleeding:** MBL, measured by modified PBLAC score, mean ± SD: **G1:** 287 ± 57 **G2:** 284 ± 50 **G3:** 230 ± 36 Menstruation duration, mean days ± SD: **G1:** 9 ± 2 **G2:** 9 ± 2 **G3:** 9 ± 1 Hemoglobin, mean g/dl ± SD: **G1**: 10.1 ± 0.4 **G2**: 9.7 ± 0.4 **G3**: 10.2 ± 0.7	**Bleeding:** MBL at 6 months, measured by modified PBLAC score, mean ± SD: **G1:** 77 ± 41 **G2:** 146 ± 21 **G3:** 154 ± 30 **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G3 vs. BL:** p<0.001 **G1 vs. G2:** p<0.01 **G1 vs. G3:** p<0.01 **G2 vs. G3:** p=NS Treatment success, n (%): **G1:** 38 (86) **G2:** 33 (75) **G3:** 30 (68) Menstruation duration, mean days ± SD: **G1:** 5 ± 2 **G2:** 7 ± 1 **G3:** 5 ± 1 **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G3 vs. BL:** p<0.001 **G1 vs. G2:** p=NS **G1 vs. G3:** p=NS **G2 vs. G3:** p=NS Hemoglobin, mean g/dl ± SD, p-value: **G1:** 10.9 ± 0.4 **G2:** 10.2 ± 0.4 **G3:** 10.8 ± 0.7 **G1 vs. BL:** p<0.01 **G2 vs. BL:** p<0.01	**Overall quality:** Poor **Risk of bias:** Randomization: High Allocation concealment: High Selective reporting: Unclear Blinding patients/personnel: Unclear Blinding outcome assessment: Unclear Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		Race/ethnicity: NR		**G3 vs. BL:** p<0.01 **G1 vs. G2:** p<0.05 **G1 vs. G3:** p<0.05 **G2 vs. G3:** p=NS **Quality of life:** NR **Pain** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events, n (%):** Irregular bleeding: **G1:** 6 (13.6) **G2:** 9 (20.4) **G3:** 12 (27.2) Breast tenderness: **G1:** 6 (13.6) **G2:** 9 (20.4) **G3:** 12 (27.2) Willing to continue treatment: **G1:** 38 (86.3) **G2:** 25 (56.8) **G3:** 19 (43.1)	

Table Notes: [a] Diagnosis established after following diagnostic workup: hemogram, modified PBLAC, prothrombin time, activated prothrombin time, ALT, AST, hormonal profile including FSH, LH, estradiol, prolactin, B-HCG, sTSH, T3 T1, Pap smear, endometrial biopsy, transvaginal sonography and saline infusion sonography, and diagnostic office hysteroscopy when needed; [b] Women over age 40; [c] PBLAC score >185 considered unresponsive; PBLAC score <185 considered response.

AUB KQ1 Evidence Table (Reference ID #802)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Lahteenmaki et al., 1998 **Country:** Finland **Enrollment period:** November 1991 to December 1993 **Intervention setting:** 3 clinics **Funding:** Leiras Oy, Turku, Finland **Author industry relationship disclosures:** None **Study Design:** RCT **Blinding:** None	**Intervention:** Levonorgestrel-releasing intrauterine system inserted according to instructions **Comparator:** Existing medical treatment **Groups:** **G1:** LNG-IUS **G2:** Control (current medical treatment) **Followup:** **G1:** 12 months **G2:** 6 months	**Inclusion criteria:** • Women with spontaneous cycles scheduled to undergo hysterectomy for treatment of excessive uterine bleeding with or without dysmenorrhea **Exclusion criteria:** One fibroid >3 cm in diameter or more than 3 uterine fibroids as assessed by ultrasonography History or current malignancy or active liver disease Adnexal tumors or cysts Pelvic Inflammatory Disease within the previous 12 months **N at enrollment:** **G1:** 28 **G2:** 28 **N at followup:** **G1:** 27 **G2:** 26[a] **Age, mean years ± SD:** **G1:** 42.7 ± 3.4 **G2:** 41.7 ± 4.5 **BMI:** NR **Parity:** NR	**Menstrual disturbance:** General well being VAS, median (95% CI): **G1:** 90 (74, 94) **G2:** 87 (77, 92) **G1 vs. G2:** p=NS Work performance VAS, median (95% CI): **G1:** 79 (62, 89) **G2:** 75 (61, 80) **G1 vs. G2:** p=NS Physical activity VAS, median (95% CI): **G1:** 88 (64, 95) **G2:** 78 (64, 92) **G1 vs. G2:** p=NS Sex life VAS, median (95% CI): **G1:** 68 (49, 86) **G2:** 66 (52, 80) **G1 vs. G2:** p=NS Leisure time activity VAS, median (95% CI): **G1:** 76 (54, 86) **G2:** 74 (64, 85) **G1 vs. G2:** p=NS	**Bleeding:** Bleeding, median days per month:[b] Months 1 to 3: **G1:** NR **G2:** NR **G1 vs. G2:** p=NS Months 4 to 6: **G1:** NR **G2:** NR **G1 vs. G2:** p=NS Spotting, median days per month:[b] Months 1 to 3: **G1:** NR **G2:** NR **G1 vs. G2:** p=0.001 Months 4 to 6: **G1:** NR **G2:** NR **G1 vs. G2:** p=0.016 **Menstrual disturbance:** General well being VAS, median (95% CI): 6 months: **G1:** 24 (14, 40) **G2:** 79 (64, 87) **G1 vs. G2:** p<0.001 12 months: **G1:** 10 (4, 29) **G2:** NR Work performance VAS, median (95% CI): 6 months: **G1:** 20 (5, 35) **G2:** 76 (54, 87) **G1 vs. G2:** p<0.001	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Unclear Blinding patients/personnel: Unclear Blinding outcome assessment: High Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		Race/ethnicity: NR		12 months: **G1:** 6 (3, 11) **G2:** NR Physical activity VAS, median (95% CI): 6 months: **G1:** 27 (9, 38) **G2:** 78 (55, 88) **G1 vs. G2:** p<0.001 12 months: **G1:** 10 (3, 28) **G2:** NR Sex life VAS, median (95% CI): 6 months: **G1:** 36 (17, 49) **G2:** 66 (51, 85) **G1 vs. G2:** p=0.002 12 months: **G1:** 8 (3, 28) **G2:** NR Leisure time activity VAS, median (95% CI): 6 months: **G1:** 11 (5, 27) **G2:** 74 (54, 86) **G1 vs. G2:** p<0.001 12 months: **G1:** 6 (3, 29) **G2:** NR **Additional interventions:** Cancelled hysterectomy at 6 months, % (95% CI): **G1:** 64.3 (44.1, 81.4) **G2:** 14.3 (4.0, 32.7) **G1 vs. G2:** p<0.001	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Underwent hysterectomy at 12 months, n (%): **G1:** 12 (57) **G2:** NR Switched to LNG-IUS at 6 months, n: **G1:** NA **G2:** 2/26 Continued with LNG-IUS at average followup of 3 years, n (%): **G1:** 13 (48) **G2:** NR **Adverse events, n:** Serious adverse events: **G1+G2:** 0	

Table Notes: [a] At 6 months, two women in G2 switched to LNG-IUS; [b] Values only displayed graphically in Figures 1 and 3 (pg. 1124).

AUB KQ1 Evidence Table (Reference ID #29)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Lukes et al., 2010 **Country:** United States **Enrollment period:** October 2006 to May 2008 **Intervention setting:** Outpatient clinic at 40 sites **Funding:** Xanodyne Pharmaceuticals and Ferring Pharmaceuticals **Author industry relationship disclosures:** 11/12 **Study Design:** RCT **Blinding:** Patients, investigators	**Intervention:** Tranexamic acid 1.3 g per dose (two 650 mg tablets) to start at onset of heavy bleeding, 3 times daily at least 6 hours apart for up to 5 days per cycle over 6 menstrual cycles (maximum dose 3.9 g) **Comparator:** Placebo **Groups:** **G1:** Tranexamic acid **G2:** Placebo **Followup:** 6 cycles	**Inclusion criteria:** • Aged 18 to 49 years • History of three or more consecutive days of heavy bleeding over at least 4 of last 6 menstrual periods During two-cycle pretreatment baseline phase, menstrual blood loss had to be at least 60 ml during first period and average at least 80 ml over both cycles Normal findings on pelvic exam No clinically important cervical cytology abnormalities or uterine pathologic findings by transvaginal ultrasonography[a] History of regularly occurring menstrual periods of no more than 10 days duration and cycle length of 21 to 35 days Normal color vision **Exclusion criteria:**[b] History or presence of significant medical problems (e.g., thromboembolic disease, coagulopathy, subarachnoid hemorrhage, endocrinopathy, or ocular disease	**Bleeding:** Duration of heavy menstrual bleeding, mean years ± SD: **G1:** 9.9 ± 9.3 **G2:** 10.1 ± 8.6 Uterine leiomyomas present at baseline, n (%): **G1:** 42 (36.5) **G2:** 26 (36.1) MBL measured by the alkaline hematin method,[c] mean ml ± SD: **G1:** 172.3 ± 95.6 **G2:** 153.0 ± 66.6 **G1 vs. G2:** p=0.11 Anemia, n (%): **G1:** 39/115 (33.9) **G2:** 13/72 (18.1)	**Bleeding:** MBL measured by the alkaline hematin method[c] reduction, mean ml (%): **G1:** 69.6 (40.4) **G2:** 12.6 (8.2) **G1 vs. G2:** p<0.001 MBL reduction ≥50 ml, % of cycles: **G1:** 56 **G2:** 19 **G1 vs G2:** p<0.001 MBL reduction ≥36 ml, % of cycles: **G1:** 69 **G2:** 29 **G1 vs. G2:** p<0.001 MBL <80 ml, cycles (%): **G1**: 181/426 (43) **G2**: 43/254 (17) **G1 vs. G2:** p<0.001 Women with ≥50% reduction in MBL from baseline, %: **G1:** 35 **G2:** 7 **G1 vs G2:** p<0.001 Hemoglobin level change from baseline, mean g/dl ± SD: **G1:** 0.02 ± 1.10 **G2:** 0.34 ± 0.66 **G1 vs. BL:** p=NS **G2 vs. BL:** p<0.001	**Overall quality:** Good **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		Severe anemia (hemoglobin < 8 g/dL) Pregnant or lactating History or presence of endometrial abnormalities or cervical carcinoma Anovulatory dysfunctional uterine bleeding, metrorrhagia, menometrorrhagia, or polymenorrhea Glaucoma, ocular hypertension, macular degeneration or retinopathies **N at enrollment:** **G1:** 123 **G2:** 73 **N at followup ITT:** **G1:** 115 **G2:** 72 **N completed study:** **G1:** 94 **G2:** 54 **Age, mean years ± SD:** **G1:** 38.7 ± 6.4 **G2:** 38.7 ± 6.8 **Race, n (%):** White: **G1:** 86 (73.5) **G2:** 51 (70.8) African American: **G1:** 23 (19.6) **G2:** 18 (25.0) Asian: **G1:** 1 (0.9)		Ferritin concentration change from baseline, mean ng/ml ± SD: **G1:** -1.21 ± 12.70 **G2:** -2.68 ± 16.15 **G1 vs. BL:** p=NS **G2 vs. BL:** p=NS Treatment compliance, % tablets taken: **G1**+**G2:** 96.3 (n=188) Treatment days per cycle, mean: **G1:** 3.4 **G2:** 3.3 **Quality of life:** MIQ limitation score, changes in least-squares mean from baseline ± SD: Social or leisure activities: **G1:** 0.85 ± 0.13 **G2:** 0.44 ± 0.12 **G1 vs. G2:** p<0.001 Physical activity: **G1:** 0.87 ± 0.13 **G2:** 0.40 ± 0.14 **G1 vs. G2:** p< 0.001 **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G2: 1 91.4) Other: **G1:** 7 (6.0) **G2:** 2 (2.8) **Years of alcohol use, n (%):** Less than 1: **G1:** 1 (1.9) **G2:** 1 (2.9) 1-5: **G1:** 9 (17.0) **G2:** 7 (20.0) More than 5: **G1:** 43 (81.1) **G2:** 27 (77.1) **Years of tobacco use, n (%):** Less than 1: **G1:** 1 (2.4) **G2:** 1 (3.7) 1-5: **G1:** 9 (22.0) **G2:** 5 (18.5) More than 5: **G1:** 31 (75.6) **G2:** 21 (77.8)		**Time to conception:** NR **Additional interventions:** NR **Adverse events:** Serious adverse events (all judged unrelated to study treatment), n: **G1:** 5 **G2:** 1 Ocular-related adverse events judged possibly or probably study related, n: **G1:** 2 **G2:** 5 Frequently reported[f] treatment emergent adverse events, n (%): Menstrual discomfort/cramps **G1:** 72 (61.5) **G2:** 36 (50.0) Headache: **G1:** 65 (55.6) **G2:** 36 (50.0) Back pain: **G1:** 28 (23.9) **G2:** 14 (19.4) Nausea: **G1:** 17 (14.5) **G2:** 11 (15.3) Anemia: **G1:** 12 (10.3) **G2:** 4 (5.6) Arthralgia:	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				G1: 11 (9.4) **G2:** 5 (6.9) Viral upper respiratory tract infection: **G1:** 9 (7.7) **G2:** 7 (9.7) Multiple allergies **G1:** 10 (8.5) **G2:** 5 (6.9) Abdominal discomfort: **G1:** 8 (6.8) **G2:** 6 (8.3) Cough: **G1:** 7 (6.0) **G2:** 5 (6.9) Insomnia: **G1:** 6 (5.1) **G2:** 6 (8.3) Fatigue: **G1:** 8 (6.8) **G2:** 3 (4.2) Muscle cramps: **G1:** 8 (6.8) **G2:** 3 (4.2) Dyspepsia: **G1:** 3 (2.6) **G2:** 8 (11.1) Migraine: **G1:** 7 (6.0) **G2:** 4 (5.6) Sinus headache: **G1:** 9 (7.7) **G2:** 2 (2.8)	

Table Notes: [a] Transvaginal ultrasonogram considered abnormal if endometrial thickness was > 12 mm or if the endometrial thickness was 5 to 12 mm and patient's clinical history suggested long-term unopposed estrogen exposure (≥ 1 year). If transvaginal ultrasonogram was considered abnormal, normal results on endometrial biopsy were required. Presence of leiomyomas was not considered an abnormal finding unless they were of sufficient number and size to warrant surgical management; [b] Participants were not allowed to use anticoagulants, aspirin, dong quai, aminocaproic acid, hydroxychloroquine during the study. Cyclooxygenase-2 inhibitors and NSAIDs were not allowed during menstrual periods, but were permitted during intermenstrual phase of the cycle. Use of acetaminophen, analgesic opioids, oral iron therapy, and vitamins were permitted throughout the study. Oral iron therapy prescribed at investigator's discretion for women with hemoglobin levels between 11 g/dL-12 g/dL at baseline. It was required for women with baseline hemoglobin < 11 g/dL and for women whose hemoglobin declined to < 11 g/dL during the study; [c] Prespecified three component primary efficacy endpoint for mean reduction in

MBL: 1) significantly greater than placebo group; 2) greater than 50 mL from baseline; and 3) greater reduction in MBL previously established to be perceived as meaningful (36 mL or higher); [d] 1 each of: tachycardia, acute bronchitis, hypoglycemia, posttraumatic stress disorder, and urticaria; [e] Deep vein thrombosis; [f] Events that occurred in more than 10 participants irrespective of causality.

AUB KQ1 Evidence Table (Reference ID #1381)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Najam et al., 2010 **Country:** India **Enrollment period:** October 2008 to September 2009 **Intervention setting:** Teaching hospital **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** Single blinded	**Intervention:** Tranexamic acid 500 mg thrice daily, from cycle day 1 to cycle day 5 **Comparator:** Combination tranexamic acid 500 mg and mefenamic acid 250 mg thrice daily from cycle day 1 to cycle day 5 for 3 cycles **Groups:** **G1:** Tranexamic acid **G2:** Tranexamic acid plus mefenamic acid **Followup:** 6 months	**Inclusion criteria:** Aged 12 to 45 years Endometrial thickness less than 5 mm using transvaginal sonography evaluation on cycle day 4, 5, or 6 for married women Normal Pap test, thyroid function test, renal function tests, liver function tests, coagulation profile Endometrium sampling for the secretory phase, only in cases of the perimenopausal age group **Exclusion criteria:** History of recent intrauterine device or hormonal therapy Anovulatory or irregular cycles Pregnancy, pelvic pathology, coagulation disturbances, polycystic ovarian disease Thyroid, liver or renal dysfunction **N at enrollment:** **G1**: 55 **G2:** 55 **N at followup:** **G1:** 55 **G2:** 55 **Age, mean years (range):** **G1:** 37 (13, 49) **G2:** 39 (12, 47) **BMI, mean kg/m^2:**	**Bleeding:** MBL measured by PBLAC,[a] score, mean (range): **G1:** 250 (221, 267) **G2:** 246 (213, 254) Hemoglobin, mean g/dl (range): **G1:** 9.5 (7.2, 11.8) **G2:** 8.6 (6.5, 10.2) No anemia (hemoglobin >11 gm %), n (%): **G1:** 2 (1.8) **G2:** 4 (3.6) Mild anemia (hemoglobin 10-11 gm %), n (%): **G1:** 13 (23.6) **G2:** 17 (30.9) Moderate anemia (hemoglobin 7-9.9 gm %), n (%): **G1:** 33 (60) **G2:** 27 (49) Severe anemia (hemoglobin 4-6.9 gm %), n (%): **G1:** 8 (7.2) **G2:** 6 (5.4)	**Bleeding:** MBL measured by PBLAC[a] score, mean: 1 month: **G1:** 185 **G2:** 155 6 months: **G1:** 125, p> 0.05 **G2:** 100, p< 0.01 **G1 vs. BL:** p=NS **G2 vs. BL:** p<0.01 Hemoglobin, mean g/dl: 1 month: **G1:** 10.2 **G2:** 10.6 **G1 vs. BL:** p=NS **G2 vs. BL:** p=0.04 3 months: **G1:** 11.4 **G2:** 11.8, **G1 vs. BL:** p=NS **G2 vs. BL:** p=0.02 6 months: **G1:** 12.0 **G2:** 12.3 **G1 vs. BL:** p=0.04 **G2 vs. BL:** p=0.016 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: Unclear Selective reporting: Unclear Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G1: 22 **G2:** 21 **Parity:** NR **Race/ethnicity:** NR Menorrhagia, n (%): **G1+G2:** 75 (68) Polymenorrhagia, n (%): **G1+G2:** 28 (25.4) Metrorrhagia, n (%): **G1+G2:** 7 (6.3) Symptom duration, median months (range): **G1:** 10.5 (4.5, 16) **G2:** 11.7 (3.6, 13.6)		**Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events, n (%):** Nausea and gastrointestinal disturbances: **G1:** 9 (16.4) **G2:** 8 (14.5) Leg cramps: **G1:** 7 (12.7) **G2:** 12 (21.8)	

Table Notes: [a] PBAC score of ≥100 indicates diagnosis of menorrhagia and signifies that MBL is more than 80 ml.

AUB KQ1 Evidence Table (Reference ID #935)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Preston et al., 1995 **Country:** United Kingdom **Enrollment period:** NR **Intervention setting:** Hospitals and clinics **Funding:** Pharmacia **Author industry relationship disclosures:** NR **Study Design:** RCT, double blind, placebo controlled **Blinding:** Patients, clinicians	**Intervention:** Tranexamic acid 1 gm, 4 times a day on days 1 to 4 and placebo on days 19 to 26 **Comparator:** Placebo on days 1 to 4 and norethisterone 5 mg twice per day on days 19 to 26 Cycle 1: Placebo Cycle 2: Placebo Cycle 3: Treatment Cycle 4: Treatment **Groups:** **G1:** Tranexamic acid **G2:** Norethisterone **Followup:** 4 months	**Inclusion criteria:** • Aged 18 or older • Cycle length 28 ± 7 days • No hormone therapy within previous 3 months • Not taking medication which might affect MBL • No contraindication to either drug • Normal renal function (serum creatinine <125 µmol/l) • Normal pelvic examination • Negative cervical cytology • Menorrhagia (average MBL over 2 cycles >80 ml per cycle) Regular cycle **Exclusion criteria:** See inclusion criteria **N at enrollment:** **G1:** 25 **G2:** 21 **N at followup:** **G1:** 25 **G2:** 21 **Age, mean years ± SD:** **G1:** 40.6 ± 4.7 **G2:** 39.3 ± 7.1 **BMI:**	**Bleeding:** MBL measured using the alkaline hematin method at cycles 1 and 2 combined,[a] mean ml ± SD: **G1:** 175 ± 84 **G2:** 173 ± 85 Hemoglobin,[b] mean g/dl ± SD: **G1:** 12.3 ± 1.2 **G2:** 12.0 ± 1.4 Serum ferritin,[b] mean µg/l ± SD: **G1:** 11.2 ± 11.4 **G2:** 8.9 ± 7.2 Transferrin,[b] mean g/dl ± SD: **G1:** 3.68 ± 0.42 **G2:** 3.64 ± 0.56	**Bleeding:** MBL measured using the alkaline hematin method at cycles 3 and 4 combined,[c] mean ml ± SD: **G1:** 97 ± 89 **G2:** 208 ± 135 **G1 vs. BL:** p<0.0001 **G2 vs. BL:** p=0.26 **G1 vs. G2:** p<0.0001 MBL estimated reduction from baseline, ml (95% CI): **G1:** 79 (62, 108) **G2:** -34 (-64, 2) **G1 vs. G2:** 113 (71, 155) MBL % change from baseline, mean (range): **G1:** -45 (-93, 23) **G2:** 20 (-62, 114) MBL < 80 ml per cycle, n: **G1:** 14/25 **G2:** 2/21 Hemoglobin, mean g/dl ± SD: **G1:** 12.9 ± 0.9 **G2:** 12.6 ± 1.6 Serum ferritin, mean µg/l ± SD: **G1:** 11.5 ± 6.0 **G2:** 10.3 ± 6.8	**Overall quality:** Fair **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Unclear Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: High Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		NR **Weight, mean kg ± SD:** **G1:** 71.2 ± 14.9 **G2:** 63.5 ± 9.2 **G1 vs. G2:** p<0.048 **Parity, n (%):** 0: **G1:** 1 (4) **G2:** 1 (5) 1: **G1:** 2 (8) **G2:** 3 (14) 2: **G1:** 13 (52) **G2:** 10 (48) 3: **G1:** 9 (36) **G2:** 6 (29) 4: **G1:** 0 **G2:** 1 (5) **Race/ethnicity:** NR		Transferrin, mean g/dl ± SD: **G1:** 3.34 ± 0.34 **G2:** 4.74 ± 0.53 **Quality of life:** General health, n (%): Better: **G1:** 12 (50) **G2:** 6 (30) Same/worse: **G1:** 12 (50) **G2:** 14 (70) Amount of flooding and leakage, n (%): Better: **G1:** 20 (83) **G2:** 9 (45) Same/worse: **G1:** 4 (17) **G2:** 11 (55) **G1 vs. G2:** p=0.008 Limitation of social activities, n (%): Better: **G1:** 16 (67) **G2:** 9 (45) Same/worse: **G1:** 8 (33) **G2:** 11 (55) **Pain:** Abdominal pain, n (%): Better: **G1:** 9 (38) **G2:** 4 (20) Same/worse: **G1:** 15 (62) **G2:** 16 (80)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Sexual function, n (%): Better: **G1:** 11 (46) **G2:** 3 (15) Same/worse: **G1:** 13 (54) **G2:** 17 (85) **G1 vs. G2:** p=0.029 **Patient satisfaction:** Assessment of blood loss during treatment compared to placebo cycle, n (%): Better: **G1:** NR **G2:** NR Same/worse: **G1:** NR **G2:** NR **G1 vs. G2:** p=0.002[d] **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events:** Dysmenorrhea, %: **G1:** 80 **G2:** 85 Headache, %: **G1:** 32 **G2:** 48 Gastrointestinal	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				symptoms including diarrhea, nausea, vomiting, and dyspepsia, %: **G1:** 12 **G2:** 33 Weight gain, n: **G1:** 2 **G2:** 0	

Table Notes: [a] Data also given for cycles 1 and 2 separately; [b] Laboratory values are from the pre-placebo phase; [c] Data also given for cycles 3 and 4 separately; [d] Patients treated with tranexamic acid were significantly better than those treated with norethisterone.

AUB KQ1 Evidence Table (Reference ID #1441)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Protheroe et al., 2007 **Country:** United Kingdom **Enrollment period:** July 2003 to January 2005 **Intervention setting:** 19 general practices **Funding:** Grant from Medical Research Council **Author industry relationship disclosures:** None **Study Design:** RCT **Blinding:** NR	**Intervention:** Self-directed, interactive computerized decision aid (Clinical Guidance Tree) and patient information leaflet Treatment options included watchful waiting, nonhormonal drug treatments (mefenamic acid, tranexamic acid, NSAIDS and ethamsylate), hormonal medications (COC and progestogens), LNG-IUS (Mirena) and surgical options (transcervical endometrial resection, abdominal or vaginal hysterectomy) **Comparator:** Control: Patient information leaflet alone **Groups:** **G1**: Decision aid **G2**: Control **Followup:** 6 months	**Inclusion criteria:** • Aged 30-55 years • Menorrhagia and consulted their general practitioner in the previous week **Exclusion criteria:** • Heavy menstrual bleeding caused by physical pathology such as confirmed or provisional diagnosis of cancer, endometriosis, fibroids, polyps and cysts • Inability to understand English • Considered unsuitable by their general practitioner (including terminal illness, mental health problems) **N at enrollment:** **G1:** 74 **G2:** 72 **N at followup (%):** **G1:** 60 (81) **G2:** 56 (78) **Age years, mean ± SD:** **G1:** 41 ± 5.2 **G2:** 41 ± 5.4 **BMI:** NR **Parity:** NR **Race/ethnicity:** NR	Decisional Conflict Scale total score,[b] mean ± SD: **G1:** 51 ± 20.6 **G2:** 50 ± 19.4 Spielberger State-Trait Anxiety Inventory score,[c] mean ± SD: **G1:** 12.7 ± 4.2 **G2:** 13.4 ± 4.2 Menorrhagic Specific Utility Scale score,[b] mean ± SD: **G1:** 36.2 ± 19.6 **G2:** 39.9 ± 21.8 Knowledge (% of correct answers), mean ± SD: **G1:** 36.7 ± 18.8 **G2:** 36.5 ± 21.0 Baseline treatment preference, n (%): Had a treatment preference at baseline: **G1:** 47 (63) **G2:** 45 (62) Tablets: **G1:** 20 (27) **G2:** 22 (30.5) Surgery: **G1:** 22 (30) **G2:** 18 (25) Hormone intrauterine device: **G1:** 5 (6.5) **G2:** 5 (7) Unsure: **G1:** 27 (36.5)	Decisional Conflict Scale total score[b] at 2 weeks, mean ± SD: **G1:** 23.4 ± 14.3 (n=69) **G2:** 40.5 ± 18.3 (n=69) **G1 vs. G2:** p<0.001 Decisional Conflict Scale total score[b] at 2 weeks, adjusted difference (95% CI): **G1 vs. G2:** -16.6 (-21.5, -11.7) Spielberger State-Trait Anxiety Inventory score,[c] mean ± SD: 2 weeks: **G1:** 11.6 ± 3.7 (n=59) **G2:** 12.2 ± 3.7 (n=61) **G1 vs. G2:** p=0.16 6 months: **G1:** 11.2 ± 4.2 (n=47) **G2:** 13.3 ± 4.9 (n=52) **G1 vs. G2:** p=0.067 Spielberger State-Trait Anxiety Inventory score,[c] adjusted difference (95% CI): 2 weeks: **G1 vs. G2:** -1.0 (-2.4, 0.4) 6 months: **G1 vs. G2:** -1.8 (-3.7, 0.1) Menorrhagic Specific Utility Scale score, mean ± SD: **G1:** 59.3 ± 30.0 (n=60) **G2:** 50.9 ± 25.1 (n=56)	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Unclear Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: Low Other: Unclear

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
			G2: 27 (37.5)	**G1 vs. G2:** p=0.033	
		Achieved higher education, n (%): **G1:** 17 (23) **G2:** 15 (21)		Menorrhagic Specific Utility Scale score, adjusted difference (95% CI): **G1 vs. G2:** 10.9 (0.9, 21.0)	
				Knowledge (% of correct answers), mean ± SD: **G1:** 59.7 ± 18.4 (n=54) **G2:** 48.8 ± 19.6 (n=54) **G1 vs. G2:** p=0.014	
				Knowledge (% of correct answers), adjusted difference (95% CI): **G1 vs. G2:** 9.3 (1.9, 16.6)	
				Bleeding: NR	
				Quality of life: NR	
				Pain: NR	
				Sexual function: NR	
				Patient satisfaction: NR	
				Fertility: NR	
				Time to conception: NR	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Additional interventions,[a] n (%): Treatment at 6 months: **G1:** 40 (71) **G2:** 45 (80) **G1 vs. G2:** p=0.268 Treatment preference at two weeks: **G1:** 49 (88) **G2:** 38 (68) **G1 vs. G2:** p=0.011 Post intervention preference matches treatment received: **G1:** 23 (58) n=40 **G2:** 20 (44) n=45 **G1 vs. G2:** p=0.198 Hospital appointment: **G1:** 19 (34) **G2:** 21 (38) **G1 vs. G2:** p=0.659 Surgical treatment: **G1:** 7 (13) **G2:** 3 (5) **G1 vs. G2:** p=0.139 Mirena: **G1:** 13 (23) **G2:** 15 (27) **G1 vs. G2:** p=0.625 Medical treatment: **G1:** 20 (36) **G2:** 27 (48) **G1 vs. G2:** p=0.198	

Table Notes: [a] For G1 and G2 total n=56 in each group unless otherwise noted; [b] Scale 0-100; [c] Scale 6-24, where higher score indicates higher anxiety.

AUB KQ1 Evidence Table (Reference ID #341)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Reid and Virtanen-Kari, 2005 **Country:** United Kingdom **Enrollment period:** May 1996 to December 1998 **Intervention setting:** District general hospital **Funding:** Schering Oy **Author industry relationship disclosures:** 2/2 **Study Design:** RCT **Blinding:** None	**Intervention:** LNG-IUS, 52 mg levonorgestrel in cylinder initial release rate 20 µg per 24 hours **Comparator:** Oral mefenamic acid, 500 mg three times daily for first 4 days of cycle **Groups:** **G1:** LNG-IUS **G2:** Mefenamic acid **Followup:** 6 cycles	**Inclusion criteria:** • Aged 18 to 47 years Good general health with regular, ovulatory menstrual cycles of 21 to 35 days Idiopathic menorrhagia (MBL ≥80 mL) confirmed in one cycle within 4 month period preceding study **Exclusion criteria:** Undiagnosed abnormal bleeding Anovulatory Submucous fibroids or fibroids with total volume of >5 cm^3 defined by ultrasound scan Uterine size of >10 cm Abnormal cervical cytology Untreated hypertension Abnormal thyroid or liver function tests Asthma Intrauterine device Treated for menorrhagia or used hormonal contraceptives within previous 4 months **N at enrollment:** **G1:** 25 **G2:** 26 **N at followup (cycle 6):** **G1:** 21 **G2:** 21 **Age, mean years:** **G1:** 39.4	**Bleeding:** MBL, measured by modified alkaline hematin technique, median ml (range): **G1:** 122 (81, 375) **G2:** 121 (85, 389) Total menstrual fluid loss,[a] median mL (range): **G1:** 183 (103-527) **G2:** 211 (91-491) PBAC score, median (range): **G1:** 240 (91-545) **G2:** 233 (77-469)	**Bleeding:** MBL, measured by modified alkaline hematin technique, median ml (range): Cycle 3: **G1:** 12 (0, 240) **G2:** 94 (29, 219) **G1 vs. G2:** p<0.001 Cycle 6: **G1:** 5 (0, 45) **G2:** 100 (46, 168) **G1 vs. G2:** p< 0.001 Total menstrual fluid loss, median mL (range): Cycle 3: **G1:** 53 (0, 459) **G2:** 151 (57, 280) **G1 vs. G2:** p<0.001 Cycle 6: **G1:** 27 (0, 156) **G2:** 157 (76, 319) **G1 vs. G2:** p<0.001 PBAC score, median (range): Cycle 3: **G1:** 49 (0, 286) **G2:** 161 (77, 262) **G1 vs. G2:** p<0.001 Cycle 6: **G1:** 25 (0, 402) **G2:** 159 (50, 307) **G1 vs. G2:** p<0.001 **Quality of life:** NR **Sexual function:** NR	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Unclear Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G2: 38.5 **BMI:** NR **Parity:** NR **Race/ethnicity:** NR		**Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events, n:** Abdominal pain: **G1:** 8/25 **G2:** 2/26 Headache: **G1:**10/25 **G2:** 10/25 Breast pain: **G1:** 6/25 **G2:** 2/26 Nausea: **G1:** 2/25 **G2:** 4/26 Diarrhea: **G1:** 1/25 **G2:** 4/25 Upper respiratory infection: **G1:** 5/25 **G2:** 5/26 LNG-IUS expulsion: **G1:** 4/25 **G2:** NA	

Table Notes: [a] Total menstrual fluid loss was determined by difference in weight between returned sanitary material and original weight. Correlations between change in total menstrual fluid loss and PBAC scores over the six cycles when all patients were analyzed together (r=0.88, p<0.0001). PBAC scores correlated with changes in MBL (r=0.53, p= 0.0007) and total menstrual fluid loss (r=0.58, p=0.0002).

AUB KQ1 Evidence Table (Reference ID #17)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Shaaban et al., 2011 **Country:** Egypt **Enrollment period:** May 2003 to March 2004 **Intervention setting:** Gynecology outpatient clinic, Assiut University **Funding:** Lab work funding provided by Assiut University; LNG-IUS donated by Bayer Schering Pharma AG; sanitary pads provided by Proctor and Gamble **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** None	**Intervention:** Levonorgestrel-releasing intrauterine system inserted per manufacturer's instructions **Comparator:** Low dose combined oral contraceptive (30 mcg of ethinyl estradiol/150 mcg levonorgestrel) **Groups:** **G1:** LNG-IUS **G2:** Combined oral contraceptive **Followup:** 12 months	**Inclusion criteria:** • Heavy menstrual bleeding (self described) • Requested contraception • 20 to 50 years old at initial assessment • Regular cycle • Living in nearby area **Exclusion criteria:** Pregnancy or history of ectopic pregnancy Puerperal sepsis Pelvic inflammatory disease Evidence of defective coagulation Ultrasound abnormalities including fibroid of any size History or evidence of malignancy or hyperplasia in the endometrial biopsy Incidental adnexal abnormality on ultrasound Contraindications to COC Previous endometrial ablation or resection Uninvestigated postcoital bleeding Untreated abnormal cervical cytology **N at enrollment:**	**Bleeding:** MBL measured by alkaline hematin method, mean ml ± SD: **G1:** 300.0 ± 150.1 **G2:** 274.3 ± 142.6 **G1 vs. G2:** p=0.383 PBLAC, mean score ± SD: **G1:** 306.7 ± 131.8 **G2:** 323.8 ± 97.3 **G1 vs. G2:** p=0.787 Hemoglobin, mean g/dl ± SD: **G1:** 10.2 ± 1.3 **G2:** 10.5 ± 1.2 **G1 vs. G2:** p=0.207 Ferritin, mean µg/dl ± SD: **G1:** 31.8 ± 108.3 **G2:** 88.8 ± 193.6 **G1 vs. G2:** p=0.057 Uterine weight, mean g ± SD: **G1:** 115.9 ± 38.6 **G2:** 128.7 ± 38.0 **G1 vs. G2:** p=0.080 HRQoL-4, health ≥ very good, n (%): **G1:** 3 (5.3) **G2:** 3 (5.3) Physically unhealthy days in past month, mean ± SD:	**Bleeding:** MBL measured by alkaline hematin method at 12 months,[a] mean ml ± SD: **G1:** 44.4 ± 34.9 **G2:** 118.2 ± 75.0 **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p<0.001 MBL reduction at 12 months, mean % ± SD: **G1:** 87.4 ± 11.3 **G2:** 35.0 ± 77.0 **G1 vs. G2:** p=0.013 PBLAC at 12 months, mean score[a] ± SD: **G1:** 31.6 ± 35.1 **G2:** 273.0 ± 238.4 **G1 vs. BL:** p<0.001 **G2 vs. BL:** p=0.129 **G1 vs. G2:** p<0.001 PBLAC score[a] reduction at 6 months, mean % ± SD: **G1:** 89.5 ± 11.7 **G2:** 41.6 ± 53.6 **G1 vs. G2:** p<0.001 PBLAC score reduction at 12 months, mean % ± SD: **G1:** 86.6 ± 17.0 **G2:** 2.5 ± 93.2 **G1 vs. G2:** p<0.001 Hemoglobin at 12	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: High Selective reporting: Low Blinding patients/personnel: High Blinding outcome assessment: Unclear Incomplete outcome reporting: Low Other: High

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G1: 56 **G2:** 56 **N (%) at followup:** **G1:** 48 (85.7) **G2:** 47 (83.9) **Age, mean years ± SD:** **G1:** 39.3 ± 6.7 **G2:** 38.7 ± 5.2 **Age at menarche, mean years ± SD:** **G1:** 11.6 ± 1.0 **G2:** 11.5 ± 1.4 **BMI, mean kg/m^2 ± SD:** **G1:** 29.6 ± 5.9 **G2:** 31.1 ± 5.7 **BMI >30 kg/m^2, n (%):** **G1:** 25 (48.1) **G2:** 32 (57.1) **Parity:** NR **Previous deliveries, median (IQR):** **G1:** 3 (1, 6.4) **G2:** 3 (2, 6) **Race/ethnicity:** NR	**G1:** 7.4 ± 2.7 **G2:** 7.5 ± 2.6 Mentally unhealthy days in past month, mean ± SD: **G1:** 5.9 ± 2.8 **G2:** 6.2 ± 3.1 Activity limitation (lost days) in past month, mean ± SD: **G1:** 6.8 ± 2.6 **G2:** 7.0 ± 2.7	months, mean g/dl ± SD: **G1:** 11.4 ± 1.0 **G2:** 10.1 ± 1.2 **G1 vs. BL:** p<0.001 **G2 vs. BL:** p=0.081 **G1 vs. G2:** p<0.001 Ferritin at 12 months, mean µg/dL ± SD: **G1:** 88.5 ± 101.6 **G2:** 54.3 ± 91.3 **G1 vs. BL:** p=0.005 **G2 vs. BL:** p=0.230 **G1 vs. G2:** p<0.001 Uterine weight at 12 months, mean g ± SD: **G1:** 98.2 ± 33.3 **G2:** 154.8 ± 54.0 **G1 vs. BL:** p<0.001 **G2 vs. BL:** p=0.004 **G1 vs. G2:** p<0.001 Total bleeding days per year,[a] mean ± SD: **G1:** 34.5 ± 12.0 **G2:** 65.1 ± 15.3 **G1 vs. G2:** p<0.001 Total spotting days per year,[a] mean ± SD: **G1:** 20.7 ± 8.9 **G2:** 18.0 ± 10.6 **G1 vs. G2:** p=0.273 **Quality of life:** HRQoL-4, health ≥ very good at 12 months, n (%): **G1:** 15 (26.8) **G2:** 13 (23.2)	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				G1 vs. BL: p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.129 Physically unhealthy days in past month at 12 months, mean ± SD: **G1:** 3.7 ± 2.0 **G2:** 4.7 ± 2.7 **G1 vs. BL:** p<0.001 **G2 vs. BL:** p=0.034 **G1 vs. G2:** p=0.186 Mentally unhealthy days in past month at 12 months, mean ± SD: **G1:** 6.7 ± 3.1 **G2:** 4.4 ± 1.7 **G1 vs. BL:** p=0.954 **G2 vs. BL:** p=0.357 **G1 vs. G2:** p=0.003 Activity limitation (lost days) in past month at 12 months, mean ± SD: **G1:** 1.6 ± 2.4 **G2:** 6.7 ± 2.2 **G1 vs. BL:** p=0.003 **G2 vs. BL:** p=0.794 **G1 vs. G2:** p<0.001 **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:**	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				NR **Time to conception:** NR **Additional interventions:** NR **Adverse Events:** Treatment failure,[b] n (%): **G1:** 6 (11) **G2:** 18 (32) **G1 vs. G2:** HR=0.30 (95% CI: 0.14, 0.73), p=0.007 Treatment failure reasons, n: Removal for lost threads with persistent bleeding: **G1:** 1 **G2:** NR Expulsion: **G1:** 1 **G2:** NR Persistent bleeding: **G1:** 4 **G2:** NR	

Table Notes: [a] Patients with amenorrhea were considered to have a MBL of 0 mL, PBLAC score of 0 and no bleeding or spotting; [b] Treatment failure defined as initiation of an alternative medical treatment, need for surgery, confirmed expulsion, or removal of LNG-IUS.

AUB KQ1 Evidence Table (Reference ID #1180)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Tsang et al., 1987 **Country:** Canada **Enrollment period:** NR **Intervention setting:** NR **Funding:** Grants from Medical Research Council of Canada; Parke-Davis Canada, Inc,[a] Ottawa Civic Hospital fund and University Medical Research fund; Dept of Obstetrics and Gynecology, University of Ottawa **Author industry relationship disclosures:** NR **Study Design:** RCT (crossover) **Blinding:** Patients, investigators	**Intervention:** Mefenamic acid 500 mg at onset of menses followed by 250 mg every 6 hours for 3 to 5 days for cycles 2 and 3 followed by placebo for cycles 4 and 5. **Comparator:** Placebo for cycles 2 and 3 followed by mefenamic acid for cycles 4 and 5. Cycle 1: Non treatment for everyone **Groups:** **G1:** Mefenamic acid **G2:** Placebo **Followup:** 5 months	**Inclusion criteria:** • Menorrhagia (mean MBL of 80 ml or more per cycle or history of prolonged or profuse menses that warranted medical and/or surgical intervention) • Regular menstrual cycles **Exclusion criteria:** See inclusion criteria **N at enrollment:** **G1+G2:** 14 **N at followup:** **G1+G2:** 10 **Age:** NR **BMI**: NR **Race/ethnicity**: NR **Parity:** NR	NR[b]	**Bleeding:** MBL measured by the alkaline hematin method reduction during treatment cycle, n: **G1+G2:** 8/10 MBL reduction during treatment cycle vs. non treatment cycle, n: **G1+G2:** p<0.05 Endometrial prostaglandin levels lower during treatment cycle, n: **G1+G2:** 9/10 **Quality of life:** NR **Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions, n:** Hysterectomy: **G1+G2:** 1/14 Combined oral contraceptive: **G1+G2:** 1/14	**Overall quality:** Poor **Risk of bias:** Randomization: Unclear Allocation concealment: Unclear Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: High Other: Low

Table Notes: [a] Mefenamic acid was a gift of Parke-Davis; [b] Results only displayed graphically.

AUB KQ1 Evidence Table (Reference ID #1059)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Van Eijkeren et al., 1992 **Country:** Netherlands **Enrollment period:** NR **Intervention setting:** Hospital **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT **Blinding:** Patients, clinicians	**Intervention:** Mefenamic acid (Ponstan) 500 mg, 3 times per day starting 5 days before expected menstrual cycle date until menstrual bleeding arrested. **Comparator:** Placebo, 3 times per day **Groups:** **G1:** Mefenamic acid **G2:** Placebo **Followup:** One control cycle, one medicated cycle, hysterectomy at following cycle	**Inclusion criteria:** Aged <45 years • Scheduled hysterectomy Measured menstrual blood loss >80ml Regular menstrual cycle **Exclusion criteria:** Use of intrauterine device Use of NSAIDs or medications interfering with homeostasis Contraindications against use of NSAIDS, such as liver or kidney function impairments, stomach ulcers, or asthmatic bronchitis Use of hormonal medications **N at enrollment:** **G1+G2:** 19 **N at followup:** **G1:** 6 **G2:** 5 **Age, mean years ± SD:** **G1:** 39.8 ± 3.6 **G2:** 39.4 ± 3.0 **BMI:** NR **Parity:** NR **Race/ethnicity:**	**Bleeding:** MBL, mean ml ± SD: **G1:** 108 ± 27 **G2:** 151 ± 46 **G1 vs. G2:** p=0.09	**Bleeding:** MBL, mean ml ± SD: **G1:** 65 ± 19 **G2:** 189 ± 69 **G1 vs. BL:** p=0.01 **G2 vs. BL:** p=0.46 **Other:** Midluteal progesterone level, mean nmol/l ± SD: **G1:** 27.3 ± 14.9 **G2:** 40.6 ± 19.8 Progesterone level at operation, mean nmol/l ± SD: **G1:** 4.7 ± 3 **G2:** 3.8 ± 3.5 Plasma levels of mefenamic acid at medicated cycle, mean mcg/ml ± SD: **G1:** 4.39 ± 3.09 **G2:** NA Plasma levels of mefenamic acid at operation, mean mcg/ml ± SD: **G1:** 2.69 ± 4.44 **G2:** NA Interval between onset of menstruation and operation, mean ± SD: **G1:** 10.5 ± 5.2 **G2:** 13.4 ± 5.8 **G1 vs. G2:** p=NS **Quality of life:** NR	**Overall quality:** Fair **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: High Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		NR		**Pain:** NR **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR **Time to conception:** NR **Additional interventions:** NR **Adverse events:** Discontinued medication because of severe skin rash and itching, n: **G1:** 1 **G2:** 0	

AUB KQ1 Evidence Table (Reference ID #1179)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Vargyas et al., 1987 **Country:** United States **Enrollment period:** NR **Intervention setting:** Academic medical center **Funding:** NR **Author industry relationship disclosures:** NR **Study Design:** RCT (crossover) **Blinding:** Patients, clinicians	**Intervention:** Meclofenamate sodium (meclomen), 100 mg three times per day for two cycles followed by placebo for two cycles **Comparator:** Placebo, three times per day for two cycles, followed by meclomen for two cycles Medication initiated after onset of menses and continued for 6 days or until end of menses whichever came first **Groups:** **G1:** Meclomen first then placebo **G2:** Placebo first thenmeclomen **Ga:** Meclomen **Gb:** Placebo **Followup:** Observation phase: 2 months Treatment phase: 2 months	**Inclusion criteria:** • Aged 16 to 42 years History of menorrhagia >60 ml in one observation cycle Negative pregnancy test **Exclusion criteria:** Anovulatory cycles (proliferative endometrium) Histological evidence of pathological changes in the endometrium (hyperplasia or atypia) Extrauterine disease Palpable leiomyoma Known sensitivity to fenamates Anticoagulant therapy Thyroid dysfunction Hepatic disease Renal disease Abnormal cervical cytological findings **N at enrollment:** **G1:** 15 **G2:** 17 **N at follow-up:** **G1:** 13 **G2:** 16 **Age, mean years (range):** **G1:** 36.4 (19, 45) **G2:** 35.3 (29, 43) **Race/ethnicity, n:** White:	**Bleeding:** MBL measured by alkaline hematin method, mean ml (SE): **G1:** 141 (17.5) **G2:** 141.8 (26.5) **G1+G2**: 141.6 (15.9) Number of bleeding days per cycle, mean (SE): **G1+G2:** 6.3 (0.41) Hemoglobin, median gm/dl: **G1+G2:** 13.2 Hematocrit, median %: **G1+G2:** 39.4 Ferritin, median ng/ml: **G1+G2:** 16.0	**Bleeding:** MBL measured by alkaline hematin method, during treatment and placebo cycles, mean ml (SE): **Ga:** 69.0 (6.34) **Gb:** 135.6 (11.3) MBL % change during treatment and placebo cycles from baseline, mean (SE): **Ga:** -48.9 (3.7) **Gb:** -9.2 (5.3) **Ga vs. Gb:** p<0.0001 Number of bleeding days per cycle, mean (SE): **Ga:** 4.8 (0.20) **Gb:** 5.4 (0.18) **Ga vs. BL:** p<0.0003 **Gb vs. BL:** p=NS **Ga vs. Gb:** p<0.0003 Number of pads/tampons used, mean (SE): **Ga:** 15.5 (0.9) **Gb:** 27.6 (2.1) **Ga vs. BL:** p<0.0001 **Gb vs. BL:** p=NS **Ga vs. Gb:** p<0.0001 Hemoglobin, gm/dl, median: **G1+G2:** 12.8 **G1+G2 vs. BL:** p=NS Hematocrit, %, median: **G1+G2:** 38.9 **G1+G2 vs. BL:** p=NS	**Overall Quality:** Good **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: Low Blinding outcome assessment: Low Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
		G1: 12 **G2:** 13 Black: **G1:** 3 **G2:** 3 **BMI:** NR **Weight, mean pounds (range):** **G1:**149.3 (108, 213) **G2:** 164.7 (120, 130) **Parity:** **G1+G2:** All but 4 patients had one or more living children **Contraception, n (%):** Intrauterine device: **G1+G2:** 7 (21) Previous sterilization: **G1+G2:** 6 (18) Barrier methods: **G1+G2:** 2 (15) Partners with vasectomies or not sexually active: **G1+G2:** 11 **Dysmenorrhea, n (%):** Severe: **G1+G2:** 10 (31) Moderate: **G1+G2:** 16 (50) Dysmenorrheic: **G1+G2:** 6 (18)		Ferritin, ng/ml, median: **G1+G2:** 14.8 **G1+G2 vs. BL:** p=NS **Quality of life:** NR **Pain:** Menstrual symptom severity assessed by patient rating,[a] mean score per cycle: Dysmenorrhea: **Ga:** 0.89 **Gb:** 1.38 **Ga vs. Gb:** p<0.006 Backache: **Ga:** 0.20 **Gb:** 0.50 **Ga vs. Gb:** p<0.02 Headache: **Ga:** 0.25 **Gb:** 0.63 **Ga vs. Gb:** p<0.002 Nausea: **Ga:** 0.13 **Gb:** 0.17 **Ga vs. Gb:** p=NS Vomiting: **Ga:** 0.0 **Gb:** 0.05 **Ga vs. Gb:** p=NS **Sexual function:** NR **Patient satisfaction:** NR **Fertility:** NR	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Time to conception: NR **Additional interventions:** NR **Adverse events[b]:** Nausea/vomiting, n: **Ga:** 4 **Gb:** NR Epigastric distress, n: **Ga:** 1 **Gb:** NR	

Table Notes: [a] Patient rated on a daily basis from none=0 to severe=3; [b] One patient discontinued the study because of gastric distress after one cycle of Meclomen. Two patients discontinued after screening phase for personal reasons.

AUB KQ1 Evidence Table (Reference ID #415, #379)

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
Author: Vuorma et al., 2004 Vuorma et al., 2003 **Country:** Finland **Enrollment period:** January 1997 to September 1999 **Intervention setting:** Gynecology outpatient clinics at 14 hospitals **Funding:** STAKES, National Research and Development Centre for Welfare and Health, and Public Health Doctoral Programmes of Helsinki and Tempere universities **Author industry relationship disclosures:** None **Study Design:** RCT **Blinding:** None	**Intervention:** Information group-mailed a decision-aid booklet explaining menorrhagia and risks and benefits of treatment options. **Comparator:** Usual care **Groups:** **G1:** Information **G2:** Control **Followup:** 12 months	**Inclusion criteria:** • Aged 35 to 54 years • Referral for menorrhagia or fibroids • Heavy menstruation as main gynecological complaint **Exclusion criteria:** Symptoms other than heavy menstrual bleeding main cause for medical care **N at enrollment:** **G1:** 184 **G2:** 179 **N at followup:** **G1:** 156 **G2:** 159 **Age, mean years (SE):** **G1:** 44.5 (0.31) **G2:** 44.3 (0.31) **BMI:** NR **Parity:** NR **Race/ethnicity:** NR **Education <12 years, n (%):** **G1:** 104 (57) **G2:** 94 (53)	Inconvenience due to heavy bleeding,[a] mean (SE): **G1:** 19.2 (0.34) **G2:** 19.5 (0.35) Menstrual pain,[b] mean (SE): **G1:** 4.9 (0.27) **G2:** 4.7 (0.27) Periods perceived as very heavy, n (%): **G1:** 112 (61) **G2:** 115 (64) Irregular periods, n (%): **G1:** 42 (23) **G2:** 46 (26) Pelvic pain or pressure, n (%): **G1:** 86 (47) **G2:** 80 (45) Anxiety,[c] mean (SE): **G1:** 36.1 (0.80) **G2:** 35.9 (0.81) Inconvenience due to heavy bleeding,[ad] mean (SE): **G1:** 19.1 (0.38) **G2:** 19.5 (0.37) Menstrual pain,[bd] mean (SE): **G1:** 4.8 (0.29) **G2:** 4.7 (0.29) Anxiety,[cd] mean (SE): **G1:** 36.0 (0.85) **G2:** 35.8 (0.85)	Satisfaction with communication with personnel in gynecology outpatient clinics,[i] median (IQR): **G1:** 36 (30, 39) **G2:** 36.5 (31, 40) **G1 vs. G2:** p=0.6 Change in anxiety level at 3 months, median (IQR): **G1:** 1 (-5, 5) **G2:** -1 (-4, 4) **G1 vs. G2:** p=0.3 Increase in treatment methods mentioned (max 6) between follow-up and baseline, mean (SE): **G1:** 0.48 (0.102) **G2:** 0.45 (0.102) **G1 vs. G2:** p=0.8 Treatment planned after 3 months, n (%): Hysterectomy: **G1:** 99 (54) **G2:** 85 (49) **G1 vs. G2:** p=0.2 Minor surgery or LNG-IUS: **G1:** 38 (21) **G2:** 52 (29) **G1 vs. G2:** p=0.06 Change in birth control method: **G1:** 4 (2) **G2:** 3 (2) **G1 vs. G2:** p=1.0 Oral medication: **G1:** 33 (18)	**Overall quality:** Poor **Risk of bias:** Randomization: Low Allocation concealment: Low Selective reporting: Low Blinding patients/personnel: High Blinding outcome assessment: High Incomplete outcome reporting: Low Other: Low

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				G2: 15 (8) **G1 vs. G2:** p=0.007 No treatment decision: **G1:** 8 (4) **G2:** 20 (11) **G1 vs. G2:** p=0.02 No visit to outpatient clinic: **G1:** 2 (1) **G2:** 4 (2) **G1 vs. G2:** p=0.4	
			Rand-36 scores,[d] mean (SE): General health: **G1:** 66 (1.5) **G2:** 67 (1.5) Physical functioning: **G1:** 86 (1.3) **G2:** 85 (1.3) Emotional well-being: **G1:** 69 (1.6) **G2:** 69 (1.5) Social functioning: **G1:** 75 (1.9) **G2:** 74 (1.8) Energy: **G1:** 55 (1.8) **G2:** 55 (1.8) Pain: **G1:** 68 (1.8) **G2:** 69 (1.8) Role functioning/physical: **G1:** 65 (3.0) **G2:** 67 (3.0) Role functioning/emotional: **G1:** 64 (3.1) **G2:** 72 (3.1)	Actual treatment received up to 12 months after first visit, n (%): Hysterectomy: **G1:** 98 (53) **G2:** 88 (49) **G1 vs. G2:** p=0.4 Minor surgery or LNG-IUS: **G1:** 30 (16) **G2:** 46 (26) **G1 vs. G2:** p=0.03 Other: **G1:** 54 (29) **G2:** 44 (25) **G1 vs. G2:** p=0.3 No treatment and no visit to outpatient clinic: **G1:** 2 (1) **G2:** 1 (1) **G1 vs. G2:** p=0.4	
			Perceived health VAS, mean (SE): **G1:** 73 (1.4) **G2:** 73 (1.4)	Number of surgical procedures used within 1 year, mean (SE): **G1:** 0.70 (0.04) **G2:** 0.73 (0.04) **G1 vs. G2:** p=0.6	
			Psychosomatic symptoms,[de] mean (SE): **G1:** 31.8 (0.59) **G2:** 32.1 (0.58)	Rand-36 scores, mean change (SE):	
			Sexual satisfaction,[df] women with partners, mean (SE): **G1:** 23.7 (0.42)		

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
			G2: 24.2 (0.42) Sexual problems,[dg] women with partners, mean (SE): **G1:** 4.70 (0.20) **G2:** 4.33 (0.20) Partner satisfaction,[dh] women with partners, mean (SE): **G1:** 17.1 (0.27) **G2:** 17.1 (0.27)	General health: **G1:** 2.2 (1.23) **G2:** 2.8 (1.22) **G1 vs. BL:** p=0.07 **G2 vs. BL:** p=0.03 **G1 vs. G2:** p=0.7 Physical functioning **G1:** 2.4 (1.33) **G2:** 2.2 (1.32) **G1 vs. BL:** p=0.04 **G2 vs. BL:** p=0.1 **G1 vs. G2:** p=0.9 Emotional well-being: **G1:** 4.7 (1.40) **G2:** 5.3 (1.39) **G1 vs. BL:** p=0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.7 Social functioning: **G1:** 5.2 (1.98) **G2:** 7.1 (1.96) **G1 vs. BL:** p=0.01 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.5 Energy: **G1:** 8.9 (1.72) **G2:** 8.8 (1.71) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.9 Pain: **G1:** 6.5 (1.96) **G2:** 6.2 (1.95) **G1 vs. BL:** p=0.002 **G2 vs. BL:** p=0.001 **G1 vs. G2:** p=0.9 Role functioning/physical: **G1:** 9.2 (3.41) **G2:** 6.3 (3.38) **G1 vs. BL:** p=0.007 **G2 vs. BL:** p=0.07	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				G1 vs. G2: p=0.5 Role functioning/emotional: **G1:** 12.6 (3.13) **G2:** 1.9 (3.09) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p=0.5 **G1 vs. G2:** p=0.01 Perceived health VAS, mean change (SE): **G1:** 2.6 (1.38) **G2:** 3.6 (1.36) **G1 vs. BL:** p=0.09 **G2 vs. BL:** p=0.003 **G1 vs. G2:** p=0.6 Psychosomatic symptoms,[e] mean change (SE): **G1:** 3.4 (53) **G2:** 3.8 (0.53) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.5 Inconvenience due to heavy bleeding,[a] mean change (SE): **G1:** 10.4 (0.58) **G2:** 10.5 (0.57) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.9 Menstrual pain,[b] mean change (SE): **G1:** 4.7 (0.29) **G2:** 4.6 (0.29) **G1 vs. BL:** p<0.001 **G2 vs. BL:** p<0.001 **G1 vs. G2:** p=0.8	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias
				Anxiety,[c] mean change (SE): **G1:** 2.0 (0.78) **G2:** 1.0 (0.78) **G1 vs. BL:** p=0.012 **G2 vs. BL:** p=0.199 **G1 vs. G2:** p=0.4 Sexual satisfaction,[f] women with partners, mean change (SE): **G1:** 0.29 (0.37) **G2:** -0.14 (0.36) **G1 vs. BL:** p=0.487 **G2 vs. BL:** p=0.688 **G1 vs. G2:** p=0.4 Sexual problems,[g] women with partners, mean change (SE): **G1:** -0.23 (0.18) **G2:** -0.15 (0.18) **G1 vs. BL:** p=0.224 **G2 vs. BL:** p=0.444 **G1 vs. G2:** p=0.8 Partner satisfaction,[h] women with partners, mean change (SE): **G1:** -0.08 (0.18) **G2:** -0.13 (0.18) **G1 vs. BL:** p=0.659 **G2 vs. BL:** p=0.436 **G1 vs. G2:** p=0.9 Satisfaction with outcome of treatment VAS, median (IQR): **G1:** 94 (75, 100) **G2:** 95 (75, 100) **G1 vs. G2:** p=0.9	

Study Description	Intervention(s)/ Comparator(s)	Patient Population	Baseline Measure(s)	Outcome Measure(s)	Overall Quality Risk of Bias

Table Notes and Comments: [a] Scale 5-25; [b] Scale for menstrual pain was calculated by multiplying the intensity of pain (0 for no pain to 6 for heaviest possible pain) by the frequency of pain (0 for never to 2 for every period); [c] Scale 20-80, higher score indicates higher level of anxiety; [d] Data from subset of women who gave 12-month follow-up information G1 (n=156) and G2 (n=159); [e] Scale 18-72; [f] Scale 5-35; [g] Scale 2-14; [h] Scale 3-21; [i] Scale 8-40.

Appendix K. Reasons for Exclusion (KQ1)

Exclusion Code	Exclusion Reason	Count
X-1	Not original research (e.g. review articles, systematic reviews, editorials, commentaries, letters to editor, etc.).	74
X-2	Not published in English language.	0
X-3	Not eligible study design (i.e., not a randomized controlled trial).	430
X-4	Study is basic science, anatomy, imaging, prevalence, physiology, diagnostic, biomarker, or biological mechanism study only.	700
X-5	Does not address key question/other (e.g., intervention unlikely to be used in the primary care setting; intervention not approved for use in the U.S.; bleeding related to pregnancy; acute/emergent bleeding, etc.).	1273
X-6	Study population consists of 20 percent or more women whose bleeding is caused by: structural abnormality (e.g., fibroids, polyps, adenomyosis); cancer; medication side effect; endometrial hyperplasia; or systemic disease (e.g., thyroid disease, coagulopathy).	300
X-7	Study population consists of post-menopausal women.	249
X-8	Study evaluates surgical or invasive intervention(s) only or surgical or invasive intervention is the only comparator**.**	220
X-9	Study evaluates contraceptive efficacy or effectiveness only.	621
X-10	Study does not report baseline and outcome data for a study population with ≥80 percent women in the target population or a subset of women in the target population.	87
X-11	Unable to obtain	4
X-12	Duplicate	1

References

1. Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1987;753:1-91. PMID: 3118580. ***X-1, X-3, X-5, X-9, X-10***

2. Phase III clinical trial with Norplant II (two covered rods): report on five years of use. Contraception. 1993 Aug;48(2):120-32. PMID: 8403909. ***X-3, X-9***

3. Hysteroscopic surgery for dysfunctional uterine bleeding. Professional Nurse. 1994;10(3):142-3. ***X-8***

4. Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Hum Reprod. 1995 Feb;10(2):308-14. PMID: 7769054. ***X-3, X-5, X-6***

5. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997 Dec;56(6):341-52. PMID: 9494767. ***X-9***

6. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. Eur J Contracept Reprod Health Care. 1998 Dec;3(4):169-78. PMID: 10036599. ***X-9***

7. Thermal ablation as a treatment for dysfunctional uterine bleeding. Point of View. 1998;36(1):14-20. ***X-8***

8. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg. Eur J Contracept Reprod Health Care. 1999 Nov;4 Suppl 2:9-15. PMID: 14677620. ***X-4, X-5***

9. Levonorgestrel intrauterine device: new preparation. An alternative. Prescrire Int. 1999 Dec;8(44):175-7. PMID: 11503815. ***X-1, X-4, X-5***

10. Raloxifene: new preparation. Not better than oestrogen. Prescrire Int. 1999 Dec;8(44):165-7. PMID: 11503811. ***X-1, X-4, X-5, X-7, X-9***

11. Which operation for menorrhagia? Drug and Therapeutics Bulletin. 2000;38(10):77-80. ***X-1, X-3, X-5, X-8***

12. Levonorgestrel. New preparation. Emergency contraceptive. Prescrire International. 2000;9(45):202-4. PMID: 11503796. ***X-1, X-3, X-5, X-9***

13. Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. Contraception. 2001 Apr;63(4):167-86. PMID: 11376646. ***X-4, X-5***

14. Levonorgestrel intra-uterine system for menorrhagia. Drug and Therapeutics Bulletin. 2001;39(11):85-7. PMID: 11760591. ***X-1, X-3, X-10***

15. Information from your family doctor. Birth control pills and bleeding. Am Fam Physician. 2002 May 15;65(10):2083. PMID: 12046777. ***X-1, X-3, X-5, X-10***

16. Hysterectomy improves quality-of-life in women with prolonged abnormal uterine bleeding. Evidence Based Healthcare and Public Health. 2004;8(5):306-7. ***X-8***

17. Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients. Prescrire Int. 2005 Apr;14(76):43-4. PMID: 15875334. ***X-1, X-4, X-5, X-9***

18. Estrogen and progestogen therapy in postmenopausal women. Fertility and Sterility. 2008;90(5 SUPPL):S88-S102. PMID: 19007655. ***X-1, X-3, X-7***

19. ACOG Committee Opinion No. 451: Von Willebrand disease in women. Obstet Gynecol. 2009 Dec;114(6):1439-43. PMID: 20134302. ***X-1, X-4, X-5, X-9***

20. Urinary problems after hysterectomy. Journal of the National Medical Association. 2010;102(7). ***X-8***

21. Abbott JA, Hawe J, Garry R. Quality of life should be considered the primary outcome for measuring success of endometrial ablation. J Am Assoc Gynecol Laparosc. 2003 Nov;10(4):491-5; discussion 5. PMID: 14738636. ***X-4, X-5, X-8, X-9***

22. Abdel Malak K, Shawki O. Management of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Gynecological Surgery. 2006;3(4):275-80. ***X-8***

23. Abdel-Aleem H, Shaaban OM, Amin AF, et al. Tamoxifen treatment of bleeding irregularities associated with Norplant use. Contraception. 2005 Dec;72(6):432-7. PMID: 16307966. ***X-5, X-6***

24. Abdelrazik N, Ghanem H. Failure of puberty in Egyptian beta thalassemic patients: experience in north east region - Dakahlia province. Hematology. 2007 Oct;12(5):449-56. PMID: 17852439. ***X-4, X-5, X-9***

25. Abdulwahid NA, Adams J, van der Spuy ZM, et al. Gonadotrophin control of follicular development. Clin Endocrinol (Oxf). 1985 Dec;23(6):613-26. PMID: 3938350. ***X-3, X-4, X-5***

26. Aberg LE, Tiitinen A, Autti TH, et al. Hyperandrogenism in girls with juvenile neuronal ceroid

lipofuscinosis. Eur J Paediatr Neurol. 2002;6(4):199-205. PMID: 12374586. ***X-4, X-5, X-6, X-9***

27. Aboulghar MA, Mansour RT, Serour GI, et al. Improvement of spontaneous pregnancy rate after stopping gonadotropin therapy for anovulatory infertility. Fertil Steril. 1991 Apr;55(4):722-5. PMID: 1901280. ***X-3, X-5***

28. Abou-Salem N, Elmazny A, El-Sherbiny W. Value of 3-dimensional sonohysterography for detection of intrauterine lesions in women with abnormal uterine bleeding. J Minim Invasive Gynecol. 2010 Mar-Apr;17(2):200-4. PMID: 20226408. ***X-4, X-5, X-9***

29. Adam J. Contraception and therapy with Tri Regol tablet. Ther Hung. 1991;39(2):75-7. PMID: 1948781. ***X-3, X-9***

30. Adeyemi AS, Adekanle DA. Progestogen-only injectable contraceptive: experience of women in Osogbo, southwestern Nigeria. Ann Afr Med. 2012 Jan-Mar;11(1):27-31. PMID: 22199044. ***X-3, X-9***

31. Affinito P, Monterubbianesi M, Primizia M, et al. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: Gestodene/ethinylestradiol and norgestimate/ethinylestradiol. Gynecological Endocrinology. 1993;7(4):259-66. PMID: 8147235. ***X-9***

32. Agarwal K, Sharma U, Acharya V. Microbial and cytopathological study of intrauterine contraceptive device users. Indian J Med Sci. 2004 Sep;58(9):394-9. PMID: 15470281. ***X-4, X-5***

33. Agnusdei D, Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporosis International. 1995;5(6):462-6. PMID: 8695969. ***X-7***

34. Agosta C, Atlante M, Benvenuti C. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause. Minerva Ginecol. 2011 Feb;63(1):11-7. PMID: 21311416. ***X-5, X-7, X-9***

35. Ahmed WU, Kirmani SR, Qureshi H, et al. Misoprostol in the treatment of NSAID-induced gastroduodenal lesions. Indian J Gastroenterol. 1991 Oct;10(4):135-6. PMID: 1748495. ***X-5***

36. Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009 Nov;80(5):436-44. PMID: 19835717. ***X-5***

37. AinMelk Y. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil Steril. 1996 Dec;66(6):962-8. PMID: 8941062. ***X-5, X-7***

38. Aisien AO, Enosolease ME. Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Niger J Clin Pract. 2010 Sep;13(3):331-5. PMID: 20857796. ***X-4, X-5***

39. Akase T, Onodera S, Jobo T, et al. A comparative study of the usefulness of toki-shakuyaku-san and an oral iron preparation in the treatment of hypochromic anemia in cases of uterine myoma. Yakugaku Zasshi. 2003 Sep;123(9):817-24. PMID: 14513774. ***X-4, X-5, X-6, X-7, X-9***

40. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 mug desogestrel and either 30 mug or 20 mug ethinyl oestradiol. British Journal of Obstetrics and Gynaecology. 1993;100(9):832-8. ***X-9***

41. Akhter H, Dunson TR, Amatya RN, et al. A five-year clinical evaluation of Norplant contraceptive subdermal implants in Bangladeshi acceptors. Contraception. 1993 Jun;47(6):569-82. PMID: 8334891. ***X-3, X-6, X-9***

42. Akkad AA, Habiba MA, Ismail N, et al. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol. 1995 Sep;86(3):330-4. PMID: 7651636. ***X-3, X-5, X-6, X-8***

43. Al Inizi SA, Ezimokhai M. Vaginal misoprostol versus dinoprostone for the management of missed abortion. Int J Gynaecol Obstet. 2003 Oct;83(1):73-4. PMID: 14511878. ***X-5, X-9***

44. Al-Azzawi F, Buckler HM. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric. 2003;6(2):118-27. PMID: 12841882. ***X-7***

45. Al-Azzawi F, Wahab M, Habiba M, et al. Continuous combined hormone replacement therapy compared with tibolone. Obstetrics and Gynecology. 1999;93(2):258-64. PMID: 9932566. ***X-7***

46. al-Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric. 2001 Dec;4(4):343-54. PMID: 11770191. ***X-5, X-7, X-10***

47. Al-Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod. 1999 Mar;14(3):636-41. PMID: 10221688. ***X-5, X-9***

48. Albert A, Altabre C, Baro F, et al. Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: a multicentric, open, prospective and non-randomized trial. Phytomedicine. 2002 Mar;9(2):85-92. PMID: 11995954. ***X-4, X-5, X-7***

49. Alborzi S, Parsanezhad ME, Dehbashi S. A comparison of hysteroscopic endometrial ablation for abnormal uterine bleeding in two groups of patients with or without endometrial preparation. Middle East Fertility Society Journal. 2002;7(2):135-9. ***X-8***

50. Alexandersen P, Byrjalsen I, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: Effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. British Journal of Obstetrics and Gynaecology. 2000;107(3):356-64. PMID: 10740332. ***X-7***

51. Alford WS, Hopkins MP. Endometrial rollerball ablation. J Reprod Med. 1996 Apr;41(4):251-4. PMID: 8728077. ***X-4, X-5, X-8, X-9***

52. Al-Khawajah MM. Finasteride for hirsutism: A dose finding study. Saudi Medical Journal. 1998;19(1):19-21. ***X-5***

53. Allais G, Bussone G, Airola G, et al. Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci. 2008 May;29 Suppl 1:S186-90. PMID: 18545931. ***X-4, X-5, X-9***

54. Allais G, Bussone G, D'Andrea G, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2011 Jan;31(2):144-51. PMID: 20660540. ***X-4, X-5, X-9***

55. Allais G, Sanchez del Rio M, Diener HC, et al. Perimenstrual migraines and their response to preventive therapy with topiramate. Cephalalgia. 2011 Jan;31(2):152-60. PMID: 20650999. ***X-4, X-5, X-9***

56. Al-Quaiz JM. Iron deficiency anemia. A study of risk factors. Saudi Med J. 2001 Jun;22(6):490-6. PMID: 11426238. ***X-4, X-5, X-9***

57. Althaus F. Sterilization is unlikely to alter most women's menstrual symptoms. Family Planning Perspectives. 1990 1990 Jan-Feb;22(1):44-5. ***X-8***

58. Alvarez-Sanchez F, Brache V, Thevenin F, et al. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol. 1996 Mar;174(3):919-22. PMID: 8633669. ***X-5, X-6***

59. Ambriz R, Pizzuto J, Morales M, et al. Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP). Nouv Rev Fr Hematol. 1986;28(5):275-9. PMID: 3808937. ***X-3, X-6***

60. Amesse LS, Boyce C, Pfaff-Amesse T. Menstrual control in the developmentally delayed adolescent: new treatment options. J Pediatr Adolesc Gynecol. 2006 Jun;19(3):237-41. PMID: 16731421. ***X-1, X-3, X-5, X-10***

61. Amesse LS, Pfaff-Amesse T, Leonardi R, et al. Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study. J Pediatr Hematol Oncol. 2005 Jul;27(7):357-63. PMID: 16012324. ***X-4, X-5, X-6***

62. Amso NN, Fernandez H, Vilos G, et al. Uterine endometrial thermal balloon therapy for the treatment of menorrhagia: long-term multicentre follow-up study. Hum Reprod. 2003 May;18(5):1082-7. PMID: 12721188. ***X-4, X-5, X-8***

63. Amso NN, Stabinsky SA, McFaul P, et al. Uterine thermal balloon therapy for the treatment of menorrhagia: the first 300 patients from a multi-centre study. International Collaborative Uterine Thermal Balloon Working Group. Br J Obstet Gynaecol. 1998 May;105(5):517-23. PMID: 9637121. ***X-4, X-5, X-8***

64. Anderer P, Saletu B, Gruber D, et al. Age-related cognitive decline in the menopause: Effects of hormone replacement therapy on cognitive event-related potentials. Maturitas. 2005;51(3):254-69. PMID: 15978969. ***X-7***

65. Andersch B. The effect of various oral contraceptive combinations on premenstrual symptoms. Int J Gynaecol Obstet. 1982 Dec;20(6):463-9. PMID: 6130993. ***X-3, X-5***

66. Andersen LF, Meinert L, Rygaard C, et al. Thermal balloon endometrial ablation: safety aspects evaluated by serosal temperature, light microscopy and electron microscopy. Eur J Obstet Gynecol Reprod Biol. 1998 Jul;79(1):63-8. PMID: 9643406. ***X-4, X-5, X-8***

67. Andersen PE, Lund N, Justesen P, et al. Uterine artery embolization of symptomatic uterine fibroida . Initial success and short-term results. Acta Radiol. 2001 Mar;42(2):234-8. PMID: 11259954. ***X-4, X-5, X-6, X-8***

68. Andersen T, Astrup A, Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: A randomized clinical trial. International Journal of Obesity. 1992;16(1):35-40. PMID: 1314242. ***X-5***

69. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990 Aug;97(8):690-4. PMID: 2119218. ***X-3***

70. Andersson K. Intrauterine release of levonorgestrel. A contraceptive and therapeutical system. Acta Obstetricia et Gynecologica Scandinavica. 1995;74(3):236-7. ***X-1, X-3, X-9, X-10***

71. Andersson K, Mattsson LA, Rybo G, et al. Intrauterine release of levonorgestrel--a new way of adding progestogen

in hormone replacement therapy. Obstet Gynecol. 1992 Jun;79(6):963-7. PMID: 1579323. ***X-5, X-10***

72. Andersson K, Ryde-Blomqvist E, Lindell K, et al. Perforations with intrauterine devices. Report from a Swedish survey. Contraception. 1998 Apr;57(4):251-5. PMID: 9649917. ***X-4, X-5, X-9***

73. Andolsek L, Kozuh-novak M, Waszak C. A comparative study of the nylon T and copper T 200. Contracept Deliv Syst. 1983 Sep;4(4):297-300. PMID: 12265805. ***X-9***

74. Annos T, Thompson IE, Taymor ML. Luteal phase deficiency and infertility: difficulties encountered in diagnosis and treatment. Obstet Gynecol. 1980 Jun;55(6):705-10. PMID: 7383457. ***X-5***

75. Anstee P, Kovacs GT. A prospective randomized study comparing the clinical effects of a norethisterone and a levonorgestrel containing low dose oestrogen oral contraceptive pills. Aust N Z J Obstet Gynaecol. 1993 Feb;33(1):81-3. PMID: 8498949. ***X-9***

76. Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Investig. 2010;30(4):211-20. PMID: 20225905. ***X-4, X-5, X-6***

77. Anttila L, Koskinen P, Erkkola R, et al. Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease. Acta Obstet Gynecol Scand. 1994 Sep;73(8):634-6. PMID: 7941988. ***X-3, X-4***

78. Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception. 2009 Nov;80(5):445-51. PMID: 19835718. ***X-5***

79. Apgar BS, DeWitt D. Diagnostic hysteroscopy. Am Fam Physician. 1992 Nov;46(5 Suppl):19S-24S, 9S-32S, 5S-6S. PMID: 1442472. ***X-1, X-3, X-4, X-5***

80. Api O, Unal O, Ugurel V, et al. Analgesic efficacy of intravenous paracetamol for outpatient fractional curettage: a randomised, controlled trial. Int J Clin Pract. 2009 Jan;63(1):105-11. PMID: 18422592. ***X-5, X-9***

81. Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: Results of a randomized, double-blind, placebo-controlled study. Headache. 2008;48(7):1012-25. PMID: 18705027. ***X-5***

82. Appel TB, Kambi AA, Birdsall C, et al. A comparison of a new graduated estrogen formulation with three constant-dosed oral contraceptives. Contraception. 1987 Jun;35(6):523-32. PMID: 3311619. ***X-9***

83. Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001 Jun;75(6):1080-7. PMID: 11384630. ***X-5, X-7***

84. Archer DF, Dorin MH, Heine W, et al. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol. 1999 Sep;94(3):323-9. PMID: 10472853. ***X-5, X-6, X-7***

85. Archer DF, Dorin MH, Heine W, et al. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Obstetrics and Gynecology. 1999;94(3):323-9. PMID: 10472853. ***X-7***

86. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007 Mar;92(3):911-8. PMID: 17192288. ***X-5, X-7, X-9***

87. Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009 Sep;92(3):1039-44. PMID: 19635614. ***X-5, X-7***

88. Archer DF, Lobo RA, Land HF, et al. A comparative study of transvaginal uterine ultrasound and endometrial biopsy for evaluating the endometrium of postmenopausal women taking hormone replacement therapy. Menopause. 1999 Fall;6(3):201-8. PMID: 10486789. ***X-4, X-5, X-7***

89. Archer DF, Maheux R, DelConte A, et al. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception. 1997 Mar;55(3):139-44. PMID: 9115001. ***X-4, X-5***

90. Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol. 1999 Nov;181(5 Pt 2):39-44. PMID: 10561674. ***X-4, X-5***

91. Archer DF, Philput CA, Weber ME. Management of irregular uterine bleeding and spotting associated with Norplant. Hum Reprod. 1996 Oct;11 Suppl 2:24-30. PMID: 8982742. ***X-4, X-5, X-6***

92. Archer DF, Philput CB, Levine AS, et al. Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users.

Contraception. 2008 Aug;78(2):106-12. PMID: 18672110. ***X-3, X-5, X-6***

93. Archer DF, Pickar JH. Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol. 2000 Dec;96(6):899-905. PMID: 11084175. ***X-5, X-7***

94. Archer DF, Pickar JH. The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: A review of methodology and recommendations for reporting of the data. Climacteric. 2002;5(1):45-59. PMID: 11974559. ***X-1, X-3, X-7***

95. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol. 1994 May;83(5 Pt 1):686-92. PMID: 8164926. ***X-7***

96. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005 Nov-Dec;12(6):716-27. PMID: 16278615. ***X-5, X-7***

97. Arias F. Cervical cerclage for the temporary treatment of patients with placenta previa. Obstet Gynecol. 1988 Apr;71(4):545-8. PMID: 3353045. ***X-5***

98. Arias RD, Jain JK, Brucker C, et al. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception. 2006 Sep;74(3):234-8. PMID: 16904417. ***X-4, X-5, X-6***

99. Armanini D, Castello R, Scaroni C, et al. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol. 2007 Mar;131(1):61-7. PMID: 17113210. ***X-4, X-5, X-9***

100. Arowojolu AO. Treatment of endometriosis with depot medroxyprogesterone acetate: a preliminary experience. Afr J Med Med Sci. 2000 Mar;29(1):55-8. PMID: 11379470. ***X-4, X-5, X-6, X-9***

101. Arowojolu AO, Okewole IA, Adekunle AO. Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception. 2002 Oct;66(4):269-73. PMID: 12413624. ***X-4, X-5, X-9***

102. Arowojolu AO, Otolorin EO, Ladipo OA. Performances of copper T 380A and multiload copper 375/250 intrauterine contraceptive devices in a comparative clinical trial. African journal of medicine and medical sciences. 1995;24(1):59-65. PMID: 7495202. ***X-9***

103. Arrenbrecht S, Caubel P, Garnero P, et al. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women. Maturitas. 2004;48(3):197-207. PMID: 15207885. ***X-7***

104. Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur J Obstet Gynecol Reprod Biol. 2005 Nov 1;123(1):87-91. PMID: 16260342. ***X-5, X-9***

105. Aslan DL, Crapanzano JP, Harshan M, et al. The Bethesda System 2001 recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers. Gynecol Oncol. 2007 Oct;107(1):86-93. PMID: 17604086. ***X-4, X-5, X-9***

106. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000 Jul;85(7):2434-8. PMID: 10902790. ***X-4, X-5, X-9***

107. Ataya K, Mercado A, Kartaginer J, et al. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril. 1988 Dec;50(6):876-81. PMID: 2904890. ***X-3, X-4, X-5***

108. Au CL, Affandi B, Rogers PA. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant implants use. Contraception. 1994 Nov;50(5):477-89. PMID: 7859456. ***X-3, X-4***

109. Aubeny E. RU486 combined with PG analogs in voluntary termination of pregnancy. Adv Contracept. 1991 Dec;7(4):339-43. PMID: 1776558. ***X-3, X-5***

110. Aubeny E, Peyron R, Turpin CL, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected]. Int J Fertil Menopausal Stud. 1995;40 Suppl 2:85-91. PMID: 8574255. ***X-3, X-5***

111. Aufricht C, Marik JL, Ettenger RB. Subcutaneous recombinant human erythropoietin in chronic renal allograft dysfunction. Pediatr Nephrol. 1998 Jan;12(1):10-3. PMID: 9502558. ***X-5, X-9***

112. Ayers JW, Birenbaum DL, Menon KM. Luteal phase dysfunction in endometriosis: elevated progesterone levels in peripheral and ovarian veins during the follicular phase. Fertil Steril. 1987 Jun;47(6):925-9. PMID: 3595900. ***X-3, X-4***

113. Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol. 1996 Apr;103(4):351-8. PMID: 8605133. ***X-5, X-7***

114. Azlin MIN, Maryasalwati I, Norzilawati MN, et al. The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea: A randomised comparative trial. Journal of Obstetrics and Gynaecology. 2008;28(4):424-6. PMID: 18604680. ***X-5, X-10***

115. Azziz R, Black VY, Knochenhauer ES, et al. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J Clin Endocrinol Metab. 1999 Mar;84(3):946-50. PMID: 10084576. ***X-3, X-5***

116. Azziz R, Rittmaster RS, Fox LM, et al. Role of the ovary in the adrenal androgen excess of hyperandrogenic women. Fertil Steril. 1998 May;69(5):851-9. PMID: 9591492. ***X-4, X-5, X-9***

117. Azziz R, Zacur HA. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. J Clin Endocrinol Metab. 1989 Sep;69(3):577-84. PMID: 2547827. ***X-3, X-4***

118. Ba MG, Moreau JC, Sokal D, et al. A 5-year clinical evaluation of Norplant implants in Senegal. Contraception. 1999 Jun;59(6):377-81. PMID: 10518232. ***X-4, X-5, X-6***

119. Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004 Sep;70(3):191-8. PMID: 15325887. ***X-4, X-5***

120. Bachmann GA, Timmons MC, Abernethy WD. Breakthrough bleeding patterns in two continuous combined estrogen/progestogen hormone replacement therapies, one of which d androgens. Journal of Women's Health. 1996;5(3):205-12. ***X-7***

121. Backman C, Sandstrom B, Solheim F. Changes in central circulation in premenopausal women during application of an estradiol valerate-norgestrel combination (Cyclabil). Acta Obstet Gynecol Scand Suppl. 1981;106:47-50. PMID: 6951875. ***X-3, X-4, X-5***

122. Baerug U, Winge T, Nordland G, et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric. 1998 Sep;1(3):219-28. PMID: 11907946. ***X-4, X-5, X-7, X-9***

123. Bagaria M, Suneja A, Vaid NB, et al. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol. 2009 Feb;49(1):77-83. PMID: 19281585. ***X-5, X-6, X-9***

124. Bahamondes L, Diaz J, Petta C, et al. Comparison of the performances of TCu380A and TCu380S IUDs up to five years. Advances in Contraception. 1999;15(4):275-81. PMID: 11145369. ***X-9***

125. Bai W, Henneicke-von Zepelin HH, Wang S, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas. 2007 Sep 20;58(1):31-41. PMID: 17587516. ***X-4, X-5, X-7, X-9***

126. Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung. 2010;60(6a):386-98. PMID: 20648930. ***X-1, X-4, X-5, X-9***

127. Bain C, Parkin DE, Cooper KG. Is outpatient diagnostic hysteroscopy more useful than endometrial biopsy alone for the investigation of abnormal uterine bleeding in unselected premenopausal women? A randomised comparison. BJOG. 2002 Jul;109(7):805-11. PMID: 12135218. ***X-4, X-5, X-8***

128. Balasch J, Creus M, Fabregues F, et al. Midluteal immunoreactive alpha-inhibin serum concentrations as markers of luteal phase deficiency. Hum Reprod. 1996 Dec;11(12):2591-4. PMID: 9021356. ***X-4, X-5, X-9***

129. Balasch J, Creus M, Marquez M, et al. The significance of luteal phase deficiency on fertility: a diagnostic and therapeutic approach. Hum Reprod. 1986 Apr;1(3):145-7. PMID: 3114310. ***X-3, X-4, X-5***

130. Balen AH, Mulders AG, Fauser BC, et al. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. Journal of Clinical Endocrinology and Metabolism. 2004;89(12):6297-304. PMID: 15579793. ***X-4, X-5***

131. Bannemerschult R, Hanker JP, Wunsch C, et al. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles. Contraception. 1997 Nov;56(5):285-90. PMID: 9437556. ***X-3, X-9***

132. Bapst JL, Ermer JC, Ferron GM, et al. Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. Contraception. 2006;74(5):414-8. PMID: 17046384. ***X-4, X-5***

133. Baracat EC, Barbosa IC, Giordano MG, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric. 2002 Mar;5(1):60-9. PMID: 11974560. ***X-5, X-7***

134. Barbosa IC, Filho CI, Faggion D, Jr., et al. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral

contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse). Contraception. 2006 Jan;73(1):30-3. PMID: 16371291. ***X-4, X-5, X-9***

135. Barbosa IC, Maia H, Jr., Coutinho E, et al. Effects of a single Silastic contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year. Contraception. 2006 Dec;74(6):492-7. PMID: 17157108. ***X-4, X-5, X-9***

136. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstetrics and Gynecology. 2002;100(6):1209-18. PMID: 12468165. ***X-6, X-7***

137. Barr F, Brabin L, Agbaje S, et al. Reducing iron deficiency anaemia due to heavy menstrual blood loss in Nigerian rural adolescents. Public Health Nutr. 1998 Dec;1(4):249-57. PMID: 10933425. ***X-4, X-5, X-9***

138. Barrington JW, Arunkalaivanan AS, Abdel-Fattah M. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol. 2003 May 1;108(1):72-4. PMID: 12694974. ***X-8***

139. Baskett TF, Farrell SA, Zilbert AW. Uterine fluid irrigation and absorption in hysteroscopic endometrial ablation. Obstet Gynecol. 1998 Dec;92(6):976-8. PMID: 9840561. ***X-5, X-8, X-9***

140. Bassol S, Cravioto MC, Durand M, et al. Mesigyna once-a-month combined injectable contraceptive: experience in Latin America. Contraception. 2000 May;61(5):309-16. PMID: 10906501. ***X-4, X-5***

141. Batar I, Kuukankorpi A, Rauramo I, et al. Two-year clinical experience with Nova-T 380, a novel copper-silver IUD. Adv Contracept. 1999;15(1):37-48. PMID: 10794045. ***X-4, X-5***

142. Bates GW, Bates SR, Whitworth NS. Reproductive failure in women who practice weight control. Fertil Steril. 1982 Mar;37(3):373-8. PMID: 6800847. ***X-3, X-5***

143. Bath LE, Critchley HO, Chambers SE, et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol. 1999 Dec;106(12):1265-72. PMID: 10609720. ***X-4, X-5, X-6, X-9***

144. Battino S, Ben-Ami M, Geslevich Y, et al. Factors associated with withdrawal bleeding after administration of oral dydrogesterone or medroxyprogesterone acetate in women with secondary amenorrhea. Gynecol Obstet Invest. 1996;42(2):113-6. PMID: 8878716. ***X-5***

145. Batukan C, Muderris II, Ozcelik B, et al. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecological Endocrinology. 2007;23(1):38-44. PMID: 17484511. ***X-5***

146. Batzer FR. Formulation and noncontraceptive uses of the new, low-dose oral contraceptive. J Reprod Med. 1984 Jul;29(7 Suppl):503-12. PMID: 6237195. ***X-1, X-3, X-5***

147. Baveja R, Bichille LK, Coyaji KJ, et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception. 1989 Jan;39(1):37-52. PMID: 2491981. ***X-9***

148. Baveja R, Bichille LK, Coyaji KJ, et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Contraception. 1989;39(1):37-52. PMID: 2491981. ***X-9***

149. Baweja R, Bhattacharya SK, Choudhury SD, et al. Indian Council of Medical Research. Task Force on Hormonal Contraception: Phase II randomized clinical trial with norethisterone oenanthate 50 mg alone and in combination with 5 mg or 2.5 mg of either estradiol valerate or cypionate as a monthly injectable contraceptive. Contraception. 1985 Oct;32(4):383-94. PMID: 3907967. ***X-9***

150. Bayhan G, Bahceci M, Demirkol T, et al. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism. Clinical and Experimental Obstetrics and Gynecology. 2000;27(3-4):203-6. PMID: 11214952. ***X-5, X-10***

151. Beals KA. Eating disorder and menstrual dysfunction screening, education, and treatment programs: survey results from NCAA Division 1 schools. Physician & Sportsmedicine. 2003;31(7):33-8. PMID: 20086473. ***X-3, X-5***

152. Beeby D, Morgan Hughes JO. Oxytocic drugs and anaesthesia. A controlled clinical trial of ergometrine, syntocinon and normal saline during evacuation of the uterus after spontaneous abortion. Anaesthesia. 1984 Aug;39(8):764-7. PMID: 6383111. ***X-5***

153. Beitins IZ, McArthur JW, Turnbull BA, et al. Exercise induces two types of human luteal dysfunction: confirmation by urinary free progesterone. J Clin Endocrinol Metab. 1991 Jun;72(6):1350-8. PMID: 1902847. ***X-3, X-4, X-5***

154. Belsey EM. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use. Contraception. 1988 Aug;38(2):207-25. PMID: 2971506. ***X-3, X-5, X-6***

155. Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in

Human Reproduction. Contraception. 1986 Sep;34(3):253-60. PMID: 3539509. ***X-1, X-3, X-5***

156. Benagiano G, Kivinen ST, Fadini R, et al. Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. Fertil Steril. 1996 Aug;66(2):223-9. PMID: 8690106. ***X-5, X-6***

157. Ben-Chetrit A, Hochner-Celnikier D, Lindenberg T, et al. Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. Isr Med Assoc J. 2005 May;7(5):302-6. PMID: 15909462. ***X-5, X-7***

158. Ben-Haroush A, Yogev Y, Mashiach R, et al. Pregnancy outcome of threatened abortion with subchorionic hematoma: possible benefit of bed-rest? Isr Med Assoc J. 2003 Jun;5(6):422-4. PMID: 12841015. ***X-4, X-5, X-9***

159. Bennett KL, Ohrmundt C, Maloni JA. Preventing intravasation in women undergoing hysteroscopic procedures. AORN J. 1996 Nov;64(5):792-9. PMID: 8922218. ***X-4, X-5, X-8, X-9***

160. Benster B, Carey A, Wadsworth F, et al. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause International. 2009;15(2):63-9. PMID: 19465671. ***X-7***

161. Berenson AB, Wiemann CM. Patient satisfaction and side effects with levonorgestrel implant (Norplant) use in adolescents 18 years of age or younger. Pediatrics. 1993 Aug;92(2):257-60. PMID: 8337026. ***X-3, X-5, X-9***

162. Berenson AB, Wiemann CM, Rickerr VI, et al. Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use. Am J Obstet Gynecol. 1997 Mar;176(3):586-92. PMID: 9077611. ***X-4, X-5***

163. Berga SL, Marcus MD, Loucks TL, et al. Recovery of ovarian activity in women with functional hypothalamic amenorrhea who were treated with cognitive behavior therapy. Fertility and Sterility. 2003 01 Oct;80(4):976-81. PMID: 2003406231. ***X-5***

164. Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharmaceutics and Drug Disposition. 2007;28(6):315-22. PMID: 17575559. ***X-4, X-5***

165. Berkowitz RS, Bernstein MR, Harlow BL, et al. Case-control study of risk factors for partial molar pregnancy. Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):788-94. PMID: 7573245. ***X-3, X-5***

166. Bertoli A, Fusco A, Magnani A, et al. Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism. Exp Clin Endocrinol Diabetes. 1995;103(1):15-20. PMID: 7621099. ***X-3, X-5***

167. Bewtra C, Kable WT, Gallagher JC. Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med. 1988 Feb;33(2):205-8. PMID: 2832598. ***X-7***

168. Bhattacharya S, Mollison J, Pinion S, et al. A comparison of bladder and ovarian function two years following hysterectomy or endometrial ablation. Br J Obstet Gynaecol. 1996 Sep;103(9):898-903. PMID: 8813310. ***X-5, X-8***

169. Bhattacharya S, Parkin DE, Reid TM, et al. A prospective randomised study of the effects of prophylactic antibiotics on the incidence of bacteraemia following hysteroscopic surgery. Eur J Obstet Gynecol Reprod Biol. 1995 Nov;63(1):37-40. PMID: 8674563. ***X-5, X-8***

170. Bij de Vaate AJ, van Doorninck CE, Visser M, et al. Endometrial aspiration before or after saline infusion sonography and the effect on specimen quality: a randomized study. J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):580-3. PMID: 18675597. ***X-4, X-5, X-9***

171. Biller BM, Baum HB, Rosenthal DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 1992 Sep;75(3):692-7. PMID: 1517356. ***X-3, X-5***

172. Billiet K, Dhont M, Vervaet C, et al. A multi-center prospective, randomized, double-blind trial studying the effect of misoprostol on the outcome of intrauterine insemination. Gynecol Obstet Invest. 2008;66(3):145-51. PMID: 18493141. ***X-5, X-9***

173. Bingol B, Gunenc MZ, Gedikbasi A, et al. Comparison of diagnostic accuracy of saline infusion sonohysterography, transvaginal sonography and hysteroscopy in postmenopausal bleeding. Arch Gynecol Obstet. 2011 Jul;284(1):111-7. PMID: 20665218. ***X-3, X-4, X-5, X-7***

174. Birbara C, Ruoff G, Sheldon E, et al. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current Medical Research and Opinion. 2006;22(1):199-210. PMID: 16393445. ***X-5***

175. Bitto A, Granese R, Triolo O, et al. Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. Phytomedicine. 2010 Sep;17(11):844-50. PMID: 20570122. ***X-6***

176. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol. 2002 Mar;186(3):389-95. PMID: 11904596. ***X-4, X-5***

177. Blankstein J, Rabinovici J, Goldenberg M, et al. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1987 Dec;65(6):1164-7. PMID: 3119650. ***X-4, X-5, X-10***

178. Bloch-Thomsen A, Silvestri S, Christiansen C, et al. Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: Levormeloxifene and raloxifene. Climacteric. 2003;6(2):159-67. PMID: 12841887. ***X-5, X-7***

179. Blode H, Klipping C, Richard F, et al. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone. Contraception. 2012 February;85(2):177-84. PMID: 2012035448. ***X-3, X-4, X-9, X-10***

180. Blum M, Blum G. The possible relationship between menorrhagia and occult hypothyroidism in IUD-wearing women. Adv Contracept. 1992 Dec;8(4):313-7. PMID: 1290333. ***X-3, X-4, X-5***

181. Blumenfeld Z, Von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Human Reproduction Update. 2008;14(6):543-52. PMID: 18824495. ***X-1, X-3, X-5***

182. Boateng J, Chi IC, Jones DB. An evaluation of six new intrauterine devices. Adv Contracept. 1994 Mar;10(1):57-70. PMID: 8030456. ***X-1, X-3, X-5, X-9***

183. Boerrigter PJ, van de Weijer PH, Baak JP, et al. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Maturitas. 1996 May;24(1-2):63-71. PMID: 8794436. ***X-5, X-7***

184. Bolaji, II, Mortimer G, Grimes H, et al. Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Gynecol Endocrinol. 1996 Feb;10(1):41-7. PMID: 8737191. ***X-3, X-7***

185. Bonduelle M, Walker JJ, Calder AA. A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgrad Med J. 1991 Sep;67(791):833-6. PMID: 1835005. ***X-5***

186. Bongers MY, Bourdrez P, Heintz AP, et al. Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health-related quality of life. Fertil Steril. 2005 Mar;83(3):724-34. PMID: 15749505. ***X-5, X-8***

187. Bongers MY, Bourdrez P, Mol BW, et al. Randomised controlled trial of bipolar radio-frequency endometrial ablation and balloon endometrial ablation. BJOG. 2004 Oct;111(10):1095-102. PMID: 15383112. ***X-5, X-8***

188. Bonn M, Eydeler U, Barkworth M, et al. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. Arzneimittel Forschung/Drug Research. 2009;59(12):651-8. PMID: 20108652. ***X-4***

189. Bonnar J. Acquired bleeding disorders: bleeding in obstetrics and surgery. Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:10-2. PMID: 7886547. ***X-3, X-5***

190. Bonnema RA, McNamara MC, Spencer AL. Contraception choices in women with underlying medical conditions. Am Fam Physician. 2010 Sep 15;82(6):621-8. PMID: 20842989. ***X-1, X-4, X-5, X-9***

191. Boonkasemsanti W, Reinprayoon D, Pruksananonda K, et al. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users. Hum Reprod. 1996 Oct;11 Suppl 2:115-23. PMID: 8982753. ***X-4, X-5, X-6***

192. Boonyarangkul A, Taneepanichskul S. Comparison of cycle control and side effects between transdermal contraceptive patch and an oral contraceptive in women older than 35 years. Journal of the Medical Association of Thailand. 2007;90(9):1715-9. PMID: 17957909. ***X-9***

193. Bouchard P, De Cicco-Nardone F, Spielmann D, et al. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women. Gynecol Endocrinol. 2005 Sep;21(3):142-8. PMID: 16353319. ***X-5, X-7***

194. Boucher M, Horbay GL, Griffin P, et al. Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. J Perinatol. 1998 May-Jun;18(3):202-7. PMID: 9659650. ***X-5, X-9***

195. Bourdy G, Walter A. Maternity and medicinal plants in Vanuatu. I. The cycle of reproduction. J Ethnopharmacol. 1992 Oct;37(3):179-96. PMID: 1453707. ***X-3, X-5***

196. Braam LAJLM, Knapen MHJ, Geusens P, et al. Factors Affecting Bone Loss in Female Endurance Athletes. A Two-Year Follow-Up Study. American Journal of Sports Medicine. 2003;31(6):889-95. PMID: 14623654. ***X-3, X-5***

197. Bratby MJ, Walker WJ. Uterine artery embolisation for symptomatic adenomyosis--mid-term results. Eur J Radiol. 2009 Apr;70(1):128-32. PMID: 18280686. ***X-4, X-5, X-8, X-9***

198. Brenner B, Wiis J. Experience with recombinant-activated factor VII in 30 patients with congenital factor

VII deficiency. Hematology. 2007 Feb;12(1):55-62. PMID: 17364994. ***X-4, X-5, X-9***

199. Breum L, Bjerre U, Bak JF, et al. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: Influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism: Clinical and Experimental. 1996;44(12):1570-6. PMID: 8786726. ***X-4, X-5***

200. Brill K, Schnitker J, Albring M. Clinical experience with a modern low-dose gestodene-containing oral contraceptive in adolescents. Adv Contracept. 1994 Dec;10(4):237-47. PMID: 7740990. ***X-3, X-9***

201. Broocks A, Pirke KM, Schweiger U, et al. Cyclic ovarian function in recreational athletes. J Appl Physiol. 1990 May;68(5):2083-6. PMID: 2361910. ***X-3, X-4, X-5***

202. Brooks PG, Serden SP. Preparation of the endometrium for ablation with a single dose of leuprolide acetate depot. J Reprod Med. 1991 Jul;36(7):477-8. PMID: 1941784. ***X-3, X-5, X-8***

203. Brown LM, Pottern LM, Hoover RN. Prenatal and perinatal risk factors for testicular cancer. Cancer Res. 1986 Sep;46(9):4812-6. PMID: 3731127. ***X-3, X-5***

204. Brown PM, Farquhar CM, Lethaby A, et al. Cost-effectiveness analysis of levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. BJOG. 2006 Jul;113(7):797-803. PMID: 16827763. ***X-8***

205. Browne DS. Endometrial resection--a comparison of techniques. Aust N Z J Obstet Gynaecol. 1996 Nov;36(4):448-52. PMID: 9006832. ***X-4, X-5, X-8***

206. Bruce D, Robinson J, Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric. 2004 Sep;7(3):261-6. PMID: 15669550. ***X-4, X-5, X-7***

207. Bruhat M, Rudolf K, Vaheri R, et al. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. Maturitas. 2001 Dec 14;40(3):259-71. PMID: 11731187. ***X-5, X-7***

208. Bruni V, Croxatto H, De La Cruz J, et al. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gestodene Study Group. Gynecol Endocrinol. 2000 Apr;14(2):90-8. PMID: 10836195. ***X-4, X-5***

209. Bruni V, Croxatto H, De La Cruz J, et al. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gynecological Endocrinology. 2000;14(2):90-8. PMID: 10836195. ***X-6, X-9***

210. Bruni V, Pontello V, Luisi S, et al. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):65-71. PMID: 18358586. ***X-4, X-5***

211. Brynhildsen J, Hammar M. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Menopause. 2002 Mar-Apr;9(2):137-44. PMID: 11875333. ***X-5, X-7***

212. Buasang K, Taneepanichskul S. Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use. J Med Assoc Thai. 2009 Mar;92(3):301-7. PMID: 19301720. ***X-4, X-5, X-6, X-9***

213. Buchanan RB, Blamey RW, Durrant KR, et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986 Sep;4(9):1326-30. PMID: 3528402. ***X-5***

214. Buckley RG, King KJ, Disney JD, et al. Serum progesterone testing to predict ectopic pregnancy in symptomatic first-trimester patients. Ann Emerg Med. 2000 Aug;36(2):95-100. PMID: 10918099. ***X-4, X-5, X-6, X-9***

215. Buckshee K, Banerjee K, Bhatla H. Uterine balloon therapy to treat menorrhagia. Int J Gynaecol Obstet. 1998 Nov;63(2):139-43. PMID: 9856319. ***X-4, X-5, X-8***

216. Buehler JW, Schulz KF, Grimes DA, et al. The risk of serious complications from induced abortion: do personal characteristics make a difference? Am J Obstet Gynecol. 1985 Sep 1;153(1):14-20. PMID: 4036997. ***X-3, X-5***

217. Bulletti C, Flamigni C, Prefetto RA, et al. Dysfunctional uterine bleeding (DUB). Ann N Y Acad Sci. 1994 Sep 30;734:80-90. PMID: 7978956. ***X-5***

218. Buppasiri P, Tangmanowutikul S, Yoosuk W. Randomized controlled trial of mefenamic acid vs paracervical block for relief of pain for outpatient uterine curettage. J Med Assoc Thai. 2005 Jul;88(7):881-5. PMID: 16241013. ***X-5, X-9***

219. Burch D, Bieshuevel E, Smith S, et al. Can endometrial protection be inferred from the bleeding pattern on combined cyclical hormone replacement therapy. Maturitas. 2000 Feb 15;34(2):155-60. PMID: 10714910. ***X-5, X-7***

220. Burch DJ, Spowart KJ, Jesinger DK, et al. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17 beta oestradiol. Br J Obstet Gynaecol. 1995 Mar;102(3):243-8. PMID: 7794851. ***X-7***

221. Busacca M, Luchini S, Molinari MA, et al. Hysteroscopic pictures following danazol therapy in endometrial hyperplasia. Acta Eur Fertil. 1987 May-Jun;18(3):197-201. PMID: 3439406. ***X-3***

222. Busfield RA, Farquhar CM, Sowter MC, et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. BJOG. 2006 Mar;113(3):257-63. PMID: 16487195. ***X-8***

223. Bushnell DM, Martin ML, Moore KA, et al. Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. Curr Med Res Opin. 2010 Dec;26(12):2745-55. PMID: 21043553. ***X-4, X-5, X-9***

224. Buyuk E, Durmusoglu F, Dokmeci C. Effect of initial gestagen treatment on bleeding patterns in postmenopausal women receiving continuous combined hormone replacement therapy. Menopause. 1999 Summer;6(2):156-60. PMID: 10374223. ***X-4, X-5, X-7***

225. Byrjalsen I, Alexandersen P, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone: effects on the postmenopausal endometrium. BJOG. 2000 Mar;107(3):347-55. PMID: 10740331. ***X-4, X-5, X-7***

226. Byrjalsen I, Bjarnason NH, Christiansen C. Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy. Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):539-49. PMID: 10076125. ***X-5, X-7***

227. Byrjalsen I, Thormann L, Meinecke B, et al. Sequential estrogen and progestogen therapy: assessment of progestational effects on the postmenopausal endometrium. Obstet Gynecol. 1992 Apr;79(4):523-8. PMID: 1532445. ***X-4, X-7***

228. Byrjalsen I, Thormann L, Riis BJ, et al. Secretory endometrial protein PP14 in serum from post-menopausal women receiving continuous combined oestradiol-cyproterone acetate: correlation with serum hormone concentrations and bleeding patterns. Maturitas. 1992 Aug;15(1):39-46. PMID: 1388220. ***X-3, X-4, X-7***

229. Cachrimanidou AC, Hellberg D, Nilsson S, et al. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception. 1993 Sep;48(3):205-16. PMID: 8222651. ***X-5, X-6, X-9***

230. Cai XM, Wu J. The mind-tranquilizing and menstruation-regulating method for acupuncture treatment of delayed menstrual cycle - A clinical controlled study. Journal of Traditional Chinese Medicine. 2009;29(1):35-8. PMID: 19514186. ***X-12***

231. Calguneri M, Ozbalkan Z, Ozturk MA, et al. Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome). Clin Rheumatol. 2006 Nov;25(6):782-8. PMID: 16547692. ***X-4, X-5, X-9***

232. Caliskan E, Filiz T, Yucesoy G, et al. Sublingual versus vaginal misoprostol for cervical ripening PRIOR to manual vacuum aspiration under local anaesthesia: A randomized study. European Journal of Contraception and Reproductive Health Care. 2007;12(4):372-7. PMID: 17853158. ***X-5***

233. Cameron IT, Baird DT. A controlled release form of 16,16-dimethyl-trans-delta 2-PGE, methyl ester for early abortion. Contraception. 1986 Feb;33(2):121-5. PMID: 3698593. ***X-3, X-5***

234. Cameron ST, Glasier AF, Gebbie A, et al. Comparison of a transdermal continuous combined and an interrupted progestogen HRT. Maturitas. 2006 Jan 10;53(1):19-26. PMID: 16325020. ***X-5, X-7***

235. Cameron ST, Walker J, Chambers S, et al. Comparison of transvaginal ultrasound, saline infusion sonography and hysteroscopy to investigate postmenopausal bleeding and unscheduled bleeding on HRT. Aust N Z J Obstet Gynaecol. 2001 Aug;41(3):291-4. PMID: 11592543. ***X-4, X-5, X-7***

236. Candiani GB, Vercellini P, Fedele L, et al. Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri. Acta Obstet Gynecol Scand. 1990;69(5):413-5. PMID: 2148663. ***X-3, X-6***

237. Canning S, Waterman M, Orsi N, et al. The efficacy of hypericum perforatum (st john's wort) for the treatment of premenstrual syndrome: A randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(3):207-25. PMID: 20155996. ***X-5***

238. Cano A, Tarin JJ, Duenas JL. Two-year prospective, randomized trial comparing an innovative twice-a- week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy. Fertility and Sterility. 1999;71(1):129-36. PMID: 9935129. ***X-7***

239. Canto De Cetina TE, Canto P, Ordonez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception. 2001 Mar;63(3):143-6. PMID: 11368986. ***X-4, X-5, X-6, X-9***

240. Canto de Cetina TE, Luna MO, Cetina Canto JA, et al. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections. Contraception. 2004 Feb;69(2):115-9. PMID: 14759615. ***X-4, X-5***

241. Carbonell JL, Rodriguez J, Aragon S, et al. Vaginal misoprostol 1000 microg for early abortion. Contraception. 2001 Mar;63(3):131-6. PMID: 11368984. ***X-4, X-5, X-9***

242. Carbonell JL, Rodriguez J, Delgado E, et al. Vaginal misoprostol 800 microg every 12 h for second-trimester abortion. Contraception. 2004 Jul;70(1):55-60. PMID: 15208053. ***X-4, X-5, X-9***

243. Carbonell JL, Varela L, Velazco A, et al. The use of misoprostol for abortion at < or = 9 weeks' gestation. Eur J Contracept Reprod Health Care. 1997 Sep;2(3):181-5. PMID: 9678090. ***X-4, X-5, X-6, X-9***

244. Cardamakis E, Georgopoulos A, Fotopoulos A, et al. Clinical experience with Norplant subdermal implant system as long-term contraception during adolescence. Eur J Contracept Reprod Health Care. 2002 Mar;7(1):36-40. PMID: 12041863. ***X-4, X-5, X-6***

245. Carlborg L. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version. Contraception. 1983;27(5):439-52. PMID: 6349925. ***X-9***

246. Carr BR. Cycle control with desogestrel-containing oral contraceptives--comparison of a monophasic and triphasic regimen. Int J Fertil Menopausal Stud. 1993 Sep-Oct;38(5):274-9. PMID: 8298666. ***X-3, X-5, X-9***

247. Carr BR, DelConte A. Using a low-dose contraceptive in women 35 years of age and over: 20 microg estradiol/100 microg levonorgestrel. Contraception. 2002 Jun;65(6):397-402. PMID: 12127636. ***X-4, X-5***

248. Carranza-Lira S, Martinez-Chequer JC, Santa Rita MT, et al. Endometrial changes according to hormone replacement therapy schedule. Menopause. 1998 Summer;5(2):86-9. PMID: 9689201. ***X-3, X-4, X-7, X-8***

249. Castaman G, Tosetto A, Federici AB, et al. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost. 2011 Apr;105(4):647-54. PMID: 21264446. ***X-4, X-5, X-6, X-9***

250. Castelo-Branco C, Vicente JJ, Pons F, et al. Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. J Reprod Med. 2001 Oct;46(10):875-9. PMID: 11725730. ***X-5, X-6, X-9***

251. Cayan F, Dilek U, Pata O, et al. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. Journal of Sexual Medicine. 2008;5(1):132-8. PMID: 17961145. ***X-7***

252. Cetin A, Cetin M. Diagnostic and therapeutic decision-making with transvaginal sonography for first trimester spontaneous abortion, clinically thought to be incomplete or complete. Contraception. 1998 Jun;57(6):393-7. PMID: 9693399. ***X-4, X-5, X-9***

253. Cetin NN, Karabacak O, Korucuoglu U, et al. Gonadotropin-releasing hormone analog combined with a low-dose oral contraceptive to treat heavy menstrual bleeding. Int J Gynaecol Obstet. 2009 Mar;104(3):236-9. PMID: 19062012. ***X-5***

254. Cetinkalp S, Karadeniz M, Erdogan M, et al. The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist. 2009;19(3):94-7. ***X-4, X-5, X-10***

255. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007 Sep;92(9):3582-9. PMID: 17579200. ***X-4, X-5, X-9***

256. Chadha Y, Mollison J, Howie F, et al. Guidelines in gynaecology: evaluation in menorrhagia and in urinary incontinence. BJOG. 2000 Apr;107(4):535-43. PMID: 10759275. ***X-4, X-5, X-9***

257. Chakraborti AS, Chatterjee P, Dutta S, et al. Rate of formation of hydrogen peroxide (H2O2) in IUD-fitted human endometrium--a preliminary report. Int J Fertil. 1982;27(3):132-3. PMID: 6128316. ***X-3, X-4, X-5***

258. Chamberlain G. Comparing treatments for menorrhagia. Nurs Times. 1992 Mar 11-17;88(11):46. PMID: 1297082. ***X-1, X-3, X-5, X-10***

259. Chamberlain G, Freeman R, Price F, et al. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1991 Jul;98(7):707-11. PMID: 1883797. ***X-3***

260. Chamberlain JA, Jamieson WM. Patient response to endometrial ablation with the Nd:YAG laser. Laser Nursing. 1989;3(3):5-11. ***X-3, X-8***

261. Chan CC, To WW. Antepartum hemorrhage of unknown origin--what is its clinical significance? Acta Obstet Gynecol Scand. 1999 Mar;78(3):186-90. PMID: 10078578. ***X-4, X-5, X-9***

262. Chan KK, Tam KF, Tse KY, et al. The use of vaginal antimicrobial after large loop excision of transformation zone: a prospective randomised trial. BJOG. 2007 Aug;114(8):970-6. PMID: 17635487. ***X-5, X-9***

263. Chan YF, Ho PC, Ma HK. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception. 1993 Jan;47(1):85-95. PMID: 8436004. ***X-3, X-5***

264. Chang BH, Edelman A, Godder K. Management of menstrual bleeding and cycle control after hematopoietic stem cell transplant. Int J Gynaecol Obstet. 2008 Jan;100(1):76-7. PMID: 17612542. ***X-5, X-9***

265. Chatterjee R, Banerjee S, Ghosh KK, et al. A study of postpill amenorrhea. Int J Gynaecol Obstet. 1980 Sep-Oct;18(2):113-4. PMID: 6108247. ***X-3, X-5, X-6***

266. Chattopdhyay B, Nigam A, Goswami S, et al. Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia. Eur Rev Med Pharmacol Sci. 2011 Jul;15(7):764-8. PMID: 21780544. ***X-4***

267. Chaudhuri SK, Das A, De KC, et al. Some hitherto unreported findings on the extragenital effects of progesterone in human females--a clinical study. Indian J Physiol Pharmacol. 1994 Jul;38(3):174-80. PMID: 7814077. ***X-3***

268. Chaudhury N, Gupta AN, Hazra MN, et al. Phase III-clinical trial with Norplant-2 (covered rods). Report of a 24-month study. National Programme of Research in Human Reproduction. Division of Human Resource Development Research Indian Council of Medical Research Ansari Nagar, New Delhi, India. Contraception. 1988 Dec;38(6):659-73. PMID: 3146464. ***X-3, X-5, X-9***

269. Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study. Eur J Contracept Reprod Health Care. 1999 Jun;4(2):75-83. PMID: 10427482. ***X-5***

270. Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 mug/20 mug versus triphasic norethindrone/ethinylestradiol 500-750-1000 mug/35 mug: A multicenter, randomized, open-label study. European Journal of Contraception and Reproductive Health Care. 1999;4(2):75-83. PMID: 10427482. ***X-9***

271. Cheewadhanaraks S, Peeyananjarassri K, Choksuchat C, et al. Interval of injections of intramuscular depot medroxyprogesterone acetate in the long-term treatment of endometriosis-associated pain: A randomized comparative trial. Gynecologic and Obstetric Investigation. 2009;68(2):116-21. PMID: 19556801. ***X-5, X-10***

272. Chen AY, Mottl-Santiago J, Vragovic O, et al. Bleeding after medication-induced termination of pregnancy with two dosing schedules of mifepristone and misoprostol. Contraception. 2006 Apr;73(4):415-9. PMID: 16531178. ***X-4, X-5, X-9***

273. Chen H, Li J, Cui T, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database of Systematic Reviews. 2011(11). ***X-1, X-3, X-5***

274. Chen JH, Wu SC, Shao WQ, et al. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women. Contraception. 1998 Jun;57(6):371-9. PMID: 9693396. ***X-3, X-9***

275. Cheng L, Zhu H, Wang A, et al. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod. 2000 Sep;15(9):1969-72. PMID: 10966997. ***X-5, X-6***

276. Cheng WC, Yen ML, Hsu SHJ, et al. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Endocrine. 2004;23(2-3):215-8. PMID: 15146102. ***X-7***

277. Cheng WF, Lin HH, Torng PL, et al. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997 Aug;66(2):233-7. PMID: 9264568. ***X-4, X-5, X-6, X-7, X-9***

278. Chetri M, Bhatta A, Amatya RN, et al. Five-year evaluation of safety, efficacy and acceptability of Norplant implants in Nepal. Adv Contracept. 1996 Sep;12(3):187-99. PMID: 8910661. ***X-4, X-5***

279. Cheung TH, Lo KW, Yim SF, et al. Dose effects of progesterone in add-back therapy during GnRHa treatment. J Reprod Med. 2005 Jan;50(1):35-40. PMID: 15730171. ***X-5, X-9***

280. Chick P. Prescribing an oral contraceptive for the individual woman. Aust Fam Physician. 1980 Feb;Suppl:8-12. PMID: 6444808. ***X-5, X-9***

281. Chimbira TH, Anderson AB, Naish C, et al. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo. Br J Obstet Gynaecol. 1980 Dec;87(12):1152-8. PMID: 7002206. ***X-3, X-5***

282. Chiwuzie J, Braimoh S, Unuigbe J, et al. Causes of maternal mortality in a semi-urban Nigerian setting. World Health Forum. 1995;16(4):405-8. PMID: 8534349. ***X-3, X-5***

283. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004 Mar 4;350(10):991-1004. PMID: 14999111. ***X-5, X-7***

284. Chompootaweep S, Kochagarn E, Tang-Usaha J, et al. Experience of Thai women in Bangkok with Norplant-2 implants. Contraception. 1998 Oct;58(4):221-5. PMID: 9866003. ***X-3, X-9***

285. Christodoulacos G, Panoulis C, Botsis D, et al. Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women. Maturitas. 2002;42(1):77-84. PMID: 12020983. ***X-4, X-7***

286. Christodoulakos GE, Botsis DS, Lambrinoudaki IV, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas. 2006 Mar 20;53(4):413-23. PMID: 16140483. ***X-4, X-5, X-7***

287. Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis. 2005 Nov;16(8):549-55. PMID: 16269927. ***X-5, X-9***

288. Chung JW, Jeong HJ, Joh JH, et al. Percutaneous transcatheter angiographic embolization in the management of obstetric hemorrhage. J Reprod Med. 2003 Apr;48(4):268-76. PMID: 12746991. ***X-4, X-5, X-6, X-8***

289. Chuni N, Chandrashekhar TS. Early pregnancy termination with a simplified mifepristone: Medical abortion outpatient regimen. Kathmandu Univ Med J (KUMJ). 2009 Jul-Sep;7(27):209-12. PMID: 20071864. ***X-4, X-5, X-9***

290. Churchyard GJ, Morgan C, Adams E, et al. A phase iia randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade RAD5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. 2011;6(8)PMID: 21857901. ***X-5***

291. Chwalisz K, Elger W, Stickler T, et al. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Human Reproduction. 2005;20(4):1090-9. PMID: 15665012. ***X-5***

292. Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril. 2007 Jun;87(6):1399-412. PMID: 17307170. ***X-5, X-6***

293. Cicardi M, Castelli R, Zingale LC, et al. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol. 1997 Feb;99(2):194-6. PMID: 9042044. ***X-4, X-5, X-9***

294. Cicinelli E, de Ziegler D, Alfonso R, et al. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril. 2005 Jun;83(6):1859-63. PMID: 15950667. ***X-4, X-5, X-7***

295. Cicinelli E, Pinto V, Tinelli R, et al. Rapid endometrial preparation for hysteroscopic surgery with oral desogestrel plus vaginal raloxifene: a prospective, randomized pilot study. Fertility and Sterility. 2007;88(3):698-701. PMID: 17678902. ***X-5, X-6***

296. Cirkel U, Ochs H, Schneider HP. A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. Eur J Obstet Gynecol Reprod Biol. 1995 Mar;59(1):61-9. PMID: 7781864. ***X-5, X-6, X-10***

297. Claessens EA, Cowell CA. Acute adolescent menorrhagia. Am J Obstet Gynecol. 1981 Feb 1;139(3):277-80. PMID: 6970521. ***X-3, X-5***

298. Clark LR, Barnes-Harper KT, Ginsburg KR, et al. Menstrual irregularity from hormonal contraception: a cause of reproductive health concerns in minority adolescent young women. Contraception. 2006 Sep;74(3):214-9. PMID: 16904414. ***X-4, X-5, X-6, X-9***

299. Clark TJ, Gupta JK. Outpatient thermal balloon ablation of the endometrium. Fertil Steril. 2004 Nov;82(5):1395-401. PMID: 15533366. ***X-4, X-5, X-8***

300. Clark TJ, Samuel N, Malick S, et al. Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: A randomized controlled trial. Obstetrics and Gynecology. 2011;117(1):109-18. PMID: 21173651. ***X-8***

301. Clegg JP, Guest JF, Hurskainen R. Cost-utility of levonorgestrel intrauterine system compared with hysterectomy and second generation endometrial ablative techniques in managing patients with menorrhagia in the UK. Curr Med Res Opin. 2007 Jul;23(7):1637-48. PMID: 17559758. ***X-5, X-8, X-9***

302. Clisham PR, Cedars MI, Greendale G, et al. Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns. Obstet Gynecol. 1992 Feb;79(2):196-201. PMID: 1731285. ***X-7***

303. Clisham PR, de Ziegler D, Lozano K, et al. Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women. Obstet Gynecol. 1991 Feb;77(2):241-6. PMID: 1846438. ***X-7***

304. Cobb KL, Bachrach LK, Greendale G, et al. Disordered eating, menstrual irregularity, and bone mineral density in female runners. Medicine and Science in Sports and Exercise. 2003;35(5):711-9. PMID: 12750578. ***X-3, X-4, X-5***

305. Cobb KL, Bachrach LK, Sowers M, et al. The effect of oral contraceptives on bone mass and stress fractures in female runners. Med Sci Sports Exerc. 2007 Sep;39(9):1464-73. PMID: 17805075. ***X-5, X-9***

306. Cochrane R, Regan L. Undetected gynaecological disorders in women with renal disease. Hum Reprod. 1997 Apr;12(4):667-70. PMID: 9159421. ***X-4, X-5, X-9***

307. Coelingh Bennink HJ, van der Steeg HJ. Failure of bromocriptine to restore the menstrual cycle in normoprolactinemic post-pill amenorrhea. Fertil Steril. 1983 Feb;39(2):238-40. PMID: 6822306. ***X-5, X-6, X-10***

308. Coenen CMH, Thomas CMG, Borm GF, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53(3):171-6. PMID: 8689882. ***X-4, X-5***

309. Cohen CR, Brown J, Moscicki AB, et al. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel(R)) in healthy young women administered twice daily for 14 days. PLoS One. 2011;6(1):e16258. PMID: 21311578. ***X-5***

310. Cohen I, Azaria R, Fishman A, et al. Endometrial cancers in postmenopausal breast cancer patients with tamoxifen treatment. Int J Gynecol Pathol. 1999 Oct;18(4):304-9. PMID: 10542937. ***X-4, X-5, X-6, X-7***

311. Cohen I, Figer A, Tepper R, et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol. 1999 Feb;72(2):202-7. PMID: 10021302. ***X-4, X-5, X-6, X-9***

312. Colacurci N, De Placido G, Mollo A, et al. Short-term use of Goserelin depot in the treatment of dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 1995;22(3):212-9. PMID: 7554259. ***X-3***

313. Colao A, Pivonello R, Di Somma C, et al. Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clin Endocrinol (Oxf). 2007 May;66(5):714-22. PMID: 17388794. ***X-4, X-5, X-9***

314. Cole LP, Potts DM, Aranda C, et al. An evaluation of the TCu 380Ag and the Multiload Cu375. Fertil Steril. 1985 Feb;43(2):214-7. PMID: 3881295. ***X-9***

315. Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol. 1993 Oct;24(10):1073-7. PMID: 8406417. ***X-3, X-6, X-8***

316. Collett D, Weerasooriya N. A modelling approach to the analysis of menstrual diary data. Stat Med. 1993 May 30;12(10):955-65. PMID: 8337552. ***X-3, X-4, X-5***

317. Comparato MR, Yabur JA, Bajares M. Contraceptive efficacy and acceptability of a monophasic oral contraceptive containing 30 microg ethinyl estradiol and 150 microg desogestrel in Latin-American women. Adv Contracept. 1998 Mar;14(1):15-26. PMID: 9587005. ***X-3, X-9***

318. Confino E, Ismajovich B, Rudick A, et al. Comparison between OM-GA Cu and Copper-T IUCDs. Contraception. 1983 Dec;28(6):521-5. PMID: 6370586. ***X-9***

319. Connor PD, Tavernier LA, Thomas SM, et al. Determining risk between Depo-Provera use and increased uterine bleeding in obese and overweight women. J Am Board Fam Pract. 2002 Jan-Feb;15(1):7-10. PMID: 11841143. ***X-4, X-5, X-9***

320. Contreras CM, Azamar-Arizmendi G, Saavedra M, et al. A Five-Day Gradual Reduction Regimen of Chlormadinone Reduces Premenstrual Anxiety and Depression: A Pilot Study. Archives of Medical Research. 2006;37(7):907-13. PMID: 16971235. ***X-5***

321. Cooper KG, Grant AM, Garratt AM. The impact of using a partially randomised patient preference design when evaluating alternative managements for heavy menstrual bleeding. Br J Obstet Gynaecol. 1997 Dec;104(12):1367-73. PMID: 9422014. ***X-5, X-8***

322. Cooper KG, Jack SA, Parkin DE, et al. Five-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. BJOG. 2001 Dec;108(12):1222-8. PMID: 11843383. ***X-5, X-8***

323. Cooper KG, Parkin DE, Garratt AM, et al. A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss. Br J Obstet Gynaecol. 1997 Dec;104(12):1360-6. PMID: 9422013. ***X-4, X-8***

324. Cooper KG, Parkin DE, Garratt AM, et al. Two-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. Br J Obstet Gynaecol. 1999 Mar;106(3):258-65. PMID: 10426646. ***X-5, X-8***

325. Corson SL. A multicenter evaluation of endometrial ablation by Hydro ThermAblator and rollerball for treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2001 Aug;8(3):359-67. PMID: 11509774. ***X-5, X-8***

326. Corson SL, Brill AI, Brooks PG, et al. One-year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists. 2000;7(4):489-97. PMID: 11044499. ***X-8***

327. Coskun E, Cakiroglu Y, Aygun BK, et al. Effect of copper intrauterine device on the cyclooxygenase and inducible nitric oxide synthase expression in the luteal phase endometrium. Contraception. 2011 Dec;84(6):637-41. PMID: 22078195. ***X-3, X-4, X-5***

328. Cosman F, Baz-Hecht M, Cushman M, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: A randomized-controlled study and review of the literature. Thrombosis Research. 2005;116(1):1-3. PMID: 15850603. ***X-7***

329. Costa SH, Vessey MP. Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet. 1993 May 15;341(8855):1258-61. PMID: 8098402. ***X-3, X-5***

330. Coulter A, Peto V, Doll H. Patients' preferences and general practitioners' decisions in the treatment of menstrual disorders. Fam Pract. 1994 Mar;11(1):67-74. PMID: 8034155. ***X-3***

331. Coulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract. 1994 Dec;11(4):394-401. PMID: 7895967. ***X-3***

332. Coutinho EM. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). Contraception. 1993 Jan;47(1):97-105. PMID: 8436005. ***X-3, X-9***

333. Coutinho EM, Boulanger GA, Goncalves MT. Regression of uterine leiomyomas after treament with gestrinone, an antiestrogen, antiprogesterone. American Journal of Obstetrics and Gynecology. 1986;155(4):761-7. PMID: 3532799. ***X-3, X-6***

334. Coutinho EM, de Souza JC, Athayde C, et al. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant. Contraception. 1996 Feb;53(2):121-5. PMID: 8838490. ***X-3, X-9***

335. Coutinho EM, Spinola P, Barbosa I, et al. Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate. Contraception. 1997 Mar;55(3):175-81. PMID: 9115007. ***X-5***

336. Coutinho EM, Spinola P, Tomaz G, et al. Efficacy, acceptability, and clinical effects of a low-dose injectable contraceptive combination of dihydroxyprogesterone acetophenide and estradiol enanthate. Contraception. 2000 Apr;61(4):277-80. PMID: 10899484. ***X-4, X-5, X-6***

337. Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care. 2002 Apr;28(2):73-7. PMID: 12396776. ***X-4, X-5***

338. Cox M, Tripp J, Blacksell S. Clinical performance of the Nova T380 intrauterine device in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care. 2002 Apr;28(2):69-72. PMID: 12396775. ***X-4, X-5***

339. Cramer DW, Liberman RF, Hornstein MD, et al. Basal hormone levels in women who use acetaminophen for menstrual pain. Fertil Steril. 1998 Aug;70(2):371-3. PMID: 9696240. ***X-4, X-5, X-9***

340. Cramer EH, Jones P, Keenan NL, et al. Is naturopathy as effective as conventional therapy for treatment of menopausal symptoms? Journal of Alternative and Complementary Medicine. 2003;9(4):529-38. PMID: 14499029. ***X-3, X-5***

341. Creasy GW, Fisher AC, Hall N, et al. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol: Effects on the lipid profile. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2003;48(3):179-86. PMID: 12698776. ***X-4, X-5***

342. Creatsas G, Cardamakis E, Deligeoroglou E, et al. Tenoxicam versus lynestrenol-ethinyl estradiol treatment of dysfunctional uterine bleeding cases during adolescence. J Pediatr Adolesc Gynecol. 1998 Nov;11(4):177-80. PMID: 9806127. ***X-5***

343. Creinin MD, Harwood B, Guido RS, et al. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet. 2004 Jul;86(1):22-6. PMID: 15207665. ***X-4, X-5, X-9***

344. Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol. 2008 Feb;111(2 Pt 1):267-77. PMID: 18238962. ***X-5***

345. Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: A randomized controlled trial. Obstetrics and Gynecology. 2006;108(5):1089-97. PMID: 17077229. ***X-5***

346. Creinin MD, Schreiber CA, Bednarek P, et al. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: A randomized controlled trial. Obstetrics and Gynecology. 2007;109(4):885-94. PMID: 17400850. ***X-5***

347. Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction. 2006;21(1):248-56. PMID: 16176939. ***X-5, X-6, X-10***

348. Crosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol. 1997 Aug;90(2):257-63. PMID: 9241305. ***X-8***

349. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000 Sep;5 Suppl 2:21-8. PMID: 11246604. ***X-4, X-5***

350. Croxatto HB, Brache V, Massai R, et al. Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception. Contraception. 2006 Jan;73(1):46-52. PMID: 16371294. ***X-4, X-5, X-9***

351. Croxatto HB, Massai MR, Salvatierra AM, et al. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters. Contraception. 1996 Aug;54(2):79-86. PMID: 8842583. ***X-4, X-5***

352. Croxatto HB, Urbancsek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod. 1999 Apr;14(4):976-81. PMID: 10221230. ***X-3, X-9***

353. Csemiczky G, Dieben T, Coeling Bennink HJ, et al. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception. 1996 Dec;54(6):333-8. PMID: 8968661. ***X-4, X-9***

354. Csermely T, Halvax L, Schmidt E, et al. Occurrence of osteopenia among adolescent girls with oligo/amenorrhea. Gynecol Endocrinol. 2002 Apr;16(2):99-105. PMID: 12012630. ***X-4, X-5, X-9***

355. Cuong DT, My Huong NT. Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem, in Vietnamese women. Contraception. 1996 Sep;54(3):169-79. PMID: 8899259. ***X-9***

356. Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertility and Sterility. 1994;61(2):281-7. PMID: 8299783. ***X-5***

357. Czeizel A, Keller S, Bod M. An aetiological evaluation of increased occurrence of congenital limb reduction abnormalities in Hungary, 1975-1978. Int J Epidemiol. 1983 Dec;12(4):445-9. PMID: 6654566. ***X-3, X-5***

358. da Silva MO, Costa MM. Reason, myths and fantasies: preliminary data and reflections about the Portuguese experience with LNG-IUS-induced hypomenorrhea. Eur J Contracept Reprod Health Care. 1999 Mar;4(1):21-5. PMID: 10367192. ***X-4, X-5***

359. Dada OA, Godfrey EM, Piaggio G, et al. A randomized, double-blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception. 2010;82(4):373-8. PMID: 20851232. ***X-5, X-9***

360. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. 1992 Mar;57(3):505-13. PMID: 1740195. ***X-3, X-4, X-5***

361. Dahmoun M, Odmark IS, Risberg B, et al. Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. Maturitas. 2004 Oct 15;49(2):114-23. PMID: 15474755. ***X-4, X-5, X-7***

362. Danli S, Qingxiang S, Guowei S. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women. Contraception. 2000 Jul;62(1):15-8. PMID: 11024223. ***X-4, X-5, X-6***

363. D'Anna R, Cannata ML, Atteritano M, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: A 1-year randomized, double-blind, placebo-controlled study. Menopause. 2007;14(4):648-55. PMID: 17251874. ***X-7***

364. d'Arcangues C, Piaggio G, Brache V, et al. Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding. Contraception. 2004 Dec;70(6):451-62. PMID: 15541406. ***X-5, X-6***

365. Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009 May;91(5):1646-53. PMID: 18423453. ***X-4, X-5***

366. Dasgupta PR, Dutta S, Banerjee P, et al. Vitamin E (alpha tocopherol) in the management of menorrhagia associated with the use of intrauterine contraceptive devices (IUCD). Int J Fertil. 1983;28(1):55-6. PMID: 6134690. ***X-5, X-6***

367. Datey S, Gaur LN, Saxena BN. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)--an Indian experience. An ICMR Task Force Study. Indian Council of Medical Research. Contraception. 1995 Mar;51(3):155-65. PMID: 7621684. ***X-3, X-6, X-9***

368. David M, Chen FC, Lichtenegger W. NO-donor nitroglycerin versus the prostaglandin gemeprost for cervical ripening in first trimester missed abortion. Int J Gynaecol Obstet. 2003 Oct;83(1):71-2. PMID: 14511877. ***X-4, X-5, X-9***

369. Davies AJ, Anderson AB, Turnbull AC. Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstet Gynecol. 1981 Jan;57(1):74-8. PMID: 7005780. ***X-5, X-6***

370. Davies GC, Feng LX, Newton JR, et al. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception. 1993 Mar;47(3):251-61. PMID: 8462316. ***X-3, X-4, X-5, X-9***

371. Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999 Apr;93(4):558-65. PMID: 10214833. ***X-4, X-5, X-7***

372. Davies KE, Halkes M, Swart M, et al. Paracervical local anaesthetic block as a useful adjunct for analgesia following endometrial balloon thermoablation. Journal of One-Day Surgery. 2007;17(3):76-8. ***X-3, X-5, X-8, X-10***

373. Davis A, Westhoff C, De Nonno L. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. J Am Med Womens Assoc. 2000;55(3 Suppl):141-4. PMID: 10846324. ***X-4, X-5, X-6, X-9***

374. Davis AR, Hendlish SK, Westhoff C, et al. Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure: results from a randomized trial. Am J Obstet Gynecol. 2007 Jan;196(1):31 e1-7. PMID: 17240222. ***X-5, X-9***

375. Davis AR, Robilotto CM, Westhoff CL, et al. Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure. Hum Reprod. 2004 Jul;19(7):1655-8. PMID: 15178656. ***X-4, X-5, X-9***

376. De Aloysio D, Altieri P, Penacchioni P, et al. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: Comparison between two regimens of HRT. Maturitas. 1998;29(3):261-4. PMID: 9699198. ***X-6, X-7***

377. de Castro A, Perez-Iglesias R, Vicandi F, et al. Comparison of two copper IUDs: the MLCu375 and the Nova-T. Adv Contracept. 1987 Dec;3(4):319-22. PMID: 3445799. ***X-9***

378. de Cetina TC, Reyes LP, Gamboa LV, et al. A comparative clinical trial of Norinyl 1 + 35 versus Norinyl 1 + 50 in Merida, Yucatan, Mexico. Adv Contracept. 1990 Jun;6(2):125-39. PMID: 2206018. ***X-9***

379. De Falco M, Staibano S, D'Armiento FP, et al. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J Soc Gynecol Investig. 2006 May;13(4):297-303. PMID: 16697947. ***X-4, X-5, X-6, X-8, X-9***

380. De Franciscis P, Cobellis L, Fornaro F, et al. Low-dose hormone therapy in the perimenopause. Int J Gynaecol Obstet. 2007 Aug;98(2):138-42. PMID: 17572422. ***X-10***

381. De Lena M, Tommasi S, Schittulli F, et al. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study. Tumori. 1990 Apr 30;76(2):190-5. PMID: 2139523. ***X-5, X-7***

382. De Leo V, la Marca A, Morgante G, et al. Comparison of two HRT regimens with bimonthly and monthly progestin administration in postmenopause. Maturitas. 1999 Jan 4;31(2):171-7. PMID: 10227012. ***X-4, X-5, X-7***

383. De Luis DA, Becerra A, Lahera M, et al. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Endocrinol Invest. 2000 Jul-Aug;23(7):428-34. PMID: 11005266. ***X-4, X-5, X-6, X-9***

384. De Nonno LJ, Westhoff C, Fielding S, et al. Timing of pain and bleeding after mifepristone-induced abortion. Contraception. 2000 Dec;62(6):305-9. PMID: 11239617. ***X-4, X-5, X-6, X-9***

385. de Souza SS, Camargos AF, de Rezende CP, et al. A randomized prospective trial comparing the levonorgestrel-releasing intrauterine system with thermal balloon ablation for the treatment of heavy menstrual bleeding. Contraception. 2010 Mar;81(3):226-31. PMID: 20159179. ***X-5, X-8***

386. de Ziegler D, Ferriani R, Moraes LA, et al. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod. 2000 Jun;15 Suppl 1:149-58. PMID: 10928426. ***X-4, X-5, X-7***

387. Delconte A, Loffer F, Grubb GS. Cycle control with oral contraceptives containing 20 mug of ethinyl estradiol: A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 mug/20 mug) and norethindrone/ethinyl estradiol (1000 mug/20 mug). Contraception. 1999;59(3):187-93. PMID: 10382082. ***X-9***

388. Demarquay G, Caclin A, Brudon F, et al. Exacerbated attention orienting to auditory stimulation in migraine patients. Clin Neurophysiol. 2011 Sep;122(9):1755-63. PMID: 21396888. ***X-4, X-5, X-9***

389. Dempsey A, Roca C, Westhoff C. Vaginal estrogen supplementation during Depo-Provera initiation: A randomized controlled trial. Contraception. 2010;82(3):250-5. PMID: 20705153. ***X-6***

390. Dennehy CE. The Use of Herbs and Dietary Supplements in Gynecology:An Evidence-Based Review. Journal of Midwifery and Women's Health. 2006;51(6):402-9. PMID: 17081929. ***X-1, X-3, X-5***

391. Dennis AR, Leeson-Payne CG, Hobbs GJ. Analgesia after Caesarean section - The use of rectal diclofenac as an adjunct to spinal morphine. Anaesthesia. 1995;50(4):297-9. PMID: 7747843. ***X-5***

392. Descargues G, Douvrin F, Degre S, et al. Abnormal placentation and selective embolization of the uterine arteries. Eur J Obstet Gynecol Reprod Biol. 2001 Nov;99(1):47-52. PMID: 11604185. ***X-4, X-5, X-6, X-8***

393. Dessole S, Coccollone E, Ambrosini G, et al. Oligomenorrhea treatment by purified FSH using a fixed protocol. Gynecol Obstet Invest. 1996;42(3):187-90. PMID: 8938472. ***X-3, X-5***

394. DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol. 1982 Mar;59(3):285-91. PMID: 6281704. ***X-5, X-10***

395. Dhingra N, Punia RS, Radotra A, et al. Arias-Stella reaction in upper genital tract in pregnant and non-pregnant women: a study of 120 randomly selected cases. Arch Gynecol Obstet. 2007 Jul;276(1):47-52. PMID: 17219163. ***X-4, X-5, X-9***

396. Di Carlo C, Sammartino A, Di Spiezio Sardo A, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause. 2005 Sep-Oct;12(5):520-5. PMID: 16145305. ***X-5, X-7***

397. Di Carlo C, Tommaselli GA, Gargano V, et al. Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric. 2010 Oct;13(5):442-6. PMID: 20575654. ***X-5, X-7***

398. Di Caro S, Hamad GG, Fernstrom MH, et al. Medical strategies for weight loss in the overweight and obese patient. Minerva Gastroenterologica e Dietologica. 2006;52(4):415-30. PMID: 17108871. ***X-1, X-3, X-5***

399. Di Lieto A, Catalano D, Miranda L, et al. Action of a prostaglandin synthetase inhibitor on IUD associated uterine bleeding. Clin Exp Obstet Gynecol. 1987;14(1):41-4. PMID: 3102127. ***X-3, X-5, X-6***

400. Diamond MP, Greene JW, Thompson JM, et al. Interaction of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception. 1985 Jun;31(6):623-32. PMID: 4042660. ***X-3, X-5, X-6***

401. Diaz J, Bahamondes L, Monteiro I, et al. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception. 2000 Aug;62(2):59-61. PMID: 11102588. ***X-4***

402. Diaz S, Herreros C, Juez G, et al. Fertility regulation in nursing women: VII. Influence of NORPLANT levonorgestrel implants upon lactation and infant growth. Contraception. 1985 Jul;32(1):53-74. PMID: 3931973. ***X-6, X-9***

403. Dickason LA, Dinsmoor MJ. Red blood cell transfusion and cesarean section. Am J Obstet Gynecol. 1992 Aug;167(2):327-30; discussion 30-2. PMID: 1497033. ***X-3, X-5***

404. Dickerson J, Bressler R, Christian CD. Liver function tests and low-dose estrogen oral contraceptives. Contraception. 1980 Dec;22(6):597-603. PMID: 7214908. ***X-3, X-4***

405. Dickey RP, Nichols JE, Steinkampf MP, et al. Highly purified human-derived follicle-stimulating hormone (Bravelle has equivalent efficacy to follitropin-beta (Follistim) in infertile women undergoing in vitro fertilization. Reproductive Biology and Endocrinology. 2003;1(03)PMID: 14609434. ***X-5***

406. Dieben TO, op ten Berg MT, Coelingh Bennink HJ. Cycle control and side effects of a new combiphasic oral contraceptive regimen. Arzneimittelforschung. 1994 Jul;44(7):877-9. PMID: 7945527. ***X-3, X-9***

407. Dildy GA, Scott JR, Saffer CS, et al. An effective pressure pack for severe pelvic hemorrhage. Obstet Gynecol. 2006 Nov;108(5):1222-6. PMID: 17077246. ***X-4, X-5, X-8, X-9***

408. Dittrich R, Parker L, Rosen JB, et al. Transdermal contraception: Evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. American Journal of Obstetrics and Gynecology. 2002;186(1):15-20. PMID: 11810078. ***X-9***

409. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol. 1989 Jul;96(7):840-4. PMID: 2765430. ***X-5***

410. Dockeray CJ, Sheppard BL, Daly L, et al. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol. 1987 Apr;24(4):309-18. PMID: 2953634. ***X-3, X-4***

411. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clinical Therapeutics. 2009;31(3):542-59. PMID: 19393844. ***X-5***

412. Doherty L, Harper A, Russell M. Menorrhagia management options. Ulster Med J. 1995 Apr;64(1):64-71. PMID: 7502405. ***X-3, X-5***

413. Doll H, Brown S, Thurston A, et al. Pyridoxine (vitamin B6) and the premenstrual syndrome: a randomized crossover trial. The Journal of the Royal College of General Practitioners. 1989;39(326):364-8. PMID: 2558186. ***X-5***

414. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012 Feb 2;366(5):409-20. PMID: 22296075. ***X-6***

415. Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012 Feb 2;366(5):421-32. PMID: 22296076. ***X-6***

416. Donnez J, Vilos G, Gannon MJ, et al. Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a 3-year follow-up

evaluation. Fertil Steril. 2001 Mar;75(3):620-2. PMID: 11239552. ***X-8***

417. Donnez J, Vilos G, Gannon MJ, et al. Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomized, double-blind study. Fertil Steril. 1997 Jul;68(1):29-36. PMID: 9207580. ***X-5, X-8, X-9***

418. Doren M, Rubig A, Coelingh Bennink HJ, et al. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause. 1999 Winter;6(4):299-306. PMID: 10614676. ***X-5, X-7***

419. Dorenberg EJ, Novakovic Z, Smith HJ, et al. Uterine fibroid embolization can still be improved: observations on post-procedure magnetic resonance imaging. Acta Radiol. 2005 Aug;46(5):547-53. PMID: 16224935. ***X-4, X-5, X-6, X-8, X-9***

420. Doyle M, Warwick A, Redman C, et al. Does application of Monsel's solution after loop diathermy excision of the transformation zone reduce post operative discharge? Results of a prospective randomised controlled trial. Br J Obstet Gynaecol. 1992 Dec;99(12):1023-4. PMID: 1341890. ***X-5, X-8***

421. Dreher E, von Fischer B. Treatment of primary dysmenorrhea and dysmenorrhea because of IUP with PG-synthetase inhibitors. Adv Prostaglandin Thromboxane Res. 1980;8:1487-93. PMID: 6769316. ***X-3, X-5, X-10***

422. Droegemueller W, Katta LR, Bright TG, et al. Triphasic Randomized Clinical Trial: comparative frequency of intermenstrual bleeding. Am J Obstet Gynecol. 1989 Nov;161(5):1407-11. PMID: 2686457. ***X-6, X-9***

423. D'Souza RE, Masters T, Bounds W, et al. Randomised controlled trial assessing the acceptability of GyneFix versus Gyne-T380S for emergency contraception. J Fam Plann Reprod Health Care. 2003 Apr;29(2):23-9. PMID: 12681033. ***X-5, X-9***

424. Du MK, Zheng HM, Chen HC, et al. Study of Norplant implants in Shanghai: three-year experience. Int J Gynaecol Obstet. 1990 Dec;33(4):345-57. PMID: 1979289. ***X-3, X-9***

425. Duclos M. A critical assessment of hormonal methods used in monitoring training status in athletes. International SportMed Journal. 2008;9(2):56-66. ***X-1, X-3, X-5***

426. Duflos-Cohade C, Amandruz M, Thibaud E. Pubertal metrorrhagia. J Pediatr Adolesc Gynecol. 1996 Feb;9(1):16-20. PMID: 9551371. ***X-4, X-5, X-9***

427. Duijkers IJM, Klipping C, Grob P, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. European Journal of Contraception and Reproductive Health Care. 2010;15(5):314-25. PMID: 20695770. ***X-4, X-9***

428. Dunphy BC, Goerzen J, Greene CA, et al. A double-blind randomised study comparing danazol and medroxyprogesterone acetate in the management of menorrhagia. Journal of Obstetrics and Gynaecology. 1998;18(6):553-5. PMID: 15512177. ***X-5***

429. Dunson TR, McLaurin VL, Israngkura B, et al. A comparative study of two low-dose combined oral contraceptives: results from a multicenter trial. Contraception. 1993 Aug;48(2):109-19. PMID: 8403908. ***X-9***

430. Durning P, Sellwood RA. Bromocriptine in severe cyclical breast pain. Br J Surg. 1982 May;69(5):248-9. PMID: 7042033. ***X-5***

431. Dushay J, Gao C, Gopalakrishnan GS, et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012 January;35(1):4-11. PMID: 2012180104. ***X-5***

432. Dusterberg B, Ellman H, Muller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol. 1996 Feb;10(1):33-9. PMID: 8737190. ***X-3, X-9***

433. Edelman AB, Koontz SL, Nichols MD, et al. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given? Obstet Gynecol. 2006 Mar;107(3):657-65. PMID: 16507938. ***X-6, X-9, X-10***

434. Edelman DA, Kothenbeutel R, Levinski MJ, et al. Comparative trials of low-dose combined oral contraceptives. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 1983;28(3):195-200. PMID: 6854550. ***X-9***

435. Edlund M, Andersson K, Rybo G, et al. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol. 1995 Nov;102(11):913-7. PMID: 8534629. ***X-5***

436. Edlund M, Blomback M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis. 2002 Apr;13(3):225-31. PMID: 11943936. ***X-5***

437. Egarter C, Geurts P, Boschitsch E, et al. The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Acta Obstetricia et Gynecologica Scandinavica. 1996;75(4):386-93. PMID: 8638462. ***X-5, X-10***

438. Egarter C, Huber J, Leikermoser R, et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas. 1996 Feb;23(1):55-62. PMID: 8861087. ***X-5, X-7***

439. Eisinger SH, Fiscella J, Bonfiglio T, et al. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):215-8. PMID: 19586708. ***X-4, X-5, X-6, X-9***

440. El Beltagy NS, Darwish EA, Kasem MS, et al. Comparison between Cupper T380 IUD and Multiload 375 IUD in early post partum insertion. Middle East Fertility Society Journal. 2011;16(2):143-8. ***X-9***

441. El Sahwi S, Kamel M, Haiba N, et al. Hysteroscopic and hysterosalpingographic study after intrauterine insertion of quinacrine pellets for non-surgical sterilization. Advances in Contraceptive Delivery Systems. 1992;8(1-2):151-9. PMID: 12285561. ***X-5, X-9***

442. Elbehery MM, Nouh AA, Mohamed ML, et al. Insulin-like growth factor binding protein-1 and glycodelin levels in uterine flushing before and after hysteroscopic polypectomy. Clin Lab. 2011;57(11-12):953-7. PMID: 22239027. ***X-3, X-4, X-8***

443. Elder MG. Injectable contraception. Clin Obstet Gynaecol. 1984 Dec;11(3):723-41. PMID: 6239732. ***X-1, X-3, X-5, X-9, X-10***

444. Elder MG, Lawson JP, Elstein M, et al. The efficacy and acceptability of a low-dose levonorgestrel intravaginal ring for contraception in a UK cohort. Contraception. 1991 Feb;43(2):129-37. PMID: 1904020. ***X-3, X-9***

445. Eldred JM, Haynes PJ, Thomas EJ. A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. Clin Endocrinol (Oxf). 1992 Oct;37(4):354-9. PMID: 1483292. ***X-4, X-5, X-6, X-9, X-10***

446. Elechi EN, Elechi GN. Surgical management of patients with severe anaemia due to acute blood loss: a case for withholding perioperative blood transfusion. East Afr Med J. 1995 Jun;72(6):343-4. PMID: 7497999. ***X-3, X-5***

447. Elkind-Hirsch KE, Darensbourg C, Ogden B, et al. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception. 2007;76(5):348-56. PMID: 17963858. ***X-4***

448. Elkind-Hirsch KE, Phillips K, Bello SM, et al. Sequential hormonal supplementation with vaginal estradiol and progesterone gel corrects the effect of clomiphene on the endometrium in oligo-ovulatory women. Human Reproduction. 2002;17(2):295-8. PMID: 11821266. ***X-5, X-6, X-10***

449. Ellison PT, Lager C, Calfee J. Low profiles of salivary progesterone among college undergraduate women. J Adolesc Health Care. 1987 Mar;8(2):204-7. PMID: 3818407. ***X-3, X-4***

450. El-Mahgoub S. The norgestrel-T-IUD. Contraception. 1980 Sep;22(3):271-86. PMID: 7438754. ***X-4, X-9***

451. El-Mazny A, Abou-Salem N. A double-blind randomized controlled trial of vaginal misoprostol for cervical priming before outpatient hysteroscopy. Fertil Steril. 2011 Oct;96(4):962-5. PMID: 21575939. ***X-4, X-5***

452. Elnashar A, Abdelmageed E, Fayed M, et al. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod. 2006 Jul;21(7):1805-8. PMID: 16543255. ***X-5, X-10***

453. Elomaa K, Ranta S, Tuominen J, et al. Charcoal treatment and risk of escape ovulation in oral contraceptive users. Human Reproduction. 2001;16(1):76-81. PMID: 11139541. ***X-9***

454. Elovainio M, Teperi J, Aalto AM, et al. Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system. Int J Behav Med. 2007;14(2):70-5. PMID: 17926434. ***X-5, X-8***

455. Elsedeek MS. Puerperal and menstrual bleeding patterns with different types of contraceptive device fitted during elective cesarean delivery. Int J Gynaecol Obstet. 2012 Jan;116(1):31-4. PMID: 22036512. ***X-5, X-9, X-10***

456. Elstein M. IUCD liability. Br J Obstet Gynaecol. 1982 Sep;89(Suppl 4):11-9. PMID: 7150526. ***X-1, X-3, X-5***

457. Eltabbakh GH, Piver MS, Hempling RE, et al. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer. Gynecol Oncol. 1997 Jul;66(1):103-7. PMID: 9234929. ***X-4, X-5, X-9***

458. Emde C, Cilluffo T, Bauerfeind P, et al. Effect of a slow-release formula of trimoprostil on intragastric acidity in healthy volunteers. Aliment Pharmacol Ther. 1988 Apr;2(2):135-41. PMID: 2979239. ***X-3, X-4, X-5***

459. Emsley R, Oosthuizen P, Koen L, et al. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008 Dec;30(12):2378-86. PMID: 19167596. ***X-5, X-9***

460. Endrikat J, Cronin M, Gerlinger C, et al. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception. 2001 Sep;64(3):201-7. PMID: 11704101. ***X-5***

461. Endrikat J, Cronin M, Gerlinger C, et al. Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene. Contraception. 2001 Aug;64(2):99-105. PMID: 11704086. ***X-5***

462. Endrikat J, Dusterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception. 1999 Nov;60(5):269-74. PMID: 10717778. ***X-5***

463. Endrikat J, Hite R, Bannemerschult R, et al. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 mug ethinylestradiol/100 mug levonorgestrel and 20 mug ethinylestradiol/500 mug norethisterone. Contraception. 2001;64(1):3-10. PMID: 11535206. ***X-9***

464. Endrikat J, Lange E, Kunz M, et al. A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women. European Journal of Contraception and Reproductive Health Care. 2007;12(3):229-39. PMID: 17763261. ***X-4, X-7***

465. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception. 1997 Mar;55(3):131-7. PMID: 9115000. ***X-6, X-9***

466. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 mug ethinylestradiol/75 mug gestodene and 30 mug ethinylestradiol/75 mug gestodene, with respect to efficacy, cycle control, and tolerance. Contraception. 1997;55(3):131-7. PMID: 9115000. ***X-9***

467. Endrikat JS, Milchev NP, Kapamadzija A, et al. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception. 2009 Jun;79(6):428-32. PMID: 19442777. ***X-4, X-5***

468. Engman M, Granberg S, Williams AR, et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009 Aug;24(8):1870-9. PMID: 19389793. ***X-5, X-6, X-9***

469. Epstein E. Management of postmenopausal bleeding in Sweden: a need for increased use of hydrosonography and hysteroscopy. Acta Obstet Gynecol Scand. 2004 Jan;83(1):89-95. PMID: 14678091. ***X-4, X-5, X-7***

470. Epstein E, Valentin L. Rebleeding and endometrial growth in women with postmenopausal bleeding and endometrial thickness < 5 mm managed by dilatation and curettage or ultrasound follow-up: a randomized controlled study. Ultrasound Obstet Gynecol. 2001 Nov;18(5):499-504. PMID: 11844172. ***X-5, X-7***

471. Erel CT, Senturk LM, Oral E, et al. Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS. Gynecol Endocrinol. 1998 Aug;12(4):223-9. PMID: 9798131. ***X-4, X-5, X-9***

472. Erel CT, Senturk LM, Oral E, et al. Results of the ACTH stimulation test in hirsute women. J Reprod Med. 1999 Mar;44(3):247-52. PMID: 10202742. ***X-3, X-4, X-5***

473. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999 May;180(5):1072-9. PMID: 10329858. ***X-5, X-7***

474. Erkkola R, Mattila L, Powles T, et al. Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women. Breast Cancer Research and Treatment. 2005;93(3):277-87. PMID: 16172794. ***X-5***

475. Eschenbach DA. Earth, motherhood, and the intrauterine device. Fertil Steril. 1992 Jun;57(6):1177-9. PMID: 1601138. ***X-1, X-3, X-9, X-10***

476. Esteve JL, Varela L, Velazco A, et al. Early abortion with 800 micrograms of misoprostol by the vaginal route. Contraception. 1999 Apr;59(4):219-25. PMID: 10457865. ***X-4, X-5, X-9***

477. Ettinger B, Kenemans P, Johnson SR, et al. Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol. 2008 Sep;112(3):653-9. PMID: 18757665. ***X-5, X-7, X-9***

478. Evans KD. A cost utility analysis of sonohysterography compared with hysteroscopic evaluation for dysfunctional uterine bleeding. Journal of Diagnostic Medical Sonography. 2000;16(2):68-72. ***X-3, X-4, X-8***

479. Ezechi OC, Jogo A, Gab-Okafor C, et al. Effect of HIV-1 infection and increasing immunosuppression on menstrual function. J Obstet Gynaecol Res. 2010 Oct;36(5):1053-8. PMID: 21058440. ***X-4, X-5***

480. Facchinetti F, De Pietri R, Giunchi M, et al. Use of meclofenamic acid in gynecology and obstetrics: effects on postsurgical stress. Clin J Pain. 1991;7 Suppl 1:S60-3. PMID: 1810523. ***X-5***

481. Facchinetti F, Neri I, Fava M, et al. Menstrual-related mood changes in patients with oligomenorrhea. Gynecol Obstet Invest. 1994;38(2):122-6. PMID: 7959339. ***X-3, X-4, X-5***

482. Fairburn CG, Jones R, Peveler RC, et al. Psychotherapy and bulimia nervosa. Longer-term effects of interpersonal psychotherapy, behavior therapy, and cognitive behavior therapy. Arch Gen Psychiatry. 1993 Jun;50(6):419-28. PMID: 8498876. ***X-5***

483. Falaschi P, Martocchia A, Proietti A, et al. High incidence of hyperandrogenism-related clinical signs in patients with multiple sclerosis. Neuro Endocrinol Lett. 2001 Aug;22(4):248-50. PMID: 11524631. ***X-4, X-5, X-6, X-9***

484. Falcone T, Desjardins C, Bourque J, et al. Dysfunctional uterine bleeding in adolescents. J Reprod Med. 1994 Oct;39(10):761-4. PMID: 7837120. ***X-3***

485. Fallahian M, Ilkhani M. Menstrual disorders in nongenital tuberculosis. Infect Dis Obstet Gynecol. 2006;2006:18452. PMID: 17093348. ***X-4, X-5, X-9***

486. Fanta M, Hill M, Belacek J, et al. Comparison of corticoid substitution versus combined oral contraception administration in the treatment of non-classic adrenal hyperplasia: a prospective study. Gynecol Endocrinol. 2009 Jun;25(6):398-402. PMID: 19903032. ***X-4, X-5, X-9***

487. Farhi J, Orvieto R, Homburg R. Administration of clomiphene citrate in patients with polycystic ovary syndrome, without inducing withdrawal bleeding, achieves comparable treatment characteristics and outcome. Fertil Steril. 2010 Apr;93(6):2077-9. PMID: 19732872. ***X-3, X-5***

488. Farkas M, Szigethy A, Sas M. Clinicopharmacological examination of Anteovin. Ther Hung. 1987;35(1):14-8. PMID: 3438859. ***X-3, X-9, X-10***

489. Farquhar CM. The levonorgestrel intrauterine system: a simple and effective alternative for the management of menorrhagia? Med J Aust. 2002 Oct 21;177(8):444-5. PMID: 12381255. ***X-8***

490. Farquhar CM, Prentice A, Barlow DH, et al. Effective treatment of subfertility: introducing the Cochrane Menstrual Disorders and Subfertility Group. Hum Reprod. 1999 Jul;14(7):1678-83. PMID: 10402367. ***X-1, X-4, X-5, X-9***

491. Farr G, Amatya R. Contraceptive efficacy of the Copper T380A and the Multiload Cu250 IUD in three developing countries. Adv Contracept. 1994 Jun;10(2):137-49. PMID: 7942261. ***X-9***

492. Farr G, Amatya R. Contraceptive efficacy of the Copper T 380A and Copper T 200 intrauterine devices: results from a comparative clinical trial in six developing countries. Contraception. 1994 Mar;49(3):231-43. PMID: 8200217. ***X-9***

493. Farr G, Amatya R, Acosta M, et al. Clinical performance of the TCu 380A and Lippes Loop IUDs in three developing countries. Contraception. 1995 Jul;52(1):17-22. PMID: 8521710. ***X-3, X-5, X-9***

494. Farr G, Amatya R, Betancourt JD, et al. Clinical performance of the TCu 380A and TCu 220C IUDs in four developing country family planning clinics. Contraception. 1994 Nov;50(5):417-29. PMID: 7859451. ***X-9***

495. Farr G, Amatya R, Doh A, et al. An evaluation of the copper-T 380A IUD's safety and efficacy at three African centers. Contraception. 1996 May;53(5):293-8. PMID: 8724619. ***X-4, X-5, X-9***

496. Farr G, Rivera R, Amatya R. Non-physician insertion of IUDs: clinical outcomes among TCu380A insertions in three developing-country clinics. Adv Contracept. 1998 Mar;14(1):45-57. PMID: 9587008. ***X-3, X-5, X-9***

497. Faundes A, Alvarez F, Brache V, et al. Endometrial thickness and oestradiol concentration in women with bleeding complaints during use of Norplant implants. Hum Reprod. 1998 Jan;13(1):188-91. PMID: 9512255. ***X-4, X-5, X-9***

498. Fedele L, Bianchi S, Baglioni A, et al. Intranasal buserelin versus surgery in the treatment of uterine leiomyomata: long-term follow-up. Eur J Obstet Gynecol Reprod Biol. 1991 Jan 4;38(1):53-7. PMID: 1899079. ***X-6, X-8***

499. Fedele L, Bianchi S, Raffaelli R, et al. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. European Journal of Obstetrics Gynecology and Reproductive Biology. 2000;88(1):91-4. PMID: 10659924. ***X-6, X-7***

500. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry. 1984 Dec;47(12):1279-82. PMID: 6392481. ***X-3, X-5***

501. Fender GR, Prentice A, Gorst T, et al. Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ. 1999 May 8;318(7193):1246-50. PMID: 10231255. ***X-5, X-10, OTHER***

502. Feng C, Sun CC, Wang TT, et al. Decreased expression of endometrial vessel AQP1 and endometrial epithelium AQP2 related to anovulatory uterine bleeding in premenopausal women. Menopause. 2008 Jul-Aug;15(4 Pt 1):648-54. PMID: 18463544. ***X-4, X-5***

503. Ferenczy A, Gelfand MM, van de Weijer PH, et al. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone. Climacteric. 2002 Mar;5(1):26-35. PMID: 11974556. ***X-5, X-7***

504. Fernandez H, Capella S, Audibert F. Uterine thermal balloon therapy under local anaesthesia for the treatment of menorrhagia: a pilot study. Hum Reprod. 1997 Nov;12(11):2511-4. PMID: 9436696. ***X-4, X-5, X-8, X-9***

505. Fernandez H, Lucas C, Hedon B, et al. One year comparison between two add-back therapies in pateints treated with a GmRH agonist for symptomatic endometriosis: A randomized double-blind trial. Human Reproduction. 2004;19(6):1465-71. PMID: 15105403. ***X-4, X-5, X-10***

506. Fernandez H, Sefrioui O, Virelizier C, et al. Hysteroscopic resection of submucosal myomas in patients with infertility. Hum Reprod. 2001 Jul;16(7):1489-92. PMID: 11425835. ***X-4, X-5, X-6, X-9***

507. Fernandez-Mentoli ME, Diez-Gibert O, Samaniego JM, et al. Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment. Fertility and Sterility. 1995;63(3):522-7. PMID: 7851581. ***X-4, X-6***

508. Ferrari CI, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf). 1997 Apr;46(4):409-13. PMID: 9196602. ***X-4, X-5, X-9***

509. Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Human Reproduction. 2010;24(12):3033-41. PMID: 19726448. ***X-3, X-5, X-6***

510. Ferrero S, Venturini PL, Gillott DJ, et al. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: A randomized controlled trial. Reproductive Biology and Endocrinology. 2011;9(88)PMID: 21693037. ***X-5, X-10***

511. Ferry S, Hannaford P, Warskyj M, et al. Carpal tunnel syndrome: a nested case-control study of risk factors in women. Am J Epidemiol. 2000 Mar 15;151(6):566-74. PMID: 10733038. ***X-4, X-5, X-9***

512. Fine PM. Ulipristal acetate: A new emergency contraceptive that is safe and more effective than levonorgestrel. Women's Health. 2011;7(1):9-17. PMID: 21175385. ***X-1, X-5, X-9***

513. Fleischmann R, Vencovsky J, Van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Annals of the Rheumatic Diseases. 2009;68(6):805-11. PMID: 19015206. ***X-5***

514. Fleming R, Haxton MJ, Hamilton MP, et al. Successful treatment of infertile women with oligomenorrhoea using a combination of an LHRH agonist and exogenous gonadotrophins. Br J Obstet Gynaecol. 1985 Apr;92(4):369-73. PMID: 3921050. ***X-3, X-4, X-5***

515. Florio P, Gubbini G, Marra E, et al. A retrospective case-control study comparing hysteroscopic resection versus hormonal modulation in treating menstrual disorders due to isthmocele. Gynecol Endocrinol. 2011 Jun;27(6):434-8. PMID: 21204608. ***X-4, X-5, X-8***

516. Focan C, Beauduin M, Majois F, et al. High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: Randomized trial with 7-year update. Clinical Breast Cancer. 2004;5(2):136-41. PMID: 15245618. ***X-5***

517. Foden-Shroff J, Redman CW, Tucker H, et al. Do routine antibiotics after loop diathermy excision reduce morbidity? Br J Obstet Gynaecol. 1998 Sep;105(9):1022-5. PMID: 9763056. ***X-5, X-8, X-9***

518. Fogelholm M, Hiilloskorpi H. Weight and diet concerns in Finnish female and male athletes. Med Sci Sports Exerc. 1999 Feb;31(2):229-35. PMID: 10063811. ***X-4, X-5, X-9***

519. Foidart JM, Sulak PJ, Schellschmidt I, et al. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception. 2006 Jan;73(1):34-40. PMID: 16371292. ***X-4, X-5***

520. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000 Jun;5(2):124-34. PMID: 10943575. ***X-4, X-5***

521. Fontaine D, Lazorthes Y, Mertens P, et al. Safety and efficacy of deep brain stimulation in refractory cluster headache: A randomized placebo-controlled double-blind trial followed by a 1-year open extension. Journal of Headache and Pain. 2010;11(1):23-31. PMID: 19936616. ***X-5***

522. Foster PA. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995 Aug;74(2):784-90. PMID: 8585022. ***X-3, X-6***

523. Fouda UM, Yossef D, Gaafar HM. Uterine artery blood flow in patients with copper intrauterine device-induced abnormal uterine bleeding. Middle East Fertility Society Journal. 2010;15(3):168-73. ***X-3, X-4, X-5***

524. Frajndlich R, von Eye Corleta H, Frantz N. Color Doppler sonographic study of the uterine artery in patients using intrauterine contraceptive devices. J Ultrasound Med. 2000 Aug;19(8):577-9. PMID: 10944044. ***X-4, X-5, X-9***

525. Franke HR, Snaaijer FF, Houben PW, et al. Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial. Gynecol Endocrinol. 2006 Dec;22(12):692-7. PMID: 17162712. ***X-5***

526. Franke HR, Snaaijer FF, Houben PWH, et al. Treatment of dysfunctional uterine bleeding in the perimenopause: The effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment - A randomized, placebo-controlled, double-blind trial. Gynecological Endocrinology. 2006;22(12):692-7. PMID: 17162712. ***X-5***

527. Franssen AM, Kauer FM, Rolland R, et al. The effect of LHRH agonist therapy in the treatment of endometriosis (Dutch experience). Prog Clin Biol Res. 1986;225:201-10. PMID: 3097666. ***X-11***

528. Fraser DI, Padwick ML, Whitehead MI, et al. The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy. Maturitas. 1989 Mar;11(1):21-34. PMID: 2725335. ***X-7***

529. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol. 1990 Nov;30(4):353-6. PMID: 2150587. ***X-3***

530. Fraser IS, Healy DL, Torode H, et al. Depot goserelin and danazol pre-treatment before rollerball endometrial ablation for menorrhagia. Obstet Gynecol. 1996 Apr;87(4):544-50. PMID: 8602306. ***X-5, X-8, X-9***

531. Fraser IS, McCarron G, Markham R, et al. Long-term treatment of menorrhagia with mefenamic acid. Obstet Gynecol. 1983 Jan;61(1):109-12. PMID: 6337354. ***X-3***

532. Fraser IS, Weisberg E, Minehan E, et al. A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings. Contraception. 2000 Apr;61(4):241-51. PMID: 10899479. ***X-4, X-5, X-6***

533. Frederick JL, Chenette PE, Paulson RJ, et al. Random urinary pregnanediol glucuronide measurements in pregnancy: lack of utility for evaluation of first-trimester vaginal bleeding. Hum Reprod. 1990 May;5(4):468-70. PMID: 2362010. ***X-3, X-4, X-5***

534. French JI, McGregor JA, Draper D, et al. Gestational bleeding, bacterial vaginosis, and common reproductive tract infections: risk for preterm birth and benefit of treatment. Obstet Gynecol. 1999 May;93(5 Pt 1):715-24. PMID: 10912974. ***X-4, X-5, X-9***

535. French L. What strategy is most likely to result in the least missed ectopic pregnancies, while also considering the likelihood of interruption of intrauterine pregnancy and cost?... commentary on Gracia CR, Barnhart KT. Diagnosing ectopic pregnancy: decision analysis comparing six strategies. OBSTET GYNECOL 2001;97:464-70. Evidence-Based Practice. 2001;4(7):10-1, insert 2p. ***X-1, X-3, X-5***

536. Friberg B, Persson BR, Willen R, et al. Endometrial destruction by hyperthermia--a possible treatment of menorrhagia. An experimental study. Acta Obstet Gynecol Scand. 1996 Apr;75(4):330-5. PMID: 8638450. ***X-4, X-5, X-8***

537. Friedman AJ, Daly M, Juneau-Norcross M, et al. Long-term medical therapy for leiomyomata uteri: A prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Human Reproduction. 1994;9(9):1618-25. PMID: 7836510. ***X-6***

538. Friedman AJ, Hoffman DI, Comite F, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991 May;77(5):720-5. PMID: 1901638. ***X-5, X-6***

539. Fruzzetti F, De Lorenzo D, Ricci C, et al. Clinical and endocrine effects of flutamide in hyperandrogenic women. Fertil Steril. 1993 Nov;60(5):806-13. PMID: 8224265. ***X-5***

540. Fukui H, Toyoshima K, Komaki R. Psychological and neuroendocrinological effects of odor of saffron (Crocus sativus). Phytomedicine. 2011 Jun 15;18(8-9):726-30. PMID: 21242071. ***X-4, X-5***

541. Fulghesu AM, Angioni S, Frau E, et al. Ultrasound in polycystic ovary syndrome - The measuring of ovarian stroma and relationship with circulating androgens: Results of a multicentric study. Human Reproduction. 2007;22(9):2501-8. PMID: 17635847. ***X-3, X-4, X-5***

542. Funder JW. Eplerenone: Hypertension, heart failure and the importance of mineralocorticoid receptor blockade. Future Cardiology. 2006;2(5):535-41. PMID: 19804189. ***X-1, X-3, X-5***

543. Funk S, Miller MM, Mishell DR, Jr., et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005 May;71(5):319-26. PMID: 15854630. ***X-4, X-5***

544. Furst DE, Manorama MV, Mary M, et al. Double-blind, randomized, controlled, pilot study comparing classic ayurvedic medicine, methotrexate, and their combination in rheumatoid arthritis. Journal of Clinical Rheumatology. 2011;17(4):185-92. PMID: 21617554. ***X-5***

545. Furtado RNV, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: A randomized controlled study. Journal of Rheumatology. 2005;32(9):1691-8. PMID: 16142862. ***X-5***

546. Gaete X, Vivanco M, Eyzaguirre FC, et al. Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. Fertil Steril. 2010 Oct;94(5):1822-6. PMID: 19796762. ***X-4, X-5, X-6, X-9***

547. Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol. 1993 Mar;12(1):69-72. PMID: 8376915. ***X-5, X-6***

548. Gallo MF, Nanda K, Grimes DA, et al. 20 g versus >20 g estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews. 2008(4)PMID: 18843653. ***X-9***

549. Gama CRB, Gama GF, Lasmar RB, et al. Clinical assessment of ethinylestradiol and cyproterone acetate in menstrual irregularities of hyper-androgenic origin. Revista Brasileira de Medicina. 2010;67(9):319-25. ***X-5***

550. Gambacciani M, Cappagli B, Piaggesi L, et al. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int. 1997;61 Suppl 1:S15-8. PMID: 9263611. ***X-4, X-5***

551. Gangale MF, Miele L, Lanzone A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf). 2011 Oct;75(4):520-7. PMID: 21569072. ***X-3, X-4***

552. Gao J, Sun HZ, Song GY, et al. Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring. Fertil Steril. 1986 Oct;46(4):626-30. PMID: 3093283. ***X-3, X-9***

553. Gao J, Wang SL, Wu SC, et al. Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel-releasing IUD and Norplant-2 implants in China. Contraception. 1990 May;41(5):485-94. PMID: 2112079. ***X-9***

554. Garceau RJ, Wajszczuk CJ, Kaunitz AM. Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives. Contraception. 2000 Dec;62(6):289-95. PMID: 11239615. ***X-4, X-5, X-6***

555. Garcia-Giralt E, Ayme Y, Carton M, et al. Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Research and Treatment. 1992;24(2):139-45. PMID: 8443401. ***X-7***

556. Gardner FJ, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet. 2000 Nov 18;356(9243):1711-7. PMID: 11095258. ***X-5, X-7***

557. Garry R. Endometrial laser ablation. Baillieres Clin Obstet Gynaecol. 1995 Jun;9(2):317-28. PMID: 7554615. ***X-3, X-8***

558. Gaspard UJ, Deville JL, Dubois M. Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women. Curr Med Res Opin. 1983;8(6):395-404. PMID: 6406157. ***X-3, X-9***

559. Gebauer G, Hafner A, Siebzehnrubl E, et al. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol. 2001 Jan;184(2):59-63. PMID: 11174480. ***X-4, X-5, X-6, X-7, X-8***

560. Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol. 1989 Sep;74(3 Pt 1):398-402. PMID: 2548135. ***X-3, X-7***

561. Geller SE, Harlow SD, Bernstein SJ. Differences in menstrual bleeding characteristics, functional status, and attitudes toward menstruation in three groups of women. Journal of Women's Health & Gender-Based Medicine. 1999;8(4):533-40. PMID: 10839708. ***X-3, X-4, X-5***

562. Gemzell-Danielsson K, Inki P, Boubli L, et al. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a multicentre prospective study. Hum Reprod. 2010 Feb;25(2):354-9. PMID: 19955104. ***X-4, X-5***

563. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertility and Sterility. 2012 March;97(3):616-22.e3. PMID: 2012128428. ***X-9, X-10***

564. Gemzell-Danielsson K, van Heusden AM, Killick SR, et al. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod. 2002 Oct;17(10):2588-93. PMID: 12351534. ***X-4, X-5, X-6, X-9***

565. Genazzani AD, Lanzoni C, Ricchieri F, et al. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol. 2007 Mar;23(3):146-52. PMID: 17454168. ***X-4, X-5, X-9***

566. Geng SS, Li HZ, Wu XK, et al. Effect of Wujijing Oral Liquid on menstrual disturbance of women. J

Ethnopharmacol. 2010 Apr 21;128(3):649-53. PMID: 20051257. ***X-6, X-10***

567. Geraghty P. Beyond birth control. The health benefits of hormonal contraception. Adv Nurse Pract. 2009 Feb;17(2):47-8, 50, 2. PMID: 19999425. ***X-1, X-3, X-5, X-10***

568. Gerber B, Krause A, Reimer T, et al. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res. 2006 Feb 15;12(4):1245-50. PMID: 16489080. ***X-5, X-7, X-9***

569. Gerli S, Gholami H, Manna C, et al. Use of ethinyl estradiol to reverse the antiestrogenic effects of clomiphene citrate in patients undergoing intrauterine insemination: a comparative, randomized study. Fertil Steril. 2000 Jan;73(1):85-9. PMID: 10632418. ***X-5, X-9***

570. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003 Nov-Dec;7(6):151-9. PMID: 15206484. ***X-4, X-5, X-9***

571. Gerli S, Papaleo E, Ferrari A, et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007 Sep-Oct;11(5):347-54. PMID: 18074942. ***X-4, X-5***

572. Geyman JP, Oliver LM, Sullivan SD. Expectant, medical, or surgical treatment of spontaneous abortion in first trimester of pregnancy? A pooled quantitative literature evaluation. J Am Board Fam Pract. 1999 Jan-Feb;12(1):55-64. PMID: 10050644. ***X-1, X-4, X-5, X-8, X-9***

573. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 1982 Aug;170(8):463-7. PMID: 6124580. ***X-3, X-5, X-6***

574. Ghatak SB, Panchal SJ. Ulipristal acetate- a novel oral emergency contraceptive: Hype or hope? International Journal of Pharmaceutical Sciences Review and Research. 2010;4(3):152-5. ***X-1, X-3, X-5, X-9***

575. Ghazizadeh S, Bakhtiari F, Rahmanpour H, et al. A randomized clinical trial to compare levonorgestrel-releasing intrauterine system (Mirena) vs trans- ervical endometrial resection for treatment of menorrhagia. International Journal of Women's Health. 2011;3(1):207-11. PMID: 2011702821. ***X-8***

576. Gheorghiade M, Khan S, Blair JEA, et al. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. American Heart Journal. 2009;158(3):437-43. PMID: 19699868. ***X-5***

577. Ghosh AK, Konar JR. The relative value of two concentrations of hypertonic saline for midtrimester abortion. Int J Gynaecol Obstet. 1980 Jan-Feb;17(4):368-71. PMID: 6102059. ***X-5***

578. Giacovazzo M, Gallo MF, Guidi V, et al. Nimesulide in the treatment of menstrual migraine. Drugs. 1993;46 Suppl 1:140-1. PMID: 7506154. ***X-5***

579. Gibson JH, Mitchell A, Reeve J, et al. Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study. Osteoporos Int. 1999;10(4):284-9. PMID: 10692976. ***X-4, X-5, X-9***

580. Gilbert WM, Moore TR, Resnik R, et al. Angiographic embolization in the management of hemorrhagic complications of pregnancy. Am J Obstet Gynecol. 1992 Feb;166(2):493-7. PMID: 1536217. ***X-3, X-5, X-8***

581. Ginsburg J, Prelevic G, Butler D, et al. Clinical experience with tibolone (Livial) over 8 years. Maturitas. 1995 Jan;21(1):71-6. PMID: 7731388. ***X-3, X-7***

582. Glasier A, Thong KJ, Dewar M, et al. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. New England Journal of Medicine. 1992;327(15):1041-4. PMID: 1522839. ***X-5, X-9***

583. Glasier AF, Wang H, Davie JE, et al. Administration of an antiprogesterone up-regulates estrogen receptors in the endometrium of women using Norplant: a pilot study. Fertil Steril. 2002 Feb;77(2):366-72. PMID: 11821099. ***X-4, X-5, X-6***

584. Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001 Jan;75(1):46-52. PMID: 11163815. ***X-4, X-5, X-6, X-9***

585. Gnoth C, Frank-Herrmann P, Schmoll A, et al. Cycle characteristics after discontinuation of oral contraceptives. Gynecol Endocrinol. 2002 Aug;16(4):307-17. PMID: 12396560. ***X-4, X-5, X-9***

586. Godfrey EM, Wu S, Dong J, et al. Gestrinone compared with mifepristone for emergency contraception: A randomized controlled trial. Obstetrics and Gynecology. 2010;115(4):740-4. PMID: 20308833. ***X-5***

587. Gol M, Akan P, Dogan E, et al. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas. 2006;53(3):252-9. PMID: 15990257. ***X-7***

588. Goldberg AB, Cardenas LH, Hubbard AE, et al. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol. Contraception. 2002 Oct;66(4):215-20. PMID: 12413614. ***X-5, X-9***

589. Goldenberg M, Cohen SB, Etchin A, et al. A randomized prospective comparative study of general versus epidural anesthesia for transcervical hysteroscopic endometrial resection. Am J Obstet Gynecol. 2001 Feb;184(3):273-6. PMID: 11228472. ***X-4, X-5, X-8, X-9***

590. Goldenberg M, Zolti M, Bider D, et al. The effect of intracervical vasopressin on the systemic absorption of glycine during hysteroscopic endometrial ablation. Obstet Gynecol. 1996 Jun;87(6):1025-9. PMID: 8649684. ***X-4, X-5, X-8, X-9***

591. Goldrath MH. Uterine tamponade for the control of acute uterine bleeding. Am J Obstet Gynecol. 1983 Dec 15;147(8):869-72. PMID: 6650623. ***X-3, X-5***

592. Goldrath MH. Use of danazol in hysteroscopic surgery for menorrhagia. J Reprod Med. 1990 Jan;35(1 Suppl):91-6. PMID: 2136915. ***X-3, X-8***

593. Goldrath MH. Evaluation of HydroThermAblator and rollerball endometrial ablation for menorrhagia 3 Years after treatment. J Am Assoc Gynecol Laparosc. 2003 Nov;10(4):505-11. PMID: 14738639. ***X-5, X-8***

594. Goldstein SR, Bhattoa HP, Neven P, et al. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass. Menopause. 2012 Jan;19(1):41-7. PMID: 21993078. ***X-5, X-7***

595. Gompel A, Bergeron C, Jondet M, et al. Endometrial safety and tolerability of AERODIOL(R) (intranasal estradiol) for 1 year. Maturitas. 2000 Oct 31;36(3):209-15. PMID: 11063903. ***X-4, X-5, X-7***

596. Gong C, Song E, Jia W, et al. A double-blind randomized controlled trial of toremifen therapy for mastalgia. Archives of Surgery. 2006;141(1):43-7. PMID: 16415410. ***X-5***

597. Gong Y, Zha Q, Li L, et al. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: A double-blinded and randomized study. Journal of Ethnopharmacology. 2012 01 Jun;141(2):592-8. PMID: 2012284219. ***X-5***

598. Gonzalez-Barcena D, Alvarez RB, Ochoa EP, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod. 1997 Sep;12(9):2028-35. PMID: 9363724. ***X-4, X-5, X-6***

599. Gorgen H, Api M, Akca A, et al. Use of the Levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet. 2009 Jun;279(6):835-40. PMID: 19018547. ***X-4***

600. Gorins A, Perret F, Tournant B, et al. A French double-blind crossover study (danazol versus placebo) in the treatment of severe fibrocystic breast disease. Eur J Gynaecol Oncol. 1984;5(2):85-9. PMID: 6373293. ***X-5***

601. Grady D, Applegate W, Bush T, et al. Heart and estrogen/progestin replacement study (HERS): Design, methods, and baseline characteristics. Controlled Clinical Trials. 1998;19(4):314-35. PMID: 9683309. ***X-7***

602. Grady D, Sawaya GF, Johnson KC, et al. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65. PMID: 19182698. ***X-5, X-7, X-9***

603. Graser T, Koytchev R, Muller A, et al. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women. Climacteric. 2000 Jun;3(2):109-18. PMID: 11910651. ***X-5, X-7***

604. Graser T, Muller A, Mellinger U, et al. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - A dose-ranging study. Maturitas. 2000;35(3):253-61. PMID: 10936742. ***X-7***

605. Graser T, Romer T, Wiedey KD, et al. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric. 2001 Dec;4(4):332-42. PMID: 11770190. ***X-4, X-5, X-7***

606. Graser T, Rossner P, Schubert K, et al. A comparative study of two levonorgestrel-containing hormone replacement therapy regimens of efficacy and tolerability variables. Maturitas. 1997 Dec 15;28(2):169-79. PMID: 9522325. ***X-5, X-7***

607. Gray RH, Parker RA, Diethelm P. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. From the World Health Organization Special Programme for Research, Development, and Research Training in Human Reproduction; Task Force on Long-acting Systemic Agents for the Regulation of Fertility. Br J Obstet Gynaecol. 1981 Mar;88(3):317-21. PMID: 7008825. ***X-9***

608. Gray RH, Parker RA, Diethelm P. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. British Journal of Obstetrics and Gynaecology. 1981;88(3):317-21. PMID: 7008825. ***X-6, X-9***

609. Greenblatt RB. Dwarfs, standing on the shoulders of giants, see further. Prog Clin Biol Res. 1982;112 Pt A:1-11. PMID: 7163294. ***X-1, X-3, X-5, X-10***

610. Greenspan SL, Resnick NM, Parker RA. The effect of hormone replacement on physical performance in community-dwelling elderly women. American Journal of Medicine. 2005;118(11):1232-9. PMID: 16271907. ***X-7***

611. Greenwood LH, Glickman MG, Schwartz PE, et al. Obstetric and nonmalignant gynecologic bleeding: treatment with angiographic embolization. Radiology. 1987 Jul;164(1):155-9. PMID: 3495816. ***X-3, X-5, X-8***

612. Grimbizis G, Tsalikis T, Tzioufa V, et al. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Hum Reprod. 1999 Feb;14(2):479-84. PMID: 10099998. ***X-3, X-6***

613. Grimes DA, Mishell DR, Jr., Shoupe D, et al. Early abortion with a single dose of the antiprogestin RU-486. Am J Obstet Gynecol. 1988 Jun;158(6 Pt 1):1307-12. PMID: 2454578. ***X-3, X-5***

614. Grodnitskaya EE, Grigoryan OR, Klinyshkova EV, et al. Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system 'NuvaRing' as compared with the standard 21/7 regime in reproductive-age women with type 1 diabetes mellitus. Gynecological Endocrinology. 2010;26(9):663-8. PMID: 20334583. ***X-5***

615. Grubb GS, Welch JD, Cole L, et al. A comparative evaluation of the safety and contraceptive effectiveness of 65 mg and 100 mg of 90-day norethindrone (NET) injectable microspheres: a multicenter study. Fertil Steril. 1989 May;51(5):803-10. PMID: 2523322. ***X-9***

616. Gruber DM, Huber JC, Melis GB, et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20mug and desogestrel 150mug. Treatments in Endocrinology. 2006;5(2):115-21. PMID: 16542051. ***X-9***

617. Gu SJ, Du MK, Zhang LD, et al. A 5-year evaluation of NORPLANT contraceptive implants in China. Obstet Gynecol. 1994 May;83(5 Pt 1):673-8. PMID: 8164924. ***X-3, X-9***

618. Guazzelli CA, Barreiros FA, Barbosa R, et al. Extended regimens of the vaginal contraceptive ring: cycle control. Contraception. 2009 Nov;80(5):430-5. PMID: 19835716. ***X-4, X-5, X-9***

619. Gudmundsson JA, Nillius SJ, Bergquist C. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results. Fertil Steril. 1986 May;45(5):617-23. PMID: 2938984. ***X-3, X-9***

620. Guest J, Chien P, Thomson M, et al. Randomised controlled trial comparing efficacy of same day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36- to 48-hour protocol. BJOG. 2005 Oct;112(10):1457. PMID: 16167962. ***X-5, X-9***

621. Guichard JP, Sauron R, Jones AB. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems. J Clin Pharmacol. 1999 Aug;39(8):811-6. PMID: 10434233. ***X-5, X-7***

622. Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception - Oral versus intravaginal - On the sexual life of women and their partners. Human Reproduction. 2005;20(4):1100-6. PMID: 15608030. ***X-5, X-9***

623. Guida M, Pellicano M, Zullo F, et al. Outpatient operative hysteroscopy with bipolar electrode: A prospective multicentre randomized study between local anaesthesia and conscious sedation. Human Reproduction. 2003;18(4):840-3. PMID: 12660281. ***X-8***

624. Guidotti M, Mauri M, Barrila C, et al. Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. J Headache Pain. 2007 Oct;8(5):283-8. PMID: 17955167. ***X-4, X-5, X-9***

625. Guilleminault C, Stoohs R, Kim YD, et al. Upper airway sleep-disordered breathing in women. Ann Intern Med. 1995 Apr 1;122(7):493-501. PMID: 7872583. ***X-3, X-5***

626. Gull B, Carlsson S, Karlsson B, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol. 2000 Mar;182(3):509-15. PMID: 10739500. ***X-4, X-5, X-7***

627. Gultekin M, Diribas K, Buru E, et al. Role of a non-hormonal oral anti-fibrinolytic hemostatic agent (tranexamic acid) for management of patients with dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 2009;36(3):163-5. PMID: 19860359. ***X-4***

628. Gunson MJ, Arnett GW, Formby B, et al. Oral contraceptive pill use and abnormal menstrual cycles in women with severe condylar resorption: a case for low serum 17beta-estradiol as a major factor in progressive condylar resorption. Am J Orthod Dentofacial Orthop. 2009 Dec;136(6):772-9. PMID: 19962599. ***X-4, X-5, X-9***

629. Gupta AN, Dhaliwal LK, Gulati K. Clinical performance with contraceptive vaginal rings containing levonorgestrel. Indian J Med Res. 1986 Sep;84:321-5. PMID: 3102365. ***X-3, X-9, X-10***

630. Gupta B, Mittal S, Misra R, et al. Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleeding. Int J Gynaecol Obstet. 2006 Dec;95(3):261-6. PMID: 16999960. ***X-8***

631. Gupta P, Singh S, Goyal V, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007;47(3):402-12. PMID: 17371357. ***X-5***

632. Gurates B, Parmaksiz C, Kilic G, et al. Treatment of symptomatic uterine leiomyoma with letrozole. Reprod Biomed Online. 2008 Oct;17(4):569-74. PMID: 18854113. ***X-4, X-5, X-6***

633. Gusberg SB. An approach to the control of carcinoma of the endometrium. CA Cancer J Clin. 1980 Jan-Feb;30(1):16-22. PMID: 6766346. ***X-5***

634. Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertility and Sterility. 1994;61(4):598-604. PMID: 8150098. ***X-3, X-5, X-10***

635. Hakimian S, Cheng-Hakimian A, Anderson GD, et al. Rufinamide: A new anti-epileptic medication. Expert Opinion on Pharmacotherapy. 2007;8(12):1931-40. PMID: 17696794. ***X-1, X-3, X-5***

636. Halbe HW, de Melo NR, Bahamondes L, et al. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care. 1998 Sep;3(3):113-20. PMID: 9853201. ***X-9***

637. Hald K, Klow NE, Qvigstad E, et al. Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial. Obstet Gynecol. 2007 Jan;109(1):20-7. PMID: 17197583. ***X-5, X-6, X-8***

638. Hald K, Klow NE, Qvigstad E, et al. Treatment of uterine myomas with transvaginal uterine artery occlusion: possibilities and limitations. J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):631-5. PMID: 18722975. ***X-4, X-5, X-6, X-8, X-9***

639. Hall P, Bahamondes L, Diaz J, et al. Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru. Contraception. 1997 Dec;56(6):353-9. PMID: 9494768. ***X-4, X-5, X-9***

640. Halmesmaki K, Hurskainen R, Teperi J, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial. BJOG. 2007 May;114(5):563-8. PMID: 17439564. ***X-8***

641. Halmesmaki K, Hurskainen R, Tiitinen A, et al. A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. Hum Reprod. 2004 Feb;19(2):378-82. PMID: 14747185. ***X-5, X-8, X-9***

642. Halmesmaki K, Hurskainen R, Tiitinen A, et al. A randomized controlled trial hysterectomy of levenorgestrel-releasing intrauterine system in the treatment of menorrhagia - Effect of FSH levels and menopausal symptoms. Human Reproduction. 2004;19(2):378-82. PMID: 14747185. ***X-8***

643. Halmesmaki KH, Hurskainen RA, Cacciatore B, et al. Effect of hysterectomy or LNG-IUS on serum inhibin B levels and ovarian blood flow. Maturitas. 2007 Jul 20;57(3):279-85. PMID: 17329045. ***X-4, X-5, X-8***

644. Halmesmaki KH, Paavonen JA, Tuppurainen MT, et al. Randomized controlled trial of the effect of hysterectomy or LNG-IUS use on bone mineral density: A five-year follow-up. Therapy. 2006;3(4):509-15. ***X-8***

645. Hamilton RA, Grant AM, Henry OA, et al. The management of bleeding in early pregnancy. Ir Med J. 1991 Mar;84(1):18-9. PMID: 2045259. ***X-3, X-5***

646. Hammar M, Christau S, Nathorst-Boos J, et al. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998 Aug;105(8):904-11. PMID: 9746385. ***X-5, X-7***

647. Hammar ML, van de Weijer P, Franke HR, et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG. 2007 Dec;114(12):1522-9. PMID: 17995496. ***X-5, X-7***

648. Hammerstein J, Daume E, Simon A, et al. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol. Contraception. 1993 Mar;47(3):263-81. PMID: 8462317. ***X-4***

649. Hamou JE. Microhysteroscopy. Clin Obstet Gynecol. 1983 Jun;26(2):285-301. PMID: 6406117. ***X-4, X-5, X-8***

650. Hampton NR, Rees MC, Lowe DG, et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod. 2005 Sep;20(9):2653-60. PMID: 15905289. ***X-4, X-5, X-9***

651. Hampton RM, Fisher AC, Pagano S, et al. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization. Fertil Steril. 2009 Aug;92(2):434-40. PMID: 18930189. ***X-4, X-5, X-9***

652. Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception. 2001;63(6):289-95. PMID: 11672549. ***X-9***

653. Hampton RM, Zhang HF, Barnowski C, et al. Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives. Contraception. 2008 Jun;77(6):415-9. PMID: 18477490. ***X-4, X-5, X-9***

654. Hanggi W, Bersinger N, Altermatt HJ, et al. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users. Maturitas. 1997 Jun;27(2):133-43. PMID: 9255748. ***X-5, X-7, X-8, X-9***

655. Haoula ZJ, Walker KF, Powell MC. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):176-9. PMID: 21741152. ***X-3, X-6***

656. Hapangama DK, Critchley HO, Henderson TA, et al. Mifepristone-induced vaginal bleeding is associated with increased immunostaining for cyclooxygenase-2 and decrease in prostaglandin dehydrogenase in luteal phase endometrium. J Clin Endocrinol Metab. 2002 Nov;87(11):5229-34. PMID: 12414896. ***X-4, X-5, X-6, X-9***

657. Haq G, Tayyab S. Control of postpartum and post abortal haemorrhage with uterine packing. J Pak Med Assoc. 2005 Sep;55(9):369-71. PMID: 16302468. ***X-4, X-5, X-9***

658. Harada T, Momoeda M, Terakawa N, et al. Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: A placebo-controlled, double-blind, randomized trial. Fertility and Sterility. 2011;95(6):1928-31. PMID: 21420678. ***X-5***

659. Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: A randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47(9):1447-51. PMID: 16981859. ***X-5, X-7***

660. Harding CM, Vail C, Brown R. Effect of oral contraceptives and some psychological factors on the menstrual experience. J Biosoc Sci. 1985 Jul;17(3):291-304. PMID: 4040913. ***X-3, X-5, X-10***

661. Harel Z, Biro F, Kollar L, et al. Supplementation with vitamin C and/or vitamin B(6) in the prevention of Depo-Provera side effects in adolescents. J Pediatr Adolesc Gynecol. 2002 Jun;15(3):153-8. PMID: 12106752. ***X-5, X-6, X-9***

662. Harper C, Winikoff B, Ellertson C, et al. Blood loss with mifepristone--misoprostol abortion: measures from a trial in China, Cuba and India. Int J Gynaecol Obstet. 1998 Oct;63(1):39-49. PMID: 9849710. ***X-4, X-5, X-9***

663. Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: A prospective, randomized, placebo-controlled study. Fertility and Sterility. 2000;74(1):24-30. PMID: 10899492. ***X-10***

664. Hasham F, Garry R, Kokri MS, et al. Fluid absorption during laser ablation of the endometrium in the treatment of menorrhagia. Br J Anaesth. 1992 Feb;68(2):151-4. PMID: 1540456. ***X-8***

665. Hashemi F, Pasyar N, Dehbashi S. Relationship of chemotherapeutic agents with menstrual disorders in nursing staff. Journal of Nursing & Midwifery. 2009;19(64):38-. ***X-11***

666. Hassan WA, Darwish AM. Impact of pulmonary tuberculosis on menstrual pattern and fertility. Clin Respir J. 2010 Jul;4(3):157-61. PMID: 20565494. ***X-4, X-5, X-9***

667. Hassanin IM, Shahin AY, Abdel-Hafeez AT, et al. Bilateral uterine artery ligation via minilaparotomy for heavy menstrual bleeding. Int J Gynaecol Obstet. 2008 Dec;103(3):222-6. PMID: 18805523. ***X-4, X-5, X-8***

668. Haugan T, Skjeldestad FE, Halvorsen LE, et al. A randomized trial on the clinical performance of Nova T380 and Gyne T380 Slimline copper IUDs. Contraception. 2007 Mar;75(3):171-6. PMID: 17303485. ***X-4, X-5***

669. Hawe JA, Phillips AG, Chien PF, et al. Cavaterm thermal balloon ablation for the treatment of menorrhagia. Br J Obstet Gynaecol. 1999 Nov;106(11):1143-8. PMID: 10549958. ***X-4, X-5, X-8***

670. Hayes JL, Achilles SL, Creinin MD, et al. Outcomes of medical abortion through 63 days in women with twin gestations. Contraception. 2011 Nov;84(5):505-7. PMID: 22018125. ***X-3, X-5***

671. Haynes PJ, Flint AP, Hodgson H, et al. Studies in menorrhagia: (a) mefenamic acid, (b) endometrial prostaglandin concentrations. Int J Gynaecol Obstet. 1980 May-Jun;17(6):567-72. PMID: 6106574. ***X-3***

672. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003 May 8;348(19):1839-54. PMID: 12642637. ***X-7***

673. He CH, Shi YE, Xu JQ, et al. A multicenter clinical study on two types of levonorgestrel tablets administered for postcoital contraception. Int J Gynaecol Obstet. 1991 Sep;36(1):43-8. PMID: 1683301. ***X-5, X-9***

674. He Y, Lu A, Zha Y, et al. Correlations between symptoms as assessed in traditional Chinese medicine (TCM) and ACR20 efficacy response: A comparison study in 396 patients with rheumatoid arthritis treated with TCM or Western medicine. Journal of Clinical Rheumatology. 2007;13(6):317-21. PMID: 18176139. ***X-5***

675. Heber KR. Medroxyprogesterone acetate as an injectable contraceptive. Aust Fam Physician. 1988 Mar;17(3):199-201, 4. PMID: 2965570. ***X-3, X-5, X-9, X-10***

676. Hee P, Pagel JD. Primary carcinoma of the fallopian tube. Eur J Obstet Gynecol Reprod Biol. 1987 Jun;25(2):131-8. PMID: 3609428. ***X-3, X-5***

677. Hehenkamp WJ, Volkers NA, Broekmans FJ, et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod. 2007 Jul;22(7):1996-2005. PMID: 17582145. ***X-5, X-6, X-8***

678. Heikinheimo O, Inki P, Kunz M, et al. Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system. Hum Reprod. 2010 Jun;25(6):1423-7. PMID: 20378611. ***X-4, X-5***

679. Heikinheimo O, Inki P, Kunz M, et al. Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. Contraception. 2010;81(6):481-6. PMID: 20472114, ***X-5***

680. Heikinheimo O, Vani S, Carpen O, et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod. 2007 Sep;22(9):2515-22. PMID: 17636280. ***X-4, X-5, X-9***

681. Heikkila M. Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device. Contraception. 1982 Jun;25(6):561-72. PMID: 6811195. ***X-3, X-4, X-9***

682. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: Results from a seven-year randomised comparison of low and standard doses. Journal of the British Menopause Society. 2004;10(3):95-102. PMID: 15494100. ***X-7***

683. Heikkinen J, Vaheri R, Timonen U. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings. Journal of the British Menopause Society. 2006;12(3):115-25. PMID: 16953985. ***X-5, X-7***

684. Heikkinen JE, Vaheri RT, Ahomaki SM, et al. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: A comparison of six different treatment regimens. American Journal of Obstetrics and Gynecology. 2000;182(3):560-7. PMID: 10739508. ***X-7***

685. Heisterberg L, Sonne-Holm S, Andersen JT, et al. Risk factors in first-trimester abortion. Acta Obstet Gynecol Scand. 1982;61(4):357-60. PMID: 7148411. ***X-3, X-4, X-5***

686. Helge EW, Kanstrup IL. Bone density in female elite gymnasts: impact of muscle strength and sex hormones. Med Sci Sports Exerc. 2002 Jan;34(1):174-80. PMID: 11782664. ***X-4, X-5, X-9***

687. Heliovaara-Peippo S, Halmesmaki K, Hurskainen R, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower abdominal pain and back pain among women treated for menorrhagia: a five-year randomized controlled trial. Acta Obstet Gynecol Scand. 2009;88(12):1389-96. PMID: 19878089. ***X-5, X-8***

688. Heliovaara-Peippo S, Halmesmaki K, Hurskainen R, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial. BJOG. 2010 Apr;117(5):602-9. PMID: 20156209. ***X-5, X-8***

689. Heliovaara-Peippo S, Oksjoki R, Halmesmaki K, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on cardiovascular disease risk factors in menorrhagia patients: A 10-year follow-up of a randomised trial. Maturitas. 2011;69(4):354-8. PMID: 21684096. ***X-8***

690. Hellberg D, Nilsson S. Pilot study to evaluate a new regimen to treat climacteric complaints with cyclic combined oestradiol valerate/medroxyprogesterone acetate. Maturitas. 1987 Apr;9(1):103-7. PMID: 2955203. ***X-3, X-7***

691. Hellgren M, Conard J, Norris L, et al. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas. 2009 Mar 20;62(3):287-93. PMID: 19268506. ***X-4, X-5, X-7, X-9***

692. Hemmerling A, Harrison W, Schroeder A, et al. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sex Transm Dis. 2009 Sep;36(9):564-9. PMID: 19543144. ***X-4, X-5, X-9***

693. Hergenroeder AC, Smith EO, Shypailo R, et al. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol. 1997 May;176(5):1017-25. PMID: 9166162. ***X-5, X-9***

694. Herzog AG. Continuous bromocriptine therapy in menstrual migraine. Neurology. 1997 Jan;48(1):101-2. PMID: 9008502. ***X-4, X-5, X-9***

695. Herzog AG, Coleman AE, Jacobs AR, et al. Interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy. Ann Neurol. 2003 Nov;54(5):625-37. PMID: 14595652. ***X-4, X-5, X-9***

696. Hickey M, Carati C, Manconi F, et al. The measurement of endometrial perfusion in norplant users: a pilot study. Hum Reprod. 2000 May;15(5):1086-91. PMID: 10783358. ***X-4, X-5, X-6, X-9***

697. Hickey M, Dwarte D, Fraser IS. Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. Hum Reprod. 1998 Nov;13(11):3190-6. PMID: 9853879. ***X-3, X-4***

698. Hickey M, Dwarte D, Fraser IS. Superficial endometrial vascular fragility in Norplant users and in

women with ovulatory dysfunctional uterine bleeding. Hum Reprod. 2000 Jul;15(7):1509-14. PMID: 10875858. ***X-4, X-5***

699. Hickey M, Fraser I, Dwarte D, et al. Endometrial vasculature in Norplant users: preliminary results from a hysteroscopic study. Hum Reprod. 1996 Oct;11 Suppl 2:35-44. PMID: 8982744. ***X-4, X-5, X-6***

700. Hickey M, Higham J, Sullivan M, et al. Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertil Steril. 2001 Feb;75(2):288-96. PMID: 11172829. ***X-4, X-5, X-7, X-9***

701. Hickey M, Pillai G, Higham JM, et al. Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Hum Reprod. 2003 May;18(5):1100-6. PMID: 12721191. ***X-4, X-5, X-6***

702. Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002 Feb;65(2):129-32. PMID: 11927115. ***X-4, X-5, X-6***

703. Hidalgo MM, Lisondo C, Juliato CT, et al. Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. Contraception. 2006 May;73(5):532-6. PMID: 16627041. ***X-4, X-5, X-9***

704. Higham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol. 1993 Nov;169(5):1134-9. PMID: 8238173. ***X-5***

705. Hill GA, Wheeler JM. Incidence of breakthrough bleeding during oral contraceptive therapy. J Reprod Med. 1991 Apr;36(4 Suppl):334-9. PMID: 2046082. ***X-3, X-4, X-5, X-9***

706. Hillard PJ. The patient's reaction to side effects of oral contraceptives. Am J Obstet Gynecol. 1989 Nov;161(5):1412-5. PMID: 2589465. ***X-3, X-9***

707. Hingorani V, Jalnawala SF, Kochhar M. Task force on hormonal contraception. Phase II randomized comparative clinical trial of Norplant(R) (six capsules) with Norplant(R)-2 (two covered rods) subdermal implants for long-term contraception: Report of a 24-month study. Contraception. 1986;33(3):233-44. PMID: 3087694. ***X-9***

708. Hingorani V, Jalnawala SF, Kochhar M, et al. Phase II randomized comparative clinical trial of Norplant (six capsules) with Norplant-2 (two covered rods) subdermal implants for long-term contraception: report of a 24-month study. National Programme of Research in Human Reproduction. Contraception. 1986 Mar;33(3):233-44. PMID: 3087694. ***X-9***

709. Hirakawa M, Tajima T, Yoshimitsu K, et al. Uterine artery embolization along with the administration of methotrexate for cervical ectopic pregnancy: technical and clinical outcomes. AJR Am J Roentgenol. 2009 Jun;192(6):1601-7. PMID: 19457824. ***X-4, X-5, X-9***

710. Hirvonen E, Allonen H, Anttila M, et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas. 1995 Jan;21(1):27-32. PMID: 7731379. ***X-3, X-9***

711. Hirvonen E, Cacciatore B, Wahlstrom T, et al. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. Br J Obstet Gynaecol. 1997 Nov;104 Suppl 16:26-31. PMID: 9389780. ***X-5, X-7***

712. Hirvonen E, Crona N, Wahlstrom T, et al. Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding. Climacteric. 2000 Dec;3(4):262-70. PMID: 11910586. ***X-4, X-5, X-7***

713. Hirvonen E, Lamberg-Allardt C, Lankinen KS, et al. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy. Br J Obstet Gynaecol. 1997 Nov;104 Suppl 16:19-25. PMID: 9389779. ***X-5, X-7, X-9***

714. Hirvonen E, Salmi T, Puolakka J, et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas. 1995 Jan;21(1):39-44. PMID: 7731382. ***X-3, X-7***

715. Horn SD, Prather S, Jones CA. A cohort analysis of pre-menopausal women with dysfunctional uterine bleeding. HMO Pract. 1996 Jun;10(2):59-64. PMID: 10158542. ***X-4, X-5, X-8***

716. Horwitz RI, Feinstein AR. The problem of "protopathic bias" in case-control studies. Am J Med. 1980 Feb;68(2):255-8. PMID: 7355896. ***X-3, X-5***

717. Hourihan HM, Sheppard BL, Bonnar J. A morphometric study of the effect of oral norethisterone or levonorgestrel on endometrial blood vessels. Contraception. 1986 Dec;34(6):603-12. PMID: 3103980. ***X-3, X-4***

718. Hovik P, Sundsbak HP, Gaasemyr M, et al. Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms. Maturitas. 1989 Mar;11(1):75-82. PMID: 2498620. ***X-4, X-5, X-7, X-10***

719. Hreinsson J, Rosenlund B, Friden B, et al. Recombinant LH is equally effective as recombinant hCG in promoting oocyte maturation in a clinical in-vitro maturation programme: A randomized study. Human Reproduction. 2003;18(10):2131-6. PMID: 14507834. ***X-5***

720. Huang KE, Bonfiglio TA, Muechler EK. Transient hyperprolactinemia in infertile women with luteal phase deficiency. Obstet Gynecol. 1991 Oct;78(4):651-5. PMID: 1923170. ***X-3, X-4, X-5***

721. Hubacher D, Reyes V, Lillo S, et al. Preventing copper intrauterine device removals due to side effects among first-time users: Randomized trial to study the effect of prophylactic ibuprofen. Human Reproduction. 2006;21(6):1467-72. PMID: 16484309. ***X-5***

722. Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG. 2002 Aug;109(8):886-93. PMID: 12197367. ***X-5, X-7***

723. Huber MG, Wildschut HI, Boer K, et al. Umbilical vein administration of oxytocin for the management of retained placenta: is it effective? Am J Obstet Gynecol. 1991 May;164(5 Pt 1):1216-9. PMID: 1709781. ***X-5***

724. Hudita D, Posea C, Ceausu I, et al. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women. Eur Rev Med Pharmacol Sci. 2003 Sep-Oct;7(5):117-25. PMID: 15214586. ***X-5, X-7***

725. Huggins GR. IUD use and unexplained vaginal bleeding. Obstet Gynecol. 1981 Oct;58(4):409-16. PMID: 7279336. ***X-3, X-5, X-6***

726. Hui-Qin L, Zhuan-Chong F, Yu-Bao W, et al. Performance of the frameless IUD (Flexigard prototype inserter) and the TCu380A after six years as part of a WHO multicenter randomized comparative clinical trial in parous women. Adv Contracept. 1999;15(3):201-9. PMID: 11019951. ***X-4, X-5***

727. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005;111(24):3274-80. PMID: 15956137. ***X-3, X-5***

728. Hurskaienen R, Teperi J, Rissanen P. A levonorgestrel releasing intrauterine system was more cost effective than was hysterectomy for menorrhagia. Evidence Based Medicine. 2001;6(4). ***X-8***

729. Hurskainen R, Salmi A, Paavonen J, et al. Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel. Mol Hum Reprod. 2000 Nov;6(11):1013-8. PMID: 11044464. ***X-4, X-5***

730. Hurskainen R, Teperi J, Aalto AM, et al. Levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of essential menorrhagia: predictors of outcome. Acta Obstet Gynecol Scand. 2004 Apr;83(4):401-3. PMID: 15005790. ***X-8***

731. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet. 2001 Jan 27;357(9252):273-7. PMID: 11214131. ***X-5, X-8***

732. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004 Mar 24;291(12):1456-63. PMID: 15039412. ***X-8***

733. Hussein M. Transvaginal Doppler sonography for evaluation of irregular uterine bleeding with DMPA. Arch Gynecol Obstet. 2011 Jun;283(6):1325-8. PMID: 20582427. ***X-4, X-5, X-9***

734. Hutspardol S, Sirachainan N, Soisamrong A, et al. Hemostatic defects in Thai adolescents with menorrhagia. J Med Assoc Thai. 2010 Apr;93(4):436-42. PMID: 20462086. ***X-4, X-5, X-6***

735. Ibanez L, Hall JE, Potau N, et al. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: Evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. Journal of Clinical Endocrinology and Metabolism. 1996;81(11):4103-7. PMID: 8923867. ***X-3, X-4***

736. Ibanez L, Lopez-Bermejo A, Diaz M, et al. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab. 2011 Aug;96(8):E1262-7. PMID: 21632811. ***X-5, X-10***

737. Ibanez L, Ong K, Ferrer A, et al. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab. 2003 Jun;88(6):2600-6. PMID: 12788862. ***X-4, X-5, X-9***

738. Ibanez L, Potau N, Marcos MV, et al. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab. 2000 Sep;85(9):3251-5. PMID: 10999817. ***X-4, X-5, X-9***

739. Ibanez L, Potau N, Marcos MV, et al. Corticotropin-releasing hormone: A potent androgen secretagogue in girls with hyperandrogenism after precocious pubarche. Journal of Clinical Endocrinology and Metabolism. 2000;84(12):4602-6. PMID: 10599726. ***X-4, X-5***

740. Ibanez L, Valls C, de Zegher F. Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: Normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. Human Reproduction. 2006;21(2):451-6. PMID: 16239318. ***X-4, X-5, X-10***

741. Ibanez L, Valls C, Potau N, et al. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab. 2000 Oct;85(10):3526-30. PMID: 11061495. ***X-4, X-5, X-9***

742. Ikomi A, Gupta N. Randomised controlled trial exists of levonorgestrel intrauterine system for menorrhagia. BMJ. 1998 Oct 31;317(7167):1250. PMID: 9794876. ***X-1, X-3***

743. Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998 Jul;83(7):2361-5. PMID: 9661609. ***X-3, X-5***

744. Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1999 May;84(5):1617-22. PMID: 10323389. ***X-4, X-5, X-6, X-9***

745. Inki P, Hurskainen R, Palo P, et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol. 2002 Oct;20(4):381-5. PMID: 12383322. ***X-4, X-5, X-8, X-9***

746. Irahara M, Uemura H, Yasui T, et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecol Obstet Invest. 2001;52(4):217-22. PMID: 11729332. ***X-5, X-6, X-9***

747. Ismail SI, Pugh DH, Gower-Thomas K, et al. A pilot evaluation of saline sonohysterography for postmenopausal bleeding with thickened endometrium. J Obstet Gynaecol. 2009 Feb;29(2):132-4. PMID: 19274548. ***X-4, X-5, X-7***

748. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia. 1995 Jul;36(7):676-81. PMID: 7555984. ***X-3, X-4, X-5***

749. Isojarvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med. 2001 Sep;111(4):290-6. PMID: 11566460. ***X-4, X-5, X-6, X-9***

750. Istre O, Johnstad B, Skajaa K, et al. Effects of indomethacin on postoperative pain and nausea after transcervical endometrial resection. Gynaecological Endoscopy. 1994;3(4):225-8. ***X-5, X-8***

751. Istre O, Skajaa K, Schjoensby AP, et al. Changes in serum electrolytes after transcervical resection of endometrium and submucous fibroids with use of glycine 1.5% for uterine irrigation. Obstet Gynecol. 1992 Aug;80(2):218-22. PMID: 1635735. ***X-3, X-8***

752. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril. 2001 Aug;76(2):304-9. PMID: 11476777. ***X-5, X-8***

753. Itoi H, Minakami H, Iwasaki R, et al. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. Maturitas. 2000 Oct 31;36(3):217-22. PMID: 11063904. ***X-4, X-5, X-7***

754. Jabiry-Zieniewicz Z, Kaminski P, Bobrowska K, et al. Menstrual function in female liver transplant recipients of reproductive age. Transplant Proc. 2009 Jun;41(5):1735-9. PMID: 19545718. ***X-4, X-5, X-6, X-9***

755. Jack SA, Cooper KG, Seymour J, et al. A randomised controlled trial of microwave endometrial ablation without endometrial preparation in the outpatient setting: patient acceptability, treatment outcome and costs. BJOG. 2005 Aug;112(8):1109-16. PMID: 16045526. ***X-8***

756. Jain A, Katewa SS, Chaudhary BL, et al. Folk herbal medicines used in birth control and sexual diseases by tribals of southern Rajasthan, India. J Ethnopharmacol. 2004 Jan;90(1):171-7. PMID: 14698527. ***X-4, X-5, X-9***

757. Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004 Oct;70(4):269-75. PMID: 15451329. ***X-4, X-5***

758. Jain JK, Meckstroth KR, Mishell DR, Jr. Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. Am J Obstet Gynecol. 1999 Dec;181(6):1386-91. PMID: 10601917. ***X-4, X-5, X-9***

759. Jain JK, Nicosia AF, Nucatola DL, et al. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids. 2003 Nov;68(10-13):1115-9. PMID: 14668006. ***X-4, X-5, X-6***

760. Jakubowicz DL, Godard E, Dewhurst J. The treatment of premenstrual tension with mefenamic acid: analysis of prostaglandin concentrations. Br J Obstet Gynaecol. 1984 Jan;91(1):78-84. PMID: 6362715. ***X-3, X-4, X-5, X-10***

761. Janssen CA. Menorrhagia and 3-keto-desogestrel-copper medicated intrauterine device. Eur J Obstet Gynecol Reprod Biol. 1999 Aug;85(2):135-6. PMID: 10610326. ***X-1, X-3***

762. Janssen CA, Scholten PC, Heintz AP. The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual blood loss: a double-blind, dose-finding, placebo-controlled study. Am J

Obstet Gynecol. 2000 Mar;182(3):575-81. PMID: 10739510. ***X-5, X-9, X-10***

763. Janssen OE, Mehlmauer N, Hahn S, et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004 Mar;150(3):363-9. PMID: 15012623. ***X-4, X-5, X-6, X-9***

764. Jarrell A, Olsen ME. Patient satisfaction with thermal balloon endometrial ablation. A retrospective review. J Reprod Med. 2003 Aug;48(8):635-6. PMID: 12971146. ***X-4, X-5, X-8***

765. Jarvela I, Tekay A, Santala M, et al. Thermal balloon endometrial ablation therapy induces a rise in uterine blood flow impedance: a randomized prospective color Doppler study. Ultrasound Obstet Gynecol. 2001 Jan;17(1):65-70. PMID: 11244659. ***X-5, X-8***

766. Jarvela I, Tekay A, Santala M, et al. Ultrasonographic features following thermal balloon endometrial ablation therapy. Gynecologic and Obstetric Investigation. 2002;54(1):11-6. PMID: 12297711. ***X-3, X-4, X-8***

767. Jenkinson C, Peto V, Coulter A. Measuring change over time: a comparison of results from a global single item of health status and the multi-dimensional SF-36 health status survey questionnaire in patients presenting with menorrhagia. Qual Life Res. 1994 Oct;3(5):317-21. PMID: 7841965. ***X-3***

768. Jenkinson C, Peto V, Coulter A. Making sense of ambiguity: evaluation of internal reliability and face validity of the SF 36 questionnaire in women presenting with menorrhagia. Quality in Health Care. 1996;5(1):9-12. PMID: 10157276. ***X-3, X-4, X-5***

769. Jensen JT. Noncontraceptive applications of the levonorgestrel intrauterine system. Curr Womens Health Rep. 2002 Dec;2(6):417-22. PMID: 12429074. ***X-1, X-4, X-5, X-9***

770. Jensen JT, Nelson AL, Costales AC. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception. 2008 Jan;77(1):22-9. PMID: 18082662. ***X-4, X-5***

771. Jensen LC, Obel EB, Lindhard A, et al. Frequency of curettage in middle-aged women treated with sequential preparations versus untreated women. Maturitas. 1992 Aug;15(1):61-9. PMID: 1326709. ***X-3, X-5, X-8***

772. Jimenez MF, Vetori D, Fagundes PA, et al. Subendometrial microvascularization and uterine artery blood flow in IUD-induced side effects (levonorgestrel intrauterine system and copper intrauterine device). Contraception. 2008 Oct;78(4):324-7. PMID: 18847582. ***X-4, X-5, X-9***

773. Jin Z, Huang G. Prevention and treatment of vaginal bleeding after drug-induced abortion by Yaoliuan capsule and its effects on menses recovery. J Huazhong Univ Sci Technolog Med Sci. 2005;25(3):346-7, 67. PMID: 16201292. ***X-5, X-9***

774. Jirapinyo M, Theppisai U, Manonai J, et al. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naive Thai women. Acta Obstet Gynecol Scand. 2003 Sep;82(9):857-66. PMID: 12911449. ***X-5, X-7***

775. Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry. 2006 Jun 1;59(11):1078-86. PMID: 16448626. ***X-4, X-5, X-9***

776. Joffre F, Tubiana JM, Pelage JP. FEMIC (Fibromes Embolises aux MICrospheres calibrees): uterine fibroid embolization using tris-acryl microspheres. A French multicenter study. Cardiovasc Intervent Radiol. 2004 Nov-Dec;27(6):600-6. PMID: 15578135. ***X-4, X-5, X-8***

777. Johannisson E, Landgren BM, Diczfalusy E. Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with the 300 mug norethisterone (NET) minipill. Contraception. 1982;25(1):13-30. PMID: 7060371. ***X-3, X-4, X-6***

778. Johnson JV, Davidson M, Archer D, et al. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause. 2002 Jan-Feb;9(1):16-22. PMID: 11791082. ***X-5, X-7***

779. Johnson JV, Grubb GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro g. Contraception. 2007 Jan;75(1):23-6. PMID: 17161119. ***X-4, X-5***

780. Johnson JV, Grubb GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 mug/ethinyl estradiol 20 mug. Contraception. 2007;75(1):23-6. PMID: 17161119. ***X-3, X-4***

781. Johnson N, Priestnall M, Marsay T, et al. A randomised trial evaluating pain and bleeding after a first trimester miscarriage treated surgically or medically. Eur J Obstet Gynecol Reprod Biol. 1997 Apr;72(2):213-5. PMID: 9134405. ***X-5, X-9***

782. Jones KP, Ravnikar VA, Schiff I. Results of human menopausal gonadotropin therapy at the Boston Hospital for Women (1979-1981). Int J Fertil. 1987 Mar-Apr;32(2):131-4. PMID: 2883138. ***X-3, X-5***

783. Joshi UM, Joshi JV, Donde UM, et al. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused

with cholesterol. Contraception. 1985 Jan;31(1):71-82. PMID: 3921309. ***X-3, X-5, X-9***

784. Jovanovic R, Barone CM, Van Natta FC, et al. Preventing infection related to insertion of an intrauterine device. J Reprod Med. 1988 Apr;33(4):347-52. PMID: 3367334. ***X-3, X-5, X-9***

785. Julian S, Naftalin NJ, Clark M, et al. An integrated care pathway for menorrhagia across the primary-secondary interface: patients' experience, clinical outcomes, and service utilisation. Qual Saf Health Care. 2007 Apr;16(2):110-5. PMID: 17403756. ***X-4, X-5, X-9***

786. Junge W, El-Samalouti V, Gerlinger C, et al. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: Open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. European Journal of Obstetrics Gynecology and Reproductive Biology. 2009;147(2):195-200. PMID: 19879683. ***X-7***

787. Jung-Hoffmann C, Kuhl H. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. Contraception. 1990 Oct;42(4):423-38. PMID: 2147887. ***X-3, X-5, X-6***

788. Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology. 2001;121(5):1073-9. PMID: 11677198. ***X-5***

789. Kadir RA, Lee CA, Sabin CA, et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia. 2002 Nov;8(6):787-93. PMID: 12410648. ***X-5, X-6, X-9***

790. Kaewrudee S, Taneepanichskul S, Jaisamraun U, et al. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use. Contraception. 1999 Jul;60(1):25-30. PMID: 10549449. ***X-4, X-5, X-6***

791. Kalmuss D, Davidson AR, Cushman LF, et al. Determinants of early implant discontinuation among low-income women. Fam Plann Perspect. 1996 Nov-Dec;28(6):256-60. PMID: 8959415. ***X-4, X-5, X-9***

792. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57(7):893-902. PMID: 18272546. ***X-5***

793. Kaneshiro B, Edelman A, Carlson N, et al. Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline: a randomized controlled trial. Obstet Gynecol. 2010 Jun;115(6):1141-9. PMID: 20502283. ***X-5, X-6***

794. Kaneshiro B, Edelman A, Carlson NE, et al. A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception. 2012 April;85(4):351-8. PMID: 2012157298. ***X-6***

795. Kanetsky PA, Mandelblatt J, Richart R, et al. Risk factors for cervical cancer in a black elderly population: preliminary findings. Ethn Dis. 1992 Fall;2(4):337-42. PMID: 1337003. ***X-3, X-5***

796. Kang JL, Wang DY, Wang XX, et al. Up-regulation of apoptosis by gonadotrophin-releasing hormone agonist in cultures of endometrial cells from women with symptomatic myomas. Hum Reprod. 2010 Sep;25(9):2270-5. PMID: 20634188. ***X-4, X-5***

797. Kapp KS, Poschauko J, Tauss J, et al. Analysis of the prognostic impact of tumor embolization before definitive radiotherapy for cervical carcinoma. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1399-404. PMID: 16029799. ***X-4, X-5, X-9***

798. Karkanis SG, Caloia D, Salenieks ME, et al. Randomized controlled trial of rectal misoprostol versus oxytocin in third stage management. J Obstet Gynaecol Can. 2002 Feb;24(2):149-54. PMID: 12196880. ***X-5, X-9***

799. Kashanian M, Shahpourian F, Zare O. A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction: a study in Iran. Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):47-51. PMID: 20185226. ***X-5***

800. Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. Contraception. 2000 May;61(5):295-302. PMID: 10906499. ***X-5***

801. Kaunitz AM, Burkman RT, Fisher AC, et al. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol. 2009 Dec;114(6):1205-12. PMID: 19935020. ***X-4, X-5***

802. Kaunitz AM, Darney PD, Ross D, et al. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009 Jul;80(1):7-17. PMID: 19501210. ***X-5***

803. Kaunitz AM, Garceau RJ, Cromie MA. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group. Contraception. 1999 Oct;60(4):179-87. PMID: 10640164. ***X-4, X-5***

804. Kauppila A, Heikkinen J, Viinikka L. Dynamic evaluation of prolactin secretion by successive TRH and metoclopramide stimulations. Acta Endocrinol (Copenh). 1986 Jan;111(1):10-6. PMID: 3080846. ***X-3, X-4, X-5***

805. Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother. 2004 Dec;58(10):582-7. PMID: 15589067. ***X-5, X-9***

806. Kayikcioglu F, Gunes M, Ozdegirmenci O, et al. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study. Contraception. 2006 May;73(5):528-31. PMID: 16627040. ***X-4, X-5, X-6, X-9***

807. Kazerooni T, Zolghadri J. The comparison of bleeding patterns with high-dose and low-dose hormone replacement therapy in postmenopausal women. Gynecol Endocrinol. 2004 Aug;19(2):64-8. PMID: 15624267. ***X-4, X-5, X-7***

808. Kazi A, Holck SE, Diethelm P. Phase IV study of the injection Norigest in Pakistan. Contraception. 1985 Oct;32(4):395-403. PMID: 3907968. ***X-3, X-9***

809. Keder LM, Rulin MC, Gruss J. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders. Am J Obstet Gynecol. 1998 Sep;179(3 Pt 1):583-5. PMID: 9757955. ***X-5, X-6, X-9***

810. Kekkonen R, Lahteenmaki P, Luukkainen T, et al. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception. Fertil Steril. 1993 Oct;60(4):610-5. PMID: 8405512. ***X-3, X-4, X-5***

811. Kelekci KH, Kelekci S, Yengel I, et al. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: Randomized comparison of three regimens. Journal of Dermatological Treatment. 2012 June;23(3):177-83. PMID: 2012280528. ***X-5***

812. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. The Lancet Oncology. 2009;10(2):135-46. PMID: 19167925. ***X-5, X-7, X-10***

813. Khan SA, Ul Amin Z, Fouzia, et al. A comparative trial of copper T 380 and Cu 375 IUCD. J Ayub Med Coll Abbottabad. 2010 Jul-Sep;22(3):185-7. PMID: 22338452. ***X-3, X-9***

814. Khanna A, Biswas AK, Dubey B, et al. Fibrinolytic activity in bleeding associated with intrauterine contraceptive devices. Indian J Med Res. 1992 Jun;96:147-9. PMID: 1512035. ***X-3, X-4***

815. Khaund A, Moss JG, McMillan N, et al. Evaluation of the effect of uterine artery embolisation on menstrual blood loss and uterine volume. BJOG. 2004 Jul;111(7):700-5. PMID: 15198761. ***X-4, X-5, X-6, X-8***

816. Kilic S, Yilmaz N, Zulfikaroglu E, et al. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology. 2011;27(9):622-9. PMID: 21105835. ***X-4, X-5, X-6, X-10***

817. Kilic S, Yuksel B, Doganay M, et al. The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement. Contraception. 2009 Aug;80(2):152-7. PMID: 19631790. ***X-5, X-6***

818. Kilonzo MM, Sambrook AM, Cook JA, et al. A cost-utility analysis of microwave endometrial ablation versus thermal balloon endometrial ablation. Value Health. 2010 Aug;13(5):528-34. PMID: 20712602. ***X-4, X-5, X-8***

819. Kim CY, Chung S, Lee JN, et al. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology. 2009;24(4):181-8. PMID: 19451828. ***X-5***

820. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002 May;63(5):408-13. PMID: 12019665. ***X-4, X-5, X-9***

821. Kim MD, Kim YM, Kim HC, et al. Uterine artery embolization for symptomatic adenomyosis: a new technical development of the 1-2-3 protocol and predictive factors of MR imaging affecting outcomes. J Vasc Interv Radiol. 2011 Apr;22(4):497-502. PMID: 21377897. ***X-4, X-5, X-8***

822. Kim MD, Lee HS, Lee MH, et al. Long-term results of symptomatic fibroids treated with uterine artery embolization: in conjunction with MR evaluation. Eur J Radiol. 2010 Feb;73(2):339-44. PMID: 19084365. ***X-4, X-5, X-6, X-8***

823. Kim SW, Shin IS, Kim JM, et al. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial. Progress in Neuro Psychopharmacology and Biological Psychiatry. 2007;31(7):1504-9. PMID: 17692448. ***X-5***

824. Kim YH, Chung HH, Kang SB, et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematol. 2009;121(1):37-41. PMID: 19332985. ***X-4, X-5, X-9***

825. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:55-68. PMID: 12650681. ***X-4, X-5, X-9***

826. Kircher C, Smith KP. Acarbose for polycystic ovary syndrome. Ann Pharmacother. 2008 Jun;42(6):847-51. PMID: 18460589. ***X-1, X-4, X-5, X-9***

827. Kirkman RJ, Pedersen JH, Fioretti P, et al. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception. 1994 Jan;49(1):33-46. PMID: 8137624. ***X-6, X-9***

828. Kirss F, Lang K, Tuimala R. Feminine life-course of Estonian women born in 1937-47: a questionnaire survey. Acta Obstet Gynecol Scand. 2006;85(2):224-8. PMID: 16532919. ***X-4, X-5, X-9***

829. Kirtava A, Crudder S, Dilley A, et al. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia. 2004 Mar;10(2):158-61. PMID: 14962204. ***X-4, X-5, X-6, X-9***

830. Kitawaki J, Kusuki I, Yamanaka K, et al. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. European Journal of Obstetrics Gynecology and Reproductive Biology. 2011;157(2):212-6. PMID: 21474232. ***X-3, X-6***

831. Kittelsen N, Istre O. A randomized study comparing levonorgestrel intrauterine system (LNG IUS) and transcervical resection of the endometrium (TCRE) in the treatment of menorrhagia: Preliminary results. Gynaecological Endoscopy. 1998;7(2):61-5. ***X-8***

832. Kjotrod SB, von During V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction. 2004;19(6):1315-22. PMID: 15117902. ***X-4, X-5, X-10***

833. Klipping C, Duijkers I, Fortier MP, et al. Long-term tolerability of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen: Results from a randomised, controlled, multicentrestudy. Journal of Family Planning and Reproductive Health Care. 2012 April;38(2):84-93. PMID: 2012264031. ***X-9***

834. Klipping C, Duijkers I, Fortier MP, et al. Contraceptive efficacy and tolerability of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen: An open-label, multicentre, randomised, controlled study. Journal of Family Planning and Reproductive Health Care. 2012 April;38(2):73-83. PMID: 2012264030. ***X-9***

835. Koetsawang S, Charoenvisal C, Banharnsupawat L, et al. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception. 1995 Apr;51(4):225-9. PMID: 7796587. ***X-9***

836. Koh SC, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia. J Thromb Haemost. 2007 Jan;5(1):133-8. PMID: 17010149. ***X-4, X-5, X-6***

837. Kohnen G, Campbell S, Irvine GA, et al. Endothelin receptor expression in human decidua. Mol Hum Reprod. 1998 Feb;4(2):185-93. PMID: 9542978. ***X-4, X-5, X-9***

838. Koike K, Yamamoto Y, Suzuki N, et al. Efficacy of porcine placental extracts with hormone therapy for postmenopausal women with knee pain. Climacteric. 2012 February;15(1):30-5. PMID: 2012007553. ***X-7***

839. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008;77(4):249-56. PMID: 18342647. ***X-5***

840. Komulainen MH, Kroger H, Tuppurainen MT, et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; A 5 year randomized trial. Maturitas. 1998;31(1):45-54. PMID: 10091204. ***X-7***

841. Kong GW, Yim SF, Cheung TH, et al. Cryotherapy as the treatment modality of postcoital bleeding: a randomised clinical trial of efficacy and safety. Aust N Z J Obstet Gynaecol. 2009 Oct;49(5):517-24. PMID: 19780737. ***X-5, X-9***

842. Koninckx PR, Spielmann D. A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women. Gynecological Endocrinology. 2005;21(2):82-9. PMID: 16294460. ***X-7***

843. Korytkowski MT, Mokan M, Horwitz MJ, et al. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995 Nov;80(11):3327-34. PMID: 7593446. ***X-3, X-4***

844. Kotsa K, Yavropoulou MP, Anastasiou O, et al. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril. 2009 Sep;92(3):1053-8. PMID: 18930208. ***X-4, X-5, X-9***

845. Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009 Apr;145(2):212-20. PMID: 19236375. ***X-6***

846. Kozman E, Collins P, Howard A, et al. The effect of an intrauterine application of two percent lignocaine gel on pain perception during Vabra endometrial sampling: a randomised double-blind, placebo-controlled trial. BJOG. 2001 Jan;108(1):87-90. PMID: 11213009. ***X-5, X-9***

847. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf). 1999 May;50(5):655-9. PMID: 10468932. ***X-4, X-5, X-6***

848. Krettek JE, Arkin SI, Chaisilwattana P, et al. Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting. Obstet Gynecol. 1993 May;81(5 (Pt 1)):728-31. PMID: 8469461. ***X-3, X-4, X-5***

849. Krikun G, Critchley H, Schatz F, et al. Abnormal uterine bleeding during progestin-only contraception may result from free radical-induced alterations in angiopoietin expression. Am J Pathol. 2002 Sep;161(3):979-86. PMID: 12213726. ***X-4, X-5, X-9***

850. Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J Reprod Med. 2004 May;49(5):361-7. PMID: 15214709. ***X-4, X-5, X-9***

851. Kriplani A, Manchanda R, Monga D, et al. Depot medroxy progesterone acetate: a poor preparatory agent for endometrial resection. Gynecol Obstet Invest. 2001;52(3):180-3. PMID: 11598360. ***X-4, X-5, X-8***

852. Kriplani A, Manchanda R, Nath J, et al. A randomized trial of danazol pretreatment prior to endometrial resection. Eur J Obstet Gynecol Reprod Biol. 2002 Jun 10;103(1):68-71. PMID: 12039468. ***X-5, X-8***

853. Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception. 2010;82(2):139-46. PMID: 20654754. ***X-4, X-5, X-10***

854. Kriplani A, Singh BM, Lal S, et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007 Jun;97(3):190-4. PMID: 17382331. ***X-4***

855. Kritz-Silverstein D, Wingard DL, Garland FC. The association of behavior and lifestyle factors with menstrual symptoms. Journal of Women's Health & Gender-Based Medicine. 1999;8(9):1185-93. PMID: 10595332. ***X-3, X-4, X-5***

856. Kroencke TJ, Scheurig C, Poellinger A, et al. Uterine artery embolization for leiomyomas: percentage of infarction predicts clinical outcome. Radiology. 2010 Jun;255(3):834-41. PMID: 20392986. ***X-4, X-5, X-6, X-8***

857. Kubba AA. The benefits of oral contraceptives. J R Soc Health. 1985 Apr;105(2):73-4. PMID: 3921718. ***X-11***

858. Kucuk M, Okman TK. Intrauterine instillation of trichloroacetic acid is effective for the treatment of dysfunctional uterine bleeding. Fertil Steril. 2005 Jan;83(1):189-94. PMID: 15652906. ***X-4***

859. Kucukozkan T, Kadioglu BG, Uygur D, et al. Chemical ablation of endometrium with trichloroacetic acid. Int J Gynaecol Obstet. 2004 Jan;84(1):41-6. PMID: 14698828. ***X-5, X-8***

860. Kuhl H, Gahn G, Romberg C. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels. Contraception. 1985;31(6):583-93. PMID: 2931247. ***X-4, X-6, X-9***

861. Kulkarni S, Wynter HH, Desai P. Hysteroscopic assessment of abnormal uterine bleeding in users of the intrauterine contraceptive device. West Indian Med J. 1993 Sep;42(3):124-5. PMID: 8273322. ***X-3, X-4, X-5***

862. Kuppermann M, Varner RE, Summitt RL, Jr., et al. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA. 2004 Mar 24;291(12):1447-55. PMID: 15039411. ***X-8***

863. Kurtoglu M, Koksoy C, Hasan E, et al. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. J Vasc Surg. 2010 Nov;52(5):1262-70. PMID: 20732787. ***X-4, X-5, X-9***

864. Kwak HM, Chi I, Gardner SD, et al. Menstrual pattern changes in laparoscopic sterilization patients whose last pregnancy was terminated by therapeutic abortion. A two-year follow-up study. J Reprod Med. 1980 Aug;25(2):67-71. PMID: 7411527. ***X-3, X-5, X-8***

865. Kwiecien M, Edelman A, Nichols MD, et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: A randomized trial. Contraception. 2003;67(1):9-13. PMID: 12521651. ***X-9***

866. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000 Mar;39(3):218-22. PMID: 10759967. ***X-4, X-5, X-6, X-9***

867. Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: A randomized double-blind study. Fertility and Sterility. 2011;95(3):1059-66. PMID: 21193187. ***X-5, X-10***

868. LaGuardia KD, Fisher AC, Bainbridge JD, et al. Suppression of estrogen-withdrawal headache with

extended transdermal contraception. Fertility and Sterility. 2005;83(6):1875-7. PMID: 15950671. ***X-5, X-9***

869. LaGuardia KD, Shangold G, Fisher A, et al. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. Contraception. 2003 Jun;67(6):431-7. PMID: 12814811. ***X-5***

870. Lakha F, Ho PC, Van der Spuy ZM, et al. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod. 2007 Sep;22(9):2428-36. PMID: 17609247. ***X-5***

871. Lal S, Kriplani A, Kulshrestha V, et al. Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system. Int J Gynaecol Obstet. 2010 May;109(2):128-30. PMID: 20223454. ***X-4***

872. Landgren BM, Aedo AR, Johannisson E, et al. Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 micrograms/24 h when used alone or in combination with transdermal systems releasing estradiol. Contraception. 1994 Jul;50(1):87-100. PMID: 7924325. ***X-3, X-6, X-9***

873. Landgren BM, Aedo AR, Johannisson E, et al. Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 mug/24h when used alone or in combination with transdermal systems releasing estradiol. Contraception. 1994;50(1):87-100. PMID: 7924325. ***X-3, X-4, X-5, X-9***

874. Landgren BM, Johannisson E, Masironi B, et al. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. Contraception. 1982 Dec;26(6):567-85. PMID: 6820337. ***X-3, X-4***

875. Landgren MB, Bennink HJ, Helmond FA, et al. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG. 2002 Oct;109(10):1109-14. PMID: 12387462. ***X-5, X-7***

876. Lang EK, Myers L. Outcome of superselective uterine artery embolization of fibroids. Journal of Women's Imaging. 2004;6(1):23. ***X-3, X-8***

877. Langer RD, Landgren BM, Rymer J, et al. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol. 2006 Nov;195(5):1320-7. PMID: 16875644. ***X-5, X-7***

878. Laoag-Fernandez JB, Maruo T, Pakarinen P, et al. Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis. Hum Reprod. 2003 Apr;18(4):694-9. PMID: 12660258. ***X-4, X-5, X-9***

879. Lappohn RE, van de Wiel HB, Brownell J. The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia. Fertil Steril. 1992 Aug;58(2):321-7. PMID: 1353028. ***X-5, X-6***

880. Larsson PG, Bergman B, Forsum U, et al. Treatment of bacterial vaginosis in women with vaginal bleeding complications or discharge and harboring Mobiluncus. Gynecol Obstet Invest. 1990;29(4):296-300. PMID: 2361638. ***X-5, X-6***

881. Laufe LE, Sokal DC, Cole LP, et al. Phase I prehysterectomy studies of the transcervical administration of quinacrine pellets. Contraception. 1996 Sep;54(3):181-6. PMID: 8899260. ***X-4, X-5, X-8, X-9***

882. Laurikka-Routti M, Haukkamaa M, Lahteenmaki P. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435. Fertil Steril. 1992 Oct;58(4):680-4. PMID: 1426309. ***X-3, X-4, X-5, X-9***

883. Lawrie TA, Hofmeyr GJ, De Jager M, et al. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol. 1998 Oct;105(10):1082-90. PMID: 9800931. ***X-5, X-6, X-9***

884. Lazovic G, Radivojevic U, Milicevic S, et al. The most frequent hormone dysfunctions in juvenile bleeding. Int J Fertil Womens Med. 2007 Jan-Feb;52(1):35-40. PMID: 17987886. ***X-4, X-5***

885. Lazzarin N, Vaquero E, Exacoustos C, et al. Low-dose aspirin and omega-3 fatty acids improve uterine artery blood flow velocity in women with recurrent miscarriage due to impaired uterine perfusion. Fertility and Sterility. 2009;92(1):296-300. PMID: 18692841. ***X-4, X-5***

886. Learman LA, Summitt RL, Jr., Varner RE, et al. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol. 2004 May;103(5 Pt 1):824-33. PMID: 15121552. ***X-8***

887. Lebwohl M, Ortonne JP, Andres P, et al. Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis. 2009 Apr;83(4):205-12. PMID: 19445311. ***X-4, X-5, X-9***

888. Lefebvre Y, Proulx L, Elie R, et al. The effects of RU-38486 on cervical ripening. Clinical studies. Am J Obstet Gynecol. 1990 Jan;162(1):61-5. PMID: 2301519. ***X-3, X-5***

889. Legro RS. Polycystic ovary syndrome: Current and future treatment paradigms. American Journal of Obstetrics and Gynecology. 1998;179(6 II):S101-S8. PMID: 9855616. ***X-1, X-3, X-5***

890. Legro RS, Muhleman DR, Comings DE, et al. A dopamine D3 receptor genotype is associated with hyperandrogenic chronic anovulation and resistant to ovulation induction with clomiphene citrate in female Hispanics. Fertil Steril. 1995 Apr;63(4):779-84. PMID: 7890062. ***X-3, X-4, X-5***

891. Legro RS, Myers ER, Barnhart HX, et al. The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril. 2006 Oct;86(4):914-33. PMID: 16963034. ***X-5, X-9***

892. Legro RS, Urbanek M, Kunselman AR, et al. Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertil Steril. 2002 Jul;78(1):51-7. PMID: 12095490. ***X-4, X-5, X-9***

893. Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception. 1996 Jun;53(6):357-61. PMID: 8773423. ***X-4, X-5***

894. Leissinger C, Becton D, Cornell C, Jr., et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. PMID: 11380629. ***X-4, X-5, X-6***

895. Lelaidier C, Baton-Saint-Mleux C, Fernandez H, et al. Mifepristone (RU 486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial. Hum Reprod. 1993 Mar;8(3):492-5. PMID: 8473474. ***X-5***

896. Lemay A, Faure N. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study. J Clin Endocrinol Metab. 1994 Dec;79(6):1716-22. PMID: 7989480. ***X-3***

897. Leminen H, Heliovaara-Peippo S, Halmesmaki K, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on premenstrual symptoms in women treated for menorrhagia: secondary analysis of a randomized controlled trial. Acta Obstet Gynecol Scand. 2012 Mar;91(3):318-25. PMID: 22168810. ***X-8***

898. Lete I, del Carme Cuesta M, Marin JM, et al. Acceptability of the levonorgestrel intrauterine system in the long-term treatment of heavy menstrual bleeding: how many women choose to use a second device? Eur J Obstet Gynecol Reprod Biol. 2011 Jan;154(1):67-70. PMID: 20728261. ***X-4***

899. Lete I, Obispo C, Izaguirre F, et al. The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction. Eur J Contracept Reprod Health Care. 2008 Sep;13(3):231-7. PMID: 18609346. ***X-4***

900. Lethaby A, Hickey M, Garry R, et al. Endometrial resection / ablation techniques for heavy menstrual bleeding. Cochrane Database of Systematic Reviews. 2009(4)PMID: 19821278. ***X-8***

901. Lethaby A, Shepperd S, Farquhar C, et al. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database of Systematic Reviews. 1999(2). ***X-8***

902. Leyden J, Shalita A, Hordinsky M, et al. Efficacy of a low-dose oral contraceptive containing 20 mug of ethinyl estradiol and 100 mug of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. Journal of the American Academy of Dermatology. 2002;47(3):399-409. PMID: 12196750. ***X-5, X-9***

903. Lhomme C, Brault P, Bourhis JH, et al. Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study. Leuk Lymphoma. 2001 Sep-Oct;42(5):1033-41. PMID: 11697620. ***X-4, X-5, X-6, X-9***

904. Li A, Felix JC, Yang W, et al. Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users. Contraception. 2007 Jul;76(1):57-65. PMID: 17586139. ***X-4, X-5, X-9***

905. Li L, Zhou Z, Huang L. Abnormal expression of MMP-9 and imbalance of MMP-9/TIMP-1 is associated with prolonged uterine bleeding after a medical abortion with mifepristone and misoprostol. Acta Obstet Gynecol Scand. 2009;88(6):673-9. PMID: 19353331. ***X-4, X-5, X-9***

906. Li X, Liu R, Zhang W, et al. Up-regulation of Fas/FasL activation contribute to the apoptosis enhancement of RU486 by Gong-Qing Decoction, a traditional Chinese prescription. Journal of Ethnopharmacology. 2011;134(2):386-92. PMID: 21195151. ***X-5***

907. Lian F, Liu HP, Wang YX, et al. Expressions of VEGF and Ki-67 in eutopic endometrium of patients with endometriosis and effect of Quyu Jiedu Recipe on VEGF expression. Chin J Integr Med. 2007 Jun;13(2):109-14. PMID: 17609908. ***X-4, X-5***

908. Liao EY, Luo XH, Deng XG, et al. The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. Endocrine Research. 2003;29(2):217-26. PMID: 12856809. ***X-7***

909. Lim AK, Agarwal R, Seckl MJ, et al. Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology.

2002 Mar;222(3):640-4. PMID: 11867779. ***X-4, X-5, X-6, X-8, X-9***

910. Lim LS, McCarthy TG, Yong YM, et al. Post-abortion insertion of MLCu 250 and MLCu 375--a comparative trial. Contraception. 1985 May;31(5):471-7. PMID: 4028724. ***X-9***

911. Limpaphayom KK, Bunyavejchevin S. Clinical effects of 17 beta-estradiol and norethisterone acetate in postmenopausal Thai women. J Med Assoc Thai. 2000 Apr;83(4):407-16. PMID: 10808701. ***X-5, X-7***

912. Lin CH, Kuo CC, Chou LS, et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. Journal of Clinical Psychopharmacology. 2010;30(5):518-25. PMID: 20814315. ***X-5***

913. Lin H. Comparison between microwave endometrial ablation and total hysterectomy. Chin Med J (Engl). 2006 Jul 20;119(14):1195-7. PMID: 16863612. ***X-4, X-5, X-8***

914. Lin KC. Relationship between pituitary reserve and efficacy of bromocriptine in women with euprolactinemic ovulatory dysfunction. Gaoxiong Yi Xue Ke Xue Za Zhi. 1994 May;10(5):222-8. PMID: 8040924. ***X-3, X-4, X-5***

915. Lin SQ, Sun LZ, Lin JF, et al. Estradiol 1mg and drospirenone 2mg as hormone replacement therapy in postmenopausal Chinese women. Climacteric. 2011;14(4):472-81. PMID: 21469973. ***X-7***

916. Lin X, Gao ES, Li D, et al. Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstet Gynecol Scand. 2007;86(9):1126-9. PMID: 17712656. ***X-5, X-6, X-9***

917. Lin YH, Hwang JL, Huang LW, et al. Use of sublingual buprenorphine for pain relief in office hysteroscopy. J Minim Invasive Gynecol. 2005 Jul-Aug;12(4):347-50. PMID: 16036196. ***X-5, X-9***

918. Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstetrics and Gynecology. 2002;100(5):853-63. PMID: 12423841. ***X-7***

919. Lindgren R, Risberg B, Hammar M, et al. Endometrial effects of transdermal estradiol/norethisterone acetate. Maturitas. 1992 Aug;15(1):71-8. PMID: 1528133. ***X-3, X-7***

920. Lindholm A, Bixo M, Bjorn I, et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2008 May;89(5):1221-8. PMID: 17603048. ***X-5, X-9***

921. Lindner HR, Zor U, Kohen F, et al. Significance of prostaglandins in the regulation of cyclic events in the ovary and uterus. Adv Prostaglandin Thromboxane Res. 1980;8:1371-90. PMID: 7376986. ***X-3, X-4***

922. Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost. 1993 Aug 2;70(2):238-40. PMID: 8236125. ***X-3, X-5***

923. Lisi F, Rinaldi L, Fishel S, et al. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril. 2005 Feb;83(2):309-15. PMID: 15705367. ***X-5, X-9***

924. Lissak A, Fruchter O, Mashiach S, et al. Immediate versus delayed treatment of perimenopausal bleeding due to benign causes by balloon thermal ablation. J Am Assoc Gynecol Laparosc. 1999 May;6(2):145-50. PMID: 10226122. ***X-3, X-5, X-8***

925. Liu X. TCM treatment for severe climacteric dysfunctional uterine bleeding--a report of 43 cases. J Tradit Chin Med. 2007 Mar;27(1):46-8. PMID: 17393627. ***X-3***

926. Lockwood CJ, Kumar P, Krikun G, et al. Effects of thrombin, hypoxia, and steroids on interleukin-8 expression in decidualized human endometrial stromal cells: implications for long-term progestin-only contraceptive-induced bleeding. J Clin Endocrinol Metab. 2004 Mar;89(3):1467-75. PMID: 15001649. ***X-4, X-5, X-9***

927. Lockwood CJ, Nemerson Y, Krikun G, et al. Steroid-modulated stromal cell tissue factor expression: a model for the regulation of endometrial hemostasis and menstruation. J Clin Endocrinol Metab. 1993 Oct;77(4):1014-9. PMID: 8408448. ***X-3, X-4***

928. Lockwood CJ, Runic R, Wan L, et al. The role of tissue factor in regulating endometrial haemostasis: implications for progestin-only contraception. Hum Reprod. 2000 Aug;15 Suppl 3:144-51. PMID: 11041230. ***X-4, X-5***

929. Loffer FD, Grainger D. Five-year follow-up of patients participating in a randomized trial of uterine balloon therapy versus rollerball ablation for treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002 Nov;9(4):429-35. PMID: 12386351. ***X-4, X-5, X-8***

930. Lofgren E, Tapanainen JS, Koivunen R, et al. Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy. Epilepsia. 2006 Sep;47(9):1441-6. PMID: 16981858. ***X-4, X-5, X-9***

931. Loh FH, Chen LH, Yu SL, et al. The efficacy of two dosages of a continuous combined hormone replacement regimen. Maturitas. 2002 Feb 26;41(2):123-31. PMID: 11836043. ***X-5, X-7***

932. Lok IH, Chan M, Tam WH, et al. Patient-controlled sedation for outpatient thermal balloon endometrial

ablation. J Am Assoc Gynecol Laparosc. 2002 Nov;9(4):436-41. PMID: 12386352. ***X-4, X-5, X-8, X-9***

933. Lok IH, Leung PL, Ng PS, et al. Life-table analysis of the success of thermal balloon endometrial ablation in the treatment of menorrhagia. Fertil Steril. 2003 Nov;80(5):1255-9. PMID: 14607584. ***X-4, X-5, X-8***

934. Lokugamage AU, Paine M, Bassaw-Balroop K, et al. Active management of the third stage at caesarean section: a randomised controlled trial of misoprostol versus syntocinon. Aust N Z J Obstet Gynaecol. 2001 Nov;41(4):411-4. PMID: 11787915. ***X-5, X-9***

935. London RS, Sundaram GS, Murphy L, et al. The effect of alpha-tocopherol on premenstrual symptomatology: a double-blind study. J Am Coll Nutr. 1983;2(2):115-22. PMID: 6350402. ***X-5***

936. Longo MF, Cohen DR, Hood K, et al. Involving patients in primary care consultations: assessing preferences using discrete choice experiments. Br J Gen Pract. 2006 Jan;56(522):35-42. PMID: 16438813. ***X-3, X-4, X-5, X-9***

937. Lopez G, Rodriguez A, Rengifo J, et al. Two-year prospective study in Colombia of Norplant implants. Obstet Gynecol. 1986 Aug;68(2):204-8. PMID: 3090492. ***X-3, X-9***

938. Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. Journal of Clinical Oncology. 2007;24(9):1409-14. PMID: 16505409. ***X-5***

939. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology. 1993;11(4):762-7. PMID: 8478668. ***X-5***

940. Loucopoulos A, Ferin M. The treatment of luteal phase defects with pulsatile infusion of gonadotropin-releasing hormone. Fertil Steril. 1987 Dec;48(6):933-6. PMID: 3119374. ***X-3, X-5***

941. Lu W, Li Q, Li J, et al. Polysaccharide from Patrinia heterophylla Bunge inhibits HeLa cell proliferation through induction of apoptosis and cell cycle arrest. Laboratory Medicine. 2009;40(3):161-6. ***X-3, X-4***

942. Lubbert H, Nauert C. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. Maturitas. 1997 Dec 15;28(2):117-25. PMID: 9522319. ***X-5, X-7***

943. Ludicke F, Gaspard UJ, Demeyer F, et al. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception. 2002 Dec;66(6):411-5. PMID: 12499033. ***X-4, X-5, X-9***

944. Luisi M, Franchi F, Bianchi S, et al. Radio-immunoassay of salivary progesterone for monitoring ovarian function in female infertility. Ann Biol Clin (Paris). 1987;45(4):449-52. PMID: 3674548. ***X-3, X-4, X-5***

945. Luisi S, Razzi S, Lazzeri L, et al. Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age. Fertil Steril. 2009 Oct;92(4):1351-4. PMID: 18930222. ***X-4***

946. Lukes AS, Muse K, Richter HE, et al. Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding. Curr Med Res Opin. 2010 Nov;26(11):2673-8. PMID: 20942615. ***X-3, X-4***

947. Lundvall F, Nielsen NC. The hemostatic effect of tranexamic acid in conisatio colli uteri. Acta Obstet Gynecol Scand. 1984;63(1):81-4. PMID: 6372362. ***X-5, X-8***

948. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, et al. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care. 2007 Sep;30(9):2309-13. PMID: 17536071. ***X-4, X-5, X-9***

949. Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception. 1987 Aug;36(2):169-79. PMID: 3123132. ***X-3, X-9***

950. Luukkainen T, Allonen H, Nielsen NC, et al. Five years' experience of intrauterine contraception with the Nova-T and the Copper-T-200. Am J Obstet Gynecol. 1983 Dec 15;147(8):885-92. PMID: 6650625. ***X-9***

951. Luukkainen T, Heikinheimo O, Haukkamaa M, et al. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. Fertil Steril. 1988 Jun;49(6):961-3. PMID: 3371492. ***X-3, X-4, X-5***

952. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med. 2001 Dec;19(4):355-63. PMID: 11727177. ***X-1, X-3, X-5***

953. Lydeking-Olsen E, Beck-Jensen JE, Setchell KDR, et al. Soymilk or progesterone for prevention of bone loss: A 2 year randomized, placebo-controlled trial. European Journal of Nutrition. 2004;43(4):246-57. PMID: 15309425. ***X-7***

954. M, Vardhanabhuti VV, Pearson SA. Education and Service Delivery: The use of transvaginal ultrasound evaluation premicrowave endometrial ablation. Ultrasound. 2011;19(1):36-8. ***X-8***

955. Ma W, Bai W, Lin C, et al. Effects of Sanyinjiao (SP6) with electroacupuncture on labour pain in women during labour. Complement Ther Med. 2011 Jan;19 Suppl 1:S13-8. PMID: 21195290. ***X-5, X-9***

956. MacGregor EA, Brandes JL, Silberstein S, et al. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. Headache. 2009 Oct;49(9):1298-314. PMID: 19788471. ***X-5, X-9***

957. MacGregor EA, Frith A, Ellis J, et al. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006 Dec 26;67(12):2159-63. PMID: 17190936. ***X-5, X-9***

958. MacGregor EA, Victor TW, Hu X, et al. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache. 2010 Apr;50(4):528-38. PMID: 20236340. ***X-4, X-5, X-9***

959. Machado RB, de Melo NR, Maia H, Jr. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception. 2010 Mar;81(3):215-22. PMID: 20159177. ***X-5***

960. Madden T, Proehl S, Allsworth JE, et al. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: A randomized controlled trial. American Journal of Obstetrics and Gynecology. 2012 February;206(2):129.e1-.e8. PMID: 2012063049. ***X-5, X-9, X-10***

961. Mady MA, Kossoff EH, McGregor AL, et al. The ketogenic diet: adolescents can do it, too. Epilepsia. 2003 Jun;44(6):847-51. PMID: 12790900. ***X-4, X-5, X-9***

962. Magalhaes J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007 Mar;75(3):193-8. PMID: 17303488. ***X-4, X-5, X-6, X-9***

963. Magill PJ, Beaumont G, Gringras M, et al. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. British Journal of General Practice. 1995;45(400):589-93. PMID: 8554838. ***X-5, X-6***

964. Magos A, Brincat M, Zilkha KJ, et al. Serum dopamine beta-hydroxylase activity in menstrual migraine. J Neurol Neurosurg Psychiatry. 1985 Apr;48(4):328-31. PMID: 4039748. ***X-3, X-4, X-5***

965. Maia H, Jr., Maltez A, Coelho G, et al. Insertion of mirena after endometrial resection in patients with adenomyosis. J Am Assoc Gynecol Laparosc. 2003 Nov;10(4):512-6. PMID: 14738640. ***X-4, X-5, X-6, X-8***

966. Maia H, Jr., Pimentel K, Casoy J, et al. Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use. Gynecol Endocrinol. 2007 Jun;23(6):320-4. PMID: 17616855. ***X-4, X-5, X-6, X-9***

967. Mainini G, Scaffa C, Rotondi M, et al. Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low dose 17beta-estradiol vaginal tablets. Clin Exp Obstet Gynecol. 2005;32(2):111-3. PMID: 16108394. ***X-5, X-7***

968. Makarainen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol. 1986 Sep;93(9):974-8. PMID: 3533137. ***X-5, X-6***

969. Makarainen L, Ylikorkala O. Ibuprofen prevents IUCD-induced increases in menstrual blood loss. Br J Obstet Gynaecol. 1986 Mar;93(3):285-8. PMID: 3516203. ***X-5, X-6***

970. Makhubele JC. Indigenous knowledge in the context of sexual and reproductive health and rights amongst the Tsonga/ Shangaan speaking people in a rural community of Limpopo Province: A social work perspective. International Journal of Health Promotion & Education. 2011;49(4):161-8. ***X-3, X-5, X-7***

971. Maloney JM, Dietze Jr P, Watson D, et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 mug ethinylestradiol in the treatment of acne vulgaris: Lesion counts, investigator ratings and subject self-assessment. Journal of Drugs in Dermatology. 2009;8(9):837-44. PMID: 19746676. ***X-5***

972. Maloney JM, Dietze P, Watson D, et al. Treatment of acne using A 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: A randomized controlled trial. Obstetrics and Gynecology. 2008;112(4):773-81. PMID: 18827119. ***X-5***

973. Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007 May;27(5):414-21. PMID: 17448179. ***X-5, X-9***

974. Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011 Dec;16(6):430-43. PMID: 21995590. ***X-9***

975. Marbaix E, Vekemans M, Galant C, et al. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in

levonorgestrel-implant users. Hum Reprod. 2000 Aug;15 Suppl 3:120-34. PMID: 11041228. ***X-4, X-5***

976. Marchant-Haycox S, Liu D, Nicholas N, et al. Patients' expectations of outcome of hysterectomy and alternative treatments for menstrual problems. J Behav Med. 1998 Jun;21(3):283-97. PMID: 9642573. ***X-4, X-5, X-8, X-9***

977. Marchbanks PA, Coulam CB, Annegers JF. An association between clomiphene citrate and ectopic pregnancy: a preliminary report. Fertil Steril. 1985 Aug;44(2):268-70. PMID: 4018282. ***X-3, X-5, X-9***

978. Marchini M, Dorta M, Bombelli F, et al. Effects of clomiphene citrate on cervical mucus: analysis of some influencing factors. Int J Fertil. 1989 Mar-Apr;34(2):154-9. PMID: 2565319. ***X-3, X-4, X-5***

979. Marcus DA, Bernstein CD, Sullivan EA, et al. A prospective comparison between ICHD-II and probability menstrual migraine diagnostic criteria. Headache. 2010 Apr;50(4):539-50. PMID: 20236338. ***X-4, X-5, X-9***

980. Marcus DA, Bernstein CD, Sullivan EA, et al. Perimenstrual eletriptan prevents menstrual migraine: an open-label study. Headache. 2010 Apr;50(4):551-62. PMID: 20236337. ***X-4, X-5, X-9***

981. Marsh F, Kremer C, Duffy S. Delivering an effective outpatient service in gynaecology. A randomised controlled trial analysing the cost of outpatient versus daycase hysteroscopy. BJOG. 2004 Mar;111(3):243-8. PMID: 14961886. ***X-5, X-8***

982. Marsh F, Thewlis J, Duffy S. Thermachoice endometrial ablation in the outpatient setting, without local anesthesia or intravenous sedation: a prospective cohort study. Fertil Steril. 2005 Mar;83(3):715-20. PMID: 15749503. ***X-4, X-5, X-8***

983. Marsh F, Thewlis J, Duffy S. Randomized controlled trial comparing Thermachoice III* in the outpatient versus daycase setting. Fertil Steril. 2007 Mar;87(3):642-50. PMID: 17109859. ***X-5, X-8***

984. Marsh MM, Butt AR, Riley SC, et al. Immunolocalization of endothelin and neutral endopeptidase in the endometrium of users of subdermally implanted levonorgestrel (Norplant). Hum Reprod. 1995 Oct;10(10):2584-9. PMID: 8567775. ***X-3, X-4, X-9***

985. Marslew U, Overgaard K, Riis BJ, et al. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol. 1992 Feb;79(2):202-10. PMID: 1309944. ***X-7***

986. Martin CW, Brown AH, Baird DT. A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary. Contraception. 1998 Aug;58(2):99-103. PMID: 9773264. ***X-5, X-9***

987. Martin V, Cady R, Mauskop A, et al. Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies. Headache. 2008 Feb;48(2):226-35. PMID: 18005144. ***X-4, X-5, X-9***

988. Martinez GH, Castaneda A, Correa JE. Vaginal bleeding patterns in users of Perlutal, a once-a-month injectable contraceptive consisting of 10 mg estradiol enanthate combined with 150 mg dihydroxyprogesterone acetophenide. A trial of 5462 woman-months. Contraception. 1998 Jul;58(1):21-7. PMID: 9743892. ***X-3, X-5, X-6***

989. Masahashi T, Wu MC, Ohsawa M, et al. Spironolactone therapy for hyperandrogenic anovulatory women--clinical and endocrinological study. Nihon Sanka Fujinka Gakkai Zasshi. 1986 Jan;38(1):95-101. PMID: 3950464. ***X-3, X-5***

990. Massai MR, Diaz S, Quinteros E, et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception. 2001 Dec;64(6):369-76. PMID: 11834236. ***X-4, X-5***

991. Massai MR, Pavez M, Fuentealba B, et al. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception. 2004 Jul;70(1):47-54. PMID: 15208052. ***X-5, X-6***

992. Matsumoto Y, Yamabe S, Sugishima T, et al. Perception of oral contraceptives among women of reproductive age in Japan: a comparison with the USA and France. J Obstet Gynaecol Res. 2011 Jul;37(7):887-92. PMID: 21450030. ***X-3, X-5***

993. Mattsson LA. Safety and tolerability of pulsed estrogen therapy: Key factors for an improved compliance. Climacteric. 2002;5(SUPPL. 2):40-5. PMID: 12482110. ***X-1, X-5***

994. Mattsson LA, Bohnet HG, Gredmark T, et al. Continuous, combined hormone replacement: Randomized comparison of transdermal and oral preparations. Obstetrics and Gynecology. 1999;94(1):61-5. PMID: 10389719. ***X-7***

995. Mattsson LA, Skouby S, Mattila L, et al. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women. Menopause International. 2007;13(3):124-31. PMID: 17785038. ***X-7***

996. Mattsson LA, Skouby SO, Heikkinen J, et al. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen. Climacteric. 2004 Mar;7(1):59-69. PMID: 15259284. ***X-5, X-7***

997. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, et al. Endometrial morphology and pituitary-gonadal axis dysfunction in women of reproductive age undergoing chronic haemodialysis--a multicentre study. Nephrol Dial Transplant. 2004 Aug;19(8):2074-7. PMID: 15173376. ***X-4, X-5, X-9***

998. Mavrelos D, Ben-Nagi J, Davies A, et al. The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial. Hum Reprod. 2010 Sep;25(9):2264-9. PMID: 20663795. ***X-5, X-6, X-8***

999. Mayagoitia SB, Hernandez-Morales C, Macias AM, et al. Luteinizing hormone releasing hormone agonist for postpartum contraception. Adv Contracept. 1996 Mar;12(1):27-41. PMID: 8739514. ***X-5, X-9***

1000. Mazaro-Costa R, Andersen ML, Hachul H, et al. Medicinal plants as alternative treatments for female sexual dysfunction: Utopian vision or possible treatment in climacteric women? Journal of Sexual Medicine. 2010;7(11):3695-714. PMID: 20722793. ***X-1, X-3, X-5***

1001. McArthur JW, Turnbull BA, Pehrson J, et al. Nalmefene enhances LH secretion in a proportion of oligo-amenorrheic athletes. Acta Endocrinol (Copenh). 1993 Apr;128(4):325-33. PMID: 8498150. ***X-3, X-4, X-5***

1002. McBride D, Hardoon S, Walters K, et al. Explaining variation in referral from primary to secondary care: cohort study. BMJ. 2010;341:c6267. PMID: 21118873. ***X-4, X-5, X-7, X-9***

1003. McCowan KA, Edelstein S. Are female ultra-endurance triathletes getting a sufficient daily carbohydrate intake? Topics in Clinical Nutrition. 2006;21(2):139-44. ***X-3, X-5***

1004. McEwan J. Hormonal contraceptive methods. Practitioner. 1985 May;229(1403):415-23. PMID: 4011568. ***X-9***

1005. McGavigan CJ, Dockery P, Metaxa-Mariatou V, et al. Hormonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel. Hum Reprod. 2003 Jan;18(1):77-84. PMID: 12525444. ***X-4, X-5, X-6***

1006. McIvor J, Cameron EW. Pregnancy after uterine artery embolization to control haemorrhage from gestational trophoblastic tumour. Br J Radiol. 1996 Jul;69(823):624-9. PMID: 8696698. ***X-4, X-5, X-9***

1007. McKenzie J, Fisher BM, Jaap AJ, et al. Effects of HRT on liver enzyme levels in women with type 2 diabetes: A randomized placebo-controlled trial. Clinical Endocrinology. 2006;65(1):40-4. PMID: 16817817. ***X-4, X-5***

1008. McLean JA, Barr SI. Cognitive dietary restraint is associated with eating behaviors, lifestyle practices, personality characteristics and menstrual irregularity in college women. Appetite. 2003 Apr;40(2):185-92. PMID: 12781168. ***X-4, X-5, X-9***

1009. McLintock C, McCowan LM, North RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG. 2009 Nov;116(12):1585-92. PMID: 19681850. ***X-4, X-5, X-9***

1010. Meirik O, Rowe PJ, Peregoudov A, et al. The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. Contraception. 2009 Aug;80(2):133-41. PMID: 19631788. ***X-5***

1011. Menyhart K. Therapeutic usefulness of anteovin. Ther Hung. 1989;37(3):168-71. PMID: 2588200. ***X-3***

1012. Mercorio F, De Simone R, Di Carlo C, et al. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study. Hum Reprod. 2003 Nov;18(11):2319-22. PMID: 14585881. ***X-4, X-5, X-6***

1013. Mercorio F, De Simone R, Landi P, et al. Oral dexketoprofen for pain treatment during diagnostic hysteroscopy in postmenopausal women. Maturitas. 2002;43(4):277-81. PMID: 12468136. ***X-7***

1014. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study. Annals of the Rheumatic Diseases. 2011;70(11):1905-13. PMID: 21798883. ***X-5***

1015. Messina ML, Bozzini N, Halbe HW, et al. Uterine artery embolization for the treatment of uterine leiomyomata. Int J Gynaecol Obstet. 2002 Oct;79(1):11-6. PMID: 12399085. ***X-4, X-5, X-6, X-8***

1016. Meuwissen JHJM, Beijers-De Bie L, Vihtamaki T, et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecological Endocrinology. 2001;15(5):349-58. PMID: 11727357. ***X-7***

1017. Meyer BH, Muller RO, De la Rey N, et al. The effects of buserelin microparticles on ovarian function in healthy women. South African Medical Journal. 1995;85(8):766-7. PMID: 8553146. ***X-4, X-9***

1018. Meyer WR, Walsh BW, Grainger DA, et al. Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstet Gynecol. 1998 Jul;92(1):98-103. PMID: 9649102. ***X-5, X-8***

1019. Michielutte R, Diseker RA, Corbett WT, et al. Characteristics of women with cervical intraepithelial

dysplasia. Prog Clin Biol Res. 1983;130:203-15. PMID: 6622455. ***X-5***

1020. Micks E, Jensen JT. Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding. Womens Health (Lond Engl). 2011 Sep;7(5):513-24. PMID: 21879819. ***X-1, X-3, X-5***

1021. Miech RP. Pathopharmacology of excessive hemorrhage in mifepristone abortions. Ann Pharmacother. 2007 Dec;41(12):2002-7. PMID: 17956963. ***X-1, X-4, X-5, X-9***

1022. Mieszczak J, Lowe ES, Plourde P, et al. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab. 2008 Jul;93(7):2751-4. PMID: 18397987. ***X-4, X-5, X-9***

1023. Migoya E, Larson P, Bergman A, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects. Journal of Clinical Pharmacology. 2011;51(9):1319-25. PMID: 21209231. ***X-4, X-5, X-9***

1024. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003 Apr;101(4):653-61. PMID: 12681866. ***X-4, X-5, X-9***

1025. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: Randomized controlled trial. Obstetrics and Gynecology. 2001;98(5):771-8. PMID: 11704167. ***X-6, X-9***

1026. Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol. 2005 Sep;106(3):473-82. PMID: 16135576. ***X-9, X-10***

1027. Miller S, Fathalla MM, Ojengbede OA, et al. Obstetric hemorrhage and shock management: using the low technology Non-pneumatic Anti-Shock Garment in Nigerian and Egyptian tertiary care facilities. BMC Pregnancy Childbirth. 2010;10:64. PMID: 20955600. ***X-4, X-5, X-9***

1028. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991 Mar;164(3):879-83. PMID: 1900665. ***X-3***

1029. Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 mug ethinyl estradiol and 3 mg drospirenone. Human Reproduction. 2006;21(9):2304-11. PMID: 16763008. ***X-6, X-9***

1030. Mints M, Luksha L, Kublickiene K. Altered responsiveness of small uterine arteries in women with idiopathic menorrhagia. Am J Obstet Gynecol. 2008 Dec;199(6):646 e1-5. PMID: 18667186. ***X-4, X-5***

1031. Mishell DR, Jr., Shoupe D, Moyer DL, et al. Postmenopausal hormone replacement with a combination estrogen-progestin regimen for five days per week. J Reprod Med. 1991 May;36(5):351-5. PMID: 2061882. ***X-3, X-7***

1032. Mitchell ES, Woods NF, Bryant J. Understanding the menopausal transition: bleeding patterns during the menopausal transition... 34th Annual Communicating Nursing Research Conference/15th Annual WIN Assembly, "Health Care Challenges Beyond 2001: Mapping the Journey for Research and Practice," held April 19-21, 2001 in Seattle, Washington. Communicating Nursing Research. 2001;34:203-. ***X-1, X-3, X-5***

1033. Mizrak A, Ugur GM, Erdaloglu P, et al. Intra-uterine bupivacaine and levobupivacaine. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2010;50(1):65-9. PMID: 20219000. ***X-4, X-5, X-8***

1034. Mizunuma H, Okano H, Soda M, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas. 1997 May;27(1):69-76. PMID: 9158080. ***X-4, X-5, X-7, X-9***

1035. Mlcochova H, Horejsi J, Martinek J, et al. Treatment of autoimunne ovarian damage in adolescent girls. Neuro Endocrinol Lett. 2005 Apr;26(2):131-5. PMID: 15855884. ***X-4, X-5, X-9***

1036. Mohamed AMM, El-Sherbiny WSM, Mostafa WAI. Combined contraceptive ring versus combined oral contraceptive (30-mug ethinylestradiol and 3-mg drospirenone). International Journal of Gynecology and Obstetrics. 2011;114(2):145-8. PMID: 21669426. ***X-9***

1037. Mohan PC, Tan BS, Kwek BH, et al. Uterine artery embolisation for symptomatic fibroids in a tertiary hospital in Singapore. Ann Acad Med Singapore. 2005 Jan;34(1):78-83. PMID: 15726223. ***X-4, X-5, X-6, X-8, X-9***

1038. Molina RC, Sandoval JZ, Montero AV, et al. Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents. J Pediatr Adolesc Gynecol. 2009 Feb;22(1):25-31. PMID: 19232299. ***X-4, X-5, X-9***

1039. Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009 Dec;35(6):1069-76. PMID: 20025633. ***X-4, X-5, X-6, X-9***

1040. Monteiro I, Bahamondes L, Diaz J, et al. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study(1). Contraception. 2002 May;65(5):325-8. PMID: 12057782. ***X-4***

1041. Moodley J, Cohen M, Devraj K, et al. Vaginal absorption of low-dose tranexamic acid from impregnated tampons. S Afr Med J. 1992 Feb 1;81(3):150-2. PMID: 1734554. ***X-3, X-5, X-6, X-10***

1042. Moore C, Carol W, Graser T, et al. Influence of dienogest on ovulation in young fertile women. Clinical Drug Investigation. 1999;18(4):271-8. ***X-4, X-5, X-9***

1043. Moore KA, Callahan TS, Maison-Blanche P, et al. Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding. Expert Opin Pharmacother. 2010 Oct;11(14):2281-90. PMID: 20698724. ***X-4, X-5, X-9***

1044. Moore KA, Morin I, Marenco T, et al. Pharmacokinetic studies in women of 2 novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding. American Journal of Therapeutics. 2012 May;19(3):190-8. PMID: 2012282788. ***X-4***

1045. Moore N, Charlesworth A, Van Ganse E, et al. Risk factors for adverse events in analgesic drug users: Results from the PAIN study. Pharmacoepidemiology and Drug Safety. 2003;12(7):601-10. PMID: 14558184. ***X-5***

1046. Moraes-de-Souza H, Kerbauy J, Yamamoto M, et al. Depressed cell-mediated immunity in iron-deficiency anemia due to chronic loss of blood. Braz J Med Biol Res. 1984;17(2):143-50. PMID: 6518338. ***X-3, X-4, X-5***

1047. Moreau C, Trussell J, Gilbert F, et al. Oral contraceptive tolerance: does the type of pill matter? Obstet Gynecol. 2007 Jun;109(6):1277-85. PMID: 17540798. ***X-4, X-5, X-9***

1048. Moreno J, Rowan AJ. A comparative study of Norinyl 1/35 versus Brevicon in Panama City, Panama. Contraception. 1987 Dec;36(6):615-25. PMID: 3446438. ***X-9***

1049. Moro M, Maraschini C, Toja P, et al. Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study. Horm Res. 1991;35(3-4):137-41. PMID: 1806467. ***X-3, X-5***

1050. Morris EP, Rymer J, Robinson J, et al. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil Steril. 2008 Feb;89(2):421-8. PMID: 17572410. ***X-5, X-6, X-9***

1051. Morris JL, Meyer C, Fathalla MMF, et al. Treating uterine atony with the nonpneumatic anti-shock garment in Egypt. African Journal of Midwifery & Women's Health. 2011 2011 Jan-Mar;5(1):37-42. ***X-3, X-5, X-6, X-10***

1052. Mossa B, Imperato F, Marziani R, et al. Hormonal replacement therapy and evaluation of intrauterine pathology in postmenopausal women: a ten-year study. Eur J Gynaecol Oncol. 2003;24(6):507-12. PMID: 14658591. ***X-4, X-5, X-7***

1053. Mourali M, Fkih C, Essoussi-Chikhaoui J, et al. Gestational trophoblastic disease in Tunisia. Tunis Med. 2008 Jul;86(7):665-9. PMID: 19472728. ***X-4, X-5, X-9***

1054. Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynaecol Obstet. 2011 Dec;115(3):224-6. PMID: 21872857. ***X-5***

1055. Muasher SJ, Kruithoff C, Simonetti S, et al. Controlled preparation of the endometrium with exogenous steroids for the transfer of frozen-thawed pre-embryos in patients with anovulatory or irregular cycles. Hum Reprod. 1991 Mar;6(3):443-5. PMID: 1955555. ***X-3, X-5***

1056. Mukherjee GG, Gajaraj AJ, Mathias J, et al. Treatment of abnormal uterine bleeding with micronized flavonoids. Int J Gynaecol Obstet. 2005 May;89(2):156-7. PMID: 15847886. ***X-3***

1057. Mulders AG, Eijkemans MJ, Imani B, et al. Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reprod Biomed Online. 2003 Sep;7(2):170-8. PMID: 14567885. ***X-4, X-5, X-9***

1058. Mulligan K, Zackin R, Clark RA, et al. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: A randomized, double-blind, placebo-controlled, multicenter trial. Archives of Internal Medicine. 2005;165(5):578-85. PMID: 15767536. ***X-5***

1059. Muneyyirci-Delale O, Richard-Davis G, Morris T, et al. Goserelin Acetate 10.8 mg Plus Iron Versus Iron Monotherapy Prior to Surgery in Premenopausal Women with Iron-Deficiency Anemia Due to Uterine Leiomyomas: Results from a Phase III, Randomized, Multicenter, Double-Blind, Controlled Trial. Clinical Therapeutics. 2007;29(8):1682-91. PMID: 17919549. ***X-6, X-8***

1060. Muneyyirci-Delale O, Weisberg GW. Do heavier women benefit from a higher dose of leuprolide acetate for suppression of serum estradiol? Int J Fertil Womens Med. 2000 Nov-Dec;45(6):368-71. PMID: 11140546. ***X-4, X-5, X-6***

1061. Munro MG, Mainor N, Basu R, et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006 Oct;108(4):924-9. PMID: 17012455. ***X-5, X-9***

1062. Murphy PA, Kern SE, Stanczyk FZ, et al. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005 Jun;71(6):402-8. PMID: 15914127. ***X-4, X-5, X-9***

1063. Murray SC, Muse KN. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy. Fertil Steril. 1997 Feb;67(2):390-3. PMID: 9022620. ***X-3, X-5***

1064. Muse K, Lukes AS, Gersten J, et al. Long-term evaluation of safety and health-related quality of life in women with heavy menstrual bleeding treated with oral tranexamic acid. Womens Health (Lond Engl). 2011 Nov;7(6):699-707. PMID: 21867401. ***X-3***

1065. Muzii L, Boni T, Bellati F, et al. GnRH analogue treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study. Fertil Steril. 2010 Sep;94(4):1496-9. PMID: 19541299. ***X-5, X-6, X-8, X-9***

1066. Muzii L, Maneschi F, Marana R, et al. Oral Estroprogestins after Laparoscopic Surgery to Excise Endometriomas: Continuous or Cyclic Administration? Results of a Multicenter Randomized Study. Journal of Minimally Invasive Gynecology. 2011;18(2):173-8. PMID: 21262590. ***X-5, X-6, X-8***

1067. Mwamburi DM, Gerrior J, Wilson IB, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: Similar results in 2 months. Clinical Infectious Diseases. 2004;38(6):895-902. PMID: 14999637. ***X-5***

1068. Myburgh KH, Watkin VA, Noakes TD. Are risk factors for menstrual dysfunction cumulative? Physician & Sportsmedicine. 1992;20(4):114. ***X-3, X-4, X-5, X-10***

1069. Nabavi SM, Koupai SA, Nejati MR, et al. Menstrual irregularities and related plasma hormone levels in multiple sclerosis patients treated with beta interferone. Acta Med Iran. 2010 Jan-Feb;48(1):36-41. PMID: 21137667. ***X-4, X-5, X-6, X-9***

1070. Nagele F, Lockwood G, Magos AL. Randomised placebo controlled trial of mefenamic acid for premedication at outpatient hysteroscopy: a pilot study. Br J Obstet Gynaecol. 1997 Jul;104(7):842-4. PMID: 9236652. ***X-4, X-5, X-8, X-9***

1071. Nagele F, O'Connor H, Baskett TF, et al. Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding. Fertil Steril. 1996 Jun;65(6):1145-50. PMID: 8641488. ***X-4, X-5, X-7, X-8, X-9***

1072. Nahidi F, Jalalinia S. Comparing the complications of 2 copper intrauterine devices: T380A and Cu-Safe 300. East Mediterr Health J. 2008 Jan-Feb;14(1):95-102. PMID: 18557456. ***X-4, X-5, X-9***

1073. Nakagawa K, Takahashi Y, Ito M, et al. Intraovarian arterial blood flow resistance in oligomenorrheal infertile women. J Assist Reprod Genet. 2006 Mar;23(3):105-10. PMID: 16758342. ***X-4, X-5, X-9***

1074. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception. 2007 Jan;75(1):16-22. PMID: 17161118. ***X-4, X-5***

1075. Nakajima ST, Brumsted JR, Riddick DH, et al. Absence of progestational activity of oral spironolactone. Fertil Steril. 1989 Jul;52(1):155-8. PMID: 2744183. ***X-3, X-4, X-5, X-6***

1076. Nand SL, Webster MA, Baber R, et al. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol. 1998 May;91(5 Pt 1):678-84. PMID: 9572210. ***X-5, X-7***

1077. Nand SL, Webster MA, Wren BG. Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy--a study of bleeding pattern, endometrial response, serum lipid and bone density changes. Aust N Z J Obstet Gynaecol. 1995 Feb;35(1):92-6. PMID: 7772012. ***X-7***

1078. Nappi C, Farace MJ, Leone F, et al. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism. Eur J Obstet Gynecol Reprod Biol. 1987 Jul;25(3):209-19. PMID: 2956138. ***X-3, X-5***

1079. Nappi RE, Sances G, Sommacal A, et al. Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause. 2006;13(5):818-25. PMID: 16894336. ***X-5, X-7***

1080. Narbone MC, Ruello C, Oliva A, et al. Hormonal disregulation and catamenial epilepsy. Funct Neurol. 1990 Jan-Mar;5(1):49-53. PMID: 2119330. ***X-3, X-4, X-5***

1081. Nassaralla CL, Stanford JB, Daly KD, et al. Characteristics of the menstrual cycle after discontinuation of oral contraceptives. J Womens Health (Larchmt). 2011 Feb;20(2):169-77. PMID: 21219248. ***X-4, X-5, X-9***

1082. Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N. Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. Contraception. 2006 Jun;73(6):584-7. PMID: 16730488. ***X-5, X-6***

1083. Navarro PA, Kaddouz D, de Ziegler D, et al. Vaginal administration of allopregnanolone to postmenopausal women undergoing estrogen replacement therapy: preliminary results. Maturitas. 2003 Oct 20;46(2):147-52. PMID: 14559386. ***X-4, X-5, X-7***

1084. Nazar H, Usmanghani K. Clinical evaluation to assess the safety and efficacy of coded herbal medicine "Dysmo-off" versus allopathic medicine "Diclofenac Sodium" for the treatment of primary dysmenorrhea. Journal of Herbal Pharmacotherapy. 2006;6(1):21-39. PMID: 17135158. ***X-5, X-10***

1085. Need JA, Forbes KL, Milazzo L, et al. Danazol in the treatment of menorrhagia: the effect of a 1 month induction dose (200 mg) and 2 month's maintenance therapy (200 mg, 100 mg, 50 mg or placebo). Aust N Z J Obstet Gynaecol. 1992 Nov;32(4):346-52. PMID: 1290434. ***X-5***

1086. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. Journal of Acquired Immune Deficiency Syndromes. 2009;51(4):416-23. PMID: 19623693. ***X-4, X-5***

1087. Nelskyla K, Korttila K, Yli-Hankala A. Comparison of sevoflurane-nitrous oxide and propofol-alfentanil-nitrous oxide anaesthesia for minor gynaecological surgery. British Journal of Anaesthesia. 1999;83(4):576-9. PMID: 10673872. ***X-5, X-8***

1088. Nelson AL. Levonorgestrel intrauterine system: a first-line medical treatment for heavy menstrual bleeding. Womens Health (Lond Engl). 2010 May;6(3):347-56. PMID: 20426599. ***X-1, X-3, X-5, X-10***

1089. Nett R, Mannix LK, Mueller L, et al. Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. Headache. 2008 Sep;48(8):1194-201. PMID: 18422606. ***X-5, X-9***

1090. Neuwirth RS, Duran AA, Singer A, et al. The endometrial ablator: a new instrument. Obstet Gynecol. 1994 May;83(5 Pt 1):792-6. PMID: 8164945. ***X-3, X-8***

1091. Neven P, Lunde T, Benedetti-Panici P, et al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. BJOG. 2003 Feb;110(2):157-67. PMID: 12618160. ***X-5, X-7, X-9***

1092. Neveu N, Granger L, St-Michel P, et al. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril. 2007 Jan;87(1):113-20. PMID: 17081535. ***X-4, X-5, X-9***

1093. Newman CB, Hurley AM, Kleinberg DL. Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin Endocrinol (Oxf). 1989 Oct;31(4):391-400. PMID: 2576397. ***X-3, X-5***

1094. Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998 Jul;51(1):307-9. PMID: 9674831. ***X-4, X-5, X-9***

1095. Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: A randomized trial. Annals of Internal Medicine. 2006;145(12):869-79. PMID: 17179056. ***X-5***

1096. Nezhat C, Karpas AE, Greenblatt RB, et al. Estradiol implants for conception control. Am J Obstet Gynecol. 1980 Dec 15;138(8):1151-6. PMID: 7446623. ***X-3, X-9***

1097. Ngai SW, Chan YM, Tang OS, et al. Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage. Hum Reprod. 2001 Jul;16(7):1493-6. PMID: 11425836. ***X-5, X-9***

1098. Ngai SW, Fan S, Li S, et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Human Reproduction. 2005;20(1):307-11. PMID: 15567882. ***X-5***

1099. Ngai SW, Yeung KC, Lao T, et al. Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised study. Br J Obstet Gynaecol. 1996 Nov;103(11):1120-3. PMID: 8917000. ***X-5, X-9***

1100. Nguyen TN, Blum J, Durocher J, et al. A randomized controlled study comparing 600 versus 1,200 microg oral misoprostol for medical management of incomplete abortion. Contraception. 2005 Dec;72(6):438-42. PMID: 16307967. ***X-5, X-9***

1101. Nicholas SL, Rulin MC. Acute vaginal bleeding in women undergoing liver transplantation. Am J Obstet Gynecol. 1994 Mar;170(3):733-6. PMID: 8141191. ***X-3, X-5, X-6***

1102. Nielsen J, Emborg C, Gydesen S, et al. Augmenting clozapine with sertindole: A double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology. 2012 April;32(2):173-8. PMID: 2012136444. ***X-5***

1103. Nielsen TF, Ravn P, Bagger YZ, et al. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study. Osteoporosis International. 2004;15(2):168-74. PMID: 14647880. ***X-7***

1104. Nijland EA, Nathorst-Boos J, Palacios S, et al. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal

women with female sexual dysfunction. Climacteric. 2009 Apr;12(2):114-21. PMID: 19177255. ***X-5, X-7, X-9***

1105. Nilsen JF, Bassoe CF. Contraception in general practice analyzed by a computerized medical record. Scand J Prim Health Care. 1987 Nov;5(4):217-20. PMID: 3423491. ***X-3, X-5***

1106. Nilsson CG, Allonen H, Diaz J, et al. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study. Fertil Steril. 1983 Feb;39(2):187-92. PMID: 6401636. ***X-9***

1107. Nilsson CG, Holma P. Menstrual blood loss with contraceptive subdermal levonorgestrel implants. Fertil Steril. 1981 Mar;35(3):304-6. PMID: 6781939. ***X-3, X-5, X-9***

1108. Nilsson CG, Luukkainen T, Diaz J, et al. Intrauterine contraception with levonorgestrel: A comparative randomised clinical performance study. Lancet. 1981;1(8220):577-80. PMID: 6110819. ***X-9***

1109. Nixon RM, Duffy SW, Fender GR. Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint. BMC Med Res Methodol. 2003 Sep 24;3:17. PMID: 14507420. ***X-3, X-5, X-10***

1110. Nixon RM, Duffy SW, Fender GR, et al. Randomization at the level of primary care practice: use of pre-intervention data and random effects models. Stat Med. 2001 Jun 30;20(12):1727-38. PMID: 11406837. ***X-3, X-5, X-10***

1111. Nixon RM, Thompson SG. Baseline adjustments for binary data in repeated cross-sectional cluster randomized trials. Statistics in Medicine. 2003;22(17):2673-92. PMID: 12939779. ***X-1, X-3, X-5, X-10***

1112. Noerpramana NP. Blood-lipid fractions: the side-effects and continuation of Norplant use. Adv Contracept. 1997 Mar;13(1):13-37. PMID: 9181182. ***X-4, X-5, X-6, X-9***

1113. Norris RV. Progesterone for premenstrual tension. J Reprod Med. 1983 Aug;28(8):509-16. PMID: 6355465. ***X-1, X-3, X-5***

1114. Notelovitz M. Contraceptive efficacy and safety of a monophasic oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol: United States clinical experience using a "Sunday start" approach. Fertil Steril. 1995 Aug;64(2):261-6. PMID: 7615100. ***X-3, X-9***

1115. Nutley T, Dunson TR. Treatment of bleeding problems associated with progestin-only contraceptives: survey results. Adv Contracept. 1997 Dec;13(4):419-28. PMID: 9404551. ***X-4, X-5, X-6***

1116. Nyboe Andersen A, Balen A, Platteau P, et al. Predicting the FSH threshold dose in women with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrate. Hum Reprod. 2008 Jun;23(6):1424-30. PMID: 18372254. ***X-4, X-5, X-9***

1117. Nygren KG, Rybo G. Prostaglandins and menorrhagia. Acta Obstet Gynecol Scand Suppl. 1983;113:101-3. PMID: 6344539. ***X-1, X-3, X-5***

1118. Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod. 2005 Feb;20(2):557-62. PMID: 15539438. ***X-5***

1119. Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 mug ethinylestradiol and 150 mug levonorgestrel: A randomized trial. Human Reproduction. 2005;20(2):557-62. PMID: 15539438. ***X-6, X-9***

1120. Odmark IS, Bixo M, Englund D, et al. Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy. Menopause. 2005 Nov-Dec;12(6):699-707. PMID: 16278613. ***X-4, X-5, X-7***

1121. O'Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry. 2002 Apr;63(4):322-30. PMID: 12000206. ***X-4, X-5, X-6, X-9***

1122. Oguz S, Sargin A, Kelekci S, et al. The role of hormone replacement therapy in endometrial polyp formation. Maturitas. 2005;50(3):231-6. PMID: 15734604. ***X-5***

1123. Ojule JD, Oriji VK, Okongwu C. A five year review of the complications of progestogen only injectable contraceptive at the University of Port-Harcourt Teaching Hospital. Niger J Med. 2010 Jan-Mar;19(1):87-95. PMID: 20232762. ***X-4, X-5, X-6, X-9***

1124. Okon MA, Lee S, Laird SM, et al. A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of 'period-free' hormone replacement therapy. Human Reproduction. 1998;13(8):2261-5. PMID: 9756307. ***X-7***

1125. Okon MA, Lee S, Laird SM, et al. A prospective randomized controlled study comparing two doses of gestodene in cyclic combined HRT preparations on endometrial physiology. Hum Reprod. 2001 Jun;16(6):1244-50. PMID: 11387299. ***X-5, X-7***

1126. Oksa S, Luukkaala T, Maenpaa J. Toremifene for premenstrual mastalgia: a randomised, placebo-controlled

crossover study. BJOG. 2006 Jun;113(6):713-8. PMID: 16709215. ***X-5, X-9***

1127. Oksa S, Parkkola R, Luukkaala T, et al. Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia. Acta Radiol. 2009 Nov;50(9):984-9. PMID: 19863407. ***X-4, X-5, X-9***

1128. Oliveira-Ribeiro M, Petta CA, De Angelo Andrade LA, et al. Endometrial histology, microvascular density and caliber, and matrix metalloproteinase-3 in users of the Nestorone-releasing contraceptive implant with and without endometrial breakthrough bleeding. Contraception. 2006 Jun;73(6):634-40. PMID: 16730498. ***X-4, X-5, X-6, X-9***

1129. Olsson SE. Contraception with subdermal implants releasing levonorgestrel. A clinical and pharmacological study. Acta Obstet Gynecol Scand Suppl. 1987;142:1-45. PMID: 3116821. ***X-9***

1130. Omodei U, Ferrazzi E, Ramazzotto F, et al. Endometrial evaluation with transvaginal ultrasound during hormone therapy: a prospective multicenter study. Fertil Steril. 2004 Jun;81(6):1632-7. PMID: 15193487. ***X-4, X-5, X-7, X-9***

1131. Orrego JJ, Chandler WF, Barkan AL. Pergolide as primary therapy for macroprolactinomas. Pituitary. 2000 Dec;3(4):251-6. PMID: 11788013. ***X-4, X-5, X-6, X-9***

1132. Otero-Flores JB, Guerrero-Carreno FJ, Vazquez-Estrada LA. A comparative randomized study of three different IUDs in nulliparous Mexican women. Contraception. 2003 Apr;67(4):273-6. PMID: 12684147. ***X-4, X-5***

1133. Otolorin EO, Falase EA, Ladipo OA. A comparative study of three oral contraceptives in Ibadan: Norinyl 1/35, Lo-Ovral and Noriday 1/50. Afr J Med Med Sci. 1990 Mar;19(1):15-22. PMID: 2109515. ***X-9***

1134. Overton C, Hargreaves J, Maresh M. A national survey of the complications of endometrial destruction for menstrual disorders: the MISTLETOE study. Minimally Invasive Surgical Techniques--Laser, EndoThermal or Endorescetion. Br J Obstet Gynaecol. 1997 Dec;104(12):1351-9. PMID: 9422012. ***X-4, X-5, X-8***

1135. Ovesen P, Moller J, Moller N, et al. Growth hormone secretory capacity and serum insulin-like growth factor I levels in primary infertile, anovulatory women with regular menses. Fertil Steril. 1992 Jan;57(1):97-101. PMID: 1730338. ***X-3, X-4***

1136. Oyelola OO, Okonofua FE, Adediran TO. Menstrual bleeding pattern and iron status in women fitted with copper and non-medicated intrauterine contraceptive devices. East Afr Med J. 1994 Apr;71(4):268-70. PMID: 8062778. ***X-3, X-5, X-9***

1137. Ozdegirmenci O, Kayikcioglu F, Akgul MA, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril. 2011 Feb;95(2):497-502. PMID: 21074150. ***X-5, X-6, X-8***

1138. Paffenbarger RS, Jr., Kampert JB, Chang HG. Characteristics that predict risk of breast cancer before and after the menopause. Am J Epidemiol. 1980 Aug;112(2):258-68. PMID: 7416152. ***X-3, X-5***

1139. Pafumi C, Ciotta L, Farina M, et al. Uterine bleeding pattern during low dosage Noretisterone acetate and 17-b-Estradiol treatment in postmenopausal patients. Minerva Ginecol. 2002 Dec;54(6):513-8. PMID: 12432336. ***X-4, X-5, X-6, X-7***

1140. Pakarinen P, Luukkainen T. Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing device. Contraception. 2005 Nov;72(5):342-5. PMID: 16246659. ***X-4, X-5***

1141. Pakarinen P, Luukkainen T, Elomaa K, et al. A 12-month comparative clinical investigation of a levonorgestrel- releasing intracervical device situated in the uterine cavity or cervical canal. Contraception. 1996;54(3):187-92. PMID: 8899261. ***X-9***

1142. Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception. 2003 Jul;68(1):31-4. PMID: 12878284. ***X-5, X-6***

1143. Pakarinen PI, Suvisaari J, Luukkainen T, et al. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles. Fertil Steril. 1997 Jul;68(1):59-64. PMID: 9207585. ***X-5***

1144. Pal MN, Pal I. Menstrual behaviour with steroid implant. J Indian Med Assoc. 1981 Jul 1;77(1):16-7. PMID: 7328324. ***X-3, X-5, X-9, X-10***

1145. Palacios S, Pornel B, Vazquez F, et al. Long-term endometrial and breast safety of a specific, standardized soy extract. Climacteric. 2010 Aug;13(4):368-75. PMID: 20380569. ***X-4, X-5, X-7***

1146. Palomba S, Orio F, Jr., Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jul;90(7):4068-74. PMID: 15840746. ***X-5, X-10***

1147. Palomba S, Orio F, Jr., Falbo A, et al. Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary

syndrome. Clin Endocrinol (Oxf). 2005 Dec;63(6):631-5. PMID: 16343096. ***X-4, X-5, X-9***

1148. Palomba S, Orio Jr F, Nardo LG, et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: A prospective parallel randomized double-blind placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism. 2004;89(10):4801-9. PMID: 15472166. ***X-5, X-8***

1149. Palomba S, Orio Jr F, Russo T, et al. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Human Reproduction. 2004;19(6):1308-14. PMID: 15117890. ***X-3, X-6***

1150. Palomba S, Orio Jr F, Russo T, et al. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporosis International. 2005;16(8):943-52. PMID: 15739035. ***X-7***

1151. Palomba S, Russo T, Orio F, Jr., et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod. 2002 Dec;17(12):3213-9. PMID: 12456626. ***X-5, X-6***

1152. Palomba S, Sena T, Morelli M, et al. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2002 May 10;102(2):199-201. PMID: 11950491. ***X-4, X-5, X-7***

1153. Palomba S, Sena T, Noia R, et al. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstet Gynecol. 2001 Dec;98(6):1053-8. PMID: 11755553. ***X-5, X-6, X-7***

1154. Palombo-Kinne E, Schellschmidt I, Schumacher U, et al. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception. 2009;79(4):282-9. PMID: 19272497. ***X-5***

1155. Pan JF, Yu YL, Wang LJ, et al. The morphologic changes of endometrial spiral arterioles in IUD-induced menorrhagia. Adv Contracept. 1994 Sep;10(3):213-22. PMID: 7863847. ***X-3, X-4***

1156. Panay N, Pritsch M, Alt J. Cyclical dydrogesterone in secondary amenorrhea: results of a double-blind, placebo-controlled, randomized study. Gynecol Endocrinol. 2007 Nov;23(11):611-8. PMID: 17891596. ***X-5, X-9***

1157. Panjari M, Bell RJ, Jane F, et al. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas. 2009 Jul 20;63(3):240-5. PMID: 19410392. ***X-5, X-7***

1158. Parazzini F, Bortolotti A, Chiantera V, et al. Goserelin acetate to avoid hysterectomy in pre-menopausal women with fibroids requiring surgery. Eur J Obstet Gynecol Reprod Biol. 1999 Nov;87(1):31-3. PMID: 10579613. ***X-5, X-6, X-8***

1159. Parazzini F, La Vecchia C, Negri E, et al. Lifelong menstrual pattern and risk of breast cancer. Oncology. 1993 Jul-Aug;50(4):222-5. PMID: 8497374. ***X-3, X-4, X-5***

1160. Park H, Yoon BS, Seong SJ, et al. Can misoprostol reduce blood loss in laparoscopy-assisted vaginal hysterectomy? Aust N Z J Obstet Gynaecol. 2011 Jun;51(3):248-51. PMID: 21631445. ***X-4, X-5, X-6, X-8***

1161. Parker RA, McDaniel EB. The use of quinesterol for the control of vaginal bleeding irregularities caused by DMPA. Contraception. 1980 Jul;22(1):1-7. PMID: 7418403. ***X-6***

1162. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertility and Sterility. 2007;87(4):725-36. PMID: 17430732. ***X-1, X-3, X-5***

1163. Parmigiani L, Furtado RNV, Lopes RV, et al. Joint lavage associated with triamcinolone hexacetonide injection in knee osteoarthritis: A randomized double-blind controlled study. Clinical Rheumatology. 2010;29(11):1311-5. PMID: 20623311. ***X-5***

1164. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000 Feb;61(2):105-11. PMID: 10802275. ***X-4, X-5***

1165. Paschopoulos M, Lavasidis LG, Vrekoussis T, et al. Greek experience in the use of Thermachoice for treating heavy menstrual bleeding: prospective study. Ann N Y Acad Sci. 2006 Dec;1092:460-5. PMID: 17308173. ***X-3, X-5, X-8***

1166. Pasquale SA, Brandeis V, Cruz RI, et al. Norplant contraceptive implants: rods versus capsules. Contraception. 1987 Sep;36(3):305-16. PMID: 3119287. ***X-3, X-9***

1167. Pasquale SA, Foldesy RG, Levine JP, et al. Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women. Fertil Steril. 1997 Nov;68(5):810-5. PMID: 9389807. ***X-4, X-5, X-7, X-9***

1168. Pasquale SA, Knuppel RA, Owens AG, et al. Irregular bleeding, body mass index and coital frequency in Norplant contraceptive users. Contraception. 1994 Aug;50(2):109-16. PMID: 7956210. ***X-3, X-6, X-9***

1169. Pauleta JR, Clode N, Graca LM. Expectant management of incomplete abortion in the first trimester. Int J Gynaecol Obstet. 2009 Jul;106(1):35-8. PMID: 19329115. ***X-4, X-5, X-9***

1170. Pazos F, Escobar-Morreale HF, Balsa J, et al. Prospective randomized study comparing the long-acting gonadotropin- releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertility and Sterility. 1999;71(1):122-8. PMID: 9935128. ***X-5***

1171. Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72(6):414-21. PMID: 16307962. ***X-5***

1172. Peillon F, Vincens M, Cesselin F, et al. Exaggerated prolactin response of thyrotropin-releasing hormone in women with anovulatory cycles: possible role of endogenous estrogens and effect of bromocriptine. Fertil Steril. 1982 Apr;37(4):530-5. PMID: 6802681. ***X-3, X-4, X-5***

1173. Pelissier C, Maroni M, Yaneva H, et al. Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas. 2001 Oct 31;40(1):85-94. PMID: 11684377. ***X-5, X-7***

1174. Peres MF, Zukerman E, da Cunha Tanuri F, et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004 Aug 24;63(4):757. PMID: 15326268. ***X-5, X-9***

1175. Perino A, Castelli A, Cucinella G, et al. A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertil Steril. 2004 Sep;82(3):731-4. PMID: 15374722. ***X-5, X-8***

1176. Perino A, Chianchiano N, Petronio M, et al. Role of leuprolide acetate depot in hysteroscopic surgery: a controlled study. Fertil Steril. 1993 Mar;59(3):507-10. PMID: 8458448. ***X-3, X-8***

1177. Perlitz Y, Rahav D, Ben-Ami M. Endometrial ablation using hysteroscopic instillation of hot saline solution into the uterus. Eur J Obstet Gynecol Reprod Biol. 2001 Nov;99(1):90-2. PMID: 11604192. ***X-4, X-5, X-8***

1178. Petta CA, Amatya R, Farr G. Clinical evaluation of the TCu 380A IUD at six Latin American centers. Contraception. 1994 Jul;50(1):17-25. PMID: 7924319. ***X-3, X-9***

1179. Pezeshki K, Feldman J, Stein DE, et al. Bleeding and spontaneous abortion after therapy for infertility. Fertil Steril. 2000 Sep;74(3):504-8. PMID: 10973646. ***X-4, X-5, X-6, X-9***

1180. Pfeifer S, Patrizio P. The female athlete: Some gynecologic considerations. Sports Medicine and Arthroscopy Review. 2002;10(1):2-9. ***X-1, X-3, X-5***

1181. Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol. 2003 Dec;56(6):683-90. PMID: 14616430. ***X-4, X-5, X-6***

1182. Phaliwong P, Taneepanichskul S. The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use. J Med Assoc Thai. 2004 Oct;87 Suppl 3:S64-8. PMID: 21213495. ***X-5, X-6***

1183. Phemister DA, Laurent S, Harrison FN, Jr. Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance. Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):175-9. PMID: 7847530. ***X-5, X-9***

1184. Phittayawechwiwat W, Thanantaseth C, Ayudhya NI, et al. Oral etoricoxib for pain relief during fractional curettage: a randomized controlled trial. J Med Assoc Thai. 2007 Jun;90(6):1053-7. PMID: 17624196. ***X-5, X-9***

1185. Phittayawechwiwat W, Thanantaseth C, Ayudhya NIN, et al. Oral etoricoxib for pain relief during fractional curettage: A ramdomized controlled trial. Journal of the Medical Association of Thailand. 2007;90(6):1053-7. PMID: 17624196. ***X-5, X-8***

1186. Phupong V, Sophonsritsuk A, Taneepanichskul S. The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use. Contraception. 2006 Mar;73(3):253-6. PMID: 16472565. ***X-5, X-6, X-9***

1187. Piaggio G, Pinol AP. Use of the equivalence approach in reproductive health clinical trials. Statistics in medicine. 2001;20(23):3571-7. PMID: 11746338. ***X-1, X-3, X-5***

1188. Pickar JH, Bottiglioni F, Archer DF. Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Menopause Study Group. Climacteric. 1998 Jun;1(2):130-6. PMID: 11913408. ***X-4, X-5, X-7***

1189. Pillai M, O'Brien K, Hill E. The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning disabilities. BJOG. 2010 Jan;117(2):216-21. PMID: 19874296. ***X-4***

1190. Pinto AB, Binder EF, Kohrt WM, et al. Effects of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy: a pilot study. Am J Obstet Gynecol. 2003 Jul;189(1):11-5. PMID: 12861131. ***X-4, X-5, X-7***

1191. Pirke KM, Fichter MM, Chlond C, et al. Disturbances of the menstrual cycle in bulimia nervosa.

Clin Endocrinol (Oxf). 1987 Aug;27(2):245-51. PMID: 3665132. ***X-3, X-4, X-5***

1192. Pirke KM, Schweiger U, Broocks A, et al. Luteinizing hormone and follicle stimulating hormone secretion patterns in female athletes with and without menstrual disturbances. Clin Endocrinol (Oxf). 1990 Sep;33(3):345-53. PMID: 2123757. ***X-3, X-4***

1193. Pirke KM, Schweiger U, Strowitzki T, et al. Dieting causes menstrual irregularities in normal weight young women through impairment of episodic luteinizing hormone secretion. Fertil Steril. 1989 Feb;51(2):263-8. PMID: 2912772. ***X-3, X-4, X-5***

1194. Pisco JM, Bilhim T, Duarte M, et al. Management of uterine artery embolization for fibroids as an outpatient procedure. J Vasc Interv Radiol. 2009 Jun;20(6):730-5. PMID: 19339205. ***X-4, X-5, X-6, X-8, X-9***

1195. Piya-Anant M, Koetsawang S, Patrasupapong N, et al. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea. Contraception. 1998 Jan;57(1):23-8. PMID: 9554247. ***X-4, X-5, X-6, X-9***

1196. Place VA, Powers M, Darley PE, et al. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol. 1985 Aug 15;152(8):1092-9. PMID: 2992278. ***X-7***

1197. Plewig G, Cunliffe WJ, Binder N, et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception. 2009;80(1):25-33. PMID: 19501212. ***X-5***

1198. Plotkin D, Miller S, Nakajima S, et al. Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, does not affect luteal function in premenopausal women. Journal of Clinical Endocrinology and Metabolism. 2002;87(7):3155-61. PMID: 12107216. ***X-4, X-5***

1199. Poindexter A, Reape KZ, Hait H. Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo. Contraception. 2008 Aug;78(2):113-9. PMID: 18672111. ***X-4, X-5***

1200. Poindexter AN, Burkman R, Fisher AC, et al. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO. Int J Fertil Womens Med. 2003 Jul-Aug;48(4):163-72. PMID: 13677549. ***X-4, X-5***

1201. Polednak AP, Janerich DT. Maternal factors in congenital limb-reduction defects. Teratology. 1985 Aug;32(1):41-50. PMID: 4035591. ***X-3, X-5***

1202. Pornel B, Spielmann D. A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period. Gynecol Endocrinol. 2005 Aug;21(2):74-81. PMID: 16294458. ***X-5, X-7***

1203. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Journal of the National Cancer Institute. 2007;99(4):283-90. PMID: 17312305. ***X-5***

1204. Prasad RN, Choolani M, Roy A, et al. Blood loss in termination of early pregnancy with mifepristone and gemeprost. Aust N Z J Obstet Gynaecol. 1995 Aug;35(3):329-31. PMID: 8546658. ***X-3, X-5***

1205. Preuss HG, Bagchi D, Bagchi M, et al. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes, Obesity and Metabolism. 2004;6(3):171-80. PMID: 15056124. ***X-5***

1206. Prezelj J, Kocijancic A, Andolsek L. Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism. Gynecol Endocrinol. 1989 Dec;3(4):281-8. PMID: 2516705. ***X-3, X-4, X-5, X-6***

1207. Price TM, Dupuis RE, Carr BR, et al. Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. Am J Obstet Gynecol. 1993 May;168(5):1400-6. PMID: 8498419. ***X-3, X-4***

1208. Prince MI, Mitchison HC, Ashley D, et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: Results of a multicentre, randomized, placebo-controlled, cross-over trial. Alimentary Pharmacology and Therapeutics. 2003;17(1):137-43. PMID: 12492743. ***X-5***

1209. Prior J, Burdge D, Maan E, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int. 2007 Oct;18(10):1345-53. PMID: 17665239. ***X-4, X-5, X-9***

1210. Prior JC, Vigna YM, Barr SI, et al. Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med. 1994 Jun;96(6):521-30. PMID: 8017450. ***X-5, X-10***

1211. Prior MV, Phipps JH, Roberts T, et al. Treatment of menorrhagia by radiofrequency heating. Int J Hyperthermia. 1991 Mar-Apr;7(2):213-20. PMID: 1880453. ***X-3, X-8***

1212. Pritts EA, Ryan IP, Mueller MD, et al. Angiogenic effects of norplant contraception on endometrial histology

and uterine bleeding. J Clin Endocrinol Metab. 2005 Apr;90(4):2142-7. PMID: 15623808. ***X-4, X-5***

1213. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy. Acta Neurologica Scandinavica. 2003;107(3):165-75. PMID: 12614309. ***X-9***

1214. Privrel T, Daubenfeld O. Clinical experience in Switzerland with the new monophasic oral contraceptive Minulet (75 mcg gestodene, 30 mcg ethinyl oestradiol). Br J Clin Pract. 1988 Jul;42(7):292-8. PMID: 3075505. ***X-3, X-9, X-10***

1215. Procter-Gray E, Cobb KL, Crawford SL, et al. Effect of oral contraceptives on weight and body composition in young female runners. Med Sci Sports Exerc. 2008 Jul;40(7):1205-12. PMID: 18580398. ***X-5, X-9***

1216. Prollius A, de Vries C, Loggenberg E, et al. Uterine artery embolisation for symptomatic fibroids: the effect of the large uterus on outcome. BJOG. 2004 Mar;111(3):239-42. PMID: 14961885. ***X-4, X-5, X-6, X-8***

1217. Pron G, Bennett J, Common A, et al. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril. 2003 Jan;79(1):120-7. PMID: 12524074. ***X-4, X-5, X-6, X-8***

1218. Pron G, Cohen M, Soucie J, et al. The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril. 2003 Jan;79(1):112-9. PMID: 12524073. ***X-4, X-5, X-6, X-8***

1219. Protheroe J, Bower P, Chew-Graham C. The use of mixed methodology in evaluating complex interventions: identifying patient factors that moderate the effects of a decision aid. Fam Pract. 2007 Dec;24(6):594-600. PMID: 18039724. ***X-5***

1220. Pulkkinen MO. Uterine activity and blood flow in response to sulprostone during midtrimester pregnancy termination. Arch Gynecol. 1981;231(1):57-9. PMID: 7332359. ***X-5***

1221. Pulkkinen MO, Dusterberg B, Hasan H, et al. Norethisterone acetate and ethinylestradiol in early human pregnancy. Teratology. 1984 Apr;29(2):241-9. PMID: 6429876. ***X-5, X-6***

1222. Pulle C, Sturlese E. Clinical trial comparing the activity and efficacy of ibuprofen isobutanolammonium vs Benzydamine hydrochloride, applied as vaginal irrigations, in patients with vaginitis. Clin Exp Obstet Gynecol. 2002;29(3):173-9. PMID: 12519036. ***X-4, X-5, X-6, X-9***

1223. Purohit R, Sharma J. Cervical clamping following ultrasound-guided uterocervical packing to control postpartum uterine hemorrhage. Int J Gynaecol Obstet. 2010 May;109(2):160-1. PMID: 20176354. ***X-5, X-8, X-9***

1224. Qi A, Yi T, Liu X, et al. Clinical observations on treatment of lupus nephritis with kidney-nourishing and toxin-removing method - A report of 60 cases. Journal of Traditional Chinese Medicine. 2006;26(4):269-74. ***X-5, X-6***

1225. Qian HL, Wang HF, Yang ML. The expression of angiopoietin-1 and -2 in the endometrium of women with abnormal bleeding induced by an intra-uterine device. J Int Med Res. 2010 Jan-Feb;38(1):100-10. PMID: 20233519. ***X-4, X-5, X-6***

1226. Quenby S, Farquharson RG. Human chorionic gonadotropin supplementation in recurring pregnancy loss: a controlled trial. Fertil Steril. 1994 Oct;62(4):708-10. PMID: 7646609. ***X-5***

1227. Quereux C, Pornel B, Bergeron C, et al. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile. Maturitas. 2006 Feb 20;53(3):299-305. PMID: 16043317. ***X-4, X-5, X-7***

1228. Querido L, Ketting E, Haspels AA. IUD insertion following induced abortion. Contraception. 1985 Jun;31(6):603-10. PMID: 3899506. ***X-3, X-5, X-9***

1229. Quigg M, Smithson SD, Fowler KM, et al. Laterality and location influence catamenial seizure expression in women with partial epilepsy. Neurology. 2009 Jul 21;73(3):223-7. PMID: 19620611. ***X-4, X-5, X-9***

1230. Qureshi NS, Edi-Osagie EC, Ogbo V, et al. First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trial. BJOG. 2005 Nov;112(11):1536-41. PMID: 16225575. ***X-5, X-9***

1231. Rabe T, Mueck AO, Deuringer FU, et al. Spacing-out of progestin--efficacy, tolerability and compliance of two regimens for hormonal replacement in the late postmenopause. Gynecol Endocrinol. 1997 Dec;11(6):383-92. PMID: 9476087. ***X-5, X-7, X-9***

1232. Rabe T, Runnebaum B, Kohlmeier M, et al. Clinical and metabolic effects of gestodene and levonorgestrel. International journal of fertility. 1987;32:29-44. PMID: 2906345. ***X-9***

1233. Rachmiel M, Kives S, Atenafu E, et al. Primary amenorrhea as a manifestation of polycystic ovarian syndrome in adolescents: a unique subgroup? Arch Pediatr Adolesc Med. 2008 Jun;162(6):521-5. PMID: 18524741. ***X-4, X-5, X-9***

1234. Radowicki S, Kunicki M. Prostate specific antigen in women with menstrual disturbances and fibrocystic mastopathy. J Endocrinol Invest. 2009 Nov;32(10):821-4. PMID: 19602918. ***X-4, X-5, X-9***

1235. Radulovic N, Norstrom A, Ekerhovd E. Outpatient cervical ripening before first-trimester surgical abortion: a comparison between misoprostol and isosorbide mononitrate. Acta Obstet Gynecol Scand. 2007;86(3):344-8. PMID: 17364311. ***X-5, X-9***

1236. Radwanska E, Headley SK, Dmowski P. Evaluation of ovarian function after tubal sterilization. J Reprod Med. 1982 Jul;27(7):376-84. PMID: 6811740. ***X-3, X-4, X-5***

1237. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010 Apr;26(4):275-80. PMID: 20222840. ***X-5, X-9***

1238. Rafie S, Choy KA. Procedures to improve prescribing and dispensing of oral contraceptives at an academic medical center. Am J Health Syst Pharm. 2012 Feb 1;69(3):249-52. PMID: 22261948. ***X-3, X-5***

1239. Ragni MV, Jankowitz RC, Jaworski K, et al. Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost. 2011 Oct;106(4):641-5. PMID: 21833452. ***X-3***

1240. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia. 2002;43(7):697-702. PMID: 12102671. ***X-4, X-9***

1241. Rai VS, Gillmer MD, Gray W. Is endometrial pre-treatment of value in improving the outcome of transcervical resection of the endometrium? Hum Reprod. 2000 Sep;15(9):1989-92. PMID: 10967001. ***X-4, X-5, X-9***

1242. Raja A, Hashmi SN, Sultana N, et al. Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. J Ayub Med Coll Abbottabad. 2005 Apr-Jun;17(2):50-3. PMID: 16092652. ***X-4, X-5, X-9***

1243. Ramos R, Apelo R, Osteria T, et al. A comparative analysis of three different dose combinations of oral contraceptives. Contraception. 1989 Feb;39(2):165-77. PMID: 2495891. ***X-9***

1244. Rasgon NL, Altshuler LL, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry. 2000 Mar;61(3):173-8. PMID: 10817101. ***X-4, X-5, X-6, X-9***

1245. Rasgon NL, Reynolds MF, Elman S, et al. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord. 2005 Dec;89(1-3):217-25. PMID: 16171873. ***X-4, X-5, X-9***

1246. Rashidi B, Haghollahi F, Shariat M, et al. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol. 2009 Jun;48(2):142-7. PMID: 19574176. ***X-4, X-5, X-9***

1247. Rasuli P, Hammond I, Al-Mutairi B, et al. Spherical versus conventional polyvinyl alcohol particles for uterine artery embolization. J Vasc Interv Radiol. 2008 Jan;19(1):42-6. PMID: 18192466. ***X-5, X-8, X-9***

1248. Rath W, Meyer D, Hildebrandt J, et al. Comparative study of various intracervically administered PG gel preparations for termination of first trimester pregnancies. Contraception. 1983 Sep;28(3):209-22. PMID: 6357631. ***X-5***

1249. Rattanachaiyanont M, Angsuwathana S, Techatrisak K, et al. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study. J Obstet Gynaecol Res. 2005 Apr;31(2):98-106. PMID: 15771634. ***X-4***

1250. Rattanachaiyanont M, Leerasiri P, Indhavivadhana S. Effectiveness of intrauterine anesthesia for pain relief during fractional curettage. Obstet Gynecol. 2005 Sep;106(3):533-9. PMID: 16135583. ***X-5, X-9***

1251. Raudaskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG. 2002 Feb;109(2):136-44. PMID: 11888095. ***X-5, X-7***

1252. Raudaskoski TH, Lahti EI, Kauppila AJ, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):114-9. PMID: 7847516. ***X-7***

1253. Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol. 2004 Dec;104(6):1314-21. PMID: 15572496. ***X-8***

1254. Raynaud JP, Levrier M, Calaf J, et al. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):309-18. PMID: 15860275. ***X-5, X-7***

1255. Razavi MK, Hwang G, Jahed A, et al. Abdominal myomectomy versus uterine fibroid embolization in the treatment of symptomatic uterine leiomyomas. AJR Am J Roentgenol. 2003 Jun;180(6):1571-5. PMID: 12760922. ***X-4, X-5, X-6, X-8***

1256. Razzi S, Luisi S, Ferretti C, et al. Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2007 Dec;135(2):188-90. PMID: 16963174. ***X-5, X-9***

1257. Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric. 2000 Sep;3(3):176-82. PMID: 11910619. ***X-5, X-7***

1258. Recio R, Hernandez-Morales C, Perez-Rodriguez RM, et al. Effects of low steroid doses administered in the mid and late follicular phase on the LH surge, ovarian steroids and follicular maturation in eumenorrheic women. Adv Contracept. 1997 Mar;13(1):39-46. PMID: 9181183. ***X-3, X-4***

1259. Rees MC, Kuhl H, Engelstein M, et al. Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen. Climacteric. 2004 Mar;7(1):23-32. PMID: 15259280. ***X-5, X-7***

1260. Reid RL, Fortier MP, Smith L, et al. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010 Dec;82(6):497-502. PMID: 21074011. ***X-4, X-5, X-9***

1261. Reig E. Tramadol in musculoskeletal pin - A survey. Clinical Rheumatology. 2002;21(1 SUPPL):S9-S12. PMID: 11954901. ***X-1, X-3, X-5***

1262. Reinders DM, Baldwin SA, Bert JL. Endometrial thermal balloon ablation using a high temperature, pulsed system: a mathematical model. J Biomech Eng. 2003 Dec;125(6):841-51. PMID: 14986409. ***X-4, X-5, X-8, X-9***

1263. Reinprayoon D, Gilmore C, Farr G, et al. Twelve-month comparative multicenter study of the TCu 380A and ML 250 intrauterine devices in Bangkok, Thailand. Contraception. 1998 Oct;58(4):201-6. PMID: 9865999. ***X-3, X-9***

1264. Reisman H, Martin D, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 mug levonorgestrel with 20 mug ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. American Journal of Obstetrics and Gynecology. 1999;181(5 II):S45-S52. ***X-6, X-9***

1265. Rekers H. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet Gynecol Scand. 1988;67(2):171-4. PMID: 2972160. ***X-3, X-9***

1266. Reslova T, Tosner J, Resl M, et al. Endometrial polyps. A clinical study of 245 cases. Arch Gynecol Obstet. 1999;262(3-4):133-9. PMID: 10326632. ***X-4, X-5, X-6, X-7***

1267. Rice C, Killick S, Hickling D, et al. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod. 1996 Apr;11(4):737-40. PMID: 8671319. ***X-9***

1268. Rich AD, Manyonda IT, Patel R, et al. A comparison of the efficacy of danazol, norethisterone, cyproterone acetate and medroxyprogesterone acetate in endometrial thinning prior to ablation: A pilot study. Gynaecological Endoscopy. 1995;4(1):59-61. ***X-3, X-5, X-6***

1269. Richter HE, Learman LA, Lin F, et al. Medroxyprogesterone acetate treatment of abnormal uterine bleeding: factors predicting satisfaction. Am J Obstet Gynecol. 2003 Jul;189(1):37-42. PMID: 12861135. ***X-3***

1270. Richtig E, Soyer HP, Posch M, et al. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European cooperative adjuvant melanoma treatment study group. Journal of Clinical Oncology. 2007;23(34):8655-63. PMID: 16260701. ***X-5***

1271. Rickenlund A, Thoren M, Nybacka A, et al. Effects of oral contraceptives on diurnal profiles of insulin, insulin-like growth factor binding protein-1, growth hormone and cortisol in endurance athletes with menstrual disturbance. Hum Reprod. 2010 Jan;25(1):85-93. PMID: 19840988. ***X-4, X-5***

1272. Rigaud AS, Andre G, Vellas B, et al. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology. 2003;60(1):148-50. PMID: 12525745. ***X-3, X-5, X-7***

1273. Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception. 1999 Sep;60(3):155-60. PMID: 10640159. ***X-4, X-5, X-6, X-9***

1274. Rizk DE. Subdermal levonorgestrel implants. Three years' experience in Cairo, Egypt. J Reprod Med. 1995 Sep;40(9):638-44. PMID: 8576880. ***X-3, X-9***

1275. Roberts TE, Tsourapas A, Middleton LJ, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ: British Medical Journal (Overseas & Retired Doctors Edition). 2011;342(7805):1012-. ***X-1, X-3, X-5, X-8***

1276. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost. 1996 Nov;76(5):692-6. PMID: 8950775. ***X-4, X-5, X-6, X-9***

1277. Rogers PA. Endometrial vasculature in Norplant users. Hum Reprod. 1996 Oct;11 Suppl 2:45-50. PMID: 8982745. ***X-4, X-5, X-6***

1278. Rogers PA, Lederman F, Plunkett D, et al. Bcl-2, Fas and caspase 3 expression in endometrium from levonorgestrel implant users with and without breakthrough bleeding. Hum Reprod. 2000 Aug;15 Suppl 3:152-61. PMID: 11041231. ***X-4, X-5***

1279. Rogers PA, Martinez F, Girling JE, et al. Influence of different hormonal regimens on endometrial microvascular density and VEGF expression in women suffering from breakthrough bleeding. Hum Reprod. 2005 Dec;20(12):3341-7. PMID: 16085661. ***X-4, X-5, X-6, X-9***

1280. Rogers PA, Plunkett D, Affandi B. Perivascular smooth muscle alpha-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding. Hum Reprod. 2000 Aug;15 Suppl 3:78-84. PMID: 11041224. ***X-4, X-5***

1281. Rogerson L, Duffy S, Crocombe W, et al. Management of menorrhagia--SMART study (Satisfaction with Mirena and Ablation: a Randomised Trial). BJOG. 2000 Oct;107(10):1325-6. PMID: 11028596. ***X1, X-3, X-5, X-6, X-8***

1282. Rogerson L, Hawe J, Duffy S. Modern approaches to management of menorrhagia. Hospital medicine. 1998;61(2):90-2. PMID: 10748784. ***X-1, X-3, X-5, X-10***

1283. Rojanasakul A, Sirimongkolkasem R, Piromsawasdi S, et al. Effects of combined ethinylestradiol and desogestrel on hormone profiles and sex hormone binding globulin in women with polycystic ovarian disease. Contraception. 1987 Dec;36(6):633-40. PMID: 2965636. ***X-3***

1284. Rolnick SJ, Flores SK, Fowler SE, et al. Conducting randomized, controlled trials. Experience with the dysfunctional uterine bleeding intervention trial. J Reprod Med. 2001 Jan;46(1):1-5, discussion -6. PMID: 11209624. ***X-8***

1285. Romer T. Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea. Eur J Obstet Gynecol Reprod Biol. 2000 May;90(1):27-9. PMID: 10767506. ***X-5, X-8***

1286. Romer T, Muller J. A simple method of coagulating endometrium in patients with therapy-resistant, recurring hypermenorrhea. J Am Assoc Gynecol Laparosc. 1999 Aug;6(3):265-8. PMID: 10459024. ***X-4, X-5, X-8***

1287. Romer T, Schwesinger G. Hormonal inhibition of endometrium for transcervical endometrial ablation--a prospective study with a 2-year follow-up. Eur J Obstet Gynecol Reprod Biol. 1997 Aug;74(2):201-3. PMID: 9306119. ***X-4, X-5, X-8, X-9***

1288. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstetrics and Gynecology. 2005;105(6):1397-404. PMID: 15932835. ***X-7***

1289. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand. 1999 Sep;78(8):716-21. PMID: 10468065. ***X-4, X-5, X-6***

1290. Ronnerdag M, Odlind V. Late bleeding problems with the levonorgestrel-releasing intrauterine system: evaluation of the endometrial cavity. Contraception. 2007 Apr;75(4):268-70. PMID: 17362704. ***X-4, X-5, X-9***

1291. Rorarius MG, Suominen P, Baer GA, et al. Diclofenac and ketoprofen for pain treatment after elective caesarean section. Br J Anaesth. 1993 Mar;70(3):293-7. PMID: 8471372. ***X-5***

1292. Rosen DM, Peek MJ. Do women with placenta praevia without antepartum haemorrhage require hospitalization? Aust N Z J Obstet Gynaecol. 1994 May;34(2):130-4. PMID: 7980298. ***X-3, X-5***

1293. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception. 1999 Dec;60(6):321-9. PMID: 10715366. ***X-5***

1294. Rosenberg MJ, Waugh MS, Higgins JE. The effect of desogestrel, gestodene, and other factors on spotting and bleeding. Contraception. 1996 Feb;53(2):85-90. PMID: 8838484. ***X-9***

1295. Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol. 1996 Feb;174(2):628-32. PMID: 8623797. ***X-3, X-5, X-9***

1296. Rosencrantz MA, Coffler MS, Haggan A, et al. Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Apr;96(4):1106-13. PMID: 21270326. ***X-4, X-5, X-9***

1297. Rosetta L, Harrison GA, Read GF. Ovarian impairments of female recreational distance runners during a season of training. Ann Hum Biol. 1998 Jul-Aug;25(4):345-57. PMID: 9667360. ***X-4, X-5, X-9***

1298. Ross AH, Boyd ME, Colgan TJ, et al. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology. Obstet Gynecol. 1993 Nov;82(5):773-9. PMID: 8414325. ***X-5, X-6, X-7***

1299. Ross D, Cooper AJ, Pryse-Davies J, et al. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet

Gynecol. 1997 Oct;177(4):937-41. PMID: 9369848. ***X-5, X-7***

1300. Roux C, Pelissier C, Fechtenbaum J, et al. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int. 2002 Mar;13(3):241-8. PMID: 11991445. ***X-5, X-7***

1301. Roy S, Mishell DR, Jr., Robertson DN, et al. Long-term reversible contraception with levonorgestrel-releasing Silastic rods. Am J Obstet Gynecol. 1984 Apr 1;148(7):1006-13. PMID: 6424474. ***X-4, X-5, X-9***

1302. Roy S, Shaw ST, Jr. Role of prostaglandins in IUD-associated uterine bleeding--effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstet Gynecol. 1981 Jul;58(1):101-6. PMID: 7243136. ***X-5, X-6***

1303. Rozenberg S, Caubel P, Lim PC. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynaecol Obstet. 2001 Mar;72(3):235-43. PMID: 11226444. ***X-4, X-5, X-7***

1304. Rozenberg S, Ylikorkala O, Arrenbrecht S. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Int J Fertil Womens Med. 1997;42 Suppl 2:376-87. PMID: 9397385. ***X-4, X-5, X-7***

1305. Rubinacci A, Peruzzi E, Modena AB, et al. Effect of low-dose transdermal E₂/NETA on the reduction of postmenopausal bone loss in women. Menopause. 2003;10(3):241-9. PMID: 12792297. ***X-7***

1306. Rubinacci A, Peruzzi E, Modena AB, et al. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. Menopause. 2003 May/June;10(3):241-9. PMID: 2003237886. ***X-7***

1307. Rulin MC, Turner JH, Dunworth R, et al. Post-tubal sterilization syndrome--a misnomer. Am J Obstet Gynecol. 1985 Jan 1;151(1):13-9. PMID: 3966496. ***X-3, X-5, X-6***

1308. Ruminjo JK, Sekadde-Kigondu CB, Karanja JG, et al. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception. 2005 Aug;72(2):138-45. PMID: 16022854. ***X-5***

1309. Runic R, Schatz F, Krey L, et al. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception. J Clin Endocrinol Metab. 1997 Jun;82(6):1983-8. PMID: 9177417. ***X-4, X-5, X-6***

1310. Runic R, Schatz F, Wan L, et al. Effects of norplant on endometrial tissue factor expression and blood vessel structure. J Clin Endocrinol Metab. 2000 Oct;85(10):3853-9. PMID: 11061549. ***X-4, X-5, X-6, X-9***

1311. Rutanen E, Hurskainen R, Finne P, et al. Induction of endometrial plasminogen activator-inhibitor 1: a possible mechanism contributing to the effect of intrauterine levonorgestrel in the treatment of menorrhagia. Fertil Steril. 2000 May;73(5):1020-4. PMID: 10785231. ***X-4, X-5, X-8***

1312. Ruuskanen A, Hippelainen M, Sipola P, et al. Uterine artery embolisation versus hysterectomy for leiomyomas: primary and 2-year follow-up results of a randomised prospective clinical trial. Eur Radiol. 2010 Oct;20(10):2524-32. PMID: 20526776. ***X-5, X-8***

1313. Rybo G, Nilsson S, Sikstrom B, et al. Naproxen in menorrhagia. Lancet. 1981 Mar 14;1(8220 Pt 1):608-9. PMID: 6110836. ***X-1, X-3***

1314. Saarikoski S, Yliskoski M, Penttila I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas. 1990 Jun;12(2):89-97. PMID: 2255266. ***X-4, X-6***

1315. Saav I, Aronsson A, Marions L, et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: A randomized controlled trial. Human Reproduction. 2007;22(10):2647-52. PMID: 17652452. ***X-5***

1316. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006 Sep;74(3):220-3. PMID: 16904415. ***X-5, X-9***

1317. Sabatini R, Orsini G, Cagiano R, et al. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception. 2007;76(5):342-7. PMID: 17963857. ***X-3, X-5, X-9***

1318. Sadan O, Frohlich EP, Driscoll JA, et al. Is it safe to prescribe hormonal contraception and replacement therapy to patients with premalignant and malignant uterine cervices? Gynecol Oncol. 1989 Aug;34(2):159-63. PMID: 2753422. ***X-3, X-4, X-5***

1319. Sadan O, Ginath S, Sofer D, et al. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata -- a pilot study. Eur J Obstet Gynecol Reprod Biol. 2001 Jun;96(2):183-6. PMID: 11384804. ***X-5, X-6***

1320. Sahota J, Barnes PMF, Mansfield E, et al. Initial UK experience of the levonorgestrel-releasing contraceptive intravaginal ring. Advances in Contraception. 1999;15(4):313-24. PMID: 11145373. ***X-3, X-9***

1321. Sahota P, Prabhakar S, Kharbanda PS, et al. Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study. Epilepsia. 2008 Dec;49(12):2069-77. PMID: 18503558. ***X-4, X-5, X-9***

1322. Said S, Omar K, Koetsawang S. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: I. Contraceptive efficacy and side effects. Contraception. 1986;34(3):223-35. PMID: 2947777. ***X-9***

1323. Said S, Omar K, Koetsawang S, et al. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1987 Jun;35(6):591-610. PMID: 2959448. ***X-6, X-9***

1324. Said S, Sadek W, Kholeif A, et al. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. II. The comparison of bleeding patterns. Contraception. 1989;40(5):531-51. PMID: 2692962. ***X-5***

1325. Said S, Sadek W, Rocca M, et al. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. Hum Reprod. 1996 Oct;11 Suppl 2:1-13. PMID: 8982739. ***X-4, X-5, X-6***

1326. Sakamoto S, Yoshino H, Shirahata Y, et al. Pharmacotherapeutic effects of kuei-chih-fu-ling-wan (keishi-bukuryo-gan) on human uterine myomas. Am J Chin Med. 1992;20(3-4):313-7. PMID: 1471615. ***X-3, X-6***

1327. Saleh WA, Burkman RT, Zacur HA, et al. A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels. Am J Obstet Gynecol. 1993 Jun;168(6 Pt 1):1740-5; discussion 5-7. PMID: 8317516. ***X-4, X-6, X-9, X-10***

1328. Salem HT, Salah M, Aly MY, et al. Acceptability of injectable contraceptives in Assiut, Egypt. Contraception. 1988 Dec;38(6):697-710. PMID: 2975583. ***X-6, X-9, X-10***

1329. Salim R, Lee C, Davies A, et al. A comparative study of three-dimensional saline infusion sonohysterography and diagnostic hysteroscopy for the classification of submucous fibroids. Hum Reprod. 2005 Jan;20(1):253-7. PMID: 15498782. ***X-4, X-5, X-6***

1330. Samsioe G, Boschitsch E, Concin H, et al. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: A randomized open-label study. Climacteric. 2006;9(5):368-79. PMID: 17080587. ***X-7***

1331. Samsioe G, Dvorak V, Genazzani AR, et al. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Maturitas. 2007;57(2):171-81. PMID: 17317046. ***X-7***

1332. Samsioe G, Hruska J. Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results. Climacteric. 2010 Feb;13(1):34-44. PMID: 20001563. ***X-4, X-5, X-7***

1333. Sanada M, Higashi Y, Nakagawa K, et al. A comparison of low-dose and standard-dose oral estrogen on forearm endothelial function in early postmenopausal women. J Clin Endocrinol Metab. 2003 Mar;88(3):1303-9. PMID: 12629123. ***X-4, X-5, X-7***

1334. Sandstrom O, Brooks L, Schantz A, et al. Interruption of early pregnancy with mifepristone in combination with gemeprost. Acta Obstet Gynecol Scand. 1999 Oct;78(9):806-9. PMID: 10535346. ***X-5, X-8, X-9***

1335. Sang GW, Shao QX, Ge RS, et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given by intramuscular injection to Chinese women. II. The comparison of bleeding patterns. Contraception. 1995 Mar;51(3):185-92. PMID: 7621686. ***X-6, X-9***

1336. Sang GW, Shao QX, Ge RS, et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and sid effects. Contraception. 1995 Mar;51(3):167-83. PMID: 7621685. ***X-9***

1337. Sang GW, Weng LJ, Shao QX, et al. Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05--a multicentre randomized clinical trial in China. Contraception. 1994 Dec;50(6):501-10. PMID: 7705093. ***X-5***

1338. Santagostino E, Mancuso ME, Morfini M, et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica. 2006 May;91(5):634-9. PMID: 16670069. ***X-4, X-5, X-9***

1339. Sapire KE. A study of bleeding patterns with two injectable contraceptives given postpartum and the effect of two non-hormonal treatments. Adv Contracept. 1991 Dec;7(4):379-87. PMID: 1837974. ***X-3, X-5, X-10***

1340. Saracoglu OF, Aksel S, Yeoman RR, et al. Endometrial estradiol and progesterone receptors in patients with luteal phase defects and endometriosis. Fertil Steril. 1985 Jun;43(6):851-5. PMID: 3996629. ***X-3, X-4***

1341. Sathanandan M, Macnamee MC, Rainsbury P, et al. Replacement of frozen-thawed embryos in artificial and

natural cycles: a prospective semi-randomized study. Hum Reprod. 1991 May;6(5):685-7. PMID: 1939549. ***X-5***

1342. Saure A, Hirvonen E, Milsom I, et al. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms. Maturitas. 1996 May;24(1-2):111-8. PMID: 8794442. ***X-5, X-7, X-9***

1343. Saure A, Planellas J, Poulsen HK, et al. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women. Maturitas. 2000 Feb 15;34(2):133-42. PMID: 10714908. ***X-5, X-6, X-7***

1344. Savabi-Esfahany M, Fadaei S, Yousefy A. Use of combined oral contraceptives: retrospective study in Isfahan, Islamic Republic of Iran. East Mediterr Health J. 2006 May-Jul;12(3-4):417-22. PMID: 17037711. ***X-4, X-5, X-9***

1345. Sayed GH, Zakherah MS, El-Nashar SA, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011 Feb;112(2):126-30. PMID: 21092958. ***X-5, X-6***

1346. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute. 2007;99(16):1232-9. PMID: 17686822. ***X-1, X-3, X-5***

1347. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002 Oct;66(4):247-50. PMID: 12413620. ***X-5, X-9***

1348. Schaison G. Emergency contragestion. Contraception. 1987;36 Suppl:7-11. PMID: 2445524. ***X-6***

1349. Schaison G, George M, Lestrat N, et al. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women. J Clin Endocrinol Metab. 1985 Sep;61(3):484-9. PMID: 2991322. ***X-3, X-5, X-9***

1350. Schatz F, Kuczynski E, Kloosterboer HJ, et al. Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: Evidence of progestogenic effects. Steroids. 2005 Nov;70(12):840-5. PMID: 16011840. ***X-4, X-5, X-7***

1351. Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006 Feb;85(2):314-25. PMID: 16595206. ***X-5, X-9***

1352. Schmidt-Gollwitzer M, Hardt W, Schmidt-Gollwitzer K, et al. Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control? Contraception. 1981 Feb;23(2):187-95. PMID: 6786826. ***X-3, X-5***

1353. Schnabel P, Merki-Feld GS, Malvy A, et al. Bioequivalence and X-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: A 3-year, randomized, double-blind study. Clinical Drug Investigation. 2012;32(6):413-22. PMID: 2012278342. ***X-4, X-5, X-9***

1354. Schorn MN. The effect of guided imagery on the third stage of labor: a pilot study. J Altern Complement Med. 2009 Aug;15(8):863-70. PMID: 19678776. ***X-4, X-5, X-9***

1355. Schroeder B, Hertweck SP, Sanfilippo JS, et al. Correlation between glycemic control and menstruation in diabetic adolescents. J Reprod Med. 2000 Jan;45(1):1-5. PMID: 10664939. ***X-4, X-5, X-6, X-9***

1356. Schulman S, Kinnman N, Lindmarker P, et al. A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders. Haemophilia. 2002;8(2):129-35. PMID: 11952848. ***X-5, X-6***

1357. Schulz KD, Schmidt-Rhode P, Weymar P, et al. The influence of a polychemotherapeutic regimen on the female endocrine control mechanisms in mammary carcinoma patients. Recent Results Cancer Res. 1980;71:162-8. PMID: 7367730. ***X-5***

1358. Schwartz JI, Agrawal NGB, Hartford AH, et al. The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin. Journal of Clinical Pharmacology. 2007;47(5):620-7. PMID: 17442687. ***X-4, X-5***

1359. Schwartz JI, Liu F, Wang YH, et al. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women. American Journal of Therapeutics. 2009;16(6):487-95. PMID: 19940609. ***X-4***

1360. Schweiger U, Laessle R, Pfister H, et al. Diet-induced menstrual irregularities: effects of age and weight loss. Fertil Steril. 1987 Nov;48(5):746-51. PMID: 3117591. ***X-3, X-4, X-5***

1361. Scialli AR, Jestila KJ. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertil Steril. 1995 Aug;64(2):313-20. PMID: 7615109. ***X-5, X-6***

1362. Sculpher MJ, Dwyer N, Browning J, et al. A survey of women's preferences regarding alternative surgical treatments for menorrhagia. Health Expectations. 1998;1(2):96-105. PMID: 11281864. ***X-3, X-5, X-8***

1363. Segal SJ, Alvarez-Sanchez F, Brache V, et al. Norplant implants: the mechanism of contraceptive action. Fertil Steril. 1991 Aug;56(2):273-7. PMID: 1906407. ***X-3, X-4, X-5, X-9***

1364. Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000 Jun 6;132(11):871-9. PMID: 10836913. ***X-5, X-6, X-9***

1365. Sekhavat L, Tabatabaii A, Dalili M, et al. Efficacy of tranexamic acid in reducing blood loss after cesarean section. J Matern Fetal Neonatal Med. 2009 Jan;22(1):72-5. PMID: 19165682. ***X-5, X-9***

1366. Sena-Martins M, Roteli-Martins CM, Tadini V, et al. Uterine artery embolization for the treatment of symptomatic myomas in Brazilian women. Sao Paulo Med J. 2003 Sep 1;121(5):185-90. PMID: 14666289. ***X-4, X-5, X-6, X-8***

1367. Sendag F, Terek MC, Karadadas N. Sequential combined transdermal and oral postmenopausal hormone replacement therapies: effects on bleeding patterns and endometrial histology. Arch Gynecol Obstet. 2001 Nov;265(4):209-13. PMID: 11789748. ***X-5, X-7***

1368. Senthong AJ, Taneepanichskul S. The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use. J Med Assoc Thai. 2009 Apr;92(4):461-5. PMID: 19374294. ***X-6***

1369. Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med. 1991 Oct;36(10):697-9. PMID: 1835500. ***X-3, X-8***

1370. Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. Eur J Contracept Reprod Health Care. 1998 Dec;3(4):179-89. PMID: 10036600. ***X-6, X-9***

1371. Serra GB, Panetta V, Colosimo M, et al. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian Multicentre Trial. Clin Ther. 1992;14 Suppl A:57-73. PMID: 1606594. ***X-3, X-6***

1372. Serup J, Bostofte E, Larsen S, et al. Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation. Acta Obstet Gynecol Scand. 1981;60(2):203-6. PMID: 7018165. ***X-6, X-9***

1373. Shaaban MM, Segal S, Salem HT, et al. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels. Fertil Steril. 1993 May;59(5):998-1002. PMID: 8486202. ***X-3, X-4, X-5, X-9***

1374. Shaamash AH, Zakhari MM. Increased serum levels of nitric oxide metabolites among users of levonorgestrel-releasing implants [corrected] a possible role in progestin-induced bleeding. Hum Reprod. 2005 Jan;20(1):302-6. PMID: 15471931. ***X-4, X-5, X-9***

1375. Shabanova SS, Ananieva LP, Alekberova ZS, et al. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2008 May-Jun;26(3):436-41. PMID: 18578965. ***X-4, X-5, X-9***

1376. Shade AR. Gynecologic and obstetric problems of the female dancer. Clin Sports Med. 1983 Nov;2(3):515-23. PMID: 6686087. ***X-1, X-3, X-5***

1377. Shamonki MI, Ziegler WF, Badger GJ, et al. Prediction of endometrial ablation success according to perioperative findings. Am J Obstet Gynecol. 2000 May;182(5):1005-7. PMID: 10819809. ***X-4, X-5, X-8***

1378. Shangold MM, Tomai TP, Cook JD, et al. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril. 1991 Dec;56(6):1040-7. PMID: 1743319. ***X-4, X-5, X-6, X-10***

1379. Shannon C, Wiebe E, Jacot F, et al. Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG. 2006 Jun;113(6):621-8. PMID: 16709204. ***X-5, X-9***

1380. Shapley M, Jordan K, Croft PR. Why women consult with increased vaginal bleeding: a case-control study. Br J Gen Pract. 2002 Feb;52(475):108-13. PMID: 11885820. ***X-4, X-5, X-9***

1381. Shapley M, Jordan K, Croft PR. Increased vaginal bleeding: the reasons women give for consulting primary care. J Obstet Gynaecol. 2003 Jan;23(1):48-50. PMID: 12623484. ***X-4, X-5, X-9***

1382. Shapley M, Jordan K, Croft PR. An investigation in primary care of the relationship between consultation behaviour, increased vaginal bleeding and mental disorder. J Obstet Gynaecol. 2004 Sep;24(6):684-6. PMID: 16147612. ***X-4, X-5, X-9***

1383. Sharma D, Dahiya K, Dora A, et al. Effect of rosiglitazone in spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Journal of Gynecologic Surgery. 2006;22(4):151-6. ***X-5***

1384. Sharma JB, Aruna J, Kumar P, et al. Comparison of efficacy of oral drotaverine plus mefenamic acid with paracervical block and with intravenous sedation for pain

relief during hysteroscopy and endometrial biopsy. Indian J Med Sci. 2009 Jun;63(6):244-52. PMID: 19602758. ***X-5, X-8, X-9***

1385. Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. Br J Obstet Gynaecol. 1984 Sep;91(9):913-6. PMID: 6433966. ***X-3***

1386. Shaw RW, Symonds IM, Tamizian O, et al. Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia. Aust N Z J Obstet Gynaecol. 2007 Aug;47(4):335-40. PMID: 17627692. ***X-8***

1387. Shaw ST, Jr., Macaulay LK, Sun NC, et al. Changes of plasminogen activator in human uterine tissue induced by intrauterine contraceptive devices. Contraception. 1983 Feb;27(2):131-40. PMID: 6682747. ***X-9***

1388. Shawki O, Peters A, Abraham-Hebert S. Hysteroscopic endometrial destruction, optimum method for preoperative endometrial preparation: a prospective, randomized, multicenter evaluation. JSLS. 2002 Jan-Mar;6(1):23-7. PMID: 12002292. ***X-5, X-8***

1389. Shearman RP. Oral contraceptives. Aust Fam Physician. 1984 Sep;13(9):685-91. PMID: 6508652. ***X-1, X-3, X-5, X-10***

1390. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol. 1981 Sep;68(3):181-7. PMID: 6790595. ***X-3, X-5***

1391. Sheikh-El-Arab Elsedeek M, Elmaghraby HAH. Predictors and characteristics of letrozole induced ovulation in comparison with clomiphene induced ovulation in anovulatory PCOS women. Middle East Fertility Society Journal. 2011;16(2):125-30. ***X-5***

1392. Sheppard BL, Bonnar J. The response of endometrial blood vessels to intrauterine contraceptive devices: an electron microscopic study. Br J Obstet Gynaecol. 1980 Feb;87(2):143-54. PMID: 7362802. ***X-3, X-4***

1393. Sheth A, Jain U, Sharma S. A randomized, double-blind study of two combined and two progestogen-only oral contraceptives. Contraception. 1982;25(3):243-52. PMID: 6804162. ***X-9***

1394. Shobeiri SF, Sharei S, Heidari A, et al. Portulaca oleracea L. in the treatment of patients with abnormal uterine bleeding: a pilot clinical trial. Phytother Res. 2009 Oct;23(10):1411-4. PMID: 19274703. ***X-4***

1395. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig. 2003 Feb;10(2):99-104. PMID: 12593999. ***X-4, X-5, X-9***

1396. Shokry M, Shahin AY, Fathalla MM, et al. Oral misoprostol reduces vaginal bleeding following surgical evacuation for first trimester spontaneous abortion. Int J Gynaecol Obstet. 2009 Nov;107(2):117-20. PMID: 19616778. ***X-5, X-9***

1397. Shoupe D. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone. Obstet Gynecol. 1994 May;83(5 Pt 1):679-85. PMID: 8164925. ***X-9***

1398. Shoupe D, Mishell DR, Jr., Brenner PF, et al. Pregnancy termination with a high and medium dosage regimen of RU 486. Contraception. 1986 May;33(5):455-61. PMID: 3757511. ***X-5***

1399. Showstack J, Lin F, Learman LA, et al. Randomized trial of medical treatment versus hysterectomy for abnormal uterine bleeding: resource use in the Medicine or Surgery (Ms) trial. Am J Obstet Gynecol. 2006 Feb;194(2):332-8. PMID: 16458625. ***X-8***

1400. Shravage J, Mekhala D, Bellad MB, et al. Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding: A double-blind randomized controlled trial. Journal of SAFOG. 2011 January-April;3(1):21-4. PMID: 2011698238. ***X-5***

1401. Shy KK, McTiernan AM, Daling JR, et al. Oral contraceptive use and the occurrence of pituitary prolactinoma. JAMA. 1983 Apr 22-29;249(16):2204-7. PMID: 6834618. ***X-3, X-5***

1402. Sibai BM, Caritis SN, Thom E, et al. Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. Am J Obstet Gynecol. 1995 May;172(5):1553-7. PMID: 7755070. ***X-5***

1403. Siboni SM, Spreafico M, Calo L, et al. Gynaecological and obstetrical problems in women with different bleeding disorders. Haemophilia. 2009 Nov;15(6):1291-9. PMID: 19664014. ***X-4, X-5, X-9***

1404. Sica S, Salutari P, Di Mario A, et al. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol. 1996 Mar;51(3):248-9. PMID: 8619413. ***X-1, X-3, X-5, X-10***

1405. Sidhu MS, Kent DR. Effects of prostaglandin E2 analogue suppository on blood loss in suction abortion. Obstet Gynecol. 1984 Jul;64(1):128-30. PMID: 6738937. ***X-5***

1406. Siegberg R, Nilsson CG, Stenman UH, et al. Sex hormone profiles in oligomenorrheic adolescent girls and

the effect of oral contraceptives. Fertil Steril. 1984 Jun;41(6):888-93. PMID: 6233177. ***X-3, X-4***

1407. Siegberg R, Nilsson CG, Stenman UH, et al. The effect of oral contraceptives on hormone profiles of oligomenorrheic adolescent cycles. Contraception. 1987 Jan;35(1):29-40. PMID: 3568657. ***X-3, X-5***

1408. Siegberg R, Ylostalo P, Laatikainen T, et al. Endocrine and clinical effects of spironolactone in female hyperandrogenism. Arch Gynecol. 1987;240(2):67-73. PMID: 3566358. ***X-6***

1409. Siegler AM. Therapeutic hysteroscopy. Acta Eur Fertil. 1986 Nov-Dec;17(6):467-71. PMID: 3630558. ***X-1, X-3, X-5***

1410. Siegler AM, Kontopoulos VG. Lysis of intrauterine adhesions under hysteroscopic control. A report of 25 operations. J Reprod Med. 1981 Jul;26(7):372-4. PMID: 7277346. ***X-3, X-5, X-8***

1411. Sihvo S, Ollila E, Hemminki E. Perceptions and satisfaction among Norplant users in Finland. Acta Obstet Gynecol Scand. 1995 Jul;74(6):441-5. PMID: 7604687. ***X-3, X-9***

1412. Silberstein SD, Berner T, Tobin J, et al. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. Headache. 2009 Oct;49(9):1283-97. PMID: 19751371. ***X-4, X-5, X-9***

1413. Silberstein SD, Massiou H, Le Jeunne C, et al. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000 Aug;96(2):237-42. PMID: 10908770. ***X-4, X-5, X-9***

1414. Simbar M, Tehrani FR, Hashemi Z, et al. A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature. Journal of Family Planning and Reproductive Health Care. 2007;33(4):271-6. PMID: 17925114. ***X-4, X-5, X-9***

1415. Simon JA, Liu JH, Speroff L, et al. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol. 2003 Jan;188(1):92-9. PMID: 12548201. ***X-5, X-7***

1416. Simon JA, Symons JP. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: A direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. Menopause. 2001;8(5):321-7. PMID: 11528357. ***X-7***

1417. Simsek T, Karakus C, Trak B. Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. Maturitas. 2002 Jul 25;42(3):243-6. PMID: 12161049. ***X-4, X-5, X-7***

1418. Singer A, Almanza R, Gutierrez A, et al. Preliminary clinical experience with a thermal balloon endometrial ablation method to treat menorrhagia. Obstet Gynecol. 1994 May;83(5 Pt 1):732-4. PMID: 8164933. ***X-3, X-8***

1419. Singh M, Saxena BB, Raghubanshi RS, et al. Biodegradable norethindrone (NET:cholesterol) contraceptive implants: phase II-A: a clinical study in women. Contraception. 1997 Jan;55(1):23-33. PMID: 9013058. ***X-3, X-9***

1420. Singh M, Saxena BB, Singh R, et al. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres (NET-90): phase III clinical study. Adv Contracept. 1997 Mar;13(1):1-11. PMID: 9181181. ***X-4, X-5***

1421. Singh N, Ghosh B, Naha M, et al. Vaginal misoprostol for cervical priming prior to diagnostic hysteroscopy - Efficacy, safety and patient satisfaction: A randomized controlled trial. Archives of Gynecology and Obstetrics. 2009;279(1):37-40. PMID: 18449549. ***X-4, X-5***

1422. Siskin GP, Shlansky-Goldberg RD, Goodwin SC, et al. A prospective multicenter comparative study between myomectomy and uterine artery embolization with polyvinyl alcohol microspheres: long-term clinical outcomes in patients with symptomatic uterine fibroids. J Vasc Interv Radiol. 2006 Aug;17(8):1287-95. PMID: 16923975. ***X-4, X-5, X-6, X-8***

1423. Siskin GP, Stainken BF, Dowling K, et al. Outpatient uterine artery embolization for symptomatic uterine fibroids: experience in 49 patients. J Vasc Interv Radiol. 2000 Mar;11(3):305-11. PMID: 10735424. ***X-4, X-5, X-6***

1424. Sivin I, Alvarez F, Mishell DR, Jr., et al. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic. Contraception. 1998 Nov;58(5):275-82. PMID: 9883382. ***X-4, X-5, X-6***

1425. Sivin I, Campodonico I, Kiriwat O, et al. The performance of levonorgestrel rod and Norplant contraceptive implants: A 5 year randomized study. Human Reproduction. 1999;13(12):3371-8. PMID: 9886517. ***X-9***

1426. Sivin I, Croxatto H, Bahamondes L, et al. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women. Contraception. 2004 Feb;69(2):137-44. PMID: 14759619. ***X-4, X-5***

1427. Sivin I, Diaz S, Croxatto HB, et al. Contraceptives for lactating women: a comparative trial of a progesterone-

releasing vaginal ring and the copper T 380A IUD. Contraception. 1997 Apr;55(4):225-32. PMID: 9179454. ***X-4, X-5***

1428. Sivin I, Mishell DR, Jr., Victor A, et al. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. III-Menstrual patterns. An international comparative trial. Contraception. 1981 Oct;24(4):377-92. PMID: 6797783. ***X-6, X-9***

1429. Sivin I, Robertson DN, Stern J, et al. Norplant: reversible implant contraception. Stud Fam Plann. 1980 Jul-Aug;11(7-8):227-35. PMID: 6996230. ***X-1, X-3, X-9, X-10***

1430. Sivin I, Sanchez FA, Diaz S, et al. Three-year experience with NORPLANT subdermal contraception. Fertil Steril. 1983 Jun;39(6):799-808. PMID: 6406273. ***X-3, X-9***

1431. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 mug/d and the copper TCu 380Ag intrauterine contraceptive devices: A multicenter study. Fertility and Sterility. 1994;61(1):70-7. PMID: 8293847. ***X-9***

1432. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991 Nov;44(5):473-80. PMID: 1797462. ***X-9***

1433. Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Contraception. 1987 Mar;35(3):245-55. PMID: 3111785. ***X-9***

1434. Sivin I, Tatum HJ. Four years of experience with the TCu 380A intrauterine contraceptive device. Fertil Steril. 1981 Aug;36(2):159-63. PMID: 7262334. ***X-3, X-9***

1435. Sivin I, Viegas O, Campodonico I, et al. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant implants as controls. Contraception. 1997 Feb;55(2):73-80. PMID: 9071515. ***X-4, X-5***

1436. Skibola CF. The effect of Fucus vesiculosus, an edible brown seaweed, upon menstrual cycle length and hormonal status in three pre-menopausal women: a case report. BMC Complement Altern Med. 2004 Aug 4;4:10. PMID: 15294021. ***X-4***

1437. Small DS, Wrishko RE, Ernest ICS, et al. Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: An open-label, single-sequence, clinical trial. Drugs and Aging. 2009;26(9):781-90. PMID: 19728751. ***X-3, X-5***

1438. Smith SK, Abel MH, Kelly RW, et al. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1981 Apr;88(4):434-42. PMID: 7225303. ***X-3, X-4***

1439. Smits MG, van der Meer YG, Pfeil JP, et al. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache. 1994 Feb;34(2):103-6. PMID: 8163364. ***X-5***

1440. Snead DB, Weltman A, Weltman JY, et al. Reproductive hormones and bone mineral density in women runners. J Appl Physiol. 1992 Jun;72(6):2149-56. PMID: 1385803. ***X-3, X-4***

1441. Socolov D, Blidaru I, Tamba B, et al. Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma. Eur J Contracept Reprod Health Care. 2011 Dec;16(6):480-7. PMID: 21942657. ***X-3, X-6***

1442. Sojo-Aranda I, Alonso-Uriarte R, Gonzalez-Diddi M, et al. The biological expression of natural progesterone. J Steroid Biochem. 1988 Aug;31(2):219-22. PMID: 3404991. ***X-3, X-5***

1443. Sone M, Arai Y, Shimizu T, et al. Phase I/II multiinstitutional study of uterine artery embolization with gelatin sponge for symptomatic uterine leiomyomata: Japan Interventional Radiology in Oncology Study Group study. J Vasc Interv Radiol. 2010 Nov;21(11):1665-71. PMID: 20884240. ***X-4, X-5, X-8***

1444. Sotnikova LS, Abramova EV, Shevtsova NM, et al. Clinical study of the efficiency of Poetam in the treatment of the anemic syndrome in pubertal uterine hemorrhages. Bull Exp Biol Med. 2006 Jul;142(1):61-5. PMID: 17369904. ***X-3, X-4, X-5***

1445. Sotnikova LS, Shevtsova NM, Sherstoboev EY, et al. Complex application of preparation containing ultralow doses of antibodies for the treatment of anemia caused by pubertal uterine bleedings. Bull Exp Biol Med. 2009 Sep;148(3):505-7. PMID: 20396724. ***X-3***

1446. Sotnikova LS, Zhdanov VV, Udut VV, et al. Influence of poetam preparation on the state of autonomic nervous system in patients with severe anemia caused by dysfunctional uterine bleedings. Bull Exp Biol Med. 2009 Sep;148(3):508-10. PMID: 20396725. ***X-3, X-5, X-10***

1447. Soysal M, Soysal S, Ozer S. A randomized controlled trial of levonorgestrel releasing IUD and thermal balloon ablation in the treatment of menorrhagia. Zentralbl Gynakol. 2002 Apr;124(4):213-9. PMID: 12080483. ***X-5, X-8***

1448. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest. 2005;59(1):29-35. PMID: 15377823. ***X-4, X-5, X-6***

1449. Speroff L, Haney AF, Gilbert RD, et al. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause. 2006;13(3):442-50. PMID: 16735941. ***X-7***

1450. Spies JB, Benenati JF, Worthington-Kirsch RL, et al. Initial experience with use of tris-acryl gelatin microspheres for uterine artery embolization for leiomyomata. J Vasc Interv Radiol. 2001 Sep;12(9):1059-63. PMID: 11535768. ***X-4, X-5, X-6, X-8***

1451. Spies JB, Cooper JM, Worthington-Kirsch R, et al. Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multicenter study. Am J Obstet Gynecol. 2004 Jul;191(1):22-31. PMID: 15295340. ***X-4, X-5, X-6, X-8***

1452. Spies JB, Cornell C, Worthington-Kirsch R, et al. Long-term outcome from uterine fibroid embolization with tris-acryl gelatin microspheres: results of a multicenter study. J Vasc Interv Radiol. 2007 Feb;18(2):203-7. PMID: 17327552. ***X-4, X-5, X-8, X-9***

1453. Spitz IM, Bardin CW, Benton L, et al. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998 Apr 30;338(18):1241-7. PMID: 9562577. ***X-4, X-5, X-6, X-9***

1454. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54(2):71-7. PMID: 8842582. ***X-9***

1455. Sporrong T, Hellgren M, Samsioe G, et al. Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints. Br J Obstet Gynaecol. 1988 Oct;95(10):1042-8. PMID: 3056498. ***X-5, X-7***

1456. Sporrong T, Rybo G, Mattsson LA, et al. An objective and subjective assessment of uterine blood loss in postmenopausal women on hormone replacement therapy. Br J Obstet Gynaecol. 1992 May;99(5):399-401. PMID: 1535788. ***X-7***

1457. Sporrong T, Samsioe G, Larsen S, et al. A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy. Maturitas. 1989 Sep;11(3):209-15. PMID: 2593864. ***X-7***

1458. Stadberg E, Mattsson LA, Uvebrant M. 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas. 1996 Feb;23(1):31-9. PMID: 8861084. ***X-7***

1459. Stadtmauer L, Harrison DD, Boyd J, et al. Pilot study evaluating a progesterone vaginal ring for luteal-phase replacement in donor oocyte recipients. Fertility and Sterility. 2009;92(5):1600-5. PMID: 18990373. ***X-5***

1460. Stamets K, Taylor DS, Kunselman A, et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertility and Sterility. 2004 March;81(3):630-7. PMID: 2004135257. ***X-5, X-10***

1461. Stanback J, Grimes D. Can intrauterine device removals for bleeding or pain be predicted at a one-month follow-up visit?: A multivariate analysis. Contraception. 1998;58(6):357-60. PMID: 10095972. ***X-3, X-5, X-6***

1462. Stein RC, Rawson NSB, Gazet JC, et al. Gestrinone in mastalgia: A randomized double blind placebo controlled trial. Breast. 1994;3(2):90-3. ***X-5***

1463. Steiner AZ, Xiang M, Mack WJ, et al. Unopposed estradiol therapy in postmenopausal women: results from two randomized trials. Obstet Gynecol. 2007 Mar;109(3):581-7. PMID: 17329508. ***X-5, X-7***

1464. Stener-Victorin E, Jedel E, Janson PO, et al. Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R387-95. PMID: 19494176. ***X-4, X-5***

1465. Stener-Victorin E, Waldenstrom U, Tagnfors U, et al. Effects of electro-acupuncture on anovulation in women with polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica. 2000;79(3):180-8. PMID: 10716298. ***X-3, X-5***

1466. Stephanie R, Labied S, Blacher S, et al. Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time. Hum Reprod. 2007 Dec;22(12):3084-91. PMID: 17921480. ***X-4, X-5***

1467. Stephen LJ, Kwan P, Shapiro D, et al. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001 Aug;42(8):1002-6. PMID: 11554885. ***X-4, X-5, X-6, X-9***

1468. Stephenson K, Neuenschwander PF, Kurdowska AK, et al. Transdermal progesterone: Effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women. International Journal of Pharmaceutical Compounding. 2008;12(4):295-304. ***X-7***

1469. Stevenson JC, Durand G, Kahler E, et al. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17beta-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study. Maturitas. 2010;67(3):227-32. PMID: 20688442. ***X-7***

1470. Stewart FH, Kaunitz AM, LaGuardia KD, et al. Extended use of transdermal norelgestromin/ethinyl estradiol: A randomized trial. Obstetrics and Gynecology. 2005;105(6):1389-96. PMID: 15932834. ***X-5, X-6, X-9***

1471. Stovall TG, Muneyyirci-Delale O, Summitt Jr RL, et al. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: A randomized controlled trial. Obstetrics and Gynecology. 1995;86(1):65-71. PMID: 7784025. ***X-6***

1472. Stovall TG, Muneyyirci-Delale O, Summitt RL, Jr., et al. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol. 1995 Jul;86(1):65-71. PMID: 7784025. ***X-6, X-8***

1473. Strokosch GR, Friedman AJ, Wu SC, et al. Effects of an Oral Contraceptive (Norgestimate/Ethinyl Estradiol) on Bone Mineral Density in Adolescent Females with Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study. Journal of Adolescent Health. 2006;39(6):819-27. PMID: 17116511. ***X-5***

1474. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). American Journal of Psychiatry. 2011;168(9):947-56. PMID: 21768610. ***X-5***

1475. Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: An open-label, multicentre, randomised, controlled study. Journal of Family Planning and Reproductive Health Care. 2012 April;38(2):94-101. PMID: 2012264032. ***X-5***

1476. Sturdee DW, Archer DF, Rakov V, et al. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric. 2008 Feb;11(1):63-73. PMID: 18202966. ***X-5, X-7***

1477. Sturdee DW, Barlow DH, Ulrich LG, et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? UK Continuous Combined HRT Study Investigators. Lancet. 1994 Oct 8;344(8928):979-82. PMID: 7934429. ***X-3, X-7***

1478. Sturdee DW, Rantala ML, Colau JC, et al. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women. Climacteric. 2004 Dec;7(4):404-11. PMID: 15799612. ***X-4, X-5, X-7, X-9***

1479. Sturdee DW, Van de Weijer P, Von Holst T. Endometrial safety of a transdermal sequential estradiol-levonorgestrel combination. Climacteric. 2002;5(2):170-7. PMID: 12051113. ***X-7***

1480. Sturgess AD, Evans DT, Mackay IR, et al. Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol. 1984 Jan;13(1):11-4. PMID: 6371236. ***X-5***

1481. Subakir SB, Abdul Madjid O, Sabariah S, et al. Oxidative stress, vitamin E and progestin breakthrough bleeding. Hum Reprod. 2000 Aug;15 Suppl 3:18-23. PMID: 11041217. ***X-4, X-5***

1482. Subakir SB, Hadisaputra W, Handoyo AE, et al. Endometrial angiogenic response in Norplant users. Hum Reprod. 1996 Oct;11 Suppl 2:51-5. PMID: 8982746. ***X-3, X-4, X-6***

1483. Subakir SB, Setiadi E, Affandi B, et al. Benefits of vitamin E supplementation to Norplant users--in vitro and in vivo studies. Toxicology. 2000 Aug 7;148(2-3):173-8. PMID: 10962136. ***X-4, X-5, X-6***

1484. Subtil D, Goeusse P, Puech F, et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: The Essai Regional Aspirine Mere-Enfant study (Part 1). BJOG: An International Journal of Obstetrics and Gynaecology. 2003;110(5):475-84. PMID: 12742332. ***X-5***

1485. Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 1):562-7. PMID: 7856686. ***X-7***

1486. Suhonen SP, Holmstrom T, Allonen HO, et al. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril. 1995 Feb;63(2):336-42. PMID: 7843440. ***X-7***

1487. Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil Womens Med. 1999 Nov-Dec;44(6):286-96. PMID: 10617250. ***X-5, X-7***

1488. Sulak PJ, Kuehl TJ, Coffee A, et al. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. American Journal of Obstetrics and Gynecology. 2006;195(4):935-41. PMID: 16647684. ***X-3, X-6***

1489. Sulak PJ, Smith V, Coffee A, et al. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol. 2008 Sep;112(3):563-71. PMID: 18757653. ***X-5, X-7***

1490. Sundarrajan C, Liao WX, Roy AC, et al. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J Clin Endocrinol Metab. 2001 Jan;86(1):135-9. PMID: 11231990. ***X-4, X-5, X-9***

1491. Sundstrom A, Seaman H, Kieler H, et al. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research

Database. BJOG. 2009 Jan;116(1):91-7. PMID: 19016686. ***X-4***

1492. Suri V, Aggarwal N, Kaur R, et al. Safety of intrauterine contraceptive device (copper T 200 B) in women with cardiac disease. Contraception. 2008 Oct;78(4):315-8. PMID: 18847580. ***X-4, X-5, X-9***

1493. Suthipongse W, Taneepanichskul S. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 mug ethinylestradiol and 150 mug levonogestrel/30 mug ethinylestradiol in Thai women. Contraception. 2004;69(1):23-6. PMID: 14720615. ***X-9***

1494. Suzuki N, Uebaba K, Kohama T, et al. French maritime pine bark extract significantly lowers the requirement for analgesic medication in dysmenorrhea: A multicenter, randomized, double-blind, placebo-controlled study. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2008;53(5):338-46. PMID: 18567279. ***X-3, X-5***

1495. Swahn ML, Kovacs L, Cekan SZ, et al. Termination of early pregnancy with ZK 98,734: pharmacokinetic behaviour and clinical effect. Hum Reprod. 1994 Jan;9(1):57-63. PMID: 8195352. ***X-3, X-5***

1496. Swenson I, Khan AR, Jahan FA. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh. Contraception. 1980 Mar;21(3):207-15. PMID: 6446442. ***X-6, X-9***

1497. Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators. Obstet Gynecol. 2000 Sep;96(3):366-72. PMID: 10960627. ***X-5, X-7***

1498. Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. Mechanisms of Development. 2000;96(2):366-72. PMID: 10960627. ***X-7***

1499. Tagore S, Yim CF, Kwek K. Dengue haemorrhagic fever complicated by eclampsia in pregnancy. Singapore Med J. 2007 Oct;48(10):e281-3. PMID: 17909667. ***X-1, X-4, X-5, X-9***

1500. Tahara M, Shimizu T, Shimoura H. Preliminary report of treatment with oral contraceptive pills for intermenstrual vaginal bleeding secondary to a cesarean section scar. Fertil Steril. 2006 Aug;86(2):477-9. PMID: 16769058. ***X-4, X-5, X-9***

1501. Tai BC, Peregoudov A, Machin D. A competing risk approach to the analysis of trials of alternative intra-uterine devices (IUDs) for fertility regulation. Statistics in Medicine. 2001;20(23):3589-600. PMID: 11746339. ***X-9***

1502. Takahashi K, Karino K, Kanasaki H, et al. Altered kinetics of pituitary response to gonadotropin-releasing hormone in women with variant luteinizing hormone: correlation with ovulatory disorders. Horm Res. 2004;61(1):27-32. PMID: 14646399. ***X-4, X-5, X-9***

1503. Takeuchi H, Kobori H, Kikuchi I, et al. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res. 2000 Oct;26(5):325-31. PMID: 11147718. ***X-4, X-5, X-6***

1504. Takeuchi S, Futamura N, Takubo S, et al. Polycystic ovary syndrome treated with laparoscopic ovarian drilling with a harmonic scalpel: A prospective, randomized study. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2002;47(10):816-20. PMID: 12418063. ***X-8***

1505. Taler SJ, Coulam CB, Annegers JF, et al. Case-control study of galactorrhea and its relationship to the use of oral contraceptives. Obstet Gynecol. 1985 May;65(5):665-8. PMID: 4039047. ***X-3, X-5***

1506. Tam WH, Yuen PM, Shan Ng DP, et al. Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized study. Gynecol Obstet Invest. 2006;62(2):84-8. PMID: 16612101. ***X-8***

1507. Tan D, Haines CJ, Limpaphayom KK, et al. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. Maturitas. 2005;52(1):35-51. PMID: 16211697. ***X-7***

1508. Taneepanichskul S, Kriengsinyot R, Jaisamrarn U. A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 microg ethinylestradio1/75 microg gestodene (Meliane) and 30 microg ethinylestradio1/75 microg gestodene (Gynera). Contraception. 2002 Dec;66(6):407-9. PMID: 12499032. ***X-5***

1509. Taneepanichskul S, Reinprayoon D, Phaosavadi S. DMPA use above the age of 35 in Thai women. Contraception. 2000 Apr;61(4):281-2. PMID: 10899485. ***X-4, X-5, X-6***

1510. Taner C, Inal M, Basogul O, et al. Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism. Gynecol Obstet Invest. 2002;54(2):105-8. PMID: 12566753. ***X-5, X-9***

1511. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception. 1995 Apr;51(4):231-5. PMID: 7796588. ***X-3***

1512. Tang OS, Gao PP, Cheng L, et al. A randomized double-blind placebo-controlled study to assess the effect of oral contraceptive pills on the outcome of medical abortion with mifepristone and misoprostol. Hum Reprod. 1999 Mar;14(3):722-5. PMID: 10221703. ***X-5, X-9***

1513. Tang OS, Lee SW, Ho PC. A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. Hum Reprod. 2002 Nov;17(11):2865-8. PMID: 12407040. ***X-5, X-9***

1514. Tang OS, Xu J, Cheng L, et al. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial. Hum Reprod. 2002 Jan;17(1):99-102. PMID: 11756369. ***X-5, X-9***

1515. Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human Reproduction. 2006;21(1):80-9. PMID: 16199429. ***X-5***

1516. Tantbirojn P, Taneepanichskul S. Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women. Contraception. 2002 Dec;66(6):401-5. PMID: 12499031. ***X-5***

1517. Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. Contraception. 2004 Oct;70(4):277-9. PMID: 15451330. ***X-5, X-6***

1518. Taskin O, Buhur A, Birincioglu M, et al. Endometrial Na+, K+-ATPase pump function and vasopressin levels during hysteroscopic surgery in patients pretreated with GnRH agonist. J Am Assoc Gynecol Laparosc. 1998 May;5(2):119-24. PMID: 9564057. ***X-4, X-5, X-8***

1519. Taskin O, Yalcinoglu A, Kucuk S, et al. The degree of fluid absorption during hysteroscopic surgery in patients pretreated with goserelin. J Am Assoc Gynecol Laparosc. 1996 Aug;3(4):555-9. PMID: 9050688. ***X-5, X-8, X-9***

1520. Tatum HJ, Beltran RS, Ramos R, et al. Immediate postplacental insertion of GYNE-T 380 and GYNE-T 380 postpartum intrauterine contraceptive devices: randomized study. Am J Obstet Gynecol. 1996 Nov;175(5):1231-5. PMID: 8942493. ***X-5***

1521. Teal SB, Dempsey-Fanning A, Westhoff C. Predictors of acceptability of medication abortion. Contraception. 2007 Mar;75(3):224-9. PMID: 17303494. ***X-5, X-9***

1522. Tehrani FR, Rashidi H, Azizi F. The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. Reprod Biol Endocrinol. 2011;9:144. PMID: 22044512. ***X-3, X-4***

1523. Tehrani FR, Simbar M, Tohidi M, et al. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reproductive Biology and Endocrinology. 2011;9(39)PMID: 21435276. ***X-3, X-4***

1524. Teichmann A, Apter D, Emerich J, et al. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception. 2009 Dec;80(6):504-11. PMID: 19913143. ***X-4, X-5***

1525. Terakawa N, Inoue M, Shimizu I, et al. Preliminary report on the use of danazol in the treatment of endometrial adenomatous hyperplasia. Cancer. 1988 Dec 15;62(12):2618-21. PMID: 3191463. ***X-3, X-9***

1526. Thomas AG, Klihr-Beall S, Siqueira L, et al. Concentration of depot medroxyprogesterone acetate and pain scores in adolescents: A randomized clinical trial. Contraception. 2005;72(2):126-9. PMID: 16022852. ***X-5, X-6, X-9***

1527. Thomas EJ. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids. Br J Obstet Gynaecol. 1996 Oct;103 Suppl 14:18-21. PMID: 8916983. ***X-3, X-6***

1528. Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1991 Nov;98(11):1155-9. PMID: 1836959. ***X-3***

1529. Thomson RL, Buckley JD, Moran LJ, et al. The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod. 2009 Aug;24(8):1976-81. PMID: 19380385. ***X-4, X-5, X-9***

1530. Thongrong P, Jarruwale P, Panichkul P. Effectiveness of paracervical block versus intravenous morphine during uterine curettage: a randomized controlled trial. J Med Assoc Thai. 2011 Apr;94(4):403-7. PMID: 21591523. ***X-5, X-8***

1531. Thonneau P, Poirel H, Fougeyrollas B, et al. A comparative analysis of fall in haemoglobin following abortions conducted by mifepristone (600 mg) and vacuum aspiration. Hum Reprod. 1995 Jun;10(6):1512-5. PMID: 7593526. ***X-3, X-5***

1532. Thorburn J, Berntsson C, Philipson M, et al. Background factors of ectopic pregnancy. I. Frequency distribution in a case-control study. Eur J Obstet Gynecol Reprod Biol. 1986 Dec;23(5-6):321-31. PMID: 3803684. ***X-3, X-4, X-5***

1533. Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen Supplements for the Treatment of Hot Flashes: The Isoflavone Clover Extract (ICE) Study: A Randomized Controlled Trial. Journal of the American Medical Association. 2003;290(2):207-14. PMID: 12851275. ***X-5, X-7***

1534. Tolley E, Loza S, Kafafi L, et al. The impact of menstrual side effects on contraceptive discontinuation: findings from a longitudinal study in Cairo, Egypt. International Family Planning Perspectives. 2005;31(1):15-23. PMID: 15888405. ***X-3, X-4, X-5***

1535. Toppozada M, El-Attar A, El-Ayyat MA, et al. Management of uterine bleeding by PGs or their synthesis inhibitors. Adv Prostaglandin Thromboxane Res. 1980;8:1459-63. PMID: 6769315. ***X-5, X-10***

1536. Towers CV, Pircon RA, Heppard M. Is tocolysis safe in the management of third-trimester bleeding? Am J Obstet Gynecol. 1999 Jun;180(6 Pt 1):1572-8. PMID: 10368505. ***X-4, X-5, X-9***

1537. Trambert JJ, Einstein MH, Banks E, et al. Uterine artery embolization in the management of vaginal bleeding from cervical pregnancy: a case series. J Reprod Med. 2005 Nov;50(11):844-50. PMID: 16419633. ***X-4, X-5, X-8, X-9***

1538. Tredway DR, Buraglio M, Hemsey G, et al. A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, premenopausal female volunteers. Fertil Steril. 2004 Dec;82(6):1587-93. PMID: 15589864. ***X-4, X-5, X-9***

1539. Trivedi P, Rocha I, Padhye A. Is routine preoperative preparation necessary for hysteroscopic endometrial resection? Gynaecological Endoscopy. 1999;8(5):287-91. ***X-8***

1540. Tsikouras P, Liberis V, Galazios G, et al. Uterine sarcoma: a report of 57 cases over a 16-year period analysis. Eur J Gynaecol Oncol. 2008;29(2):129-34. PMID: 18459545. ***X-4, X-5, X-9***

1541. Tuchman M, Hee A, Emeribe U, et al. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20(12):1019-26. PMID: 17140280. ***X-5, X-9***

1542. Tuchman MM, Hee A, Emeribe U, et al. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22(10):877-86. PMID: 18788838. ***X-5, X-9***

1543. Tuppurainen M, Harma K, Komulainen M, et al. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: A 5-year follow-up. Maturitas. 2010;66(4):423-30. PMID: 20547017. ***X-7***

1544. Tur-Kaspa I, Gal M, Hartman M, et al. A prospective evaluation of uterine abnormalities by saline infusion sonohysterography in 1,009 women with infertility or abnormal uterine bleeding. Fertil Steril. 2006 Dec;86(6):1731-5. PMID: 17007850. ***X-4, X-5, X-9***

1545. Turnbull AC, Rees MC. Gestrinone in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990 Aug;97(8):713-5. PMID: 2205289. ***X-3***

1546. Turner JA, Mancl L, Huggins KH, et al. Targeting temporomandibular disorder pain treatment to hormonal fluctuations: A randomized clinical trial. Pain. 2011;152(9):2074-84. PMID: 21680092. ***X-5***

1547. Ulmann A, Dubois C, Philibert D. Fertility control with RU 486. Horm Res. 1987;28(2-4):274-8. PMID: 3331378. ***X-1, X-3, X-5***

1548. Ulmann A, Silvestre L. RU486: the French experience. Hum Reprod. 1994 Jun;9 Suppl 1:126-30. PMID: 7962459. ***X-3, X-5***

1549. Ulmann A, Teutsch G, Philibert D. RU 486. Sci Am. 1990 Jun;262(6):42-8. PMID: 2343294. ***X-11***

1550. Ulstein M, Svendsen E, Steier A, et al. Clinical experience with a triphasic oral contraceptive. Acta Obstet Gynecol Scand. 1984;63(3):233-6. PMID: 6428157. ***X-3, X-9***

1551. Umbarje K. Thermal Balloon Endometrial Ablation (TBEA): an audit of pain management. Journal of One-Day Surgery. 2009;19(3):78-80. ***X-8***

1552. Unfer V, Casini ML, Costabile L, et al. High dose of phytoestrogens can reverse the antiestrogenic effects of clomiphene citrate on the endometrium in patients undergoing intrauterine insemination: a randomized trial. J Soc Gynecol Investig. 2004 Jul;11(5):323-8. PMID: 15219887. ***X-5, X-9***

1553. Ushiroyama T, Araki R, Sakuma K, et al. Efficacy of the kampo medicine Xiong-Gui-Jiao-Ai-Tang, a traditional herbal medicine, in the treatment of threatened abortion in early pregnancy. American Journal of Chinese Medicine. 2006;34(5):731-40. PMID: 17080540. ***X-5***

1554. Ushiroyama T, Ikeda A, Higashio S, et al. Unkei-to for correcting luteal phase defects. J Reprod Med. 2003 Sep;48(9):729-34. PMID: 14562640. ***X-4, X-5, X-9***

1555. Ushiroyama T, Ikeda A, Sakai M, et al. Effects of unkei-to, an herbal medicine, on endocrine function and ovulation in women with high basal levels of luteinizing hormone secretion. J Reprod Med. 2001 May;46(5):451-6. PMID: 11396371. ***X-4, X-5, X-10***

1556. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal

patients. The Esclim Study Group. Am J Obstet Gynecol. 1999 Jul;181(1):71-9. PMID: 10411798. ***X-5, X-7, X-9***

1557. Utian WH, Gass MLS, Pickar JH. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. Menopause. 2004;11(3):306-14. PMID: 15167310. ***X-7***

1558. Uygur D, Yesildaglar N, Erkaya S. Effect on sexual life - A comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate. Gynecological Endocrinology. 2005;20(4):209-12. PMID: 16019363. ***X-7***

1559. Vairojanavong K, Limchitti D, Sasivimolkul V. Clinical trial of the efficacy of mefenamic acid in relief of menorrhagia and/or dysmenorrhoea. J Med Assoc Thai. 1983 Feb;66(2):99-105. PMID: 6343540. ***X-3, X-5***

1560. van de Weijer PH, Barentsen R, de Vries M, et al. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Gynecol. 1999 Apr;93(4):551-7. PMID: 10214832. ***X-5, X-6, X-7***

1561. van de Weijer PH, Barentsen R, Kenemans P. Women's expectations and acceptance of cyclic induced HRT bleeds. Maturitas. 1998 Nov 16;30(3):257-63. PMID: 9881325. ***X-3, X-5, X-6***

1562. van de Weijer PH, Scholten PC, van der Mooren MJ, et al. Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone. Climacteric. 1999 Jun;2(2):101-9. PMID: 11910662. ***X-5, X-7***

1563. van de Weijer PH, Sturdee DW, von Holst T. Estradiol and levonorgestrel: effects on bleeding pattern when administered in a sequential combined regimen with a new transdermal patch. Climacteric. 2002 Mar;5(1):36-44. PMID: 11974558. ***X-5, X-7***

1564. van den Berg I, Liem YS, Wesseldijk F, et al. Complex regional pain syndrome type 1 may be associated with menstrual cycle disorders: a case-control study. Complement Ther Med. 2009 Oct-Dec;17(5-6):262-8. PMID: 19942105. ***X-4, X-5, X-9***

1565. Van Den Heuvel MW, Van Bragt AJM, Alnabawy AKM, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168-74. PMID: 16102549. ***X-4, X-9***

1566. van der Straten A, Napierala S, Cheng H, et al. A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe. Contraception. 2007;76(5):389-99. PMID: 17963865. ***X-5, X-9***

1567. van Dessel HJ, Schoot BC, Schipper I, et al. Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen. Hum Reprod. 1996 Mar;11(3):478-85. PMID: 8671250. ***X-3, X-4, X-5***

1568. Van Doorn HC, Timmermans A, Opmeer BC, et al. What is the recurrence rate of postmenopausal bleeding in women who have a thin endometrium during a first episode of postmenopausal bleeding? Acta Obstet Gynecol Scand. 2008;87(1):89-93. PMID: 18158632. ***X-4, X-5, X-7***

1569. van Eijkeren MA, Christiaens GC, Geuze JJ, et al. Morphology of menstrual hemostasis in essential menorrhagia. Lab Invest. 1991 Feb;64(2):284-94. PMID: 1997737. ***X-3, X-4***

1570. van Kets H, Vrijens M, Van Trappen Y, et al. The frameless GyneFix intrauterine implant: a major improvement in efficacy, expulsion and tolerance. Adv Contracept. 1995 Jun;11(2):131-42. PMID: 7491854. ***X-3, X-9***

1571. Van Kets HE, Van der Pas H, Delbarge W, et al. A randomized comparative study of the TCu380A and Cu-Safe 300 IUDs. Adv Contracept. 1995 Jun;11(2):123-9. PMID: 7491853. ***X-9***

1572. van Santbrink EJ, Hohmann FP, Eijkemans MJ, et al. Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment. Eur J Endocrinol. 2005 Apr;152(4):611-7. PMID: 15817918. ***X-5, X-9***

1573. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009 Dec;49(12):2719-28. PMID: 19682342. ***X-5***

1574. Vance ML, Cragun JR, Reimnitz C, et al. CV 205-502 treatment of hyperprolactinemia. J Clin Endocrinol Metab. 1989 Feb;68(2):336-9. PMID: 2521863. ***X-4, X-5***

1575. Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception. 2008;77(3):162-70. PMID: 18279685. ***X-4, X-5, X-9***

1576. Varner RE, Ireland CC, Summitt RL, Jr., et al. Medicine or Surgery (Ms): a randomized clinical trial comparing hysterectomy and medical treatment in premenopausal women with abnormal uterine bleeding. Control Clin Trials. 2004 Feb;25(1):104-18. PMID: 14980755. ***X-8***

1577. Vega RR, Barraza-Vazquez A, Vega MG, et al. GnRH agonist for postpartum contraception: biochemical,

hormonal and endometrial effects. Adv Contracept. 1996 Mar;12(1):15-25. PMID: 8739513. ***X-4, X-5, X-9***

1578. Veldhuis HM, Vos AG, Lagro-Janssen AL. Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract. 2004 Sep;10(3):82-7. PMID: 15534571. ***X-4, X-5, X-9***

1579. Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol. 2004 Oct;24(7):798-800. PMID: 15763792. ***X-4, X-5, X-6, X-9***

1580. Vercellin P, Perin A, Consonn R, et al. Does preoperative treatment with a gonadotropin-releasing hormone agonist improve the outcome of endometrial resection? J Am Assoc Gynecol Laparosc. 1998 Nov;5(4):357-60. PMID: 9782138. ***X-4, X-5, X-8***

1581. Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010 May 1;93(7):2150-61. PMID: 19328469. ***X-4, X-5, X-9***

1582. Vercellini P, Bocciolone L, Colombo A, et al. Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas. Acta Obstet Gynecol Scand. 1993 Jul;72(5):369-73. PMID: 8392268. ***X-3, X-6, X-8***

1583. Vercellini P, Colombo A, Mauro F, et al. Paracervical anesthesia for outpatient hysteroscopy. Fertility and Sterility. 1994;62(5):1083-5. PMID: 7646610. ***X-5, X-8***

1584. Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. American Journal of Obstetrics and Gynecology. 1996;175(2):396-401. PMID: 8765259. ***X-5, X-10***

1585. Vercellini P, Perino A, Consonni R, et al. Treatment with a gonadotrophin releasing hormone agonist before endometrial resection: a multicentre, randomised controlled trial. Br J Obstet Gynaecol. 1996 Jun;103(6):562-8. PMID: 8645650. ***X-5, X-8, X-9***

1586. Vercellini P, Sacerdote P, Trespidi L, et al. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study. Fertil Steril. 1994 Nov;62(5):938-42. PMID: 7926138. ***X-5, X-6***

1587. Vercellini P, Soma M, Moro GL. Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility and Sterility. 1996;66(6):911-9. PMID: 8941054. ***X-4, X-5, X-10***

1588. Vercellini P, Vendola N, Colombo A, et al. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest. 1992;34(2):102-4. PMID: 1398260. ***X-3, X-5, X-6***

1589. Vetr M, Sobek A. Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism. Acta Univ Palacki Olomuc Fac Med. 1993;135:55-7. PMID: 7976677. ***X-3, X-5***

1590. Vickers MR, Martin J, Meade TW, et al. The Women's International Study of Long-duration Oestrogen after Menopause (WISDOM): A randomised controlled trial. BMC Women's Health. 2007;7(2)PMID: 17324282. ***X-7***

1591. Vidal-Puig AJ, Munoz-Torres M, Jodar-Gimeno E, et al. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol. 1994 Apr;130(4):333-8. PMID: 8162160. ***X-3, X-5***

1592. Vigano GL, Mannucci PM, Lattuada A, et al. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol. 1989 May;31(1):32-5. PMID: 2705441. ***X-3, X-6***

1593. Vilos GA, Fortin CA, Sanders B, et al. Clinical trial of the uterine thermal balloon for treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 1997 Nov;4(5):559-65. PMID: 9348362. ***X-4, X-5, X-8***

1594. Vilos GA, Vilos EC, Pendley L. Endometrial ablation with a thermal balloon for the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 1996 May;3(3):383-7. PMID: 9050660. ***X-4, X-5, X-8***

1595. Vimala N, Mittal S, Kumar S, et al. A randomized comparison of sublingual and vaginal misoprostol for cervical priming before suction termination of first-trimester pregnancy. Contraception. 2004 Aug;70(2):117-20. PMID: 15288215. ***X-5, X-9***

1596. Vincent AJ, Malakooti N, Zhang J, et al. Endometrial breakdown in women using Norplant is associated with migratory cells expressing matrix metalloproteinase-9 (gelatinase B). Hum Reprod. 1999 Mar;14(3):807-15. PMID: 10221718. ***X-3, X-4***

1597. Vincent AJ, Zhang J, Ostor A, et al. Matrix metalloproteinase-1 and -3 and mast cells are present in the endometrium of women using progestin-only contraceptives. Hum Reprod. 2000 Jan;15(1):123-30. PMID: 10611200. ***X-4, X-5***

1598. Vincent AJ, Zhang J, Ostor A, et al. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding? Hum Reprod. 2002 May;17(5):1189-98. PMID: 11980737. ***X-4, X-5***

1599. Vincenti E, Tambuscio B, Marchesoni D, et al. Use of intramyometrial injection of prostaglandin F 2 alpha in the management of intractable hemorrhage due to uterine atony. Clin Exp Obstet Gynecol. 1982;9(1):26-30. PMID: 6959742. ***X-3, X-5***

1600. Viniker DA. Late luteal phase dydrogesterone in combination with clomiphene or tamoxifen in the treatment of infertility associated with irregular and infrequent menstruation: enhancing patient compliance. Hum Reprod. 1996 Jul;11(7):1435-7. PMID: 8671482. ***X-3, X-5***

1601. Volkers NA, Hehenkamp WJ, Birnie E, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years' outcome from the randomized EMMY trial. Am J Obstet Gynecol. 2007 Jun;196(6):519 e1-11. PMID: 17547877. ***X-5, X-6, X-8, X-9***

1602. von Holst T, Lang E, Winkler U, et al. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas. 2002 Dec 10;43(4):265-75. PMID: 12468135. ***X-5, X-6, X-7***

1603. von Kesseru E, Aydinlik S, Etchepareborda JJ. Multicentred, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive; final three-year report. Contraception. 1994 Oct;50(4):329-37. PMID: 7813221. ***X-3, X-9***

1604. von Kesseru E, Aydinlik S, Etchepareborda JJ, et al. A multicentred, two-year, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive. Contraception. 1991 Dec;44(6):589-98. PMID: 1773616. ***X-3, X-9***

1605. von Kesseru E, Etchepareborda JJ, Wikinski R, et al. Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns. Contraception. 2000 May;61(5):317-22. PMID: 10906502. ***X-4, X-5, X-6***

1606. Von Seggern RL, Mannix LK, Adelman JU. Rofecoxib in the Prevention of Perimenstrual Migraine: An Open-Label Pilot Trial. Headache. 2004;44(2):160-5. PMID: 14756855. ***X-5***

1607. Vorsanger GJ, Xiang J, Gana TJ, et al. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. Journal of Opioid Management. 2008;4(2):87-97. PMID: 18557165. ***X-5***

1608. Vuorma S, Rissanen P, Aalto AM, et al. Impact of patient information booklet on treatment decision - A randomized trial among women with heavy menstruation. Health Expectations. 2003;6(4):290-7. PMID: 15040791. ***X-5***

1609. Vuorma S, Rissanen P, Aalto AM, et al. Factors predicting choice of treatment for menorrhagia in gynaecology outpatient clinics. Soc Sci Med. 2003 Apr;56(8):1653-60. PMID: 12639582. ***X-4***

1610. Wahab M, Al-Azzawi F. Trimegestone: Expanding therapeutic choices for the treatment of the menopause. Expert Opinion on Investigational Drugs. 2001;10(9):1737-44. PMID: 11772282. ***X-1, X-3, X-5***

1611. Wahab M, Thompson J, Al-Azzawi F. The distribution of endometrial leukocytes and their proliferation markers in trimegestone-treated postmenopausal women compared to the endometrium of the natural cycle: A dose-ranging study. Human Reproduction. 1999;14(5):1201-6. PMID: 10325261. ***X-3, X-4, X-7***

1612. Wahab M, Thompson J, Al-Azzawi F. The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy. BJOG. 2000 Mar;107(3):329-34. PMID: 10740328. ***X-5, X-7***

1613. Wahab M, Thompson J, Whitehead M, et al. The effect of a change in the dose of trimegestone on the pattern of bleeding in estrogen-treated post-menopausal women: 6 month extension of a dose-ranging study. Hum Reprod. 2002 May;17(5):1386-90. PMID: 11980769. ***X-4, X-5, X-7***

1614. Walberg JL, Johnston CS. Menstrual function and eating behavior in female recreational weight lifters and competitive body builders. Med Sci Sports Exerc. 1991 Jan;23(1):30-6. PMID: 1997810. ***X-3, X-4, X-5***

1615. Walberg-Rankin J, Edmonds CE, Gwazdauskas FC. Diet and weight changes of female bodybuilders before and after competition. Int J Sport Nutr. 1993 Mar;3(1):87-102. PMID: 8499941. ***X-3, X-5***

1616. Wang F, Shen X, Guo X, et al. Analgesic effectiveness of flurbiprofen axetil after uterine curettage on abortion: A randomized controlled trial. Acute Pain. 2009;11(2):43-50. ***X-5***

1617. Wang HS, Wang TH, Soong YK. Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea. Changgeng Yi Xue Za Zhi. 1999 Sep;22(3):423-32. PMID: 10584414. ***X-4, X-5, X-6, X-9***

1618. Wang HS, Wang TH, Soong YK. Cyclic changes in serum levels of insulin-like growth factor binding protein-1 in women treated with clomiphene citrate and tamoxifen. Gynecol Endocrinol. 2000 Aug;14(4):236-44. PMID: 11075292. ***X-4, X-5***

1619. Wang HS, Wang TH, Soong YK. Elevation of insulin-like growth factor-binding protein-1 mRNA expression following hormone replacement therapy. Hum Reprod. 2000 Jan;15(1):50-4. PMID: 10611187. ***X-4, X-5, X-7***

1620. Wang IY, Russell P, Fraser IS. Endometrial morphometry in users of intrauterine contraceptive devices and women with ovulatory dysfunctional uterine bleeding: a comparison with normal endometrium. Contraception. 1995 Apr;51(4):243-8. PMID: 7796590. ***X-3, X-4***

1621. Wang J, Zhang G, Shi H, et al. Dextran uterine artery embolization to treat fibroids. Chin Med J (Engl). 2002 Aug;115(8):1132-6. PMID: 12215276. ***X-4, X-5, X-6, X-8***

1622. Wang MC, Hsu MC, Chien LW, et al. Effects of auricular acupressure on menstrual symptoms and nitric oxide for women with primary dysmenorrhea. Journal of Alternative and Complementary Medicine. 2009;15(3):235-42. PMID: 19292653. ***X-5***

1623. Wang Y, Xu B, Dai S, et al. An efficient conservative treatment modality for cervical pregnancy: angiographic uterine artery embolization followed by immediate curettage. Am J Obstet Gynecol. 2011 Jan;204(1):31 e1-7. PMID: 20889136. ***X-4, X-5, X-9***

1624. Warming L, Ravn P, Spielman D, et al. Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause. 2004 May-Jun;11(3):337-42. PMID: 15167314. ***X-5, X-7***

1625. Warner P. Preferences regarding treatments for period problems: relationship to menstrual and demographic factors. J Psychosom Obstet Gynaecol. 1994 Jun;15(2):93-110. PMID: 7921011. ***X-3, X-5***

1626. Warner P, Critchley HO, Lumsden MA, et al. Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management. BMJ. 2001 Jul 7;323(7303):24-8. PMID: 11440940. ***X-4, X-5, X-9***

1627. Warner P, Guttinger A, Glasier AF, et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Hum Reprod. 2010 Feb;25(2):345-53. PMID: 19897857. ***X-4, X-5, X-9***

1628. Warren MP, Brooks-Gunn J, Fox RP, et al. Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: A longitudinal study. Fertility and Sterility. 2003;80(2):398-404. PMID: 12909505. ***X-5***

1629. Warren MP, Perlroth NE. The effects of intense exercise on the female reproductive system. Journal of Endocrinology. 2001;170(1):3-11. PMID: 11431132. ***X-1, X-3, X-5***

1630. Wartenberg KE, Mayer SA. Reducing the risk of ICH enlargement. Journal of the Neurological Sciences. 2007;261(1-2):99-107. PMID: 17631908. ***X-5***

1631. Wasnich RD, Bagger YZ, Hosking DJ, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause. 2004;11(6 I):622-30. PMID: 15545790. ***X-7***

1632. Watson P, Besch N, Bowes WA, Jr. Management of acute and subacute puerperal inversion of the uterus. Obstet Gynecol. 1980 Jan;55(1):12-6. PMID: 7352052. ***X-3, X-5, X-6***

1633. Webb A, Shochet T, Bigrigg A, et al. Effect of hormonal emergency contraception on bleeding patterns. Contraception. 2004 Feb;69(2):133-5. PMID: 14759618. ***X-4, X-5, X-9***

1634. Weeks AD, Duffy SR, Walker JJ. Uterine ultrasonographic changes with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 1999 Jan;180(1 Pt 1):8-13. PMID: 9914569. ***X-4, X-5, X-8, X-9***

1635. Weeks AD, Duffy SR, Walker JJ. A double-blind randomised trial of leuprorelin acetate prior to hysterectomy for dysfunctional uterine bleeding. BJOG. 2000 Mar;107(3):323-8. PMID: 10740327. ***X-5, X-8***

1636. Wegienka G, Baird DD. Potential bias due to excluding oral contraceptive users when estimating menstrual cycle characteristics. Am J Epidemiol. 2003 Nov 15;158(10):947-50. PMID: 14607802. ***X-4, X-5, X-9***

1637. Wehr E, Pieber TR, Obermayer-Pietsch B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. J Endocrinol Invest. 2011 Nov;34(10):757-63. PMID: 21613813. ***X-3, X-5***

1638. Weingrill CO, Mussio W, Moraes CR, et al. Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia. Fertil Steril. 1992 Feb;57(2):331-5. PMID: 1735484. ***X-5, X-6***

1639. Weinstein MC. Estrogen use in postmenopausal women--costs, risks, and benefits. N Engl J Med. 1980 Aug 7;303(6):308-16. PMID: 6770270. ***X-1, X-3, X-7***

1640. Weisberg E, Brache V, Alvarez F, et al. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen. Contraception. 2005 Jul;72(1):46-52. PMID: 15964292. ***X-5, X-6, X-9, X-10***

1641. Weisberg E, Croxatto HB, Findlay JK, et al. A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon(R). Contraception. 2011 Dec;84(6):600-8. PMID: 22078189. ***X-4***

1642. Weisberg E, Fraser IS, Lacarra M, et al. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive

vaginal ring. Contraception. 1999;59(5):311-8. PMID: 10494485. ***X-3, X-9***

1643. Weisberg E, Fraser IS, Mishell Jr DR, et al. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception. 1999;59(5):305-10. PMID: 10494484. ***X-3, X-9***

1644. Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod. 2006 Jan;21(1):295-302. PMID: 16284061. ***X-5, X-6, X-9***

1645. Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod. 2009 Aug;24(8):1852-61. PMID: 19369294. ***X-5, X-6***

1646. Weisberg M, Goldrath MH, Berman J, et al. Hysteroscopic endometrial ablation using free heated saline for the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2000 Aug;7(3):311-6. PMID: 10924623. ***X-4, X-5, X-8***

1647. Weise HC, Fiedler K, Kato K. Buserelin suppression of endogenous gonadotropin secretion in infertile women with ovarian feedback disorders given human menopausal/human chorionic gonadotropin treatment. Fertil Steril. 1988 Mar;49(3):399-403. PMID: 3125067. ***X-3, X-5, X-10***

1648. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004 Sep 2;351(10):987-97. PMID: 15342807. ***X-4, X-5, X-9***

1649. Wen J, Li Y, Wang L, et al. Comparative cost-effectiveness of three intrauterine devices: A multi-center randomized trial. Journal of Evidence Based Medicine. 2010;3(2):76-82. PMID: 21349048. ***X-5, X-9***

1650. Weng LJ, Xu D, Zheng HZ, et al. Clinical experience with triphasic oral contraceptive (Triquilar) in 527 women in China. Contraception. 1991 Mar;43(3):263-71. PMID: 2036797. ***X-3, X-9***

1651. Westhoff C, Kaunitz AM, Korver T, et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17beta-estradiol: A randomized controlled trial. Obstetrics and Gynecology. 2012 May;119(5):989-99. PMID: 2012235235. ***X-9***

1652. Westhoff C, Osborne LM, Schafer JE, et al. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstetrics and Gynecology. 2005;106(1):89-96. PMID: 15994622. ***X-6, X-9***

1653. Westphal LM, Polan ML, Trant AS. Double-blind, placebo-controlled study of FertilityBlend: A nutritional supplement for improving fertility in women. Clinical and Experimental Obstetrics and Gynecology. 2006;33(4):205-8. PMID: 17211965. ***X-5***

1654. White WB, Hanes V, Chauhan V, et al. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension. 2006;48(2):246-53. PMID: 16801478. ***X-7***

1655. Wiegratz I, Stahlberg S, Manthey T, et al. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception. 2011;84(2):133-43. PMID: 21757054. ***X-9***

1656. Wigington S. Depo-Provera: an injectable contraceptive. Nurs Times. 1981 Oct 14-20;77(42):1794-8. PMID: 6458020. ***X-1, X-3, X-5, X-10***

1657. Wijesinghe PS, Padumadasa GS, Palihawadana TS, et al. A trial of expectant management in incomplete miscarriage. Ceylon Med J. 2011 Mar;56(1):10-3. PMID: 21542427. ***X-5, X-9***

1658. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):824-30. PMID: 8456888. ***X-7***

1659. Wilansky DL, Greisman B. Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol. 1989 Mar;160(3):673-7. PMID: 2929691. ***X-3, X-4, X-6***

1660. Wildemeersch D, Batar I, Affandi B, et al. The 'frameless' intrauterine system for long-term, reversible contraception: A review of 15 years of clinical experience. Journal of Obstetrics and Gynaecology Research. 2003;29(3):164-73. PMID: 12841701. ***X-1, X-3, X-5, X-9***

1661. Wildemeersch D, Dhont M, Temmerman M, et al. GyneFix-LNG: preliminary clinical experience with a copper and levonorgestrel-releasing intrauterine system. Eur J Contracept Reprod Health Care. 1999 Mar;4(1):15-9. PMID: 10367191. ***X-4***

1662. Wildemeersch D, Schacht E. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care. 2001 Jun;6(2):93-101. PMID: 11518454. ***X-3***

1663. Wildemeersch D, Schacht E, Wildemeersch P. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study. Contraception. 2002 Aug;66(2):93-9. PMID: 12204781. ***X-4, X-5, X-9***

1664. Wildemeersch D, Schacht E, Wildemeersch P. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women. Maturitas. 2003 Mar 28;44(3):237-45. PMID: 12648887. ***X-4***

1665. Wildemeersch D, van der Pas H, Thiery M, et al. The Copper-Fix (Cu-Fix): a new concept in IUD technology. Adv Contracept. 1988 Sep;4(3):197-205. PMID: 3071109. ***X-1, X-3, X-9***

1666. Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab. 2008 Dec;93(12):4664-71. PMID: 18765509. ***X-4, X-5, X-6***

1667. Williams DB, Voigt BJ, Fu YS, et al. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol. 1994 Nov;84(5):787-93. PMID: 7936513. ***X-7***

1668. Williams NI, Reed JL, Leidy HJ, et al. Estrogen and progesterone exposure is reduced in response to energy deficiency in women aged 25-40 years. Hum Reprod. 2010 Sep;25(9):2328-39. PMID: 20605898. ***X-3, X-5, X-10***

1669. Wimberly YH, Cotton S, Wanchick AM, et al. Attitudes and experiences with levonorgestrel 100 microg/ethinyl estradiol 20 microg among women during a 3-month trial. Contraception. 2002 Jun;65(6):403-6. PMID: 12127637. ***X-4, X-5, X-9***

1670. Wing DA, Paul RH, Millar LK. Management of the symptomatic placenta previa: a randomized, controlled trial of inpatient versus outpatient expectant management. Am J Obstet Gynecol. 1996 Oct;175(4 Pt 1):806-11. PMID: 8885726. ***X-4, X-5, X-9***

1671. Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol. 2001 Dec 1;99(2):238-43. PMID: 11788179. ***X-4***

1672. Winkler UH, Ferguson H, Mulders JAPA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 mug ethinylestradiol. Contraception. 2004;69(6):469-76. PMID: 15157791. ***X-6, X-9***

1673. Witjaksono J, Lau TM, Affandi B, et al. Oestrogen treatment for increased bleeding in Norplant users: preliminary results. Hum Reprod. 1996 Oct;11 Suppl 2:109-14. PMID: 8982752. ***X-5, X-6***

1674. Wolfe BMJ, Koval JJ, Nisker JA. Impact on postmenopausal symptoms of adding continuous C-21 versus C-19 progestin to estrogen. Maturitas. 1999;33(2):153-61. PMID: 10597880. ***X-7***

1675. Wollter-Svensson LO, Stadberg E, Andersson K, et al. Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstet Gynecol Scand. 1997 May;76(5):449-54. PMID: 9197448. ***X-5, X-10***

1676. Wollter-Svensson LO, Stadberg E, Andersson K, et al. Intrauterine administration of levonorgestrel 5 and 10 mug/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstetricia et Gynecologica Scandinavica. 1997;76(5):449-54. PMID: 9197448. ***X-4, X-5***

1677. Wong AYK, Tang L. An open and randomized study comparing the efficacy of standard danazol and modified triptorelin regimens for postoperative disease management of moderate to severe endometriosis. Fertility and Sterility. 2004;81(6):1522-7. PMID: 15193471. ***X-5, X-8***

1678. Wong RC, Bell RJ, Thunuguntla K, et al. Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users. Contraception. 2009 Nov;80(5):452-6. PMID: 19835719. ***X-4, X-5, X-9***

1679. Wonodirekso S, Affandi B, Siregar B, et al. Endometrial epithelial integrity and subepithelial reticular fibre expression in progestin contraceptive acceptors. Hum Reprod. 2000 Aug;15 Suppl 3:189-96. PMID: 11041235. ***X-4, X-5***

1680. Wood SL, Brain PH. Medical management of missed abortion: a randomized clinical trial. Obstet Gynecol. 2002 Apr;99(4):563-6. PMID: 12039111. ***X-5, X-9***

1681. Woolley JA, Seleem S, Hills FA, et al. Raised circulating levels of interleukin-6 in women with an intrauterine contraceptive device. Gynecol Obstet Invest. 1996;42(4):241-3. PMID: 8979095. ***X-3, X-4, X-5***

1682. Worthington-Kirsch RL, Popky GL, Hutchins FL, Jr. Uterine arterial embolization for the management of leiomyomas: quality-of-life assessment and clinical response. Radiology. 1998 Sep;208(3):625-9. PMID: 9722838. ***X-4, X-5, X-6, X-8***

1683. Wren BG, McFarland K, Edwards L, et al. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric. 2000 Sep;3(3):155-60. PMID: 11910616. ***X-4, X-5, X-7***

1684. Wright VC, Schieve LA, Reynolds MA, et al. Assisted reproductive technology surveillance -- United States, 2001. MMWR: Morbidity & Mortality Weekly Report. 2004;53(SS-1):1-20. PMID: 15123982. ***X-3, X-5***

1685. Wu S, Godfrey EM, Wojdyla D, et al. Copper T380A intrauterine device for emergency contraception: a

prospective, multicentre, cohort clinical trial. BJOG. 2010 Sep;117(10):1205-10. PMID: 20618314. ***X-4, X-5***

1686. Wu YJJ, Luo SF, Yang SH, et al. Vascular response of Raynaud's phenomenon to nifedipine or herbal medication (Duhuo-Tisheng Tang with Danggui-Sini Tang): A preliminary study. Chang Gung Medical Journal. 2008;31(5):492-502. PMID: 19097597. ***X-3, X-5***

1687. Xiao B, Wu SC, Chong J, et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003 Apr;79(4):963-9. PMID: 12749438. ***X-4***

1688. Xiao B, Zeng T, Wu S, et al. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception. 1995 Jun;51(6):359-65. PMID: 7554977. ***X-3, X-4***

1689. Xiao BL, Zhang XL, Feng DD. Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel. Contraception. 1985 Nov;32(5):455-71. PMID: 3936678. ***X-3, X-9***

1690. Xing S, Wu Y, Liu J, et al. A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin. Chin Med J (Engl). 2003 Apr;116(4):584-7. PMID: 12875727. ***X-5, X-7***

1691. Yamashita Y, Harada M, Yamamoto H, et al. Transcatheter arterial embolization of obstetric and gynaecological bleeding: efficacy and clinical outcome. Br J Radiol. 1994 Jun;67(798):530-4. PMID: 8032805. ***X-3, X-6, X-8***

1692. Yang LC, Lan Y, Hu J, et al. Relatively high bone mineral density in Chinese adolescent dancers despite lower energy intake and menstrual disorder. Biomed Environ Sci. 2010 Apr;23(2):130-6. PMID: 20514988. ***X-4, X-5, X-9***

1693. Yang TS, Liang WH, Chang SP, et al. Effects of period-free hormone replacement therapy in postmenopausal women in Taiwan. Chinese Medical Journal. 2002;65(1):23-8. PMID: 11939671. ***X-7***

1694. Yang TS, Tsan SH, Chen CR, et al. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. Chinese Medical Journal. 1999;62(5):308-15. PMID: 10389286. ***X-7***

1695. Yanushpolsky E, Hurwitz S, Greenberg L, et al. Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone--impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertil Steril. 2011 Feb;95(2):617-20. PMID: 20537624. ***X-5, X-6, X-9***

1696. Yarkoni S, Anteby SO. Treatment of IUD related menorrhagia by indomethacin. Clin Exp Obstet Gynecol. 1984;11(4):120-2. PMID: 6437699. ***X-5, X-6***

1697. Yasui T, Uemura H, Tezuka M, et al. Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res. 2001;56(1-2):38-44. PMID: 11815726. ***X-5, X-7***

1698. Yeh LLL, Liu JY, Lin KS, et al. A randomised placebo-controlled trial of a traditional Chinese herbal formula in the treatment of primary dysmenorrhoea. PLoS One. 2007;2(8)PMID: 17710126. ***X-5***

1699. Yeshaya A, Orvieto R, Kauschansky A, et al. A delayed starting schedule of oral contraception: the effect on the incidence of breakthrough bleeding and compliance in women. Eur J Contracept Reprod Health Care. 1996 Sep;1(3):263-5. PMID: 9678125. ***X-4, X-5, X-6***

1700. Yildirim G, Tugrul S, Uslu H, et al. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. Arch Gynecol Obstet. 2006 Feb;273(5):268-73. PMID: 16315025. ***X-5, X-7***

1701. Yildizhan B, Yildizhan R, Ozkesici B, et al. Transvaginal ultrasonography and saline infusion sonohysterography for the detection of intra-uterine lesions in pre- and post-menopausal women with abnormal uterine bleeding. J Int Med Res. 2008 Nov-Dec;36(6):1205-13. PMID: 19094428. ***X-4, X-5***

1702. Yin M, Zhu P, Luo H, et al. The presence of mast cells in the human endometrium pre- and post-insertion of intrauterine devices. Contraception. 1993 Sep;48(3):245-54. PMID: 8222654. ***X-3, X-4***

1703. Yingna S, Yang X, Xiuyu Y, et al. Clinical characteristics and treatment of gestational trophoblastic tumor with vaginal metastasis. Gynecol Oncol. 2002 Mar;84(3):416-9. PMID: 11855880. ***X-4, X-5, X-6, X-9***

1704. Ylanen K, Laatikainen T, Lahteenmaki P, et al. Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses. Acta Obstet Gynecol Scand. 2003 Feb;82(2):167-72. PMID: 12648180. ***X-4, X-5, X-8***

1705. Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol. 1986 Jul;68(1):10-2. PMID: 3523328. ***X-3, X-5, X-6***

1706. Ylikorkala O, Tiitinen A, Hulkko S, et al. Decrease in symptoms, blood loss and uterine size with nafarelin acetate before abdominal hysterectomy: a placebo-controlled, double-blind study. Hum Reprod. 1995 Jun;10(6):1470-4. PMID: 7593517. ***X-3, X-8***

1707. Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the

reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol. 1983 Jan;90(1):78-83. PMID: 6336951. ***X-5, X-6***

1708. Ylikorkala O, Wahlstrom T, Caubel P, et al. Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate. Acta Obstet Gynecol Scand. 2002 Jul;81(7):654-60. PMID: 12190841. ***X-5, X-7***

1709. Yong EL, Glasier A, Hillier H, et al. Effect of cyclofenil on hormonal dynamics, follicular development and cervical mucus in normal and oligomenorrhoeic women. Hum Reprod. 1992 Jan;7(1):39-43. PMID: 1551955. ***X-4, X-5***

1710. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005 Sep;106(3):492-501. PMID: 16135578. ***X-5, X-9***

1711. Youssef G, Maguid AA, El-Inany H. Progesterone supplementation in clomiphene citrate treated anovulatory patients with menstrual irregularities: A randomized controlled trial. Middle East Fertility Society Journal. 2000;5(3):209-12. ***X-5***

1712. Yuan HN, Wang CY, Sze CW, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008 Jun;28(3):264-370. PMID: 18480682. ***X-5, X-9***

1713. Zachariae H, Abrams B, Bleehen SS, et al. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability. Dermatology. 1998;196(2):231-6. PMID: 9568413. ***X-5, X-9***

1714. Zafar S. Role of metformin in correcting hyperinsulinemia, menstrual irregularity and anovulation in polycystic ovary syndrome. J Ayub Med Coll Abbottabad. 2005 Oct-Dec;17(4):54-6. PMID: 16599037. ***X-4, X-5, X-9***

1715. Zaidi J, Jacobs H, Campbell S, et al. Blood flow changes in the ovarian and uterine arteries in women with polycystic ovary syndrome who respond to clomiphene citrate: correlation with serum hormone concentrations. Ultrasound Obstet Gynecol. 1998 Sep;12(3):188-96. PMID: 9793191. ***X-3, X-4***

1716. Zalel Y, Shulman A, Lidor A, et al. The local progestational effect of the levonorgestrel-releasing intrauterine system: a sonographic and Doppler flow study. Hum Reprod. 2002 Nov;17(11):2878-80. PMID: 12407042. ***X-4, X-5, X-6***

1717. Zapico A, Grassa A, Martinez E, et al. Endometrial resection and preoperative LH-RH agonists: a prospective 5-year trial. Eur J Obstet Gynecol Reprod Biol. 2005 Mar 1;119(1):114-8. PMID: 15734095. ***X-4, X-5, X-6, X-8, X-9***

1718. Zervou S, Klentzeris LD, Old RW. Nitric oxide synthase expression and steroid regulation in the uterus of women with menorrhagia. Mol Hum Reprod. 1999 Nov;5(11):1048-54. PMID: 10541567. ***X-4, X-5***

1719. Zhang HJ. 76 cases of hypomenorrhea treated by acupuncture to regulate the menstrual cycle. J Tradit Chin Med. 2009 Sep;29(3):177-8. PMID: 19894379. ***X-3, X-5, X-10***

1720. Zhao G, Li M, Zhu P, et al. A preliminary morphometric study on the endometrium from patients treated with indomethacin-releasing copper intrauterine device. Hum Reprod. 1997 Jul;12(7):1563-6. PMID: 9262297. ***X-4, X-5, X-6***

1721. Zhao S, Choksuchat C, Zhao Y, et al. Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant. Contraception. 2009 Jun;79(6):469-78. PMID: 19442784. ***X-4, X-5, X-9***

1722. Zheng SR, Zheng HM, Qian SZ, et al. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999 Jul;60(1):1-8. PMID: 10549446. ***X-5, X-6***

1723. Zheng SR, Zheng HM, Qian SZ, et al. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracept Reprod Health Care. 1999 Jun;4(2):85-93. PMID: 10427483. ***X-4, X-5***

1724. Zheng XL, Lo LL. Studies on IUD-induced menorrhagia and increased synthesis of prostacyclin in endometrium. J Tongji Med Univ. 1988;8(4):232-4. PMID: 3150468. ***X-3, X-4, X-5, X-6***

1725. Zhou L, Xiao B. Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial. Contraception. 2001 Aug;64(2):107-12. PMID: 11704087. ***X-4, X-5, X-9***

1726. Zhu PD, Luo HZ, Xu RH, et al. The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium--a comparative study of three IUDs. A morphometric study of 96 cases. Contraception. 1989 Oct;40(4):425-38. PMID: 2510968. ***X-3, X-4***

1727. Zhuang Y, Huang L. Uterine artery embolization compared with methotrexate for the management of pregnancy implanted within a cesarean scar. Am J Obstet Gynecol. 2009 Aug;201(2):152 e1-3. PMID: 19527897. ***X-5, X-9***

1728. Ziaei S, Rajaei L, Faghihzadeh S, et al. Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route. Contraception. 2002 May;65(5):329-31. PMID: 12057783. ***X-4, X-5***

1729. Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest. 2005 Jan;28(1):49-53. PMID: 15816371. ***X-4, X-5, X-9***

1730. Zupi E, Luciano AA, Marconi D, et al. The use of topical anesthesia in diagnostic hysteroscopy and endometrial biopsy. J Am Assoc Gynecol Laparosc. 1994 May;1(3):249-52. PMID: 9050495. ***X-4, X-8***

1731. Zupi E, Marconi D, Sbracia M, et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertility and Sterility. 2004;82(5):1303-8. PMID: 15533351. ***X-5, X-6, X-10***

1732. Zupi E, Sbracia M, Marconi D, et al. TNFalpha expression in hyperplastic endometrium. Am J Reprod Immunol. 2000 Sep;44(3):153-9. PMID: 11028902. ***X-4, X-5***

1733. Zwart JJ, Yazdani ST, Harvey MS, et al. Underreporting of major obstetric haemorrhage in the Netherlands. Transfus Med. 2010 Apr;20(2):118-22. PMID: 19708894. ***X-4, X-5, X-9***

1734. Lukes AS, Freeman EW, Van Drie D, et al. Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study. Womens Health (Lond Engl). 2011 Sep;7(5):591-8. PMID: 21879827. ***X-3***

Appendix L. Reasons for Exclusion (KQ2)

Exclusion code	Exclusion reason	Count
X-1	Not original research (e.g. review articles, systematic reviews, editorials, commentaries, letters to editor, etc.).	104
X-2	Does not include data from a population of 1600 or more.	1916
X-3	Reporting of harms is from a general population or reporting of harms is not an objective of the paper/study.	913
X-4	Does not report harms data for a selected intervention included in KQ1 (i.e., LNG-IUS; progestogen; tranexamic acid; cabergoline; ethamsylate; exenatide; metformin).	2044
X-5	Study is basic science, anatomy, imaging, prevalence, physiology, diagnostic, biomarker, or biological mechanism study only.	4
X-6	Study of men only.	17
X-7	Study population consists of post-menopausal women or a population aged over 65 years.	101
X-8	Other	26
X-11	Unable to obtain	4
X-12	Duplicate	0

References

1. Tranexamic acid. Med Lett Drugs Ther. 1987 Sep 25;29(749):89-90. PMID: 3626975. ***X-1***

2. Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol. 1989 Sep;18(3):538-45. PMID: 2807655. ***X-4***

3. Breast cancer and combined oral contraceptives: results from a multinational study. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Br J Cancer. 1990 Jan;61(1):110-9. PMID: 2404507. ***X-4***

4. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition. BMJ. 1991 Jun 8;302(6789):1367-71. PMID: 1676318. ***X-2***

5. Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in indonesian men. World Health Organization. Task Force on Methods for the Regulation of Male Fertility. Fertil Steril. 1993 Dec;60(6):1062-8. PMID: 8243687. ***X-2, X-3, X-4***

6. History of long-term use of depot-medroxyprogesterone acetate in patients with cervical dysplasia; case-control analysis nested in a cohort study. The New Zealand Contraception and Health Study Group. Contraception. 1994 Nov;50(5):443-9. PMID: 7859453. ***X-8***

7. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995 Dec 16;346(8990):1582-8. PMID: 7500749. ***X-4***

8. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996 Aug 24;348(9026):505-10. PMID: 8757152. ***X-4***

9. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997 Dec;56(6):341-52. PMID: 9494767. ***X-2, X-4***

10. Premature closure of the fetal ductus arteriosus after maternal use of non-steroidal anti-inflammatory drugs. Adverse Drug Reactions Advisory Committee. Med J Aust. 1998 Sep 7;169(5):270-1. PMID: 9762067. ***X-2***

11. Are adult drugs cool for kids? Diabetes Obes Metab. 2001 Oct;3(5):383. PMID: 11710340. ***X-1***

12. Venous thrombosis with cyproterone. Prescrire Int. 2002 Aug;11(60):116. PMID: 12199266. ***X-1***

13. Coxibs: no better than other NSAIDS. Prescrire Int. 2004 Dec;13(74):226. PMID: 15612145. ***X-1***

14. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk. J Pain Palliat Care Pharmacother. 2005;19(4):83-97. PMID: 16431839. ***X-1***

15. Drug-induced male infertility. Prescrire Int. 2007 Feb;16(87):22. PMID: 17323530. ***X-4, X-6***

16. Drospirenone: high risk of venous thrombosis. Prescrire Int. 2011 Feb;20(113):43-5. PMID: 21488592. ***X-1***

17. Aabakken L, Weberg R, Lygren I, et al.; Gastrointestinal bleeding: dyspeptic symptoms and clinical course in relation to use of non-steroidal antiinflammatory drugs. Scand J Rheumatol. 1991;20(5):366-9. PMID: 1947900. ***X-2***

18. Aabakken L, Weberg R, Lygren I, et al.; Gastrointestinal bleeding associated with the use of non-steroidal, anti-inflammatory drugs--symptomatology and clinical course. Agents Actions. 1992;Spec No:C86-7. PMID: 1442342. ***X-2, X-4***

19. Aalykke C, Lauritsen JM, Hallas J, et al.; Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology. 1999 Jun;116(6):1305-9. PMID: 10348813. ***X-2, X-3, X-4***

20. Aarsand AK, Carlsen SM; Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. J Intern Med. 1998 Aug;244(2):169-74. PMID: 10095804. ***X-2, X-3, X-4***

21. Abbasi AA, Kasmikha R, Sotingeanu DG; Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. Endocr Pract. 2000 Nov-Dec;6(6):442-6. PMID: 11155215. ***X-2***

22. Abbasi S, Gerdes JS, Sehdev HM, et al.; Neonatal outcome after exposure to indomethacin in utero: a retrospective case cohort study. Am J Obstet Gynecol. 2003 Sep;189(3):782-5. PMID: 14526313. ***X-2, X-4***

23. Abdala C; Effects of aspirin on distortion product otoacoustic emission suppression in human adults: a comparison with neonatal data. J Acoust Soc Am. 2005 Sep;118(3 Pt 1):1566-75. PMID: 16240817. ***X-4***

24. Abid S, Mumtaz K, Jafri W, et al.; Pill-induced esophageal injury: endoscopic features and clinical

outcomes. Endoscopy. 2005 Aug;37(8):740-4. PMID: 16032493. ***X-2***

25. Abraham NS, Castillo DL, Hartman C; National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2008 Jul;28(1):97-106. PMID: 18397385. ***X-4, X-7***

26. Abraham NS, Cohen DC, Rivers B, et al.; Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription. Aliment Pharmacol Ther. 2006 Jul 15;24(2):299-306. PMID: 16842456. ***X-2, X-3, X-4***

27. Abraham NS, Hartman C, Hasche J; Reduced hospitalization cost for upper gastrointestinal events that occur among elderly veterans who are gastroprotected. Clin Gastroenterol Hepatol. 2010 Apr;8(4):350-6; quiz e45. PMID: 20096378. ***X-4, X-7***

28. Abraham S, Luscombe G, Soo I; Oral contraception and cyclic changes in premenstrual and menstrual experiences. J Psychosom Obstet Gynaecol. 2003 Sep;24(3):185-93. PMID: 14584305. ***X-2, X-3, X-4***

29. Abramov Y, Borik S, Yahalom C, et al.; Does postmenopausal hormone replacement therapy affect intraocular pressure? J Glaucoma. 2005 Aug;14(4):271-5. PMID: 15990606. ***X-2, X-4***

30. Abs R, Verhelst J, Maiter D, et al.; Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998 Feb;83(2):374-8. PMID: 9467544. ***X-2***

31. Acharya M, Dunning J; Does the use of non-steroidal anti-inflammatory drugs after cardiac surgery increase the risk of renal failure? Interact Cardiovasc Thorac Surg. 2010 Oct;11(4):461-7. PMID: 20639308. ***X-2, X-4***

32. Achkar JP, Al-Haddad M, Lashner B, et al.; Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol. 2005 Jan;3(1):60-6. PMID: 15645406. ***X-2, X-3***

33. Adams HP, Jr., Nibbelink DW, Torner JC, et al.; Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study. Arch Neurol. 1981 Jan;38(1):25-9. PMID: 7458720. ***X-2, X-3, X-4***

34. Adeyemi AS, Adekanle DA; Progestogen-only injectable contraceptive: experience of women in Osogbo, southwestern Nigeria. Ann Afr Med. 2012 Jan-Mar;11(1):27-31. PMID: 22199044. ***X-2***

35. Adhiyaman V, Asghar M, Oke A, et al.; Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med. 2001 Oct;94(10):512-4. PMID: 11581344. ***X-2***

36. Affandi B, Santoso SS, Djajadilaga, et al.; Five-year experience with Norplant. Contraception. 1987 Oct;36(4):417-28. PMID: 3127111. ***X-2, X-3, X-4***

37. Agrawal A, Gerson CR, Seligman I, et al.; Postoperative hemorrhage after tonsillectomy: use of ketorolac tromethamine. Otolaryngol Head Neck Surg. 1999 Mar;120(3):335-9. PMID: 10064634. ***X-2, X-4***

38. Agrawal NM, Patel R, Mahatma M, et al.; Nonsteroidal anti-inflammatory drugs and acute upper gastrointestinal bleeding: a prospective study. J Assoc Acad Minor Phys. 1991;2(2):64-6. PMID: 1810582. ***X-2***

39. Agrawal NM, Roth S, Graham DY, et al.; Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med. 1991 Aug 1;115(3):195-200. PMID: 1905501. ***X-2, X-3, X-4***

40. Aguas M, Pons M, Barrera N, et al.; Prevention of non-steroidal antiinflammatory drugs-induced gastropathy: follow up of protocol adherence. Rev Esp Enferm Dig. 2002 Nov;94(11):679-86. PMID: 12690991. ***X-2***

41. Aguilar C, Reza A, Garcia JE, et al.; Biguanide related lactic acidosis: incidence and risk factors. Arch Med Res. 1992 Spring;23(1):19-24. PMID: 1308787. ***X-2, X-4***

42. Ahmed YI, Azeem S, Khan O, et al.; Stevens Johnson syndrome in Pakistan: a ten-year survey. J Pak Med Assoc. 2004 Jun;54(6):312-5. PMID: 15366796. ***X-2, X-4***

43. Ahsberg K, Hoglund P, Kim WH, et al.; Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol. 2010 Dec;45(12):1404-15. PMID: 20695720. ***X-2, X-4***

44. Ahsberg K, Hoglund P, Stael von Holstein C; Mortality from peptic ulcer bleeding: the impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther. 2010 Sep;32(6):801-10. PMID: 20653635. ***X-2, X-4***

45. AinMelk Y; Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil Steril. 1996 Dec;66(6):962-8. PMID: 8941062. ***X-2, X-4***

46. Aisien AO; Intrauterine contraceptive device (IUCD): acceptability and effectiveness in a tertiary institution. Afr J Med Med Sci. 2007 Sep;36(3):193-200. PMID: 18390056. ***X-4***

47. Aisien AO, Enosolease ME; Haemostatic function in Norplant (levonorgestrel) users: a 3-year prospective experience in Benin-City, Nigeria. Niger Postgrad Med J. 2009 Jun;16(2):126-31. PMID: 19606192. ***X-2***

48. Aisien AO, Enosolease ME, Shobowale MO; Evaluation of haemostatic function in Nigerian Norplant acceptors after 12 months of use. J Obstet Gynaecol. 2005 May;25(4):377-81. PMID: 16091325. ***X-2, X-3, X-4***

49. Aisien AO, Sagay AS, Imade GE, et al.; Changes in menstrual and haematological indices among Norplant acceptors. Contraception. 2000 Apr;61(4):283-6. PMID: 10899486. ***X-4***

50. Aithal PG, Day CP; The natural history of histologically proved drug induced liver disease. Gut. 1999 May;44(5):731-5. PMID: 10205214. ***X-2, X-3, X-4***

51. Aizen E, Kagan G, Assy B, et al.; Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia. Isr Med Assoc J. 2005 Feb;7(2):78-81. PMID: 15729955. ***X-2, X-3, X-4***

52. Akhtar AJ, Shaheen M; Upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs in African-American and Hispanic elderly patients. Ethn Dis. 2003 Fall;13(4):528-33. PMID: 14632273. ***X-2***

53. Akhtar AJ, Shaheen MA; For the patient. Treating pain without causing complications. Ethn Dis. 2003 Fall;13(4):550. PMID: 14632282. ***X-1***

54. Akima S, Kent A, Reynolds GJ, et al.; Indomethacin and renal impairment in neonates. Pediatr Nephrol. 2004 May;19(5):490-3. PMID: 15007713. ***X-4***

55. Akre K, Ekstrom AM, Signorello LB, et al.; Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer. 2001 Apr 6;84(7):965-8. PMID: 11286478. ***X-4***

56. Akyol-Salman I, Lece-Sertoz D, Baykal O; Topical pranoprofen 0.1% is as effective anti-inflammatory and analgesic agent as diclofenac sodium 0.1% after strabismus surgery. J Ocul Pharmacol Ther. 2007 Jun;23(3):280-3. PMID: 17593012. ***X-2, X-3, X-4***

57. al-Alaiyan S, Seshia MM, Casiro OG; Neurodevelopmental outcome of infants exposed to indomethacin antenatally. J Perinat Med. 1996;24(4):405-11. PMID: 8880639. ***X-2, X-4***

58. Alam S, Purdie DM, Johnson AG; Evaluation of the potential interaction between NaCl and prostaglandin inhibition in elderly individuals with isolated systolic hypertension. J Hypertens. 1999 Aug;17(8):1195-202. PMID: 10466476. ***X-2, X-3, X-4***

59. Al-Amro SA, Al-Kharfi TM, Thabit AA, et al.; Risk factors for acute retinopathy of prematurity. Ann Ophthalmol (Skokie). 2007 Spring;39(2):107-11. PMID: 17984498. ***X-2, X-4***

60. al-Assi MT, Genta RM, Karttunen TJ, et al.; Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use. Endoscopy. 1996 Feb;28(2):229-33. PMID: 8739738. ***X-2***

61. Al-Azzam SI, AlMahasneh F, Mhaidat N, et al.; Prophylactic use of aspirin does not induce anaemia among adults. J Clin Pharm Ther. 2010 Aug;35(4):415-9. PMID: 20853549. ***X-4***

62. Albengres E; Features of the French postmarketing drug surveillance system. Application to cutaneous effects of nonsteroidal antiinflammatory drugs. J Rheumatol Suppl. 1988 Oct;17:20-3. PMID: 3204616. ***X-1, X-2, X-3, X-4***

63. Albu S, Tomescu E, Mexca Z, et al.; Recurrence rates in endonasal surgery for polyposis. Acta Otorhinolaryngol Belg. 2004;58(1):79-86. PMID: 15517841. ***X-2***

64. Aldoori WH, Giovannucci EL, Rimm EB, et al.; Use of acetaminophen and nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic diverticular disease in men. Arch Fam Med. 1998 May-Jun;7(3):255-60. PMID: 9596460. ***X-6***

65. Aldrete JA; Epidural injections of indomethacin for postlaminectomy syndrome: a preliminary report. Anesth Analg. 2003 Feb;96(2):463-8, table of contents. PMID: 12538197. ***X-2, X-4***

66. Aldrink JH, Ma M, Wang W, et al.; Safety of ketorolac in surgical neonates and infants 0 to 3 months old. J Pediatr Surg. 2011 Jun;46(6):1081-5. PMID: 21683202. ***X-2, X-4***

67. Alexandersen P, Byrjalsen I, Christiansen C; Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. BJOG. 2000 Mar;107(3):356-64. PMID: 10740332. ***X-2, X-4***

68. Alexandersen P, Haarbo J, Christiansen C; Impact of combined hormone replacement therapy on serum lipid metabolism: new aspects. Gynecol Endocrinol. 1997 Aug;11(4):281-8. PMID: 9272426. ***X-2, X-4***

69. Alexandersen P, Riis BJ, Christiansen C; Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab. 1999 Sep;84(9):3013-20. PMID: 10487657. ***X-2, X-3, X-4***

70. Alexopoulou A, Dourakis SP, Mantzoukis D, et al.; Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med. 2008 Nov;19(7):505-10. PMID: 19013378. ***X-2***

71. Aljadhey H, Tu W, Hansen RA, et al.; Risk of hyperkalemia associated with selective COX-2 inhibitors.

Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1194-8. PMID: 20842761. ***X-2, X-4***

72. Allen B, Edwards IR; A safety profile of controlled release naproxen tablets. N Z Med J. 1989 Jun 28;102(870):310-2. PMID: 2662065. ***X-2, X-4***

73. Allen LaPointe NM, Kramer JM, DeLong ER, et al.; Patient-reported frequency of taking aspirin in a population with coronary artery disease. Am J Cardiol. 2002 May 1;89(9):1042-6. PMID: 11988192. ***X-3, X-4***

74. Allonen H, Luukkainen T, Nielsen NC, et al.; Factors affecting the clinical performance of Nova T and Copper T 200. Obstet Gynecol. 1984 Oct;64(4):524-9. PMID: 6384847. ***X-3, X-4***

75. Allred J, Wong W, Kafetz K; Elderly people taking non-steroidal anti-inflammatory drugs are unlikely to have excess renal impairment. Postgrad Med J. 1989 Oct;65(768):735-7. PMID: 2616399. ***X-2, X-4***

76. al-Momen AK, al-Meshari A, al-Nuaim L, et al.; Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996 Nov;69(2):121-4. PMID: 8902444. ***X-2, X-4***

77. Alobid I, Benitez P, Bernal-Sprekelsen M, et al.; The impact of asthma and aspirin sensitivity on quality of life of patients with nasal polyposis. Qual Life Res. 2005 Apr;14(3):789-93. PMID: 16022071. ***X-2, X-3, X-4***

78. Alsheikh-Ali AA, Abourjaily HM, Karas RH; Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol. 2002 Jun 1;89(11):1308-10. PMID: 12031736. ***X-4***

79. Alvares JF, Kulkarni SG, Bhatia SJ, et al.; Prospective evaluation of medication-induced esophageal injury and its relation to esophageal function. Indian J Gastroenterol. 1999 Jul-Sep;18(3):115-7. PMID: 10407565. ***X-2, X-4***

80. Alvarez C, Marti-Bonmati L, Novella-Maestre E, et al.; Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007 Aug;92(8):2931-7. PMID: 17456571. ***X-2***

81. Alvarez F, Brache V, Tejada AS, et al.; Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants. Contraception. 1998 Oct;58(4):211-4. PMID: 9866001. ***X-2, X-3, X-4***

82. Alvarez-Sanchez F, Brache V, Thevenin F, et al.; Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol. 1996 Mar;174(3):919-22. PMID: 8633669. ***X-2, X-3, X-4***

83. Amar YG, Frenkiel S, Sobol SE; Outcome analysis of endoscopic sinus surgery for chronic sinusitis in patients having Samter's triad. J Otolaryngol. 2000 Feb;29(1):7-12. PMID: 10709165. ***X-2, X-3, X-4***

84. Ambegaonkar A, Livengood K, Craig T, et al.; Predicting the risk for gastrointestinal toxicity in patients taking NSAIDs: the Gastrointestinal Toxicity Survey. Adv Ther. 2004 Sep-Oct;21(5):288-300. PMID: 15727398. ***X-2***

85. Amin SB, Kamaluddeen M, Sangem M; Neurodevelopmental outcome of premature infants after exposure to antenatal indomethacin. Am J Obstet Gynecol. 2008 Jul;199(1):41 e1-8. PMID: 18455131. ***X-2, X-4***

86. Andersch B, Milsom I, Rybo G; An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand. 1988;67(7):645-8. PMID: 3073625. ***X-2***

87. Andersen H, Jacobsen BB, Kastrup KW, et al.; Treatment of girls with excessive height prediction. Follow-up of forty girls treated with intramuscular estradiol and progesterone. Acta Paediatr Scand. 1980 May;69(3):293-7. PMID: 7376855. ***X-2, X-3, X-4***

88. Andersen V, Ostergaard M, Christensen J, et al.; Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:407. PMID: 19930591. ***X-2, X-3***

89. Andersohn F, Schade R, Suissa S, et al.; Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke. 2006 Jul;37(7):1725-30. PMID: 16728684. ***X-4***

90. Andersohn F, Suissa S, Garbe E; Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 2006 Apr 25;113(16):1950-7. PMID: 16618816. ***X-4***

91. Anderson GL, Chlebowski RT, Rossouw JE, et al.; Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006 Sep 20;55(2):103-15. PMID: 16815651. ***X-7***

92. Anderson M, Bedi SS, Boston PF, et al.; A long-term study of flurbiprofen sustained-release. Br J Clin Pract. 1988 Jan;42(1 Suppl):15-8. PMID: 3196643. ***X-2***

93. Andersson K, Batar I, Rybo G; Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception. 1992 Dec;46(6):575-84. PMID: 1493717. ***X-2, X-4***

94. Andolsek KM, Burkman RT, Jr., Kafrissen ME, et al.; Metabolic effects and efficacy of a triphasic oral

contraceptive (norgestimate/ethinyl estradiol). Int J Fertil Menopausal Stud. 1993;38 Suppl 3:122-5. PMID: 8260970. ***X-11***

95. Andolsek L, Kovacic J, Kozuh M, et al.; Influence of oral contraceptives on the incidence of premalignant and malignant lesions of the cervix. Contraception. 1983 Dec;28(6):505-19. PMID: 6673904. ***X-4***

96. Andrade P, Brinca A, Goncalo M; Patch testing in fixed drug eruptions--a 20-year review. Contact Dermatitis. 2011 Oct;65(4):195-201. PMID: 21702758. ***X-2***

97. Andriessen P, Struis NC, Niemarkt H, et al.; Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus. Acta Paediatr. 2009 May;98(5):797-803. PMID: 19187396. ***X-2, X-3, X-4***

98. Anker SD, Comin Colet J, Filippatos G, et al.; Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009 Dec 17;361(25):2436-48. PMID: 19920054. ***X-2, X-3, X-4***

99. Anstee P, Kovacs GT; A prospective randomized study comparing the clinical effects of a norethisterone and a levonorgestrel containing low dose oestrogen oral contraceptive pills. Aust N Z J Obstet Gynaecol. 1993 Feb;33(1):81-3. PMID: 8498949. ***X-2***

100. Anthuber S, Schramm GA, Heskamp ML; Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Investig. 2010;30(4):211-20. PMID: 20225905. ***X-4***

101. Antonucci R, Cuzzolin L, Arceri A, et al.; Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur J Clin Pharmacol. 2009 Mar;65(3):223-30. PMID: 19048246. ***X-2, X-4***

102. Anwar M; An evaluation of IUD insertion by a non-clinical delivery system. Adv Contracept. 1992 Dec;8(4):303-12. PMID: 1290332. ***X-2***

103. Araujo E, Jr., Bernardini L, Frederick JL, et al.; Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction. J Assist Reprod Genet. 1994 Feb;11(2):74-8. PMID: 7819706. ***X-2, X-4***

104. Arboleya LR, de la Figuera E, Soledad Garcia M, et al.; Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. Curr Med Res Opin. 2003;19(4):288-97. PMID: 12841921. ***X-2, X-3, X-4***

105. Archer DF, Dorin M, Lewis V, et al.; Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001 Jun;75(6):1080-7. PMID: 11384630. ***X-7***

106. Archer DF, Dorin MH, Heine W, et al.; Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol. 1999 Sep;94(3):323-9. PMID: 10472853. ***X-2, X-4***

107. Archer DF, Furst K, Tipping D, et al.; A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol. 1999 Oct;94(4):498-503. PMID: 10511348. ***X-2, X-4***

108. Archer DF, Philput CA, Weber ME; Management of irregular uterine bleeding and spotting associated with Norplant. Hum Reprod. 1996 Oct;11 Suppl 2:24-30. PMID: 8982742. ***X-2, X-4***

109. Archer DF, Pickar JH; Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol. 2000 Dec;96(6):899-905. PMID: 11084175. ***X-4, X-7***

110. Archer DF, Pickar JH, Bottiglioni F; Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol. 1994 May;83(5 Pt 1):686-92. PMID: 8164926. ***X-7***

111. Archimandritis A, Tzivras M, Sougioultzis S, et al.; Rapid urease test is less sensitive than histology in diagnosing Helicobacter pylori infection in patients with non-variceal upper gastrointestinal bleeding. J Gastroenterol Hepatol. 2000 Apr;15(4):369-73. PMID: 10824879. ***X-2, X-3, X-4***

112. Ardizzone S, Maconi G, Russo A, et al.; Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006 Jan;55(1):47-53. PMID: 15972298. ***X-2, X-3, X-4***

113. Arellano FM, Yood MU, Wentworth CE, et al.; Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):861-72. PMID: 17086563. ***X-4***

114. Argina H, Lukman HY; Norplant implants in Ethiopia. East Afr Med J. 1997 Apr;74(4):258-62. PMID: 9299831. ***X-2, X-3, X-4***

115. Armero C, Garcia-Donato G, Lopez-Quilez A; Bayesian methods in cost-effectiveness studies: objectivity, computation and other relevant aspects. Health Econ. 2010 Jun;19(6):629-43. PMID: 19424994. ***X-1, X-2***

116. Armstrong D, Arnold R, Classen M, et al.; Prospective multicentre study of risk factors associated

with delayed healing of recurrent duodenal ulcers (RUDER). RUDER Study Group. Gut. 1993 Oct;34(10):1319-26. PMID: 8244095. ***X-4***

117. Armstrong D, Blum AL, Arnold R, et al.; RUDER: interim evaluation of a 2-year, multicentre study of risk factors for duodenal ulcer relapse. Z Gastroenterol Verh. 1991 Mar;26:171-2. PMID: 1714137. ***X-4***

118. Arnolds S, Dellweg S, Clair J, et al.; Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010 Jul;33(7):1509-15. PMID: 20357372. ***X-2, X-3, X-4***

119. Arowojolu AO, Ladipo OA; Nonmenstrual adverse events associated with subdermal contraceptive implants containing normegestrel and levonorgestrel. Afr J Med Med Sci. 2003 Mar;32(1):27-31. PMID: 15030062. ***X-2, X-4***

120. Arowojolu AO, Okewole IA; Vaginal bleeding following the use of a single dose of 1.5mg levonorgestrel (LNG) for emergency contraception. West Afr J Med. 2004 Jul-Sep;23(3):191-3. PMID: 15587826. ***X-2, X-3, X-4***

121. Arowojolu AO, Otolorin EO, Ladipo OA; Serum copper levels in users of multiload intra-uterine contraceptive devices. Afr J Med Med Sci. 1989 Dec;18(4):295-9. PMID: 2558561. ***X-2, X-4***

122. Arowojolu AO, Otolorin EO, Ladipo OA; Performances of copper T 380A and multiload copper 375/250 intrauterine contraceptive devices in a comparative clinical trial. Afr J Med Med Sci. 1995 Mar;24(1):59-65. PMID: 7495202. ***X-3, X-4***

123. Arvanitakis Z, Grodstein F, Bienias JL, et al.; Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology. 2008 Jun 3;70(23):2219-25. PMID: 18519870. ***X-2, X-4***

124. Asche CV, McAdam-Marx C, Shane-McWhorter L, et al.; Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Drugs Aging. 2008;25(7):611-22. PMID: 18582148. ***X-7***

125. Ashorn M, Verronen P, Ruuska T, et al.; Upper endoscopic findings in children with active juvenile chronic arthritis. Acta Paediatr. 2003 May;92(5):558-61. PMID: 12839284. ***X-2***

126. Ashworth NL, Peloso PM, Muhajarine N, et al.; A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen. J Rheumatol. 2004 May;31(5):951-6. PMID: 15124256. ***X-4***

127. Ashworth NL, Peloso PM, Muhajarine N, et al.; Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. J Rheumatol. 2005 Nov;32(11):2212-7. PMID: 16265705. ***X-4***

128. Aslam N, Blunt S, Latthe P; Effectiveness and tolerability of levonorgestrel intrauterine system in adolescents. J Obstet Gynaecol. 2010;30(5):489-91. PMID: 20604653. ***X-2, X-4***

129. Asscheman H, Giltay EJ, Megens JA, et al.; A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011 Apr;164(4):635-42. PMID: 21266549. ***X-2***

130. Attanasio R, Baldelli R, Pivonello R, et al.; Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab. 2003 Nov;88(11):5258-65. PMID: 14602759. ***X-2, X-3, X-4***

131. Atteritano M, Marini H, Minutoli L, et al.; Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007 Aug;92(8):3068-75. PMID: 17682090. ***X-2, X-3, X-4***

132. Attridge JT, Clark R, Gordon PV; New insights into spontaneous intestinal perforation using a national data set (3): antenatal steroids have no adverse association with spontaneous intestinal perforation. J Perinatol. 2006 Nov;26(11):667-70. PMID: 17024144. ***X-2, X-4***

133. Attridge JT, Clark R, Walker MW, et al.; New insights into spontaneous intestinal perforation using a national data set: (2) two populations of patients with perforations. J Perinatol. 2006 Mar;26(3):185-8. PMID: 16493433. ***X-2, X-3, X-4***

134. Aun MV, Bisaccioni C, Garro LS, et al.; Outcomes and safety of drug provocation tests. Allergy Asthma Proc. 2011 Jul-Aug;32(4):301-6. PMID: 21781406. ***X-2, X-4***

135. Avidan B, Sonnenberg A, Schnell TG, et al.; Risk factors of oesophagitis in arthritic patients. Eur J Gastroenterol Hepatol. 2001 Sep;13(9):1095-9. PMID: 11564962. ***X-2***

136. Avidan B, Sonnenberg A, Schnell TG, et al.; Risk factors for erosive reflux esophagitis: a case-control study. Am J Gastroenterol. 2001 Jan;96(1):41-6. PMID: 11197285. ***X-4***

137. Awad JN, Kebaish KM, Donigan J, et al.; Analysis of the risk factors for the development of post-operative spinal epidural haematoma. J Bone Joint Surg Br. 2005 Sep;87(9):1248-52. PMID: 16129751. ***X-3, X-4***

138. Awad OG, Fasano MB, Lee JH, et al.; Asthma outcomes after endoscopic sinus surgery in aspirin-tolerant versus aspirin-induced asthmatic patients. Am J Rhinol. 2008 Mar-Apr;22(2):197-203. PMID: 18416980. ***X-2, X-3, X-4***

139. Axelrod D, Preston S; Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum. 1988 Jun;31(6):803-5. PMID: 2454635. ***X-2, X-3, X-4***

140. Aydinli B, Yilmaz O, Ozturk G, et al.; Is perforated marginal ulcer after the surgery of gastroduodenal ulcer associated with inadequate treatment for Helicobacter pylori eradication? Langenbecks Arch Surg. 2007 Sep;392(5):593-9. PMID: 17370084. ***X-2***

141. Ayral X, Mackillop N, Genant HK, et al.; Arthroscopic evaluation of potential structure-modifying drug in osteoarthritis of the knee. A multicenter, randomized, double-blind comparison of tenidap sodium vs piroxicam. Osteoarthritis Cartilage. 2003 Mar;11(3):198-207. PMID: 12623291. ***X-2, X-3, X-4***

142. Azoulay L, Schneider-Lindner V, Dell'aniello S, et al.; Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010 Apr;19(4):335-42. PMID: 20052677. ***X-8***

143. Azuma A, Nukiwa T, Tsuboi E, et al.; Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7. PMID: 15665326. ***X-2, X-4***

144. Ba MG, Moreau JC, Sokal D, et al.; A 5-year clinical evaluation of Norplant implants in Senegal. Contraception. 1999 Jun;59(6):377-81. PMID: 10518232. ***X-2, X-4***

145. Backstrom M, Hagg S, Mjorndal T, et al.; Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf. 2002 Apr-May;11(3):239-45. PMID: 12051124. ***X-4***

146. Bacq Y, Sapey T, Brechot MC, et al.; Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology. 1997 Aug;26(2):358-64. PMID: 9252146. ***X-2***

147. Bae SC, Corzillius M, Kuntz KM, et al.; Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford). 2003 Jan;42(1):46-53. PMID: 12509612. ***X-4***

148. Baenkler HW; Functional-eicosanoid-test (FET) and disease. J Physiol Pharmacol. 2006 Dec;57 Suppl 12:65-72. PMID: 17244955. ***X-2, X-3, X-4***

149. Baenziger O, Waldvogel K, Ghelfi D, et al.; Can dopamine prevent the renal side effects of indomethacin? A prospective randomized clinical study. Klin Padiatr. 1999 Nov-Dec;211(6):438-41. PMID: 10592922. ***X-2, X-3, X-4***

150. Baeten JM, Nyange PM, Richardson BA, et al.; Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol. 2001 Aug;185(2):380-5. PMID: 11518896. ***X-2***

151. Baeyertz JD, Hartfield VJ; The Nova-T 200 intrauterine contraceptive device: a 12 year study. N Z Med J. 1997 May 9;110(1043):169-71. PMID: 9196502. ***X-2, X-4***

152. Bagshaw SN, Edwards D, Tucker AK; Ethinyl oestradiol and D-norgestrel is an effective emergency postcoital contraceptive: a report of its use in 1,200 patients in a family planning clinic. Aust N Z J Obstet Gynaecol. 1988 May;28(2):137-40. PMID: 3228408. ***X-2, X-3, X-4***

153. Bahamondes L, Hidalgo M, Petta CA, et al.; Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant. J Reprod Med. 2003 Aug;48(8):637-40. PMID: 12971147. ***X-2***

154. Bahamondes MV, Monteiro I, Canteiro R, et al.; Length of the endometrial cavity and intrauterine contraceptive device expulsion. Int J Gynaecol Obstet. 2011 Apr;113(1):50-3. PMID: 21272883. ***X-2***

155. Bahamondes MV, Monteiro I, Castro S, et al.; Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod. 2010 May;25(5):1158-64. PMID: 20185512. ***X-2***

156. Bahrami H, Daryani NE, Haghpanah B, et al.; Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005 Apr;100(4):856-61. PMID: 15784032. ***X-2, X-3, X-4***

157. Bailey R, Sinha C, Burgess LP; Ketorolac tromethamine and hemorrhage in tonsillectomy: a prospective, randomized, double-blind study. Laryngoscope. 1997 Feb;107(2):166-9. PMID: 9023238. ***X-2, X-4***

158. Bailie R, Katzenellenbogen J, Hoffman M, et al.; A case control study of breast cancer risk and exposure to injectable progestogen contraceptives. Methods and patterns of use among controls. S Afr Med J. 1997 Mar;87(3):302-5. PMID: 9137342. ***X-2, X-4***

159. Baiza-Duran LM, Quintana-Hau J, Tornero-Montano R, et al.; Comparison of the efficacy and safety of a novel meloxicam ophthalmic formulation with a reference diclofenac solution in cataract surgery. Int J Clin Pharmacol Ther. 2009 Feb;47(2):89-95. PMID: 19203564. ***X-4***

160. Bak S, Andersen M, Tsiropoulos I, et al.; Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study. Stroke. 2003 Feb;34(2):379-86. PMID: 12574546. ***X-4***

161. Bakhru A, Stanwood N; Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population. Obstet Gynecol. 2006 Aug;108(2):378-86. PMID: 16880309. ***X-2, X-3, X-4***

162. Bakke OM, Manocchia M, de Abajo F, et al.; Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995 Jul;58(1):108-17. PMID: 7628177. ***X-1, X-2, X-3, X-4***

163. Bakowsky VS, Hanly JG; Complications of nonsteroidal antiiflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center. J Rheumatol. 1999 Jul;26(7):1557-63. PMID: 10405945. ***X-2***

164. Balali-Mood M, Critchley JA, Proudfoot AT, et al.; Mefenamic acid overdosage. Lancet. 1981 Jun 20;1(8234):1354-6. PMID: 6113321. ***X-2, X-4***

165. Baldaszti E, Wimmer-Puchinger B, Loschke K; Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception. 2003 Feb;67(2):87-91. PMID: 12586318. ***X-2, X-3, X-4***

166. Balle C, Schollmeyer P; Morbidity of patients with analgesic-associated nephropathy on regular dialysis treatment and after renal transplantation. Klin Wochenschr. 1990 Jan 4;68(1):38-42. PMID: 2106598. ***X-2, X-4***

167. Balogh A; Clinical and endocrine effects of long-term hormonal contraception. Acta Med Hung. 1986;43(2):97-102. PMID: 3588164. ***X-2, X-4***

168. Balogun OR, Raji HO; Clinical experience with injectable progestogen- only contraceptives at University of Ilorin teaching hospital: a five year review. Niger Postgrad Med J. 2009 Dec;16(4):260-3. PMID: 20037621. ***X-2, X-3, X-4***

169. Banerji MA, Purkayastha D, Francis BH; Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res Clin Pract. 2010 Nov;90(2):182-90. PMID: 20655609. ***X-8***

170. Banhidy F, Acs N, Puho E, et al.; A population-based case-control teratologic study of oral dipyrone treatment during pregnancy. Drug Saf. 2007;30(1):59-70. PMID: 17194171. ***X-4***

171. Bank S, Greenberg RE, Magier D, et al.; The efficacy and tolerability of famotidine and ranitidine on the healing of active duodenal ulcer and during six-month maintenance treatment, with special reference to NSAID/aspirin-related ulcers. Clin Ther. 1991 Mar-Apr;13(2):304-18. PMID: 1863945. ***X-2, X-3, X-4***

172. Bannwarth B, Dorval E, Caekaert A, et al.; Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole. J Rheumatol. 2002 Sep;29(9):1975-80. PMID: 12233895. ***X-2, X-3, X-4***

173. Baraldi A, Ballestri M, Rapana R, et al.; Acute renal failure of medical type in an elderly population. Nephrol Dial Transplant. 1998;13 Suppl 7:25-9. PMID: 9870433. ***X-2***

174. Barbosa IC, Filho CI, Faggion D, Jr., et al.; Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse). Contraception. 2006 Jan;73(1):30-3. PMID: 16371291. ***X-2, X-4***

175. Bardia A, Olson JE, Vachon CM, et al.; Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011 Feb;126(1):149-55. PMID: 20669045. ***X-4, X-7***

176. Barkin JS, Ross BS; Medical therapy for chronic gastrointestinal bleeding of obscure origin. Am J Gastroenterol. 1998 Aug;93(8):1250-4. PMID: 9707046. ***X-2, X-4***

177. Barletta GM, Smoyer WE, Bunchman TE, et al.; Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol. 2003 Aug;18(8):833-7. PMID: 12774223. ***X-2, X-4***

178. Barnabei VM, Cochrane BB, Aragaki AK, et al.; Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73. PMID: 15863546. ***X-4, X-7***

179. Barnard L, Lavoie D, Lajeunesse N; Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern. Drug Saf. 2006;29(7):613-20. PMID: 16808553. ***X-4***

180. Barnum JL, Sistino JJ; Renal dysfunction in cardiac surgery: identifying potential risk factors. Perfusion. 2009 Mar;24(2):139-42. PMID: 19654159. ***X-2***

181. Baron JA, Cole BF, Sandler RS, et al.; A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003 Mar 6;348(10):891-9. PMID: 12621133. ***X-2, X-3, X-4***

182. Barreiros FA, Guazzelli CA, Barbosa R, et al.; Extended regimens of the contraceptive vaginal ring:

evaluation of clinical aspects. Contraception. 2010 Mar;81(3):223-5. PMID: 20159178. ***X-2, X-4***

183. Bartle WR, Gupta AK, Lazor J; Nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding. A case-control study. Arch Intern Med. 1986 Dec;146(12):2365-7. PMID: 3490836. ***X-2, X-4***

184. Bas M, Greve J, Stelter K, et al.; Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med. 2010 Sep;56(3):278-82. PMID: 20447725. ***X-2, X-3, X-4***

185. Basnayake S, Higgins JE, Miller PC, et al.; Early symptoms and discontinuation among users of oral contraceptives in Sri Lanka. Stud Fam Plann. 1984 Nov-Dec;15(6 Pt 1):285-90. PMID: 6393460. ***X-2***

186. Bassol S, Alvarado G, Arreola RG, et al.; A 13-month multicenter clinical experience of a low-dose monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene in Latin American women. Contraception. 2003 May;67(5):367-72. PMID: 12742559. ***X-2, X-4***

187. Bassol S, Carranza-Lira S, Celis-Gonzalez C, et al.; The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women. Maturitas. 2005 Mar 14;50(3):189-95. PMID: 15734600. ***X-2***

188. Bastuji-Garin S, Zahedi M, Guillaume JC, et al.; Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients. Age Ageing. 1993 Nov;22(6):450-6. PMID: 8310891. ***X-2, X-7***

189. Batar I; One-year clinical experience with FlexiGard. Contraception. 1992 Oct;46(4):307-12. PMID: 1486769. ***X-2, X-3, X-4***

190. Batar I, Lampe LG, Allonen H; Clinical experience with intrauterine contraceptive devices (IUDs) inserted with and without tail. Acta Chir Hung. 1988;29(4):385-93. PMID: 3239338. ***X-2, X-4***

191. Batar I, Lampe LG, Allonen H; Clinical experiences with intrauterine devices inserted with and without tail. Int J Gynaecol Obstet. 1991 Oct;36(2):137-40. PMID: 1683316. ***X-4***

192. Battaglia C, Cianciosi A, Mancini F, et al.; Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study. Menopause. 2009 Jul-Aug;16(4):803-9. PMID: 19194341. ***X-2***

193. Battino S, Ben-Ami M, Geslevich Y, et al.; Factors associated with withdrawal bleeding after administration of oral dydrogesterone or medroxyprogesterone acetate in women with secondary amenorrhea. Gynecol Obstet Invest. 1996;42(2):113-6. PMID: 8878716. ***X-2, X-3, X-4***

194. Battistella M, Mamdami MM, Juurlink DN, et al.; Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005 Jan 24;165(2):189-92. PMID: 15668365. ***X-4***

195. Baudouin C, Nordmann JP, Denis P, et al.; Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch Clin Exp Ophthalmol. 2002 Nov;240(11):929-35. PMID: 12486516. ***X-2, X-4***

196. Baughman RP, Lower EE; Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Mar;21(1):43-8. PMID: 15127974. ***X-2, X-4***

197. Baumelou E, Guiguet M, Mary JY; Epidemiology of aplastic anemia in France: a case-control study. I. Medical history and medication use. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood. 1993 Mar 15;81(6):1471-8. PMID: 8453094. ***X-2, X-4***

198. Baur DM, Klotsche J, Hamnvik OP, et al.; Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 2011 Oct;60(10):1363-71. PMID: 21081242. ***X-2, X-4***

199. Bavry AA, Khaliq A, Gong Y, et al.; Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med. 2011 Jul;124(7):614-20. PMID: 21596367. ***X-4***

200. Bayan K, Tuzun Y, Yilmaz S, et al.; Clarifying the relationship between ABO/Rhesus blood group antigens and upper gastrointestinal bleeding. Dig Dis Sci. 2009 May;54(5):1029-34. PMID: 18716867. ***X-2, X-3, X-4***

201. Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al.; Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011 Feb;95(2):492-6. PMID: 20883991. ***X-2, X-3***

202. Beardon PH, Brown SV, McDevitt DG; Gastrointestinal events in patients prescribed non-steroidal anti-inflammatory drugs: a controlled study using record linkage in Tayside. Q J Med. 1989 Jun;71(266):497-505. PMID: 2602546. ***X-4***

203. Becker A, Leber A, von Ziegler F, et al.; Comparison of progression of coronary calcium in postmenopausal women on versus not on estrogen/progestin therapy. Am J Cardiol. 2007 Feb 1;99(3):374-8. PMID: 17261401. ***X-2, X-7***

204. Beksinska ME, Kleinschmidt I, Smit JA, et al.; Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception.

Contraception. 2009 Aug;80(2):128-32. PMID: 19631787. ***X-2***

205. Beksinska ME, Smit JA, Kleinschmidt I, et al.; Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception. Contraception. 2010 Jan;81(1):30-4. PMID: 20004270. ***X-2, X-4***

206. Bell D, Marasco S, Almeida A, et al.; Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. Heart Surg Forum. 2010 Aug;13(4):E257-9. PMID: 20719731. ***X-2***

207. Bellary SV, Isaacs PE, Lee FI; Upper gastrointestinal lesions in elderly patients presenting for endoscopy: relevance of NSAID usage. Am J Gastroenterol. 1991 Aug;86(8):961-4. PMID: 1858761. ***X-2***

208. Belsey JD; Non-steroidal anti-inflammatory induced upper gastrointestinal event rates in patients awaiting joint replacement in the United Kingdom. An epidemiologically-based burden of disease model. Curr Med Res Opin. 2003;19(4):306-12. PMID: 12841923. ***X-1, X-4***

209. Benagiano G; Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol. Int J Fertil. 1989 Sep;34 Suppl:31-9. PMID: 2576255. ***X-2, X-4***

210. Benahmed S, Picot MC, Dumas F, et al.; Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions. Arch Intern Med. 2005 Jul 11;165(13):1500-5. PMID: 16009865. ***X-2, X-3, X-4***

211. Benavides S, Striet J, Germak J, et al.; Efficacy and safety of hypoglycemic drugs in children with type 2 diabetes mellitus. Pharmacotherapy. 2005 Jun;25(6):803-9. PMID: 15927898. ***X-2, X-4***

212. Bennett K, Teeling M, Feely J; "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2003 Nov;59(8-9):645-9. PMID: 12942226. ***X-3, X-4***

213. Bensen WG, Zhao SZ, Burke TA, et al.; Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol. 2000 Aug;27(8):1876-83. PMID: 10955327. ***X-4***

214. Berenson AB, Rahman M; Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol. 2009 Mar;200(3):329 e1-8. PMID: 19254592. ***X-2***

215. Berenson AB, Wiemann CM; Use of levonorgestrel implants versus oral contraceptives in adolescence: a case-control study. Am J Obstet Gynecol. 1995 Apr;172(4 Pt 1):1128-35; discussion 35-7. PMID: 7726249. ***X-2, X-4***

216. Berenson AB, Wiemann CM, Rickerr VI, et al.; Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use. Am J Obstet Gynecol. 1997 Mar;176(3):586-92. PMID: 9077611. ***X-2***

217. Bergenstal RM, Garrison LP, Jr., Miller LA, et al.; Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011 Dec;27(12):2335-42. PMID: 22085180. ***X-2***

218. Berger RE; Urinary tract infection in the users of depot-medroxyprogesterone acetate. J Urol. 2005 Sep;174(3):941. PMID: 16093999. ***X-1, X-2***

219. Berges-Gimeno MP, Simon RA, Stevenson DD; The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy. 2002 Oct;32(10):1491-6. PMID: 12372130. ***X-2, X-4***

220. Bergqvist A, Jacobson J, Harris S; A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecol Endocrinol. 1997 Jun;11(3):187-94. PMID: 9209899. ***X-2, X-3, X-4***

221. Berlin JM, Rigel DS; Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008 Jul;7(7):669-73. PMID: 18664159. ***X-2, X-3, X-4***

222. Berman M, Cardone D, Sharples L, et al.; Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients. Ann Thorac Surg. 2010 Nov;90(5):1432-6. PMID: 20971234. ***X-2***

223. Bernard GR, Vincent JL, Laterre PF, et al.; Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8;344(10):699-709. PMID: 11236773. ***X-3, X-4***

224. Bernier MO, Mikaeloff Y, Hudson M, et al.; Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum. 2009 Apr 15;61(4):476-81. PMID: 19333988. ***X-4***

225. Bernstein CN, Singh S, Graff LA, et al.; A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010 Sep;105(9):1994-2002. PMID: 20372115. ***X-2, X-3, X-4***

226. Bertolini S, Elicio N, Cordera R, et al.; Effects of three low-dose oral contraceptive formulations on lipid metabolism. Acta Obstet Gynecol Scand. 1987;66(4):327-32. PMID: 2962417. ***X-2***

227. Bertuola F, Morando C, Menniti-Ippolito F, et al.; Association between drug and vaccine use and acute

immune thrombocytopenia in childhood: a case-control study in Italy. Drug Saf. 2010 Jan 1;33(1):65-72. PMID: 20000868. ***X-4***

228. Beunza JJ, Martinez-Gonzalez MA, Bes-Rastrollo M, et al.; Aspirin, non-aspirin analgesics and the risk of hypertension in the SUN cohort. Rev Esp Cardiol. 2010 Mar;63(3):286-93. PMID: 20196989. ***X-4***

229. Beutler AI, Chesnut GT, Mattingly JC, et al.; FPIN's Clinical Inquiries. Aspirin use in children for fever or viral syndromes. Am Fam Physician. 2009 Dec 15;80(12):1472. PMID: 20000310. ***X-1, X-4***

230. Bhat P, Cervantes-Castaneda RA, Doctor PP, et al.; Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm. 2009 May-Jun;17(3):185-90. PMID: 19585361. ***X-2, X-3, X-4***

231. Bhattacharyya T, Levin R, Vrahas MS, et al.; Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum. 2005 Jun 15;53(3):364-7. PMID: 15934108. ***X-4***

232. Bianchi Porro G, Ardizzone S, Petrillo M, et al.; Endoscopic assessment of the effects of dipyrone (metamizol) in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adult volunteers. Digestion. 1996;57(3):186-90. PMID: 8739093. ***X-2, X-4***

233. Bianchi Porro G, Lazzaroni M, Petrillo M, et al.; Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study. Ital J Gastroenterol Hepatol. 1998 Feb;30(1):43-7. PMID: 9615264. ***X-2, X-3, X-4***

234. Bianchi Porro G, Parente F, Imbesi V, et al.; Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. Gut. 1996 Jul;39(1):22-6. PMID: 8881802. ***X-2, X-4***

235. Bianco MA, Rotondano G, Buri L, et al.; Gastro-protective strategies in primary care in Italy: the "Gas.Pro." survey. Dig Liver Dis. 2010 May;42(5):359-64. PMID: 20005189. ***X-4***

236. Biancone L, Tosti C, Geremia A, et al.; Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther. 2004 Apr 1;19(7):755-64. PMID: 15043516. ***X-2, X-4***

237. Biere-Rafi S, Di Nisio M, Gerdes V, et al.; Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):635-42. PMID: 21462279. ***X-4***

238. Bijol V, Mendez GP, Nose V, et al.; Granulomatous interstitial nephritis: a clinicopathologic study of 46 cases from a single institution. Int J Surg Pathol. 2006 Jan;14(1):57-63. PMID: 16501836. ***X-2, X-3, X-4***

239. Bilker WB, Berlin JA, Gail MH, et al.; An efficient design for verifying disease outcome status in large cohorts with rare exposures and low disease rates. Stat Med. 1999 Nov 30;18(22):3021-36. PMID: 10544304. ***X-1***

240. Biller BM, Molitch ME, Vance ML, et al.; Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996 Jun;81(6):2338-43. PMID: 8964874. ***X-2***

241. Bingham CO, 3rd, Ince A, Haraoui B, et al.; Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr Med Res Opin. 2009 May;25(5):1131-42. PMID: 19317607. ***X-3, X-4***

242. Bingham CO, 3rd, Sebba AI, Rubin BR, et al.; Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford). 2007 Mar;46(3):496-507. PMID: 16936327. ***X-2, X-3, X-4***

243. Birt CM; The use of topical ketorolac 0.5% for pain relief following cyclophotocoagulation. Ophthalmic Surg Lasers Imaging. 2003 Sep-Oct;34(5):381-5. PMID: 14509461. ***X-2, X-3, X-4***

244. Biskupiak JE, Brixner DI, Howard K, et al.; Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother. 2006;20(3):7-14. PMID: 16931473. ***X-4***

245. Bitto A, Granese R, Triolo O, et al.; Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. Phytomedicine. 2010 Sep;17(11):844-50. PMID: 20570122. ***X-2, X-3, X-4***

246. Bivins HA, Jr., Newman RB, Fyfe DA, et al.; Randomized trial of oral indomethacin and terbutaline sulfate for the long-term suppression of preterm labor. Am J Obstet Gynecol. 1993 Oct;169(4):1065-70. PMID: 8238121. ***X-2, X-4***

247. Bjorklund K, Nordstrom ML, Odlind V; Combined oral contraceptives do not increase the risk of back and pelvic pain during pregnancy or after delivery. Acta Obstet Gynecol Scand. 2000 Nov;79(11):979-83. PMID: 11081684. ***X-2***

248. Black C, Kaye JA, Jick H; Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill. Br J Clin Pharmacol. 2002 Jun;53(6):637-40. PMID: 12047488. ***X-4***

249. Blaicher AM, Landsteiner HT, Al-Falaki O, et al.; Acetylsalicylic acid, diclofenac, and lornoxicam, but not rofecoxib, affect platelet CD 62 expression. Anesth Analg. 2004 Apr;98(4):1082-5, table of contents. PMID: 15041603. ***X-2, X-3, X-4***

250. Blanco G, Martinez C, Ladero JM, et al.; Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics. 2008 Jan;18(1):37-43. PMID: 18216720. ***X-2, X-3, X-4***

251. Blix HS, Viktil KK, Moger TA, et al.; Use of renal risk drugs in hospitalized patients with impaired renal function--an underestimated problem? Nephrol Dial Transplant. 2006 Nov;21(11):3164-71. PMID: 16880181. ***X-2, X-3, X-4***

252. Blomqvist P, Feltelius N, Ekbom A, et al.; Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions. J Rheumatol. 2000 May;27(5):1171-7. PMID: 10813283. ***X-4***

253. Blonde L, Dailey GE, Jabbour SA, et al.; Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004 Apr;20(4):565-72. PMID: 15119994. ***X-2, X-4***

254. Blonde L, Klein EJ, Han J, et al.; Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006 Jul;8(4):436-47. PMID: 16776751. ***X-2, X-3, X-4***

255. Bloom BS; Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med. 1988 Feb 22;84(2A):20-4. PMID: 3348239. ***X-3, X-4***

256. Bloom BS; Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1989 May;149(5):1019-22. PMID: 2719496. ***X-4***

257. Blot WJ, Fischer T, Nielsen GL, et al.; Outcome of upper gastro-intestinal bleeding and use of ibuprofen versus paracetamol. Pharm World Sci. 2004 Dec;26(6):319-23. PMID: 15683100. ***X-2, X-4***

258. Blot WJ, McLaughlin JK; Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137-42. PMID: 10890286. ***X-2***

259. Blower AL, Brooks A, Fenn GC, et al.; Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther. 1997 Apr;11(2):283-91. PMID: 9146764. ***X-2, X-4***

260. Bluhm RE, Adedoyin A, McCarver DG, et al.; Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther. 1999 Jun;65(6):598-605. PMID: 10391665. ***X-2, X-4***

261. Blumenfeld Z, Boulman N, Leiba R, et al.; High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand J Clin Lab Invest. 2007;67(3):257-63. PMID: 17454839. ***X-2, X-3***

262. Bobrzynski A, Beben P, Budzynski A, et al.; Incidence of complications of peptic ulcers in patients with Helicobacter pylori (Hp) infection and/or NSAID use in the era of Hp eradication. Med Sci Monit. 2002 Aug;8(8):CR554-7. PMID: 12165741. ***X-4***

263. Bodelon C, Doherty JA, Chen C, et al.; Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol. 2009 Dec 15;170(12):1512-7. PMID: 19897512. ***X-1, X-2, X-4***

264. Bodmer M, Becker C, Meier C, et al.; Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 2011 Nov;123(2):200-4. PMID: 21802715. ***X-4***

265. Bodmer M, Becker C, Meier C, et al.; Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol. 2012 Apr;107(4):620-6. PMID: 22290402. ***X-3, X-8***

266. Bogazzi F, Buralli S, Manetti L, et al.; Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract. 2008 Dec;62(12):1864-9. PMID: 18462372. ***X-2***

267. Boissonnault WG, Meek PD; Risk factors for anti-inflammatory-drug- or aspirin-induced gastrointestinal complications in individuals receiving outpatient physical therapy services. J Orthop Sports Phys Ther. 2002 Oct;32(10):510-7. PMID: 12403202. ***X-4***

268. Bokesch PM, Szabo G, Wojdyga R, et al.; A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). J Thorac Cardiovasc Surg. 2012 May;143(5):1022-9. PMID: 21724197. ***X-2, X-4***

269. Bolaji, II, Mortimer G, Grimes H, et al.; Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Gynecol Endocrinol. 1996 Feb;10(1):41-7. PMID: 8737191. ***X-2, X-3, X-4***

270. Bonanomi MT, Dantas NC, Medeiros FA; Retinal nerve fibre layer thickness measurements in patients using chloroquine. Clin Experiment Ophthalmol. 2006 Mar;34(2):130-6. PMID: 16626426. ***X-2, X-3, X-4***

271. Bonfils P, Avan P; Non-specific bronchial hyperresponsiveness is a risk factor for steroid insensitivity in nasal polyposis. Acta Otolaryngol. 2004 Apr;124(3):290-6. PMID: 15143747. ***X-2, X-3, X-4***

272. Bonfils P, Avan P, Malinvaud D; Influence of allergy on the symptoms and treatment of nasal polyposis. Acta Otolaryngol. 2006 Aug;126(8):839-44. PMID: 16846927. ***X-2, X-3, X-4***

273. Bonnar J, Sheppard BL; Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996 Sep 7;313(7057):579-82. PMID: 8806245. ***X-2, X-3, X-4***

274. Bonner GF, Fakhri A, Vennamaneni SR; A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis. 2004 Nov;10(6):751-7. PMID: 15626893. ***X-2***

275. Bonner GF, Walczak M, Kitchen L, et al.; Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol. 2000 Aug;95(8):1946-8. PMID: 10950040. ***X-2, X-4***

276. Bonny AE, Britto MT, Huang B, et al.; Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J Pediatr Adolesc Gynecol. 2004 Apr;17(2):109-15. PMID: 15050987. ***X-2***

277. Bor S, Dagli U, Sarer B, et al.; A retrospective study demonstrating properties of nonvariceal upper gastrointestinal bleeding in Turkey. Turk J Gastroenterol. 2011 Jun;22(3):249-54. PMID: 21805414. ***X-2***

278. Borgstrom A, Kask K, Gulinello M, et al.; Patients with adverse mood effects from combined oral contraceptives have lower levels of prepulse inhibition than healthy controls. Psychoneuroendocrinology. 2008 May;33(4):487-96. PMID: 18329179. ***X-2, X-3, X-4***

279. Bori Segura G, Torres y Gutierrez Rubio A, Herrera Gomez LE, et al.; Efficacy and tolerability of acemetacin, a non-steroidal anti-inflammatory drug, in Mexican patients: result of the ETAPAM Study. Proc West Pharmacol Soc. 2002;45:104-7. PMID: 12434547. ***X-4***

280. Bornebroek M, de Lau LM, Haag MD, et al.; Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology. 2007;28(4):193-6. PMID: 17851257. ***X-4***

281. Bortnichak EA, Sachs RM; Piroxicam in recent epidemiologic studies. Am J Med. 1986 Nov 28;81(5B):44-8. PMID: 3491542. ***X-1, X-2, X-3, X-4***

282. Bosetti C, Bravi F, Talamini R, et al.; Aspirin and risk of endometrial cancer: a case-control study from Italy. Eur J Cancer Prev. 2010 Sep;19(5):401-3. PMID: 20698055. ***X-2, X-4***

283. Bosetti C, Talamini R, Franceschi S, et al.; Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer. 2003 Mar 10;88(5):672-4. PMID: 12618872. ***X-4***

284. Bottoni A, Criscuolo D; Cutaneous adverse reactions following the administration of nonsteroidal antiinflammatory drugs and antibiotics: an Italian survey. Int J Clin Pharmacol Ther Toxicol. 1992 Jul;30(7):257-9. PMID: 1387114. ***X-2, X-4***

285. Bouaziz E, Canonico M, Verstuyft C, et al.; Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study. Maturitas. 2009 Oct 20;64(2):136-8. PMID: 19782484. ***X-2, X-4, X-7***

286. Boukthir S, Mazigh SM, Kalach N, et al.; The effect of non-steroidal anti-inflammatory drugs and Helicobacter pylori infection on the gastric mucosa in children with upper gastrointestinal bleeding. Pediatr Surg Int. 2010 Feb;26(2):227-30. PMID: 19823852. ***X-2***

287. Boulinguez S, Reix S, Bedane C, et al.; Role of drug exposure in aphthous ulcers: a case-control study. Br J Dermatol. 2000 Dec;143(6):1261-5. PMID: 11122030. ***X-2***

288. Bouvy ML, Heerdink ER, Hoes AW, et al.; Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf. 2003;26(13):983-9. PMID: 14583072. ***X-2***

289. Bowker SL, Majumdar SR, Veugelers P, et al.; Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006 Feb;29(2):254-8. PMID: 16443869. ***X-3***

290. Bowrey DJ, Morris-Stiff GJ; Drug allergy: fact or fiction? Int J Clin Pract. 1998 Jan-Feb;52(1):20-1. PMID: 9536562. ***X-2, X-3, X-4***

291. Boyapati SM, Bostick RM, McGlynn KA, et al.; Calcium, vitamin D, and risk for colorectal adenoma: dependency on vitamin D receptor BsmI polymorphism and nonsteroidal anti-inflammatory drug use? Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):631-7. PMID: 12869402. ***X-2, X-4***

292. Boyd EJ, Penston JG, Russell RI, et al.; Hiatal hernial ulcers: clinical features and follow-up. Postgrad Med J. 1991 Oct;67(792):900-3. PMID: 1684655. ***X-2, X-3, X-4***

293. Bozkurt B, Torre-Amione G, Warren MS, et al.; Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001 Feb 27;103(8):1044-7. PMID: 11222463. ***X-2, X-4***

294. Bracco F, Battaglia A, Chouza C, et al.; The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind,

levodopa-controlled study. CNS Drugs. 2004;18(11):733-46. PMID: 15330687. ***X-2***

295. Bradbury F; How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract Suppl. 2004 Oct(144):27-32. PMID: 16035400. ***X-3, X-4***

296. Bradley MC, Hughes CM, Cantwell MM, et al.; Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer. 2010 Apr 27;102(9):1415-21. PMID: 20372155. ***X-4***

297. Brahimi N, Routier E, Raison-Peyron N, et al.; A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010 Jul-Aug;20(4):461-4. PMID: 20507840. ***X-2, X-4***

298. Bramlage P, Binz C, Gitt AK, et al.; Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. Cardiovasc Diabetol. 2010;9:53. PMID: 20843379. ***X-3, X-4***

299. Bratt H, Skjeldestad FE, Cullberg Valentin K; A randomized trial of three copper IUDs (MLCu250, MLCu375 and Nova-T). Acta Obstet Gynecol Scand. 1988;67(3):247-51. PMID: 3051876. ***X-2, X-3, X-4***

300. Braun JM, Schneider B, Beuth HJ; Therapeutic use, efficiency and safety of the proteolytic pineapple enzyme Bromelain-POS in children with acute sinusitis in Germany. In Vivo. 2005 Mar-Apr;19(2):417-21. PMID: 15796206. ***X-2, X-4***

301. Brazer SR, Tyor MP, Pancotto FS, et al.; Studies of gastric ulcer disease by community-based gastroenterologists. Am J Gastroenterol. 1990 Jul;85(7):824-8. PMID: 2371983. ***X-2***

302. Breda A, Bui MH, Liao JC, et al.; Association of bowel rest and ketorolac analgesia with short hospital stay after laparoscopic donor nephrectomy. Urology. 2007 May;69(5):828-31. PMID: 17482915. ***X-2, X-3, X-4***

303. Breitner JC, Haneuse SJ, Walker R, et al.; Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009 Jun 2;72(22):1899-905. PMID: 19386997. ***X-7***

304. Bremer JP, Ullrich S, Laudien M, et al.; Methotrexate plus leflunomide for the treatment of relapsingWegener's granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol. 2010 Jan-Feb;28(1 Suppl 57):67-71. PMID: 20412706. ***X-2, X-4***

305. Breuer T, Martin K, Wilhelm M, et al.; The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg. 2009 Jan;35(1):167-71; author reply 71. PMID: 19027313. ***X-2***

306. Breuer-Katschinski B, Nemes K, Rump B, et al.; Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion. 2000;61(2):129-34. PMID: 10705177. ***X-2, X-4***

307. Bricker SR, Savage ME, Hanning CD; Peri-operative blood loss and non-steroidal anti-inflammatory drugs: an investigation using diclofenac in patients undergoing transurethral resection of the prostate. Eur J Anaesthesiol. 1987 Nov;4(6):429-34. PMID: 3328684. ***X-2, X-6***

308. Briesacher B, Kamal-Bahl S, Hochberg M, et al.; Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Arch Intern Med. 2004 Aug 9-23;164(15):1679-84. PMID: 15302639. ***X-3, X-4***

309. Brinker A, Goldkind L, Bonnel R, et al.; Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging. 2004;21(7):479-84. PMID: 15132714. ***X-3, X-4***

310. Briscoe TA, Anderson D, Usifo OS, et al.; A retrospective analysis of the efficacy and safety of metformin in the African-American patient. J Natl Med Assoc. 1997 Nov;89(11):728-30. PMID: 9375476. ***X-2***

311. Brock J, Sauaia A, Ahnen D, et al.; Process of care and outcomes for elderly patients hospitalized with peptic ulcer disease: results from a quality improvement project. JAMA. 2001 Oct 24-31;286(16):1985-93. PMID: 11667935. ***X-3, X-4***

312. Brown DA, Vartan CM; Risk of venous thromboembolism with drospirenone-containing oral contraceptives. Am J Health Syst Pharm. 2011 Jun 1;68(11):1003-10. PMID: 21593228. ***X-1, X-2***

313. Brown EG, Waller PC, Sallie BA; Tiaprofenic acid and severe cystitis. Postgrad Med J. 1998 Jul;74(873):443-4. PMID: 9799928. ***X-4***

314. Brown JS, Kulldorff M, Chan KA, et al.; Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007 Dec;16(12):1275-84. PMID: 17955500. ***X-2, X-3, X-4***

315. Brown MD; Norplant: a welcome new contraceptive. Kans Med. 1993 Apr;94(4):110-1. PMID: 8487456. ***X-1***

316. Brown NJ, Berkowitz RG; Epistaxis in healthy children requiring hospital admission. Int J Pediatr Otorhinolaryngol. 2004 Sep;68(9):1181-4. PMID: 15302149. ***X-2, X-3, X-4***

317. Brucker C; Controlled trial with a monthly combination injectable contraceptive in Europe. Gynecol Endocrinol. 2001 Aug;15 Suppl 3:11-4. PMID: 11570312. ***X-2***

318. Brune K, Katus HA, Moecks J, et al.; N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial. Clin Chem. 2008 Jul;54(7):1149-57. PMID: 18451314. ***X-2, X-3, X-4***

319. Brunser O, Espinoza J, Araya M, et al.; Chronic iron intake and diarrhoeal disease in infants. A field study in a less-developed country. Eur J Clin Nutr. 1993 May;47(5):317-26. PMID: 8319667. ***X-2, X-4***

320. Brzeski M, Madhok R, Capell HA; Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs. Br J Rheumatol. 1991 Oct;30(5):370-2. PMID: 1913008. ***X-2, X-3, X-4***

321. Buchbinder R, Forbes A, Kobben F, et al.; Clinical features of tiaprofenic acid (surgam) associated cystitis and a study of risk factors for its development. J Clin Epidemiol. 2000 Oct;53(10):1013-9. PMID: 11027933. ***X-2, X-4***

322. Buck ML; Clinical experience with ketorolac in children. Ann Pharmacother. 1994 Sep;28(9):1009-13. PMID: 7803871. ***X-2, X-4***

323. Buckshee K, Kumar S, Saraya L; Contraceptive vaginal ring--a rising star on the contraceptive horizon. Adv Contracept. 1990 Sep;6(3):177-83. PMID: 2123369. ***X-2, X-4***

324. Bueno H, Bardaji A, Patrignani P, et al.; Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol. 2010 Apr 15;105(8):1102-6. PMID: 20381660. ***X-4***

325. Bunton RW, Barrett DC, Palmer DG; Reintroduction of anti-inflammatory drug therapy after drug-associated gastro-intestinal disturbances. N Z Med J. 1982 Aug 25;95(714):582-4. PMID: 6982441. ***X-2***

326. Bunyaratavej N, Keorochana S, Pithkul S; Safety and efficacy of meloxicam 7.5 mg in the treatment of osteoarthritis in Thai patients. J Med Assoc Thai. 2001 Oct;84 Suppl 2:S542-6. PMID: 11853278. ***X-2, X-4***

327. Burch DJ, Spowart KJ, Jesinger DK, et al.; A dose-ranging study of the use of cyclical dydrogesterone with continuous 17 beta oestradiol. Br J Obstet Gynaecol. 1995 Mar;102(3):243-8. PMID: 7794851. ***X-2, X-4***

328. Burkhardt H, Bruckner D, Gladisch R; Risk factors of worsening renal function in hospitalized elderly patients. J Nephrol. 2005 Mar-Apr;18(2):166-73. PMID: 15931644. ***X-2, X-3, X-4***

329. Burnhill MS; The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives. Int J Fertil Womens Med. 1999 Jan-Feb;44(1):19-30. PMID: 10206196. ***X-4***

330. Burns B, Watkins L, Goadsby PJ; Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study. Lancet Neurol. 2008 Nov;7(11):1001-12. PMID: 18845482. ***X-2, X-3, X-4***

331. Buse JB, Klonoff DC, Nielsen LL, et al.; Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007 Jan;29(1):139-53. PMID: 17379054. ***X-2, X-3, X-4***

332. Butler AJ, Green A, Cohen M; Multi-centre open study of a triphasic levonorgestrel-ethinyloestradiol combined oral contraceptive ('Trinordiol'). Curr Med Res Opin. 1987;10(8):503-13. PMID: 2960493. ***X-4***

333. Buurma H, De Smet PA, Egberts AC; Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf. 2006;29(8):723-32. PMID: 16872246. ***X-4***

334. Buysschaert M, Preumont V, Oriot PR, et al.; One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010 Nov;36(5):381-8. PMID: 20598606. ***X-2, X-4***

335. Byamugisha JK, Mirembe FM, Faxelid E, et al.; A randomized clinical trial of two emergency contraceptive pill regimens in a Ugandan population. Acta Obstet Gynecol Scand. 2010 May;89(5):670-6. PMID: 20423278. ***X-2, X-4***

336. Bytzer P, Talley NJ, Jones MP, et al.; Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther. 2001 Jan;15(1):137-42. PMID: 11136287. ***X-2***

337. Caballero-Gordo A, Lopez-Nazareno N, Calderay M, et al.; Oral cabergoline. Single-dose inhibition of puerperal lactation. J Reprod Med. 1991 Oct;36(10):717-21. PMID: 1683403. ***X-2***

338. Cabrol D, Jannet D, Pannier E; Treatment of symptomatic polyhydramnios with indomethacin. Eur J Obstet Gynecol Reprod Biol. 1996 May;66(1):11-5. PMID: 8735752. ***X-2, X-3, X-4***

339. Cady RK, Banks J, Jones BA, et al.; Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination. Curr Med Res Opin. 2009 Nov;25(11):2711-21. PMID: 19778164. ***X-4***

340. Caglar GS, Tasci Y, Kayikcioglu F, et al.; Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 2008 Apr;137(2):227-31. PMID: 17499419. ***X-2, X-3, X-4***

341. Cagnacci A, Ferrari S, Tirelli A, et al.; Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. Contraception. 2009 Jul;80(1):34-9. PMID: 19501213. ***X-2, X-3, X-4***

342. Cai XM, Wu J; The mind-tranquilizing and menstruation-regulating method for acupuncture treatment of delayed menstrual cycle--a clinical controlled study. J Tradit Chin Med. 2009 Mar;29(1):35-8. PMID: 19514186. ***X-2, X-3, X-4***

343. Calabrese AT, Coley KC, DaPos SV, et al.; Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002 Feb 25;162(4):434-7. PMID: 11863476. ***X-2, X-3, X-4***

344. Caldwell JR, Roth SH, Wu WC, et al.; Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med. 1987 Sep 28;83(3B):74-82. PMID: 3310631. ***X-2, X-3, X-4***

345. Caldwell M, Reilly C; Effects of topical nepafenac on corneal epithelial healing time and postoperative pain after PRK: a bilateral, prospective, randomized, masked trial. J Refract Surg. 2008 Apr;24(4):377-82. PMID: 18500088. ***X-2, X-3, X-4***

346. Caliskan E, Ozturk N, Dilbaz BO, et al.; Analysis of risk factors associated with uterine perforation by intrauterine devices. Eur J Contracept Reprod Health Care. 2003 Sep;8(3):150-5. PMID: 14667326. ***X-2, X-4***

347. Calle EE, Feigelson HS, Hildebrand JS, et al.; Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer. 2009 Mar 1;115(5):936-45. PMID: 19156895. ***X-4, X-7***

348. Callejo J, Diaz J, Ruiz A, et al.; Effect of a low-dose oral contraceptive containing 20 microg ethinylestradiol and 150 microg desogestrel on dysmenorrhea. Contraception. 2003 Sep;68(3):183-8. PMID: 14561538. ***X-2, X-3, X-4***

349. Calvo-Alen J, De Cos MA, Rodriguez-Valverde V, et al.; Subclinical renal toxicity in rheumatic patients receiving longterm treatment with nonsteroidal antiinflammatory drugs. J Rheumatol. 1994 Sep;21(9):1742-7. PMID: 7799360. ***X-2***

350. Cameron IT, Haining R, Lumsden MA, et al.; The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol. 1990 Jul;76(1):85-8. PMID: 2359570. ***X-2, X-3, X-4***

351. Cameron IT, Leask R, Kelly RW, et al.; The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins. 1987 Jul;34(1):99-110. PMID: 3685399. ***X-2, X-3, X-4***

352. Campbell DR, Haber MM, Sheldon E, et al.; Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol. 2002 Sep;97(9):2208-14. PMID: 12358234. ***X-2, X-3, X-4***

353. Campbell K, Steele RJ; Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case-control study. Br J Surg. 1991 Feb;78(2):190-1. PMID: 2015469. ***X-2***

354. Campbell KL, De Beaux AC; Non-steroidal anti-inflammatory drugs and appendicitis in patients aged over 50 years. Br J Surg. 1992 Sep;79(9):967-8. PMID: 1307702. ***X-2***

355. Campos-Fernandez Mdel M, Ponce-De-Leon-Rosales S, Archer-Dubon C, et al.; Incidence and risk factors for cutaneous adverse drug reactions in an intensive care unit. Rev Invest Clin. 2005 Nov-Dec;57(6):770-4. PMID: 16708902. ***X-2, X-4***

356. Cannon GW, Holden WL, Juhaeri J, et al.; Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol. 2004 Oct;31(10):1906-11. PMID: 15468352. ***X-4***

357. Cano A, Calaf J, Molina J; The lipid and clinical effects of sequential transdermal estradiol and estradiol/norethisterone acetate in 674 women. Arch Gynecol Obstet. 2003 Oct;268(4):317-22. PMID: 14504877. ***X-2, X-4***

358. Cano A, Tarin JJ, Duenas JL; Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy. Fertil Steril. 1999 Jan;71(1):129-36. PMID: 9935129. ***X-2, X-4***

359. Canto TE, Vera L, Polanco LE, et al.; Mini-pill in lactating women. Contraception. 1989 Jun;39(6):589-601. PMID: 2752751. ***X-2***

360. Capizzi R, Landi F, Milani M, et al.; Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator-masked, controlled trial. Br J Dermatol. 2004 Aug;151(2):481-4. PMID: 15327558. ***X-2, X-3, X-4***

361. Capriles-Behrens E, Caplin J, Sanchez-Borges M; NSAID facial angioedema in a selected pediatric atopic population. J Investig Allergol Clin Immunol. 2000 Sep-Oct;10(5):277-9. PMID: 11108437. ***X-2***

362. Capuano A, Motola G, Russo F, et al.; Adverse drug events in two emergency departments in Naples, Italy: an observational study. Pharmacol Res. 2004 Dec;50(6):631-6. PMID: 15501703. ***X-4***

363. Carbonell N, Verstuyft C, Massard J, et al.; CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin. Clin Pharmacol Ther. 2010 Jun;87(6):693-8. PMID: 20445534. ***X-2, X-4***

364. Carcopino X, Akkawi R, Conroy R, et al.; Specific timing for colposcopy: is it worthwhile? Obstet Gynecol. 2008 Feb;111(2 Pt 1):373-7. PMID: 18238975. ***X-2, X-3, X-4***

365. Cardamakis E, Georgopoulos A, Fotopoulos A, et al.; Clinical experience with Norplant subdermal implant system as long-term contraception during adolescence. Eur J Contracept Reprod Health Care. 2002 Mar;7(1):36-40. PMID: 12041863. ***X-2, X-4***

366. Cardoso F, Polonia J, Santos A, et al.; Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet. 1997 Dec;59(3):237-43. PMID: 9486514. ***X-2***

367. Cardoso JC, Canelas MM, Goncalo M, et al.; Photopatch testing with an extended series of photoallergens: a 5-year study. Contact Dermatitis. 2009 Jun;60(6):325-9. PMID: 19489967. ***X-2, X-3, X-4***

368. Carne X, Rios J, Torres F; Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care. Methods Find Exp Clin Pharmacol. 2009 Oct;31(8):533-40. PMID: 19967102. ***X-4***

369. Carney DE, Nicolette LA, Ratner MH, et al.; Ketorolac reduces postoperative narcotic requirements. J Pediatr Surg. 2001 Jan;36(1):76-9. PMID: 11150441. ***X-2, X-3, X-4***

370. Carr BR; Cycle control with desogestrel-containing oral contraceptives--comparison of a monophasic and triphasic regimen. Int J Fertil Menopausal Stud. 1993 Sep-Oct;38(5):274-9. PMID: 8298666. ***X-4***

371. Carson JL; A case study: nonsteroidal antiinflammatory drugs and gastrointestinal bleeding. J Rheumatol Suppl. 1988 Oct;17:24-7. PMID: 3264583. ***X-4***

372. Carson JL, Strom BL, Duff A, et al.; Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med. 1993 Jun 14;153(11):1331-6. PMID: 8507123. ***X-2, X-4***

373. Carson JL, Strom BL, Morse ML, et al.; The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1987 Jun;147(6):1054-9. PMID: 3496062. ***X-4***

374. Carson JL, Strom BL, Soper KA, et al.; The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med. 1987 Jan;147(1):85-8. PMID: 3492182. ***X-4***

375. Carton E, Caldwell MT, McDonald G, et al.; Specialized intestinal metaplasia in patients with gastro-oesophageal reflux disease. Br J Surg. 2000 Jan;87(1):116-21. PMID: 10606922. ***X-2, X-3, X-4***

376. Caruso S, Agnello C, Intelisano G, et al.; Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception. 2005 Jul;72(1):19-23. PMID: 15964287. ***X-2, X-4***

377. Caruso S, Grillo C, Agnello C, et al.; A prospective study evidencing rhinomanometric and olfactometric outcomes in women taking oral contraceptives. Hum Reprod. 2001 Nov;16(11):2288-94. PMID: 11679506. ***X-2, X-4***

378. Carvajal A, Arias LH, Vega E, et al.; Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study. Eur J Clin Pharmacol. 2004 Aug;60(6):439-44. PMID: 15221157. ***X-2, X-3, X-4***

379. Casado-Arroyo R, Scheiman JM, Polo-Tomas M, et al.; Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States. Aliment Pharmacol Ther. 2010 Sep;32(5):689-95. PMID: 20626380. ***X-2, X-3, X-4***

380. Casati V, Gerli C, Franco A, et al.; Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study. Ann Thorac Surg. 2001 Aug;72(2):470-5. PMID: 11515884. ***X-2, X-4***

381. Casella G, Villanacci V, Fisogni S, et al.; Colonic left-side increase of eosinophils: a clue to drug-related colitis in adults. Aliment Pharmacol Ther. 2009 Mar 1;29(5):535-41. PMID: 19077107. ***X-2, X-3***

382. Cassidy N, Duggan E, Williams DJ, et al.; The epidemiology and type of medication errors reported to the National Poisons Information Centre of Ireland. Clin Toxicol (Phila). 2011 Jul;49(6):485-91. PMID: 21824059. ***X-4***
X-8

383. Cassina M, De Santis M, Cesari E, et al.; First trimester diclofenac exposure and pregnancy outcome. Reprod Toxicol. 2010 Nov;30(3):401-4. PMID: 20438830. ***X-2, X-4***

384. Castelao JE, Yuan JM, Gago-Dominguez M, et al.; Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 2000 Apr;82(7):1364-9. PMID: 10755416. ***X-4***

385. Castellsague J, Holick CN, Hoffman CC, et al.; Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Pharmacotherapy. 2009 Dec;29(12):1397-407. PMID: 19947799. ***X-4***

386. Castellsague X, Diaz M, Vaccarella S, et al.; Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011 Oct;12(11):1023-31. PMID: 21917519. ***X-1, X-4, X-8***

387. Castelo-Branco C, Moyano D, Gomez O, et al.; Long-term safety and tolerability of flutamide for the treatment of hirsutism. Fertil Steril. 2009 Apr;91(4):1183-8. PMID: 18339379. ***X-2, X-3, X-4***

388. Castle PE, Walker JL, Schiffman M, et al.; Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer. 2005 Dec 20;117(6):1007-12. PMID: 15986443. ***X-4***

389. Catalano O; Greater curvature antral flattening due to nonsteroidal antiinflammatory drugs. Rofo. 1997 Aug;167(2):122-4. PMID: 9309163. ***X-2***

390. Cataldi L, Leone R, Moretti U, et al.; Potential risk factors for the development of acute renal failure in preterm newborn infants: a case-control study. Arch Dis Child Fetal Neonatal Ed. 2005 Nov;90(6):F514-9. PMID: 16244211. ***X-2, X-4***

391. Caughey GE, Roughead EE, Pratt N, et al.; Stroke risk and NSAIDs: an Australian population-based study. Med J Aust. 2011 Nov 7;195(9):525-9. PMID: 22060087. ***X-7***

392. Caunedo-Alvarez A, Gomez-Rodriguez BJ, Romero-Vazquez J, et al.; Macroscopic small bowel mucosal injury caused by chronic nonsteroidal anti-inflammatory drugs (NSAID) use as assessed by capsule endoscopy. Rev Esp Enferm Dig. 2010 Feb;102(2):80-5. PMID: 20361843. ***X-2***

393. Cebollero-Santamaria F, Smith J, Gioe S, et al.; Selective outpatient management of upper gastrointestinal bleeding in the elderly. Am J Gastroenterol. 1999 May;94(5):1242-7. PMID: 10235201. ***X-2, X-3***

394. Cepeda MS, Farrar JT, Baumgarten M, et al.; Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003 Aug;74(2):102-12. PMID: 12891220. ***X-4***

395. Cerhan JR, Anderson KE, Janney CA, et al.; Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer. 2003 Sep 20;106(5):784-8. PMID: 12866040. ***X-4, X-7***

396. Chalasani N, Patel K, Clark WS, et al.; The prevalence and significance of leukocytosis in upper gastrointestinal bleeding. Am J Med Sci. 1998 Apr;315(4):233-6. PMID: 9537636. ***X-2, X-3, X-4***

397. Chalmers RT, Darling Iii RC, Wingard JT, et al.; Randomized clinical trial of tranexamic acid-free fibrin sealant during vascular surgical procedures. Br J Surg. 2010 Dec;97(12):1784-9. PMID: 20730858. ***X-2, X-4***

398. Cham E, Hall L, Ernst AA, et al.; Awareness and use of over-the-counter pain medications: a survey of emergency department patients. South Med J. 2002 May;95(5):529-35. PMID: 12005011. ***X-2, X-3, X-4***

399. Chan AT, Manson JE, Albert CM, et al.; Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006 Mar 28;113(12):1578-87. PMID: 16534006. ***X-4***

400. Chan FK, Hung LC, Suen BY, et al.; Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002 Dec 26;347(26):2104-10. PMID: 12501222. ***X-2, X-3, X-4***

401. Chan FK, Sung JJ, Ching JY, et al.; Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2001 Jan;15(1):19-24. PMID: 11136274. ***X-2***

402. Chan FK, Sung JJ, Chung SC, et al.; Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997 Oct 4;350(9083):975-9. PMID: 9329511. ***X-2, X-3, X-4***

403. Chan HL, Wu JC, Chan FK, et al.; Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. Gastrointest Endosc. 2001 Apr;53(4):438-42. PMID: 11275883. ***X-4***

404. Chan JK, Sleat G, Sharma S, et al.; Gastroprotection in trauma patients receiving non-steroidal anti-inflammatory drugs. Surgeon. 2010 Aug;8(4):206-10. PMID: 20569940. ***X-2, X-3, X-4***

405. Chan SS, Luben R, Bergmann MM, et al.; Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther. 2011 Sep;34(6):649-55. PMID: 21790683. ***X-4***

406. Chan TM, Tse KC, Tang CS, et al.; Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005 Apr;16(4):1076-84. PMID: 15728784. ***X-2, X-3, X-4***

407. Chan TY, Critchley JA, Lau JT, et al.; The relationship between upper gastrointestinal hemorrhage and drug use: a case control study. Int J Clin Pharmacol Ther. 1996 Jul;34(7):304-8. PMID: 8832307. ***X-2***

408. Chande N, Driman DK, Reynolds RP; Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation. Scand J Gastroenterol. 2005 Mar;40(3):343-7. PMID: 15932175. ***X-2, X-3, X-4***

409. Chang CH, Chen HC, Lin JW, et al.; Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):763-71. PMID: 21618340. ***X-4***

410. Chang CH, Lin JW, Chen HC, et al.; Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan. Gut. 2011 Oct;60(10):1372-8. PMID: 21415083. ***X-4***

411. Chang CH, Shau WY, Kuo CW, et al.; Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke. 2010 Sep;41(9):1884-90. PMID: 20671253. ***X-4***

412. Chang CY, Wu MS, Lee CT, et al.; Prospective survey for the etiology and outcome of peptic ulcer bleeding: a community based study in southern Taiwan. J Formos Med Assoc. 2011 Apr;110(4):223-9. PMID: 21540004. ***X-2***

413. Chang JY, Locke GR, Schleck CD, et al.; Risk factors for chronic constipation and a possible role of analgesics. Neurogastroenterol Motil. 2007 Nov;19(11):905-11. PMID: 17988275. ***X-2***

414. Charonis G, Larsson PG; Prolonged use of intrauterine contraceptive device as a risk factor for tubo-ovarian abscess. Acta Obstet Gynecol Scand. 2009;88(6):680-4. PMID: 19412803. ***X-2***

415. Chasan-Taber L, Willett WC, Stampfer MJ, et al.; A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care. 1997 Mar;20(3):330-5. PMID: 9051382. ***X-4***

416. Chassaignon C, Letoumelin P, Pateron D; Upper gastrointestinal haemorrhage in Emergency Departments in France: causes and management. Eur J Emerg Med. 2003 Dec;10(4):290-5. PMID: 14676507. ***X-2, X-4***

417. Chattopdhyay B, Nigam A, Goswami S, et al.; Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia. Eur Rev Med Pharmacol Sci. 2011 Jul;15(7):764-8. PMID: 21780544. ***X-2, X-4***

418. Chaudhuri SK, Das A, De KC, et al.; Some hitherto unreported findings on the extragenital effects of progesterone in human females--a clinical study. Indian J Physiol Pharmacol. 1994 Jul;38(3):174-80. PMID: 7814077. ***X-2, X-3***

419. Check JH, Rankin A, Teichman M; The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil Steril. 1986 Apr;45(4):575-7. PMID: 3956772. ***X-2, X-3, X-4***

420. Cheetham TC, Levy G, Niu F, et al.; Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother. 2009 Nov;43(11):1765-73. PMID: 19809010. ***X-4***

421. Cheetham TC, Levy G, Spence M; Predicting the risk of gastrointestinal bleeding due to nonsteroidal antiinflammatory drugs: NSAID electronic assessment of risk. J Rheumatol. 2003 Oct;30(10):2241-4. PMID: 14528523. ***X-4***

422. Chegini N, Rhoton-Vlasak A, Williams RS; Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil Steril. 2003 Sep;80(3):564-70. PMID: 12969699. ***X-2, X-3, X-4***

423. Chen C, Li Y, Chen F, et al.; Estrogen receptor beta genetic variants and combined oral contraceptive use as relates to the risk of hypertension in Chinese women. Arch Med Res. 2010 Nov;41(8):599-605. PMID: 21199728. ***X-2, X-3***

424. Chen CH, Chiu CC, Huang MC, et al.; Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):925-31. PMID: 18082302. ***X-2, X-3, X-4***

425. Chen FP, Lee N, Wang CH, et al.; Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril. 1998 Feb;69(2):267-73. PMID: 9496340. ***X-2, X-4***

426. Chen JY, Wu GJ, Mok MS, et al.; Effect of adding ketorolac to intravenous morphine patient-controlled analgesia on bowel function in colorectal surgery patients--a prospective, randomized, double-blind study. Acta Anaesthesiol Scand. 2005 Apr;49(4):546-51. PMID: 15777304. ***X-2, X-3, X-4***

427. Chen MJ, Yang WS, Chen HF, et al.; Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome. Hum Reprod. 2010 Mar;25(3):779-85. PMID: 20093255. ***X-2, X-3, X-4***

428. Chen QJ, Xiang WP, Zhang DK, et al.; Efficacy and safety of a levonorgestrel enteric-coated tablet as an over-the-counter drug for emergency contraception: a Phase IV

clinical trial. Hum Reprod. 2011 Sep;26(9):2316-21. PMID: 21672924. ***X-4***

429. Chen TM, Lin CC, Huang PT, et al.; Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2011 May;26(5):858-65. PMID: 21251068. ***X-2, X-3***

430. Cheraghali AM; Injectable diclofenac: a painful shot into Iran's health system. Soc Sci Med. 2006 Sep;63(6):1597-601. PMID: 16782253. ***X-2, X-4***

431. Cherian PT, Cherian S, Singh P; Long-term follow-up of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy. Gastrointest Endosc. 2007 Sep;66(3):491-7. PMID: 17640640. ***X-2, X-3, X-4***

432. Chi IC, Potts M, Wilkens LR, et al.; Performance of the copper T-380A intrauterine device in breastfeeding women. Contraception. 1989 Jun;39(6):603-18. PMID: 2666018. ***X-2, X-4***

433. Chi IC, Waszak CS, Wilkens LR; Do insertion-related problems affect subsequent IUD performance? Contraception. 1986 Nov;34(5):497-503. PMID: 3816233. ***X-2, X-4***

434. Chiba T, Sato K, Kudara N, et al.; Upper gastrointestinal disorders induced by non-steroidal anti-inflammatory drugs. Inflammopharmacology. 2008 Feb;16(1):16-20. PMID: 18256801. ***X-2***

435. Chin CJ, Franklin JH, Turner B, et al.; Ketorolac in thyroid surgery: quantifying the risk of hematoma. J Otolaryngol Head Neck Surg. 2011 Jun 1;40(3):196-9. PMID: 21518639. ***X-2, X-4***

436. Chittacharoen A, Domhardt R, Manonai J, et al.; Efficacy and tolerability of the hormone replacement drug estradiol valerate/levonorgestrel in the treatment of menopausal syndrome in Thai women. Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):645-51. PMID: 14671683. ***X-2, X-4***

437. Chlebowski RT, Anderson GL, Gass M, et al.; Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 Oct 20;304(15):1684-92. PMID: 20959578. ***X-7***

438. Chlebowski RT, Hendrix SL, Langer RD, et al.; Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003 Jun 25;289(24):3243-53. PMID: 12824205. ***X-7***

439. Chlebowski RT, Kuller LH, Prentice RL, et al.; Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009 Feb 5;360(6):573-87. PMID: 19196674. ***X-4, X-7***

440. Cho E, Curhan G, Hankinson SE, et al.; Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med. 2011 Sep 12;171(16):1487-93. PMID: 21911634. ***X-4***

441. Choi HK, Seeger JD, Kuntz KM; Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. Am J Med. 2004 May 1;116(9):621-9. PMID: 15093759. ***X-4, X-7***

442. Choi KH, Kim AJ, Son IJ, et al.; Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. J Korean Med Sci. 2010 Mar;25(3):337-41. PMID: 20191029. ***X-2***

443. Choi NK, Hahn S, Yoon BW, et al.; Potential bias caused by control selection in secondary data analysis: nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke. Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):604-9. PMID: 20049849. ***X-4***

444. Choi NK, Park BJ, Jeong SW, et al.; Nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study. Stroke. 2008 Mar;39(3):845-9. PMID: 18258834. ***X-4***

445. Chokrungvaranon N, Chentanez T, Arakaki RF; Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes. Endocrine. 2007 Dec;32(3):311-6. PMID: 18266113. ***X-2, X-4***

446. Choma NN, Griffin MR, Huang RL, et al.; An algorithm to identify incident myocardial infarction using Medicaid data. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1064-71. PMID: 19718697. ***X-2, X-3, X-4***

447. Choo PW, Donahue JG, Platt R; Ibuprofen and skin and soft tissue superinfections in children with varicella. Ann Epidemiol. 1997 Oct;7(7):440-5. PMID: 9349910. ***X-4***

448. Chotnopparatpattara P, Taneepanichskul S, Treratanachat S, et al.; Relationship between progesterone receptor level in endometrium and bleeding pattern in depot medroxyprogesterone acetate users. J Med Assoc Thai. 2003 Feb;86(2):172-7. PMID: 12678156. ***X-2, X-3, X-4***

449. Chou TC, Chang HY, Chen CJ, et al.; Effect of hand dermatitis on the total body burden of chromium after ferrous sulfate application in cement among cement workers. Contact Dermatitis. 2008 Sep;59(3):151-6. PMID: 18759895. ***X-2, X-3, X-4***

450. Choudhary DR, Naithani R, Mahapatra M, et al.; Intracranial hemorrhage in childhood immune thrombocytopenic purpura. Pediatr Blood Cancer. 2009 Apr;52(4):529-31. PMID: 19058201. ***X-2, X-3, X-4***

451. Chow GK, Fabrizio MD, Steer T, et al.; Prospective double-blind study of effect of ketorolac administration

after laparoscopic urologic surgery. J Endourol. 2001 Mar;15(2):171-4. PMID: 11325088. ***X-2, X-3, X-4***

452. Chowdhury A, Ganguly G, Chowdhury D, et al.; Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study. Indian J Gastroenterol. 2001 Nov-Dec;20(6):227-9. PMID: 11817775. ***X-2, X-3, X-4***

453. Christen WG, Ajani UA, Schaumberg DA, et al.; Aspirin use and risk of cataract in posttrial follow-up of Physicians' Health Study I. Arch Ophthalmol. 2001 Mar;119(3):405-12. PMID: 11231774. ***X-4***

454. Christensen ST, Sondergaard B, Honore PH, et al.; Pharmacy student driven detection of adverse drug reactions in the community pharmacy setting. Pharmacoepidemiol Drug Saf. 2011 Apr;20(4):399-404. PMID: 21442686. ***X-2, X-3, X-4***

455. Christie GA, Lucas C, Bateman DN, et al.; Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses. Eur J Clin Pharmacol. 2006 Dec;62(12):989-93. PMID: 17089106. ***X-2, X-3, X-4***

456. Chrubasik S, Kunzel O, Model A, et al.; Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain. Rheumatology (Oxford). 2001 Dec;40(12):1388-93. PMID: 11752510. ***X-2, X-3, X-4***

457. Chrubasik S, Kunzel O, Thanner J, et al.; A 1-year follow-up after a pilot study with Doloteffin for low back pain. Phytomedicine. 2005 Jan;12(1-2):1-9. PMID: 15693701. ***X-2, X-3, X-4***

458. Ciarrocca KN, Greenberg MS; A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):159-63. PMID: 10468458. ***X-2, X-3, X-4***

459. Cibere J, Sibley JT, Haga M; Rheumatologists' adherence to guidelines for misoprostol use in patients at high risk for nonsteroidal antiinflammatory drug gastropathy. J Rheumatol. 2002 Feb;29(2):339-46. PMID: 11838854. ***X-2, X-3, X-4***

460. Cino M, Greenberg GR; Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol. 2002 Apr;97(4):915-21. PMID: 12003427. ***X-2, X-4***

461. Civic D, Scholes D, Ichikawa L, et al.; Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception. 2000 Jun;61(6):385-90. PMID: 10958882. ***X-2***

462. Clark MK, Dillon JS, Sowers M, et al.; Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obes (Lond). 2005 Oct;29(10):1252-8. PMID: 15997247. ***X-2***

463. Clark MK, Sowers MR, Nichols S, et al.; Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2004 Dec;82(6):1580-6. PMID: 15589863. ***X-2***

464. Clark MK, Stockdale CK, Railsback L, et al.; Differences in cervical cytologic and histologic findings between women using depot-medroxyprogesterone acetate and oral contraceptives. J Low Genit Tract Dis. 2011 Jul;15(3):219-23. PMID: 21716050. ***X-2***

465. Clarke LL, Schmitt K, Bono CA, et al.; Norplant selection and satisfaction among low-income women. Am J Public Health. 1998 Aug;88(8):1175-81. PMID: 9702143. ***X-2, X-3, X-4***

466. Clayton R, Chaudhry S, Ali I, et al.; Mucosal (oral and vulval) lichen planus in women: are angiotensin-converting enzyme inhibitors protective, and beta-blockers and non-steroidal anti-inflammatory drugs associated with the condition? Clin Exp Dermatol. 2010 Jun;35(4):384-7. PMID: 19874335. ***X-2***

467. Cleophas TJ, Tavenier P, Niemeyer MG; The risk of emergency intestinal bleeding among users of acenocoumarin: a population-based cohort study. Angiology. 1993 Feb;44(2):85-92. PMID: 8434814. ***X-2, X-4***

468. Clerc S, Vuilleumier H, Frascarolo P, et al.; Is the effect of inguinal field block with 0.5% bupivacaine on postoperative pain after hernia repair enhanced by addition of ketorolac or S(+) ketamine? Clin J Pain. 2005 Jan-Feb;21(1):101-5. PMID: 15599137. ***X-2, X-3, X-4***

469. Cleves MA, Savell VH, Jr., Raj S, et al.; Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Defects Res A Clin Mol Teratol. 2004 Mar;70(3):107-13. PMID: 15039924. ***X-2, X-4***

470. Clinard F, Sgro C, Bardou M, et al.; Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol. 2004 Jun;60(4):279-83. PMID: 15103437. ***X-4***

471. Clinch D; Why not have definitive trials of gastrointestinal safety for non-steroidal anti-inflammatory drugs? Discussion paper. J R Soc Med. 1988 Mar;81(3):158-60. PMID: 3357159. ***X-1, X-2, X-3, X-4***

472. Clinton OP, Priestman TJ, Latief TN, et al.; A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer. Clin Oncol (R Coll Radiol). 1995;7(4):251-6. PMID: 8845325. ***X-2, X-3***

473. Clunie M, Crone LA, Klassen L, et al.; Psychiatric side effects of indomethacin in parturients. Can J Anaesth. 2003 Jun-Jul;50(6):586-8. PMID: 12826551. ***X-2, X-4***

474. Coaccioli S, Allegra A, Di Cato L, et al.; Clinical efficacy and tolerance of nabumetone in articular and non-articular rheumatic disorders: personal experience during 12 weeks of treatment. Panminerva Med. 1998 Jun;40(2):110-5. PMID: 9689831. ***X-2, X-4***

475. Coffee AL, Sulak PJ, Kuehl TJ; Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception. 2007 Jun;75(6):444-9. PMID: 17519150. ***X-2, X-4***

476. Cohen AD, Bonneh DY, Reuveni H, et al.; Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol. 2005;85(4):299-303. PMID: 16191849. ***X-2***

477. Cohen JS; Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med. 2001 Apr 9;161(7):957-64. PMID: 11295958. ***X-2, X-3, X-4***

478. Cohen M, Sapoznikov B, Niv Y; Primary and secondary nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol. 2007 Oct;41(9):810-3. PMID: 17881925. ***X-3, X-4***

479. Cohen S, Cannon GW, Schiff M, et al.; Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. 2001 Sep;44(9):1984-92. PMID: 11592358. ***X-2, X-3, X-4***

480. Colacurci N, De Placido G, Mollo A, et al.; Short-term use of Goserelin depot in the treatment of dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 1995;22(3):212-9. PMID: 7554259. ***X-2, X-3, X-4***

481. Colao A, Abs R, Barcena DG, et al.; Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf). 2008 Jan;68(1):66-71. PMID: 17760883. ***X-2***

482. Colao A, Di Sarno A, Guerra E, et al.; Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf). 2007 Sep;67(3):426-33. PMID: 17573902. ***X-2, X-3***

483. Colao A, Galderisi M, Di Sarno A, et al.; Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008 Oct;93(10):3777-84. PMID: 18682513. ***X-2***

484. Colao A, Vitale G, Di Sarno A, et al.; Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab. 2004 Jun;89(6):2770-5. PMID: 15181056. ***X-2, X-3, X-4***

485. Cole LP, Potts DM, Aranda C, et al.; An evaluation of the TCu 380Ag and the Multiload Cu375. Fertil Steril. 1985 Feb;43(2):214-7. PMID: 3881295. ***X-2, X-4***

486. Collen MJ, Abdulian JD; Do non-steroidal anti-inflammatory drugs cause duodenal ulcer? Evaluation of basal acid output and ulcer complications. J Gastroenterol Hepatol. 1996 Jun;11(6):520-3. PMID: 8792303. ***X-2***

487. Colli E, Tong D, Penhallegon R, et al.; Reasons for contraceptive discontinuation in women 20-39 years old in New Zealand. Contraception. 1999 Apr;59(4):227-31. PMID: 10457866. ***X-4***

488. Collins AJ, Davies J, Dixon AS; A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. Br J Rheumatol. 1988 Apr;27(2):106-9. PMID: 3365527. ***X-3, X-4***

489. Colt HG, Shapiro AP; Drug-induced illness as a cause for admission to a community hospital. J Am Geriatr Soc. 1989 Apr;37(4):323-6. PMID: 2921453. ***X-2***

490. Comfort MB, Tse AS, Tsang AC, et al.; A study of the comparative efficacy of three common analgesics in the control of pain after third molar surgery under local anaesthesia. Aust Dent J. 2002 Dec;47(4):327-30. PMID: 12587769. ***X-3, X-4***

491. Comfort VK, Code WE, Rooney ME, et al.; Naproxen premedication reduces postoperative tubal ligation pain. Can J Anaesth. 1992 Apr;39(4):349-52. PMID: 1348663. ***X-2, X-4***

492. Confino E, Ismajovich B, Rudick A, et al.; Comparison between OM-GA Cu and Copper-T IUCDs. Contraception. 1983 Dec;28(6):521-5. PMID: 6370586. ***X-2, X-4***

493. Conforti A, Leone R, Moretti U, et al.; Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001;24(14):1081-90. PMID: 11735663. ***X-4***

494. Connell EB; Minimizing the metabolic risks of oral contraceptives through patient counseling and monitoring. J Reprod Med. 1986 Sep;31(9 Suppl):934-8. PMID: 3772914. ***X-1***

495. Connelly CS, Panush RS; Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med. 1991 Oct;151(10):1963-6. PMID: 1929684. ***X-2***

496. Conner P, Soderqvist G, Skoog L, et al.; Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat. 2003 Mar;78(2):159-65. PMID: 12725416. ***X-2***

497. Connor PD, Tavernier LA, Thomas SM, et al.; Determining risk between Depo-Provera use and increased uterine bleeding in obese and overweight women. J Am Board Fam Pract. 2002 Jan-Feb;15(1):7-10. PMID: 11841143. ***X-2***

498. Cooper JW; Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. South Med J. 1999 May;92(5):485-90. PMID: 10342894. ***X-2***

499. Cooper KG, Jack SA, Parkin DE, et al.; Five-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. BJOG. 2001 Dec;108(12):1222-8. PMID: 11843383. ***X-2, X-3, X-4***

500. Cooper KG, Parkin DE, Garratt AM, et al.; A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss. Br J Obstet Gynaecol. 1997 Dec;104(12):1360-6. PMID: 9422013. ***X-2, X-3, X-4***

501. Cooper KG, Parkin DE, Garratt AM, et al.; Two-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. Br J Obstet Gynaecol. 1999 Mar;106(3):258-65. PMID: 10426646. ***X-2***

502. Cormican LJ, Farooque S, Altmann DR, et al.; Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity. Clin Exp Allergy. 2005 Jun;35(6):717-22. PMID: 15969660. ***X-2, X-4***

503. Cormio M, Citerio G, Spear S, et al.; Control of fever by continuous, low-dose diclofenac sodium infusion in acute cerebral damage patients. Intensive Care Med. 2000 May;26(5):552-7. PMID: 10923729. ***X-2, X-4***

504. Corre KA, Spielberg TE; Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point. Ann Emerg Med. 1988 Feb;17(2):145-9. PMID: 3257365. ***X-1, X-2, X-3, X-4***

505. Cortes-Prieto J, Juez-Martel P; Incidences of breast cancer throughout long-term hormone replacement therapy. J Steroid Biochem Mol Biol. 2007 May;104(3-5):180-9. PMID: 17467269. ***X-2, X-3, X-4***

506. Cote GA, Norvell JP, Rice JP, et al.; Use of gastroprotection in patients discharged from hospital on nonsteroidal anti-inflammatory drugs. Am J Ther. 2008 Sep-Oct;15(5):444-9. PMID: 18806520. ***X-2, X-3, X-4***

507. Couser RJ, Hoekstra RE, Ferrara TB, et al.; Neurodevelopmental follow-up at 36 months' corrected age of preterm infants treated with prophylactic indomethacin. Arch Pediatr Adolesc Med. 2000 Jun;154(6):598-602. PMID: 10850507. ***X-2, X-4***

508. Cox ER, Motheral B, Mager D; Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s). Am J Manag Care. 2003 Dec;9(12):785-94. PMID: 14712755. ***X-3, X-4***

509. Cox M, Blacksell S; Clinical performance of the levonorgestrel intra-uterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 12-month report. Br J Fam Plann. 2000 Jul;26(3):143-7. PMID: 10920290. ***X-2, X-3, X-4***

510. Cox M, Blacksell SE; Clinical performance of the Nova-T380 IUD in routine use by the UK Family Planning and Reproductive Health Research Network: 12-month report. Br J Fam Plann. 2000 Jul;26(3):148-51. PMID: 10920291. ***X-2, X-4***

511. Cozzi R, Attanasio R, Lodrini S, et al.; Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004 Aug;61(2):209-15. PMID: 15272916. ***X-2, X-3***

512. Cramer DW, Harlow BL, Titus-Ernstoff L, et al.; Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998 Jan 10;351(9096):104-7. PMID: 9439495. ***X-2, X-3, X-4***

513. Crandall CJ, Markovic D, Huang MH, et al.; Predictors of breast discomfort among women initiating menopausal hormone therapy. Menopause. 2010 May-Jun;17(3):462-70. PMID: 20009961. ***X-2***

514. Crawford ML, Waller PC, Wood SM; Severe cystitis associated with tiaprofenic acid. Br J Urol. 1997 Apr;79(4):578-84. PMID: 9126086. ***X-2, X-4***

515. Creinin MD, Lisman R, Strickler RC; Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril. 1999 Oct;72(4):646-51. PMID: 10521103. ***X-1, X-4***

516. Critchley HO, Wang H, Jones RL, et al.; Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod. 1998 May;13(5):1218-24. PMID: 9647550. ***X-2***

517. Critchley HO, Wang H, Kelly RW, et al.; Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod. 1998 May;13(5):1210-7. PMID: 9647549. ***X-2, X-4***

518. Cromer BA, Bonny AE, Stager M, et al.; Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril. 2008 Dec;90(6):2060-7. PMID: 18222431. ***X-2***

519. Cromer BA, Smith RD, Blair JM, et al.; A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics. 1994 Nov;94(5):687-94. PMID: 7936897. ***X-2, X-3, X-4***

520. Cromer BA, Stager M, Bonny A, et al.; Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004 Dec;35(6):434-41. PMID: 15581522. ***X-2***

521. Cropsey KL, Matthews C, Campbel S, et al.; Long-term, reversible contraception use among high-risk women treated in a university-based gynecology clinic: comparison between IUD and depo-provera. J Womens Health (Larchmt). 2010 Feb;19(2):349-53. PMID: 20109106. ***X-2***

522. Cross RK, Wilson KT, Binion DG; Polypharmacy and Crohn's disease. Aliment Pharmacol Ther. 2005 May 15;21(10):1211-6. PMID: 15882241. ***X-2, X-3, X-4***

523. Cruz-Correa M, Hylind LM, Romans KE, et al.; Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology. 2002 Mar;122(3):641-5. PMID: 11874996. ***X-2, X-4***

524. Cullen DJ, Hawkey GM, Greenwood DC, et al.; Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut. 1997 Oct;41(4):459-62. PMID: 9391242. ***X-2, X-4***

525. Cullins VE, Blumenthal PD, Remsburg RE, et al.; Preliminary experience with Norplant in an inner city population. Contraception. 1993 Feb;47(2):193-203. PMID: 8449019. ***X-2, X-3, X-4***

526. Cunnington M, Webb D, Qizilbash N, et al.; Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf. 2008 Jun;17(6):601-8. PMID: 18383442. ***X-4***

527. Cuong DT, My Huong NT; Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem, in Vietnamese women. Contraception. 1996 Sep;54(3):169-79. PMID: 8899259. ***X-2, X-4***

528. Curhan GC, Willett WC, Rosner B, et al.; Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002 Oct 28;162(19):2204-8. PMID: 12390063. ***X-4***

529. Currie CJ, Poole CD, Gale EA; The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009 Sep;52(9):1766-77. PMID: 19572116. ***X-3***

530. Curtis JR, Cheng H, Delzell E, et al.; Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. Med Care. 2008 Sep;46(9):969-75. PMID: 18725852. ***X-4***

531. Curtis JR, Olivieri J, Allison JJ, et al.; A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs. Am J Manag Care. 2005 Sep;11(9):537-43. PMID: 16159043. ***X-2, X-3, X-4***

532. Cury DB, Moss AC; Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010 Aug;16(8):1393-6. PMID: 19998457. ***X-2, X-4***

533. Cushman M, Kuller LH, Prentice R, et al.; Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004 Oct 6;292(13):1573-80. PMID: 15467059. ***X-7***

534. Czeizel AE, Kodaj I; A changing pattern in the association of oral contraceptives and the different groups of congenital limb deficiencies. Contraception. 1995 Jan;51(1):19-24. PMID: 7750279. ***X-4***

535. da Silva Dal Pizzol T, Schuler-Faccini L, Mengue SS, et al.; Dipyrone use during pregnancy and adverse perinatal events. Arch Gynecol Obstet. 2009 Mar;279(3):293-7. PMID: 18568358. ***X-4***

536. da Silva MO, Costa MM; Reason, myths and fantasies: preliminary data and reflections about the Portuguese experience with LNG-IUS-induced hypomenorrhea. Eur J Contracept Reprod Health Care. 1999 Mar;4(1):21-5. PMID: 10367192. ***X-2, X-3, X-4***

537. Dai C, Stafford RS, Alexander GC; National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med. 2005 Jan 24;165(2):171-7. PMID: 15668363. ***X-3, X-4***

538. Dalmau A, Sabate A, Acosta F, et al.; Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg. 2000 Jul;91(1):29-34. PMID: 10866882. ***X-2, X-3, X-4***

539. Dalton SO, Johansen C, Mellemkjaer L, et al.; Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003 Jan 13;163(1):59-64. PMID: 12523917. ***X-4***

540. Dammann HG, Saleki M, Torz M, et al.; Effects of buffered and plain acetylsalicylic acid formulations with and without ascorbic acid on gastric mucosa in healthy

subjects. Aliment Pharmacol Ther. 2004 Feb 1;19(3):367-74. PMID: 14984384. ***X-2, X-4***

541. Daniel E, Thorne JE, Newcomb CW, et al.; Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010 Mar;149(3):423-32 e1-2. PMID: 20042178. ***X-2, X-3, X-4***

542. Daniels S, Robbins J, West CR, et al.; Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Clin Ther. 2009 Jun;31(6):1192-208. PMID: 19695387. ***X-1, X-2, X-3, X-4***

543. Daperno M, Sostegni R, Canaparo R, et al.; Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2009 Oct 15;30(8):843-53. PMID: 19650826. ***X-2, X-3, X-4***

544. Dastjerdi MS, Kazemi F, Najafian A, et al.; An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. Int J Obes (Lond). 2007 Apr;31(4):713-7. PMID: 16969361. ***X-2, X-3, X-4***

545. Davies NM, Jamali F; COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci. 2004 Oct 29;7(3):332-6. PMID: 15576013. ***X-1, X-4***

546. Davis A, Godwin A, Lippman J, et al.; Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000 Dec;96(6):913-20. PMID: 11084177. ***X-2, X-3, X-4***

547. Davis AR, Kroll R, Soltes B, et al.; Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril. 2008 May;89(5):1059-63. PMID: 17658522. ***X-2, X-3, X-4***

548. Davis JM, Hendricks-Munoz KD, Hagberg D, et al.; The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus. Dev Pharmacol Ther. 1990;14(1):15-9. PMID: 2311476. ***X-4***

549. Dawkins TN, Barclay CA, Gardiner RL, et al.; Safety of intravenous use of ketorolac in infants following cardiothoracic surgery. Cardiol Young. 2009 Feb;19(1):105-8. PMID: 19134246. ***X-2, X-4***

550. de Abajo FJ, Garcia Rodriguez LA; Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1. PMID: 11228592. ***X-4***

551. de Abajo FJ, Rodriguez LA, Montero D; Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999 Oct 23;319(7217):1106-9. PMID: 10531103. ***X-4***

552. de Aloysio D, Mauloni M, Roncuzzi A, et al.; Effects of an oral contraceptive combination containing 0.150 mg desogestrel plus 0.020 mg ethinyl estradiol on healthy premenopausal women. Arch Gynecol Obstet. 1993;253(1):15-9. PMID: 8328816. ***X-2, X-4***

553. de Andrade RP; A multicenter clinical evaluation of a new monophasic combination: Minulet (gestodene and ethinyl estradiol). Int J Fertil. 1989 Sep;34 Suppl:22-30. PMID: 2576253. ***X-4***

554. De Bellis A, Colao A, Savoia A, et al.; Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies. Clin Endocrinol (Oxf). 2008 Aug;69(2):285-91. PMID: 18221394. ***X-2, X-3***

555. de Carvalho MN, Nobre F, Mendes MC, et al.; Low-dose transdermal hormone therapy does not interfere with the blood pressure of hypertensive menopausal women: a pilot study. Blood Press Monit. 2008 Oct;13(5):277-83. PMID: 18799953. ***X-2, X-4***

556. De Caterina R, Ruigomez A, Rodriguez LA; Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med. 2010 Sep 13;170(16):1450-5. PMID: 20837831. ***X-2***

557. De Groote D, Perrier d'Hauterive S, Pintiaux A, et al.; Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18-35 years old. Contraception. 2009 Aug;80(2):187-93. PMID: 19631796. ***X-2***

558. de Jong DJ, Tielen J, Habraken CM, et al.; 5-Aminosalicylates and effects on renal function in patients with Crohn's disease. Inflamm Bowel Dis. 2005 Nov;11(11):972-6. PMID: 16239842. ***X-2, X-4***

559. de Jong JC, van den Berg PB, Tobi H, et al.; Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 2003 Jun;55(6):591-5. PMID: 12814454. ***X-4***

560. de Jonge ET, Yigit R, Molenberghs G, et al.; Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system. Contraception. 2007 Aug;76(2):91-5. PMID: 17656176. ***X-2, X-3, X-4***

561. De Ledinghen V, Heresbach D, Fourdan O, et al.; Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut. 1999 Feb;44(2):270-3. PMID: 9895389. ***X-2***

562. de Ledinghen V, Mannant PR, Foucher J, et al.; Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study. J Hepatol. 1996 May;24(5):570-3. PMID: 8773912. ***X-2, X-4***

563. De Santis M, Cavaliere AF, Straface G, et al.; Failure of the emergency contraceptive levonorgestrel and the risk of adverse effects in pregnancy and on fetal development: an observational cohort study. Fertil Steril. 2005 Aug;84(2):296-9. PMID: 16084867. ***X-2, X-3, X-4***

564. De Silva B, Banney L, Uttley W, et al.; Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis. Pediatr Dermatol. 2000 Nov-Dec;17(6):480-3. PMID: 11123786. ***X-2***

565. De Valle MB, Av Klinteberg V, Alem N, et al.; Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006 Oct 15;24(8):1187-95. PMID: 17014577. ***X-2, X-4***

566. de Vlam K, Lories RJ; Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford). 2006 Mar;45(3):321-4. PMID: 16234275. ***X-2, X-4***

567. de Vries F, Setakis E, van Staa TP; Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes. Br J Clin Pharmacol. 2010 Sep;70(3):429-38. PMID: 20716244. ***X-4***

568. de Vries NK, Jagroep FK, Jaarsma AS, et al.; Continuous indomethacin infusion may be less effective than bolus infusions for ductal closure in very low birth weight infants. Am J Perinatol. 2005 Feb;22(2):71-5. PMID: 15731984. ***X-2, X-3, X-4***

569. de Waal WJ, Torn M, de Muinck Keizer-Schrama SM, et al.; Long term sequelae of sex steroid treatment in the management of constitutionally tall stature. Arch Dis Child. 1995 Oct;73(4):311-5. PMID: 7492194. ***X-2***

570. DeBisschop M; What are the risks of long-term NSAIDs and COX-2 inhibitors? J Fam Pract. 2003 Mar;52(3):199-200. PMID: 12620173. ***X-1, X-3, X-4***

571. Dedier J, Stampfer MJ, Hankinson SE, et al.; Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002 Nov;40(5):604-8; discussion 1-3. PMID: 12411450. ***X-4***

572. Defrance C, Bousquet PJ, Demoly P; Evaluating the negative predictive value of provocation tests with nonsteroidal anti-inflammatory drugs. Allergy. 2011 Nov;66(11):1410-4. PMID: 21722141. ***X-2***

573. DeFronzo RA, Okerson T, Viswanathan P, et al.; Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008 Oct;24(10):2943-52. PMID: 18786299. ***X-2***

574. Degner F, Sigmund R, Zeidler H; Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther. 2000 Apr;22(4):400-10. PMID: 10823362. ***X-4***

575. Deguchi M, Rapoff AJ, Zdeblick TA; Posterolateral fusion for isthmic spondylolisthesis in adults: analysis of fusion rate and clinical results. J Spinal Disord. 1998 Dec;11(6):459-64. PMID: 9884288. ***X-2, X-3, X-4***

576. del Carmen Cravioto M, Alvarado G, Canto-de-Cetina T, et al.; A multicenter comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant and Norplant-II. Contraception. 1997 Jun;55(6):359-67. PMID: 9262932. ***X-2, X-4***

577. Del Dotto P, Gambaccini G, Caneparo D, et al.; Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists. Neurol Sci. 2003 Oct;24(3):170-1. PMID: 14598071. ***X-2***

578. Delgrange E, Daems T, Verhelst J, et al.; Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009 May;160(5):747-52. PMID: 19223454. ***X-2, X-3***

579. Delzell E, Shapiro S; Commentary on the National Kidney Foundation position paper on analgesics and the kidney. Am J Kidney Dis. 1996 Nov;28(5):783-5. PMID: 9158222. ***X-1***

580. Demco TA, Sutton H, Demco CJ, et al.; Topical diclofenac sodium compared with prednisolone acetate after phacoemulsification-lens implant surgery. Eur J Ophthalmol. 1997 Jul-Sep;7(3):236-40. PMID: 9352276. ***X-2, X-4***

581. Depont F, Fourrier A, Merliere Y, et al.; The CADEUS study: methods and logistics. Pharmacoepidemiol Drug Saf. 2007 May;16(5):571-80. PMID: 17121428. ***X-1, X-4, X-7***

582. Dequeker J, Hawkey C, Kahan A, et al.; Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998 Sep;37(9):946-51. PMID: 9783758. ***X-4***

583. Devi DP, Sushma M, Guido S; Drug-induced upper gastrointestinal disorders requiring hospitalization: a five-year study in a South Indian hospital. Pharmacoepidemiol Drug Saf. 2004 Dec;13(12):859-62. PMID: 15386699. ***X-2***

584. Devi K, George S, Criton S, et al.; Carbamazepine--the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol. 2005 Sep-Oct;71(5):325-8. PMID: 16394456. ***X-2, X-4***

585. Devin JK, Lakhani VT, Byrd BF, 3rd, et al.; Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract. 2008 Sep;14(6):672-7. PMID: 18996784. ***X-2***

586. Dhawan V, Medcalf P, Stegie F, et al.; Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. J Neural Transm. 2005 May;112(5):661-8. PMID: 15785862. ***X-2***

587. Di Carlo C, Tommaselli GA, Gargano V, et al.; Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric. 2010 Oct;13(5):442-6. PMID: 20575654. ***X-2, X-3, X-4***

588. Di Fiore F, Lecleire S, Merle V, et al.; Changes in characteristics and outcome of acute upper gastrointestinal haemorrhage: a comparison of epidemiology and practices between 1996 and 2000 in a multicentre French study. Eur J Gastroenterol Hepatol. 2005 Jun;17(6):641-7. PMID: 15879726. ***X-4***

589. Di Paolo MC, Paoluzi OA, Pica R, et al.; Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. Dig Liver Dis. 2001 Oct;33(7):563-9. PMID: 11816545. ***X-2, X-4***

590. Di Sarno A, Landi ML, Cappabianca P, et al.; Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001 Nov;86(11):5256-61. PMID: 11701688. ***X-2***

591. Di Silverio F, Sciarra A; Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer. J Urol. 2003 Nov;170(5):1812-6. PMID: 14532782. ***X-2, X-3, X-4***

592. Diav-Citrin O, Park YH, Veerasuntharam G, et al.; The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology. 1998 Jan;114(1):23-8. PMID: 9428214. ***X-2, X-4***

593. Diaz J, Bahamondes L, Diaz M, et al.; Evaluation of the performance of the copper T380A IUD up to ten years. Is this IUD a reversible but potentially permanent method? Adv Contracept. 1992 Dec;8(4):275-80. PMID: 1290329. ***X-2, X-3, X-4***

594. Diaz J, Bahamondes L, Monteiro I, et al.; Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception. 2000 Aug;62(2):59-61. PMID: 11102588. ***X-2***

595. Diaz J, Faundes A, Olmos P, et al.; Bleeding complaints during the first year of norplant implants use and their impact on removal rate. Contraception. 1996 Feb;53(2):91-5. PMID: 8838485. ***X-2, X-3, X-4***

596. Diaz J, Pinto Neto A, Diaz M, et al.; Long-term evaluation of the clinical performance of the TCu200B and the TCu380A in Campinas, Brazil. Adv Contracept. 1992 Mar;8(1):67-72. PMID: 1590103. ***X-3, X-4***

597. Diaz J, Pinto Neto AM, Bahamondes L, et al.; Performance of the copper T 200 in parous adolescents: are copper IUDs suitable for these women? Contraception. 1993 Jul;48(1):23-8. PMID: 8403902. ***X-2, X-4***

598. Diaz RL, Gardeazabal J, Manrique P, et al.; Greater allergenicity of topical ketoprofen in contact dermatitis confirmed by use. Contact Dermatitis. 2006 May;54(5):239-43. PMID: 16689806. ***X-4***

599. Diaz S, Pavez M, Brandeis A, et al.; A longitudinal study on cortisol, prolactin and thyroid hormones in users of Norplant subdermal implants or a copper T device. Contraception. 1989 Oct;40(4):505-17. PMID: 2510969. ***X-2, X-4***

600. Diaz S, Pavez M, Miranda P, et al.; Long-term follow-up of women treated with Norplant implants. Contraception. 1987 Jun;35(6):551-67. PMID: 3117490. ***X-2, X-4***

601. Diaz S, Zepeda A, Maturana X, et al.; Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauterine devices. Contraception. 1997 Oct;56(4):223-32. PMID: 9408703. ***X-2, X-3, X-4***

602. Dichtwald S, Weinbroum AA, Sorkine P, et al.; Metformin-associated lactic acidosis following acute kidney injury. Efficacious treatment with continuous renal replacement therapy. Diabet Med. 2012 Feb;29(2):245-50. PMID: 21977945. ***X-2***

603. Diestelhorst M, Schmidl B, Konen W, et al.; Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03%, and indomethacin 1.0% in controlling postoperative inflammation. J Cataract Refract Surg. 1996;22 Suppl 1:788-93. PMID: 9279673. ***X-2, X-3, X-4***

604. Dincer D, Duman A, Dikici H, et al.; NSAID-related upper gastrointestinal bleeding: are risk factors considered during prophylaxis? Int J Clin Pract. 2006 May;60(5):546-8. PMID: 16700851. ***X-2***

605. Dinesh KU, Subish P, Pranaya M, et al.; Pattern of potential drug-drug interactions in diabetic out-patients in a tertiary care teaching hospital in Nepal. Med J Malaysia. 2007 Oct;62(4):294-8. PMID: 18551932. ***X-2, X-3, X-4***

606. Ding WY, Lee CK, Choon SE; Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2010 Jul;49(7):834-41. PMID: 20618508. ***X-2***

607. Dinger J, Assmann A, Mohner S, et al.; Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care. 2010 Jul;36(3):123-9. PMID: 20659364. ***X-4***

608. Dinger J, Bardenheuer K, Minh TD; Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011 Mar;83(3):211-7. PMID: 21310281. ***X-4***

609. Dinger JC, Bardenheuer K, Assmann A; International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study). BMC Med Res Methodol. 2009;9:77. PMID: 19922634. ***X-1***

610. Dinger JC, Heinemann LA, Kuhl-Habich D; The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007 May;75(5):344-54. PMID: 17434015. ***X-4***

611. Dinis PB, Gomes A; Sinusitis and asthma: how do they interrelate in sinus surgery? Am J Rhinol. 1997 Nov-Dec;11(6):421-8. PMID: 9438054. ***X-2, X-3, X-4***

612. Diogo LP, Saitovitch D, Biehl M, et al.; Is there an association between non-steroidal anti-inflammatory drugs and contrast nephropathy? Arq Bras Cardiol. 2010 Dec;95(6):726-31. PMID: 21109911. ***X-2***

613. Dionne RA, Snyder J, Hargreaves KM; Analgesic efficacy of flurbiprofen in comparison with acetaminophen, acetaminophen plus codeine, and placebo after impacted third molar removal. J Oral Maxillofac Surg. 1994 Sep;52(9):919-24; discussion 25-6. PMID: 8064454. ***X-3, X-4***

614. Dizon CD, Allen LM, Ornstein MP; Menstrual and contraceptive issues among young women with developmental delay: a retrospective review of cases at the Hospital for Sick Children, Toronto. J Pediatr Adolesc Gynecol. 2005 Jun;18(3):157-62. PMID: 15970247. ***X-2, X-3, X-4***

615. Doan S, Lerouic JF, Robin H, et al.; Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmology. 2001 Sep;108(9):1565-8. PMID: 11535451. ***X-2, X-3, X-4***

616. Dominick KL, Bosworth HB, Jeffreys AS, et al.; Nonsteroidal antiinflammatory drug use among patients with GI bleeding. Ann Pharmacother. 2004 Jul-Aug;38(7-8):1159-64. PMID: 15187205. ***X-4, X-7***

617. Domschke S, Domschke W; Longer relapse-free period after sucralfate than after H2-blocker treatment of duodenal and gastric ulcers. Am J Med. 1991 Aug 8;91(2A):74S-83S. PMID: 1679297. ***X-3, X-4***

618. Donnenfeld ED, Nichamin LD, Hardten DR, et al.; Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery. Am J Ophthalmol. 2011 Mar;151(3):420-6 e1. PMID: 21145532. ***X-2, X-3, X-4***

619. Dore DD, Norman H, Loughlin J, et al.; Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010 May;81(5):408-13. PMID: 20399947. ***X-4***

620. Doren M, Rubig A, Coelingh Bennink HJ, et al.; Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause. 1999 Winter;6(4):299-306. PMID: 10614676. ***X-2, X-4***

621. Dorjgochoo T, Shu XO, Li HL, et al.; Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer. 2009 May 15;124(10):2442-9. PMID: 19170208. ***X-4***

622. Dormuth CR, Maclure M, Carney G, et al.; Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS One. 2009;4(6):e6080. PMID: 19562036. ***X-4***

623. Dougados M, Gueguen A, Nakache JP, et al.; Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford). 1999 Mar;38(3):235-44. PMID: 10325662. ***X-2, X-4***

624. Dougherty PL; Menstrual suppression: benefits and risks of continuous combined oral contraceptives. Nurs Womens Health. 2008 Jun;12(3):243-8. PMID: 18557855. ***X-1***

625. Dowd JE, Cimaz R, Fink CW; Nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children. Arthritis Rheum. 1995 Sep;38(9):1225-31. PMID: 7575716. ***X-2***

626. Doycheva D, Zierhut M, Blumenstock G, et al.; Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2011 Aug;249(8):1235-43. PMID: 21720813. ***X-2, X-3, X-4***

627. Doyle G, Furey S, Berlin R, et al.; Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther. 1999 Jul;13(7):897-906. PMID: 10383524. ***X-2***

628. Doyle NM, Gardner MO, Wells L, et al.; Outcome of very low birth weight infants exposed to antenatal

indomethacin for tocolysis. J Perinatol. 2005 May;25(5):336-40. PMID: 15861198. ***X-2, X-3, X-4***

629. Dreiser RL, Benevelli DC; Long term tolerability profile of nimesulide in the treatment of osteoarthritis. Drugs. 1993;46 Suppl 1:270-4. PMID: 7506188. ***X-2, X-4***

630. Driver JA, Logroscino G, Lu L, et al.; Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. BMJ. 2011;342:d198. PMID: 21252104. ***X-4, X-6***

631. Du MK, Chow LP, Zheng HM, et al.; A 10-year follow-up study of contraceptive Norplant implants. Int J Gynaecol Obstet. 2000 Mar;68(3):249-56. PMID: 10699196. ***X-4***

632. Du MK, Zheng HM, Chen HC, et al.; Study of Norplant implants in Shanghai: three-year experience. Int J Gynaecol Obstet. 1990 Dec;33(4):345-57. PMID: 1979289. ***X-2, X-3, X-4***

633. Duan L, Yan D, Zeng W, et al.; Effect of progesterone treatment due to threatened abortion in early pregnancy for obstetric and perinatal outcomes. Early Hum Dev. 2010 Jan;86(1):41-3. PMID: 20079582. ***X-2, X-3, X-4***

634. Dubos F, Hue V, Grandbastien B, et al.; Bacterial skin infections in children hospitalized with varicella: a possible negative impact of non-steroidal anti-inflammatory drugs? Acta Derm Venereol. 2008;88(1):26-30. PMID: 18176746. ***X-2, X-4***

635. Dugoff L, Jones OW, 3rd, Allen-Davis J, et al.; Assessing the acceptability of Norplant contraceptive in four patient populations. Contraception. 1995 Jul;52(1):45-9. PMID: 8521714. ***X-2, X-3, X-4***

636. Duijkers I, Engels L, Klipping C; Length of the menstrual cycle after discontinuation of oral contraceptives. Gynecol Endocrinol. 2005 Feb;20(2):74-9. PMID: 15823825. ***X-2, X-3, X-4***

637. Dunn K, Kovacs GT; Do copper containing intrauterine contraceptive devices need to be changed after 2 years? Clin Reprod Fertil. 1983 Dec;2(4):283-7. PMID: 6678604. ***X-1, X-2, X-3, X-4***

638. Dunn N; 10-minute consultation: adverse drug event. BMJ. 2003 May 10;326(7397):1018. PMID: 12742925. ***X-1***

639. Dunn N, Thorogood M, Faragher B, et al.; Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ. 1999 Jun 12;318(7198):1579-83. PMID: 10364115. ***X-3, X-4***

640. Dunson TR, McLaurin VL, Grubb GS, et al.; A multicenter clinical trial of a progestin-only oral contraceptive in lactating women. Contraception. 1993 Jan;47(1):23-35. PMID: 8435999. ***X-4***

641. Duong HV, Westfield KC, Chalkley TH; Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. J Cataract Refract Surg. 2007 Nov;33(11):1925-9. PMID: 17964399. ***X-2, X-3, X-4***

642. Durrieu G, Olivier P, Montastruc JL; COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database. Eur J Clin Pharmacol. 2005 Sep;61(8):611-4. PMID: 16133552. ***X-2, X-3, X-4***

643. Dushay J, Gao C, Gopalakrishnan GS, et al.; Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012 Jan;35(1):4-11. PMID: 22040840. ***X-2***

644. Dusterberg B, Brill K; Clinical experience with a low-dose oral contraceptive containing gestodene. Adv Contracept. 1990 Dec;6 Suppl:37-49; discussion 50. PMID: 2291446. ***X-11***

645. Dutka J, Dutka L, Janiszewski M, et al.; Cost analysis and sociomedical aspects of the conservative and surgical treatment of hip osteoarthritis. Ortop Traumatol Rehabil. 2008 Nov-Dec;10(6):537-46. PMID: 19153542. ***X-2, X-3, X-4***

646. Earl HM, Rubens RD, Knight RK, et al.; Norethisterone acetate in the treatment of advanced breast cancer. Clin Oncol. 1984 Jun;10(2):103-9. PMID: 6734001. ***X-2, X-3, X-4***

647. East-Innis AD, Thompson DS; Cutaneous drug reactions in patients admitted to the dermatology unit at the University Hospital of the West Indies, Kingston, Jamaica. West Indian Med J. 2009 Jun;58(3):227-30. PMID: 20043529. ***X-4***

648. Ebeling K, Ray R, Nischan P, et al.; Combined oral contraceptives containing chlormadinone acetate and breast cancer: results of a case-control study. Br J Cancer. 1991 May;63(5):804-8. PMID: 1710136. ***X-4***

649. Eberlein B, Eicke C, Reinhardt HW, et al.; Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008 Jan;22(1):73-82. PMID: 18181976. ***X-3, X-4***

650. Ebert MP, Schafer C, Chen J, et al.; Protective role of heat shock protein 27 in gastric mucosal injury. J Pathol. 2005 Oct;207(2):177-84. PMID: 16041694. ***X-3, X-4***

651. Edwards MJ, Kollenberg SJ, Brandt ML, et al.; Surgery for peptic ulcer disease in children in the post-histamine2-blocker era. J Pediatr Surg. 2005 May;40(5):850-4. PMID: 15937829. ***X-2, X-4***

652. Egarter C, Putz M, Strohmer H, et al.; Ovarian function during low-dose oral contraceptive use.

Contraception. 1995 Jun;51(6):329-33. PMID: 7554971. ***X-2, X-4***

653. Egberg N, van Beek A, Gunnervik C, et al.; Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. Contraception. 1998 Aug;58(2):93-8. PMID: 9773263. ***X-2, X-4***

654. Egberts AC, Meyboom RH, van Puijenbroek EP; Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf. 2002;25(6):453-8. PMID: 12071783. ***X-1***

655. Eilertsen AL, Sandvik L, Mowinckel MC, et al.; Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Thromb Res. 2007;120(3):371-9. PMID: 17156824. ***X-2, X-3, X-4***

656. Ekenel M, Avsar E, Imeryuz N, et al.; Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen. Eur J Gastroenterol Hepatol. 2003 Apr;15(4):403-6. PMID: 12655261. ***X-2, X-4***

657. Ekici F, Atasay B, Gunlemez A, et al.; Management of patent ductus arteriosus in preterm infants. Anadolu Kardiyol Derg. 2006 Mar;6(1):28-33. PMID: 16524797. ***X-2, X-3, X-4***

658. Elder MG, Lawson JP, Elstein M, et al.; The efficacy and acceptability of a low-dose levonorgestrel intravaginal ring for contraception in a UK cohort. Contraception. 1991 Feb;43(2):129-37. PMID: 1904020. ***X-2, X-3, X-4***

659. Elhakim M, Siam A, Rashed I, et al.; Topical tenoxicam from pharyngeal pack reduces postoperative sore throat. Acta Anaesthesiol Scand. 2000 Jul;44(6):733-6. PMID: 10903018. ***X-2, X-3, X-4***

660. Eliakim R, Karmeli F, Rachmilewitz D; Ketotifen--old drug, new indication: reduction of gastric mucosal injury. Scand J Gastroenterol. 1993 Mar;28(3):202-4. PMID: 8446844. ***X-2, X-3, X-4***

661. Eliakim R, Ophir M, Rachmilewitz D; Duodenal mucosal injury with nonsteroidal antiinflammatory drugs. J Clin Gastroenterol. 1987 Aug;9(4):395-9. PMID: 3498747. ***X-2***

662. Elkik F, Basdevant A, Jackanicz TM, et al.; Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel. J Clin Endocrinol Metab. 1986 Jul;63(1):29-35. PMID: 3086360. ***X-2, X-3, X-4***

663. Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al.; Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2008;93(7):2670-8. PMID: 18460557. ***X-2, X-3, X-4***

664. Elovainio M, Teperi J, Aalto AM, et al.; Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system. Int J Behav Med. 2007;14(2):70-5. PMID: 17926434. ***X-2***

665. el-Reshaid K, Kapoor M, Johny KV, et al.; Acute renal failure in Kuwait--a prospective study. J Trop Med Hyg. 1993 Oct;96(5):323-9. PMID: 8411309. ***X-2, X-3, X-4***

666. Elseviers MM, D'Haens G, Lerebours E, et al.; Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol. 2004 Feb;61(2):83-9. PMID: 14989626. ***X-2, X-4***

667. Elwatidy S, Jamjoom Z, Elgamal E, et al.; Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Spine (Phila Pa 1976). 2008 Nov 15;33(24):2577-80. PMID: 19011538. ***X-2***

668. Endo H, Hosono K, Inamori M, et al.; Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol. 2009;44(6):544-9. PMID: 19373431. ***X-2***

669. Endo N, Kato S, Haruyama K, et al.; Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol. 2010 Dec;88(8):896-900. PMID: 19725815. ***X-2, X-3, X-4***

670. Endrikat J, Dusterberg B, Ruebig A, et al.; Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception. 1999 Nov;60(5):269-74. PMID: 10717778. ***X-2, X-4***

671. Endrikat J, Jaques MA, Mayerhofer M, et al.; A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception. 1995 Oct;52(4):229-35. PMID: 8605781. ***X-2***

672. Endrikat J, Klipping C, Cronin M, et al.; An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception. 2002 Mar;65(3):215-21. PMID: 11929643. ***X-2, X-4***

673. Endrikat J, Mih E, Dusterberg B, et al.; A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or

30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception. 2004 Mar;69(3):179-87. PMID: 14969664. ***X-2, X-4***

674. Endrikat J, Noah M, Gerlinger C, et al.; Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations. Contraception. 2001 Oct;64(4):217-22. PMID: 11747870. ***X-2, X-4***

675. Endrikat J, Shapiro H, Lukkari-Lax E, et al.; A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can. 2009 Apr;31(4):340-7. PMID: 19497153. ***X-2, X-3***

676. Engeland A, Skurtveit S, Morland J; Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol. 2007 Aug;17(8):597-602. PMID: 17574863. ***X-4***

677. Engoren M, Hadaway J, Schwann TA, et al.; Ketorolac improves graft patency after coronary artery bypass grafting: a propensity-matched analysis. Ann Thorac Surg. 2011 Aug;92(2):603-9. PMID: 21801915. ***X-2, X-4***

678. Engoren MC, Habib RH, Zacharias A, et al.; Postoperative analgesia with ketorolac is associated with decreased mortality after isolated coronary artery bypass graft surgery in patients already receiving aspirin: a propensity-matched study. J Cardiothorac Vasc Anesth. 2007 Dec;21(6):820-6. PMID: 18068059. ***X-2, X-4***

679. Erbagci Z; Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with delayed, pronounced and prolonged autoreactivity. J Dermatol. 2004 May;31(5):376-82. PMID: 15187304. ***X-2***

680. Ericson A, Kallen BA; Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol. 2001 Jul-Aug;15(4):371-5. PMID: 11489592. ***X-4***

681. Ernst E, Schmolzl C, Matrai A, et al.; Hemorheological effects of oral contraceptives. Contraception. 1989 Nov;40(5):571-80. PMID: 2692965. ***X-2, X-4***

682. Ernst ME, Iyer SS, Doucette WR; Drug-related problems and quality of life in arthritis and low back pain sufferers. Value Health. 2003 Jan-Feb;6(1):51-8. PMID: 12535238. ***X-2, X-3, X-4***

683. Eroglu K, Akkuzu G, Vural G, et al.; Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception. 2006 Nov;74(5):376-81. PMID: 17046378. ***X-2, X-4***

684. Esparza F, Cobian C, Jimenez JF, et al.; Topical ketoprofen TDS patch versus diclofenac gel: efficacy and tolerability in benign sport related soft-tissue injuries. Br J Sports Med. 2007 Mar;41(3):134-9. PMID: 17138642. ***X-2, X-3, X-4***

685. Espey E, Steinhart J, Ogburn T, et al.; Depo-provera associated with weight gain in Navajo women. Contraception. 2000 Aug;62(2):55-8. PMID: 11102587. ***X-2***

686. Espinoza LR, Jara LJ, Martinez-Osuna P, et al.; Refractory nephrotic syndrome in lupus nephritis: favorable response to indomethacin therapy. Lupus. 1993 Feb;2(1):9-14. PMID: 8485564. ***X-2, X-4***

687. Essving P, Axelsson K, Kjellberg J, et al.; Reduced hospital stay, morphine consumption, and pain intensity with local infiltration analgesia after unicompartmental knee arthroplasty. Acta Orthop. 2009 Apr;80(2):213-9. PMID: 19404806. ***X-2, X-3, X-4***

688. Etienney I, Beaugerie L, Viboud C, et al.; Non-steroidal anti-inflammatory drugs as a risk factor for acute diarrhoea: a case crossover study. Gut. 2003 Feb;52(2):260-3. PMID: 12524410. ***X-2***

689. Etminan M, Delaney JA, Bressler B, et al.; Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ. 2011 May 17;183(8):899-904. PMID: 21502354. ***X-4***

690. Etminan M, Levesque L, Fitzgerald JM, et al.; Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case-control study. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1188-92. PMID: 19298582. ***X-4***

691. Etminan M, Suissa S; NSAID use and the risk of Parkinson's disease. Curr Drug Saf. 2006 Aug;1(3):223-5. PMID: 18690932. ***X-4***

692. Evans A, Perez I, Yu G, et al.; Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke. 2001 Dec 1;32(12):2828-32. PMID: 11739981. ***X-2, X-3, X-4***

693. Evans JM, Macgregor AM, Murray FE, et al.; No association between non-steroidal anti-inflammatory drugs and acute appendicitis in a case-control study. Br J Surg. 1997 Mar;84(3):372-4. PMID: 9117311. ***X-2, X-4***

694. Evans JM, McGregor E, McMahon AD, et al.; Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM. 1995 Aug;88(8):551-7. PMID: 7648241. ***X-4***

695. Evans JM, McMahon AD, McGilchrist MM, et al.; Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ. 1995 Jul 1;311(6996):22-6. PMID: 7613317. ***X-4***

696. Evans JM, McMahon AD, Murray FE, et al.; Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997 May;40(5):619-22. PMID: 9203940. ***X-4***

697. Evers S, Husstedt IW; Alternatives in drug treatment of chronic paroxysmal hemicrania. Headache. 1996 Jul-Aug;36(7):429-32. PMID: 8783475. ***X-2, X-3, X-4***

698. Eyster ME, Asaad SM, Gold BD, et al.; Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs. Haemophilia. 2007 May;13(3):279-86. PMID: 17498077. ***X-4***

699. Fagnani F, Bouvenot G, Valat JP, et al.; Medico-economic analysis of diacerein with or without standard therapy in the treatment of osteoarthritis. Pharmacoeconomics. 1998 Jan;13(1 Pt 2):135-46. PMID: 10176148. ***X-2, X-3, X-4***

700. Fakeye O, Balogh S; Effect of Norplant contraceptive use on hemoglobin, packed cell volume and menstrual bleeding patterns. Contraception. 1989 Mar;39(3):265-74. PMID: 2496950. ***X-2, X-4***

701. Famodu AA; Serial changes in plasma fibrinogen concentration and fibrinolytic activity in African women on oral contraceptive pills. Afr J Reprod Health. 1997 Sep;1(2):90-5. PMID: 10214418. ***X-2***

702. Fan M, Sujuan G; Menstrual bleeding patterns in Chinese women using the Norplant subdermal implant. Hum Reprod. 1996 Oct;11 Suppl 2:14-9. PMID: 8982740. ***X-2, X-4***

703. Fanos V, Benini D, Verlato G, et al.; Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. Fundam Clin Pharmacol. 2005 Apr;19(2):187-93. PMID: 15810899. ***X-2, X-4***

704. Farley TM, Meirik O, Chang CL, et al.; Combined oral contraceptives, smoking, and cardiovascular risk. J Epidemiol Community Health. 1998 Dec;52(12):775-85. PMID: 10396518. ***X-4***

705. Farmer RD, Lawrenson R; Utilization patterns of oral contraceptives in UK general practice. Contraception. 1996 Apr;53(4):211-5. PMID: 8706438. ***X-2, X-3, X-4***

706. Farmer RD, Lawrenson RA, Thompson CR, et al.; Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997 Jan 11;349(9045):83-8. PMID: 8996419. ***X-4***

707. Farmer RD, Lawrenson RA, Todd JC, et al.; A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol. 2000 Jun;49(6):580-90. PMID: 10848722. ***X-4***

708. Farr G, Rivera R; Interactions between intrauterine contraceptive device use and breast-feeding status at time of intrauterine contraceptive device insertion: analysis of TCu-380A acceptors in developing countries. Am J Obstet Gynecol. 1992 Jul;167(1):144-51. PMID: 1442918. ***X-4***

709. Farr G, Rivera R, Amatya R; Non-physician insertion of IUDs: clinical outcomes among TCu380A insertions in three developing-country clinics. Adv Contracept. 1998 Mar;14(1):45-57. PMID: 9587008. ***X-2, X-3, X-4***

710. Faundes D, Bahamondes L, Faundes A, et al.; No relationship between the IUD position evaluated by ultrasound and complaints of bleeding and pain. Contraception. 1997 Jul;56(1):43-7. PMID: 9306030. ***X-2, X-3, X-4***

711. Fauno P, Petersen KD, Husted SE; Increased blood loss after preoperative NSAID. Retrospective study of 186 hip arthroplasties. Acta Orthop Scand. 1993 Oct;64(5):522-4. PMID: 8237316. ***X-2, X-4***

712. Fayaz MK, Abel RJ, Pugh SC, et al.; Opioid-sparing effects of diclofenac and paracetamol lead to improved outcomes after cardiac surgery. J Cardiothorac Vasc Anesth. 2004 Dec;18(6):742-7. PMID: 15650984. ***X-2, X-4***

713. Feenstra J, Heerdink ER, Grobbee DE, et al.; Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med. 2002 Feb 11;162(3):265-70. PMID: 11822918. ***X-4, X-7***

714. Felder JB, Korelitz BI, Rajapakse R, et al.; Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000 Aug;95(8):1949-54. PMID: 10950041. ***X-2***

715. Felfernig M, Salat A, Kimberger O, et al.; Preemptive analgesia by lornoxicam--an NSAID--significantly inhibits perioperative platelet aggregation. Eur J Anaesthesiol. 2008 Sep;25(9):726-31. PMID: 18471341. ***X-2, X-3, X-4***

716. Fenner H; Evaluation of the efficacy and safety of NSAIDs. A new methodological approach. Scand J Rheumatol Suppl. 1989;80:32-9. PMID: 2688078. ***X-1***

717. Fenske WK, Pournaras DJ, Aasheim ET, et al.; Can a protocol for glycaemic control improve type 2 diabetes outcomes after gastric bypass? Obes Surg. 2012 Jan;22(1):90-6. PMID: 22052198. ***X-2***

718. Ferenczy A, Gelfand MM; Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas. 1997 Apr;26(3):219-26. PMID: 9147354. ***X-2, X-3, X-4***

719. Ferguson MA, Mackay SM, Ramchandani SR, et al.; Cryptogenic emboli in patients with patent foramen ovale or atrial septal defect associated with the use of nonsteroidal anti-inflammatory drugs. Cardiology. 2009;113(1):20-4. PMID: 18931493. ***X-2***

720. Ferraro-Peyret C, Coury F, Tebib JG, et al.; Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535-43. PMID: 15535831. ***X-2, X-3, X-4***

721. Ferrero S, Camerini G, Ragni N, et al.; Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. Hum Reprod. 2010 Jan;25(1):94-100. PMID: 19820247. ***X-2, X-3, X-4***

722. Ferrero S, Camerini G, Seracchioli R, et al.; Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009 Dec;24(12):3033-41. PMID: 19726448. ***X-2, X-4***

723. Fielder JH; The Vioxx debacle. IEEE Eng Med Biol Mag. 2005 Mar-Apr;24(2):106-9. PMID: 15825852. ***X-1***

724. Figueras A, Capella D, Castel JM, et al.; Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations. Eur J Clin Pharmacol. 1994;47(4):297-303. PMID: 7875178. ***X-4***

725. Figus M, Fogagnolo P, Lazzeri S, et al.; Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. Eur J Ophthalmol. 2010 Sep-Oct;20(5):811-8. PMID: 20383847. ***X-2, X-3, X-4***

726. Fiore LD, Ezekowitz MD, Brophy MT, et al.; Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002 Feb 5;105(5):557-63. PMID: 11827919. ***X-3, X-4***

727. Fischer LM, Schlienger RG, Matter CM, et al.; Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy. 2005 Apr;25(4):503-10. PMID: 15977911. ***X-4, X-7***

728. Fisman EZ, Tenenbaum A, Benderly M, et al.; Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology. 1999;91(3):195-202. PMID: 10516414. ***X-3***

729. Fitzgerald GA; Coxibs and cardiovascular disease. N Engl J Med. 2004 Oct 21;351(17):1709-11. PMID: 15470192. ***X-1***

730. Flach AJ, Dolan BJ, Donahue ME, et al.; Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Ophthalmology. 1998 Sep;105(9):1775-9. PMID: 9754191. ***X-2, X-4***

731. Flato B, Vinje O, Forre O; Toxicity of antirheumatic and anti-inflammatory drugs in children. Clin Rheumatol. 1998;17(6):505-10. PMID: 9890680. ***X-2***

732. Fleischmann RM; Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. J Rheumatol Suppl. 1992 Nov;36:32-40. PMID: 1474533. ***X-4***

733. Fleming R, Hopkinson ZE, Wallace AM, et al.; Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002 Feb;87(2):569-74. PMID: 11836287. ***X-2, X-3***

734. Fletcher AP; Profile of a large-scale cohort study. Drugs. 1990;40 Suppl 5:43-7. PMID: 2081492. ***X-11***

735. Flick ED, Chan KA, Bracci PM, et al.; Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case-control study. Am J Epidemiol. 2006 Sep 1;164(5):497-504. PMID: 16840523. ***X-4***

736. Flint SR, O'Sullivan C, Arthur N; An update of adverse drug reactions of relevance to general dental practice. J Ir Dent Assoc. 2000;46(2):67-70. PMID: 11326529. ***X-1***

737. Florentinus SR, Heerdink ER, de Boer A, et al.; The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):437-41. PMID: 15937867. ***X-4***

738. Foeldvari I, Szer IS, Zemel LS, et al.; A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol. 2009 Jan;36(1):174-82. PMID: 19012356. ***X-2***

739. Fontana RJ, Sanyal AJ, Mehta S, et al.; Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol. 2006 May;101(5):983-92. PMID: 16573786. ***X-2, X-3, X-4***

740. Fontbonne A, Andre P, Eschwege E; BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance. Diabete Metab. 1991 May;17(1 Pt 2):249-54. PMID: 1936485. ***X-1***

741. Ford AC, Forman D, Bailey AG, et al.; Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol. 2007 May;102(5):957-65. PMID: 17313501. ***X-4***

742. Fored CM, Ejerblad E, Lindblad P, et al.; Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001 Dec 20;345(25):1801-8. PMID: 11752356. ***X-2, X-4***

743. Forget P, Vandenhende J, Berliere M, et al.; Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010 Jun 1;110(6):1630-5. PMID: 20435950. ***X-2, X-4***

744. Foroutan M, Loloei B, Irvani S, et al.; Accuracy of rapid urease test in diagnosing Helicobacter pylori infection in patients using NSAIDs. Saudi J Gastroenterol. 2010 Apr-Jun;16(2):110-2. PMID: 20339181. ***X-2, X-4***

745. Forrest JB, Camu F, Greer IA, et al.; Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery. Br J Anaesth. 2002 Feb;88(2):227-33. PMID: 11883386. ***X-4***

746. Fortuny J, Johnson CC, Bohlke K, et al.; Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1154-9 e3. PMID: 17644046. ***X-2, X-4***

747. Fortuny J, Kogevinas M, Garcia-Closas M, et al.; Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1696-702. PMID: 16985032. ***X-2, X-4***

748. Fosbol EL, Folke F, Jacobsen S, et al.; Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes. 2010 Jul;3(4):395-405. PMID: 20530789. ***X-4***

749. Fosbol EL, Gislason GH, Jacobsen S, et al.; Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009 Feb;85(2):190-7. PMID: 18987620. ***X-4***

750. Foster M, Kendall R, Todd M; COX-2 inhibitor safety in the workers' compensation market. Lippincotts Case Manag. 2005 Jul-Aug;10(4):217-20. PMID: 16056119. ***X-1***

751. Fournier A, Berrino F, Clavel-Chapelon F; Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008 Jan;107(1):103-11. PMID: 17333341. ***X-4***

752. Fourrier-Reglat A, Cuong HM, Lassalle R, et al.; Concordance between prescriber- and patient-reported previous medical history and NSAID indication in the CADEUS cohort. Pharmacoepidemiol Drug Saf. 2010 May;19(5):474-81. PMID: 20437457. ***X-4***

753. Foutch PG; Diverticular bleeding: are nonsteroidal anti-inflammatory drugs risk factors for hemorrhage and can colonoscopy predict outcome for patients? Am J Gastroenterol. 1995 Oct;90(10):1779-84. PMID: 7572894. ***X-2***

754. Fraenkel L, Bogardus ST, Jr., Concato J, et al.; Treatment options in knee osteoarthritis: the patient's perspective. Arch Intern Med. 2004 Jun 28;164(12):1299-304. PMID: 15226163. ***X-2, X-3, X-4***

755. Fraj J, Valero A, Vives R, et al.; Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases. Allergy. 2008 Jan;63(1):112-5. PMID: 18053020. ***X-2, X-3, X-4***

756. Franck H, Rau R, Herborn G; Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol. 1996 May;15(3):266-70. PMID: 8793258. ***X-2, X-4***

757. Francois P, Desrumaux A, Cans C, et al.; Prevalence and risk factors of suppurative complications in children with pneumonia. Acta Paediatr. 2010 Jun;99(6):861-6. PMID: 20178517. ***X-2***

758. Frankel A, Sohn A, Patel RV, et al.; Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis. J Drugs Dermatol. 2011 Jun;10(6):666-72. PMID: 21637908. ***X-2, X-3, X-4***

759. Fraser D, Whitehead M, Schenkel L, et al.; Does low-dose, transdermal, norethisterone acetate reliably cause endometrial transformation in postmenopausal oestrogen-users? Maturitas. 1993 Jan;16(1):23-30. PMID: 8429801. ***X-2, X-4***

760. Fraser IS, McCarron G; Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991 Feb;31(1):66-70. PMID: 1872778. ***X-2, X-3, X-4***

761. Fraser IS, McCarron G, Markham R, et al.; Long-term treatment of menorrhagia with mefenamic acid. Obstet Gynecol. 1983 Jan;61(1):109-12. PMID: 6337354. ***X-2***

762. Fraser IS, Pearse C, Shearman RP, et al.; Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet Gynecol. 1981 Nov;58(5):543-51. PMID: 7029369. ***X-2, X-3, X-4***

763. Fraser IS, Romer T, Parke S, et al.; Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and

dienogest: A randomized, double-blind Phase III trial. Human Reproduction. 2011;26(10):2698-708. PMID: 21784734. ***X-2, X-3***

764. Fraser JS, Muller AF, Smith DJ, et al.; Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther. 2001 Aug;15(8):1131-7. PMID: 11472315. ***X-2, X-3, X-4***

765. Freedland SJ, Blanco-Yarosh M, Sun JC, et al.; Ketorolac-based analgesia improves outcomes for living kidney donors. Transplantation. 2002 Mar 15;73(5):741-5. PMID: 11907420. ***X-2, X-3, X-4***

766. Friedman S, Flidel-Rimon O, Steinberg M, et al.; Indomethacin tocolysis and white matter injury in preterm infants. J Matern Fetal Neonatal Med. 2005 Aug;18(2):87-91. PMID: 16203592. ***X-4***

767. Fries J; Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol Suppl. 1996;102:3-8. PMID: 8628980. ***X-4***

768. Fries JF; Safety issues related to DMARD therapy. J Rheumatol Suppl. 1990 Nov;25:14-7. PMID: 2273518. ***X-1, X-4***

769. Fries JF; ARAMIS and toxicity measurement. (Arthritis Rheumatism and Aging Medical Information System). J Rheumatol. 1995 May;22(5):995-7. PMID: 8587097. ***X-1, X-2, X-3, X-4***

770. Fries JF, Williams CA, Bloch DA; The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1991 Nov;34(11):1353-60. PMID: 1953813. ***X-4***

771. Fries JF, Williams CA, Bloch DA, et al.; Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991 Sep;91(3):213-22. PMID: 1892140. ***X-4***

772. Fries JF, Williams CA, Ramey D, et al.; The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum. 1993 Mar;36(3):297-306. PMID: 8452574. ***X-4***

773. Friesecke S, Abel P, Roser M, et al.; Outcome of severe lactic acidosis associated with metformin accumulation. Crit Care. 2010;14(6):R226. PMID: 21171991. ***X-2***

774. Friis S, Thomassen L, Sorensen HT, et al.; Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev. 2008 Apr;17(2):88-96. PMID: 18287865. ***X-4***

775. Fromm GL, Freedman RS, Fritsche HA, et al.; Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors. Cancer. 1991 Nov 1;68(9):1885-9. PMID: 1833046. ***X-2, X-3, X-4***

776. Froud T, Faradji RN, Pileggi A, et al.; The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008 Jul 15;86(1):36-45. PMID: 18622276. ***X-2, X-4***

777. Fuchs N, Dusterberg B, Weber-Diehl F, et al.; The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene. Contraception. 1995 Jun;51(6):335-9. PMID: 7554972. ***X-4***

778. Fugere P; Five years experience of intrauterine contraception with the Nova-T. Contraception. 1990 Jan;41(1):1-7. PMID: 2302943. ***X-2, X-3, X-4***

779. Fujii AM, Brown E, Mirochnick M, et al.; Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol. 2002 Oct-Nov;22(7):535-40. PMID: 12368968. ***X-2, X-3, X-4***

780. Fujii T, Nakabayashi T, Hashimoto S, et al.; Correlation between serum triglycerides and gastro-duodenal ulcer associated with low-dose aspirin. Hepatogastroenterology. 2009 Jul-Aug;56(93):1241-4. PMID: 19760979. ***X-2, X-4***

781. Fujimori S, Gudis K, Takahashi Y, et al.; Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest. 2010 Jun;40(6):504-10. PMID: 20412292. ***X-2***

782. Fujisawa N, Inamori M, Endo H, et al.; Incidence of and risk factors for upper gastrointestinal complications in patients taking low-dose aspirin in Japan. Hepatogastroenterology. 2011 Jan-Feb;58(105):229-34. PMID: 21510320. ***X-2, X-4***

783. Fujita WH, McCormick CL, Parneix-Spake A; An exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba. Int J Dermatol. 2007 Jul;46(7):700-5. PMID: 17614797. ***X-2, X-3, X-4***

784. Fuldeore MJ, Marx SE, Chwalisz K, et al.; Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin. 2010 Mar;26(3):729-36. PMID: 20092387. ***X-2, X-3, X-4***

785. Fuller JR, Bevin TH, Molteno AC, et al.; Anti-inflammatory fibrosis suppression in threatened trabeculectomy bleb failure produces good long term control of intraocular pressure without risk of sight threatening complications. Br J Ophthalmol. 2002 Dec;86(12):1352-4. PMID: 12446362. ***X-2, X-3, X-4***

786. Furberg CD, Vittinghoff E, Davidson M, et al.; Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002 Feb 26;105(8):917-22. PMID: 11864918. ***X-3, X-4***

787. Gabb GM, Ryan P, Wing LM, et al.; Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med. 1996 Dec;26(6):777-82. PMID: 9028507. ***X-2, X-3, X-4***

788. Gabriel SE, Campion ME, O'Fallon WM; A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1994 Mar;37(3):333-41. PMID: 8129789. ***X-2, X-3, X-4***

789. Gabriel SE, Sunku J, Salvarani C, et al.; Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997 Oct;40(10):1873-8. PMID: 9336424. ***X-2***

790. Gadsby R, Holden J; The Multiload CU250 in general practice. Practitioner. 1988 Dec;232(1460):1343, 7. PMID: 3256888. ***X-1, X-2, X-3, X-4***

791. Gagne JJ, Maio V, Rabinowitz C; Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther. 2008 Apr;33(2):141-51. PMID: 18315779. ***X-3, X-4***

792. Gal P, Ransom JL, Schall S, et al.; Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response. J Perinatol. 1990 Mar;10(1):20-6. PMID: 2313390. ***X-2, X-3, X-4***

793. Galasko CS, Courtney P, Jayne M, et al.; Comparison of the efficacy of naproxen sodium and dihydrocodeine tartrate in the treatment of post-operative pain. Curr Med Res Opin. 1988;10(10):656-62. PMID: 3371081. ***X-2, X-3, X-4***

794. Gallagher PF, Barry PJ, Ryan C, et al.; Inappropriate prescribing in an acutely ill population of elderly patients as determined by Beers' Criteria. Age Ageing. 2008 Jan;37(1):96-101. PMID: 17933759. ***X-2, X-3, X-4***

795. Gallelli L, Colosimo M, Pirritano D, et al.; Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs. Clin Drug Investig. 2007;27(2):115-22. PMID: 17217316. ***X-4***

796. Gallerani M, Simonato M, Manfredini R, et al.; Risk of hospitalization for upper gastrointestinal tract bleeding. J Clin Epidemiol. 2004 Jan;57(1):103-10. PMID: 15019017. ***X-4***

797. Gallicchio L, Visvanathan K, Burke A, et al.; Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer. 2007 Jul 1;121(1):211-15. PMID: 17330846. ***X-4***

798. Ganacharya S, Bhattoa HP, Batar I; Ectopic pregnancy among non-medicated and copper-containing intrauterine device users: a 10-year follow-up. Eur J Obstet Gynecol Reprod Biol. 2003 Nov 10;111(1):78-82. PMID: 14557017. ***X-4***

799. Ganacharya S, Bhattoa HP, Batar I; Pre-malignant and malignant cervical pathologies among inert and copper-bearing intrauterine contraceptive device users: a 10-year follow-up study. Eur J Contracept Reprod Health Care. 2006 Jun;11(2):89-97. PMID: 16854681. ***X-4***

800. Ganie MA, Khurana ML, Eunice M, et al.; Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab. 2004 Jun;89(6):2756-62. PMID: 15181054. ***X-2, X-4***

801. Garamvolgyi G; Change to Tri-Regol from other oral contraceptives. Ther Hung. 1991;39(3):122-4. PMID: 1818425. ***X-2, X-3, X-4***

802. Garbe E, Andersohn F, Bronder E, et al.; Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol. 2011 Sep;154(5):644-53. PMID: 21749359. ***X-2, X-4***

803. Garcia Rodriguez LA, Barreales Tolosa L; Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007 Feb;132(2):498-506. PMID: 17258728. ***X-4***

804. Garcia Rodriguez LA, Egan K, FitzGerald GA; Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? PLoS Med. 2007 May;4(5):e157. PMID: 17518513. ***X-4***

805. Garcia Rodriguez LA, Gonzalez-Perez A; Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer. 2004 Aug 2;91(3):525-9. PMID: 15226764. ***X-4***

806. Garcia Rodriguez LA, Gonzalez-Perez A; Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med. 2005;3:17. PMID: 16316472. ***X-4***

807. Garcia Rodriguez LA, Gonzalez-Perez A, Johansson S, et al.; Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther. 2005 Aug 15;22(4):309-15. PMID: 16097997. ***X-4***

808. Garcia Rodriguez LA, Hernandez-Diaz S; Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001 Sep;12(5):570-6. PMID: 11505178. ***X-4***

809. Garcia Rodriguez LA, Hernandez-Diaz S; Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003 Mar;14(2):240-6. PMID: 12606892. ***X-4***

810. Garcia Rodriguez LA, Hernandez-Diaz S; Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004 Jan 1;159(1):23-31. PMID: 14693656. ***X-4***

811. Garcia Rodriguez LA, Jick H; Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994 Mar 26;343(8900):769-72. PMID: 7907735. ***X-4***

812. Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, et al.; Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011 Mar 15;123(10):1108-15. PMID: 21357821. ***X-4***

813. Garcia Rodriguez LA, Perez Gutthann S, Walker AM, et al.; The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ. 1992 Oct 10;305(6858):865-8. PMID: 1422399. ***X-4***

814. Garcia Rodriguez LA, Ruigomez A; Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology. 1999 May;10(3):228-32. PMID: 10230829. ***X-2, X-3, X-4***

815. Garcia Rodriguez LA, Ruigomez A, Jick H; A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy. 1997 Jul-Aug;17(4):721-8. PMID: 9250549. ***X-4***

816. Garcia Rodriguez LA, Tacconelli S, Patrignani P; Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008 Nov 11;52(20):1628-36. PMID: 18992652. ***X-4***

817. Garcia Rodriguez LA, Walker AM, Perez Gutthann S; Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology. 1992 Jul;3(4):337-42. PMID: 1637896. ***X-4***

818. Garcia Rodriguez LA, Williams R, Derby LE, et al.; Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994 Feb 14;154(3):311-6. PMID: 8297198. ***X-4***

819. Garcia-Gonzalez MA, Lanas A, Savelkoul PH, et al.; Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. Clin Exp Immunol. 2003 Dec;134(3):525-31. PMID: 14632761. ***X-2, X-3, X-4***

820. Garcia-Porrua C, Gonzalez-Gay MA, Lopez-Lazaro L; Drug associated cutaneous vasculitis in adults in northwestern Spain. J Rheumatol. 1999 Sep;26(9):1942-4. PMID: 10493674. ***X-2***

821. Gardner MO, Owen J, Skelly S, et al.; Preterm delivery after indomethacin. A risk factor for neonatal complications? J Reprod Med. 1996 Dec;41(12):903-6. PMID: 8979204. ***X-2, X-4***

822. Garza-Flores J; Cyclofem/Cyclo-Provera: emerging countries' perspective. Int J Gynaecol Obstet. 1998 Aug;62 Suppl 1:S31-6. PMID: 9806236. ***X-4***

823. Garza-Flores J, Martinez M, Valles De Bourges V, et al.; Comparative assessment of two low-dose oral contraceptives, Lo-Femenal and Lo-Estrin, in Mexican women. Adv Contracept. 1992 Dec;8(4):291-301. PMID: 1290331. ***X-2***

824. Garza-Flores J, Moraks del Olmo A, Fuziwara JL, et al.; Introduction of cyclofem once-a-month injectable contraceptive in Mexico. Contraception. 1998 Jul;58(1):7-12. PMID: 9743890. ***X-4***

825. Garza-Flores J, Valles de Bourges V, Martinez M, et al.; Safety and efficacy of a combined oral contraceptive: gestodene 75 micrograms plus ethinyl estradiol 30 micrograms in Mexican women. Adv Contracept. 1994 Mar;10(1):19-26. PMID: 8030449. ***X-2, X-4***

826. Gasse C, Christensen S, Riis A, et al.; Preadmission use of SSRIs alone or in combination with NSAIDs and 30-day mortality after peptic ulcer bleeding. Scand J Gastroenterol. 2009;44(11):1288-95. PMID: 19891579. ***X-4***

827. Gasse C, Hollowell J, Meier CR, et al.; Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost. 2005 Sep;94(3):537-43. PMID: 16268469. ***X-4***

828. Gazarian M, Berkovitch M, Koren G, et al.; Experience with misoprostol therapy for NSAID gastropathy in children. Ann Rheum Dis. 1995 Apr;54(4):277-80. PMID: 7763105. ***X-2, X-3, X-4***

829. Geborek P, Crnkic M, Petersson IF, et al.; Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002 Sep;61(9):793-8. PMID: 12176803. ***X-2, X-4***

830. Geczy M, Peltier L, Wolbach R; Naproxen tolerability in the elderly: a summary report. J Rheumatol. 1987 Apr;14(2):348-54. PMID: 3599004. ***X-7***

831. Geisser P, Rumyantsev V; Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschung. 2010;60(6a):373-85. PMID: 20648929. ***X-2, X-4***

832. Gemzell-Danielsson K, Inki P, Boubli L, et al.; Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a

multicentre prospective study. Hum Reprod. 2010 Feb;25(2):354-9. PMID: 19955104. ***X-2, X-4***

833. Genkinger JM, De Vivo I, Stampfer MJ, et al.; Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int J Cancer. 2007 May 15;120(10):2221-5. PMID: 17290403. ***X-4, X-6***

834. Georgiev DB, Manassiev NA; Effect of long-term continuous combined hormone replacement therapy with estradiol valerate and either dienogest or norethisterone acetate on mammographic density in postmenopausal women. Medscape Womens Health. 2002 Jul-Aug;7(4):1. PMID: 12466733. ***X-2, X-3, X-4***

835. Gerais AS, Alwahab S, Omran KF, et al.; A comparative study of two estrogen dosages in combined oral contraceptives among Sudanese women. Int J Gynaecol Obstet. 1983 Dec;21(6):459-68. PMID: 6141106. ***X-2, X-4***

836. Germond M, Capelli P, Bruno G, et al.; Comparison of the efficacy and safety of two formulations of micronized progesterone (Ellios and Utrogestan) used as luteal phase support after in vitro fertilization. Fertil Steril. 2002 Feb;77(2):313-7. PMID: 11821089. ***X-2, X-4***

837. Geyer M, Peter S, Buhler H, et al.; Application of bleeding prophylactic criteria (NICE) in patients with acute gastrointestinal bleeding. A Swiss prospective study. Swiss Med Wkly. 2007 Mar 10;137(9-10):146-50. PMID: 17370155. ***X-2, X-3, X-4***

838. Giannoudis PV, MacDonald DA, Matthews SJ, et al.; Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br. 2000 Jul;82(5):655-8. PMID: 10963160. ***X-2***

839. Gibson PR, Fixa B, Pekarkova B, et al.; Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2006 Apr 1;23(7):1017-26. PMID: 16573804. ***X-2, X-3, X-4***

840. Giercksky KE; Piroxicam and gastrointestinal bleeding. Am J Med. 1986 Nov 28;81(5B):2-5. PMID: 3491541. ***X-2, X-4***

841. Giercksky KE, Huseby G, Rugstad HE; Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol Suppl. 1989;163:3-8. PMID: 2683027. ***X-4***

842. Gill JK, Maskarinec G, Wilkens LR, et al.; Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol. 2007 Nov 15;166(10):1150-8. PMID: 17698973. ***X-4***

843. Giordano N, Senesi M, Battisti E, et al.; Tolerability of nabumetone: a pilot in vitro study showing absence of injury to articular cartilage. Int J Tissue React. 1996;18(4-6):105-8. PMID: 9195245. ***X-4***

844. Giribela CR, Rubira MC, Melo NR, et al.; Effect of a low-dose oral contraceptive on venous endothelial function in healthy young women: preliminary results. Clinics (Sao Paulo). 2007 Apr;62(2):151-8. PMID: 17505700. ***X-2, X-4***

845. Girolami A, Spiezia L, Girolami B, et al.; Effect of age on oral contraceptive-induced venous thrombosis. Clin Appl Thromb Hemost. 2004 Jul;10(3):259-63. PMID: 15247983. ***X-2, X-3***

846. Gisbert JP, Gonzalez L, de Pedro A, et al.; Helicobacter pylori and bleeding duodenal ulcer: prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 2001 Jul;36(7):717-24. PMID: 11444470. ***X-2, X-3, X-4***

847. Gisbert JP, Legido J, Garcia-Sanz I, et al.; Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Dig Liver Dis. 2004 Feb;36(2):116-20. PMID: 15002818. ***X-2***

848. Gislason GH, Jacobsen S, Rasmussen JN, et al.; Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006 Jun 27;113(25):2906-13. PMID: 16785336. ***X-4***

849. Gislason GH, Rasmussen JN, Abildstrom SZ, et al.; Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009 Jan 26;169(2):141-9. PMID: 19171810. ***X-4***

850. Giugliano D, Quatraro A, Consoli G, et al.; Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993;44(2):107-12. PMID: 8453955. ***X-2, X-4***

851. Giuseppe P, Antonino R, Alessandro DB, et al.; Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 1997 Jan;78(1):74-8. PMID: 9012626. ***X-2, X-3, X-4***

852. Glantz S, Glantz JC, Campbell-Heider N, et al.; Norplant use among urban minority women in the United States. Contraception. 2000 Feb;61(2):83-90. PMID: 10802272. ***X-2, X-3, X-4***

853. Glantz S, Schaff E, Campbell-Heider N, et al.; Contraceptive implant use among inner city teens. J Adolesc Health. 1995 May;16(5):389-95. PMID: 7662690. ***X-2, X-3***

854. Glasier A, Yan Y, Wellings K; How do health care professionals respond to advice on adverse side effects of contraceptive methods? The case of Depo Provera. Contraception. 2007 Jul;76(1):18-22. PMID: 17586131. ***X-2, X-3, X-4***

855. Glasier AF, Wang H, Davie JE, et al.; Administration of an antiprogesterone up-regulates estrogen receptors in the endometrium of women using Norplant: a pilot study. Fertil Steril. 2002 Feb;77(2):366-72. PMID: 11821099. ***X-2, X-3, X-4***

856. Gleason JM, Slezak JM, Jung H, et al.; Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction. J Urol. 2011 Apr;185(4):1388-93. PMID: 21334642. ***X-6***

857. Gleeson MH, Davis AJ; Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a case-control study. Aliment Pharmacol Ther. 2003 Mar 15;17(6):817-25. PMID: 12641504. ***X-2***

858. Glueck CJ, Bornovali S, Pranikoff J, et al.; Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med. 2004 Aug;21(8):829-36. PMID: 15270785. ***X-2, X-4***

859. Glueck CJ, Pranikoff J, Aregawi D, et al.; Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil Steril. 2008 Mar;89(3):625-34. PMID: 17678910. ***X-2, X-3, X-4***

860. Glueck CJ, Wang P, Kobayashi S, et al.; Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 2002 Mar;77(3):520-5. PMID: 11872206. ***X-2, X-3, X-4***

861. Gobeaux-Castadot MJ, Boria MC, Chervenak FA, et al.; Five year clinical experience with the Copper 7 intrauterine device. Int J Gynaecol Obstet. 1981 Jun;19(3):181-92. PMID: 6120864. ***X-2, X-3, X-4***

862. Godil A, DeGuzman L, Schilling RC, 3rd, et al.; Recent nonsteroidal anti-inflammatory drug use increases the risk of early recurrence of bleeding in patients presenting with bleeding ulcer. Gastrointest Endosc. 2000 Feb;51(2):146-51. PMID: 10650255. ***X-2***

863. Goh H, Bourne R; Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case-control study. Ann R Coll Surg Engl. 2002 Mar;84(2):93-6. PMID: 11995772. ***X-2***

864. Goh JE, Sadler L, Rowan J; Metformin for gestational diabetes in routine clinical practice. Diabet Med. 2011 Sep;28(9):1082-7. PMID: 21679232. ***X-2, X-3***

865. Goicoechea M, Caramelo C, Ochando A, et al.; Antiplatelet therapy alters iron requirements in hemodialysis patients. Am J Kidney Dis. 2000 Jul;36(1):80-7. PMID: 10873876. ***X-2, X-3, X-4***

866. Gokmen O, Yapar Eyi EG; Hormone replacement therapy and lipid-lipoprotein concentrations. Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):31-41. PMID: 10428319. ***X-4, X-7***

867. Golbs S, Domhardt R, Presl J, et al.; Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in the Czech Republic. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):689-96. PMID: 12616963. ***X-2***

868. Golbs S, Domhardt R, Radowicky S, et al.; Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in Poland. Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):585-92. PMID: 12616705. ***X-2***

869. Goldenberg NA, Jacobson L, Manco-Johnson MJ; Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen. Ann Intern Med. 2005 Apr 5;142(7):506-9. PMID: 15809462. ***X-2***

870. Goldstein JL, Chan FK, Lanas A, et al.; Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials. Aliment Pharmacol Ther. 2011 Oct;34(7):808-16. PMID: 21810115. ***X-4***

871. Goldstein JL, Cryer B, Amer F, et al.; Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1167-74. PMID: 17916545. ***X-2, X-4***

872. Goldstein JL, Eisen GM, Lewis B, et al.; Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005 Feb;3(2):133-41. PMID: 15704047. ***X-2***

873. Goldstein JL, Huang B, Amer F, et al.; Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther. 2004 Oct;26(10):1637-43. PMID: 15598480. ***X-2, X-3, X-4***

874. Goldstein JL, Johanson JF, Suchower LJ, et al.; Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol. 2005 Dec;100(12):2650-7. PMID: 16393215. ***X-2, X-3, X-4***

875. Goldstein JL, Lowry SC, Lanza FL, et al.; The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther. 2006 May 15;23(10):1489-98. PMID: 16669964. ***X-2, X-7***

876. Goldstein JL, Zhao SZ, Burke TA, et al.; Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and

naproxen in an insured population in the United States. Am J Gastroenterol. 2003 Dec;98(12):2627-34. PMID: 14687808. ***X-4***

877. Gomez F, Ruiz P, Lopez R, et al.; Treatment with megestrol acetate improves human immunodeficiency virus-associated immune thrombocytopenia. Clin Diagn Lab Immunol. 2002 May;9(3):583-7. PMID: 11986264. ***X-2, X-3, X-4***

878. Gomez HF, McClafferty HH, Flory D, et al.; Prevention of gastrointestinal iron absorption by chelation from an orally administered premixed deferoxamine/charcoal slurry. Ann Emerg Med. 1997 Nov;30(5):587-92. PMID: 9360566. ***X-3, X-4***

879. Goni AZ, Lacruz RL, Paricio JJ, et al.; The levonorgestrel intrauterine system as an alternative to hysterectomy for the treatment of idiopathic menorrhagia. Gynecol Endocrinol. 2009 Sep;25(9):581-6. PMID: 19562603. ***X-2, X-3, X-4***

880. Gonzalez Baron M, Feliu J, Espinosa E, et al.; Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group. Ann Oncol. 1994 Apr;5(4):323-7. PMID: 8075028. ***X-2, X-4***

881. Gonzalez E, Gutierrez E, Galeano C, et al.; Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008 Apr;73(8):940-6. PMID: 18185501. ***X-2, X-3, X-4***

882. Gooch K, Culleton BF, Manns BJ, et al.; NSAID use and progression of chronic kidney disease. Am J Med. 2007 Mar;120(3):280 e1-7. PMID: 17349452. ***X-7, X-8***

883. Goodson NJ, Brookhart AM, Symmons DP, et al.; Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009 Mar;68(3):367-72. PMID: 18408253. ***X-2, X-4***

884. Gordon P, Rutledge J, Sawin R, et al.; Early postnatal dexamethasone increases the risk of focal small bowel perforation in extremely low birth weight infants. J Perinatol. 1999 Dec;19(8 Pt 1):573-7. PMID: 10645522. ***X-2, X-3, X-4***

885. Gorgen H, Api M, Akca A, et al.; Use of the Levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet. 2009 Jun;279(6):835-40. PMID: 19018547. ***X-2***

886. Gracia CR, Sammel MD, Charlesworth S, et al.; Sexual function in first-time contraceptive ring and contraceptive patch users. Fertil Steril. 2010 Jan;93(1):21-8. PMID: 18976753. ***X-2, X-3***

887. Graff-Iversen S, Hammar N, Thelle DS, et al.; Hormone therapy and mortality during a 14-year follow-up of 14 324 Norwegian women. J Intern Med. 2004 Nov;256(5):437-45. PMID: 15485480. ***X-7***

888. Graff-Iversen S, Tverdal A, Stensvold I; Cardiovascular risk factors in Norwegian women using oral contraceptives: results from a cardiovascular health screening 1985-88. Contraception. 1996 Jun;53(6):337-44. PMID: 8773420. ***X-4***

889. Graham DJ, Campen D, Hui R, et al.; Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005 Feb 5-11;365(9458):475-81. PMID: 15705456. ***X-4***

890. Graham DY, Agrawal NM, Campbell DR, et al.; Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002 Jan 28;162(2):169-75. PMID: 11802750. ***X-2, X-3, X-4***

891. Graham DY, Opekun AR, Willingham FF, et al.; Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005 Jan;3(1):55-9. PMID: 15645405. ***X-2, X-4***

892. Graham EM, Atz AM, Gillis J, et al.; Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2012 May;143(5):1069-76. PMID: 22075061. ***X-2, X-4***

893. Graser T, Koytchev R, Muller A, et al.; Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women. Climacteric. 2000 Jun;3(2):109-18. PMID: 11910651. ***X-4, X-7***

894. Greenberg JD, Bingham CO, 3rd, Abramson SB, et al.; Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis Rheum. 2005 Feb 15;53(1):12-7. PMID: 15696570. ***X-4***

895. Greenberg JD, Fisher MC, Kremer J, et al.; The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol. 2009 May-Jun;27(3):395-401. PMID: 19604430. ***X-3, X-4***

896. Greendale GA, Espeland M, Slone S, et al.; Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up

Study. Arch Intern Med. 2002 Mar 25;162(6):665-72. PMID: 11911720. ***X-2, X-4***

897. Greendale GA, Reboussin BA, Sie A, et al.; Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med. 1999 Feb 16;130(4 Pt 1):262-9. PMID: 10068383. ***X-2***

898. Greene GF, Millard OH, Norman RW, et al.; Cystitis associated with tiaprofenic acid. J Urol. 1994 Oct;152(4):1101-2. PMID: 8072073. ***X-2***

899. Greenson JK, Stern RA, Carpenter SL, et al.; The clinical significance of focal active colitis. Hum Pathol. 1997 Jun;28(6):729-33. PMID: 9191008. ***X-2***

900. Greer JB, Modugno F, Allen GO, et al.; Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol. 2005 Apr;105(4):731-40. PMID: 15802398. ***X-2, X-3, X-4***

901. Griffin MR, Piper JM, Daugherty JR, et al.; Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991 Feb 15;114(4):257-63. PMID: 1987872. ***X-7***

902. Griffin MR, Smalley WE; Drugs and ulcers: clues about mucosal protection from epidemiologic studies. J Clin Gastroenterol. 1995;21 Suppl 1:S113-9. PMID: 8775002. ***X-4, X-5***

903. Grigorieva V, Chen-Mok M, Tarasova M, et al.; Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003 May;79(5):1194-8. PMID: 12738516. ***X-2, X-3, X-4***

904. Grimaldi-Bensouda L, Rossignol M, Danchin N, et al.; Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs. Heart. 2011 Nov;97(22):1834-40. PMID: 21880652. ***X-4***

905. Grimmelt AC, Cohen CD, Fehr T, et al.; Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol. 2009 Feb;71(2):125-9. PMID: 19203504. ***X-2, X-4***

906. Grodstein F, Skarupski KA, Bienias JL, et al.; Anti-inflammatory agents and cognitive decline in a bi-racial population. Neuroepidemiology. 2008;30(1):45-50. PMID: 18259082. ***X-4, X-7***

907. Grohs JG, Schmidt M, Wanivenhaus A; Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthop. 2007 Feb;78(1):95-8. PMID: 17453399. ***X-2, X-4***

908. Gronich N, Lavi I, Rennert G; Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011 Dec 13;183(18):E1319-25. PMID: 22065352. ***X-4***

909. Grosset K, Needleman F, Macphee G, et al.; Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord. 2004 Nov;19(11):1370-4. PMID: 15389984. ***X-2, X-4, X-8***

910. Grover R, Jones BM, Waterhouse N; The prevention of haematoma following rhytidectomy: a review of 1078 consecutive facelifts. Br J Plast Surg. 2001 Sep;54(6):481-6. PMID: 11513508. ***X-2, X-3, X-4***

911. Grover SA, Coupal L, Zowall H; Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Hypertension. 2005 Jan;45(1):92-7. PMID: 15545508. ***X-3, X-4***

912. Grover V, Usha R, Gupta U, et al.; Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. Asia Oceania J Obstet Gynaecol. 1990 Sep;16(3):255-9. PMID: 2088249. ***X-2, X-3, X-4***

913. Grubb GS, Moore D, Anderson NG; Pre-introductory clinical trials of Norplant implants: a comparison of seventeen countries' experience. Contraception. 1995 Nov;52(5):287-96. PMID: 8585885. ***X-3, X-4***

914. Gruber EM, Shukla AC, Reid RW, et al.; Synthetic antifibrinolytics are not associated with an increased incidence of baffle fenestration closure after the modified Fontan procedure. J Cardiothorac Vasc Anesth. 2000 Jun;14(3):257-9. PMID: 10890476. ***X-2, X-3, X-4***

915. Gu SJ, Du MK, Zhang LD, et al.; A 5-year evaluation of NORPLANT contraceptive implants in China. Obstet Gynecol. 1994 May;83(5 Pt 1):673-8. PMID: 8164924. ***X-4***

916. Guang-Sheng F, Mei-Lu B, Li-Nan C, et al.; Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin Drug Investig. 2010;30(6):387-96. PMID: 20201608. ***X-2, X-4***

917. Guazzelli CA, Barreiros FA, Barbosa R, et al.; Extended regimens of the vaginal contraceptive ring: cycle control. Contraception. 2009 Nov;80(5):430-5. PMID: 19835716. ***X-2, X-3, X-4***

918. Guazzelli CA, Jacobucci MS, Barbieri M, et al.; Monthly injectable contraceptive use by adolescents in Brazil: evaluation of clinical aspects. Contraception. 2007 Jul;76(1):45-8. PMID: 17586136. ***X-2, X-3, X-4***

919. Gudmundsdottir ES, Jonsson H; CPH 82 (Reumacon) in refractory inflammatory arthritis. Scand J Rheumatol. 2000;29(5):323-5. PMID: 11093600. ***X-2, X-4***

920. Guess HA, West R, Strand LM, et al.; Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol. 1988;41(1):35-45. PMID: 3257254. ***X-4***

921. Gulliford M, Latinovic R; Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev. 2004 May-Jun;20(3):239-45. PMID: 15133756. ***X-3***

922. Gulmez SE, Droz-Perroteau C, Lassalle R, et al.; Are traditional NSAIDs prescribed appropriately among French elderly with osteoarthritis? Results from the CADEUS cohort. Eur J Clin Pharmacol. 2011 Aug;67(8):833-8. PMID: 21387168. ***X-4, X-8***

923. Guney M, Oral B, Karahan N, et al.; Expression of leukaemia inhibitory factor (LIF) during the window of implantation in copper T380A intrauterine device users. Eur J Contracept Reprod Health Care. 2007 Sep;12(3):212-9. PMID: 17763259. ***X-2, X-3, X-4***

924. Gunter MJ, Canzian F, Landi S, et al.; Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1126-31. PMID: 16775170. ***X-2, X-3, X-4***

925. Gunthert AR, Faber M, Knappe G, et al.; Early onset vulvar Lichen Sclerosus in premenopausal women and oral contraceptives. Eur J Obstet Gynecol Reprod Biol. 2008 Mar;137(1):56-60. PMID: 18055095. ***X-2***

926. Gupta A, Daggett C, Ludwick J, et al.; Ketorolac after congenital heart surgery: does it increase the risk of significant bleeding complications? Paediatr Anaesth. 2005 Feb;15(2):139-42. PMID: 15675931. ***X-2, X-4***

927. Gupta I, Mahajan U, Sawhney H; Concurrent copper T insertion with medical termination of pregnancy in women with previous caesarean section delivery. Indian J Med Res. 1988 May;87:450-2. PMID: 3169901. ***X-4***

928. Gurwitz JH, Avorn J, Bohn RL, et al.; Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994 Sep 14;272(10):781-6. PMID: 8078142. ***X-4, X-7***

929. Gurwitz JH, Avorn J, Ross-Degnan D, et al.; Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. JAMA. 1990 Jul 25;264(4):471-5. PMID: 2366280. ***X-2***

930. Guslandi M, Foppa L, Fanti L, et al.; Nonsteroidal anti-inflammatory drugs and gastric mucosal blood flow. J Clin Gastroenterol. 1999 Apr;28(3):258-60. PMID: 10192617. ***X-2***

931. Gutthann SP, Garcia Rodriguez LA, Raiford DS; Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 1997 Jan;8(1):18-24. PMID: 9116088. ***X-4***

932. Haag MD, Bos MJ, Hofman A, et al.; Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med. 2008 Jun 9;168(11):1219-24. PMID: 18541831. ***X-7***

933. Hagglund H, Remberger M, Klaesson S, et al.; Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood. 1998 Dec 15;92(12):4568-72. PMID: 9845522. ***X-2***

934. Hahn HS, Yoon SG, Hong JS, et al.; Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009 Aug;19(6):1068-73. PMID: 19820370. ***X-2, X-3, X-4***

935. Haimov-Kochman R, Doviner V, Amsalem H, et al.; Intraperitoneal levonorgestrel-releasing intrauterine device following uterine perforation: the role of progestins in adhesion formation. Hum Reprod. 2003 May;18(5):990-3. PMID: 12721174. ***X-2***

936. Haines CJ, Chung TK, Lau TK; Sonographic measurement of endometrial thickness as a predictor of vaginal bleeding in women using continuous combined hormone replacement therapy. Gynecol Obstet Invest. 1997;44(3):187-90. PMID: 9359646. ***X-3, X-4***

937. Hall P, Bahamondes L, Diaz J, et al.; Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru. Contraception. 1997 Dec;56(6):353-9. PMID: 9494768. ***X-4***

938. Hall P, Maclachlan N, Thorn N, et al.; Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol. 1987 Jun;94(6):554-8. PMID: 3304401. ***X-2, X-3, X-4***

939. Hall R, Lonngren T, Tyden O, et al.; The intrauterine contraceptive device, "Multiload Cu 250": a regulatory problem. Regul Toxicol Pharmacol. 1991 Aug;14(1):41-7. PMID: 1947244. ***X-1, X-2, X-4***

940. Hallas J, Lauritsen J, Villadsen HD, et al.; Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol. 1995 May;30(5):438-44. PMID: 7638569. ***X-4***

941. Halmesmaki KH, Paavonen JA, Tuppurainen MT, et al.; Randomized controlled trial of the effect of hysterectomy or LNG-IUS use on bone mineral density: A five-year follow-up. Therapy. 2006;3(4):509-15. ***X-2***

942. Hamid S, Yakoob J, Jafri W, et al.; Frequency of NSAID induced peptic ulcer disease. J Pak Med Assoc. 2006 May;56(5):218-22. PMID: 16767948. ***X-2***

943. Hammad TA, Graham DJ, Staffa JA, et al.; Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):315-21. PMID: 18302311. ***X-4***

944. Hammerman C, Glaser J, Kaplan M, et al.; Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Pediatrics. 1998 Nov;102(5):E56. PMID: 9794986. ***X-2, X-3, X-4***

945. Hammerstein J, Daume E, Simon A, et al.; Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol. Contraception. 1993 Mar;47(3):263-81. PMID: 8462317. ***X-2, X-3, X-4***

946. Hampton NR, Rees MC, Lowe DG, et al.; Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod. 2005 Sep;20(9):2653-60. PMID: 15905289. ***X-2, X-3, X-4***

947. Hanauer SB, Sandborn WJ, Kornbluth A, et al.; Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov;100(11):2478-85. PMID: 16279903. ***X-2, X-3, X-4***

948. Hancock DB, Haberg SE, Furu K, et al.; Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. Pediatr Allergy Immunol. 2011 Aug;22(5):528-36. PMID: 21294776. ***X-4***

949. Hancock DB, Martin ER, Stajich JM, et al.; Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol. 2007 Apr;64(4):576-80. PMID: 17420321. ***X-2, X-4***

950. Hanggi W, Bersinger N, Altermatt HJ, et al.; Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users. Maturitas. 1997 Jun;27(2):133-43. PMID: 9255748. ***X-2, X-4, X-7***

951. Hannaford P; Postmarketing surveillance study of Norplant in developing countries. Lancet. 2001 Jun 9;357(9271):1815-6. PMID: 11410183. ***X-1, X-4***

952. Hannaford PC, Kay CR, Vessey MP, et al.; Combined oral contraceptives and liver disease. Contraception. 1997 Mar;55(3):145-51. PMID: 9115002. ***X-4***

953. Hannibal CG, Jensen A, Sharif H, et al.; Risk of thyroid cancer after exposure to fertility drugs: results from a large Danish cohort study. Hum Reprod. 2008 Feb;23(2):451-6. PMID: 18065402. ***X-4***

954. Hannibal CG, Rossing MA, Wicklund KG, et al.; Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol. 2008 Jun 15;167(12):1430-7. PMID: 18390840. ***X-2, X-4***

955. Hansen JM, Hallas J, Lauritsen JM, et al.; Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol. 1996 Feb;31(2):126-30. PMID: 8658033. ***X-2, X-3, X-4***

956. Hansen KE, Cush J, Singhal A, et al.; The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum. 2004 Apr 15;51(2):228-32. PMID: 15077264. ***X-2, X-4***

957. Hardo PG, Chalmers DM, Jakeways M, et al.; Management of NSAIDs-related dyspepsia in the community. Br J Clin Pract. 1993 Sep-Oct;47(5):241-2. PMID: 8292467. ***X-2, X-3, X-4***

958. Harel Z, Biro FM, Kollar LM; Depo-Provera in adolescents: effects of early second injection or prior oral contraception. J Adolesc Health. 1995 May;16(5):379-84. PMID: 7662688. ***X-2***

959. Harel Z, Biro FM, Kollar LM, et al.; Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant. J Adolesc Health. 1996 Aug;19(2):118-23. PMID: 8863083. ***X-2***

960. Harel Z, Johnson CC, Gold MA, et al.; Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010 Apr;81(4):281-91. PMID: 20227543. ***X-2, X-4***

961. Harel Z, Wolter K, Gold MA, et al.; Biopsychosocial variables associated with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: adolescents who lost 5% or more from baseline vs. those who lost less than 5%. Contraception. 2010 Dec;82(6):503-12. PMID: 21074012. ***X-2***

962. Harley C, Wagner S; The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clin Ther. 2003 Jan;25(1):139-49. PMID: 12637116. ***X-4***

963. Harley EH, Dattolo RA; Ibuprofen for tonsillectomy pain in children: efficacy and complications. Otolaryngol Head Neck Surg. 1998 Nov;119(5):492-6. PMID: 9807075. ***X-2, X-4***

964. Harris CL, Raisch DW, Abhyankar U, et al.; GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs. Ann Pharmacother. 2006 Nov;40(11):1924-31. PMID: 17047140. ***X-6***

965. Harris RE, Namboodiri KK, Farrar WB; Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996 Mar;7(2):203-5. PMID: 8834563. ***X-4***

966. Harris TG, Miller L, Kulasingam SL, et al.; Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol. 2009 May;200(5):489 e1-8. PMID: 19375566. ***X-2***

967. Harrison-Woolrych M, Ashton J, Coulter D; Insertion of the Multiload Cu375 intrauterine device; experience in over 16,000 New Zealand women. Contraception. 2002 Dec;66(6):387-91. PMID: 12499029. ***X-4***

968. Harrison-Woolrych M, Ashton J, Coulter D; Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported? Contraception. 2003 Jan;67(1):53-6. PMID: 12521659. ***X-4***

969. Harrison-Woolrych M, Herbison P, McLean R, et al.; Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. Drug Saf. 2005;28(5):435-42. PMID: 15853444. ***X-4***

970. Hart RG, Pearce LA, Rothbart RM, et al.; Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 2000 Jan;35(1):183-7. PMID: 10636278. ***X-2, X-3, X-4***

971. Hartnell NR, Wilson JP; Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004 Jun;24(6):743-9. PMID: 15222664. ***X-2, X-3, X-4***

972. Harvey PW, Heywood PF, Nesheim MC, et al.; The effect of iron therapy on malarial infection in Papua New Guinean schoolchildren. Am J Trop Med Hyg. 1989 Jan;40(1):12-8. PMID: 2644855. ***X-3, X-4***

973. Hasan SS, Khan FH, Ahmed M; Comparison of ketorolac with morphine for intra-operative analgesia in patients undergoing total abdominal hysterectomy. J Pak Med Assoc. 2003 Oct;53(10):467-71. PMID: 14696887. ***X-2, X-4***

974. Hassan EO, el-Nahal N, el-Hussein M; Acceptability of the once-a-month injectable contraceptives Cyclofem and Mesigyna in Egypt. Contraception. 1994 May;49(5):469-88. PMID: 8045133. ***X-2, X-3, X-4***

975. Hassan EO, Kafafi L, el Husseini M, et al.; The acceptability of Norplant in Egypt. Adv Contracept. 1992 Dec;8(4):331-48. PMID: 1365819. ***X-3, X-4***

976. Hassanein M, Hanif W, Malik W, et al.; Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011 Jul;27(7):1367-74. PMID: 21568833. ***X-2, X-4***

977. Hauta-Aho M, Tirkkonen T, Vahlberg T, et al.; The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med. 2009;41(8):619-28. PMID: 19711211. ***X-4***

978. Hawkey C, Kahan A, Steinbruck K, et al.; Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol. 1998 Sep;37(9):937-45. PMID: 9783757. ***X-3, X-4***

979. Hawkey C, Talley NJ, Yeomans ND, et al.; Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol. 2005 May;100(5):1028-36. PMID: 15842575. ***X-4***

980. Hawkey CJ; Naproxen sodium did not lead to substantially more upper gastrointestinal tract bleeding than ibuprofen during short term use as an analgesic. Gut. 1998 Sep;43(3):315. PMID: 9863472. ***X-1, X-2, X-4***

981. Hawkey CJ; Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut. 2000 Mar;46(3):310-1. PMID: 10673289. ***X-2***

982. Hawkey CJ, Hawkey GM, Everitt S, et al.; Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol. 2006 Jun;61(6):730-7. PMID: 16722837. ***X-2***

983. Hawkey CJ, Naesdal J, Wilson I, et al.; Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut. 2002 Sep;51(3):336-43. PMID: 12171953. ***X-2, X-4***

984. Hayashi K, Walker AM; Japanese and American reports of randomized trials: differences in the reporting of adverse effects. Control Clin Trials. 1996 Apr;17(2):99-110. PMID: 8860062. ***X-1, X-2, X-3, X-4***

985. Hayashi Y, Yamamoto H, Kita H, et al.; Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy. World J Gastroenterol. 2005 Aug 21;11(31):4861-4. PMID: 16097059. ***X-2***

986. Hayashi Y, Yamamoto H, Taguchi H, et al.; Nonsteroidal anti-inflammatory drug-induced small-bowel lesions identified by double-balloon endoscopy: endoscopic features of the lesions and endoscopic treatments for diaphragm disease. J Gastroenterol. 2009;44 Suppl 19:57-63. PMID: 19148795. ***X-2***

987. Haydardedeoglu B, Simsek E, Kilicdag EB, et al.; Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2009 Apr;105(1):32-5. PMID: 19155004. ***X-2***

988. Hayes E, Moroz L, Pizzi L, et al.; A cost decision analysis of 4 tocolytic drugs. Am J Obstet Gynecol. 2007 Oct;197(4):383 e1-6. PMID: 17904969. ***X-2, X-3, X-4***

989. Hayes JH, Anderson KE, Folsom AR; Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2226-31. PMID: 17119050. ***X-4***

990. Heaney M, Looney Y, McKinstry C, et al.; Sequential clot strength analyses following diclofenac in pediatric adenotonsillectomy. Paediatr Anaesth. 2007 Nov;17(11):1078-82. PMID: 17897274. ***X-2, X-3, X-4***

991. Hedderson MM, Ferrara A, Williams MA, et al.; Androgenicity of progestins in hormonal contraceptives and the risk of gestational diabetes mellitus. Diabetes Care. 2007 May;30(5):1062-8. PMID: 17303784. ***X-2***

992. Hedenmalm K, Samuelsson E; Fatal venous thromboembolism associated with different combined oral contraceptives: a study of incidences and potential biases in spontaneous reporting. Drug Saf. 2005;28(10):907-16. PMID: 16180940. ***X-4***

993. Hedenmalm K, Samuelsson E, Spigset O; Pulmonary embolism associated with combined oral contraceptives: reporting incidences and potential risk factors for a fatal outcome. Acta Obstet Gynecol Scand. 2004 Jun;83(6):576-85. PMID: 15144341. ***X-4***

994. Hedenmalm K, Spigset O; Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002 Jul;58(4):265-74. PMID: 12136373. ***X-4***

995. Heerdink ER, Leufkens HG, Herings RM, et al.; NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998 May 25;158(10):1108-12. PMID: 9605782. ***X-4, X-7***

996. Heikkinen J, Vaheri R, Timonen U; A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings. J Br Menopause Soc. 2006 Sep;12(3):115-25. PMID: 16953985. ***X-2, X-4***

997. Heinemann LA, Kluft C, Spannagl M, et al.; The association between extrinsic activated protein C resistance and venous thromboembolism in women. Contraception. 2002 Nov;66(5):297-304. PMID: 12443958. ***X-2, X-4***

998. Helin-Salmivaara A, Huttunen T, Gronroos JM, et al.; Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur J Clin Pharmacol. 2007 Apr;63(4):403-8. PMID: 17347805. ***X-4***

999. Helin-Salmivaara A, Huupponen R, Virtanen A, et al.; Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2005 Jul;61(5-6):425-31. PMID: 15952021. ***X-4***

1000. Helin-Salmivaara A, Klaukka T, Huupponen R; Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. Eur J Clin Pharmacol. 2003 Sep;59(5-6):477-82. PMID: 12937872. ***X-3, X-4***

1001. Helin-Salmivaara A, Saarelainen S, Gronroos JM, et al.; Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population. Scand J Gastroenterol. 2007 Aug;42(8):923-32. PMID: 17613921. ***X-4***

1002. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al.; NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006 Jul;27(14):1657-63. PMID: 16731535. ***X-4***

1003. Heliovaara-Peippo S, Halmesmaki K, Hurskainen R, et al.; The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial. BJOG. 2010 Apr;117(5):602-9. PMID: 20156209. ***X-2***

1004. Heliovaara-Peippo S, Oksjoki R, Halmesmaki K, et al.; The effect of hysterectomy or levonorgestrel-releasing intrauterine system on cardiovascular disease risk factors in menorrhagia patients: a 10-year follow-up of a randomised trial. Maturitas. 2011 Aug;69(4):354-8. PMID: 21684096. ***X-2, X-4***

1005. Helsper CW, Smeets HM, Numans ME, et al.; Trends and determinants of adequate gastroprotection in patients chronically using NSAIDs. Pharmacoepidemiol Drug Saf. 2009 Sep;18(9):800-6. PMID: 19572313. ***X-4***

1006. Hemmelgarn B, Levesque LE, Suissa S; Anti-diabetic drug use and the risk of motor vehicle crash in the elderly. Can J Clin Pharmacol. 2006 Winter;13(1):e112-20. PMID: 16585812. ***X-7***

1007. Henderson SO, Swadron S, Newton E; Comparison of intravenous ketorolac and meperidine in the treatment of

biliary colic. J Emerg Med. 2002 Oct;23(3):237-41. PMID: 12426013. ***X-2, X-4***

1008. Hendricks SK, Smith JR, Moore DE, et al.; Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol. 1990 Apr;97(4):312-6. PMID: 2340255. ***X-2, X-4***

1009. Henker J, Muller S, Laass MW, et al.; Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol. 2008 Sep;46(9):874-5. PMID: 18810672. ***X-2, X-3, X-4***

1010. Hennekens CH, Borzak S; Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2008 Mar;13(1):41-50. PMID: 18287589. ***X-1, X-2, X-3, X-4***

1011. Hennessy S, Kinman JL, Berlin JA, et al.; Lack of hepatotoxic effects of parenteral ketorolac in the hospital setting. Arch Intern Med. 1997 Nov 24;157(21):2510-4. PMID: 9385304. ***X-4***

1012. Henriksson AE, Nilsson TK, Bergavist D; Bleeding time and concentrations of von Willebrand factor in patients with acute upper gastrointestinal bleeding. Eur J Surg. 1996 Aug;162(8):627-31. PMID: 8891620. ***X-2, X-3, X-4***

1013. Henriksson P, Blomback M, Bratt G, et al.; Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer. Med Oncol Tumor Pharmacother. 1989;6(3):219-25. PMID: 2515399. ***X-2, X-4***

1014. Henriksson P, Edhag O, Eriksson A, et al.; Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer. Br J Urol. 1989 Feb;63(2):186-90. PMID: 2649197. ***X-2, X-6***

1015. Henry D, Dobson A, Turner C; Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology. 1993 Oct;105(4):1078-88. PMID: 8405852. ***X-4***

1016. Henry D, Page J, Whyte I, et al.; Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol. 1997 Jul;44(1):85-90. PMID: 9241101. ***X-2***

1017. Henry DA; Epidemiological assessment of the association between NSAIDS and peptic ulcer complications. Agents Actions Suppl. 1988;24:85-94. PMID: 3263760. ***X-1***

1018. Henshaw C, Foreman D, Belcher J, et al.; Can one induce premenstrual symptomatology in women with prior hysterectomy and bilateral oophorectomy? J Psychosom Obstet Gynaecol. 1996 Mar;17(1):21-8. PMID: 8860883. ***X-2, X-4***

1019. Henz S, Maeder MT, Huber S, et al.; Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant. 2008 Dec;23(12):3939-45. PMID: 18614817. ***X-4***

1020. Heresbach D, Raoul JL, Bretagne JF, et al.; Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy. Gut. 1992 Dec;33(12):1608-11. PMID: 1487160. ***X-2, X-3, X-4***

1021. Herings RM, Goettsch WG; Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother. 2004 May;38(5):760-3. PMID: 15031416. ***X-4***

1022. Hermansson M, Ekedahl A, Ranstam J, et al.; Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. BMC Gastroenterol. 2009;9:25. PMID: 19379513. ***X-4***

1023. Hernan MA, Logroscino G, Garcia Rodriguez LA; Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology. 2006 Apr 11;66(7):1097-9. PMID: 16606925. ***X-4***

1024. Hernandez-Diaz S, Garcia Rodriguez LA; Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22. PMID: 16987411. ***X-3, X-4***

1025. Hernandez-Diaz S, Rodriguez LA; Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001 Jun 1;153(11):1089-93. PMID: 11390328. ***X-4***

1026. Herrera JA, Gonzalez M; Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis. Am J Ther. 2003 Nov-Dec;10(6):468-72. PMID: 14624289. ***X-2, X-3, X-4***

1027. Herth FJ, Becker HD, Ernst A; Aspirin does not increase bleeding complications after transbronchial biopsy. Chest. 2002 Oct;122(4):1461-4. PMID: 12377879. ***X-2, X-4***

1028. Hettinger ME, Gill DJ, Robin JB, et al.; Evaluation of diclofenac sodium 0.1% ophthalmic solution in the treatment of ocular symptoms after bilateral radial keratotomy. Cornea. 1997 Jul;16(4):406-13. PMID: 9220237. ***X-3, X-4***

1029. Heuser P, Tonga K, Hopkins R, et al.; Specific oral contraceptive use and venous thromboembolism resulting in hospital admission. N Z Med J. 2004 Nov 26;117(1206):U1176. PMID: 15570345. ***X-2, X-4***

1030. Hickey M, Dwarte D, Fraser IS; Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod. 2000 Jul;15(7):1509-14. PMID: 10875858. ***X-2, X-3, X-4***

1031. Hickey M, Fraser IS; Surface vascularization and endometrial appearance in women with menorrhagia or using levonorgestrel contraceptive implants. Implications for the mechanisms of breakthrough bleeding. Hum Reprod. 2002 Sep;17(9):2428-34. PMID: 12202436. ***X-2, X-3, X-4***

1032. Hickok DE, Hollenbach KA, Reilley SF, et al.; The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol. 1989 Jun;160(6):1525-30; discussion 30-1. PMID: 2660576. ***X-2, X-4***

1033. Hidalgo M, Bahamondes L, Perrotti M, et al.; Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002 Feb;65(2):129-32. PMID: 11927115. ***X-2***

1034. Higashi N, Taniguchi M, Mita H, et al.; Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2004 Feb;113(2):277-83. PMID: 14767442. ***X-2, X-3, X-4***

1035. Higashi N, Taniguchi M, Mita H, et al.; A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy. 2002 Oct;32(10):1484-90. PMID: 12372129. ***X-3, X-4***

1036. Higham CE, Chung TT, Lawrance J, et al.; Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf). 2009 Jul;71(1):86-91. PMID: 19018786. ***X-2, X-4***

1037. Hilditch JR, Lewis J, Ross AH, et al.; A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas. 1996 Jul;24(3):177-84. PMID: 8844631. ***X-2, X-4***

1038. Hill GA, Wheeler JM; Incidence of breakthrough bleeding during oral contraceptive therapy. J Reprod Med. 1991 Apr;36(4 Suppl):334-9. PMID: 2046082. ***X-4***

1039. Hill J, Bird H; Patient knowledge and misconceptions of osteoarthritis assessed by a validated self-completed knowledge questionnaire (PKQ-OA). Rheumatology (Oxford). 2007 May;46(5):796-800. PMID: 17178737. ***X-2, X-3, X-4***

1040. Hillman AL, Bloom BS; Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1989 Sep;149(9):2061-5. PMID: 2505706. ***X-3, X-4***

1041. Hippisley-Cox J, Coupland C; Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005 Jun 11;330(7504):1366. PMID: 15947398. ***X-4***

1042. Hippisley-Cox J, Coupland C, Logan R; Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005 Dec 3;331(7528):1310-6. PMID: 16322018. ***X-4***

1043. Hirneiss C, Neubauer AS, Kampik A, et al.; Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked study. Graefes Arch Clin Exp Ophthalmol. 2005 Aug;243(8):768-73. PMID: 15756571. ***X-2, X-4***

1044. Hite RC, Bannemerschult R, Fox-Kuchenbecker P, et al.; Large observational trial of a new low-dose oral contraceptive containing 20 micrograms ethinylestradiol and 100 micrograms levonorgestrel (Miranova) in Germany. Eur J Contracept Reprod Health Care. 1999 Mar;4(1):7-13. PMID: 10367190. ***X-4***

1045. Ho PC, Kwan MS; A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Hum Reprod. 1993 Mar;8(3):389-92. PMID: 8473453. ***X-2, X-4***

1046. Hochain P, Berkelmans I, Czernichow P, et al.; Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol. 1995 May;7(5):419-26. PMID: 7614104. ***X-2, X-3, X-4***

1047. Hodis HN, Mack WJ, Azen SP, et al.; Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003 Aug 7;349(6):535-45. PMID: 12904518. ***X-2, X-4***

1048. Hoer A, Gothe H, Schiffhorst G, et al.; Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):854-8. PMID: 17323403. ***X-4***

1049. Hogan DB, Campbell NR, Crutcher R, et al.; Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. CMAJ. 1994 Aug 1;151(3):315-22. PMID: 8039085. ***X-4, X-7***

1050. Hoibraaten E, Mowinckel MC, de Ronde H, et al.; Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol. 2001 Nov;115(2):415-20. PMID: 11703344. ***X-2, X-4***

1051. Holdaway IM, Croxson MS, Ibbertson HK, et al.; Cyproterone acetate as initial treatment and maintenance therapy for hirsutism. Acta Endocrinol (Copenh). 1985 Aug;109(4):522-9. PMID: 2930987. ***X-2***

1052. Hollenz M, Stolte M, Leodolter A, et al.; NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care. Dig Dis. 2006;24(1-2):189-94. PMID: 16699277. ***X-2***

1053. Holma P; Long-term experience with Norplant contraceptive implants in Finland. Contraception. 1985 Mar;31(3):231-41. PMID: 3922674. ***X-2, X-3, X-4***

1054. Holmberg L, Iversen OE, Rudenstam CM, et al.; Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008 Apr 2;100(7):475-82. PMID: 18364505. ***X-2***

1055. Holt S, Rigoglioso V, Sidhu M, et al.; Nonsteroidal antiinflammatory drugs and lower gastrointestinal bleeding. Dig Dis Sci. 1993 Sep;38(9):1619-23. PMID: 8359073. ***X-2, X-4***

1056. Holt VL, Daling JR, McKnight B, et al.; Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol. 1992 Apr;79(4):529-33. PMID: 1553170. ***X-2, X-4***

1057. Holvoet J, Terriere L, Van Hee W, et al.; Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. Gut. 1991 Jul;32(7):730-4. PMID: 1855677. ***X-2***

1058. Homouda K; The effect on intrauterine device position and performance of a modified TCu380A insertion technique. Eur J Contracept Reprod Health Care. 2002 Mar;7(1):31-5. PMID: 12041862. ***X-2, X-3, X-4***

1059. Hood HM, Wark C, Burgess PA, et al.; Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in medicare patients hospitalized with peptic ulcer disease. Arch Intern Med. 1999 Jan 25;159(2):149-54. PMID: 9927097. ***X-3, X-4***

1060. Hook EB; Cardiovascular birth defects and prenatal exposure to female sex hormones: a reevaluation of data reanalysis from a large prospective study. Teratology. 1994 Mar;49(3):162-6. PMID: 8059421. ***X-4***

1061. Hopkins C, Browne JP, Slack R, et al.; The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg. 2007 Oct;137(4):555-61. PMID: 17903570. ***X-3, X-4***

1062. Hoppe G; Progestins and oral contraceptive-induced lipoprotein changes: a prospective study. Contraception. 1987 Mar;35(3):299-305. PMID: 2956056. ***X-1***

1063. Hoppu K, Kettunen K, Remes R; Maternal drug treatment and human milk banking. Int J Clin Pharmacol Ther. 1994 Sep;32(9):488-90. PMID: 7820332. ***X-2, X-3, X-4***

1064. Horackova M, Charvat J, Hasa J, et al.; Life-threatening renal failure caused by vasomotor nephropathy associated with nonsteroidal anti-inflammatory drugs. Int J Clin Pharmacol Res. 2004;24(4):117-22. PMID: 15754916. ***X-2, X-4***

1065. Horbach SJ, Lopes RD, da CGJC, et al.; Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med. 2011 Nov;124(11):1036-42. PMID: 22017782. ***X-2, X-3***

1066. Horlocker TT, Bajwa ZH, Ashraf Z, et al.; Risk assessment of hemorrhagic complications associated with nonsteroidal antiinflammatory medications in ambulatory pain clinic patients undergoing epidural steroid injection. Anesth Analg. 2002 Dec;95(6):1691-7, table of contents. PMID: 12456441. ***X-2, X-4***

1067. Horn PL, Wrona S, Beebe AC, et al.; A retrospective quality improvement study of ketorolac use following spinal fusion in pediatric patients. Orthop Nurs. 2010 Sep-Oct;29(5):342-3. PMID: 20856090. ***X-2, X-3, X-4***

1068. Horowitz J, Kukora JS, Ritchie WP, Jr.; All perforated ulcers are not alike. Ann Surg. 1989 Jun;209(6):693-6; discussion 6-7. PMID: 2730181. ***X-2, X-3, X-4***

1069. Horsdal HT, Sondergaard F, Johnsen SP, et al.; Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. Pharmacoepidemiol Drug Saf. 2011 Apr;20(4):331-7. PMID: 21442682. ***X-3***

1070. Hosono S, Ohno T, Kimoto H, et al.; Reduction in blood glucose values following indomethacin therapy for patent ductus arteriosus. Pediatr Int. 1999 Oct;41(5):525-8. PMID: 10530066. ***X-2, X-4***

1071. Hosono S, Ohono T, Kimoto H, et al.; Preventive management of hypoglycemia in very low-birthweight infants following indomethacin therapy for patent ductus arteriosus. Pediatr Int. 2001 Oct;43(5):465-8. PMID: 11737706. ***X-2, X-3, X-4***

1072. Houck CS, Wilder RT, McDermott JS, et al.; Safety of intravenous ketorolac therapy in children and cost savings with a unit dosing system. J Pediatr. 1996 Aug;129(2):292-6. PMID: 8765630. ***X-4***

1073. Hov GG, Skjeldestad FE, Hilstad T; Use of IUD and subsequent fertility--follow-up after participation in a

randomized clinical trial. Contraception. 2007 Feb;75(2):88-92. PMID: 17241835. ***X-2, X-3, X-4***

1074. Howard BV, Hsia J, Ouyang P, et al.; Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation. 2004 Jul 13;110(2):201-6. PMID: 15226212. ***X-2***

1075. Howard RL, Avery AJ, Howard PD, et al.; Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003 Aug;12(4):280-5. PMID: 12897361. ***X-4***

1076. Hoyo C, Cousins DS, Bisgrove EZ, et al.; Depo medroxyprogesterone acetate (DMPA) and combined oral contraceptives and cervical carcinoma in-situ in women aged 50 years and under. West Indian Med J. 2004 Dec;53(6):406-12. PMID: 15816269. ***X-2***

1077. Hritz I, Kuester D, Vieth M, et al.; Secretory leukocyte protease inhibitor expression in various types of gastritis: a specific role of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2006 Mar;18(3):277-82. PMID: 16462541. ***X-2, X-3, X-4***

1078. Hsia J, Otvos JD, Rossouw JE, et al.; Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1666-71. PMID: 18599797. ***X-4***

1079. Hsia J, Simon JA, Lin F, et al.; Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation. 2000 Oct 31;102(18):2228-32. PMID: 11056097. ***X-7***

1080. Hsiang KW, Chen TS, Lin HY, et al.; Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan. Clin Ther. 2010 Jul;32(7):1294-303. PMID: 20678677. ***X-2, X-4***

1081. Hsiao FY, Huang WF, Wen YW, et al.; Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 2009;32(8):675-90. PMID: 19591532. ***X-3***

1082. Hsiao FY, Tsai YW, Wen YW, et al.; Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):786-91. PMID: 20607752. ***X-2, X-4***

1083. Hsu PI, Lai KH, Lo GH, et al.; Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut. 2002 Jul;51(1):15-20. PMID: 12077085. ***X-2, X-3***

1084. Hsu PI, Lai KH, Tseng HH, et al.; Risk factors for presentation with bleeding in patients with Helicobacter pylori-related peptic ulcer diseases. J Clin Gastroenterol. 2000 Jun;30(4):386-91. PMID: 10875466. ***X-2, X-3, X-4***

1085. Huang ES, Strate LL, Ho WW, et al.; Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med. 2011 May;124(5):426-33. PMID: 21531232. ***X-4***

1086. Huang WF, Hsiao FY, Wen YW, et al.; Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Clin Ther. 2006 Nov;28(11):1827-36. PMID: 17213003. ***X-4***

1087. Huang YC, Tsai SK, Huang CH, et al.; Intravenous tenoxicam reduces uterine cramps after Cesarean delivery. Can J Anaesth. 2002 Apr;49(4):384-7. PMID: 11927478. ***X-2, X-3, X-4***

1088. Hubacher D, Chen PL, Park S; Side effects from the copper IUD: do they decrease over time? Contraception. 2009 May;79(5):356-62. PMID: 19341847. ***X-4***

1089. Hubacher D, Fortney J; Follow-up visits after IUD insertion. Are more better? J Reprod Med. 1999 Sep;44(9):801-6. PMID: 10509305. ***X-4***

1090. Hubacher D, Goco N, Gonzalez B, et al.; Factors affecting continuation rates of DMPA. Contraception. 1999 Dec;60(6):345-51. PMID: 10715369. ***X-2, X-3, X-4***

1091. Hubacher D, Lara-Ricalde R, Taylor DJ, et al.; Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001 Aug 23;345(8):561-7. PMID: 11529209. ***X-4***

1092. Hubbard R, Venn A, Smith C, et al.; Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):743-7. PMID: 9517585. ***X-2, X-4***

1093. Hudic I, Szekeres-Bartho J, Fatusic Z, et al.; Dydrogesterone supplementation in women with threatened preterm delivery--the impact on cytokine profile, hormone profile, and progesterone-induced blocking factor. J Reprod Immunol. 2011 Dec;92(1-2):103-7. PMID: 22032897. ***X-2***

1094. Hudson M, Rahme E, Richard H, et al.; Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum. 2007 Apr 15;57(3):516-23. PMID: 17394181. ***X-7***

1095. Hudson M, Richard H, Pilote L; Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-

inflammatory drugs: population based study. BMJ. 2005 Jun 11;330(7504):1370. PMID: 15947399. ***X-4, X-7***

1096. Huerta C, Castellsague J, Varas-Lorenzo C, et al.; Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9. PMID: 15754275. ***X-4***

1097. Huerta C, Varas-Lorenzo C, Castellsague J, et al.; Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. 2006 Nov;92(11):1610-5. PMID: 16717069. ***X-7***

1098. Hug H, Bagatto D, Dannecker R, et al.; ADRIS - The Adverse Drug Reactions Information Scheme. Clin Neuropharmacol. 2004 Jan-Feb;27(1):44-8. PMID: 15090937. ***X-1***

1099. Huggins GR; IUD use and unexplained vaginal bleeding. Obstet Gynecol. 1981 Oct;58(4):409-16. PMID: 7279336. ***X-4***

1100. Hui CK, Lai KC, Yuen MF, et al.; Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding? Aliment Pharmacol Ther. 2002 May;16(5):929-36. PMID: 11966501. ***X-2, X-4***

1101. Huic M, Mucolic V, Vrhovac B, et al.; Adverse drug reactions resulting in hospital admission. Int J Clin Pharmacol Ther. 1994 Dec;32(12):675-82. PMID: 7881707. ***X-4***

1102. Hulley S, Grady D, Bush T, et al.; Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605-13. PMID: 9718051. ***X-7***

1103. Hurskainen R, Teperi J, Rissanen P, et al.; Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet. 2001 Jan 27;357(9252):273-7. PMID: 11214131. ***X-2***

1104. Hussain N, Alsulaiman R, Burtin P, et al.; The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther. 2007 Mar 1;25(5):579-84. PMID: 17305758. ***X-2, X-4***

1105. Hwang H, Murphy JJ, Gow KW, et al.; Are localized intestinal perforations distinct from necrotizing enterocolitis? J Pediatr Surg. 2003 May;38(5):763-7. PMID: 12720189. ***X-2, X-3, X-4***

1106. Hynes MC, Calder P, Rosenfeld P, et al.; The use of tranexamic acid to reduce blood loss during total hip arthroplasty: an observational study. Ann R Coll Surg Engl. 2005 Mar;87(2):99-101. PMID: 15826417. ***X-2, X-3, X-4***

1107. Hyvarinen H, Salmenkyla S, Sipponen P; Helicobacter pylori-negative duodenal and pyloric ulcer: role of NSAIDs. Digestion. 1996;57(5):305-9. PMID: 8886573. ***X-2, X-3, X-4***

1108. Iamandescu IB; NSAIDs-induced asthma: peculiarities related to background and association with other drug or non-drugs etiological agents. Allergol Immunopathol (Madr). 1989 Nov-Dec;17(6):285-90. PMID: 2635829. ***X-2, X-4***

1109. Iannucci TA, Besinger RE, Fisher SG, et al.; Effect of dual tocolysis on the incidence of severe intraventricular hemorrhage among extremely low-birth-weight infants. Am J Obstet Gynecol. 1996 Oct;175(4 Pt 1):1043-6. PMID: 8885773. ***X-2, X-4***

1110. Ibanez L, Morlans M, Vidal X, et al.; Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. Kidney Int. 2005 Jun;67(6):2393-8. PMID: 15882284. ***X-4***

1111. Ibanez L, Vidal X, Ballarin E, et al.; Population-based drug-induced agranulocytosis. Arch Intern Med. 2005 Apr 25;165(8):869-74. PMID: 15851637. ***X-4***

1112. Ibanez-Cuevas V, Lopez-Briz E, Guardiola-Chorro MT; Pharmacist intervention reduces gastropathy risk in patients using NSAIDs. Pharm World Sci. 2008 Dec;30(6):947-54. PMID: 18932013. ***X-4***

1113. Ibraheim M, Ikomi A; An evaluation of troublesome inter-menstrual bleeding in menorrhagic users of the LNG-IUS. J Obstet Gynaecol. 2005 May;25(4):384-5. PMID: 16091327. ***X-2***

1114. Idilman R, Bektas M, Cinar K, et al.; The characteristics and clinical outcome of drug-induced liver injury: a single-center experience. J Clin Gastroenterol. 2010 Jul;44(6):e128-32. PMID: 20551776. ***X-4***

1115. Iglehart IW, 3rd, Edlow DW, Mills L, Jr., et al.; The presence of Campylobacter pylori in nonsteroidal antiinflammatory drug associated gastritis. J Rheumatol. 1989 May;16(5):599-603. PMID: 2754664. ***X-2, X-3, X-4***

1116. Iitaka K, Ishidate T, Hojo M, et al.; Idiopathic membranoproliferative glomerulonephritis in Japanese children. Pediatr Nephrol. 1995 Jun;9(3):272-7. PMID: 7632509. ***X-2, X-3, X-4***

1117. Ike RW, Arnold WJ, Rothschild EW, et al.; Tidal irrigation versus conservative medical management in patients with osteoarthritis of the knee: a prospective randomized study. Tidal Irrigation Cooperating Group. J Rheumatol. 1992 May;19(5):772-9. PMID: 1613709. ***X-2, X-4***

1118. Ikechebelu JI, Onwusulu DN; Missing IUD string: prevalence, diagnosis and retrieval in Nnewi, Nigeria. Niger J Med. 2009 Jul-Sep;18(3):303-5. PMID: 20120651. ***X-2, X-4***

1119. Ilkhanoff L, Lewis JD, Hennessy S, et al.; Potential limitations of electronic database studies of prescription non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and risk of myocardial infarction (MI). Pharmacoepidemiol Drug Saf. 2005 Aug;14(8):513-22. PMID: 15959879. ***X-3, X-4***

1120. Imhof M, Epstein S, Ohmann C, et al.; Poor late prognosis of bleeding peptic ulcer. Langenbecks Arch Surg. 2007 Sep;392(5):587-91. PMID: 17632731. ***X-2, X-3, X-4***

1121. Imperiale TF, Horwitz RI; Scientific standards and the design of case-control research. Biomed Pharmacother. 1989;43(3):187-96. PMID: 2775855. ***X-1, X-2, X-3, X-4***

1122. Inki P, Hurskainen R, Palo P, et al.; Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol. 2002 Oct;20(4):381-5. PMID: 12383322. ***X-2***

1123. Inman WH; Prescription-event monitoring. A preliminary study of benoxaprofen and fenbufen. Acta Med Scand Suppl. 1984;683:119-26. PMID: 6234753. ***X-1, X-4***

1124. Inoue M, Caldarone CA, Frndova H, et al.; Safety and efficacy of ketorolac in children after cardiac surgery. Intensive Care Med. 2009 Sep;35(9):1584-92. PMID: 19562323. ***X-2, X-4***

1125. Insua J, Mavros P, Hunsche E, et al.; Exposure to nonsteroidal anti-inflammatory drugs among older adult patients hospitalized for peptic ulcer disease in Argentina: A case-control study. Am J Geriatr Pharmacother. 2006 Sep;4(3):251-9. PMID: 17062326. ***X-2***

1126. Inzucchi SE, Masoudi FA, Wang Y, et al.; Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care. 2005 Jul;28(7):1680-9. PMID: 15983320. ***X-7***

1127. Irani J, Ravery V, Pariente JL, et al.; Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol. 2002 Nov;168(5):1985-8. PMID: 12394690. ***X-2***

1128. Irvine GA, Campbell-Brown MB, Lumsden MA, et al.; Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol. 1998 Jun;105(6):592-8. PMID: 9647148. ***X-2, X-3, X-4***

1129. Ishikawa N, Fuchigami T, Matsumoto T, et al.; Helicobacter pylori infection in rheumatoid arthritis: effect of drugs on prevalence and correlation with gastroduodenal lesions. Rheumatology (Oxford). 2002 Jan;41(1):72-7. PMID: 11792883. ***X-2, X-3, X-4***

1130. Ishikawa S, Inaba T, Mizuno M, et al.; Incidence of serious upper gastrointestinal bleeding in patients taking non-steroidal anti-inflammatory drugs in Japan. Acta Med Okayama. 2008 Feb;62(1):29-36. PMID: 18323869. ***X-4***

1131. Isidro ML, Penin MA, Nemina R, et al.; Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine. 2007 Aug;32(1):79-82. PMID: 17992605. ***X-2***

1132. Isik B, Arslan M, Ozsoylar O, et al.; Effects of preoperative lornoxicam versus tramadol on postoperative pain and adverse effects in adult tonsillectomy patients. Agri. 2009 Jul;21(3):113-20. PMID: 19780002. ***X-2, X-4***

1133. Istre O, Trolle B; Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril. 2001 Aug;76(2):304-9. PMID: 11476777. ***X-2***

1134. Itsekson A, Lazarov A, Cordoba M, et al.; Premenstrual syndrome and associated skin diseases related to hypersensitivity to female sex hormones. J Reprod Med. 2004 Mar;49(3):195-9. PMID: 15098889. ***X-2***

1135. Izumi K, Kadono Y, Shima T, et al.; Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. Anticancer Res. 2010 Dec;30(12):5201-5. PMID: 21187513. ***X-2, X-3, X-4***

1136. Jackson-Northey K, Evans MF; Taking NSAIDs during pregnancy. Is it safe? Can Fam Physician. 2002 Mar;48:483-5. PMID: 11935712. ***X-1, X-4***

1137. Jacob A, Matiello M, Weinshenker BG, et al.; Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009 Sep;66(9):1128-33. PMID: 19752302. ***X-2, X-3, X-4***

1138. Jacob AN, Salinas K, Adams-Huet B, et al.; Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab. 2007 May;9(3):386-93. PMID: 17391167. ***X-2, X-3, X-4***

1139. Jacobs P, Fransman D, Coghlan P; Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood donors. J Clin Apher. 1993;8(2):89-95. PMID: 8226711. ***X-2, X-3, X-4***

1140. Jain JK, Ota F, Mishell DR; Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive. Contraception. 2000 Mar;61(3):195-8. PMID: 10827333. ***X-2***

1141. Jallad RS, Bronstein MD; Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology. 2009;90(1):82-92. PMID: 19439914. ***X-2, X-3***

1142. James MW, Chen CM, Goddard WP, et al.; Risk factors for gastrointestinal malignancy in patients with iron-deficiency anaemia. Eur J Gastroenterol Hepatol. 2005 Nov;17(11):1197-203. PMID: 16215432. ***X-2, X-3, X-4***

1143. Jamison RN, Raymond SA, Slawsby EA, et al.; Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine (Phila Pa 1976). 1998 Dec 1;23(23):2591-600. PMID: 9854758. ***X-2, X-4***

1144. Jankovic SM, Aleksic J, Rakovic S, et al.; Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis. J Nephrol. 2009 Jul-Aug;22(4):502-7. PMID: 19662606. ***X-2***

1145. Janssen M, Dijkmans BA, Lamers CB, et al.; A gastroscopic study of the predictive value of risk factors for non-steroidal anti-inflammatory drug-associated ulcer disease in rheumatoid arthritis patients. Br J Rheumatol. 1994 May;33(5):449-54. PMID: 8173849. ***X-2, X-3, X-4***

1146. Jarernsiripornkul N, Chaisrisawadsuk S, Chaiyakum A, et al.; Patient self-reporting of potential adverse drug reactions to non-steroidal anti-inflammatory drugs in Thailand. Pharm World Sci. 2009 Oct;31(5):559-64. PMID: 19575308. ***X-3, X-4***

1147. Jaspersen D, Labenz J, Willich SN, et al.; Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study. Dig Liver Dis. 2006 Apr;38(4):233-8. PMID: 16413233. ***X-4***

1148. Jaszewski R; Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal antiinflammatory drug therapy. J Clin Gastroenterol. 1990 Feb;12(1):10-3. PMID: 2303676. ***X-2***

1149. Jaszewski R, Calzada R, Dhar R; Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin. Dig Dis Sci. 1989 Sep;34(9):1361-4. PMID: 2766902. ***X-2, X-3, X-4***

1150. Jaszewski R, Crane SA; The effect of 15(R)-15-methyl prostaglandin E2 (Arbacet) on the healing of aspirin or nonsteroidal antiinflammatory drug-induced gastric mucosal lesions: an endoscopic study. Am J Gastroenterol. 1987 Dec;82(12):1271-4. PMID: 3318402. ***X-2, X-3, X-4***

1151. Jeanfils S, Joly P, Young P, et al.; Indomethacin treatment of eighteen patients with Sweet's syndrome. J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):436-9. PMID: 9091476. ***X-2, X-3, X-4***

1152. Jedel E, Labrie F, Oden A, et al.; Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E37-45. PMID: 20943753. ***X-2, X-4***

1153. Jeffries MA, Scheiman JM, Fendrick AM; Helicobacter pylori eradication: kill the bug and save the pill? Am J Gastroenterol. 1998 Jul;93(7):1183-4. PMID: 9672364. ***X-1, X-2***

1154. Jenner PN; A 12-month postmarketing surveillance study of nabumetone. A preliminary report. Drugs. 1990;40 Suppl 5:80-6. PMID: 2081502. ***X-4***

1155. Jenq CC, Tian YC, Wu HH, et al.; Effectiveness of oral and intravenous iron therapy in haemodialysis patients. Int J Clin Pract. 2008 Mar;62(3):416-22. PMID: 17511797. ***X-2, X-3, X-4***

1156. Jensen JT, Parke S, Mellinger U, et al.; Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: A randomized controlled trial. Obstetrics and Gynecology. 2011;117(4):777-87. PMID: 21422847. ***X-2, X-3, X-4***

1157. Jeon SB, Song HS, Kim BJ, et al.; Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur Neurol. 2010;64(1):51-7. PMID: 20606449. ***X-2, X-3, X-4***

1158. Jespersen J, Endrikat J, Dusterberg B, et al.; A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel. Contraception. 2005 Aug;72(2):98-104. PMID: 16022847. ***X-2, X-4***

1159. Jeyakumar A, Brickman TM, Williamson ME, et al.; Nonsteroidal anti-inflammatory drugs and postoperative bleeding following adenotonsillectomy in pediatric patients. Arch Otolaryngol Head Neck Surg. 2008 Jan;134(1):24-7. PMID: 18209131. ***X-2, X-4***

1160. Jick H, Jick SS, Gurewich V, et al.; Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995 Dec 16;346(8990):1589-93. PMID: 7500750. ***X-4***

1161. Jick H, Kaye JA, Russmann S, et al.; Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy. 2006 Oct;26(10):1379-87. PMID: 16999647. ***X-4***

1162. Jick H, Kaye JA, Vasilakis-Scaramozza C, et al.; Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ. 2000 Nov 11;321(7270):1190-5. PMID: 11073511. ***X-4***

1163. Jick H, Myers MW, Dean AD; The risk of sulfasalazine- and mesalazine-associated blood disorders.

Pharmacotherapy. 1995 Mar-Apr;15(2):176-81. PMID: 7624265. ***X-4***

1164. Jick S, Kaye JA, Li L, et al.; Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2007 Jul;76(1):4-7. PMID: 17586129. ***X-2, X-4***

1165. Jick SS; The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy. 2000 Jul;20(7):741-4. PMID: 10907963. ***X-4***

1166. Jick SS, Hagberg KW, Hernandez RK, et al.; Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception. 2010 Jan;81(1):16-21. PMID: 20004268. ***X-4***

1167. Jick SS, Hernandez RK; Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151. PMID: 21511805. ***X-2, X-4***

1168. Jick SS, Jick H; Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Contraception. 2006 Oct;74(4):290-2. PMID: 16982227. ***X-4***

1169. Jick SS, Jick H; The contraceptive patch in relation to ischemic stroke and acute myocardial infarction. Pharmacotherapy. 2007 Feb;27(2):218-20. PMID: 17253912. ***X-4***

1170. Jick SS, Kaye JA, Russmann S, et al.; Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception. 2006 Jun;73(6):566-70. PMID: 16730485. ***X-2***

1171. Jimoh AA; Complications of intrauterine contraceptive device (IUD) use at the University of Ilorin Teaching Hospital, Ilorin. Niger J Med. 2004 Jul-Sep;13(3):244-9. PMID: 15532225. ***X-2***

1172. Jindabanjerd K, Taneepanichskul S; The use of levonorgestrel - IUD in the treatment of uterine myoma in Thai women. J Med Assoc Thai. 2006 Oct;89 Suppl 4:S147-51. PMID: 17726816. ***X-2, X-3, X-4***

1173. Jobanputra P, Amarasena R, Maggs F, et al.; Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord. 2008;9:48. PMID: 18405372. ***X-2, X-4***

1174. Jockheck M, Willms R, Volkmann R, et al.; Prevention of periarticular heterotopic ossification after endoprosthetic hip joint replacement by means of diclofenac. Arch Orthop Trauma Surg. 1998;117(6-7):337-40. PMID: 9709846. ***X-2, X-4***

1175. Joeres-Nguyen-Xuan TH, Boehm SK, Joeres L, et al.; Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. Inflamm Bowel Dis. 2010 Feb;16(2):256-62. PMID: 19637333. ***X-2, X-3, X-4***

1176. Johannes CB, Koro CE, Quinn SG, et al.; The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12. PMID: 17245800. ***X-2, X-4***

1177. Johansson JE, Andersson SO, Holmberg L, et al.; Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup. J Urol. 1991 Mar;145(3):519-22; discussion 22-3. PMID: 1997702. ***X-2, X-4***

1178. John BK, Arramraju S, Shalomov A, et al.; Antiplatelet agents do not impact the hospital course in patients with gastrointestinal bleeding. J Clin Gastroenterol. 2011 Aug;45(7):583-9. PMID: 21293292. ***X-2, X-4***

1179. Johnsen SP, Larsson H, Tarone RE, et al.; Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005 May 9;165(9):978-84. PMID: 15883235. ***X-4***

1180. Johnsen SP, Pedersen L, Friis S, et al.; Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case-control study. Stroke. 2003 Feb;34(2):387-91. PMID: 12574547. ***X-4***

1181. Johnsen SP, Sorensen HT, Mellemkjoer L, et al.; Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost. 2001 Aug;86(2):563-8. PMID: 11522004. ***X-4***

1182. Johnsen V, Borg G, Trang LE, et al.; Auranofin (SK&F) in early rheumatoid arthritis: results from a 24-month double-blind, placebo-controlled study. Effect on clinical and biochemical assessments. Scand J Rheumatol. 1989;18(5):251-60. PMID: 2688083. ***X-2, X-4***

1183. Johnson DE, Babaian RJ, Swanson DA, et al.; Medical castration using megestrol acetate and minidose estrogen. Urology. 1988 May;31(5):371-4. PMID: 3284149. ***X-2, X-3, X-4***

1184. Johnson JA, Majumdar SR, Simpson SH, et al.; Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002 Dec;25(12):2244-8. PMID: 12453968. ***X-3***

1185. Johnson KC, Margolis KL, Espeland MA, et al.; A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women's Health Initiative Memory Study. J Am Geriatr Soc. 2008 Aug;56(8):1449-58. PMID: 18637980. ***X-3, X-4***

1186. Johnson KH, Millard PS; Oral contraceptives and breast cancer. J Fam Pract. 1996 Oct;43(4):340-1. PMID: 8874363. ***X-1, X-4***

1187. Johnson M, Krosnick A, Carson P, et al.; A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes. Clin Ther. 1998 Jul-Aug;20(4):691-8. PMID: 9737829. ***X-2, X-3, X-4***

1188. Johnson RL, Hemington-Gorse SJ, Dhital SK; Do cosmetic surgeons consider estrogen-containing drugs to be of significant risk in the development of thromboembolism? Aesthetic Plast Surg. 2008 Sep;32(5):743-7. PMID: 18446403. ***X-2, X-4***

1189. Johnson ST, Fueger JT, Gottschall JL; One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm. Transfusion. 2007 Apr;47(4):697-702. PMID: 17381629. ***X-2, X-3, X-4***

1190. Jones CW; A post-marketing surveillance study of Voltarol 75 mg SR in the primary care setting. Br J Clin Pract. 1996 Oct-Nov;50(7):390-5. PMID: 9015913. ***X-3, X-4***

1191. Jonsson PE, Olsson AM, Petersson BA, et al.; Intravenous indomethacin and oxycone-papaverine in the treatment of acute renal colic. A double-blind study. Br J Urol. 1987 May;59(5):396-400. PMID: 3297230. ***X-2, X-3, X-4***

1192. Jordan HL, Bruinsma FJ, Thomson RJ, et al.; Adolescent exposure to high-dose estrogen and subsequent effects on lactation. Reprod Toxicol. 2007 Nov-Dec;24(3-4):397-402. PMID: 17531440. ***X-2, X-4***

1193. Jordan HL, Hopper JL, Thomson RJ, et al.; Influence of high-dose estrogen exposure during adolescence on mammographic density for age in adulthood. Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):121-9. PMID: 20056630. ***X-2, X-3, X-4***

1194. Jorn LP, Lindstrand A, Toksvig-Larsen S; Tourniquet release for hemostasis increases bleeding. A randomized study of 77 knee replacements. Acta Orthop Scand. 1999 Jun;70(3):265-7. PMID: 10429602. ***X-2, X-3, X-4***

1195. Juby A, Davis P; Psychological profiles of patients with upper gastrointestinal symptomatology induced by non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 1991 Apr;50(4):211-3. PMID: 2029202. ***X-2, X-3, X-4***

1196. Julkunen HA; Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol. 1991;20(6):427-33. PMID: 1771400. ***X-2***

1197. Juurlink DN, Mamdani MM, Kopp A, et al.; Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc. 2004 May;52(5):794-8. PMID: 15086664. ***X-2, X-4***

1198. Kabadi UM; United Kingdom prospective diabetes study: a different perspective. Endocr Pract. 2002 Jan-Feb;8(1):61-4. PMID: 11939763. ***X-1***

1199. Kaimal N, Schofield J, Zaki A, et al.; Effects of exenatide in poorly controlled type 2 diabetes. QJM. 2012 Apr;105(4):321-6. PMID: 22056400. ***X-2, X-3***

1200. Kalaichelvan V, Maw AA, Singh K; Actinomyces in cervical smears of women using the intrauterine device in Singapore. Contraception. 2006 Apr;73(4):352-5. PMID: 16531165. ***X-2, X-4***

1201. Kaliterna V, Kucisec-Tepes N, Pejkovic L, et al.; An intrauterine device as a possible cause of change in the microbial flora of the female genital system. J Obstet Gynaecol Res. 2011 Aug;37(8):1035-40. PMID: 21481090. ***X-2***

1202. Kallio H, Paloheimo M, Maunuksela EL; Haemorrhage and risk factors associated with retrobulbar/peribulbar block: a prospective study in 1383 patients. Br J Anaesth. 2000 Nov;85(5):708-11. PMID: 11094585. ***X-2, X-3, X-4***

1203. Kamber N, Davis WA, Bruce DG, et al.; Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Med J Aust. 2008 Apr 21;188(8):446-9. PMID: 18429709. ***X-2, X-4***

1204. Kanat-Pektas M, Ozat M, Gungor T; The effects of TCu-380A on cervicovaginal flora. Arch Gynecol Obstet. 2008 May;277(5):429-32. PMID: 17972087. ***X-2, X-4***

1205. Kane LA, Sparrow MJ; Postcoital contraception: a family planning study. N Z Med J. 1989 Apr 12;102(865):151-3. PMID: 2649811. ***X-2, X-3, X-4***

1206. Kang NS, Yoo KH, Cheon H, et al.; Indomethacin treatment decreases renal blood flow velocity in human neonates. Biol Neonate. 1999 Nov;76(5):261-5. PMID: 10516392. ***X-2, X-4***

1207. Kang SB, Cho KJ, Moon KH, et al.; Does low-dose aspirin increase blood loss after spinal fusion surgery? Spine J. 2011 Apr;11(4):303-7. PMID: 21474081. ***X-2, X-4***

1208. Kaplan B, Farris KB, Kirking DM; Assessing physician choice of nonsteroidal antiinflammatory drugs in a health maintenance organization. Ann Pharmacother. 1993 Nov;27(11):1393-9. PMID: 8286817. ***X-3, X-4***

1209. Kaplan RC, Heckbert SR, Koepsell TD, et al.; Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators. J Am Geriatr Soc. 2001 Feb;49(2):126-33. PMID: 11207865. ***X-7***

1210. Kaplan RC, Heckbert SR, Psaty BM; Risk factors for hospitalized upper or lower gastrointestinal tract bleeding in treated hypertensives. Prev Med. 2002 Apr;34(4):455-62. PMID: 11914052. ***X-2***

1211. Kapoor DA, Weitzel S, Mowad JJ, et al.; Use of indomethacin suppositories in the prophylaxis of recurrent ureteral colic. J Urol. 1989 Dec;142(6):1428-30. PMID: 2685362. ***X-2, X-3, X-4***

1212. Karakus S, Kiran G, Ciralik H; Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial. Aust N Z J Obstet Gynaecol. 2009 Dec;49(6):685-8. PMID: 20070724. ***X-2, X-3, X-4***

1213. Karkouti K, Wijeysundera DN, Yau TM, et al.; The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg. 2010 Jan 1;110(1):21-9. PMID: 19910626. ***X-3***

1214. Kars M, Delgado V, Holman ER, et al.; Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008 Sep;93(9):3348-56. PMID: 18559921. ***X-2***

1215. Karsay K; The relationship between vascular headaches and low-dose oral contraceptives. Ther Hung. 1990;38(4):181-5. PMID: 2094059. ***X-1, X-2, X-3, X-4***

1216. Kasemsarn P, Kulthanan K, Tuchinda P, et al.; Cutaneous reactions to non-steroidal anti-inflammatory drugs. J Drugs Dermatol. 2011 Oct;10(10):1160-7. PMID: 21968666. ***X-2***

1217. Katic BJ, Golden W, Cady RK, et al.; GERD prevalence in migraine patients and the implication for acute migraine treatment. J Headache Pain. 2009 Feb;10(1):35-43. PMID: 19009231. ***X-4***

1218. Katschinski BD, Logan RF; Changes in birth-cohort pattern of peptic ulcer mortality in England and Wales. Postgrad Med J. 1991 Sep;67(791):825-8. PMID: 1946128. ***X-4***

1219. Katsinelos P, Christodoulou K, Pilpilidis I, et al.; Colopathy associated with the systemic use of nonsteroidal antiinflammatory medications. An underestimated entity. Hepatogastroenterology. 2002 Mar-Apr;49(44):345-8. PMID: 11995447. ***X-2***

1220. Kaufman DW, Kelly JP; Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Clin Pharmacol. 2001 Feb;51(2):174-6. PMID: 11259991. ***X-2, X-4***

1221. Kaufman DW, Kelly JP, Sheehan JE, et al.; Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther. 1993 Apr;53(4):485-94. PMID: 8477566. ***X-4***

1222. Kaufman DW, Kelly JP, Wiholm BE, et al.; The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol. 1999 Nov;94(11):3189-96. PMID: 10566713. ***X-4***

1223. Kaunitz AM, Bissonnette F, Monteiro I, et al.; Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Sep;116(3):625-32. PMID: 20733445. ***X-2, X-4***

1224. Kaunitz AM, Miller PD, Rice VM, et al.; Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006 Aug;74(2):90-9. PMID: 16860045. ***X-2***

1225. Kaunitz AM, Portman DJ, Hait H, et al.; Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive. Contraception. 2009 May;79(5):350-5. PMID: 19341846. ***X-2, X-4***

1226. Kawasaki T, Kurosawa H, Ikeda H, et al.; Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial. J Bone Miner Metab. 2008;26(3):279-87. PMID: 18470670. ***X-2, X-3, X-4***

1227. Kawase Y, Ishii T, Arai H, et al.; Gastrointestinal perforation in very low-birthweight infants. Pediatr Int. 2006 Dec;48(6):599-603. PMID: 17168981. ***X-2***

1228. Kay RM, Directo MP, Leathers M, et al.; Complications of ketorolac use in children undergoing operative fracture care. J Pediatr Orthop. 2010 Oct-Nov;30(7):655-8. PMID: 20864848. ***X-2, X-4***

1229. Kay RM, Leathers M, Directo MP, et al.; Perioperative ketorolac use in children undergoing lower extremity osteotomies. J Pediatr Orthop. 2011 Oct-Nov;31(7):783-6. PMID: 21926877. ***X-2, X-3, X-4***

1230. Keating J, Chandran H; Antiinflammatory drugs and emergency surgery for peptic ulcers in the Waikato. N Z Med J. 1992 Apr 8;105(931):127-9. PMID: 1560923. ***X-2, X-3***

1231. Keder LM, Rulin MC, Gruss J; Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders. Am J Obstet Gynecol. 1998 Sep;179(3 Pt 1):583-5. PMID: 9757955. ***X-3, X-4***

1232. Keim SA, Klebanoff MA; Aspirin use and miscarriage risk. Epidemiology. 2006 Jul;17(4):435-9. PMID: 16755260. ***X-4***

1233. Kekkonen R, Lahteenmaki P, Luukkainen T, et al.; Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception. Fertil Steril. 1993 Oct;60(4):610-5. PMID: 8405512. ***X-2, X-3, X-4***

1234. Keles GT, Topcu I, Ekici Z, et al.; Evaluation of piroxicam-beta-cyclodextrin as a preemptive analgesic in functional endoscopic sinus surgery. Braz J Med Biol Res. 2010 Aug;43(8):806-11. PMID: 20602016. ***X-2, X-4***

1235. Keljo DJ, Sugerman KS; Pancreatitis in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1997 Jul;25(1):108-12. PMID: 9226539. ***X-2***

1236. Kellner H, Bornholdt K, Hein G; Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. Clin Rheumatol. 2010 Aug;29(8):913-20. PMID: 20496042. ***X-2, X-4***

1237. Kelly JP, Kaufman DW, Jurgelon JM, et al.; Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996 Nov 23;348(9039):1413-6. PMID: 8937281. ***X-2, X-3, X-4***

1238. Kemmeren JM, Tanis BC, van den Bosch MA, et al.; Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002 May;33(5):1202-8. PMID: 11988591. ***X-2***

1239. Kemppainen H, Raiha I, Sourander L; Clinical presentation of bleeding peptic ulcer in the elderly. Aging (Milano). 1996 Jun;8(3):184-8. PMID: 8862193. ***X-2***

1240. Kenangil G, Ozekmekci S, Koldas L, et al.; Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg. 2007 May;109(4):350-3. PMID: 17307289. ***X-2***

1241. Kennedy AD, Sculpher MJ, Coulter A, et al.; Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA. 2002 Dec 4;288(21):2701-8. PMID: 12460093. ***X-2, X-3, X-4***

1242. Kepczyk T, Kadakia SC; Prospective evaluation of gastrointestinal tract in patients with iron-deficiency anemia. Dig Dis Sci. 1995 Jun;40(6):1283-9. PMID: 7781448. ***X-2, X-3, X-4***

1243. Kerr SJ, Rowett DS, Sayer GP, et al.; All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study. Br J Clin Pharmacol. 2011 Jun;71(6):936-42. PMID: 21276041. ***X-4, X-6***

1244. Kerstens PJ, Boerbooms AM, Jeurissen ME, et al.; Radiological and clinical results of longterm treatment of rheumatoid arthritis with methotrexate and azathioprine. J Rheumatol. 2000 May;27(5):1148-55. PMID: 10813280. ***X-2, X-3, X-4***

1245. Kessing LV, Nilsson FM; Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord. 2003 Feb;73(3):261-9. PMID: 12547295. ***X-2, X-3, X-4***

1246. Kessler WF, Shires GT, 3rd, Fahey TJ, 3rd; Surgical complications of nonsteroidal antiinflammatory drug-induced small bowel ulceration. J Am Coll Surg. 1997 Sep;185(3):250-4. PMID: 9291402. ***X-2***

1247. Kewitz H; Rare but serious risks associated with non-narcotic analgesics: clinical experience. Med Toxicol. 1986;1 Suppl 1:86-92. PMID: 3821433. ***X-4***

1248. Keyl C, Uhl R, Beyersdorf F, et al.; High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg. 2011 May;39(5):e114-21. PMID: 21295991. ***X-2***

1249. Khalafallah A, Dennis A, Bates J, et al.; A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med. 2010 Sep;268(3):286-95. PMID: 20546462. ***X-2, X-3, X-4***

1250. Khalid SK, Lane J, Navarro V, et al.; Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol. 2009 Sep;7(9):994-9; quiz 13-4. PMID: 19394441. ***X-2***

1251. Khan FM; A six-month parallel group comparison of fenbufen and naproxen in the treatment of rheumatoid arthritis. Clin Ther. 1983;5(5):483-7. PMID: 6352034. ***X-2, X-3, X-4***

1252. Khan HA, Amitava AK; Topical diclofenac versus dexamethasone after strabismus surgery: a double-blind randomized clinical trial of anti-inflammatory effect and ocular hypertensive response. Indian J Ophthalmol. 2007 Jul-Aug;55(4):271-5. PMID: 17595475. ***X-2, X-3, X-4***

1253. Kharlip J, Salvatori R, Yenokyan G, et al.; Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009 Jul;94(7):2428-36. PMID: 19336508. ***X-2, X-3***

1254. Khattab S, Mohsen IA, Aboul Foutouh I, et al.; Can metformin reduce the incidence of gestational diabetes

mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. Gynecol Endocrinol. 2011 Oct;27(10):789-93. PMID: 21247239. ***X-2, X-3***

1255. Khomassuridze AG, Tsertsvadze GL, Tsereteli TG; Intrauterine device and pelvic inflammatory disease. Adv Contracept. 1997 Mar;13(1):71-8. PMID: 9181187. ***X-2, X-4***

1256. Khoo SK, Coglan MJ, Wright GR, et al.; Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium. Med J Aust. 1998 Mar 2;168(5):216-20. PMID: 9539899. ***X-2, X-4***

1257. Kidon MI, Liew WK, Chiang WC, et al.; Hypersensitivity to paracetamol in Asian children with early onset of nonsteroidal anti-inflammatory drug allergy. Int Arch Allergy Immunol. 2007;144(1):51-6. PMID: 17505137. ***X-2, X-3, X-4***

1258. Kierkegaard A; Side and site of deep vein thrombosis in women using oral contraceptives. Acta Obstet Gynecol Scand. 1985;64(5):399-402. PMID: 4061060. ***X-2***

1259. Kiilholma P, Tuimala R, Kivinen S, et al.; Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril. 1995 Nov;64(5):903-8. PMID: 7589632. ***X-2, X-3, X-4***

1260. Kim J, Lee KH, Yoo S, et al.; Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents. 2009 Nov;34(5):434-8. PMID: 19726164. ***X-2***

1261. Kim JG, Graham DY; Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group. Am J Gastroenterol. 1994 Feb;89(2):203-7. PMID: 8304304. ***X-2, X-3, X-4***

1262. Kim JH, Park BL, Cheong HS, et al.; Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. PLoS One. 2010;5(11):e13818. PMID: 21072201. ***X-2, X-3, X-4***

1263. Kim JT, Sherman O, Cuff G, et al.; A double-blind prospective comparison of rofecoxib vs ketorolac in reducing postoperative pain after arthroscopic knee surgery. J Clin Anesth. 2005 Sep;17(6):439-43. PMID: 16171664. ***X-2, X-3, X-4***

1264. Kim S, Martin C, Galanko J, et al.; Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. Am J Epidemiol. 2008 Dec 1;168(11):1292-300. PMID: 18945689. ***X-4***

1265. Kim SH, Choi JH, Lee KW, et al.; The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005 Mar;35(3):339-44. PMID: 15784113. ***X-2, X-3, X-4***

1266. Kim SH, Kang YM, Cho BY, et al.; Histamine N-methyltransferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria. Allergy. 2009 Feb;64(2):213-21. PMID: 19178400. ***X-3, X-4***

1267. Kim SH, Nam EJ, Kim YK, et al.; Functional variability of the adenosine A3 receptor (ADORA3) gene polymorphism in aspirin-induced urticaria. Br J Dermatol. 2010 Nov;163(5):977-85. PMID: 20716228. ***X-2, X-3, X-4***

1268. Kim SH, Son JK, Yang EM, et al.; A functional promoter polymorphism of the human IL18 gene is associated with aspirin-induced urticaria. Br J Dermatol. 2011 Nov;165(5):976-84. PMID: 21692767. ***X-2, X-4***

1269. Kim SH, Ye YM, Lee SK, et al.; Association of TNF-alpha genetic polymorphism with HLA DPB1*0301. Clin Exp Allergy. 2006 Oct;36(10):1247-53. PMID: 17014432. ***X-2, X-3, X-4***

1270. Kim SJ, Lo WR, Hubbard GB, 3rd, et al.; Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial. Arch Ophthalmol. 2008 Sep;126(9):1203-8. PMID: 18779478. ***X-2, X-3, X-4***

1271. Kimmel SE, Berlin JA, Reilly M, et al.; Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005 Feb 1;142(3):157-64. PMID: 15684203. ***X-4***

1272. Kimmerle R, Weiss R, Berger M, et al.; Effectiveness, safety, and acceptability of a copper intrauterine device (CU Safe 300) in type I diabetic women. Diabetes Care. 1993 Sep;16(9):1227-30. PMID: 8404424. ***X-2, X-4***

1273. Kirkman RJ, Bromham DR, O'Connor TP, et al.; Prospective multicentre study comparing levonorgestrel implants with a combined contraceptive pill: final results. Br J Fam Plann. 1999 Jul;25(2):36-40. PMID: 10454652. ***X-2, X-3, X-4***

1274. Kirshon B, Poindexter AN, 3rd; Contraception: a risk factor for endometriosis. Obstet Gynecol. 1988 Jun;71(6 Pt 1):829-31. PMID: 3368167. ***X-2, X-4***

1275. Kitchen PA, Levi AJ, Domizio P, et al.; Microscopic colitis: the tip of the iceberg? Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1199-204. PMID: 12439114. ***X-2***

1276. Kivijarvi A, Gronroos M; Positional factors of the uterus play a contributing part in IUD failure. Acta Obstet

Gynecol Scand. 1983;62(1):67-70. PMID: 6858628. ***X-3, X-4***

1277. Kjaersgaard-Andersen P, Frich LH, Sojbjerg JO, et al.; Heterotopic bone formation following total shoulder arthroplasty. J Arthroplasty. 1989;4(2):99-104. PMID: 2501455. ***X-2, X-4***

1278. Kjos SL, Ballagh SA, La Cour M, et al.; The copper T380A intrauterine device in women with type II diabetes mellitus. Obstet Gynecol. 1994 Dec;84(6):1006-9. PMID: 7970454. ***X-2, X-4***

1279. Kjos SL, Peters RK, Xiang A, et al.; Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA. 1998 Aug 12;280(6):533-8. PMID: 9707143. ***X-2***

1280. Kjos SL, Shoupe D, Douyan S, et al.; Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 1):1822-7. PMID: 2256489. ***X-2, X-4***

1281. Kjotrod SB, von During V, Carlsen SM; Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum Reprod. 2004 Jun;19(6):1315-22. PMID: 15117902. ***X-2, X-3, X-4***

1282. Klavon SL, Grubb GS; Insertion site complications during the first year of NORPLANT use. Contraception. 1990 Jan;41(1):27-37. PMID: 2105871. ***X-4***

1283. Klein BE, Klein R, Lee KE, et al.; Drug use and five-year incidence of age-related cataracts: The Beaver Dam Eye Study. Ophthalmology. 2001 Sep;108(9):1670-4. PMID: 11535471. ***X-4***

1284. Klein WA, Krevsky B, Klepper L, et al.; Nonsteroidal antiinflammatory drugs and upper gastrointestinal hemorrhage in an urban hospital. Dig Dis Sci. 1993 Nov;38(11):2049-55. PMID: 8223081. ***X-2, X-3, X-4***

1285. Kleinhans M, Linzbach L, Zedlitz S, et al.; Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis. 2002 Aug;47(2):100-2. PMID: 12423408. ***X-2, X-3, X-4***

1286. Kleinknecht D, Landais P, Goldfarb B; Drug-associated acute renal failure. A prospective collaborative study of 81 biopsied patients. Adv Exp Med Biol. 1987;212:125-8. PMID: 3618352. ***X-2***

1287. Kleinstein J; Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertil Steril. 2005 Jun;83(6):1641-9. PMID: 15950631. ***X-2, X-3, X-4***

1288. Kleynhans L, Du Plessis N, Black GF, et al.; Medroxyprogesterone acetate alters Mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users. PLoS One. 2011;6(9):e24639. PMID: 21931790. ***X-2***

1289. Kluft C, Endrikat J, Mulder SM, et al.; A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception. 2006 Apr;73(4):336-43. PMID: 16531162. ***X-2, X-4***

1290. Knapp P, Gardner PH, Carrigan N, et al.; Perceived risk of medicine side effects in users of a patient information website: a study of the use of verbal descriptors, percentages and natural frequencies. Br J Health Psychol. 2009 Sep;14(Pt 3):579-94. PMID: 18992183. ***X-2, X-3, X-4***

1291. Kneer W, Rother I, Rother M, et al.; A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation. Curr Drug Saf. 2009 Jan;4(1):5-10. PMID: 19149519. ***X-2, X-4***

1292. Knijff-Dutmer EA, Postma MJ, van der Palen J, et al.; Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study. Clin Ther. 2004 Jul;26(7):1160-7. PMID: 15336481. ***X-4***

1293. Knijff-Dutmer EA, Schut GA, van de Laar MA; Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother. 2003 Jan;37(1):12-6. PMID: 12503926. ***X-4***

1294. Knijff-Dutmer EA, Van der Palen J, Schut G, et al.; The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users. QJM. 2003 Jul;96(7):513-20. PMID: 12881594. ***X-2, X-3, X-4***

1295. Kocak I, Yalvac IS, Kocak A, et al.; Comparison of the anti-inflammatory effects of diclofenac and flurbiprofen eye drops after cataract extraction. Acta Ophthalmol Scand. 1998 Jun;76(3):343-5. PMID: 9686850. ***X-2, X-4***

1296. Koch M, Dezi A, Tarquini M, et al.; Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Dig Liver Dis. 2000 Mar;32(2):138-51. PMID: 10975790. ***X-4***

1297. Koetsawang S, Charoenvisal C, Banharnsupawat L, et al.; Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.

Contraception. 1995 Apr;51(4):225-9. PMID: 7796587. ***X-2, X-3, X-4***

1298. Kohli HS; NSAIDs and bleeding ulcers. Natl Med J India. 1994 Nov-Dec;7(6):278-9. PMID: 7841880. ***X-1, X-4***

1299. Kohne CH, De Greve J, Hartmann JT, et al.; Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol. 2008 May;19(5):920-6. PMID: 18065406. ***X-2, X-3, X-4***

1300. Kokki H, Kokki M; Ketoprofen versus paracetamol (acetaminophen) or ibuprofen in the management of fever: results of two randomized, double-blind, double-dummy, parallel-group, repeated-dose, multicentre, phase III studies in children. Clin Drug Investig. 2010;30(6):375-86. PMID: 20380479. ***X-4***

1301. Kokki H, Nikanne E, Ahonen R; The feasibility of pain treatment at home after adenoidectomy with ketoprofen tablets in small children. Paediatr Anaesth. 2000;10(5):531-5. PMID: 11012958. ***X-2, X-4***

1302. Kokki H, Nikanne E, Tuovinen K; I.v. intraoperative ketoprofen in small children during adenoidectomy: a dose-finding study. Br J Anaesth. 1998 Dec;81(6):870-4. PMID: 10211011. ***X-2, X-4***

1303. Kokki H, Salonen A, Nikanne E; Perioperative intravenous ketoprofen neither prolongs operation time nor delays discharge after adenoidectomy in children. Paediatr Anaesth. 2001 Jan;11(1):59-64. PMID: 11123733. ***X-2, X-3, X-4***

1304. Kolt SD, Kronborg IJ, Yeomans ND; High prevalence of duodenal ulcer in Indochinese immigrants attending an Australian university hospital. J Gastroenterol Hepatol. 1993 Mar-Apr;8(2):128-32. PMID: 8471749. ***X-4***

1305. Komericki P, Arbab E, Grims R, et al.; Tryptase as severity marker in drug provocation tests. Int Arch Allergy Immunol. 2006;140(2):164-9. PMID: 16601354. ***X-2, X-3, X-4***

1306. Koncz TA, Lister SP, Makinson GT; Gastroprotection in patients prescribed non-selective NSAIDs, and the risk of related hospitalization. Curr Med Res Opin. 2008 Dec;24(12):3405-12. PMID: 19032122. ***X-4***

1307. Koninckx PR, Spielmann D; A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women. Gynecol Endocrinol. 2005 Aug;21(2):82-9. PMID: 16294460. ***X-2, X-3, X-4***

1308. Koro CE, Bowlin SJ, Weiss SR; Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):697-703. PMID: 15654719. ***X-3***

1309. Koseoglu BG, Ozturk S, Kocak H, et al.; The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery. Yonsei Med J. 2008 Oct 31;49(5):742-7. PMID: 18972594. ***X-2, X-3***

1310. Kossoff EH, Mankad DN; Medication-overuse headache in children: is initial preventive therapy necessary? J Child Neurol. 2006 Jan;21(1):45-8. PMID: 16551452. ***X-2, X-3, X-4***

1311. Kotzan J, Wade W, Yu HH; Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001 Sep;18(9):1367-72. PMID: 11683254. ***X-4***

1312. Kouides PA, Byams VR, Philipp CS, et al.; Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009 Apr;145(2):212-20. PMID: 19236375. ***X-2, X-3***

1313. Kovo M, Weissman A, Gur D, et al.; Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. J Matern Fetal Neonatal Med. 2006 Jul;19(7):415-9. PMID: 16923696. ***X-2***

1314. Koyama H, Tominaga T, Asaishi K, et al.; A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancer. Oncology. 1999;56(4):283-90. PMID: 10343191. ***X-2, X-4***

1315. Kozer E, Barr J, Bulkowstein M, et al.; A prospective study of multiple supratherapeutic acetaminophen doses in febrile children. Vet Hum Toxicol. 2002 Apr;44(2):106-9. PMID: 11931497. ***X-2, X-4***

1316. Kozlowski KJ, Rickert VI, Hendon A, et al.; Adolescents and Norplant: preliminary findings of side effects. J Adolesc Health. 1995 May;16(5):373-8. PMID: 7662687. ***X-2, X-4***

1317. Kraag GR, Gordon DA, Menard HA, et al.; Patient compliance with tenoxicam in family practice. Clin Ther. 1994 May-Jun;16(3):581-93. PMID: 7923322. ***X-3, X-4***

1318. Kremer JM, Malamood H, Maliakkal B, et al.; Fish oil dietary supplementation for prevention of indomethacin induced gastric and small bowel toxicity in healthy volunteers. J Rheumatol. 1996 Oct;23(10):1770-3. PMID: 8895156. ***X-3, X-4***

1319. Kresanov I, Nikkanen V, Klemi P; Disturbances of the endometrium in the luteal phase of cycles stimulated for in vitro fertilization and of normal cycles treated with vaginal progesterone. Ann Chir Gynaecol Suppl. 1994;208:33-9. PMID: 8092768. ***X-2, X-3, X-4***

1320. Kriplani A, Kulshrestha V, Agarwal N, et al.; Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol. 2006 Oct;26(7):673-8. PMID: 17071438. ***X-2***

1321. Kriplani A, Singh BM, Lal S, et al.; Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007 Jun;97(3):190-4. PMID: 17382331. ***X-2, X-4***

1322. Krunic A, Ciurea A, Scheman A; Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol. 2008 Jan;58(1):60-2. PMID: 17964689. ***X-2, X-3, X-4***

1323. Kruse W, Eggert-Kruse W, Rampmaier J, et al.; Compliance with short-term high-dose ethinyl oestradiol in young patients with primary infertility. New insights from the use of electronic devices. Agents Actions Suppl. 1990;29:105-15. PMID: 2316431. ***X-2, X-3, X-4***

1324. Kruse W, Eggert-Kruse W, Rampmaier J, et al.; Compliance and adverse drug reactions: a prospective study with ethinylestradiol using continuous compliance monitoring. Clin Investig. 1993 Jun;71(6):483-7. PMID: 8353409. ***X-2, X-4***

1325. Krysiak R, Gdula-Dymek A, Okopien B; Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol. 2011 Apr 1;107(7):1010-8 e1. PMID: 21276586. ***X-2, X-3, X-4***

1326. Kubicsek T, Kazy Z, Czeizel AE; Teratogenic potential of tribenoside, a drug for the treatment of haemorrhoids and varicose veins--a population-based case--control study. Reprod Toxicol. 2011 May;31(4):464-9. PMID: 21182931. ***X-4***

1327. Kubota K, Kubota N, Pearce GL, et al.; Signalling drug-induced rash with 36 drugs recently marketed in the United Kingdom and studied by Prescription-Event Monitoring. Int J Clin Pharmacol Ther. 1995 Apr;33(4):219-25. PMID: 7620692. ***X-4***

1328. Kucuk T, Ertan K; Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol. 2008;35(1):57-60. PMID: 18390083. ***X-2, X-3***

1329. Kuehl K, Carr W, Yanchick J, et al.; Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury. Int J Sports Med. 2011 Aug;32(8):635-43. PMID: 21563042. ***X-2, X-3***

1330. Kulkarni J, Liew J, Garland KA; Depression associated with combined oral contraceptives--a pilot study. Aust Fam Physician. 2005 Nov;34(11):990. PMID: 16299641. ***X-2***

1331. Kulkarni SG, Parikh SS, Shankhpal PD, et al.; Gastric emptying of solids in long-term NSAID users: correlation with endoscopic findings and Helicobacter pylori status. Am J Gastroenterol. 1999 Feb;94(2):382-6. PMID: 10022633. ***X-2***

1332. Kulnigg S, Stoinov S, Simanenkov V, et al.; A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008 May;103(5):1182-92. PMID: 18371137. ***X-2, X-3, X-4***

1333. Kumar Nair PA, Pai MG, Gazal HA, et al.; Indomethacin prophylaxis for intraventricular hemorrhage in very low birth weight babies. Indian Pediatr. 2004 Jun;41(6):551-8. PMID: 15235161. ***X-2, X-4***

1334. Kumar RK, Yu VY; Prolonged low-dose indomethacin therapy for patent ductus arteriosus in very low birthweight infants. J Paediatr Child Health. 1997 Feb;33(1):38-41. PMID: 9069042. ***X-2, X-4***

1335. Kuo HW, Tsai SS, Tiao MM, et al.; Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):745-51. PMID: 20582905. ***X-4***

1336. Kupczyk M, Kuprys I, Gorski P, et al.; Aspirin intolerance and allergy to house dust mites: important factors associated with development of severe asthma. Ann Allergy Asthma Immunol. 2004 Apr;92(4):453-8. PMID: 15104198. ***X-2, X-3, X-4***

1337. Kupczyk M, Kurmanowska Z, Kuprys-Lipinska I, et al.; Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge. Respir Med. 2010 Oct;104(10):1404-9. PMID: 20452758. ***X-2, X-4***

1338. Kuptniratsaikul V, Pinthong T, Bunjob M, et al.; Efficacy and safety of Derris scandens Benth extracts in patients with knee osteoarthritis. J Altern Complement Med. 2011 Feb;17(2):147-53. PMID: 21309709. ***X-2, X-3, X-4***

1339. Kurahara K, Matsumoto T, Iida M, et al.; Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations. Am J Gastroenterol. 2001 Feb;96(2):473-80. PMID: 11232693. ***X-4***

1340. Kurata JH, Nogawa AN, Noritake D; NSAIDs increase risk of gastrointestinal bleeding in primary care patients with dyspepsia. J Fam Pract. 1997 Sep;45(3):227-35. PMID: 9300002. ***X-2***

1341. Kurth T, Glynn RJ, Walker AM, et al.; Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003 Sep 9;108(10):1191-5. PMID: 12939216. ***X-4***

1342. Kurth T, Glynn RJ, Walker AM, et al.; Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003 Aug;42(2):234-44. PMID: 12900803. ***X-4, X-6***

1343. Kurth T, Hennekens CH, Sturmer T, et al.; Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med. 2005 Sep 12;165(16):1903-9. PMID: 16157836. ***X-6***

1344. Kushnir A, Pinheiro JM; Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts. BMC Clin Pharmacol. 2011;11:8. PMID: 21718490. ***X-2***

1345. Kyriakidis AV, Perysinakis I, Alexandris I, et al.; Parecoxib sodium in the treatment of postoperative pain after Lichtenstein tension-free mesh inguinal hernia repair. Hernia. 2011 Feb;15(1):59-64. PMID: 20957399. ***X-2, X-3, X-4***

1346. La Vecchia C, Parazzini F, Negri E, et al.; Breast cancer and combined oral contraceptives: an Italian case-control study. Eur J Cancer Clin Oncol. 1989 Nov;25(11):1613-8. PMID: 2591454. ***X-4***

1347. Laan W, Selten JP, Grobbee DE, et al.; Non-steroidal anti-inflammatory drugs and the risk of psychosis. Eur Neuropsychopharmacol. 2007 Mar;17(4):309-11. PMID: 17097858. ***X-2, X-3, X-4***

1348. Labenz J, Peitz U, Kohl H, et al.; Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study. Ital J Gastroenterol Hepatol. 1999 Mar;31(2):110-5. PMID: 10363194. ***X-2, X-3, X-4***

1349. Lachance K, Savoie M, Bernard M, et al.; Oral ferrous sulfate does not increase preoperative hemoglobin in patients scheduled for hip or knee arthroplasty. Ann Pharmacother. 2011 Jun;45(6):764-70. PMID: 21666087. ***X-2, X-3, X-4***

1350. LaCivita C, Funkhouser E, Miller MJ, et al.; Patient-reported communications with pharmacy staff at community pharmacies: the Alabama NSAID Patient Safety Study, 2005-2007. J Am Pharm Assoc (2003). 2009 Sep-Oct;49(5):e110-7. PMID: 20797933. ***X-2, X-3***

1351. Lacroix I, Lapeyre-Mestre M, Bagheri H, et al.; Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol. 2004 Apr;18(2):201-6. PMID: 15066135. ***X-2***

1352. LaDuca JR, Bouman PH, Gaspari AA; Nonsteroidal antiinflammatory drug-induced pseudoporphyria: a case series. J Cutan Med Surg. 2002 Jul-Aug;6(4):320-6. PMID: 12118363. ***X-2, X-3***

1353. Lafrance JP, Miller DR; Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol Drug Saf. 2009 Oct;18(10):923-31. PMID: 19585463. ***X-6, X-7***

1354. Laharie D, Droz-Perroteau C, Benichou J, et al.; Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol. 2010 Mar;69(3):295-302. PMID: 20233201. ***X-4***

1355. Laharie D, Seneschal J, Schaeverbeke T, et al.; Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol. 2010 Dec;53(6):1035-40. PMID: 20801541. ***X-2, X-4***

1356. Lahteenmaki P, Bardin CW, Elomaa K, et al.; Selection and performance of the levonorgestrel-releasing intrauterine system. Acta Obstet Gynecol Scand Suppl. 1997;164:69-74. PMID: 9225643. ***X-2, X-3, X-4***

1357. Lahteenmaki P, Haukkamaa M, Puolakka J, et al.; Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ. 1998 Apr 11;316(7138):1122-6. PMID: 9552948. ***X-2, X-3, X-4***

1358. Lai KC, Chu KM, Hui WM, et al.; Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005 Nov;118(11):1271-8. PMID: 16271912. ***X-2, X-3, X-4***

1359. Lai KC, Lam SK, Chu KM, et al.; Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. Aliment Pharmacol Ther. 2003 Oct 15;18(8):829-36. PMID: 14535877. ***X-2, X-3, X-4***

1360. Lai KC, Lam SK, Chu KM, et al.; Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002 Jun 27;346(26):2033-8. PMID: 12087138. ***X-2, X-3, X-4***

1361. Laibovitz RA, Koester J, Schaich L, et al.; Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther. 1995 Fall;11(3):361-8. PMID: 8590268. ***X-2, X-3, X-4***

1362. Laine L; NSAID-induced gastroduodenal injury: what's the score? Gastroenterology. 1991 Aug;101(2):555-7. PMID: 2065932. ***X-1, X-2***

1363. Laine L, Connors LG, Reicin A, et al.; Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003 Feb;124(2):288-92. PMID: 12557133. ***X-4***

1364. Laine L, Curtis SP, Cryer B, et al.; Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther. 2010 Nov;32(10):1240-8. PMID: 20955443. ***X-4***

1365. Laine L, Curtis SP, Langman M, et al.; Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008 Nov;135(5):1517-25. PMID: 18823986. ***X-4***

1366. Laine L, Goldkind L, Curtis SP, et al.; How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009 Feb;104(2):356-62. PMID: 19174782. ***X-4, X-7***

1367. Laine L, Sloane R, Ferretti M, et al.; A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 1995 Nov;42(5):428-33. PMID: 8566633. ***X-2***

1368. Laine L, Wogen J, Yu H; Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology. 2003 Aug;125(2):389-95. PMID: 12891540. ***X-4***

1369. Laine LA, Bentley E, Chandrasoma P; Effect of oral iron therapy on the upper gastrointestinal tract. A prospective evaluation. Dig Dis Sci. 1988 Feb;33(2):172-7. PMID: 3257437. ***X-2, X-4***

1370. Lal S, Kriplani A, Kulshrestha V, et al.; Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system. Int J Gynaecol Obstet. 2010 May;109(2):128-30. PMID: 20223454. ***X-2, X-3, X-4***

1371. Lalau JD, Race JM; Lactic acidosis in metformin therapy. Drugs. 1999;58 Suppl 1:55-60; discussion 75-82. PMID: 10576527. ***X-1, X-4***

1372. Lanas A, Bajador E, Serrano P, et al.; Effects of nitrate and prophylactic aspirin on upper gastrointestinal bleeding: a retrospective case-control study. J Int Med Res. 1998 Jun-Jul;26(3):120-8. PMID: 9718466. ***X-2, X-4***

1373. Lanas A, Bajador E, Serrano P, et al.; Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000 Sep 21;343(12):834-9. PMID: 10995862. ***X-4***

1374. Lanas A, Fuentes J, Benito R, et al.; Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002 Apr;16(4):779-86. PMID: 11929396. ***X-2, X-4***

1375. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al.; Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007 Mar;102(3):507-15. PMID: 17338735. ***X-4***

1376. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al.; Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006 Dec;55(12):1731-8. PMID: 16687434. ***X-4***

1377. Lanas A, Garcia-Tell G, Armada B, et al.; Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med. 2011;9:38. PMID: 21489310. ***X-4***

1378. Lanas A, Hirschowitz BI; Significant role of aspirin use in patients with esophagitis. J Clin Gastroenterol. 1991 Dec;13(6):622-7. PMID: 1761835. ***X-2, X-3, X-4***

1379. Lanas A, Remacha B, Sainz R, et al.; Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol. 2000 Feb;95(2):513-9. PMID: 10685760. ***X-2***

1380. Lanas A, Rodrigo L, Marquez JL, et al.; Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol. 2003 Jul;38(7):693-700. PMID: 12889553. ***X-2, X-4***

1381. Lanas A, Sekar MC, Hirschowitz BI; Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology. 1992 Sep;103(3):862-9. PMID: 1499936. ***X-2, X-4***

1382. Lanas A, Serrano P, Bajador E, et al.; Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol. 2003 Feb;15(2):173-8. PMID: 12560762. ***X-4***

1383. Lang BA, Finlayson LA; Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr. 1994 Apr;124(4):639-42. PMID: 8151484. ***X-2***

1384. Lange R, Lentz R; Comparison ketoprofen, ibuprofen and naproxen sodium in the treatment of tension-type headache. Drugs Exp Clin Res. 1995;21(3):89-96. PMID: 7555617. ***X-2, X-4***

1385. Langeveld JW, Lycklama a Nijeholt AA, Jonas U; Oestrogen in the treatment of prostatic carcinoma. What is the safe and effective dose of ethinyloestradiol? Br J Urol. 1989 Jan;63(1):76-9. PMID: 2920266. ***X-2, X-4***

1386. Langman M, Kahler KH, Kong SX, et al.; Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):517-24. PMID: 11828834. ***X-3, X-4***

1387. Langman M, Kong SX, Zhang Q, et al.; Safety and patient tolerance of standard and slow-release formulations of NSAIDs. Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):61-6. PMID: 12616849. ***X-4***

1388. Langman MJ; Anti-inflammatory drug intake and the risk of ulcer complications. Med Toxicol. 1986;1 Suppl 1:34-8. PMID: 3493403. ***X-1, X-2, X-3, X-4***

1389. Langman MJ; Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? Pharmacoepidemiol Drug Saf. 2001 Jan-Feb;10(1):13-9. PMID: 11417061. ***X-7***

1390. Langman MJ, Weil J, Wainwright P, et al.; Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994 Apr 30;343(8905):1075-8. PMID: 7909103. ***X-7***

1391. Lanza LL, Walker AM, Bortnichak EA, et al.; Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med. 1995 Jul 10;155(13):1371-7. PMID: 7794085. ***X-4***

1392. Lao CS; Application of CUSUM technique and beta-binomial model in monitoring adverse drug reactions. J Biopharm Stat. 1997 May;7(2):227-39. PMID: 9136066. ***X-4***

1393. Lapane KL, Spooner JJ, Mucha L, et al.; Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc. 2001 May;49(5):577-84. PMID: 11380750. ***X-7***

1394. Lapane KL, Spooner JJ, Pettitt D; The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis. Am J Manag Care. 2001 Apr;7(4):402-8. PMID: 11310194. ***X-3, X-4***

1395. Lapeyre-Mestre M, de Castro AM, Bareille MP, et al.; Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol. 2006 Aug;20(4):391-5. PMID: 16867024. ***X-4***

1396. Laporte JR, Carne X, Vidal X, et al.; Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet. 1991 Jan 12;337(8733):85-9. PMID: 1670734. ***X-4***

1397. Laporte JR, Ibanez L, Vidal X, et al.; Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411-20. PMID: 15144234. ***X-4***

1398. Larsen A, Kvien TK, Schattenkirchner M, et al.; Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol. 2001;30(3):135-42. PMID: 11469522. ***X-2, X-3, X-4***

1399. Larsen K, Tos M; A long-term follow-up study of nasal polyp patients after simple polypectomies. Eur Arch Otorhinolaryngol. 1997;254 Suppl 1:S85-8. PMID: 9065636. ***X-2, X-3***

1400. Larsson B, Hagstrom B, Viberg L, et al.; Long-term clinical experience with the Cu-7-IUD. Evaluation of a prospective study. Contraception. 1981 Apr;23(4):387-97. PMID: 7273759. ***X-2, X-4***

1401. Lassen A, Hallas J, Schaffalitzky de Muckadell OB; Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: a population-based cohort study. Am J Gastroenterol. 2006 May;101(5):945-53. PMID: 16573778. ***X-4***

1402. Lassise DL, Savitz DA, Hamman RF, et al.; Invasive cervical cancer and intrauterine device use. Int J Epidemiol. 1991 Dec;20(4):865-70. PMID: 1800424. ***X-2, X-4***

1403. Lassner KJ, Chen CH, Kropsch LA, et al.; Comparative study of safety and efficacy of IUD insertions by physicians and nursing personnel in Brazil. Bull Pan Am Health Organ. 1995 Sep;29(3):206-15. PMID: 8520606. ***X-3, X-4***

1404. Laszlo A, Kelly JP, Kaufman DE, et al.; Clinical aspects of upper gastrointestinal bleeding associated with the use of nonsteroidal antiinflammatory drugs. Am J Gastroenterol. 1998 May;93(5):721-5. PMID: 9625116. ***X-2, X-4***

1405. Lawrenson R, Todd JC, Leydon GM, et al.; Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol. 2000 Jun;49(6):591-6. PMID: 10848723. ***X-2, X-3, X-4***

1406. Layton D, Heeley E, Hughes K, et al.; Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology (Oxford). 2003 May;42(5):622-31. PMID: 12709537. ***X-2, X-4***

1407. Layton D, Heeley E, Shakir SA; Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event

Monitoring data. J Clin Pharm Ther. 2004 Apr;29(2):171-81. PMID: 15068407. ***X-4***

1408. Layton D, Hughes K, Harris S, et al.; Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford). 2003 Nov;42(11):1332-41. PMID: 12810929. ***X-4***

1409. Layton D, Riley J, Wilton LV, et al.; Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol. 2003 Feb;55(2):166-74. PMID: 12580988. ***X-4***

1410. Layton D, Souverein PC, Heerdink ER, et al.; Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands. Drug Saf. 2008;31(2):143-58. PMID: 18217790. ***X-4***

1411. Lebbe M, Hubinont C, Bernard P, et al.; Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf). 2010 Aug;73(2):236-42. PMID: 20455894. ***X-2***

1412. Lee CH, Wang JD, Chen PC; Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):708-14. PMID: 20582911. ***X-4***

1413. Lee J, Rajadurai VS, Tan KW, et al.; Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. Pediatrics. 2003 Aug;112(2):345-50. PMID: 12897285. ***X-2, X-3, X-4***

1414. Lee MC, Lee S, Suh DC, et al.; A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea. Curr Med Res Opin. 2003;19(7):597-602. PMID: 14606981. ***X-2, X-3, X-4***

1415. Lee SC, Rha DW, Chang WH; Rapid analgesic onset of intra-articular hyaluronic acid with ketorolac in osteoarthritis of the knee. J Back Musculoskelet Rehabil. 2011;24(1):31-8. PMID: 21248398. ***X-2, X-3, X-4***

1416. Lee SH, Han CD, Yang IH, et al.; Prescription pattern of NSAIDs and the prevalence of NSAID-induced gastrointestinal risk factors of orthopaedic patients in clinical practice in Korea. J Korean Med Sci. 2011 Apr;26(4):561-7. PMID: 21468265. ***X-4***

1417. Lee TA, Bartle B, Weiss KB; Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med. 2007 Jan;120(1):98 e9-16. PMID: 17208086. ***X-4, X-6***

1418. Lee TY, Yang YS, Tseng LH, et al.; Norplant-2 subdermal contraceptive system: experience in Taiwan. J Formos Med Assoc. 1993 May;92(5):446-50. PMID: 8104598. ***X-2, X-4***

1419. Leeyaphan C, Kulthanan K, Jongjarearnprasert K, et al.; Drug-induced angioedema without urticaria: prevalence and clinical features. J Eur Acad Dermatol Venereol. 2010 Jun;24(6):685-91. PMID: 19925599. ***X-4***

1420. Legeby M, Sandelin K, Wickman M, et al.; Analgesic efficacy of diclofenac in combination with morphine and paracetamol after mastectomy and immediate breast reconstruction. Acta Anaesthesiol Scand. 2005 Oct;49(9):1360-6. PMID: 16146476. ***X-2, X-3, X-4***

1421. Legras A, Giraudeau B, Jonville-Bera AP, et al.; A multicentre case-control study of nonsteroidal anti-inflammatory drugs as a risk factor for severe sepsis and septic shock. Crit Care. 2009;13(2):R43. PMID: 19331665. ***X-2, X-4***

1422. Lehtinen K, Kaarela K, Ahonen M, et al.; A six-month follow-up study of a slow-release indomethacin tablet in rheumatic diseases. Clin Rheumatol. 1987 Dec;6(4):606-7. PMID: 3329590. ***X-1***

1423. LeLorier J; Patterns of prescription of nonsteroidal antiinflammatory drugs and gastroprotective agents. J Rheumatol Suppl. 1995 Feb;43:26-7. PMID: 7752128. ***X-4, X-7***

1424. Lemberg A, Fernandez MA, Coll C, et al.; Reyes's syndrome, encephalopathy, hyperammonemia and acetyl salicylic acid ingestion in a city hospital of Buenos Aires, Argentina. Curr Drug Saf. 2009 Jan;4(1):17-21. PMID: 19149521. ***X-2, X-3, X-4***

1425. Lemmel EM, Leeb B, De Bast J, et al.; Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin. 2002;18(3):146-53. PMID: 12094824. ***X-3, X-4***

1426. Leonardi C, Strober B, Gottlieb AB, et al.; Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010 Aug;9(8):928-37. PMID: 20684143. ***X-2, X-3, X-4***

1427. Leonhardt A, Strehl R, Barth H, et al.; High efficacy and minor renal effects of indomethacin treatment during individualized fluid intake in premature infants with patent ductus arteriosus. Acta Paediatr. 2004 Feb;93(2):233-40. PMID: 15046280. ***X-2, X-4***

1428. Lera G, Vaamonde J, Rodriguez M, et al.; Cabergoline in Parkinson's disease: long-term follow-up. Neurology. 1993 Dec;43(12):2587-90. PMID: 7902970. ***X-2***

1429. Leroy S, Marc E, Bavoux F, et al.; Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study. Clin Drug Investig. 2010;30(3):179-85. PMID: 20155990. ***X-2***

1430. Lesko SM, Louik C, Vezina RM, et al.; Asthma morbidity after the short-term use of ibuprofen in children. Pediatrics. 2002 Feb;109(2):E20. PMID: 11826230. ***X-4***

1431. Lesko SM, O'Brien KL, Schwartz B, et al.; Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics. 2001 May;107(5):1108-15. PMID: 11331694. ***X-2***

1432. Lete I, del Carme Cuesta M, Marin JM, et al.; Acceptability of the levonorgestrel intrauterine system in the long-term treatment of heavy menstrual bleeding: how many women choose to use a second device? Eur J Obstet Gynecol Reprod Biol. 2011 Jan;154(1):67-70. PMID: 20728261. ***X-2, X-3***

1433. Lete I, Obispo C, Izaguirre F, et al.; The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction. Eur J Contracept Reprod Health Care. 2008 Sep;13(3):231-7. PMID: 18609346. ***X-2, X-4***

1434. Levi Z, Rozen P, Hazazi R, et al.; Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol. 2009 Apr;104(4):933-8. PMID: 19293792. ***X-2, X-3***

1435. Levine RA, Petokas S, Nandi J, et al.; Effects of nonsteroidal, antiinflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers. Dig Dis Sci. 1988 Jun;33(6):660-6. PMID: 3371138. ***X-2, X-4***

1436. Levy R, Matitiau A, Ben Arie A, et al.; Indomethacin and corticosteroids: an additive constrictive effect on the fetal ductus arteriosus. Am J Perinatol. 1999;16(8):379-83. PMID: 10772195. ***X-2, X-3, X-4***

1437. Lewis JD, Schinnar R, Bilker WB, et al.; Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):393-401. PMID: 17066486. ***X-2, X-3, X-4***

1438. Lewis JD, Strom BL, Localio AR, et al.; Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):328-35. PMID: 18188866. ***X-2, X-3, X-4***

1439. Lewis MA, Spitzer WO, Heinemann LA, et al.; Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996 Jan 13;312(7023):88-90. PMID: 8555936. ***X-2, X-4***

1440. Li CF, Lee SS, Pun TC; A pilot study on the acceptability of levonorgestrel-releasing intrauterine device by young, single, nulliparous Chinese females following surgical abortion. Contraception. 2004 Mar;69(3):247-50. PMID: 14969674. ***X-2, X-3, X-4***

1441. Li CF, Wong CY, Chan CP, et al.; A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. Contraception. 2003 Feb;67(2):101-5. PMID: 12586320. ***X-2***

1442. Li CH, Chang WH, Shih SC, et al.; Perforated peptic ulcer in southeastern Taiwan. J Gastroenterol Hepatol. 2010 Sep;25(9):1530-6. PMID: 20796151. ***X-2, X-3, X-4***

1443. Li CI, Beaber EF, Tang MT, et al.; Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res. 2012 Apr 15;72(8):2028-35. PMID: 22369929. ***X-2***

1444. Li DK, Liu L, Odouli R; Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003 Aug 16;327(7411):368. PMID: 12919986. ***X-2***

1445. Li L; A conditional sequential sampling procedure for drug safety surveillance. Stat Med. 2009 Nov 10;28(25):3124-38. PMID: 19691034. ***X-1, X-2***

1446. Li Voti G, Acierno C, Tulone V, et al.; Relationship between upper gastrointestinal bleeding and non steroidal anti-inflammatory drugs in children. Pediatr Surg Int. 1997 Apr;12(4):264-5. PMID: 9099642. ***X-2***

1447. Li Y, Chen F, Zhou L, et al.; COC use, ACE/AGT gene polymorphisms, and risk of stroke. Pharmacogenet Genomics. 2010 May;20(5):298-306. PMID: 20300047. ***X-2, X-4***

1448. Liao EY, Luo XH, Deng XG, et al.; The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. Endocr Res. 2003 May;29(2):217-26. PMID: 12856809. ***X-2, X-4***

1449. Liao WC, Hou MC, Chang CJ, et al.; Potential precipitating factors of esophageal variceal bleeding: a case-control study. Am J Gastroenterol. 2011 Jan;106(1):96-103. PMID: 20823836. ***X-2, X-3, X-4***

1450. Licata A, Calvaruso V, Cappello M, et al.; Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. Dig Liver Dis. 2010 Feb;42(2):143-8. PMID: 19625223. ***X-2, X-4***

1451. Lidegaard O; The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study. Acta Obstet Gynecol Scand. 1997 Mar;76(3):252-60. PMID: 9093141. ***X-2***

1452. Lidegaard O, Kreiner S; Cerebral thrombosis and oral contraceptives. A case-control study. Contraception. 1998 May;57(5):303-14. PMID: 9673837. ***X-2***

1453. Lidegaard O, Lokkegaard E, Svendsen AL, et al.; Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890. PMID: 19679613. ***X-4***

1454. Liguori L; Iron protein succinylate in the treatment of iron deficiency: controlled, double-blind, multicenter clinical trial on over 1,000 patients. Int J Clin Pharmacol Ther Toxicol. 1993 Mar;31(3):103-23. PMID: 8468108. ***X-2, X-3, X-4***

1455. Lim CH, Heatley RV; Prospective study of acute gastrointestinal bleeding attributable to anti-inflammatory drug ingestion in the Yorkshire region of the United Kingdom. Postgrad Med J. 2005 Apr;81(954):252-4. PMID: 15811890. ***X-2***

1456. Lindegard B, Hillbom M, Brody S; High-dose estrogen-progestagen oral contraceptives: a risk factor for aneurysmal subarachnoid hemorrhage? Acta Neurol Scand. 1987 Jul;76(1):37-45. PMID: 3630643. ***X-4***

1457. Lindh I, Ellstrom AA, Milsom I; The long-term influence of combined oral contraceptives on body weight. Hum Reprod. 2011 Jul;26(7):1917-24. PMID: 21507999. ***X-2***

1458. Lindoff C, Rybo G, Astedt B; Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost. 1993 Aug 2;70(2):238-40. PMID: 8236125. ***X-8***

1459. Lindquist M, Pettersson M, Edwards IR, et al.; How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. ADR Signals Analysis Project (ASAP) Team. Pharmacol Toxicol. 1997 May;80(5):211-7. PMID: 9181599. ***X-2, X-4***

1460. Lindvall G, Sartipy U, Ivert T, et al.; Aprotinin is not associated with postoperative renal impairment after primary coronary surgery. Ann Thorac Surg. 2008 Jul;86(1):13-9. PMID: 18573391. ***X-2, X-3, X-4***

1461. Liossis SN, Bounas A, Andonopoulos AP; Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006 Aug;45(8):1005-8. PMID: 16490756. ***X-2, X-3, X-4***

1462. Lipscomb GR, Campbell F, Rees WD; The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 1997 Oct;11(5):907-12. PMID: 9354199. ***X-2***

1463. Lipscomb GR, Rees WD; Gastric mucosal injury and adaptation to oral and rectal administration of naproxen. Aliment Pharmacol Ther. 1996 Apr;10(2):133-8. PMID: 8730240. ***X-2, X-4***

1464. Lipson A, Stoy DB, LaRosa JC, et al.; Progestins and oral contraceptive-induced lipoprotein changes: a prospective study. Contraception. 1986 Aug;34(2):121-34. PMID: 3096633. ***X-2, X-4***

1465. Lipworth L, Friis S, Blot WJ, et al.; A population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther. 2004 May-Jun;11(3):156-63. PMID: 15133529. ***X-4***

1466. Lisse J, Espinoza L, Zhao SZ, et al.; Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M167-75. PMID: 11253158. ***X-2, X-4***

1467. Lisse JR, Perlman M, Johansson G, et al.; Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003 Oct 7;139(7):539-46. PMID: 14530224. ***X-4***

1468. Liu MY, Lin HH, Chen PC; Duodenal ulcer hemorrhage with and without dyspepsia. Am J Gastroenterol. 1990 Oct;85(10):1343-5. PMID: 2220727. ***X-2, X-3, X-4***

1469. Liu NJ, Lee CS, Tang JH, et al.; Outcomes of bleeding peptic ulcers: a prospective study. J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 2):e340-7. PMID: 17944885. ***X-2, X-4***

1470. Livesey JR, Watson MG, Kelly PJ, et al.; Do patients with epistaxis have drug-induced platelet dysfunction? Clin Otolaryngol Allied Sci. 1995 Oct;20(5):407-10. PMID: 8582070. ***X-2***

1471. Ljung R, Lu Y, Lagergren J; High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study. Drugs Aging. 2011 Jun 1;28(6):469-76. PMID: 21639406. ***X-4***

1472. Llorente Melero MJ, Tenias Burillo JM, Del Val Antonana A, et al.; Influence of nonsteroidal anti-inflammatory drugs on clinical course in upper gastrointestinal tract bleeding. Rev Esp Enferm Dig. 1999 Jul;91(7):497-507. PMID: 10477368. ***X-2***

1473. Llorente Melero MJ, Tenias Burillo JM, Zaragoza Marcet A; Comparative incidence of upper gastrointestinal

bleeding associated with individual non-steroidal anti-inflammatory drugs. Rev Esp Enferm Dig. 2002 Jan;94(1):7-18. PMID: 12073673. ***X-4***

1474. Lockhat FB, Emembolu JO, Konje JC; The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum Reprod. 2004 Jan;19(1):179-84. PMID: 14688179. ***X-2, X-3, X-4***

1475. Lockhat FB, Emembolu JO, Konje JC; The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005 Mar;20(3):789-93. PMID: 15608040. ***X-2, X-4***

1476. Lockie LM; Tolerability and efficacy of long-term daily administration of indomethacin for moderate to severe chronic arthritic disorders. Clin Ther. 1986;8(4):398-405. PMID: 3731210. ***X-2, X-4***

1477. Loebstein R, Dushinat M, Vesterman-Landes J, et al.; Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol. 2011 Feb;51(2):173-80. PMID: 20484611. ***X-3***

1478. Lombroso GL, vicariotto F, Quaranta S, et al.; Study of a new intrauterine device, the multiload 250 CU. Acta Eur Fertil. 1980 Sep;11(3):221-4. PMID: 7468105. ***X-2, X-3, X-4***

1479. Loperfido S, Monica F, Maifreni L, et al.; Bleeding peptic ulcer occurring in hospitalized patients: analysis of predictive and risk factors and comparison with out-of-hospital onset of hemorrhage. Dig Dis Sci. 1994 Apr;39(4):698-705. PMID: 8149834. ***X-2***

1480. Lopez G, Rodriguez A, Rengifo J, et al.; Two-year prospective study in Colombia of Norplant implants. Obstet Gynecol. 1986 Aug;68(2):204-8. PMID: 3090492. ***X-2, X-4***

1481. Loughlin J, Seeger JD, Eng PM, et al.; Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. Contraception. 2008 Nov;78(5):377-83. PMID: 18929734. ***X-4***

1482. Luchese S, Manica JL, Zielinsky P; Intrauterine ductus arteriosus constriction: analysis of a historic cohort of 20 cases. Arq Bras Cardiol. 2003 Oct;81(4):405-10, 399-404. PMID: 14666282. ***X-2, X-3, X-4***

1483. Lucky AW, Henderson TA, Olson WH, et al.; Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):746-54. PMID: 9366821. ***X-2, X-3, X-4***

1484. Ludwig M, Schwartz P, Babahan B, et al.; Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. Eur J Obstet Gynecol Reprod Biol. 2002 Jun 10;103(1):48-52. PMID: 12039463. ***X-2, X-3, X-4***

1485. Luisi S, Razzi S, Lazzeri L, et al.; Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age. Fertil Steril. 2009 Oct;92(4):1351-4. PMID: 18930222. ***X-2, X-4***

1486. Lukes AS, Moore KA, Muse KN, et al.; Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Oct;116(4):865-75. PMID: 20859150. ***X-2***

1487. Lund SS, Tarnow L, Stehouwer CD, et al.; Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obes Metab. 2007 May;9(3):394-407. PMID: 17391168. ***X-2, X-3, X-4***

1488. Lundberg GD; Esomeprazole prevents aspirin-induced ulcers. Medscape J Med. 2008;10(12):285. PMID: 19242591. ***X-4***

1489. Lundgren R, Sundin T, Colleen S, et al.; Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study. Scand J Urol Nephrol. 1986;20(2):101-5. PMID: 3529368. ***X-2, X-4***

1490. Lundstrom E, Christow A, Kersemaekers W, et al.; Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002 Apr;186(4):717-22. PMID: 11967497. ***X-2, X-4***

1491. Lundstrom E, Wilczek B, von Palffy Z, et al.; Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric. 2001 Mar;4(1):42-8. PMID: 11379377. ***X-2***

1492. Luo JC, Lin HY, Chang FY, et al.; Occurrence of peptic ulcer disease in connective tissue disease patients associated with xerostomia. Aliment Pharmacol Ther. 2003 Jan;17(2):217-24. PMID: 12534406. ***X-2***

1493. Lurie G, Thompson P, McDuffie KE, et al.; Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol. 2007 Mar;109(3):597-607. PMID: 17329510. ***X-4***

1494. Luthra UK, Mitra AB, Prabhakar AK, et al.; Copper containing intrauterine devices and cervical carcinogenesis--48 months follow up. Indian J Med Res. 1980 Nov;72:659-64. PMID: 7203566. ***X-4***

1495. Luyckx AS, Gaspard UJ, Romus MA, et al.; Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study. Fertil Steril. 1986 May;45(5):635-42. PMID: 2938985. ***X-2, X-3, X-4***

1496. Lyytinen HK, Dyba T, Ylikorkala O, et al.; A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer. 2010 Jan 15;126(2):483-9. PMID: 19588504. ***X-7***

1497. Maca SM, Amon M, Findl O, et al.; Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery. Am J Ophthalmol. 2010 May;149(5):777-84. PMID: 20152959. ***X-2, X-3, X-4***

1498. MacDonald MR, Eurich DT, Majumdar SR, et al.; Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care. 2010 Jun;33(6):1213-8. PMID: 20299488. ***X-3***

1499. MacDonald TM, Morant SV, Goldstein JL, et al.; Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut. 2003 Sep;52(9):1265-70. PMID: 12912856. ***X-4***

1500. MacDonald TM, Morant SV, Robinson GC, et al.; Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ. 1997 Nov 22;315(7119):1333-7. PMID: 9402773. ***X-7***

1501. Machado RB, de Melo NR, Maia H, Jr., et al.; Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles. Contraception. 2010 Feb;81(2):102-6. PMID: 20103445. ***X-2***

1502. Madan J, Fiascone J, Balasubramanian V, et al.; Predictors of ductal closure and intestinal complications in very low birth weight infants treated with indomethacin. Neonatology. 2008;94(1):45-51. PMID: 18196930. ***X-2, X-3, X-4***

1503. Maddali MM, Rajakumar MC; Tranexamic acid and primary coronary artery bypass surgery: a prospective study. Asian Cardiovasc Thorac Ann. 2007 Aug;15(4):313-9. PMID: 17664205. ***X-2, X-3, X-4***

1504. Mafuva C, Djarova T, Matarira HT; Influence of combined oral contraceptives on the onset of cervical intraepithelial neoplasia. Afr J Health Sci. 2002 Jul-Dec;9(3-4):129-37. PMID: 17298156. ***X-2***

1505. Magos AL, Brewster E, Singh R, et al.; The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol. 1986 Dec;93(12):1290-6. PMID: 3801360. ***X-2, X-3, X-4***

1506. Mahmood M, Malone DC, Skrepnek GH, et al.; Potential drug-drug interactions within Veterans Affairs medical centers. Am J Health Syst Pharm. 2007 Jul 15;64(14):1500-5. PMID: 17617500. ***X-3, X-4***

1507. Maia H, Jr., Casoy J, Correia T, et al.; Activation of NF-kappaB and COX-2 expression is associated with breakthrough bleeding in patients using oral contraceptives in extended regimens. Gynecol Endocrinol. 2010 Apr;26(4):265-9. PMID: 19757243. ***X-2, X-4, X-5***

1508. Maiden L, Thjodleifsson B, Seigal A, et al.; Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007 Sep;5(9):1040-5. PMID: 17625980. ***X-2***

1509. Maieron R, Stimac D, Avellini C, et al.; Acute gastrointestinal bleeding due to Meckel's diverticulum heterotopic gastric mucosa. Ital J Gastroenterol. 1996 May;28(4):225-8. PMID: 8842839. ***X-2***

1510. Maj S, Centkowski P; A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland. Med Sci Monit. 2004 Sep;10(9):PI93-5. PMID: 15328493. ***X-3, X-4***

1511. Maj S, Lis Y; The incidence of metamizole sodium-induced agranulocytosis in Poland. J Int Med Res. 2002 Sep-Oct;30(5):488-95. PMID: 12449518. ***X-4***

1512. Major CA, Lewis DF, Harding JA, et al.; Tocolysis with indomethacin increases the incidence of necrotizing enterocolitis in the low-birth-weight neonate. Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):102-6. PMID: 8296809. ***X-2, X-4***

1513. Malgarinos G, Gikas A, Delicha E, et al.; Pregnancy and inflammatory bowel disease: a prospective case-control study. Rev Med Chir Soc Med Nat Iasi. 2007 Jul-Sep;111(3):613-9. PMID: 18293689. ***X-2, X-3, X-4***

1514. Malhotra S, Jain S, Pandhi P; Drug-related visits to the medical emergency department: a prospective study from India. Int J Clin Pharmacol Ther. 2001 Jan;39(1):12-8. PMID: 11204932. ***X-4***

1515. Malik MH, Gray J, Kay PR; Early aseptic loosening of cemented total hip arthroplasty: the influence of non-steroidal anti-inflammatory drugs and smoking. Int Orthop. 2004 Aug;28(4):211-3. PMID: 15048587. ***X-2, X-4***

1516. Mamdani M, Juurlink DN, Lee DS, et al.; Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004 May 29;363(9423):1751-6. PMID: 15172772. ***X-4***

1517. Mamdani M, Rochon P, Juurlink DN, et al.; Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003 Feb 24;163(4):481-6. PMID: 12588209. ***X-7***

1518. Mamdani M, Rochon PA, Juurlink DN, et al.; Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002 Sep 21;325(7365):624. PMID: 12242172. ***X-7***

1519. Mamdani M, Warren L, Kopp A, et al.; Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario. CMAJ. 2006 Dec 5;175(12):1535-8. PMID: 17146090. ***X-4, X-7***

1520. Man CY, Cheung IT, Cameron PA, et al.; Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007 May;49(5):670-7. PMID: 17276548. ***X-2, X-4***

1521. Manas MD, Domper A, Albillos A, et al.; Endoscopic follow-up of gastric ulcer in a population at intermediate risk for gastric cancer. Rev Esp Enferm Dig. 2009 May;101(5):317-24. PMID: 19527077. ***X-2, X-3, X-4***

1522. Mangan SA, Larsen PG, Hudson S; Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2002 Apr;15(2):79-82. PMID: 12057528. ***X-2***

1523. Mangano DT, Tudor IC, Dietzel C; The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006 Jan 26;354(4):353-65. PMID: 16436767. ***X-3***

1524. Mangoni AA, Woodman RJ, Gaganis P, et al.; Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol. 2010 Jun;69(6):689-700. PMID: 20565461. ***X-7***

1525. Mangoni AA, Woodman RJ, Gilbert AL, et al.; Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community. Pharmacoepidemiol Drug Saf. 2010 May;19(5):490-8. PMID: 20437458. ***X-4, X-7***

1526. Manguso F, Riccio E, Nucci G, et al.; Helicobacter pylori infection in bleeding peptic ulcer patients after non-steroidal antiinflammatory drug consumption. World J Gastroenterol. 2011 Oct 28;17(40):4509-16. PMID: 22110282. ***X-2***

1527. Manicourt DH, Bevilacqua M, Righini V, et al.; Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs R D. 2005;6(5):261-71. PMID: 16128596. ***X-2***

1528. Manji RA, Grocott HP, Leake J, et al.; Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth. 2012 Jan;59(1):6-13. PMID: 22065333. ***X-8***

1529. Manning BJ, O'Brien N, Aravindan S, et al.; The effect of aspirin on blood loss and transfusion requirements in patients with femoral neck fractures. Injury. 2004 Feb;35(2):121-4. PMID: 14736467. ***X-2, X-4***

1530. Mansfield JC, Greenaway JR, Contractor BR, et al.; Open access gastroscopy findings are unrelated to the use of aspirin and non-steroidal anti-inflammatory drugs. Br J Gen Pract. 1997 Dec;47(425):825-6. PMID: 9463986. ***X-4***

1531. Manson JE, Hsia J, Johnson KC, et al.; Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003 Aug 7;349(6):523-34. PMID: 12904517. ***X-7***

1532. Mao K, Guillebaud J; Influence of removal of intrauterine contraceptive devices on colonisation of the cervix by actinomyces-like organisms. Contraception. 1984 Dec;30(6):535-44. PMID: 6529911. ***X-2, X-4***

1533. Maoz KB, Brenner S; Drug rash with eosinophilia and systemic symptoms syndrome: sex and the causative agent. Skinmed. 2007 Nov-Dec;6(6):271-3. PMID: 17975358. ***X-2, X-3, X-4***

1534. Marini H, Bitto A, Altavilla D, et al.; Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. J Clin Endocrinol Metab. 2008 Dec;93(12):4787-96. PMID: 18796517. ***X-2, X-4***

1535. Marini H, Bitto A, Altavilla D, et al.; Efficacy of genistein aglycone on some cardiovascular risk factors and homocysteine levels: A follow-up study. Nutr Metab Cardiovasc Dis. 2010 Jun;20(5):332-40. PMID: 19631515. ***X-2, X-4***

1536. Marks M, Gravitt PE, Gupta SB, et al.; Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand. J Infect Dis. 2011 Nov 15;204(10):1505-13. PMID: 21964399. ***X-2***

1537. Marpeau L, Bouillie J, Barrat J, et al.; Obstetrical advantages and perinatal risks of indomethacin: a report of 818 cases. Fetal Diagn Ther. 1994 Mar-Apr;9(2):110-5. PMID: 8185837. ***X-2, X-4***

1538. Marshall SF, Bernstein L, Anton-Culver H, et al.; Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005 Jun 1;97(11):805-12. PMID: 15928301. ***X-4***

1539. Marteau P, Tennenbaum R, Elefant E, et al.; Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther. 1998 Nov;12(11):1101-8. PMID: 9845399. ***X-2, X-3, X-4***

1540. Martin BK, Szekely C, Brandt J, et al.; Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008 Jul;65(7):896-905. PMID: 18474729. ***X-7***

1541. Martin HL, Jr., Nyange PM, Richardson BA, et al.; Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998 Oct;178(4):1053-9. PMID: 9806034. ***X-8***

1542. Martin K, Breuer T, Gertler R, et al.; Tranexamic acid versus varepsilon-aminocaproic acid: efficacy and safety in paediatric cardiac surgery. Eur J Cardiothorac Surg. 2011 Jun;39(6):892-7. PMID: 21115357. ***X-2***

1543. Martin K, Knorr J, Breuer T, et al.; Seizures after open heart surgery: comparison of epsilon-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth. 2011 Feb;25(1):20-5. PMID: 21272777. ***X-2***

1544. Martin K, Wiesner G, Breuer T, et al.; The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg. 2008 Dec;107(6):1783-90. PMID: 19020118. ***X-2***

1545. Martin RM, Biswas P, Mann RD; The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol. 2000 Jul;50(1):35-42. PMID: 10886116. ***X-4***

1546. Martinez-Ramirez HR, Jalomo-Martinez B, Cortes-Sanabria L, et al.; Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis. 2006 Jan;47(1):78-87. PMID: 16377388. ***X-2, X-3, X-4***

1547. Martini AC, Molina RI, Tissera AD, et al.; Analysis of semen from patients chronically treated with low or moderate doses of aspirin-like drugs. Fertil Steril. 2003 Jul;80(1):221-2. PMID: 12849830. ***X-2, X-6***

1548. Maru S, Koch GG, Stender M, et al.; Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care. 2005 Jan;28(1):20-6. PMID: 15616228. ***X-3***

1549. Maruo T, Mishell DR, Ben-Chetrit A, et al.; Vaginal rings delivering progesterone and estradiol may be a new method of hormone replacement therapy. Fertil Steril. 2002 Nov;78(5):1010-6. PMID: 12413986. ***X-2, X-3, X-4***

1550. Mascarenhas L, van Beek A, Bennink HC, et al.; A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. Hum Reprod. 1998 Nov;13(11):3057-60. PMID: 9853856. ***X-2, X-3, X-4***

1551. Massai MR, Diaz S, Quinteros E, et al.; Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception. 2001 Dec;64(6):369-76. PMID: 11834236. ***X-2, X-4***

1552. Massai MR, Pavez M, Fuentealba B, et al.; Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception. 2004 Jul;70(1):47-54. PMID: 15208052. ***X-2, X-3, X-4***

1553. Massaro M, Di Carlo C, Gargano V, et al.; Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. Contraception. 2010 Mar;81(3):209-14. PMID: 20159176. ***X-2, X-4***

1554. Masse PG, Livingstone MM, Duguay C, et al.; Testing the tyrosine/catecholamine hypothesis of oral contraceptive-induced psychological side-effects: a controlled study on triphasil. Ann Nutr Metab. 2001;45(3):102-9. PMID: 11423701. ***X-2***

1555. Massimo Claar G, Monaco S, Del Vecchio Blanco C, et al.; Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 1998 May;12(5):463-8. PMID: 9663727. ***X-2, X-3, X-4***

1556. Masso Gonzalez EL, Garcia Rodriguez LA; Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding: an observational study. Aliment Pharmacol Ther. 2008 Sep 1;28(5):629-37. PMID: 18616644. ***X-2, X-3, X-4***

1557. Mastalerz L, Sanak M, Gawlewicz-Mroczka A, et al.; Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax. 2008 Jan;63(1):27-34. PMID: 17584993. ***X-3, X-4***

1558. Masters T, Everett S, May M, et al.; Outcomes at 1 year for the first 200 patients fitted with GyneFix at Margaret Pyke Centre. Eur J Contracept Reprod Health Care. 2002 Jun;7(2):65-70. PMID: 12201324. ***X-2, X-4***

1559. Matikainen M, Kangas E; Relation of the use of analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) to upper gastrointestinal bleeding: a preliminary report of a Finnish case-control prospective study. Pharmacol Toxicol. 1994;75 Suppl 2:51-2. PMID: 7816782. ***X-2***

1560. Matikainen M, Kangas E; Is there a relationship between the use of analgesics and non-steroidal anti-

inflammatory drugs and acute upper gastrointestinal bleeding? A Finnish case-control prospective study. Scand J Gastroenterol. 1996 Sep;31(9):912-6. PMID: 8888440. ***X-2, X-4***

1561. Matson SC, Henderson KA, McGrath GJ; Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol. 1997 Feb;10(1):18-23. PMID: 9061630. ***X-2***

1562. Matsumoto T, Esaki M, Kurahara K, et al.; Double-contrast barium enteroclysis as a patency tool for nonsteroidal anti-inflammatory drug-induced enteropathy. Dig Dis Sci. 2011 Nov;56(11):3247-53. PMID: 21567189. ***X-2, X-3, X-4***

1563. Matsumoto T, Iida M, Matsui T, et al.; Non-specific multiple ulcers of the small intestine unrelated to non-steroidal anti-inflammatory drugs. J Clin Pathol. 2004 Nov;57(11):1145-50. PMID: 15509673. ***X-2, X-3, X-4***

1564. Matsumoto T, Nakamura S, Esaki M, et al.; Endoscopic features of chronic nonspecific multiple ulcers of the small intestine: comparison with nonsteroidal anti-inflammatory drug-induced enteropathy. Dig Dis Sci. 2006 Aug;51(8):1357-63. PMID: 16868823. ***X-2, X-3, X-4***

1565. Matsuno K, Kunihiro E, Yamatoya O, et al.; Surveillance of adverse reactions due to ciprofloxacin in Japan. Drugs. 1995;49 Suppl 2:495-6. PMID: 8549413. ***X-4***

1566. Matteson EL, Yachyshyn V, Yachyshyn J, et al.; Trends in hospitalizations for gastrointestinal bleeding among patients with rheumatoid arthritis in Rochester, Minnesota, 1950-1991. J Rheumatol. 1995 Aug;22(8):1471-7. PMID: 7473468. ***X-2, X-3, X-4***

1567. Matthewson K, Pugh S, Northfield TC; Which peptic ulcer patients bleed? Gut. 1988 Jan;29(1):70-4. PMID: 3343016. ***X-2, X-3***

1568. Matthieu L, Meuleman L, Van Hecke E, et al.; Contact and photocontact allergy to ketoprofen. The Belgian experience. Contact Dermatitis. 2004 Apr;50(4):238-41. PMID: 15186381. ***X-2, X-4***

1569. May FW, Rowett DS, Gilbert AL, et al.; Outcomes of an educational-outreach service for community medical practitioners: non-steroidal anti-inflammatory drugs. Med J Aust. 1999 May 17;170(10):471-4. PMID: 10376022. ***X-2, X-3, X-4***

1570. Mazzuca SA, Brandt KD, Katz BP, et al.; Comparison of general internists, family physicians, and rheumatologists managing patients with symptoms of osteoarthritis of the knee. Arthritis Care Res. 1997 Oct;10(5):289-99. PMID: 9362595. ***X-2, X-3, X-4***

1571. McAdams M, Staffa JA, Dal Pan GJ; The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs. Contraception. 2007 Oct;76(4):278-81. PMID: 17900437. ***X-4***

1572. McAfee AT, Koro C, Landon J, et al.; Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25. PMID: 17551989. ***X-3***

1573. McAlister FA, Eurich DT, Majumdar SR, et al.; The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 2008 Jul;10(7):703-8. PMID: 18571471. ***X-3***

1574. McAlister FA, Ghali WA, Gong Y, et al.; Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation. 2006 Jun 6;113(22):2572-8. PMID: 16735672. ***X-4***

1575. McCarthy CJ, McDermott M, Hourihane D, et al.; Chemical gastritis induced by naproxen in the absence of Helicobacter pylori infection. J Clin Pathol. 1995 Jan;48(1):61-3. PMID: 7706522. ***X-2, X-4***

1576. McCarthy T, Ramachandran L, Huang HS, et al.; Postabortion insertion of the Nova T and MLCu250: preliminary results of a comparative study. Adv Contracept. 1985 Jun;1(2):161-5. PMID: 3842217. ***X-2, X-4***

1577. McFarlane-Anderson N, Bazuaye PE, Jackson MD, et al.; Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican women. BMC Womens Health. 2008;8:9. PMID: 18513406. ***X-2***

1578. McGavigan CJ, Dockery P, Metaxa-Mariatou V, et al.; Hormonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel. Hum Reprod. 2003 Jan;18(1):77-84. PMID: 12525444. ***X-2, X-3, X-4***

1579. McGettigan P, Han P, Henry D; Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships. Br J Clin Pharmacol. 2006 Sep;62(3):358-65. PMID: 16934052. ***X-2, X-4***

1580. McGettigan P, Han P, Jones L, et al.; Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol. 2008 Jun;65(6):927-34. PMID: 18384446. ***X-2, X-3, X-4***

1581. McGonigle KF, Karlan BY, Barbuto DA, et al.; Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. Gynecol Oncol. 1994 Oct;55(1):126-32. PMID: 7959253. ***X-2, X-4***

1582. McGough P, Bigrigg A; Effect of depot medroxyprogesterone acetate on bone density in a Scottish industrial city. Eur J Contracept Reprod Health Care. 2007 Sep;12(3):253-9. PMID: 17763264. ***X-2***

1583. McGwin G, Jr., Sims RV, Pulley L, et al.; Relations among chronic medical conditions, medications, and automobile crashes in the elderly: a population-based case-control study. Am J Epidemiol. 2000 Sep 1;152(5):424-31. PMID: 10981455. ***X-2, X-3, X-4***

1584. McKenna PJ, Mylotte MJ; Laparoscopic removal of translocated intrauterine contraceptives devices. Br J Obstet Gynaecol. 1982 Feb;89(2):163-5. PMID: 6461352. ***X-2, X-3, X-4***

1585. McKenna TJ, Cunningham SK; A role for a non-androgenic anovulant in the management of hirsutism. Ir J Med Sci. 1991 Jul;160(7):194-6. PMID: 1757211. ***X-2, X-3, X-4***

1586. McLaurin VL, Dunson BA, Dunson TR; A comparative study of 35 mcg and 50 mcg combined oral contraceptives: results from a multicenter clinical trial. Contraception. 1991 Nov;44(5):489-503. PMID: 1797464. ***X-4***

1587. McLeod RS, Wolff BG, Steinhart AH, et al.; Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995 Aug;109(2):404-13. PMID: 7615189. ***X-2, X-3, X-4***

1588. McMahon AD; Observation and experiment with the efficacy of drugs: a warning example from a cohort of nonsteroidal anti-inflammatory and ulcer-healing drug users. Am J Epidemiol. 2001 Sep 15;154(6):557-62. PMID: 11549561. ***X-4***

1589. McMahon AD, Evans JM, MacDonald TM; Hypersensitivity reactions associated with exposure to naproxen and ibuprofen: a cohort study. J Clin Epidemiol. 2001 Dec;54(12):1271-4. PMID: 11750197. ***X-4***

1590. McPherson C, Gal P, Ransom JL, et al.; Indomethacin pharmacodynamics are altered by surfactant: a possible challenge to current indomethacin dosing guidelines created before surfactant availability. Pediatr Cardiol. 2010 May;31(4):505-10. PMID: 20063159. ***X-2, X-3, X-4***

1591. Meeker ND, Goldsby R, Terrill KR, et al.; Dapsone therapy for children with immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003 Feb;25(2):173-5. PMID: 12571474. ***X-1, X-2, X-3, X-4***

1592. Mehta S, Dasarathy S, Tandon RK, et al.; A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis. Am J Gastroenterol. 1992 Aug;87(8):996-1000. PMID: 1642224. ***X-2***

1593. Mehta S, Lang B; Long-term followup of naproxen-induced pseudoporphyria in juvenile rheumatoid arthritis. Arthritis Rheum. 1999 Oct;42(10):2252-4. PMID: 10524703. ***X-2***

1594. Meirik O, Farley TM, Sivin I; Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization. Obstet Gynecol. 2001 Apr;97(4):539-47. PMID: 11275025. ***X-4***

1595. Meirik O, Rowe PJ, Peregoudov A, et al.; The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. Contraception. 2009 Aug;80(2):133-41. PMID: 19631788. ***X-4***

1596. Meisel AD; Clinical benefits and comparative safety of piroxicam. Analysis of worldwide clinical trials data. Am J Med. 1986 Nov 28;81(5B):15-21. PMID: 3538866. ***X-1, X-4***

1597. Mejersjo C, Wenneberg B; Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial. J Oral Rehabil. 2008 Oct;35(10):729-38. PMID: 18482350. ***X-2, X-3, X-4***

1598. Mellemkjaer L, Blot WJ, Sorensen HT, et al.; Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol. 2002 Feb;53(2):173-81. PMID: 11851641. ***X-4***

1599. Meloni A, Melis M, Alba E, et al.; Medical therapy in the management of preterm birth. J Matern Fetal Neonatal Med. 2009;22 Suppl 3:72-6. PMID: 19925364. ***X-1***

1600. Mendoza N, Pison JA, Fernandez M, et al.; Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas. 2002 Apr 25;41(4):289-98. PMID: 12034516. ***X-2***

1601. Menges M, Chan CC, Zeitz M, et al.; Higher concentration of matrix-metalloproteinase 1 (interstitial collagenase) in H. pylori-compared to NSAID-induced gastric ulcers. Z Gastroenterol. 2000 Nov;38(11):887-91. PMID: 11132534. ***X-2, X-3, X-4***

1602. Menniti-Ippolito F, Sagliocca L, Da Cas R, et al.; Niflumic acid and cutaneous reactions in children. Arch Dis Child. 2001 May;84(5):430-1. PMID: 11316692. ***X-4***

1603. Ment LR, Oh W, Ehrenkranz RA, et al.; Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics. 1994 Apr;93(4):543-50. PMID: 8134206. ***X-2, X-3, X-4***

1604. Ment LR, Vohr B, Allan W, et al.; Outcome of children in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics. 2000 Mar;105(3 Pt 1):485-91. PMID: 10699097. ***X-2, X-4***

1605. Mercadante S, David F, Riina S, et al.; Injustifiable use of gastroprotection in advanced cancer patients. Palliat Med. 2007 Oct;21(7):631-3. PMID: 17942503. ***X-2, X-3, X-4***

1606. Mercadante S, Fusco F, Valle A, et al.; Factors involved in gastrointestinal bleeding in advanced cancer patients followed at home. Support Care Cancer. 2004 Feb;12(2):95-8. PMID: 14673626. ***X-2, X-3***

1607. Merki-Feld GS, Gosewinkel A, Imthurn B, et al.; Tubal pathology: the role of hormonal contraception, intrauterine device use and Chlamydia trachomatis infection. Gynecol Obstet Invest. 2007;63(2):114-20. PMID: 17095873. ***X-2, X-4***

1608. Merki-Feld GS, Neff M, Keller PJ; A 2-year prospective study on the effects of depot medroxyprogesterone acetate on bone mass-response to estrogen and calcium therapy in individual users. Contraception. 2003 Feb;67(2):79-86. PMID: 12586317. ***X-2***

1609. Merki-Feld GS, Rosselli M, Dubey RK, et al.; Long-term effects of combined oral contraceptives on markers of endothelial function and lipids in healthy premenopausal women. Contraception. 2002 Mar;65(3):231-6. PMID: 11929645. ***X-2, X-4***

1610. Merki-Feld GS, Schwarz D, Imthurn B, et al.; Partial and complete expulsion of the Multiload 375 IUD and the levonorgestrel-releasing IUD after correct insertion. Eur J Obstet Gynecol Reprod Biol. 2008 Mar;137(1):92-6. PMID: 17353086. ***X-2***

1611. Merry AF, Sidebotham DA, Middleton NG, et al.; Tenoxicam 20 mg or 40 mg after thoracotomy: a prospective, randomized, double-blind, placebo-controlled study. Anaesth Intensive Care. 2002 Apr;30(2):160-6. PMID: 12002922. ***X-2, X-4***

1612. Mertens JC, Willemsen G, Van Saase JL, et al.; Polymyalgia rheumatica and temporal arteritis: a retrospective study of 111 patients. Clin Rheumatol. 1995 Nov;14(6):650-5. PMID: 8608683. ***X-2, X-4***

1613. Mesker T, van Rheenen PF, Norbruis OF, et al.; Pediatric Crohn's disease activity at diagnosis, its influence on pediatrician's prescribing behavior, and clinical outcome 5 years later. Inflamm Bowel Dis. 2009 Nov;15(11):1670-7. PMID: 19418567. ***X-2, X-3, X-4***

1614. Messeri A, Busoni P, Noccioli B, et al.; Analgesic efficacy and tolerability of ketoprofen lysine salt vs paracetamol in common paediatric surgery. A randomized, single-blind, parallel, multicentre trial. Paediatr Anaesth. 2003 Sep;13(7):574-8. PMID: 12950856. ***X-2, X-3, X-4***

1615. Metzner JE, Frank T, Kunz I, et al.; Study on the pharmacokinetics of synthetic genistein after multiple oral intake in post-menopausal women. Arzneimittelforschung. 2009;59(10):513-20. PMID: 19998579. ***X-2, X-3, X-4***

1616. Meunier A, Aspenberg P, Good L; Celecoxib does not appear to affect prosthesis fixation in total knee replacement: A randomized study using radiostereometry in 50 patients. Acta Orthop. 2009 Feb;80(1):46-50. PMID: 19234885. ***X-2, X-3, X-4***

1617. Meunier A, Lisander B, Good L; Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Acta Orthop. 2007 Oct;78(5):661-7. PMID: 17966026. ***X-2, X-3, X-4***

1618. Meyer AM, Ramzan NN, Heigh RI, et al.; Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 2006 Jan;51(1):168-72. PMID: 16416231. ***X-2***

1619. Michaelis J, Michaelis H, Gluck E, et al.; Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology. 1983 Feb;27(1):57-64. PMID: 6845218. ***X-4***

1620. Micu MC, Micu R, Ostensen M; Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies. Arthritis Care Res (Hoboken). 2011 Sep;63(9):1334-8. PMID: 21618455. ***X-2, X-3***

1621. Mikaeloff Y, Kezouh A, Suissa S; Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease. Br J Clin Pharmacol. 2008 Feb;65(2):203-9. PMID: 18251759. ***X-4***

1622. Mikos M, Grzanka P, Sladek K, et al.; High-resolution computed tomography evaluation of peripheral airways in asthma patients: comparison of focal and diffuse air trapping. Respiration. 2009;77(4):381-8. PMID: 18577849. ***X-2, X-3, X-4***

1623. Milam MR, Pollock JW, Nick AM, et al.; The effect of hormonal contraception on the adequacy of colposcopic examination of the cervix. Am J Obstet Gynecol. 2005 May;192(5):1368-9. PMID: 15902111. ***X-2, X-3, X-4***

1624. Milano M; Increased risk for dental caries in asthmatic children. Tex Dent J. 1999 Sep;116(9):35-42. PMID: 10860081. ***X-2***

1625. Miller K; Effect of gastric mucosal protection in nonrheumatoid patients with short-term nonsteroidal anti-inflammatory drug therapy: a prospective randomized multicenter study. Hepatogastroenterology. 1997 May-Jun;44(15):872-9. PMID: 9222707. ***X-2, X-3, X-4***

1626. Miller L, Patton DL, Meier A, et al.; Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol. 2000 Sep;96(3):431-9. PMID: 10960638. ***X-2***

1627. Millican S, Cottrell N, Green B; Do risk factors for lactic acidosis influence dosing of metformin? J Clin Pharm Ther. 2004 Oct;29(5):449-54. PMID: 15482389. ***X-2, X-4***

1628. Min KA, Zhu X, Oh JM, et al.; Effect of oxolamine on anticoagulant effect of warfarin. Am J Health Syst Pharm. 2006 Jan 15;63(2):153-6. PMID: 16390929. ***X-4***

1629. Miner P, Hanauer S, Robinson M, et al.; Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995 Feb;40(2):296-304. PMID: 7851193. ***X-2, X-3, X-4***

1630. Minocha A, Greenbaum DS, Gardiner J; Effect of non-steroidal anti-inflammatory drugs on formation of gallbladder stones. Vet Hum Toxicol. 1994 Dec;36(6):514-6. PMID: 7900267. ***X-2, X-4***

1631. Mira M, McNeil D, Fraser IS, et al.; Mefenamic acid in the treatment of premenstrual syndrome. Obstet Gynecol. 1986 Sep;68(3):395-8. PMID: 3526218. ***X-2, X-3, X-4***

1632. Mishell DR, Jr., Roy S; Copper intrauterine contraceptive device event rates following insertion 4 to 8 weeks post partum. Am J Obstet Gynecol. 1982 May 1;143(1):29-35. PMID: 7081309. ***X-2, X-3, X-4***

1633. Misra JS, Engineer AD, Das K, et al.; Cervical carcinogenesis and contraception. Diagn Cytopathol. 1991;7(4):346-52. PMID: 1935511. ***X-3***

1634. Misra JS, Engineer AD, Tandon P; Cervical cytology associated with levonorgestrel contraception. Acta Cytol. 1995 Jan-Feb;39(1):45-9. PMID: 7847008. ***X-2***

1635. Misra JS, Tandon P, Srivastava A, et al.; Cervical cytological studies in women inserted with Norplant-I contraceptive. Diagn Cytopathol. 2003 Sep;29(3):136-9. PMID: 12951680. ***X-2, X-4***

1636. Mita H, Higashi N, Taniguchi M, et al.; Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clin Exp Allergy. 2004 Aug;34(8):1262-9. PMID: 15298568. ***X-2, X-3, X-4***

1637. Miyake K, Ueki N, Suzuki K, et al.; Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:67-72. PMID: 15943850. ***X-2, X-3, X-4***

1638. Mockenhaupt M, Kelly JP, Kaufman D, et al.; The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003 Oct;30(10):2234-40. PMID: 14528522. ***X-4***

1639. Moffett BS, Wann TI, Carberry KE, et al.; Safety of ketorolac in neonates and infants after cardiac surgery. Paediatr Anaesth. 2006 Apr;16(4):424-8. PMID: 16618297. ***X-2, X-3, X-4***

1640. Moggia AV, Harris GS, Dunson TR, et al.; A comparative study of a progestin-only oral contraceptive versus non-hormonal methods in lactating women in Buenos Aires, Argentina. Contraception. 1991 Jul;44(1):31-43. PMID: 1893700. ***X-2, X-4***

1641. Moghetti P, Castello R, Negri C, et al.; Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000 Jan;85(1):139-46. PMID: 10634377. ***X-2, X-3, X-4***

1642. Moghissi KS; Add-back therapy in the treatment of endometriosis: the North American experience. Br J Obstet Gynaecol. 1996 Oct;103 Suppl 14:14. PMID: 8916981. ***X-2***

1643. Mogul HR, Peterson SJ, Weinstein BI, et al.; Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia. Heart Dis. 2001 Sep-Oct;3(5):285-92. PMID: 11975807. ***X-2, X-3, X-4***

1644. Moise KJ, Jr.; Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol. 1993 May;168(5):1350-3. PMID: 8498410. ***X-2, X-4***

1645. Mok CC, Lau CS, Wong RW; Clinical characteristics, treatment, and outcome of adult onset Still's disease in southern Chinese. J Rheumatol. 1998 Dec;25(12):2345-51. PMID: 9858428. ***X-2, X-3, X-4***

1646. Molina RC, Sandoval JZ, Montero AV, et al.; Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents. J Pediatr Adolesc Gynecol. 2009 Feb;22(1):25-31. PMID: 19232299. ***X-2***

1647. Momoeda M, Harada T, Terakawa N, et al.; Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009 Dec;35(6):1069-76. PMID: 20025633. ***X-2***

1648. Mona Eng P, Seeger JD, Loughlin J, et al.; Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. Contraception. 2007 Feb;75(2):101-7. PMID: 17241838. ***X-2, X-3, X-4***

1649. Monagle J, Molnar A, Shearer W; Oral medication for post-Caesarean analgesia. Aust N Z J Obstet Gynaecol. 1998 May;38(2):169-71. PMID: 9653853. ***X-2, X-4***

1650. Montalto M, Curigliano V, Santoro L, et al.; Prophylactic aspirin therapy does not increase faecal calprotectin concentrations. Eur J Gastroenterol Hepatol. 2006 Sep;18(9):965-7. PMID: 16894309. ***X-2, X-3, X-4***

1651. Monteiro I, Bahamondes L, Diaz J, et al.; Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study(1). Contraception. 2002 May;65(5):325-8. PMID: 12057782. ***X-2, X-3***

1652. Montes FR, Pardo DF, Carreno M, et al.; Risk factors associated with postoperative seizures in patients undergoing cardiac surgery who received tranexamic acid: a case-control study. Ann Card Anaesth. 2012 Jan-Mar;15(1):6-12. PMID: 22234015. ***X-2***

1653. Montes R, Nantes O, Alonso A, et al.; The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients. Br J Haematol. 2008 Dec;143(5):727-33. PMID: 18950464. ***X-2, X-3, X-4***

1654. Moodley M, Sewart S, Herrington CS, et al.; The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer. Int J Gynecol Cancer. 2003 Nov-Dec;13(6):834-42. PMID: 14675321. ***X-2, X-3, X-4***

1655. Moon KW, Kim J, Kim JH, et al.; Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia. Rheumatology (Oxford). 2011 Dec;50(12):2278-82. PMID: 22019809. ***X-2***

1656. Moore N, Diris H, Martin K, et al.; NSAID use profiles derived from reimbursement data in France. Therapie. 2004 Sep-Oct;59(5):541-6. PMID: 15648307. ***X-2, X-3, X-4***

1657. Moore RA, Derry S, McQuay HJ; Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord. 2007;8:73. PMID: 17683540. ***X-4***

1658. Morabia A, Szklo M, Stewart W, et al.; Consistent lack of association between breast cancer and oral contraceptives using either hospital or neighborhood controls. Prev Med. 1993 Mar;22(2):178-86. PMID: 8483857. ***X-2, X-4***

1659. Morales WJ, Madhav H; Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol. 1993 Jul;169(1):97-102. PMID: 8333483. ***X-2, X-4***

1660. Morant SV, Pettitt D, MacDonald TM, et al.; Application of a propensity score to adjust for channelling bias with NSAIDs. Pharmacoepidemiol Drug Saf. 2004 Jun;13(6):345-53. PMID: 15170763. ***X-4***

1661. Moreau C, Trussell J, Gilbert F, et al.; Oral contraceptive tolerance: does the type of pill matter? Obstet Gynecol. 2007 Jun;109(6):1277-85. PMID: 17540798. ***X-4***

1662. Morgando A, Giordanino C, Baronio M, et al.; Role of Helicobacter pylori infection in peptic ulcer haemorrhage. Minerva Med. 2006 Feb;97(1):47-50. PMID: 16565698. ***X-2***

1663. Moride Y, Abenhaim L; Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994 Jul;47(7):731-7. PMID: 7722586. ***X-2, X-3, X-4***

1664. Moride Y, Ducruet T, Boivin JF, et al.; Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. Can J Clin Pharmacol. 2005 Summer;12(2):e201-11. PMID: 15998959. ***X-3, X-4***

1665. Moride Y, Ducruet T, Boivin JF, et al.; Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis Res Ther. 2005;7(2):R333-42. PMID: 15743481. ***X-4***

1666. Morimoto LM, Newcomb PA, Ulrich CM, et al.; Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8. PMID: 12376501. ***X-2, X-3, X-4***

1667. Morley-Forster P, Newton PT, Cook MJ; Ketorolac and indomethacin are equally efficacious for the relief of minor postoperative pain. Can J Anaesth. 1993 Dec;40(12):1126-30. PMID: 8281587. ***X-2, X-3, X-4***

1668. Morris AJ, Murray L, Sturrock RD, et al.; Short report: the effect of misoprostol on the anaemia of NSAID enteropathy. Aliment Pharmacol Ther. 1994 Jun;8(3):343-6. PMID: 7918931. ***X-2, X-3, X-4***

1669. Morris CR, Harvey IM, Stebbings WS, et al.; Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease. Br J Surg. 2003 Oct;90(10):1267-72. PMID: 14515298. ***X-4***

1670. Morrison C, Waszak C, Katz K, et al.; Clinical outcomes of two early postpartum IUD insertion programs in Africa. Contraception. 1996 Jan;53(1):17-21. PMID: 8631184. ***X-2, X-3, X-4***

1671. Morrison CS, Richardson BA, Celentano DD, et al.; Prospective clinical trials designed to assess the use of hormonal contraceptives and risk of HIV acquisition. J Acquir Immune Defic Syndr. 2005 Mar;38 Suppl 1:S17-8. PMID: 15867602. ***X-8***

1672. Mosis G, Dieleman JP, Stricker B, et al.; A randomized database study in general practice yielded quality data but patient recruitment in routine consultation was not practical. J Clin Epidemiol. 2006 May;59(5):497-502. PMID: 16632138. ***X-2, X-3, X-4***

1673. Motola D, Vargiu A, Leone R, et al.; Hepatic adverse drug reactions: a case/non-case study in Italy. Eur J Clin Pharmacol. 2007 Jan;63(1):73-9. PMID: 17119945. ***X-4***

1674. Motsko SP, Rascati KL, Busti AJ, et al.; Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006;29(7):621-32. PMID: 16808554. ***X-6, X-7***

1675. Moyes VJ, Metcalfe KA, Drake WM; Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur J Endocrinol. 2008 Nov;159(5):541-5. PMID: 18708434. ***X-2, X-3, X-4***

1676. Mudd PA, Katial RK, Alam R, et al.; Variations in expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in nasal mucosa of aspirin-sensitive versus aspirin-tolerant patients with nasal polyposis. Ann Allergy Asthma Immunol. 2011 Oct;107(4):353-9. PMID: 21962096. ***X-2, X-3, X-4***

1677. Mudge DW, Tan KS, Miles R, et al.; Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal transplant patients. BMC Nephrol. 2009;10:14. PMID: 19500381. ***X-1, X-2, X-3, X-4***

1678. Mulberg AE, Linz C, Bern E, et al.; Identification of nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis. J Pediatr. 1993 Apr;122(4):647-9. PMID: 8463919. ***X-2***

1679. Muneyyirci-Delale O, Karacan M; Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43(1):24-7. PMID: 9532466. ***X-2, X-3***

1680. Munger MA, Gardner SF, Ateshkadi A, et al.; Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study. Pharmacotherapy. 2008 Jul;28(7):834-42. PMID: 18576898. ***X-2, X-3, X-4***

1681. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al.; Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003 Jun;30(6):1277-9. PMID: 12784403. ***X-2, X-3, X-4***

1682. Munro FJ, Young SJ, Broome IJ, et al.; Intravenous tenoxicam for analgesia following laparoscopic cholecystectomy. Anaesth Intensive Care. 1998 Feb;26(1):56-60. PMID: 9513669. ***X-3, X-4***

1683. Murata Y, Itakura A, Matsuzawa K, et al.; Possible antenatal and perinatal related factors in development of cystic periventricular leukomalacia. Brain Dev. 2005 Jan;27(1):17-21. PMID: 15626536. ***X-2, X-3, X-4***

1684. Murkes D, Conner P, Leifland K, et al.; Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril. 2011 Mar 1;95(3):1188-91. PMID: 21067727. ***X-2***

1685. Muss HB, Case LD, Atkins JN, et al.; Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol. 1994 Aug;12(8):1630-8. PMID: 8040675. ***X-2, X-3, X-4***

1686. Muzii L, Marana R, Caruana P, et al.; Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. Am J Obstet Gynecol. 2000 Sep;183(3):588-92. PMID: 10992178. ***X-2, X-4***

1687. Myer L, Denny L, Wright TC, et al.; Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol. 2007 Feb;36(1):166-74. PMID: 17175547. ***X-8***

1688. Mylotte MJ, Loudon N; Interim insertion of Multiload Cu 250 IUCD. Br J Obstet Gynaecol. 1982 Sep;89(Suppl 4):41-2. PMID: 6758838. ***X-2, X-4***

1689. Nachtigall LB, Valassi E, Lo J, et al.; Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010 Jan;72(1):53-8. PMID: 19508591. ***X-2***

1690. Nachtigall MJ, Smilen SW, Nachtigall RD, et al.; Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol. 1992 Nov;80(5):827-30. PMID: 1328978. ***X-2, X-4***

1691. Nagata C, Matsushita Y, Inaba S, et al.; Unapproved use of high-dose combined pills in Japan: a community study on prevalence and health characteristics of the users. Prev Med. 1997 Jul-Aug;26(4):565-9. PMID: 9245680. ***X-4***

1692. Nahidi F, Jalalinia S; Comparing the complications of 2 copper intrauterine devices: T380A and Cu-Safe 300. East Mediterr Health J. 2008 Jan-Feb;14(1):95-102. PMID: 18557456. ***X-2, X-4***

1693. Najam R, Agarwal D, Tyagi R, et al.; Comparison of traneximic acid with a combination of traneximic acid and mefenamic acid in reducing menstrual blood loss in ovulatory dysfunctional uterine bleeding (DUB). Journal of

Clinical and Diagnostic Research. 2010;4(5):3020-5. ***X-2, X-3, X-4***

1694. Nakaoka S, Ishizaki T, Urushihara H, et al.; Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease. Intern Med. 2011;50(7):687-94. PMID: 21467699. ***X-2, X-7***

1695. Nakashima S, Arai S, Mizuno Y, et al.; A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:60-6. PMID: 15943849. ***X-2***

1696. Nakayama M, Iwakiri R, Hara M, et al.; Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy. J Gastroenterol. 2009;44(9):912-8. PMID: 19436943. ***X-2, X-4***

1697. Nakhai-Pour HR, Broy P, Sheehy O, et al.; Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011 Oct 18;183(15):1713-20. PMID: 21896698. ***X-4***

1698. Nanda K, Morrison CS, Kwok C, et al.; Discontinuation of oral contraceptives and depot medroxyprogesterone acetate among women with and without HIV in Uganda, Zimbabwe and Thailand. Contraception. 2011 Jun;83(6):542-8. PMID: 21570552. ***X-4***

1699. Nankhonya JM, Datta-Chaudhuri ML, Bhan GL; Acute upper gastrointestinal hemorrhage in older people: a prospective study in two neighboring districts. J Am Geriatr Soc. 1997 Jun;45(6):752-4. PMID: 9180673. ***X-2, X-3, X-4***

1700. Nappi C, Tommaselli GA, Morra I, et al.; Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study. Acta Obstet Gynecol Scand. 2009;88(9):1031-5. PMID: 19639462. ***X-2, X-3, X-4***

1701. Narendranathan M, Chitra P, Kurien M, et al.; Ketotifen in prevention of indomethacin-induced gastropathy. Indian J Gastroenterol. 1999 Apr-Jun;18(2):76-7. PMID: 10319538. ***X-2, X-3, X-4***

1702. Neafsey PJ; Double trouble: acetaminophen increases the risk of upper GI complications for people taking NSAIDs. Home Healthc Nurse. 2004 Sep;22(9):641-2. PMID: 15359177. ***X-1***

1703. Nelson C, Rigel D, Smith S, et al.; Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7. PMID: 15303784. ***X-2, X-3, X-4***

1704. Nesher G, Sonnenblick M, Dwolatzky T; Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients. J Rheumatol. 1995 Apr;22(4):713-6. PMID: 7791169. ***X-2, X-3, X-4***

1705. Nesher G, Zimran A, Hershko C; Reduced incidence of hyperkalemia and azotemia in patients receiving sulindac compared with indomethacin. Nephron. 1988;48(4):291-5. PMID: 3362274. ***X-2, X-4***

1706. Ness RB, Dodge RC, Edwards RP, et al.; Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol. 2011 Mar;21(3):188-96. PMID: 21109450. ***X-4***

1707. Nessa A, Latif SA, Uddin MM, et al.; Serum HDL-cholesterol in women using low dose oral contraceptives. Mymensingh Med J. 2007 Jul;16(2 Suppl):S3-6. PMID: 17917628. ***X-2, X-4***

1708. Nestrud RM, Hill DE, Arrington RW, et al.; Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Dev Pharmacol Ther. 1980;1(2-3):125-36. PMID: 6765467. ***X-2, X-3, X-4***

1709. Nettis E, Colanardi MC, Ferrannini A, et al.; Immune tolerance to drugs. (II).: Long-term tolerability of nimesulide in patients with NSAID hypersensitivity. Immunopharmacol Immunotoxicol. 2004 Aug;26(3):469-80. PMID: 15518179. ***X-2, X-4***

1710. Nettis E, Colanardi MC, Ferrannini A, et al.; Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2005 Jan;94(1):29-33. PMID: 15702812. ***X-2, X-3, X-4***

1711. Nettis E, Colanardi MC, Paola RD, et al.; Tolerance test in patients with multiple drug allergy syndrome. Immunopharmacol Immunotoxicol. 2001 Nov;23(4):617-26. PMID: 11792020. ***X-2, X-3, X-4***

1712. Nettis E, Marcandrea M, Maggio GD, et al.; Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. Immunopharmacol Immunotoxicol. 2001 Nov;23(4):585-95. PMID: 11792017. ***X-4***

1713. Neumann K; NIMRA-survey: NSAIDs impact on mortality. Results of an Austrian Survey in 2006. Wien Med Wochenschr. 2008;158(3-4):119-26. PMID: 18330529. ***X-4***

1714. Neutel CI, Appel WC; The effect of alcohol abuse on the risk of NSAID-related gastrointestinal events. Ann Epidemiol. 2000 May;10(4):246-50. PMID: 10854958. ***X-4***

1715. Neven P, Lunde T, Benedetti-Panici P, et al.; A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone

replacement therapy containing oestradiol and norethisterone acetate. BJOG. 2003 Feb;110(2):157-67. PMID: 12618160. ***X-2, X-3, X-4***

1716. Ng A, Temple A, Smith G, et al.; Early analgesic effects of parecoxib versus ketorolac following laparoscopic sterilization: a randomized controlled trial. Br J Anaesth. 2004 Jun;92(6):846-9. PMID: 15121727. ***X-2, X-3, X-4***

1717. Ng FH, Wong SY, Lam KF, et al.; Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010 Jan;138(1):82-8. PMID: 19837071. ***X-2, X-3, X-4***

1718. Ng JL, Morgan DJ, Loh NK, et al.; Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis. Med J Aust. 2011 Mar 21;194(6):313-6. PMID: 21426288. ***X-2, X-4***

1719. Ng JM, Mellor DD, Masson EA, et al.; Sulphonyurea as a cause of severe hypoglycaemia in the community. Prim Care Diabetes. 2010 Apr;4(1):61-3. PMID: 20064751. ***X-2, X-4***

1720. Ng PC, So KW, Fok TF, et al.; Comparing sulindac with indomethacin for closure of ductus arteriosus in preterm infants. J Paediatr Child Health. 1997 Aug;33(4):324-8. PMID: 9323621. ***X-2, X-4***

1721. Ng YW, Liang S, Singh K; Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism--a randomized comparative study. Contraception. 2009 Jan;79(1):24-8. PMID: 19041437. ***X-2, X-3***

1722. Nguyen M, Dougados M, Berdah L, et al.; Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994 Apr;37(4):529-36. PMID: 8147930. ***X-2, X-4***

1723. Nguyen P, Nava-Ocampo A, Levy A, et al.; Effect of iron content on the tolerability of prenatal multivitamins in pregnancy. BMC Pregnancy Childbirth. 2008;8:17. PMID: 18482454. ***X-2, X-4***

1724. Nichols GA, Conner C, Brown JB; Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin. 2010 Sep;26(9):2127-35. PMID: 20658898. ***X-3, X-4***

1725. Nickel JC, Forrest JB, Tomera K, et al.; Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol. 2005 Apr;173(4):1252-5. PMID: 15758763. ***X-2, X-3, X-4***

1726. Nicolau-Raducu R, Subramaniam K, Marquez J, et al.; Safety and efficacy of tranexamic acid compared with aprotinin in thoracic aortic surgery with deep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth. 2010 Feb;24(1):73-9. PMID: 19717314. ***X-2***

1727. Niebyl JR, Blake DA, White RD, et al.; The inhibition of premature labor with indomethacin. Am J Obstet Gynecol. 1980 Apr 15;136(8):1014-9. PMID: 7369252. ***X-2, X-3, X-4***

1728. Nielsen GL, Sorensen HT, Larsen H, et al.; Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ. 2001 Feb 3;322(7281):266-70. PMID: 11157526. ***X-4***

1729. Nielsen GL, Sorensen HT, Mellemkjoer L, et al.; Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001 Nov;111(7):541-5. PMID: 11705430. ***X-4***

1730. Nielsen NC, Nygren KG, Allonen H; Three years of experience after post-abortal insertion of Nova-T and Copper-T-200. Acta Obstet Gynecol Scand. 1984;63(3):261-4. PMID: 6730944. ***X-2, X-3, X-4***

1731. Niemi T, Tanskanen P, Taxell C, et al.; Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol. 1999 Jul;11(3):188-94. PMID: 10414674. ***X-2, X-4***

1732. Nishiike S, Kato T, Nagai M, et al.; Preoperative flurbiprofen for pain prevention after tonsillectomy in adults. J Clin Anesth. 2007 Dec;19(8):596-600. PMID: 18083473. ***X-2, X-3, X-4***

1733. Niv Y, Battler A, Abuksis G, et al.; Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci. 2005 Jan;50(1):78-80. PMID: 15712641. ***X-2, X-4***

1734. Niwa K, Onogi K, Wu Y, et al.; Clinical implication of medroxyprogesterone acetate against advanced ovarian carcinoma: a pilot study. Eur J Gynaecol Oncol. 2008;29(3):252-5. PMID: 18592789. ***X-2, X-3, X-4***

1735. Niwa Y, Nakamura M, Miyahara R, et al.; Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study. Digestion. 2009;80(4):260-6. PMID: 19844108. ***X-2, X-3, X-4***

1736. Niwa Y, Nakamura M, Ohmiya N, et al.; Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol. 2008;43(4):270-6. PMID: 18458842. ***X-2, X-3, X-4***

1737. Noble PW, Albera C, Bradford WZ, et al.; Pirfenidone in patients with idiopathic pulmonary fibrosis

(CAPACITY): two randomised trials. Lancet. 2011 May 21;377(9779):1760-9. PMID: 21571362. ***X-2, X-3, X-4***

1738. Noerpramana NP; A cohort study of Norplant implant: side-effects and acceptance. Adv Contracept. 1995 Jun;11(2):97-114. PMID: 7491860. ***X-2, X-4***

1739. Noerpramana NP; Blood-lipid fractions: the side-effects and continuation of Norplant use. Adv Contracept. 1997 Mar;13(1):13-37. PMID: 9181182. ***X-2, X-4***

1740. Noize P, Benard-Laribiere A, Aulois-Griot M, et al.; Cutaneous adverse effects of ketoprofen for topical use: clinical patterns and costs. Am J Clin Dermatol. 2010;11(2):131-6. PMID: 20141234. ***X-2, X-4***

1741. Noren GN, Sundberg R, Bate A, et al.; A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008 Jul 20;27(16):3057-70. PMID: 18344185. ***X-1, X-4***

1742. Norgard B, Fonager K, Pedersen L, et al.; Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003 Feb;52(2):243-7. PMID: 12524407. ***X-2, X-4***

1743. Norgard B, Pedersen L, Johnsen SP, et al.; COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther. 2004 Apr 1;19(7):817-25. PMID: 15043523. ***X-4***

1744. Norton ME, Merrill J, Cooper BA, et al.; Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med. 1993 Nov 25;329(22):1602-7. PMID: 8232428. ***X-2, X-3, X-4***

1745. Ntaios G, Chatzinikolaou A, Kaiafa G, et al.; Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med. 2009 Mar;20(2):171-3. PMID: 19327607. ***X-3, X-4***

1746. Nunes AP, Lapane KL, Weinstock MA; Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):922-9. PMID: 21688346. ***X-2***

1747. Nygren KG, Nielsen NC, Pyorala T, et al.; Intrauterine contraception with Nova-T and copper-T-200 during three years. Contraception. 1981 Nov;24(5):529-42. PMID: 7032839. ***X-2, X-4***

1748. O'Brien FB, Stewart WC, Sturtevant FM; Incidence of pelvic inflammatory disease in clinical trials with Cu-7 (intrauterine copper contraceptive): a statistical analysis. Contraception. 1983 Feb;27(2):111-22. PMID: 6851553. ***X-4***

1749. O'Connor R, O'Leary M, Ballot J, et al.; A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Jan;59(1):79-87. PMID: 16642371. ***X-2, X-3, X-4***

1750. Odin P, Oehlwein C, Storch A, et al.; Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta Neurol Scand. 2006 Jan;113(1):18-24. PMID: 16367894. ***X-2***

1751. Odmark IS, Jonsson B, Backstrom T; Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate. Am J Obstet Gynecol. 2001 May;184(6):1131-8. PMID: 11349178. ***X-2, X-3, X-4***

1752. O'Donovan DJ, Baetiong A, Adams K, et al.; Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. J Perinatol. 2003 Jun;23(4):286-90. PMID: 12774134. ***X-2, X-4***

1753. Oeda T, Masaki M, Yamamoto K, et al.; High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. J Neural Transm. 2009 Feb;116(2):171-8. PMID: 19082526. ***X-2***

1754. Ofori B, Oraichi D, Blais L, et al.; Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol. 2006 Aug;77(4):268-79. PMID: 16929547. ***X-4***

1755. Oh JM, Kim SH, Suh CH, et al.; Lack of association of glutathione S-transferase P1 Ile105Val polymorphism with aspirin-intolerant asthma. Korean J Intern Med. 2005 Sep;20(3):232-6. PMID: 16295782. ***X-2, X-3, X-4***

1756. Ojala R, Ikonen S, Tammela O; Perinatal indomethacin treatment and neonatal complications in preterm infants. Eur J Pediatr. 2000 Mar;159(3):153-5. PMID: 10664225. ***X-2, X-4***

1757. Ojala R, Ruuska T, Karikoski R, et al.; Gastroesophageal endoscopic findings and gastrointestinal symptoms in preterm neonates with and without perinatal indomethacin exposure. J Pediatr Gastroenterol Nutr. 2001 Feb;32(2):182-8. PMID: 11321390. ***X-2, X-4***

1758. Ojule JD, Oriji VK, Okongwu C; A five year review of the complications of progestogen only injectable contraceptive at the University of Port-Harcourt Teaching Hospital. Niger J Med. 2010 Jan-Mar;19(1):87-95. PMID: 20232762. ***X-2***

1759. Okie S; Raising the safety bar--the FDA's coxib meeting. N Engl J Med. 2005 Mar 31;352(13):1283-5. PMID: 15800221. ***X-1***

1760. Okunlola MA, Owonikoko KM, Roberts OA, et al.; Discontinuation pattern among IUCD users at the family planning clinic, University College Hospital, Ibadan. J Obstet Gynaecol. 2006 Feb;26(2):152-6. PMID: 16483976. ***X-2, X-4***

1761. Oldfield K, Milne R, Vessey M; The effects on mortality of the use of combined oral contraceptives. Br J Fam Plann. 1998 Apr;24(1):2-6. PMID: 9719700. ***X-4***

1762. Olokoba AB, Olokoba LB, Jimoh AA; Upper gastrointestinal tract bleeding in Ilorin, Nigeria--a report of 30 cases. Niger J Clin Pract. 2009 Sep;12(3):240-4. PMID: 19803017. ***X-2, X-4***

1763. Olsen JC, McGrath NA, Schwarz DG, et al.; A double-blind randomized clinical trial evaluating the analgesic efficacy of ketorolac versus butorphanol for patients with suspected biliary colic in the emergency department. Acad Emerg Med. 2008 Aug;15(8):718-22. PMID: 18637080. ***X-2, X-3, X-4***

1764. Olsen NJ, Branch VK, Jonnala G, et al.; Phase 1, placebo-controlled, dose escalation trial of chicory root extract in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord. 2010;11:156. PMID: 20618964. ***X-2, X-3, X-4***

1765. Omar HA, Zakharia RM, Kanungo S, et al.; Incidence of galactorrhea in young women using Depot-Medroxyprogesterone Acetate. ScientificWorldJournal. 2006;6:538-41. PMID: 16680366. ***X-2***

1766. Onder G, Penninx BW, Landi F, et al.; Depression and adverse drug reactions among hospitalized older adults. Arch Intern Med. 2003 Feb 10;163(3):301-5. PMID: 12578510. ***X-7***

1767. Ong TZ, Hawkey CJ, Ho KY; Nonsteroidal anti-inflammatory drug use is a significant cause of peptic ulcer disease in a tertiary hospital in Singapore: a prospective study. J Clin Gastroenterol. 2006 Oct;40(9):795-800. PMID: 17016134. ***X-2, X-3***

1768. Ono M, Miki N, Amano K, et al.; Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab. 2010 Jun;95(6):2672-9. PMID: 20357175. ***X-2, X-3***

1769. Ono M, Miki N, Kawamata T, et al.; Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008 Dec;93(12):4721-7. PMID: 18812485. ***X-2, X-3***

1770. Onodera T, Majima T, Sawaguchi N, et al.; Risk of deep venous thrombosis in drain clamping with tranexamic acid and carbazochrome sodium sulfonate hydrate in total knee arthroplasty. J Arthroplasty. 2012 Jan;27(1):105-8. PMID: 21435821. ***X-2***

1771. Ooba N, Yamaguchi T, Kubota K; The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Drug Saf. 2011 Apr 1;34(4):329-38. PMID: 21417505. ***X-3, X-4, X-8***

1772. Ootani H, Iwakiri R, Shimoda R, et al.; Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol. 2006 Jan;41(1):41-6. PMID: 16501856. ***X-2, X-3, X-4***

1773. Opatrny L, Dell'Aniello S, Assouline S, et al.; Hormone replacement therapy use and variations in the risk of breast cancer. BJOG. 2008 Jan;115(2):169-75; discussion 75. PMID: 18081598. ***X-7***

1774. Orlowski JP; Whatever happened to Reye's syndrome? Did it ever really exist? Crit Care Med. 1999 Aug;27(8):1582-7. PMID: 10470768. ***X-2, X-3, X-4***

1775. Ornbjerg LM, Andersen HB, Kryger P, et al.; What do patients in rheumatologic care know about the risks of NSAIDs? J Clin Rheumatol. 2008 Apr;14(2):69-73. PMID: 18391673. ***X-2, X-3, X-4***

1776. Orr-Walker BJ, Evans MC, Ames RW, et al.; The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf). 1998 Nov;49(5):615-8. PMID: 10197077. ***X-2, X-4***

1777. Ortayli N, Bulut A, Sahin T, et al.; Immediate postabortal contraception with the levonorgestrel intrauterine device, Norplant, and traditional methods. Contraception. 2001 Jun;63(6):309-14. PMID: 11672552. ***X-2, X-4***

1778. Ortonne JP, Queille-Roussel C, Duteil L; 3% diclofenac in 2.5% hyaluronic acid (Solaraze) does not induce photosensitivity or phototoxicity alone or in combination with sunscreens. Eur J Dermatol. 2006 Jul-Aug;16(4):385-90. PMID: 16935795. ***X-2, X-4***

1779. Ostensen M, Ostensen H; Safety of nonsteroidal antiinflammatory drugs in pregnant patients with rheumatic disease. J Rheumatol. 1996 Jun;23(6):1045-9. PMID: 8782138. ***X-2, X-4***

1780. Otley CC, Fewkes JL, Frank W, et al.; Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs. Arch Dermatol. 1996 Feb;132(2):161-6. PMID: 8629823. ***X-2, X-4***

1781. Owens JM, Shroyer KR, Kingdom TT; Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients. Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):579-87. PMID: 16785401. ***X-2, X-3, X-4***

1782. Owen-Smith V, Hannaford PC, Warskyj M, et al.; Effects of changes in smoking status on risk estimates for myocardial infarction among women recruited for the Royal College of General Practitioners' Oral Contraception Study in the UK. J Epidemiol Community Health. 1998 Jul;52(7):420-4. PMID: 9799875. ***X-4***

1783. Ozcagli E, Sardas S, Biri A; Assessment of DNA damage in postmenopausal women under hormone replacement therapy. Maturitas. 2005 Jul 16;51(3):280-5. PMID: 15978971. ***X-2, X-4***

1784. Ozdil B, Cosar A, Akkiz H, et al.; Atherosclerosis and acetylsalicylic acid are independent risk factors for hemorrhage in patients with gastric or duodenal ulcer. Anadolu Kardiyol Derg. 2011 Feb;11(1):53-6. PMID: 21220246. ***X-2, X-3, X-4***

1785. Ozkaya-Bayazit E, Bayazit H, Ozarmagan G; Drug related clinical pattern in fixed drug eruption. Eur J Dermatol. 2000 Jun;10(4):288-91. PMID: 10846256. ***X-2***

1786. P S, P M, Pr S; Systemic adverse drug reactions: a preliminary report from the regional pharmacovigilance center, western Nepal. Pak J Pharm Sci. 2008 Oct;21(4):465-7. PMID: 18930872. ***X-2, X-4***

1787. Pacor ML, Di Lorenzo G, Mansueto P, et al.; Relationship between human leucocyte antigen class I and class II and chronic idiopathic urticaria associated with aspirin and/or NSAIDs hypersensitivity. Mediators Inflamm. 2006;2006(5):62489. PMID: 17392574. ***X-2, X-3, X-4***

1788. Paganini-Hill A, Clark LJ, Henderson VW, et al.; Clock drawing: analysis in a retirement community. J Am Geriatr Soc. 2001 Jul;49(7):941-7. PMID: 11527486. ***X-3, X-4***

1789. Page AJ, Reid SA, Speedy DB, et al.; Exercise-associated hyponatremia, renal function, and nonsteroidal antiinflammatory drug use in an ultraendurance mountain run. Clin J Sport Med. 2007 Jan;17(1):43-8. PMID: 17304005. ***X-2, X-4***

1790. Page J, Henry D; Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000 Mar 27;160(6):777-84. PMID: 10737277. ***X-2***

1791. Pakalnis A, Butz C, Splaingard D, et al.; Emotional problems and prevalence of medication overuse in pediatric chronic daily headache. J Child Neurol. 2007 Dec;22(12):1356-9. PMID: 18174551. ***X-2, X-3, X-4***

1792. Pakarinen P, Luukkainen T; Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing device. Contraception. 2005 Nov;72(5):342-5. PMID: 16246659. ***X-2, X-4***

1793. Pakarinen P, Luukkainen T, Elomaa K, et al.; A 12-month comparative clinical investigation of a levonorgestrel-releasing intracervical device situated in the uterine cavity or cervical canal. Contraception. 1996 Sep;54(3):187-92. PMID: 8899261. ***X-2***

1794. Pakarinen PI, Suvisaari J, Luukkainen T, et al.; Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles. Fertil Steril. 1997 Jul;68(1):59-64. PMID: 9207585. ***X-2, X-3, X-4***

1795. Pal S, Bhattacharya KF, Agapito C, et al.; A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm. 2001;108(1):71-7. PMID: 11261748. ***X-2***

1796. Pala L, Monami M, Lamanna C, et al.; Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. Acta Diabetol. 2010 Dec;47(Suppl 1):7-11. PMID: 19290462. ***X-2, X-3, X-4***

1797. Palayekar V, Joshi JV, Hazari KT, et al.; Chlamydia trachomatis detected in cervical smears from Copper-T users by DFA test. Adv Contracept. 1996 Jun;12(2):145-52. PMID: 8863910. ***X-2, X-4***

1798. Palikhe NS, Kim SH, Cho BY, et al.; Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma. Respir Med. 2008 Aug;102(8):1132-9. PMID: 18595682. ***X-2, X-3, X-4***

1799. Palma-Carlos AG, Medina M, Palma-Carlos ML; Prevalence of drug allergy in an out-patient population. Eur Ann Allergy Clin Immunol. 2006 May;38(5):142-5. PMID: 17058844. ***X-2***

1800. Palmer K; The Vioxx fallout. Minn Med. 2005 Mar;88(3):26-30. PMID: 15852592. ***X-1***

1801. Palomba S, Falbo A, Di Cello A, et al.; Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertil Steril. 2011 Nov;96(5):1128-33. PMID: 21917254. ***X-2, X-3***

1802. Palomba S, Falbo A, Russo T, et al.; Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007 Aug;92(8):3128-35. PMID: 17519312. ***X-2, X-3, X-4***

1803. Palomba S, Orio F, Jr., Nardo LG, et al.; Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab. 2004 Oct;89(10):4801-9. PMID: 15472166. ***X-2, X-3, X-4***

1804. Palomba S, Orio F, Jr., Russo T, et al.; BsmI vitamin D receptor genotypes influence the efficacy of

antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int. 2005 Aug;16(8):943-52. PMID: 15739035. ***X-2, X-3, X-4***

1805. Pan YS, Chen LT, Tseng CA, et al.; Clinical and endoscopic features of non-steroidal anti-inflammatory drug-induced colorectal ulcerations. J Formos Med Assoc. 2005 Nov;104(11):804-10. PMID: 16496059. ***X-4***

1806. Pandi SP, Hadjar LN, Prihyugiharto T; Introductory trial of the once-a-month injectable contraceptive, Cyclofem, in Indonesia. Adv Contracept. 1993 Mar;9(1):33-40. PMID: 8342452. ***X-3, X-4***

1807. Pandya BJ, Bron M, McCall T, et al.; Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus. Curr Med Res Opin. 2011 Jan;27(1):189-95. PMID: 21142610. ***X-2, X-3***

1808. Pang W, Mok MS, Ku MC, et al.; Patient-controlled analgesia with morphine plus lysine acetyl salicylate. Anesth Analg. 1999 Oct;89(4):995-8. PMID: 10512278. ***X-2, X-4***

1809. Panidis D, Georgopoulos NA, Piouka A, et al.; The impact of oral contraceptives and metformin on anti-Mullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol. 2011 Aug;27(8):587-92. PMID: 20836726. ***X-2, X-3***

1810. Pantalone KM, Kattan MW, Yu C, et al.; The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009 Jun;46(2):145-54. PMID: 19194648. ***X-3***

1811. Pantoja M, Medeiros T, Baccarin MC, et al.; Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception. 2010 Feb;81(2):107-11. PMID: 20103446. ***X-2***

1812. Papadima A, Lagoudianakis EE, Antonakis PT, et al.; Parecoxib vs. lornoxicam in the treatment of postoperative pain after laparoscopic cholecystectomy: a prospective randomized placebo-controlled trial. Eur J Anaesthesiol. 2007 Feb;24(2):154-8. PMID: 16938157. ***X-2, X-3, X-4***

1813. Papatheodoridis GV, Papadelli D, Cholongitas E, et al.; Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. Am J Med. 2004 May 1;116(9):601-5. PMID: 15093756. ***X-2, X-3, X-4***

1814. Paquette L, Friedlich P, Ramanathan R, et al.; Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates. J Perinatol. 2006 Aug;26(8):486-92. PMID: 16791261. ***X-2, X-4***

1815. Pardo Cabello AJ, Gonzalez Contreras LG, Manzano Gamero MV, et al.; Prevalence of fatal adverse drug reactions in hospitalized patients. Int J Clin Pharmacol Ther. 2009 Oct;47(10):596-602. PMID: 19825322. ***X-2***

1816. Pareja JA, Caminero AB, Franco E, et al.; Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia. 2001 Nov;21(9):906-10. PMID: 11903285. ***X-2, X-4***

1817. Parikh A, Scadding GK, Gray P, et al.; High levels of nitric oxide synthase activity are associated with nasal polyp tissue from aspirin-sensitive asthmatics. Acta Otolaryngol. 2002 Apr;122(3):302-5. PMID: 12030579. ***X-2, X-3, X-4***

1818. Parikh V, Gandhi AS; Safety of copper T as contraceptive after caesarean section. J Indian Med Assoc. 1989 May;87(5):113-5. PMID: 2600433. ***X-2, X-3, X-4***

1819. Parilla BV, Grobman WA, Holtzman RB, et al.; Indomethacin tocolysis and risk of necrotizing enterocolitis. Obstet Gynecol. 2000 Jul;96(1):120-3. PMID: 10862854. ***X-2, X-4***

1820. Park HK, Lee SH, Chu K, et al.; Effects of celecoxib on volumes of hematoma and edema in patients with primary intracerebral hemorrhage. J Neurol Sci. 2009 Apr 15;279(1-2):43-6. PMID: 19168192. ***X-2, X-4***

1821. Park JJ, Kim JW, Kim HJ, et al.; The prevalence of and risk factors for Barrett's esophagus in a Korean population: A nationwide multicenter prospective study. J Clin Gastroenterol. 2009 Nov-Dec;43(10):907-14. PMID: 19417682. ***X-4***

1822. Park JS, Chang HS, Park CS, et al.; Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics. 2005 Jul;15(7):483-92. PMID: 15970796. ***X-2, X-3, X-4***

1823. Park SY, Moon SH, Park MS, et al.; The effects of ketorolac injected via patient controlled analgesia postoperatively on spinal fusion. Yonsei Med J. 2005 Apr 30;46(2):245-51. PMID: 15861498. ***X-2, X-4***

1824. Parkin L, Sharples K, Hernandez RK, et al.; Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011;342:d2139. PMID: 21511804. ***X-2, X-4***

1825. Parthasarathi G, Ramesh M, Nyfort-Hansen K, et al.; Clinical pharmacy in a South Indian teaching hospital. Ann Pharmacother. 2002 May;36(5):927-32. PMID: 11978174. ***X-2, X-3, X-4***

1826. Partridge CG, Campbell JH, Alvarado F; The effect of platelet-altering medications on bleeding from minor oral surgery procedures. J Oral Maxillofac Surg. 2008 Jan;66(1):93-7. PMID: 18083421. ***X-2***

1827. Pashankar DS, Bishop WP, Mitros FA; Chemical gastropathy: a distinct histopathologic entity in children. J Pediatr Gastroenterol Nutr. 2002 Nov;35(5):653-7. PMID: 12454581. ***X-2***

1828. Pasina L, Nobili A, Tettamanti M, et al.; Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: analysis of prescriptions. Int J Clin Pharmacol Ther. 2010 Nov;48(11):735-43. PMID: 20979932. ***X-4***

1829. Paspatis GA, Matrella E, Kapsoritakis A, et al.; An epidemiological study of acute upper gastrointestinal bleeding in Crete, Greece. Eur J Gastroenterol Hepatol. 2000 Nov;12(11):1215-20. PMID: 11111778. ***X-2***

1830. Pasquale SA, Knuppel RA, Owens AG, et al.; Irregular bleeding, body mass index and coital frequency in Norplant contraceptive users. Contraception. 1994 Aug;50(2):109-16. PMID: 7956210. ***X-2, X-4***

1831. Passalacqua G, Milanese M, Mincarini M, et al.; Single-dose oral tolerance test with alternative compounds for the management of adverse reactions to drugs. Int Arch Allergy Immunol. 2002 Nov;129(3):242-7. PMID: 12444322. ***X-2***

1832. Passarelli MC, Jacob-Filho W, Figueras A; Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging. 2005;22(9):767-77. PMID: 16156680. ***X-2, X-4***

1833. Pastuszak A, Pinelli M, Koren G; Pregnancy outcome following fetal exposure to tiaprofenic acid in the first trimester. Am J Perinatol. 1993 Sep;10(5):354-7. PMID: 8240592. ***X-2, X-3, X-4***

1834. Patel BR; A comparative study of subsyde-CR versus meloxicam in rheumatic disorders. J Indian Med Assoc. 2000 May;98(5):250-2. PMID: 11002624. ***X-4***

1835. Patel H, Barr A, Jeejeebhoy KN; Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol. 2009 Mar;23(3):170-6. PMID: 19319380. ***X-2, X-4***

1836. Patel P, Khulusi S, Mendall MA, et al.; Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet. 1995 Nov 18;346(8986):1315-8. PMID: 7475768. ***X-2, X-3, X-4***

1837. Patel RM, Marfatia YS; Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):430. PMID: 18810845. ***X-2, X-4***

1838. Pathan E, Gaitonde S, Rajadhyaksha S, et al.; A longitudinal study of serum creatinine levels in patients of rheumatoid arthritis on long term NSAID therapy. J Assoc Physicians India. 2003 Nov;51:1045-9. PMID: 15260386. ***X-2***

1839. Patino FG, Olivieri J, Allison JJ, et al.; Nonsteroidal antiinflammatory drug toxicity monitoring and safety practices. J Rheumatol. 2003 Dec;30(12):2680-8. PMID: 14719213. ***X-2, X-3, X-4***

1840. Patterson MK, Castellsague J, Walker AM; Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):982-8. PMID: 18711705. ***X-4***

1841. Pavlicevic I, Kuzmanic M, Rumboldt M, et al.; Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008 Fall;15(3):e372-82. PMID: 18953082. ***X-2, X-3***

1842. Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, et al.; Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy. J Med Econ. 2011;14(6):705-8. PMID: 21892855. ***X-3, X-8***

1843. Pearce HM, Layton D, Wilton LV, et al.; Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol. 2005 Jul;60(1):98-102. PMID: 15963100. ***X-4***

1844. Peck JD, Hulka BS, Poole C, et al.; Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):361-8. PMID: 11927496. ***X-2, X-3, X-4***

1845. Peckham GJ, Miettinen OS, Ellison RC, et al.; Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. J Pediatr. 1984 Aug;105(2):285-91. PMID: 6379136. ***X-2, X-4***

1846. Pecora PG, Kaplan B; Corticosteroids and ulcers: is there an association? Ann Pharmacother. 1996 Jul-Aug;30(7-8):870-2. PMID: 8826575. ***X-1, X-2***

1847. Pedersen OD, Jensen HK; Long-term treatment with transcutaneous estradiol and oral medroxyprogesterone acetate. Acta Obstet Gynecol Scand. 1992 Dec;71(8):593-8. PMID: 1336917. ***X-2, X-4***

1848. Pedersen-Bjergaard U, Andersen M, Hansen PB; Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91. J Intern Med. 1996 Jun;239(6):509-15. PMID: 8656144. ***X-2***

1849. Peers T, Stevens JE, Graham J, et al.; Norplant implants in the UK: first year continuation and removals. Contraception. 1996 Jun;53(6):345-51. PMID: 8773421. ***X-3, X-4***

1850. Peltier AP; Practical management of NSAID gastropathy in rheumatic patients. Scand J Rheumatol Suppl. 1989;78:12-7; discussion 30-2. PMID: 2786645. ***X-1, X-3, X-4***

1851. Penning-van Beest F, Erkens J, Petersen KU, et al.; Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol. 2005 Jul;61(5-6):439-44. PMID: 15947920. ***X-4, X-8***

1852. Penning-van Beest FJ, Koerselman J, Herings RM; Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci. 2007 Dec;29(6):671-5. PMID: 17453356. ***X-4***

1853. Penston JG, Wormsley KG; Nine years of maintenance treatment with ranitidine for patients with duodenal ulcer disease. Aliment Pharmacol Ther. 1992 Oct;6(5):629-45. PMID: 1420753. ***X-2, X-4***

1854. Penta de Peppo A, Pierri MD, Scafuri A, et al.; Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J. 1995;22(3):231-6. PMID: 7580360. ***X-2, X-3, X-4***

1855. Pentti K, Honkanen R, Tuppurainen MT, et al.; Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study. Eur J Endocrinol. 2006 Jan;154(1):101-7. PMID: 16381998. ***X-4, X-7***

1856. Perdriger A, Mariette X, Kuntz JL, et al.; Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. J Rheumatol. 2006 May;33(5):865-9. PMID: 16652418. ***X-2, X-4***

1857. Perez Gutthann S, Garcia Rodriguez LA; The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology. 1993 Nov;4(6):496-501. PMID: 8268277. ***X-4***

1858. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, et al.; Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med. 1996 Nov 25;156(21):2433-9. PMID: 8944736. ***X-4***

1859. Perez-Gutthann S, Garcia-Rodriguez LA, Duque-Oliart A, et al.; Low-dose diclofenac, naproxen, and ibuprofen cohort study. Pharmacotherapy. 1999 Jul;19(7):854-9. PMID: 10417034. ***X-4***

1860. Perez-Ruiz F, Calabozo M, Herrero-Beites AM, et al.; Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron. 2000 Nov;86(3):287-91. PMID: 11096285. ***X-2***

1861. Perneger TV, Whelton PK, Klag MJ; Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994 Dec 22;331(25):1675-9. PMID: 7969358. ***X-2***

1862. Perrone J, Phillips C, Gaieski D; Occult metformin toxicity in three patients with profound lactic acidosis. J Emerg Med. 2011 Mar;40(3):271-5. PMID: 18571361. ***X-2***

1863. Persson I, Adami HO, Norell SE, et al.; Evaluation of a prescription based record-linkage model for epidemiological studies of long-term adverse effects of drugs--with special regard to combined oral contraceptives. Eur J Clin Pharmacol. 1991;40(5):489-93. PMID: 1884723. ***X-1, X-4***

1864. Persson I, Thurfjell E, Bergstrom R, et al.; Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer. 1997 Sep 4;72(5):758-61. PMID: 9311590. ***X-4, X-7***

1865. Persson PE, Nilsson OS, Berggren AM; Do non-steroidal anti-inflammatory drugs cause endoprosthetic loosening? A 10-year follow-up of a randomized trial on ibuprofen for prevention of heterotopic ossification after hip arthroplasty. Acta Orthop. 2005 Dec;76(6):735-40. PMID: 16470423. ***X-2, X-4***

1866. Peters N, Jay N, Barraud D, et al.; Metformin-associated lactic acidosis in an intensive care unit. Crit Care. 2008;12(6):R149. PMID: 19036140. ***X-8***

1867. Petersen KR, Brooks L, Jacobsen N, et al.; Clinical performance of intrauterine devices in nulligravidae: is the length of the endometrial cavity of significance? Acta Eur Fertil. 1991 Jul-Aug;22(4):225-8. PMID: 1844327. ***X-2, X-3, X-4***

1868. Petersen KR, Christiansen E, Madsbad S, et al.; Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. Contraception. 1999 Dec;60(6):337-44. PMID: 10715368. ***X-2, X-4***

1869. Petersen KR, Skouby SO, Sidelmann J, et al.; Assessment of endothelial function during oral contraception in women with insulin-dependent diabetes mellitus. Metabolism. 1994 Nov;43(11):1379-83. PMID: 7968593. ***X-2, X-3***

1870. Petric M, Tasic L, Sukljevic S; Nonsteroidal anti-inflammatory drug usage and gastrointestinal outcomes in the Republic of Serbia. J Pain Palliat Care Pharmacother. 2009;23(1):40-7. PMID: 19296354. ***X-4***

1871. Petty GW, Brown RD, Jr., Whisnant JP, et al.; Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Ann Intern Med. 1999 Jan 5;130(1):14-22. PMID: 9890845. ***X-2, X-4***

1872. Pham T, Le Henanff A, Ravaud P, et al.; Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with

diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis. 2004 Dec;63(12):1611-7. PMID: 15331394. ***X-2, X-3, X-4***

1873. Phemister DA, Laurent S, Harrison FN, Jr.; Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance. Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):175-9. PMID: 7847530. ***X-2, X-4***

1874. Phupong V, Sophonsritsuk A, Taneepanichskul S; The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use. Contraception. 2006 Mar;73(3):253-6. PMID: 16472565. ***X-2, X-3, X-4***

1875. Pierce SJ, Gazvani MR, Farquharson RG; Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil Steril. 2000 Nov;74(5):964-8. PMID: 11056241. ***X-2, X-4***

1876. Pietrzak B, Kaminski P, Wielgos M, et al.; Combined oral contraception in women after renal transplantation. Neuro Endocrinol Lett. 2006 Oct;27(5):679-82. PMID: 17159814. ***X-2, X-4***

1877. Piette F, Teillet L, Naudin R, et al.; Efficacy of misoprostol in the prophylaxis of gastroduodenal lesions induced by short-term nonsteroidal antiinflammatory drug therapy in elderly patients. A multicenter double-blind, placebo-controlled trial. Rev Rhum Engl Ed. 1997 Apr;64(4):259-66. PMID: 9178399. ***X-2, X-3, X-4***

1878. Pikkarainen E, Lehtonen-Veromaa M, Mottonen T, et al.; Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception. 2008 Sep;78(3):226-31. PMID: 18692613. ***X-2***

1879. Pillai L, Burnett BP, Levy RM; GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Curr Med Res Opin. 2010 May;26(5):1055-63. PMID: 20225990. ***X-2, X-4***

1880. Piller R, Chang-Claude J, Linseisen J; Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Eur J Cancer Prev. 2006 Jun;15(3):225-32. PMID: 16679865. ***X-2, X-3, X-4***

1881. Pilotto A, Franceschi M, Leandro G, et al.; Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1091-7. PMID: 15569111. ***X-7***

1882. Pilotto A, Franceschi M, Longoa MG, et al.; Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Dig Liver Dis. 2004 Oct;36(10):666-70. PMID: 15506665. ***X-2, X-3, X-4***

1883. Pilotto A, Leandro G, Di Mario F, et al.; Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study. Dig Dis Sci. 1997 Mar;42(3):586-91. PMID: 9073143. ***X-2***

1884. Pilotto A, Seripa D, Franceschi M, et al.; Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007 Aug;133(2):465-71. PMID: 17681167. ***X-2, X-3, X-4***

1885. Pinheiro SP, Tworoger SS, Cramer DW, et al.; Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol. 2009 Jun 1;169(11):1378-87. PMID: 19342401. ***X-4***

1886. Pini LA, Sternieri E; Active reporting scheme: an example to evaluate specific adverse drug reactions. Acta Physiol Hung. 1990;75 Suppl:237-8. PMID: 2371875. ***X-4***

1887. Pink D, Lindner T, Mrozek A, et al.; Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol. 2006 Jun;101(3):464-9. PMID: 16368128. ***X-2, X-4***

1888. Piper JM, Ray WA, Daugherty JR, et al.; Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991 May 1;114(9):735-40. PMID: 2012355. ***X-4, X-7***

1889. Piya-Anant M, Koetsawang S, Patrasupapong N, et al.; Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea. Contraception. 1998 Jan;57(1):23-8. PMID: 9554247. ***X-2, X-3, X-4***

1890. Plaza V, Serrano J, Picado C, et al.; Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. Eur Respir J. 2002 May;19(5):846-52. PMID: 12030723. ***X-2, X-3, X-4***

1891. Plu-Bureau G, Le MG, Thalabard JC, et al.; Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. Cancer Detect Prev. 1999;23(4):290-6. PMID: 10403900. ***X-2, X-4***

1892. Pochobradsky MG, Mele G, Beretta A, et al.; Post-marketing survey of nimesulide in the short-term treatment of osteoarthritis. Drugs Exp Clin Res. 1991;17(3):197-204. PMID: 1914847. ***X-4***

1893. Pohjolainen T, Jekunen A, Autio L, et al.; Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (Phila Pa 1976). 2000 Jun 15;25(12):1579-85. PMID: 10851109. ***X-3, X-4, X-5***

1894. Polaneczky M, Guarnaccia M, Alon J, et al.; Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Fam Plann Perspect. 1996 Jul-Aug;28(4):174-8. PMID: 8853283. ***X-2***

1895. Polati E, Finco G, Gottin L, et al.; Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg. 1998 Feb;85(2):199-201. PMID: 9501815. ***X-2, X-3, X-4***

1896. Polimeni G, Salvo F, Cutroneo P, et al.; Adverse reactions induced by NSAIDs and antibacterials: analysis of spontaneous reports from the Sicilian regional database. Drug Saf. 2006;29(5):449-59. PMID: 16689558. ***X-2***

1897. Pongsatha S, Muttarak M, Chaovisitseree S, et al.; Mammographic changes related to different types of hormonal therapies. J Med Assoc Thai. 2006 Feb;89(2):123-9. PMID: 16578996. ***X-2***

1898. Pongwecharak J, Tengmeesri N, Malanusorn N, et al.; Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci. 2009 Aug;31(4):481-6. PMID: 19462255. ***X-3***

1899. Pookarnjanamorakot C, Laohacharoensombat W, Jaovisidha S; The clinical efficacy of piroxicam fast-dissolving dosage form for postoperative pain control after simple lumbar spine surgery: a double-blinded randomized study. Spine (Phila Pa 1976). 2002 Mar 1;27(5):447-51. PMID: 11880827. ***X-2, X-3, X-4***

1900. Pope J, Jerome D, Fenlon D, et al.; Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol. 2003 Mar;30(3):480-4. PMID: 12610805. ***X-2, X-4***

1901. Post MS, Rosing J, Van Der Mooren MJ, et al.; Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol. 2002 Dec;119(4):1017-23. PMID: 12472583. ***X-2, X-3, X-4***

1902. Potter LS, Dalberth BT, Canamar R, et al.; Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department. Contraception. 1997 Nov;56(5):305-12. PMID: 9437559. ***X-2***

1903. Pradhan BB, Tatsumi RL, Gallina J, et al.; Ketorolac and spinal fusion: does the perioperative use of ketorolac really inhibit spinal fusion? Spine (Phila Pa 1976). 2008 Sep 1;33(19):2079-82. PMID: 18698276. ***X-2, X-3, X-4***

1904. Prakash J, Niwas SS, Parekh A, et al.; Multiple myeloma--presenting as acute kidney injury. J Assoc Physicians India. 2009 Jan;57:23-6. PMID: 19753754. ***X-2, X-3, X-4***

1905. Prata N, Gessessew A, Cartwright A, et al.; Provision of injectable contraceptives in Ethiopia through community-based reproductive health agents. Bull World Health Organ. 2011 Aug 1;89(8):556-64. PMID: 21836754. ***X-2, X-4***

1906. Pratt N, Roughead EE, Ryan P, et al.; Differential impact of NSAIDs on rate of adverse events that require hospitalization in high-risk and general veteran populations: a retrospective cohort study. Drugs Aging. 2010 Jan 1;27(1):63-71. PMID: 20030433. ***X-4***

1907. Prentice RL, Chlebowski RT, Stefanick ML, et al.; Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol. 2008 May 15;167(10):1207-16. PMID: 18372396. ***X-4, X-7***

1908. Prentice RL, Manson JE, Langer RD, et al.; Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol. 2009 Jul 1;170(1):12-23. PMID: 19468079. ***X-4, X-7***

1909. Preshaw PM, Knutsen MA, Mariotti A; Experimental gingivitis in women using oral contraceptives. J Dent Res. 2001 Nov;80(11):2011-5. PMID: 11759012. ***X-2, X-4***

1910. Preston JT, Cameron IT, Adams EJ, et al.; Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995 May;102(5):401-6. PMID: 7612535. ***X-2, X-4***

1911. Price-Forbes AN, Callaghan R, Allen ME, et al.; A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Rheumatology (Oxford). 2005 Jul;44(7):921-4. PMID: 15827035. ***X-4***

1912. Protti A, Russo R, Tagliabue P, et al.; Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care. 2010;14(1):R22. PMID: 20170489. ***X-2, X-3, X-4***

1913. Proudman SM, Keen HI, Stamp LK, et al.; Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum. 2007 Oct;37(2):99-111. PMID: 17391739. ***X-2, X-4***

1914. Psaty BM, Weiss NS; NSAID trials and the choice of comparators--questions of public health importance. N Engl J Med. 2007 Jan 25;356(4):328-30. PMID: 17251528. ***X-1***

1915. Publig W, Wustinger C, Zandl C; Non-steroidal anti-inflammatory drugs (NSAID) cause gastrointestinal ulcers mainly in Helicobacter pylori carriers. Wien Klin Wochenschr. 1994;106(9):276-9. PMID: 8023522. ***X-2***

1916. Pullar T, Murphy B, Taggart A, et al.; Patterns of out-patients non-steroidal anti-inflammatory drug prescribing in two teaching hospital rheumatology units--implications for post-marketing surveillance. J Clin Pharm Ther. 1990 Aug;15(4):267-72. PMID: 2229206. ***X-2, X-3, X-4***

1917. Puri AS, Monga R, Garg S, et al.; Diaphragm disease of duodenum following long-term NSAIDs use: endoscopic management. Indian J Gastroenterol. 2004 Sep-Oct;23(5):189-90. PMID: 15599008. ***X-2, X-3, X-4***

1918. Qin LH, Goldberg JM, Hao G; A 4-year follow-up study of women with Norplant-2 contraceptive implants. Contraception. 2001 Nov;64(5):301-3. PMID: 11777490. ***X-2, X-4***

1919. Quaratino D, Romano A, Papa G, et al.; Long-term tolerability of nimesulide and acetaminophen in nonsteroidal antiinflammatory drug-intolerant patients. Ann Allergy Asthma Immunol. 1997 Jul;79(1):47-50. PMID: 9236499. ***X-2, X-3, X-4***

1920. Quehenberger P, Loner U, Kapiotis S, et al.; Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 1996 Nov;76(5):729-34. PMID: 8950781. ***X-4, X-5***

1921. Quigley CA, Crowe BJ, Anglin DG, et al.; Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002 May;87(5):2033-41. PMID: 11994337. ***X-2, X-3, X-4***

1922. Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J, et al.; Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain. 1996 May-Jun;65(2-3):221-5. PMID: 8826510. ***X-2, X-3, X-4***

1923. Quinones Estevez MD; Are selective COX-2 inhibitors a safe option in patients with intolerance to nonsteroidal antiinflammatory drugs? J Investig Allergol Clin Immunol. 2009;19(4):328-30. PMID: 19639736. ***X-2***

1924. Quiralte J, Blanco C, Castillo R, et al.; Anaphylactoid reactions due to nonsteroidal antiinflammatory drugs: clinical and cross-reactivity studies. Ann Allergy Asthma Immunol. 1997 Mar;78(3):293-6. PMID: 9087155. ***X-2, X-4***

1925. Quiralte J, Delgado J, Saenz de San Pedro B, et al.; Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2004 Oct;93(4):360-4. PMID: 15521372. ***X-2, X-4***

1926. Quiralte J, Saenz de San Pedro B, Florido JJ; Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol. 2002 Jul;89(1):63-6. PMID: 12141722. ***X-2, X-4***

1927. Rabe T, Mueck AO, Deuringer FU, et al.; Spacing-out of progestin--efficacy, tolerability and compliance of two regimens for hormonal replacement in the late postmenopause. Gynecol Endocrinol. 1997 Dec;11(6):383-92. PMID: 9476087. ***X-2, X-4***

1928. Rabeneck L, Wristers K, Goldstein JL, et al.; Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. Am J Gastroenterol. 2002 Jan;97(1):32-9. PMID: 11808967. ***X-4***

1929. Radat F, Sakh D, Lutz G, et al.; Psychiatric comorbidity is related to headache induced by chronic substance use in migraineurs. Headache. 1999 Jul-Aug;39(7):477-80. PMID: 11279930. ***X-2, X-3, X-4***

1930. Rager KM, Fowler A, Omar HA; Successful treatment of depot medroxyprogesterone acetate-related vaginal bleeding improves continuation rates in adolescents. ScientificWorldJournal. 2006;6:353-5. PMID: 16547584. ***X-2, X-3, X-4***

1931. Raghu G, Brown KK, Costabel U, et al.; Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008 Nov 1;178(9):948-55. PMID: 18669816. ***X-2, X-3, X-4***

1932. Ragni N, Boccardo E, Viglino S, et al.; Oral contraception and breast pathology. Acta Eur Fertil. 1981 Jun;12(2):141-63. PMID: 6794288. ***X-1, X-2, X-3, X-4***

1933. Rahman A, Segasothy M, Samad SA, et al.; Analgesic use and chronic renal disease in patients with headache. Headache. 1993 Sep;33(8):442-5. PMID: 8262786. ***X-2***

1934. Rahme E, Bardou M, Dasgupta K, et al.; Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford). 2007 Feb;46(2):265-72. PMID: 16844699. ***X-4, X-7***

1935. Rahme E, Barkun A, Nedjar H, et al.; Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol. 2008 Apr;103(4):872-82. PMID: 18371130. ***X-4, X-7***

1936. Rahme E, Barkun AN, Toubouti Y, et al.; Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis Rheum. 2007 Jun 15;57(5):748-55. PMID: 17530673. ***X-3, X-4***

1937. Rahme E, Choquette D, Beaulieu M, et al.; Impact of a general practitioner educational intervention on osteoarthritis treatment in an elderly population. Am J Med. 2005 Nov;118(11):1262-70. PMID: 16271911. ***X-2, X-3, X-4***

1938. Rahme E, Joseph L, Kong SX, et al.; Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum. 2000 Apr;43(4):917-24. PMID: 10765939. ***X-4, X-7***

1939. Rahme E, Joseph L, Kong SX, et al.; Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol. 2001 Aug;52(2):185-92. PMID: 11488776. ***X-4, X-7***

1940. Rahme E, Nedjar H; Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford). 2007 Mar;46(3):435-8. PMID: 17255138. ***X-7***

1941. Rahme E, Nedjar H, Bizzi A, et al.; Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther. 2007 Nov 15;26(10):1387-98. PMID: 17892525. ***X-4, X-7***

1942. Rahme E, Pettitt D, LeLorier J; Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis Rheum. 2002 Nov;46(11):3046-54. PMID: 12428249. ***X-7***

1943. Rahme E, Watson DJ, Kong SX, et al.; Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2007 May;16(5):493-503. PMID: 17086567. ***X-4, X-7***

1944. Rajagopalan R, Iyer S, Perez A; Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab. 2005 Mar;7(2):161-9. PMID: 15715889. ***X-4***

1945. Rakhshani F, Mohammadi M; Contraception continuation rates and reasons for discontinuation in Zahedan, Islamic Republic of Iran. East Mediterr Health J. 2004 May;10(3):260-7. PMID: 16212200. ***X-8***

1946. Ramadan FH, Masoodi N, El-Solh AA; Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther. 2005 Jun;30(3):233-9. PMID: 15896240. ***X-2, X-3, X-4***

1947. Ramakrishnan K, Johnson AD; Gastroduodenal ulcer perforation. Br J Clin Pract. 1986 Sep;40(9):371-2. PMID: 3801262. ***X-2, X-4***

1948. Ramam M, Bhat R, Jindal S, et al.; Patient-reported multiple drug reactions: clinical profile and results of challenge testing. Indian J Dermatol Venereol Leprol. 2010 Jul-Aug;76(4):382-6. PMID: 20657119. ***X-2***

1949. Ramirez Hidalgo A, Pujol Ribera E; Use of the intrauterine device: efficacy and safety. Eur J Contracept Reprod Health Care. 2000 Sep;5(3):198-207. PMID: 11131785. ***X-2***

1950. Ramsoekh D, van Leerdam ME, Rauws EA, et al.; Outcome of peptic ulcer bleeding, nonsteroidal anti-inflammatory drug use, and Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2005 Sep;3(9):859-64. PMID: 16234022. ***X-2***

1951. Rao G; Aspirin preparation and risk of GI bleeding. J Fam Pract. 1997 Mar;44(3):242-3. PMID: 9071237. ***X-1, X-4***

1952. Rao GR, Ghosh S, Dhurat R, et al.; Efficacy, safety, and tolerability of microsphere adapalene vs. conventional adapalene for acne vulgaris. Int J Dermatol. 2009 Dec;48(12):1360-5. PMID: 20415678. ***X-2, X-4***

1953. Rashad S, Revell P, Hemingway A, et al.; Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 1989 Sep 2;2(8662):519-22. PMID: 2570233. ***X-2, X-4***

1954. Rasheed SM, Abdelmonem AM; Complications among adolescents using copper intrauterine contraceptive devices. Int J Gynaecol Obstet. 2011 Dec;115(3):269-72. PMID: 21872240. ***X-2, X-4***

1955. Rask O, Nilsson KO, Berntorp E; Oestrogen treatment of constitutional tall stature in girls: is there a risk of thrombosis or bleeding? Acta Paediatr. 2008 Mar;97(3):342-7. PMID: 18298783. ***X-2, X-4***

1956. Raskin JB, White RH, Jaszewski R, et al.; Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996 Feb;91(2):223-7. PMID: 8607484. ***X-2, X-3, X-4***

1957. Rasmussen VG, Poulsen SH, Dupont E, et al.; Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease. J Intern Med. 2008 Jan;263(1):90-8. PMID: 18036161. ***X-2***

1958. Ratner RE, Maggs D, Nielsen LL, et al.; Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006 Jul;8(4):419-28. PMID: 16776749. ***X-2, X-3, X-4***

1959. Rattray B, Nugent DJ, Young G; Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia. 2006 Sep;12(5):514-7. PMID: 16919082. ***X-2, X-4***

1960. Raudaskoski TH, Tomas EI, Paakkari IA, et al.; Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. Maturitas. 1995 Jun;22(1):47-53. PMID: 7666816. ***X-2, X-4***

1961. Raverot G, Jacob M, Jouanneau E, et al.; Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol (Oxf). 2009 Apr;70(4):588-92. PMID: 18673461. ***X-2***

1962. Rawal N, Kroner K, Simin-Geertsen M, et al.; Safety of lornoxicam in the treatment of postoperative pain: a post-marketing study of analgesic regimens containing lornoxicam compared with standard analgesic treatment in 3752 day-case surgery patients. Clin Drug Investig. 2010;30(10):687-97. PMID: 20701400. ***X-4***

1963. Rawson NS; Impact of preexisting health conditions on the outcome of an adverse drug reaction alerting program: gastrointestinal disorders before piroxicam and sulindac therapy. Ann Pharmacother. 1995 Jul-Aug;29(7-8):676-80. PMID: 8520079. ***X-3, X-4***

1964. Rawson NS, Inman WH; Prescription-Event Monitoring. Recent experience with 5 NSAIDs. Med Toxicol. 1986;1 Suppl 1:79-82. PMID: 3821431. ***X-4***

1965. Rawson NS, Nourjah P, Grosser SC, et al.; Factors associated with celecoxib and rofecoxib utilization. Ann Pharmacother. 2005 Apr;39(4):597-602. PMID: 15755796. ***X-4***

1966. Ray WA, Chung CP, Stein CM, et al.; Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007 Sep;133(3):790-8. PMID: 17854591. ***X-4***

1967. Ray WA, Stein CM, Byrd V, et al.; Educational program for physicians to reduce use of non-steroidal anti-inflammatory drugs among community-dwelling elderly persons: a randomized controlled trial. Med Care. 2001 May;39(5):425-35. PMID: 11317091. ***X-2, X-3, X-4***

1968. Ray WA, Stein CM, Daugherty JR, et al.; COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002 Oct 5;360(9339):1071-3. PMID: 12383990. ***X-2, X-4***

1969. Ray WA, Varas-Lorenzo C, Chung CP, et al.; Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. PMID: 20031832. ***X-4***

1970. Raynauld JP, Martel-Pelletier J, Bias P, et al.; Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009 Jun;68(6):938-47. PMID: 18653484. ***X-2, X-3, X-4***

1971. Reasbeck PG, Rice ML, Reasbeck JC; Double-blind controlled trial of indomethacin as an adjunct to narcotic analgesia after major abdominal surgery. Lancet. 1982 Jul 17;2(8290):115-8. PMID: 6123836. ***X-2, X-3, X-4***

1972. Rebbeck TR, Troxel AB, Norman S, et al.; Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol. 2007 Dec 15;166(12):1392-9. PMID: 17827444. ***X-2, X-3, X-4***

1973. Rehan N, Inayatullah A, Chaudhary I; Norplant: reasons for discontinuation and side-effects. Eur J Contracept Reprod Health Care. 2000 Jun;5(2):113-8. PMID: 10943573. ***X-2, X-4***

1974. Reid PC, Virtanen-Kari S; Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG. 2005 Aug;112(8):1121-5. PMID: 16045528. ***X-2, X-3***

1975. Reid RW, Zimmerman AA, Laussen PC, et al.; The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Anesth Analg. 1997 May;84(5):990-6. PMID: 9141920. ***X-2, X-3, X-4***

1976. Reiff A, Lovell DJ, Adelsberg JV, et al.; Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006 May;33(5):985-95. PMID: 16583464. ***X-2, X-4***

1977. Reijman M, Bierma-Zeinstra SM, Pols HA, et al.; Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum. 2005 Oct;52(10):3137-42. PMID: 16200593. ***X-4, X-7***

1978. Reinhart DJ, Goldberg ME, Roth JV, et al.; Transdermal fentanyl system plus im ketorolac for the treatment of postoperative pain. Can J Anaesth. 1997 Apr;44(4):377-84. PMID: 9104519. ***X-2, X-4***

1979. Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, et al.; Effects of the etonogestrel-releasing contraceptive implant (Implanon on parameters of breastfeeding

compared to those of an intrauterine device. Contraception. 2000 Nov;62(5):239-46. PMID: 11172794. ***X-2, X-4***

1980. Reiter SL, Baer LJ; Initial selection of oral contraceptives. J Reprod Med. 1990 May;35(5):547-8. PMID: 2352250. ***X-2***

1981. Renier M, Buytaert P; Open prospective multicenter trial with a new monophasic contraceptive combination containing gestodene. Contraception. 1991 May;43(5):413-21. PMID: 1914456. ***X-4***

1982. Resseguie LJ, Hick JF, Bruen JA, et al.; Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974. Fertil Steril. 1985 Apr;43(4):514-9. PMID: 3987922. ***X-2, X-4***

1983. Reuben SS, Ablett D, Kaye R; High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion. Can J Anaesth. 2005 May;52(5):506-12. PMID: 15872130. ***X-2, X-4***

1984. Rexrode KM, Buring JE, Glynn RJ, et al.; Analgesic use and renal function in men. JAMA. 2001 Jul 18;286(3):315-21. PMID: 11466097. ***X-6***

1985. Reyes-Morales H, Mino-Leon D, Doubova SV, et al.; Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico. Int J Clin Pharmacol Ther. 2012 Jan;50(1):1-9. PMID: 22192639. ***X-2, X-4***

1986. Rheinlaender C, Helfenstein D, Walch E, et al.; Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr. 2009 Jan;98(1):36-42. PMID: 18764861. ***X-2, X-4***

1987. Rhemrev PE, van Os WA, Edelman DA, et al.; Medical removals of the Multiload IUD. Adv Contracept. 1988 Jun;4(2):125-30. PMID: 3213669. ***X-3, X-4***

1988. Rice MM, Graves AB, McCurry SM, et al.; Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: The Kame Project. Arch Intern Med. 2000 Jun 12;160(11):1641-9. PMID: 10847257. ***X-2***

1989. Richards J, Johnson A, Fox G, et al.; A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics. 2009 Aug;124(2):e287-93. PMID: 19651568. ***X-2, X-3, X-4***

1990. Richardson BA, Otieno PA, Mbori-Ngacha D, et al.; Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS. 2007 Mar 30;21(6):749-53. PMID: 17413696. ***X-2***

1991. Riddell RH, Tanaka M, Mazzoleni G; Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut. 1992 May;33(5):683-6. PMID: 1612488. ***X-2***

1992. Riddle R, Ryser CN, Morton AA, et al.; The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. J Pediatr Psychol. 2006 Apr;31(3):262-71. PMID: 15872147. ***X-2, X-4***

1993. Riley AP, Stewart MK, Chakraborty J; Program- and method-related determinants of first DMPA use duration in rural Bangladesh. Stud Fam Plann. 1994 Sep-Oct;25(5):255-67. PMID: 7871551. ***X-2, X-4***

1994. Rimbas M, Marinescu M, Voiosu MR, et al.; NSAID-induced deleterious effects on the proximal and mid small bowel in seronegative spondyloarthropathy patients. World J Gastroenterol. 2011 Feb 28;17(8):1030-5. PMID: 21448355. ***X-2, X-3, X-4***

1995. Risques RA, Vaughan TL, Li X, et al.; Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55. PMID: 18086770. ***X-2, X-3, X-4***

1996. Ritchie LD; A clinical evaluation of flurbiprofen LAT and piroxicam gel: a multicentre study in general practice. Clin Rheumatol. 1996 May;15(3):243-7. PMID: 8793254. ***X-2, X-3, X-4***

1997. Rivera R, Gousse A; Does postmenopausal hormone therapy cause urinary incontinence? Nat Clin Pract Urol. 2006 Jun;3(6):304-5. PMID: 16763639. ***X-1, X-2, X-4, X-7***

1998. Rivers JK, McLean DI; An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol. 1997 Oct;133(10):1239-42. PMID: 9382562. ***X-2, X-3, X-4***

1999. Rizk DE; Subdermal levonorgestrel implants. Three years' experience in Cairo, Egypt. J Reprod Med. 1995 Sep;40(9):638-44. PMID: 8576880. ***X-2, X-4***

2000. Robe PA, Martin D, Albert A, et al.; A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. BMC Cancer. 2006;6:29. PMID: 16448552. ***X-2, X-3, X-4***

2001. Robert E, Musatti L, Piscitelli G, et al.; Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 1996 Jul-Aug;10(4):333-7. PMID: 8829257. ***X-2, X-8***

2002. Robertson DJ, Larsson H, Friis S, et al.; Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007 Sep;133(3):755-60. PMID: 17678921. ***X-4***

2003. Robinson JL, Griest S, James KE, et al.; Impact of aspirin intolerance on outcomes of sinus surgery.

Laryngoscope. 2007 May;117(5):825-30. PMID: 17473677. ***X-2, X-3, X-4***

2004. Robinson R, China S, Bunkheila A, et al.; Mirena intrauterine system in the treatment of menstrual disorders: a survey of UK patients' experience, acceptability and satisfaction. J Obstet Gynaecol. 2008 Oct;28(7):728-31. PMID: 19065370. ***X-2***

2005. Rodriguez A, Reviriego J, Karamanos V, et al.; Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study. Cardiovasc Diabetol. 2011;10:18. PMID: 21314919. ***X-3, X-4***

2006. Roll A, Wuthrich B, Schmid-Grendelmeier P, et al.; Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs. Swiss Med Wkly. 2006 Oct 28;136(43-44):684-90. PMID: 17183430. ***X-2, X-3, X-4***

2007. Romer T; Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea. Eur J Obstet Gynecol Reprod Biol. 2000 May;90(1):27-9. PMID: 10767506. ***X-2, X-3***

2008. Romieu I, Fabre A, Fournier A, et al.; Postmenopausal hormone therapy and asthma onset in the E3N cohort. Thorax. 2010 Apr;65(4):292-7. PMID: 20142267. ***X-4, X-7***

2009. Romsing J, Ostergaard D, Walther-Larsen S, et al.; Analgesic efficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomy. Acta Anaesthesiol Scand. 1998 Aug;42(7):770-5. PMID: 9698951. ***X-2, X-3, X-4***

2010. Ronnerdag M, Odlind V; Late bleeding problems with the levonorgestrel-releasing intrauterine system: evaluation of the endometrial cavity. Contraception. 2007 Apr;75(4):268-70. PMID: 17362704. ***X-2***

2011. Ronquist G, Rodriguez LA, Ruigomez A, et al.; Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate. 2004 Jan 1;58(1):50-6. PMID: 14673952. ***X-3, X-4***

2012. Rooney TW, Furst DE, Koehnke R, et al.; Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol. 1993 Aug;20(8):1297-302. PMID: 8230008. ***X-2, X-4***

2013. Roos Y; Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. Neurology. 2000 Jan 11;54(1):77-82. PMID: 10636129. ***X-2, X-3, X-4***

2014. Rosenberg JA, Goldstein JL; Safety and efficacy of lumiracoxib compared with NSAIDs. Nat Clin Pract Gastroenterol Hepatol. 2005 Jan;2(1):14-5. PMID: 16265092. ***X-1, X-2, X-4***

2015. Rosenberg L, Palmer JR, Rao RS, et al.; Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med. 2001 Apr 23;161(8):1065-70. PMID: 11322840. ***X-4***

2016. Ross AH, Boyd ME, Colgan TJ, et al.; Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology. Obstet Gynecol. 1993 Nov;82(5):773-9. PMID: 8414325. ***X-2, X-4***

2017. Rossing MA, Daling JR, Weiss NS, et al.; Past use of an intrauterine device and risk of tubal pregnancy. Epidemiology. 1993 May;4(3):245-51. PMID: 8512988. ***X-2, X-4***

2018. Roth S, Bennett R, Caldron P, et al.; Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study. Semin Arthritis Rheum. 1990 Feb;19(4 Suppl 2):11-9. PMID: 2181673. ***X-2***

2019. Roth SH, Bennett R, Caldron P, et al.; A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol. 1994 Jun;21(6):1118-23. PMID: 7932425. ***X-2***

2020. Roth SH, Tindall EA, Jain AK, et al.; A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993 Nov 22;153(22):2565-71. PMID: 8239849. ***X-2***

2021. Roth-Cline MD; Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs. Circulation. 2006 May 9;113(18):2253-9. PMID: 16684875. ***X-1, X-2, X-3, X-4***

2022. Roto P, Sainio H, Reunala T, et al.; Addition of ferrous sulfate to cement and risk of chromium dermatitis among construction workers. Contact Dermatitis. 1996 Jan;34(1):43-50. PMID: 8789225. ***X-2, X-4***

2023. Roughead EE, Ramsay E, Pratt N, et al.; NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. Drug Saf. 2008;31(11):997-1003. PMID: 18840019. ***X-3, X-4***

2024. Roujeau JC, Kelly JP, Naldi L, et al.; Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995 Dec 14;333(24):1600-7. PMID: 7477195. ***X-2***

2025. Roumie CL, Arbogast PG, Mitchel EF, Jr., et al.; Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. J Gen Intern Med. 2005 Oct;20(10):879-83. PMID: 16191131. ***X-3, X-4***

2026. Roumie CL, Choma NN, Kaltenbach L, et al.; Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. PMID: 19637402. ***X-4***

2027. Rovensky J, Micekova D; Six-month prospective study to monitor the treatment of rheumatic diseases with sustained-release flurbiprofen. Drugs Exp Clin Res. 2000;26(1):19-24. PMID: 10761533. ***X-2, X-3, X-4***

2028. Rovensky J, Micekova D, Gubzova Z, et al.; Treatment of knee osteoarthritis with a topical non-steroidal antiinflammatory drug. Results of a randomized, double-blind, placebo-controlled study on the efficacy and safety of a 5% ibuprofen cream. Drugs Exp Clin Res. 2001;27(5-6):209-21. PMID: 11951579. ***X-2, X-4***

2029. Rowan JA; A trial in progress: gestational diabetes. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial). Diabetes Care. 2007 Jul;30 Suppl 2:S214-9. PMID: 17596475. ***X-2***

2030. Rowlands S, Guillebaud J, Bounds W, et al.; Side effects of danazol compared with an ethinyloestradiol/norgestrel combination when used for postcoital contraception. Contraception. 1983 Jan;27(1):39-49. PMID: 6839757. ***X-2, X-3, X-4***

2031. Rozenberg S, Ylikorkala O, Arrenbrecht S; Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Int J Fertil Womens Med. 1997;42 Suppl 2:376-87. PMID: 9397385. ***X-2***

2032. Rozendaal L, le Cessie S, Wit JM, et al.; Growth-reductive therapy in children with marfan syndrome. J Pediatr. 2005 Nov;147(5):674-9. PMID: 16291362. ***X-2, X-4***

2033. Rubinstein ML, Halpern-Felsher BL, Irwin CE, Jr.; An evaluation of the use of the transdermal contraceptive patch in adolescents. J Adolesc Health. 2004 May;34(5):395-401. PMID: 15093794. ***X-2, X-3, X-4***

2034. Ruel MA, Wang F, Bourke ME, et al.; Is tranexamic acid safe in patients undergoing coronary endarterectomy? Ann Thorac Surg. 2001 May;71(5):1508-11. PMID: 11383791. ***X-2, X-4***

2035. Rugstad HE, Hundal O, Holme I, et al.; Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Clin Rheumatol. 1986 Sep;5(3):389-98. PMID: 3536263. ***X-4***

2036. Ruigomez A, Garcia Rodriguez LA, Wallander MA, et al.; Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004 Oct 1;20(7):751-60. PMID: 15379835. ***X-3, X-4***

2037. Ruminjo JK, Achwal I, Ruminjo IN; Acceptability of Norplant contraceptive subdermal implants in Kenya. East Afr Med J. 1994 Sep;71(9):558-61. PMID: 7875087. ***X-3, X-4***

2038. Russo P, Papa V, Russo S, et al.; Topical nonsteroidal anti-inflammatory drugs in uncomplicated cataract surgery: effect of sodium naproxen. Eur J Ophthalmol. 2005 Sep-Oct;15(5):598-606. PMID: 16167290. ***X-2, X-3, X-4***

2039. Ryan P, Hetzel DJ, Shearman DJ, et al.; Risk factors for ulcerative reflux oesophagitis: a case-control study. J Gastroenterol Hepatol. 1995 May-Jun;10(3):306-12. PMID: 7548808. ***X-2, X-4***

2040. Ryan PJ, Singh SP, Guillebaud J; Depot medroxyprogesterone and bone mineral density. J Fam Plann Reprod Health Care. 2002 Jan;28(1):12-5. PMID: 16259808. ***X-2***

2041. Rybo G, Andersson K, Odlind V; Hormonal intrauterine devices. Ann Med. 1993 Apr;25(2):143-7. PMID: 8489751. ***X-8***

2042. Saag KG, Rubenstein LM, Chrischilles EA, et al.; Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol. 1995 Nov;22(11):2142-7. PMID: 8596158. ***X-7***

2043. Sabatini R, Cagiano R; Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006 Sep;74(3):220-3. PMID: 16904415. ***X-2***

2044. Sachar D; Exposure to mesalamine during pregnancy increased preterm deliveries (but not birth defects) and decreased birth weight. Gut. 1998 Sep;43(3):316. PMID: 9863473. ***X-2, X-4***

2045. Sadikot SM, Mogensen CE; Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract. 2008 Dec;82(3):391-5. PMID: 18945509. ***X-2, X-3, X-4***

2046. Sagay AS, Okeahialam BN, Imade GE; Electrocardiographic changes among Nigerian Norplant users. West Afr J Med. 2002 Apr-Jun;21(2):146-8. PMID: 12403039. ***X-2, X-4***

2047. Sagay AS, Okeahialam BN, Imade GE, et al.; Evaluation of cardiovascular morbidity in Nigerian women after 3 years of Norplant contraception. Afr J Reprod Health. 2008 Apr;12(1):47-53. PMID: 20695154. ***X-2, X-4***

2048. Sahi SP, Basu SK, Bansal SK; Non-steroidal anti-inflammatory drugs and gastrointestinal bleeding in the

elderly. Br J Clin Pract. 1990 Jan;44(1):22-3, 7. PMID: 2317434. ***X-2***

2049. Sahin Y, Unluhizarci K, Yilmazsoy A, et al.; The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007 Dec;67(6):904-8. PMID: 17666089. ***X-2***

2050. Sairanen J, Tammela TL, Leppilahti M, et al.; Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005 Dec;174(6):2235-8. PMID: 16280777. ***X-2, X-3, X-4***

2051. Saito Y, Morimoto T, Ogawa H, et al.; Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011 Feb;34(2):280-5. PMID: 21270185. ***X-3, X-4***

2052. Sakai H, Minami Y, Kanetake H, et al.; Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group. Cancer Chemother Pharmacol. 1994;35 Suppl:S23-6. PMID: 7994782. ***X-2, X-3, X-4***

2053. Sakamoto C, Sugano K, Ota S, et al.; Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006 Sep;62(9):765-72. PMID: 16821007. ***X-2***

2054. Salih BA, Abasiyanik MF, Bayyurt N, et al.; H pylori infection and other risk factors associated with peptic ulcers in Turkish patients: a retrospective study. World J Gastroenterol. 2007 Jun 21;13(23):3245-8. PMID: 17589905. ***X-4***

2055. Salim AS; A new approach to the treatment of nonsteroidal anti-inflammatory drugs induced gastric bleeding by free radical scavengers. Surg Gynecol Obstet. 1993 May;176(5):484-90. PMID: 8480273. ***X-2, X-3, X-4***

2056. Saloheimo P, Ahonen M, Juvela S, et al.; Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006 Jan;37(1):129-33. PMID: 16322483. ***X-2, X-4***

2057. Salokorpi T, Eronen M, von Wendt L; Growth and development until 18 months of children exposed to tocolytics indomethacin or nylidrin. Neuropediatrics. 1996 Aug;27(4):174-7. PMID: 8892364. ***X-2, X-4***

2058. Salonen A, Silvola J, Kokki H; Does 1 or 2 g paracetamol added to ketoprofen enhance analgesia in adult tonsillectomy patients? Acta Anaesthesiol Scand. 2009 Oct;53(9):1200-6. PMID: 19572937. ***X-2, X-3, X-4***

2059. Salvo F, Polimeni G, Cutroneo PM, et al.; Allergic reactions to oral drugs: A case/non-case study from an Italian spontaneous reporting database (GIF). Pharmacol Res. 2008 Sep-Oct;58(3-4):202-7. PMID: 18692136. ***X-4***

2060. Sammartino A, Di Carlo C, Mandato VD, et al.; Effects of genistein on the endometrium: ultrasonographic evaluation. Gynecol Endocrinol. 2003 Feb;17(1):45-9. PMID: 12724018. ***X-2, X-3, X-4***

2061. Sammour RN, Ohel G, Cohen M, et al.; Oral naproxen versus oral tramadol for analgesia after cesarean delivery. Int J Gynaecol Obstet. 2011 May;113(2):144-7. PMID: 21435642. ***X-2, X-3***

2062. Samonis G, Margioris AN, Bafaloukos D, et al.; Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG+MPA in generalized breast cancer. Oncology. 1994 Sep-Oct;51(5):411-5. PMID: 8052481. ***X-2, X-3, X-4***

2063. Samsioe G, Boschitsch E, Concin H, et al.; Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. Climacteric. 2006 Oct;9(5):368-79. PMID: 17080587. ***X-2, X-3, X-4***

2064. Samuelsson E, Hagg S; Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstet Gynecol Scand. 2004 Jul;83(7):674-81. PMID: 15225194. ***X-4***

2065. Sanak M, Kielbasa B, Bochenek G, et al.; Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin Exp Allergy. 2004 Dec;34(12):1899-904. PMID: 15663565. ***X-2, X-3, X-4***

2066. Sanchez Andrada S, Rodriguez Valverde V; A double-blind randomised controlled trial of droxicam versus indomethacin in rheumatoid arthritis. Eur J Rheumatol Inflamm. 1991;11(4):15-20. PMID: 1365485. ***X-2, X-3, X-4***

2067. Sanchez Palacios A, Schamann F, Garcia JA, et al.; Sensitization to neumoallergens influence in mothers of asthmatic children. Allergol Immunopathol (Madr). 1996 Jan-Feb;24(1):7-12. PMID: 8882754. ***X-2, X-3, X-4***

2068. Sander M, Spies CD, Martiny V, et al.; Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care. 2010;14(4):R148. PMID: 20682059. ***X-2***

2069. Sanders SA, Graham CA, Bass JL, et al.; A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001 Jul;64(1):51-8. PMID: 11535214. ***X-2***

2070. Sandler DP, Burr FR, Weinberg CR; Nonsteroidal anti-inflammatory drugs and the risk for chronic renal

disease. Ann Intern Med. 1991 Aug 1;115(3):165-72. PMID: 2058870. ***X-2***

2071. Sandoval HP, De Castro LE, Vroman DT, et al.; Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. J Ocul Pharmacol Ther. 2006 Aug;22(4):251-7. PMID: 16910866. ***X-2, X-3, X-4***

2072. Sang GW, Shao QX, Ge RS, et al.; A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and sid effects. Contraception. 1995 Mar;51(3):167-83. PMID: 7621685. ***X-4***

2073. Sangem M, Asthana S, Amin S; Multiple courses of indomethacin and neonatal outcomes in premature infants. Pediatr Cardiol. 2008 Sep;29(5):878-84. PMID: 18094917. ***X-2, X-3, X-4***

2074. Sangi-Haghpeykar H, Poindexter AN, 3rd, Bateman L, et al.; Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. 1996 Aug;88(2):227-33. PMID: 8692507. ***X-2***

2075. Sapoznikov B, Vilkin A, Hershkovici M, et al.; Minidose aspirin and gastrointestinal bleeding--a retrospective, case-control study in hospitalized patients. Dig Dis Sci. 2005 Sep;50(9):1621-4. PMID: 16133960. ***X-2, X-4***

2076. Sapp AV, Lindbloom EJ; Do third-generation oral contraceptives (OCs) increase the risk of venous thrombosis? J Fam Pract. 2001 Oct;50(10):893. PMID: 11674894. ***X-1, X-2, X-4***

2077. Saran R, Dykstra DM, Wolfe RA, et al.; Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2002 Dec;40(6):1255-63. PMID: 12460045. ***X-3, X-4***

2078. Sardella A, Uglietti D, Demarosi F, et al.; Benzydamine hydrochloride oral rinses in management of burning mouth syndrome. A clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Dec;88(6):683-6. PMID: 10625850. ***X-2, X-3, X-4***

2079. Sasahara K, Uchida Y, Matsuda K, et al.; Role of energy metabolism in drug-induced acute gastric mucosal injuries in humans. J Gastroenterol Hepatol. 2000 Feb;15(2):127-32. PMID: 10735535. ***X-2, X-3, X-4***

2080. Saubermann LJ, Wolf JL; Mesalamine: safe at first look. Inflamm Bowel Dis. 1999 May;5(2):148-9. PMID: 10338388. ***X-4***

2081. Savabi-Esfahany M, Fadaei S, Yousefy A; Use of combined oral contraceptives: retrospective study in Isfahan, Islamic Republic of Iran. East Mediterr Health J. 2006 May-Jul;12(3-4):417-22. PMID: 17037711. ***X-2***

2082. Savage AH, Anderson BL, Simhan HN; The safety of prolonged indomethacin therapy. Am J Perinatol. 2007 Apr;24(4):207-13. PMID: 17447185. ***X-2, X-4***

2083. Savage KJ, Clarkson PM; Oral contraceptive use and exercise-induced muscle damage and recovery. Contraception. 2002 Jul;66(1):67-71. PMID: 12169383. ***X-2, X-4***

2084. Savage RL, Moller PW, Ballantyne CL, et al.; Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum. 1993 Jan;36(1):84-90. PMID: 8424842. ***X-2***

2085. Sawaya GF, Grady D, Kerlikowske K, et al.; The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). Ann Intern Med. 2000 Dec 19;133(12):942-50. PMID: 11119395. ***X-7***

2086. Sawhney MS, McDougall H, Nelson DB, et al.; Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci. 2010 Jun;55(6):1637-42. PMID: 20195757. ***X-2, X-3, X-4***

2087. Saxena T, Maheshwari S, Goyal RK; Serum insulin assay: an important therapeutic tool in management of freshly diagnosed type 2 diabetes mellitus. J Assoc Physicians India. 2000 Aug;48(8):815-7. PMID: 11273476. ***X-2, X-3, X-4***

2088. Scapa E, Horowitz M, Waron M, et al.; Duodenal ulcer in the elderly. J Clin Gastroenterol. 1989 Oct;11(5):502-6. PMID: 2794428. ***X-2, X-3***

2089. Scarabin PY, Plu-Bureau G, Zitoun D, et al.; Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity. Thromb Haemost. 1995 Sep;74(3):928-32. PMID: 8571323. ***X-2***

2090. Scaricabarozzi I, Chinea B, Scotti A; Imidazole salicylate in the treatment of osteoarthrosis and musculoskeletal trauma: a postmarketing survey. Clin Ther. 1988;10(2):229-36. PMID: 3273866. ***X-2, X-4***

2091. Schachter AD, Arbus GS, Alexander RJ, et al.; Non-steroidal anti-inflammatory drug-associated nephrotoxicity in Bartter syndrome. Pediatr Nephrol. 1998 Nov;12(9):775-7. PMID: 9874326. ***X-2, X-4***

2092. Schad SG, Kraus A, Haubitz I, et al.; Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis. Arthritis Res Ther. 2007;9(1):R10. PMID: 17266758. ***X-2***

2093. Schaefer MG, Plowman BK, Morreale AP, et al.; Interaction of rofecoxib and celecoxib with warfarin. Am J Health Syst Pharm. 2003 Jul 1;60(13):1319-23. PMID: 12901032. ***X-2, X-4***

2094. Schaeverbeke T, Broutet N, Zerbib F, et al.; Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. Am J Gastroenterol. 2005 Dec;100(12):2637-43. PMID: 16393213. ***X-2, X-4***

2095. Schalekamp T, Klungel OH, Souverein PC, et al.; Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med. 2008 Jan 28;168(2):180-5. PMID: 18227365. ***X-4***

2096. Schatz H, Schoppel K, Lehwalder D, et al.; Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions. Exp Clin Endocrinol Diabetes. 2003 Aug;111(5):262-6. PMID: 12951631. ***X-4***

2097. Schechter BA, Trattler W; Efficacy and safety of bromfenac for the treatment of corneal ulcer pain. Adv Ther. 2010 Oct;27(10):756-61. PMID: 20845001. ***X-2, X-4***

2098. Scheiman JM; What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel? Nat Clin Pract Gastroenterol Hepatol. 2005 May;2(5):212-3. PMID: 16265202. ***X-2***

2099. Schernhammer ES, Kang JH, Chan AT, et al.; A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst. 2004 Jan 7;96(1):22-8. PMID: 14709735. ***X-4***

2100. Schiappacasse V, Diaz S, Zepeda A, et al.; Health and growth of infants breastfed by Norplant contraceptive implants users: a six-year follow-up study. Contraception. 2002 Jul;66(1):57-65. PMID: 12169382. ***X-2, X-4***

2101. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al.; Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011 May 24;123(20):2226-35. PMID: 21555710. ***X-4***

2102. Schmid M, Gode U, Schafer D, et al.; Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. Acta Otolaryngol. 1999 Mar;119(2):277-80. PMID: 10320091. ***X-2, X-3, X-4***

2103. Schmidt M, Christiansen CF, Horvath-Puho E, et al.; Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost. 2011 Jul;9(7):1326-33. PMID: 21592304. ***X-4***

2104. Schmidt M, Pedersen L, Maeng M, et al.; Nonsteroidal antiinflammatory drug use and cardiovascular risks after coronary stent implantation. Pharmacotherapy. 2011 May;31(5):458-68. PMID: 21923427. ***X-4***

2105. Schneeweiss S, Glynn RJ, Avorn J, et al.; NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1134-42. PMID: 19844943. ***X-4***

2106. Schneeweiss S, Glynn RJ, Avorn J, et al.; A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005 Jan;58(1):98-102. PMID: 15649677. ***X-3, X-4***

2107. Schneider C, Jick SS, Meier CR; Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009 Oct;12(5):445-53. PMID: 19565370. ***X-4***

2108. Schneider V, Levesque LE, Zhang B, et al.; Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol. 2006 Nov 1;164(9):881-9. PMID: 17005625. ***X-7***

2109. Schnitzer TJ, Kivitz A, Frayssinet H, et al.; Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. Osteoarthritis Cartilage. 2010 May;18(5):629-39. PMID: 20202489. ***X-2, X-4***

2110. Scholes D, LaCroix AZ, Ichikawa LE, et al.; Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002 Sep;13(5):581-7. PMID: 12192229. ***X-2***

2111. Scholes D, LaCroix AZ, Ichikawa LE, et al.; The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception. 2004 Feb;69(2):99-104. PMID: 14759613. ***X-2, X-4***

2112. Schramm G, Heckes B; Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception. 2007 Aug;76(2):84-90. PMID: 17656175. ***X-4***

2113. Schuetz E, Sanchez J, Garcia-Barbal J, et al.; Therapeutic activity, clinical and gastric tolerance of 20mg daily dose of droxicam in comparison with piroxicam in patients with degenerative joint disease. Eur J Rheumatol Inflamm. 1991;11(4):21-8. PMID: 1365486. ***X-2, X-4***

2114. Schultz ST, Klonoff-Cohen HS, Wingard DL, et al.; Acetaminophen (paracetamol) use, measles-mumps-rubella vaccination, and autistic disorder: the results of a parent

survey. Autism. 2008 May;12(3):293-307. PMID: 18445737. ***X-2, X-4***

2115. Schwarz BE, Pierce C, Walden CE, et al.; Reference period analysis of vaginal bleeding with triphasic oral contraceptive agents containing norethindrone or levonorgestrel: a comparison study. Int J Fertil. 1992 May-Jun;37(3):176-82. PMID: 1355765. ***X-2, X-3, X-4***

2116. Schwingl PJ, Shelton J; Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives. Contraception. 1997 Mar;55(3):125-9. PMID: 9114999. ***X-2, X-4***

2117. Scott DL, Berry H, Capell H, et al.; The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology (Oxford). 2000 Oct;39(10):1095-101. PMID: 11035129. ***X-2, X-3, X-4***

2118. Scott KA, Martin JH, Inder WJ; Acidosis in the hospital setting: is metformin a common precipitant? Intern Med J. 2010 May;40(5):342-6. PMID: 19323699. ***X-2***

2119. Scuderi B, Driussi GB, Chizzolini M, et al.; Effectiveness and tolerance of piroxicam 0.5% and diclofenac sodium 0.1% in controlling inflammation after cataract surgery. Eur J Ophthalmol. 2003 Jul;13(6):536-40. PMID: 12948311. ***X-2, X-3, X-4***

2120. Seaman HE, de Vries CS, Farmer RD; The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD. Pharmacoepidemiol Drug Saf. 2003 Oct-Nov;12(7):541-50. PMID: 14558177. ***X-4***

2121. Seaman HE, de Vries CS, Farmer RD; Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):427-36. PMID: 15269926. ***X-4***

2122. Sebaldt RJ, Petrie A, Goldsmith CH, et al.; Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study. Am J Manag Care. 2004 Nov;10(11 Pt 1):742-50. PMID: 15623264. ***X-2, X-3, X-4***

2123. See Y, Ng SC, Tho KS, et al.; Are antacids necessary as routine prescriptives with non-steroidal anti-inflammatory drugs? Ann Acad Med Singapore. 1998 Mar;27(2):219-22. PMID: 9663314. ***X-2, X-4***

2124. Seeger JD, Loughlin J, Eng PM, et al.; Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol. 2007 Sep;110(3):587-93. PMID: 17766604. ***X-4***

2125. Segal R, Lubart E, Leibovitz A, et al.; Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med. 2003 Oct 15;115(6):462-6. PMID: 14563503. ***X-2, X-4***

2126. Segal R, Lubart E, Leibovitz A, et al.; Renal effects of low dose aspirin in elderly patients. Isr Med Assoc J. 2006 Oct;8(10):679-82. PMID: 17125112. ***X-2, X-3, X-4***

2127. Segall-Gutierrez P, Xiang AH, Watanabe RM, et al.; Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use. Contraception. 2012 Jan;85(1):36-41. PMID: 22067800. ***X-2***

2128. Segasothy M, Cheong I, Kong BC, et al.; Further evidence of analgesic nephropathy in Malaysia. Med J Malaysia. 1986 Dec;41(4):377-9. PMID: 3670164. ***X-2***

2129. Segasothy M, Chin GL, Sia KK, et al.; Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. Br J Rheumatol. 1995 Feb;34(2):162-5. PMID: 7704463. ***X-2***

2130. Segasothy M, Samad SA, Zulfigar A, et al.; Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis. 1994 Jul;24(1):17-24. PMID: 8023820. ***X-2***

2131. Segstro R, Morley-Forster PK, Lu G; Indomethacin as a postoperative analgesic for total hip arthroplasty. Can J Anaesth. 1991 Jul;38(5):578-81. PMID: 1934204. ***X-2, X-4***

2132. Seidowsky A, Nseir S, Houdret N, et al.; Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med. 2009 Jul;37(7):2191-6. PMID: 19487945. ***X-2, X-3, X-4***

2133. Sell S, Phillips O, Handel M; No difference between two doses of diclofenac in prophylaxis of heterotopic ossifications after total hip arthroplasty. Acta Orthop Scand. 2004 Feb;75(1):45-9. PMID: 15022805. ***X-2, X-4***

2134. Sen M, Ozol D, Bozer M; Influence of preemptive analgesia on pulmonary function and complications for laparoscopic cholecystectomy. Dig Dis Sci. 2009 Dec;54(12):2742-7. PMID: 19117121. ***X-2, X-3, X-4***

2135. Sener M, Yilmazer C, Yilmaz I, et al.; Patient-controlled analgesia with lornoxicam vs. dipyrone for acute postoperative pain relief after septorhinoplasty: a prospective, randomized, double-blind, placebo-controlled study. Eur J Anaesthesiol. 2008 Mar;25(3):177-82. PMID: 17953792. ***X-2, X-3, X-4***

2136. Senna GE, Passalacqua G, Dama A, et al.; Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol. 2003 Dec;35(10):393-6. PMID: 14768525. ***X-2, X-3, X-4***

2137. Sereepapong W, Chotnopparatpattara P, Taneepanichskul S, et al.; Endometrial progesterone and estrogen receptors and bleeding disturbances in depot medroxyprogesterone acetate users. Hum Reprod. 2004 Mar;19(3):547-52. PMID: 14998949. ***X-2, X-3, X-4***

2138. Serni U; Global safety of etodolac: reports from worldwide postmarketing surveillance studies. Rheumatol Int. 1990;10 Suppl:23-7. PMID: 2150568. ***X-1, X-4***

2139. Serrano P, Lanas A, Arroyo MT, et al.; Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002 Nov;16(11):1945-53. PMID: 12390104. ***X-2, X-4***

2140. Shaaban MM, Salah M; A two-year experience with Norplant implants in Assiut, Egypt. Contraception. 1984 Apr;29(4):335-43. PMID: 6430639. ***X-2, X-3, X-4***

2141. Shaaban MM, Salah M, Zarzour A, et al.; A prospective study of NORPLANT implants and the TCu 380AgIUD in Assiut, Egypt. Stud Fam Plann. 1983 Jun-Jul;14(6-7):163-9. PMID: 6414117. ***X-2, X-4***

2142. Shaaban MM, Zakherah MS, El-Nashar SA, et al.; Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011 Jan;83(1):48-54. PMID: 21134503. ***X-2, X-3, X-4***

2143. Shaamash AH, Sayed GH, Hussien MM, et al.; A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception. 2005 Nov;72(5):346-51. PMID: 16246660. ***X-2, X-4***

2144. Shaamash AH, Zakhari MM; Increased serum levels of nitric oxide metabolites among users of levonorgestrel-releasing implants [corrected] a possible role in progestin-induced bleeding. Hum Reprod. 2005 Jan;20(1):302-6. PMID: 15471931. ***X-2, X-4***

2145. Shaarawy M, El-Mallah SY, Seoudi S, et al.; Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception. 2006 Oct;74(4):297-302. PMID: 16982229. ***X-2***

2146. Shaffer CL, Gal P, Ransom JL, et al.; Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med. 2002 Feb;30(2):343-8. PMID: 11889306. ***X-2, X-4***

2147. Shah DD, Fonarow GC, Horwich TB; Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail. 2010 Mar;16(3):200-6. PMID: 20206893. ***X-2, X-4***

2148. Shah JA, Edwards CM, Probert CS; Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. Eur J Gastroenterol Hepatol. 2008 Mar;20(3):169-73. PMID: 18301295. ***X-2, X-4***

2149. Shah SK, Arthur A, Yang YC, et al.; A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept. J Drugs Dermatol. 2011 Aug;10(8):866-72. PMID: 21818507. ***X-2, X-3, X-4***

2150. Shaheen SO, Newson RB, Henderson AJ, et al.; Prenatal paracetamol exposure and risk of asthma and elevated immunoglobulin E in childhood. Clin Exp Allergy. 2005 Jan;35(1):18-25. PMID: 15649261. ***X-4***

2151. Shainhouse JZ, Grierson LM, Naseer Z; A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee. Am J Ther. 2010 Nov-Dec;17(6):566-76. PMID: 20216203. ***X-2, X-4***

2152. Shamim N, Rehan N, Inayatullah A; Use of Norplant in Pakistan: two years experience. J Pak Med Assoc. 1994 Jan;44(1):3-7. PMID: 8158837. ***X-2, X-3, X-4***

2153. Shankel SW, Johnson DC, Clark PS, et al.; Acute renal failure and glomerulopathy caused by nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1992 May;152(5):986-90. PMID: 1580726. ***X-2***

2154. Shapiro S, Rosenberg L, Hoffman M, et al.; Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol. 2000 Feb 15;151(4):396-403. PMID: 10695598. ***X-4***

2155. Shargil AA; Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int J Fertil. 1985;30(1):15, 8-28. PMID: 2862116. ***X-2, X-3, X-4***

2156. Sharma A, Gupta R, Ram J, et al.; Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol. 1997 Sep;45(3):177-80. PMID: 9475021. ***X-2, X-3, X-4***

2157. Sharma S; Upper gastrointestinal bleeding after hip and knee arthroplasty. Orthopedics. 2006 Mar;29(3):255-7. PMID: 16539204. ***X-2***

2158. Sharma S, Chang DW, Koutz C, et al.; Incidence of hematoma associated with ketorolac after TRAM flap breast reconstruction. Plast Reconstr Surg. 2001 Feb;107(2):352-5. PMID: 11214049. ***X-2, X-4***

2159. Sharma ST, Wickham EP, 3rd, Nestler JE; Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract. 2007 Jul-Aug;13(4):373-9. PMID: 17669713. ***X-2, X-3, X-4***

2160. Sharma VK, Sethuraman G, Kumar B; Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh, India. J Postgrad Med. 2001 Apr-Jun;47(2):95-9. PMID: 11832597. ***X-2***

2161. Sharma VK, Sethuraman G, Minz A; Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol. 2008 May-Jun;74(3):238-40. PMID: 18583791. ***X-2***

2162. Shaw RW, Symonds IM, Tamizian O, et al.; Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia. Aust N Z J Obstet Gynaecol. 2007 Aug;47(4):335-40. PMID: 17627692. ***X-2, X-3***

2163. Shawki O, Peters A, Abraham-Hebert S; Hysteroscopic endometrial destruction, optimum method for preoperative endometrial preparation: a prospective, randomized, multicenter evaluation. JSLS. 2002 Jan-Mar;6(1):23-7. PMID: 12002292. ***X-2, X-4***

2164. Shaya FT, Blume SW, Blanchette CM, et al.; Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med. 2005 Jan 24;165(2):181-6. PMID: 15668364. ***X-4***

2165. Sheffield CA, Kane MP, Busch RS, et al.; Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract. 2008 Apr;14(3):285-92. PMID: 18463034. ***X-2, X-3, X-4***

2166. Shegem NS, Alsheek Nasir AM, Batieha AM, et al.; Effects of short term metformin administration on androgens in diabetic men. Saudi Med J. 2004 Jan;25(1):75-8. PMID: 14758385. ***X-2, X-3, X-4***

2167. Shen B, Fazio VW, Remzi FH, et al.; Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. Dig Dis Sci. 2007 Dec;52(12):3321-8. PMID: 17410449. ***X-2, X-3, X-4***

2168. Sheng J, Zhang WY, Zhang JP, et al.; The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009 Mar;79(3):189-93. PMID: 19185671. ***X-2***

2169. Shepherd WF, Fsadni MG, Raj PS; A clinical evaluation of diclofenac-gentamicin combination eye drops in the control of inflammation after cataract surgery. Diclofenac-Gentamicin versus Gentamicin Study Group. Ocul Immunol Inflamm. 1998 Mar;6(1):13-8. PMID: 9798189. ***X-2, X-3, X-4***

2170. Sherman KJ, Daling JR, McKnight B, et al.; Hormonal factors in vulvar cancer. A case-control study. J Reprod Med. 1994 Nov;39(11):857-61. PMID: 7853273. ***X-2, X-4***

2171. Shi W, Wang YM, Li SL, et al.; Adverse effect of drug-induced emotional problems on work and daily activities. A principal component as an independent predictor of ADRs in Shanghai patients with osteo-arthropathy taking nabumetone. Int J Clin Pharmacol Ther. 2004 Jun;42(6):321-7. PMID: 15222724. ***X-2, X-3, X-4***

2172. Shi W, Wang YM, Li SL, et al.; Risk factors of adverse drug reaction from non-steroidal anti-inflammatory drugs in Shanghai patients with arthropathy. Acta Pharmacol Sin. 2004 Mar;25(3):357-65. PMID: 15000891. ***X-2***

2173. Shibuya T, Ohkusa T, Yokoyama T, et al.; Colonic mucosal lesions associated with long-term or short-term administration of nonsteroidal anti-inflammatory drugs. Colorectal Dis. 2010 Nov;12(11):1113-21. PMID: 19817771. ***X-2, X-4***

2174. Shiffman ML, Farrel MT, Yee YS; Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc. 1994 Jul-Aug;40(4):458-62. PMID: 7926536. ***X-2, X-4***

2175. Shimizu S, Nakamura S, Kishino M, et al.; Role of antithrombotic therapy and nonsteroidal anti-inflammatory drug use in bleeding gastroduodenal ulcers. Intern Med. 2009;48(9):631-7. PMID: 19420807. ***X-2***

2176. Shin D, Kim S, Kim CS, et al.; Postoperative pain management using intravenous patient-controlled analgesia for pediatric patients. J Craniofac Surg. 2001 Mar;12(2):129-33. PMID: 11314621. ***X-2, X-4***

2177. Shin YS, Lee YW, Choi YH, et al.; Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers. Pharmacoepidemiol Drug Saf. 2009 Oct;18(10):910-5. PMID: 19621345. ***X-2, X-4***

2178. Shiraishi M, Kamo T, Hotta M, et al.; Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease. J Neural Transm. 2004 Jun;111(6):725-32. PMID: 15168219. ***X-2***

2179. Shiuey Y, Ambati BK, Adamis AP; A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis. Ophthalmology. 2000 Aug;107(8):1512-7. PMID: 10919900. ***X-2, X-3, X-4***

2180. Shore-Lesserson L, Reich DL, Vela-Cantos F, et al.; Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Anesth Analg. 1996 Jul;83(1):18-26. PMID: 8659732. ***X-2, X-4***

2181. Shorr RI, Ray WA, Daugherty JR, et al.; Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993 Jul 26;153(14):1665-70. PMID: 8333804. ***X-4, X-7***

2182. Shorter NA, Liu JY, Mooney DP, et al.; Indomethacin-associated bowel perforations: a study of possible risk factors. J Pediatr Surg. 1999 Mar;34(3):442-4. PMID: 10211650. ***X-2, X-4***

2183. Shoupe D; Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone. Obstet Gynecol. 1994 May;83(5 Pt 1):679-85. PMID: 8164925. ***X-2, X-4***

2184. Shoupe D, Mishell DR, Jr., Bopp BL, et al.; The significance of bleeding patterns in Norplant implant users. Obstet Gynecol. 1991 Feb;77(2):256-60. PMID: 1899135. ***X-2, X-3, X-4***

2185. Shrivastava D, Rao TK, Sinert R, et al.; The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis. Am J Kidney Dis. 1995 Jun;25(6):904-9. PMID: 7771487. ***X-2, X-3, X-4***

2186. Shrivastava M, Uchit G, Chakravarti A, et al.; Adverse drug reactions reported in Indira Gandhi Government Medical College and Hospital, Nagpur. J Assoc Physicians India. 2011 May;59:296-9. PMID: 21751606. ***X-4***

2187. Shulman LP; The use of triphasic oral contraceptives in a continuous use regimen. Contraception. 2005 Aug;72(2):105-10. PMID: 16022848. ***X-2, X-4***

2188. Sidney S, Petitti DB, Soff GA, et al.; Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004 Jul;70(1):3-10. PMID: 15208046. ***X-2***

2189. Silberstein SD, Armellino JJ, Hoffman HD, et al.; Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled studies. Clin Ther. 1999 Mar;21(3):475-91. PMID: 10321417. ***X-2, X-3, X-4***

2190. Sillars B, Davis WA, Hirsch IB, et al.; Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab. 2010 Sep;12(9):757-65. PMID: 20649627. ***X-2***

2191. Silverberg KM, Vaughn TC, Hansard LJ, et al.; Vaginal (Crinone 8%) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. Fertil Steril. 2012 Feb;97(2):344-8. PMID: 22188983. ***X-2, X-3, X-4***

2192. Silverman HS, Pfeifer MP; Relation between use of anti-inflammatory agents and left ventricular free wall rupture during acute myocardial infarction. Am J Cardiol. 1987 Feb 1;59(4):363-4. PMID: 3812291. ***X-2***

2193. Silverstein FE, Faich G, Goldstein JL, et al.; Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55. PMID: 10979111. ***X-4***

2194. Simenon G, Van Gossum A, Adler M, et al.; Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol. 1990 Nov;17(11):1491-4. PMID: 1980311. ***X-2, X-4***

2195. Simon CH, Dijkmans BA, Breedveld FC; Variations in the monitoring and management of the side effects of antirheumatic drugs by means of laboratory tests. Clin Exp Rheumatol. 1997 Nov-Dec;15(6):633-9. PMID: 9444419. ***X-2, X-3, X-4***

2196. Simon JA, Lin F, Vittinghoff E, et al.; The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS). Ann Epidemiol. 2006 Feb;16(2):138-45. PMID: 16039873. ***X-7***

2197. Simon LS, Weaver AL, Graham DY, et al.; Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999 Nov 24;282(20):1921-8. PMID: 10580457. ***X-2***

2198. Simon LS, Zhao SZ, Arguelles LM, et al.; Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis. Clin Ther. 1998 Nov-Dec;20(6):1218-35; discussion 192-3. PMID: 9916614. ***X-4***

2199. Simunic V, Tomic V, Tomic J, et al.; Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007 Jan;87(1):83-7. PMID: 17081536. ***X-2, X-3, X-4***

2200. Sinclair HK, Bond CM, Hannaford PC; Long term follow-up studies of users of nonprescription medicines purchased from community pharmacies: some methodological issues. Drug Saf. 2001;24(12):929-38. PMID: 11735649. ***X-2, X-4***

2201. Singh G, Fries JF, Williams CA, et al.; Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 1991 Feb;18(2):188-94. PMID: 1673721. ***X-4***

2202. Singh G, Ramey DR, Morfeld D, et al.; Gastrointestinal tract complications of nonsteroidal anti-

inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996 Jul 22;156(14):1530-6. PMID: 8687261. ***X-4***

2203. Singh K, Viegas OA, Fong YF, et al.; Acceptability of Norplant implants for fertility regulation in Singapore. Contraception. 1992 Jan;45(1):39-47. PMID: 1591920. ***X-2, X-4***

2204. Singh K, Viegas OA, Loke DF, et al.; Evaluation of liver function and lipid metabolism following Norplant-2 rods removal. Adv Contracept. 1993 Sep;9(3):233-9. PMID: 8237578. ***X-2, X-4***

2205. Singh K, Viegas OA, Ratnam SS; Norplant contraceptive subdermal implants: one year experience in Singapore. Contraception. 1988 May;37(5):457-69. PMID: 3136971. ***X-2, X-4***

2206. Singh K, Viegas OA, Ratnam SS; A three-year evaluation of hemostatic function in Singaporean Norplant-2 rod acceptors. Adv Contracept. 1990 Jun;6(2):81-9. PMID: 2119546. ***X-2***

2207. Singh R, al-Amari M; Clinical performance of intrauterine device TCu-380 A in Benghazi, Libyan Arab Jamahiriya. East Mediterr Health J. 2000 Sep-Nov;6(5-6):1073-82. PMID: 12197330. ***X-2, X-4***

2208. Siskind V; Confidence intervals for the excess risk in case-control studies. Stat Med. 1996 Jul 30;15(14):1535-44. PMID: 8855479. ***X-1, X-2, X-8***

2209. Sivak-Sears NR, Schwartzbaum JA, Miike R, et al.; Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am J Epidemiol. 2004 Jun 15;159(12):1131-9. PMID: 15191930. ***X-2, X-4***

2210. Sivin I, Diaz S, Pavez M, et al.; Two-year comparative trial of the Gyne T* 380 Slimline and Gyne T* 380 intrauterine copper devices. Contraception. 1991 Nov;44(5):481-7. PMID: 1797463. ***X-4***

2211. Sivin I, Mishell DR, Jr., Darney P, et al.; Levonorgestrel capsule implants in the United States: a 5-year study. Obstet Gynecol. 1998 Sep;92(3):337-44. PMID: 9721766. ***X-2, X-4***

2212. Sivin I, Stern J; Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril. 1994 Jan;61(1):70-7. PMID: 8293847. ***X-2***

2213. Sivin I, Stern J, Coutinho E, et al.; Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991 Nov;44(5):473-80. PMID: 1797462. ***X-2***

2214. Skander MP, Ryan FP; Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly. BMJ. 1988 Oct 1;297(6652):833-4. PMID: 3140938. ***X-2, X-7***

2215. Skjeldestad F, Bratt H; Fertility after complicated and non-complicated use of IUDs. A controlled prospective study. Adv Contracept. 1988 Sep;4(3):179-84. PMID: 3239478. ***X-2, X-3, X-4***

2216. Slattery ML, Curtin K, Ma K, et al.; Diet activity, and lifestyle associations with p53 mutations in colon tumors. Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):541-8. PMID: 12050095. ***X-2, X-3, X-4***

2217. Slattery ML, Schaffer D, Edwards SL, et al.; Are dietary factors involved in DNA methylation associated with colon cancer? Nutr Cancer. 1997;28(1):52-62. PMID: 9200151. ***X-4***

2218. Slatyer MA, Hensley MJ, Lopert R; A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study. Am J Sports Med. 1997 Jul-Aug;25(4):544-53. PMID: 9240990. ***X-2, X-3, X-4***

2219. Smalley W, Stein CM, Arbogast PG, et al.; Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2002 Aug;46(8):2195-200. PMID: 12209525. ***X-3, X-4***

2220. Smalley WE, Ray WA, Daugherty JR, et al.; Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995 Mar 15;141(6):539-45. PMID: 7900721. ***X-4, X-7***

2221. Smedley FH, Taube M, Leach R, et al.; Non-steroidal anti-inflammatory drug ingestion: retrospective study of 272 bleeding or perforated peptic ulcers. Postgrad Med J. 1989 Dec;65(770):892-5. PMID: 2616429. ***X-2***

2222. Smets HL, De Haes JF, De Swaef A, et al.; Exposure of the elderly to potential nephrotoxic drug combinations in Belgium. Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):1014-9. PMID: 18763247. ***X-3, X-4***

2223. Smith I, Wilde A; Secondary tonsillectomy haemorrhage and non-steroidal anti-inflammatory drugs. J Laryngol Otol. 1999 Jan;113(1):28-30. PMID: 10341915. ***X-2***

2224. Smith KJ, Skelton HG, Yeager J, et al.; Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation. Dermatology. 1997;195(4):353-8. PMID: 9529556. ***X-4***

2225. Smith MA, Hampton C, Rodier L, et al.; Informatics. Detecting risks in elderly patients taking NSAIDs. Nurse Pract. 2011 Apr;36(4):51-3. PMID: 21422979. ***X-1***

2226. Smith NL, Wiley JR, Legault C, et al.; Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Menopause. 2008 Nov-Dec;15(6):1145-50. PMID: 19186375. ***X-2, X-7***

2227. Smith TR, Sunshine A, Stark SR, et al.; Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005 Sep;45(8):983-91. PMID: 16109111. ***X-2, X-3, X-4***

2228. Snaith A, Pugh L, Simpson CR, et al.; The potential for interaction between warfarin and coprescribed medication: a retrospective study in primary care. Am J Cardiovasc Drugs. 2008;8(3):207-12. PMID: 18533741. ***X-4***

2229. Snell ES; Regulatory decisions and the pharmaceutical industry. Med Toxicol. 1986;1 Suppl 1:130-6. PMID: 3821429. ***X-1, X-2, X-3, X-4***

2230. Snowden R; General assessment of the Multiload Cu250 intrauterine device. UK network of IUCD research clinics. Br J Obstet Gynaecol. 1982 Sep;89(Suppl 4):58-65. PMID: 7150529. ***X-2, X-3, X-4***

2231. Snyder BK, Clark RF; Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial. Ann Emerg Med. 1999 Apr;33(4):400-5. PMID: 10092717. ***X-2, X-3, X-4***

2232. So LY, Fok TF, Sung RY, et al.; Preterm infants with patent ductus arteriosus: treatment with an enteral preparation of indomethacin. Ann Trop Paediatr. 1992;12(4):403-8. PMID: 1283670. ***X-2, X-3, X-4***

2233. Sobande AA, Al-Bar HM, Archibong EI, et al.; Efficacy and acceptability of depo-medroxyprogesterone acetate injection. As a method of contraception in Saudi Arabia. Saudi Med J. 2000 Apr;21(4):348-51. PMID: 11533816. ***X-2***

2234. Soderstrom RM; Will progesterone save the IUD? J Reprod Med. 1983 May;28(5):305-8. PMID: 6152982. ***X-2***

2235. Soeprono R; Extended use of the Multiload Cu-250. Adv Contracept. 1988 Jun;4(2):109-13. PMID: 3213667. ***X-4***

2236. Soheilian M, Karimi S, Ramezani A, et al.; Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina. 2010 Mar;30(3):509-15. PMID: 19952986. ***X-2, X-4***

2237. Sohn SH, Penzias AS, Emmi AM, et al.; Administration of progesterone before oocyte retrieval negatively affects the implantation rate. Fertil Steril. 1999 Jan;71(1):11-4. PMID: 9935109. ***X-2, X-3, X-4***

2238. Sokic-Milutinovic A, Krstic M, Rozer-Smolovic B, et al.; Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study. Dig Dis Sci. 2010 Oct;55(10):2887-92. PMID: 20094785. ***X-2***

2239. Solak O, Metin M, Esme H, et al.; Effectiveness of gabapentin in the treatment of chronic post-thoracotomy pain. Eur J Cardiothorac Surg. 2007 Jul;32(1):9-12. PMID: 17442584. ***X-2, X-4***

2240. Solomon DH, Avorn J, Sturmer T, et al.; Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May;54(5):1378-89. PMID: 16645966. ***X-7***

2241. Solomon DH, Cadarette SM, Choudhry NK, et al.; A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab. 2009 Aug;94(8):2792-8. PMID: 19470635. ***X-7***

2242. Solomon DH, Glynn RJ, Bohn R, et al.; The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol. 2003 Apr;30(4):792-8. PMID: 12672201. ***X-4, X-7***

2243. Solomon DH, Glynn RJ, Rothman KJ, et al.; Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008 Aug 15;59(8):1097-104. PMID: 18668605. ***X-4***

2244. Solomon DH, Rassen JA, Glynn RJ, et al.; The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010 Dec 13;170(22):1979-86. PMID: 21149754. ***X-4***

2245. Solomon DH, Schneeweiss S, Glynn RJ, et al.; Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004 May 4;109(17):2068-73. PMID: 15096449. ***X-7***

2246. Solomon DH, Schneeweiss S, Glynn RJ, et al.; Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003 Dec 15;115(9):715-20. PMID: 14693324. ***X-7***

2247. Solomon KD, Turkalj JW, Whiteside SB, et al.; Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Arch Ophthalmol. 1997 Sep;115(9):1119-22. PMID: 9298051. ***X-2, X-3, X-4***

2248. Somigliana E, Vercellini P, Vigano P, et al.; Endometriosis and estroprogestins: the chicken or the egg causality dilemma. Fertil Steril. 2011 Jan;95(1):431-3. PMID: 20883987. ***X-2***

2249. Sonmezer M, Atabekoglu C, Cengiz B, et al.; Depot-medroxyprogesterone acetate in anticoagulated patients with previous hemorrhagic corpus luteum. Eur J

Contracept Reprod Health Care. 2005 Mar;10(1):9-14. PMID: 16036292. ***X-2***

2250. Sood A, Midha V, Sood N, et al.; Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003 May-Jun;22(3):79-81. PMID: 12839376. ***X-2, X-4***

2251. Sood BG, Lulic-Botica M, Holzhausen KA, et al.; The risk of necrotizing enterocolitis after indomethacin tocolysis. Pediatrics. 2011 Jul;128(1):e54-62. PMID: 21690109. ***X-2, X-4***

2252. Sopena F, Lanas A, Sainz R; Esophageal motility and intraesophageal pH patterns in patients with esophagitis and chronic nonsteroidal anti-inflammatory drug use. J Clin Gastroenterol. 1998 Dec;27(4):316-20. PMID: 9855260. ***X-2***

2253. Soraisham AS, Dalgleish S, Singhal N; Antenatal indomethacin tocolysis is associated with an increased need for surgical ligation of patent ductus arteriosus in preterm infants. J Obstet Gynaecol Can. 2010 May;32(5):435-42. PMID: 20500951. ***X-2, X-4***

2254. Soraisham AS, Sauve R, Singhal N; Indomethacin tocolysis and neurodevelopmental outcome. Indian J Pediatr. 2011 Aug;78(8):946-52. PMID: 21318396. ***X-2, X-4***

2255. Soranna L, Cucinelli F, Perri C, et al.; Individual effect of E2 and dydrogesterone on insulin sensitivity in post-menopausal women. J Endocrinol Invest. 2002 Jun;25(6):547-50. PMID: 12109627. ***X-2, X-4***

2256. Sorensen HT, Jacobsen J, Norgaard M, et al.; Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther. 2006 Jul 1;24(1):111-6. PMID: 16803609. ***X-4***

2257. Sorensen HT, Mellemkjaer L, Blot WJ, et al.; Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000 Sep;95(9):2218-24. PMID: 11007221. ***X-2, X-4***

2258. Souter D, Harding J, McCowan L, et al.; Antenatal indomethacin--adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol. 1998 Feb;38(1):11-6. PMID: 9521382. ***X-2, X-4***

2259. Souyri C, Olivier P, Grolleau S, et al.; Severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs. Clin Exp Dermatol. 2008 May;33(3):249-55. PMID: 18261144. ***X-2***

2260. Souza AI, Batista Filho M, Bresani CC, et al.; Adherence and side effects of three ferrous sulfate treatment regimens on anemic pregnant women in clinical trials. Cad Saude Publica. 2009 Jun;25(6):1225-33. PMID: 19503953. ***X-2, X-4***

2261. Sowers JR, White WB, Pitt B, et al.; The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005 Jan 24;165(2):161-8. PMID: 15668361. ***X-2, X-4***

2262. Soylu A, Dolapcioglu C, Dolay K, et al.; Endoscopic and histopathological evaluation of acute gastric injury in high-dose acetaminophen and nonsteroidal anti-inflammatory drug ingestion with suicidal intent. World J Gastroenterol. 2008 Nov 21;14(43):6704-10. PMID: 19034975. ***X-2***

2263. Soysal M, Soysal S, Ozer S; A randomized controlled trial of levonorgestrel releasing IUD and thermal balloon ablation in the treatment of menorrhagia. Zentralbl Gynakol. 2002 Apr;124(4):213-9. PMID: 12080483. ***X-2***

2264. Soysal ME, Soysal S, Gurses E, et al.; Laparoscopic presacral neurolysis for endometriosis-related pelvic pain. Hum Reprod. 2003 Mar;18(3):588-92. PMID: 12615830. ***X-2, X-3, X-4***

2265. Speirs CJ, Dollery CT, Inman WH, et al.; Postmarketing surveillance of enalapril. II: Investigation of the potential role of enalapril in deaths with renal failure. BMJ. 1988 Oct 1;297(6652):830-2. PMID: 2846102. ***X-2, X-4***

2266. Spektor S, Agus S, Merkin V, et al.; Low-dose aspirin prophylaxis and risk of intracranial hemorrhage in patients older than 60 years of age with mild or moderate head injury: a prospective study. J Neurosurg. 2003 Oct;99(4):661-5. PMID: 14567600. ***X-2, X-4***

2267. Spellacy WN, Birk SA, Buggie J, et al.; Prospective carbohydrate metabolism studies in women using a low-estrogen oral contraceptive for one year. J Reprod Med. 1981 Jun;26(6):295-8. PMID: 7019435. ***X-2, X-3, X-4***

2268. Spellacy WN, Tsibris AM, Tsibris JC, et al.; Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethinyl estradiol. Contraception. 1994 Feb;49(2):125-30. PMID: 8143452. ***X-2, X-4***

2269. Spiller HA, Weber JA, Winter ML, et al.; Multicenter case series of pediatric metformin ingestion. Ann Pharmacother. 2000 Dec;34(12):1385-8. PMID: 11144693. ***X-2, X-4***

2270. Spitzer WO, Lewis MA, Heinemann LA, et al.; Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996 Jan 13;312(7023):83-8. PMID: 8555935. ***X-4***

2271. Sporrong T, Rybo G, Mattsson LA, et al.; An objective and subjective assessment of uterine blood loss in postmenopausal women on hormone replacement therapy.

Br J Obstet Gynaecol. 1992 May;99(5):399-401. PMID: 1535788. ***X-2, X-3, X-4***

2272. Srinivasan S, Rao G; Does using nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy increase the risk of adverse events? J Fam Pract. 2001 May;50(5):467. PMID: 11350713. ***X-1***

2273. Srinivasjois RM, Nathan EA, Doherty DA, et al.; Renal impairment associated with indomethacin treatment for patent ductus arteriosus in extremely preterm neonates--is postnatal age at start of treatment important? J Matern Fetal Neonatal Med. 2006 Dec;19(12):793-9. PMID: 17190690. ***X-2, X-3, X-4***

2274. Srisupandit S; A three-year study of the copper-7 minigravigard intrauterine contraceptive device in nulliparous women. J Med Assoc Thai. 1988 Jun;71(6):294-7. PMID: 3171448. ***X-4***

2275. St Germaine CG, Bogaty P, Boyer L, et al.; Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. Am J Cardiol. 2010 Jun 15;105(12):1740-5. PMID: 20538124. ***X-2***

2276. St Sauver JL, Lieber MM, Slager SL, et al.; Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement. BJU Int. 2011 Nov;108(10):1610-5. PMID: 21481131. ***X-2, X-3, X-4***

2277. Staab D, Kaufmann R, Brautigam M, et al.; Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol. 2005 Sep;16(6):527-33. PMID: 16176401. ***X-2, X-3, X-4***

2278. Stack WA, Atherton JC, Hawkey GM, et al.; Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther. 2002 Mar;16(3):497-506. PMID: 11876703. ***X-2, X-4***

2279. Stalman A, Tsai JA, Segerdahl M, et al.; Ketorolac but not morphine exerts inflammatory and metabolic effects in synovial membrane after knee arthroscopy: a double-blind randomized prospective study using the microdialysis technique. Reg Anesth Pain Med. 2009 Nov-Dec;34(6):557-64. PMID: 19916211. ***X-2, X-4***

2280. Stanback J, Qureshi ZP, Sekkade-Kigondu C; Advance provision of oral contraceptives to family planning clients in Kenya. East Afr Med J. 2002 May;79(5):257-8. PMID: 12638810. ***X-2, X-3, X-4***

2281. Steen KS, Lems WF, Aertsen J, et al.; Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis. Ann Rheum Dis. 2001 May;60(5):443-7. PMID: 11302864. ***X-2, X-4***

2282. Steen KS, Nurmohamed MT, Visman I, et al.; Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Feb;67(2):256-9. PMID: 17604285. ***X-4***

2283. Stein CM, Griffin MR, Taylor JA, et al.; Educational program for nursing home physicians and staff to reduce use of non-steroidal anti-inflammatory drugs among nursing home residents: a randomized controlled trial. Med Care. 2001 May;39(5):436-45. PMID: 11317092. ***X-2, X-3, X-4***

2284. Stephanie R, Labied S, Blacher S, et al.; Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time. Hum Reprod. 2007 Dec;22(12):3084-91. PMID: 17921480. ***X-2***

2285. Stevens-Simon C, Kelly L, Wallis J; The timing of norplant insertion and postpartum depression in teenagers. J Adolesc Health. 2000 Jun;26(6):408-13. PMID: 10822182. ***X-2, X-4***

2286. Stewart I, Thomas A; Mefenamic acid compared with diclofenac sodium in elderly patients with osteoarthritis. Br J Clin Pract. 1988 Aug;42(8):316-20. PMID: 3061435. ***X-7***

2287. Stiasny-Kolster K, Benes H, Peglau I, et al.; Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology. 2004 Dec 28;63(12):2272-9. PMID: 15623686. ***X-2***

2288. Stika CS, Gross GA, Leguizamon G, et al.; A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am J Obstet Gynecol. 2002 Sep;187(3):653-60. PMID: 12237643. ***X-2, X-4***

2289. Stolk P, Souverein PC, Leufkens HG, et al.; The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study. Pharmacopsychiatry. 2007 May;40(3):111-5. PMID: 17541886. ***X-4***

2290. Stolte M, Karimi D, Vieth M, et al.; Strictures, diaphragms, erosions or ulcerations of ischemic type in the colon should always prompt consideration of nonsteroidal anti-inflammatory drug-induced lesions. World J Gastroenterol. 2005 Oct 7;11(37):5828-33. PMID: 16270393. ***X-2, X-3, X-4***

2291. Strate LL, Liu YL, Huang ES, et al.; Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology. 2011 May;140(5):1427-33. PMID: 21320500. ***X-4***

2292. Stray N, Weberg R; A prospective study of same day bi-directional endoscopy in the evaluation of patients with occult gastrointestinal bleeding. Scand J Gastroenterol. 2006 Jul;41(7):844-50. PMID: 16785199. ***X-2, X-3, X-4***

2293. Stroehmann I; A rheumatologist's viewpoint. Eur J Rheumatol Inflamm. 1991;11(3):7-11. PMID: 1365482. ***X-1***

2294. Strom BL, Berlin JA, Kinman JL, et al.; Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996 Feb 7;275(5):376-82. PMID: 8569017. ***X-4***

2295. Strom BL, Carson JL, Schinnar R, et al.; The effect of indication on the risk of hypersensitivity reactions associated with tolmetin sodium vs other nonsteroidal antiinflammatory drugs. J Rheumatol. 1988 Apr;15(4):695-9. PMID: 3397980. ***X-11***

2296. Strom BL, Carson JL, Schinnar R, et al.; Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med. 1993 Sep 27;153(18):2119-24. PMID: 8379803. ***X-4***

2297. Strom BL, Schinnar R, Bilker WB, et al.; Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen. Arch Intern Med. 1997 Dec 8-22;157(22):2626-31. PMID: 9531232. ***X-4***

2298. Sturdee DW, Ulrich LG, Barlow DH, et al.; The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG. 2000 Nov;107(11):1392-400. PMID: 11117768. ***X-7***

2299. Sturgeon SR, Brinton LA, Berman ML, et al.; Intrauterine device use and endometrial cancer risk. Int J Epidemiol. 1997 Jun;26(3):496-500. PMID: 9222773. ***X-2, X-4***

2300. Sturkenboom M, Nicolosi A, Cantarutti L, et al.; Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics. Pediatrics. 2005 Jul;116(1):e26-33. PMID: 15930187. ***X-4***

2301. Sturkenboom MC, Burke TA, Dieleman JP, et al.; Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii23-31. PMID: 14585915. ***X-2, X-3, X-4***

2302. Sturkenboom MC, Burke TA, Tangelder MJ, et al.; Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1137-47. PMID: 14653834. ***X-2, X-3, X-4***

2303. Sturkenboom MC, Romano F, Simon G, et al.; The iatrogenic costs of NSAID therapy: a population study. Arthritis Rheum. 2002 Apr 15;47(2):132-40. PMID: 11954006. ***X-4***

2304. Su BH, Lin HC, Chiu HY, et al.; Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008 Mar;93(2):F94-9. PMID: 17768157. ***X-2, X-3, X-4***

2305. Suarez RD, Grobman WA, Parilla BV; Indomethacin tocolysis and intraventricular hemorrhage. Obstet Gynecol. 2001 Jun;97(6):921-5. PMID: 11384697. ***X-2, X-4***

2306. Sucato DJ, Lovejoy JF, Agrawal S, et al.; Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2008 May 1;33(10):1119-24. PMID: 18449047. ***X-2, X-4***

2307. Sucato GS, Land SR, Murray PJ, et al.; Adolescents' experiences using the contraceptive patch versus pills. J Pediatr Adolesc Gynecol. 2011 Aug;24(4):197-203. PMID: 21454110. ***X-2, X-3***

2308. Sudano I, Flammer AJ, Periat D, et al.; Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010 Nov 2;122(18):1789-96. PMID: 20956208. ***X-2, X-3, X-4***

2309. Sugiyama T, Nishikawa K, Komatsu Y, et al.; Attributable risk of H. pylori in peptic ulcer disease: does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers? Dig Dis Sci. 2001 Feb;46(2):307-10. PMID: 11281179. ***X-2, X-3, X-4***

2310. Suh DC, Hunsche E, Shin HC, et al.; Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK. Rheumatology (Oxford). 2008 Apr;47(4):458-63. PMID: 18263598. ***X-2, X-3, X-4***

2311. Suissa S; Statistical methods in pharmacoepidemiology. Principles in managing error. Drug Saf. 1991 Sep-Oct;6(5):381-9. PMID: 1930744. ***X-1***

2312. Suissa S, Ernst P, Hudson M, et al.; Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med. 2004 Jul 15;117(2):87-92. PMID: 15234643. ***X-4***

2313. Suissa S, Spitzer WO, Rainville B, et al.; Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod. 2000 Apr;15(4):817-21. PMID: 10739826. ***X-4***

2314. Sukel MP, van der Linden MW, Chen C, et al.; Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):9-19. PMID: 17963198. ***X-4***

2315. Suleiman UL, Harrison M, Britton A, et al.; H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. Eur J

Cancer Prev. 2000 Jun;9(3):185-91. PMID: 10954258. ***X-2, X-4***

2316. Suman VJ, Van Winter JT, Evans MP, et al.; Levonorgestrel contraceptive implants in female patients 14 to 21 years old. Mayo Clin Proc. 1998 Jan;73(1):10-6. PMID: 9443673. ***X-2, X-3, X-4***

2317. Suri V, Aggarwal N, Kaur R, et al.; Safety of intrauterine contraceptive device (copper T 200 B) in women with cardiac disease. Contraception. 2008 Oct;78(4):315-8. PMID: 18847580. ***X-2, X-4***

2318. Suwanmalee O, Taneepanichskul S; A clinical study of transdermal contraceptive patch in Thai women. J Med Assoc Thai. 2006 Oct;89 Suppl 4:S1-4. PMID: 17726805. ***X-2, X-4***

2319. Svanes C, Soreide JA, Skarstein A, et al.; Smoking and ulcer perforation. Gut. 1997 Aug;41(2):177-80. PMID: 9301495. ***X-2, X-4***

2320. Sweet BV, Townsend KA, Tsai CY; Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients. Am J Health Syst Pharm. 2004 Sep 15;61(18):1917-21. PMID: 15487881. ***X-2, X-4***

2321. Sweileh WM; Potential adverse effects of a low-dose aspirin-diuretic combination on kidney function. Int J Clin Pharmacol Ther. 2007 Nov;45(11):601-5. PMID: 18077925. ***X-2, X-4***

2322. Swigris JJ, Olson AL, Fischer A, et al.; Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006 Jul;130(1):30-6. PMID: 16840379. ***X-2, X-4***

2323. Swislocki AL, Khuu Q, Liao E, et al.; Safety and efficacy of metformin in a restricted formulary. Am J Manag Care. 1999 Jan;5(1):62-8. PMID: 10345968. ***X-2, X-4***

2324. Sy FS, Osteria TS, Opiniano V, et al.; Effect of oral contraceptive on liver function tests of women with schistosomiasis in the Philippines. Contraception. 1986 Sep;34(3):283-94. PMID: 3098499. ***X-2, X-4***

2325. Szczeklik A, Nizankowska E, Duplaga M; Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000 Sep;16(3):432-6. PMID: 11028656. ***X-2, X-4***

2326. Szer IS, Goldenstein-Schainberg C, Kurtin PS; Paucity of renal complications associated with nonsteroidal antiinflammatory drugs in children with chronic arthritis. J Pediatr. 1991 Nov;119(5):815-7. PMID: 1941392. ***X-2***

2327. Tadesse E; Return of fertility after an IUD removal for planned pregnancy: a six year prospective study. East Afr Med J. 1996 Mar;73(3):169-71. PMID: 8698014. ***X-2, X-4***

2328. Tadesse E, van Brandenburg WJ, Exalto N; Intrauterine devices: results of a separate clinical and ultrasound follow-up study. Eur J Obstet Gynecol Reprod Biol. 1985 May;19(5):289-95. PMID: 3894102. ***X-2, X-4***

2329. Taha AS, Angerson WJ, Prasad R, et al.; Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther. 2007 Oct 15;26(8):1171-8. PMID: 17894659. ***X-4***

2330. Taheri M, Rahimi M, Naderi M, et al.; Effects of a subdermal levonorgestrel contraceptive implant (Norplant) on serum cholesterol, triglycerides, ALT and AST in Iranian women. Contraception. 2006 Jan;73(1):56-8. PMID: 16371296. ***X-2, X-3, X-4***

2331. Takami T, Yoda H, Kawakami T, et al.; Usefulness of indomethacin for patent ductus arteriosus in full-term infants. Pediatr Cardiol. 2007 Jan-Feb;28(1):46-50. PMID: 17203336. ***X-2, X-3, X-4***

2332. Tal S, Shavit Y, Stern F, et al.; Association between vitamin B12 levels and mortality in hospitalized older adults. J Am Geriatr Soc. 2010 Mar;58(3):523-6. PMID: 20158555. ***X-2, X-4***

2333. Talamini G, Tommasi M, Amadei V, et al.; Risk factors of peptic ulcer in 4943 inpatients. J Clin Gastroenterol. 2008 Apr;42(4):373-80. PMID: 18277902. ***X-4***

2334. Talamini G, Zamboni G, Cavallini G; Antral mucosal Helicobacter pylori infection density as a risk factor of duodenal ulcer. Digestion. 1997;58(3):211-7. PMID: 9243115. ***X-2, X-4***

2335. Tam WH, Yuen PM, Shan Ng DP, et al.; Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized study. Gynecol Obstet Invest. 2006;62(2):84-8. PMID: 16612101. ***X-2, X-4***

2336. Tamai H, Katoh K, Yamaguchi T, et al.; The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am Heart J. 2002 Mar;143(3):506-13. PMID: 11868058. ***X-2, X-3, X-4***

2337. Tamblyn RM, McLeod PJ, Abrahamowicz M, et al.; Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. CMAJ. 1996 Apr 15;154(8):1177-84. PMID: 8612253. ***X-3, X-4***

2338. Tammemagi CM, Freedman MT, Church TR, et al.; Factors associated with human small aggressive non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2082-9. PMID: 17932357. ***X-2, X-3, X-4***

2339. Tan T, Cabrita IZ, Hensman D, et al.; Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf). 2010 Sep;73(3):369-74. PMID: 20550538. ***X-2***

2340. Taneepanichskul S, Intaraprasert S, Phuapradit W, et al.; Use of Norplant implants in asymptomatic HIV-1 infected women. Contraception. 1997 Apr;55(4):205-7. PMID: 9179451. ***X-2, X-4***

2341. Taneepanichskul S, Intaraprasert S, Theppisai U, et al.; Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception. 1997 Jul;56(1):1-3. PMID: 9306024. ***X-2, X-4***

2342. Taneepanichskul S, Intharasakda P; Efficacy and side effects of Norplant use in Thai women above the age of 35 years. Contraception. 2001 Nov;64(5):305-7. PMID: 11777491. ***X-2, X-4***

2343. Taneepanichskul S, Tanprasertkul C; Use of Norplant implants in the immediate postpartum period among asymptomatic HIV-1-positive mothers. Contraception. 2001 Jul;64(1):39-41. PMID: 11535212. ***X-2, X-4***

2344. Tang OS, Tang G, Yip PS, et al.; Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception. 2000 Oct;62(4):161-4. PMID: 11137068. ***X-2, X-4***

2345. Tang T, Glanville J, Hayden CJ, et al.; Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human Reproduction. 2006;21(1):80-9. PMID: 16199429. ***X-2, X-3, X-4***

2346. Tangkiatkumjai M, Vadcharavivad S, Mahachai V; Prediction of UGIB event in NSAID users: a model development. J Med Assoc Thai. 2005 May;88(5):672-7. PMID: 16149687. ***X-2, X-3, X-4***

2347. Tanis BC, van den Bosch MA, Kemmeren JM, et al.; Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001 Dec 20;345(25):1787-93. PMID: 11752354. ***X-2***

2348. Tao MH, Xu WH, Zheng W, et al.; Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. Int J Cancer. 2006 Nov 1;119(9):2142-7. PMID: 16823853. ***X-4***

2349. Targownik LE, Al-Mamfud A; The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease. Aliment Pharmacol Ther. 2006 Mar 15;23(6):743-9. PMID: 16556176. ***X-2, X-4***

2350. Targownik LE, Metge CJ, Leung S, et al.; The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008 Apr;134(4):937-44. PMID: 18294634. ***X-4***

2351. Tarone RE, Blot WJ, McLaughlin JK; Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther. 2004 Jan-Feb;11(1):17-25. PMID: 14704592. ***X-1***

2352. Tartagni M, Schonauer LM, De Salvia MA, et al.; Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril. 2000 Apr;73(4):718-23. PMID: 10731531. ***X-2, X-3, X-4***

2353. Tata LJ, Fortun PJ, Hubbard RB, et al.; Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther. 2005 Aug 1;22(3):175-81. PMID: 16091054. ***X-4***

2354. Tavani A, Scotti L, Bosetti C, et al.; Aspirin and risk of renal cell cancer in Italy. Eur J Cancer Prev. 2010 Jul;19(4):272-4. PMID: 20351553. ***X-2, X-4***

2355. Tay HL, Evans JM, McMahon AD, et al.; Aspirin, nonsteroidal anti-inflammatory drugs, and epistaxis. A regional record linkage case control study. Ann Otol Rhinol Laryngol. 1998 Aug;107(8):671-4. PMID: 9716869. ***X-4***

2356. Techapornroong M, Akrawinthawong K, Cheungpasitporn W, et al.; Anaphylaxis: a ten years inpatient retrospective study. Asian Pac J Allergy Immunol. 2010 Dec;28(4):262-9. PMID: 21337910. ***X-4***

2357. Teeling M, O'Connor H, Feely J, et al.; What therapies have replaced rofecoxib in Ireland? Br J Clin Pharmacol. 2007 Oct;64(4):536-41. PMID: 17555468. ***X-4***

2358. Teichmann A, Apter D, Emerich J, et al.; Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception. 2009 Dec;80(6):504-11. PMID: 19913143. ***X-2, X-4***

2359. Terra SG, Somayaji V, Schwartz S, et al.; A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*. Exp Clin Endocrinol Diabetes. 2011 Jul;119(7):401-7. PMID: 21472661. ***X-2, X-3, X-4***

2360. Tewari S, Kaushish R, Sharma S, et al.; Role of low dose aspirin in prevention of pregnancy induced hypertension. J Indian Med Assoc. 1997 Feb;95(2):43-4, 7. PMID: 9357241. ***X-2, X-4***

2361. Tharavanij T, Betancourt A, Messinger S, et al.; Improved long-term health-related quality of life after islet transplantation. Transplantation. 2008 Nov 15;86(9):1161-7. PMID: 19005394. ***X-2, X-3, X-4***

2362. Thiefin G, Schwalm MS; Underutilization of gastroprotective drugs in patients receiving non-steroidal anti-inflammatory drugs. Dig Liver Dis. 2011 Mar;43(3):209-14. PMID: 21051300. ***X-4***

2363. Thillainayagam AV, Tabaqchali S, Warrington SJ, et al.; Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers. Dig Dis Sci. 1994 May;39(5):1085-9. PMID: 8174421. ***X-2, X-4***

2364. Thomas DB, Ray RM; Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception. 1995 Nov;52(5):307-12. PMID: 8585888. ***X-8***

2365. Thomas DB, Ye Z, Ray RM; Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception. 1995 Jan;51(1):25-31. PMID: 7750280. ***X-8***

2366. Thome-Kromer B, Bonk I, Klatt M, et al.; Toward the identification of liver toxicity markers: a proteome study in human cell culture and rats. Proteomics. 2003 Oct;3(10):1835-62. PMID: 14625847. ***X-2, X-3, X-4***

2367. Thompson MR; Indomethacin and perforated duodenal ulcer. Br Med J. 1980 Feb 16;280(6212):448. PMID: 7370529. ***X-2***

2368. Thomsen RW, Riis A, Christensen S, et al.; Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Aliment Pharmacol Ther. 2006 Nov 15;24(10):1431-8. PMID: 17032286. ***X-4***

2369. Thomsen SF, Kyvik KO, Skadhauge LR, et al.; Regular use of non-steroidal anti-inflammatory drugs increases the risk of adult-onset asthma: a population-based follow-up study. Clin Respir J. 2009 Apr;3(2):82-4. PMID: 20298382. ***X-4***

2370. Thomson WM, Spencer AJ, Slade GD, et al.; Is medication a risk factor for dental caries among older people? Community Dent Oral Epidemiol. 2002 Jun;30(3):224-32. PMID: 12000346. ***X-2, X-4***

2371. Thong-Ngam D, Chayanupatkul M, Klaikeaw N, et al.; Effect of rebamipide on gastric ulcer healing caused by Helicobacter pylori and/or NSAIDs or non NSAIDs-non H. pylori. J Med Assoc Thai. 2009 Sep;92(9):1207-12. PMID: 19772181. ***X-2, X-3, X-4***

2372. Thorogood M, Hannaford PC; The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol. 1998 Dec;105(12):1296-9. PMID: 9883921. ***X-4***

2373. Thrift AG, McNeil JJ, Forbes A, et al.; Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study. BMJ. 1999 Mar 20;318(7186):759-64. PMID: 10082697. ***X-2, X-4***

2374. Tibble JA, Sigthorsson G, Foster R, et al.; Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002 Aug;123(2):450-60. PMID: 12145798. ***X-2, X-3, X-4***

2375. Tilakaratne A, Soory M, Ranasinghe AW, et al.; Effects of hormonal contraceptives on the periodontium, in a population of rural Sri-Lankan women. J Clin Periodontol. 2000 Oct;27(10):753-7. PMID: 11034123. ***X-2***

2376. Tildesley G, Ehsanullah RS, Wood JR; Ranitidine in the treatment of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drugs. Br J Rheumatol. 1993 Jun;32(6):474-8. PMID: 8508283. ***X-2, X-3, X-4***

2377. Tilleul P, Weickmans H, Sean PT, et al.; Cost analysis applied to postoperative analgesia regimens: a comparison between parecoxib and propacetamol. Pharm World Sci. 2007 Aug;29(4):374-9. PMID: 17310303. ***X-2, X-3, X-4***

2378. Tilyard MW, Dovey SM; A comparison of tiaprofenic acid, mefenamic acid and placebo in the treatment of dysmenorrhoea in general practice. Aust N Z J Obstet Gynaecol. 1992 May;32(2):165-8. PMID: 1520205. ***X-2, X-4***

2379. Ting RZ, Szeto CC, Chan MH, et al.; Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med. 2006 Oct 9;166(18):1975-9. PMID: 17030830. ***X-2***

2380. Titchen T, Cranswick N, Beggs S; Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital. Br J Clin Pharmacol. 2005 Jun;59(6):718-23. PMID: 15948937. ***X-3***

2381. Todd J, Lawrenson R, Farmer RD, et al.; Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database. Hum Reprod. 1999 Jun;14(6):1500-5. PMID: 10357966. ***X-4***

2382. Toh S, Garcia Rodriguez LA, Hernan MA; Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to

electronic medical records. Pharmacoepidemiol Drug Saf. 2011 Aug;20(8):849-57. PMID: 21717528. ***X-4***

2383. Toker MI, Erdem H, Erdogan H, et al.; The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial. Am J Ophthalmol. 2006 May;141(5):902-5. PMID: 16527227. ***X-2, X-3, X-4***

2384. Toljamo KT, Niemela SE, Karttunen TJ, et al.; The role of Herpes simplex and Helicobacter pylori infection in the etiology of persistent or recurrent gastric erosions: a follow-up study. Dig Dis Sci. 2002 Apr;47(4):818-22. PMID: 11991616. ***X-2, X-3, X-4***

2385. Tornhamre S, Ehnhage A, Kolbeck KG, et al.; Uncoupled regulation of leukotriene C4 synthase in platelets from aspirin-intolerant asthmatics and healthy volunteers after aspirin treatment. Clin Exp Allergy. 2002 Nov;32(11):1566-73. PMID: 12569976. ***X-4***

2386. Torres DM, Jones FJ, Shaw JC, et al.; Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology. 2011 Nov;54(5):1631-9. PMID: 21748770. ***X-2, X-3, X-4***

2387. Torres-Galvan MJ, Ortega N, Sanchez-Garcia F, et al.; LTC4-synthase A-444C polymorphism: lack of association with NSAID-induced isolated periorbital angioedema in a Spanish population. Ann Allergy Asthma Immunol. 2001 Dec;87(6):506-10. PMID: 11770699. ***X-2, X-3, X-4***

2388. Tramer MR, Moore RA, Reynolds DJ, et al.; Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000 Mar;85(1-2):169-82. PMID: 10692616. ***X-1, X-2, X-4***

2389. Trattler W, McDonald M; Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation. Cornea. 2007 Jul;26(6):665-9. PMID: 17592313. ***X-2, X-3, X-4***

2390. Traversa G, Bianchi C, Da Cas R, et al.; Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003 Jul 5;327(7405):18-22. PMID: 12842950. ***X-4***

2391. Traversa G, Walker AM, Ippolito FM, et al.; Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. Epidemiology. 1995 Jan;6(1):49-54. PMID: 7888445. ***X-4***

2392. Tremaine WJ, Schroeder KW, Harrison JM, et al.; A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol. 1994 Dec;19(4):278-82. PMID: 7876505. ***X-2, X-3, X-4***

2393. Tremollieres FA, Pouilles JM, Ribot C; Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int. 2001;12(5):385-90. PMID: 11444087. ***X-2, X-3, X-4***

2394. Trenkwalder C, Hogl B, Benes H, et al.; Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med. 2008 Jul;9(5):572-4. PMID: 17921065. ***X-2***

2395. Trewin VF, Lawrence CJ, Rae SA, et al.; Development and use of a gastropathy index for ranking the safety of non-steroidal anti-inflammatory drugs in the elderly. J Clin Pharm Ther. 1994 Jun;19(3):209-14. PMID: 7962226. ***X-4, X-7***

2396. Trinavarat A, Atchaneeyasakul LO, Surachatkumtonekul T, et al.; Comparison of topical prednisolone acetate, ketorolac tromethamine and fluorometholone acetate in reducing inflammation after phacoemulsification. J Med Assoc Thai. 2003 Feb;86(2):143-50. PMID: 12678152. ***X-2, X-4***

2397. Trinh XB, Tjalma WA, Makar AP, et al.; Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008 Jul;90(1):17-22. PMID: 17706209. ***X-2***

2398. Trombetta D, Imbesi S, Vita G, et al.; Possible link between history of hypersensitivity to a specific non-steroidal anti-inflammatory drug (NSAID) and positive results following challenge test to alternative NSAIDS. Arzneimittelforschung. 2009;59(8):410-4. PMID: 19813464. ***X-2, X-4***

2399. Trossarelli GF, Gennarelli G, Benedetto C, et al.; Climacteric symptoms and control of the cycle in women aged 35 years or older taking an oral contraceptive with 0.150 mg desogestrel and 0.020 mg ethinylestradiol. Contraception. 1995 Jan;51(1):13-8. PMID: 7750278. ***X-2***

2400. Trus T, Winthrop AL, Pipe S, et al.; Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. J Pediatr Surg. 1993 Sep;28(9):1137-9. PMID: 8308678. ***X-2, X-4***

2401. Tsalikis T, Stamatopoulos P, Kalachanis J, et al.; Experience with the MLCu250 IUD. Adv Contracept. 1986 Dec;2(4):393-8. PMID: 3565139. ***X-2, X-3, X-4***

2402. Tsesmeli NE, Kotsaftis PS, Savopoulos CG, et al.; Incidence and etiology of acute non-malignant upper gastrointestinal bleeding in northern Greece. J Gastroenterol Hepatol. 2007 Jul;22(7):1009-13. PMID: 17608846. ***X-2***

2403. Tsokos M, Schmoldt A; Contribution of nonsteroidal anti-inflammatory drugs to deaths associated

with peptic ulcer disease: a prospective toxicological analysis of autopsy blood samples. Arch Pathol Lab Med. 2001 Dec;125(12):1572-4. PMID: 11735692. ***X-2***

2404. Tsong Y; Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting. J Biopharm Stat. 1995 Mar;5(1):95-114. PMID: 7613562. ***X-1, X-2, X-3, X-4***

2405. Tsubota A, Kumada H, Arase Y, et al.; Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999 Oct;11(10):1077-83. PMID: 10524635. ***X-2, X-4***

2406. Tsuchiya T, Ayaki M, Onishi T, et al.; Three-year prospective randomized study of incidence of posterior capsule opacification in eyes treated with topical diclofenac and betamethasone. Ophthalmic Res. 2003 Mar-Apr;35(2):67-70. PMID: 12646745. ***X-2, X-4***

2407. Tsumura H, Fujita T, Tamura I, et al.; Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients. J Gastroenterol. 2010 Sep;45(9):944-51. PMID: 20499110. ***X-2***

2408. Tsuruoka N, Iwakiri R, Hara M, et al.; NSAIDs are a significant risk factor for colonic diverticular hemorrhage in elder patients: evaluation by a case-control study. J Gastroenterol Hepatol. 2011 Jun;26(6):1047-52. PMID: 21198829. ***X-2, X-3, X-4***

2409. Tu P, Qiu S, Fang H, et al.; Acceptance, efficacy, and side effects of Norplant implants in four counties in north China. Stud Fam Plann. 1997 Jun;28(2):122-31. PMID: 9216032. ***X-2, X-4***

2410. Tubert-Bitter P, Begaud B, Moride Y, et al.; Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach. J Clin Epidemiol. 1996 Jan;49(1):121-3. PMID: 8598505. ***X-1, X-2, X-3, X-4***

2411. Tugwell PS, Wells GA, Shainhouse JZ; Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004 Oct;31(10):2002-12. PMID: 15468367. ***X-2, X-4***

2412. Tuomikoski P, Haapalahti P, Sarna S, et al.; Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy. Ann Med. 2010 Jul;42(5):334-43. PMID: 20429800. ***X-2***

2413. Turajane T, Wongbunnak R, Patcharatrakul T, et al.; Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. J Med Assoc Thai. 2009 Dec;92 Suppl 6:S19-26. PMID: 20128070. ***X-4***

2414. Tursi A, Brandimarte G, Daffina R; Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis. 2002 Jul;34(7):510-5. PMID: 12236485. ***X-2, X-3, X-4***

2415. Tursi A, Brandimarte G, Giorgetti GM, et al.; Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis. 2007 Sep;22(9):1103-8. PMID: 17390144. ***X-2, X-3, X-4***

2416. Tworoger SS, Fairfield KM, Colditz GA, et al.; Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007 Oct 15;166(8):894-901. PMID: 17656616. ***X-4***

2417. Tzeng JI, Mok MS; Combination of intramuscular Ketorolac and low dose epidural morphine for the relief of post-caesarean pain. Ann Acad Med Singapore. 1994 Nov;23(6 Suppl):10-3. PMID: 7710217. ***X-2, X-4***

2418. Tzoulaki I, Molokhia M, Curcin V, et al.; Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731. PMID: 19959591. ***X-3***

2419. Ubeira FM, Anadon AM, Salgado A, et al.; Synergism between prior Anisakis simplex infections and intake of NSAIDs, on the risk of upper digestive bleeding: a case-control study. PLoS Negl Trop Dis. 2011 Jun;5(6):e1214. PMID: 21738810. ***X-2***

2420. Ucar SK, Paterson WF, Donaldson MD, et al.; Ethinyl estradiol treatment for growth limitation in girls with Marfan's syndrome--experience from a single center. Endocr Res. 2009;34(4):109-20. PMID: 19878071. ***X-2, X-3, X-4***

2421. Uchikova E, Pehlivanov B; Effect of two low-dose gestodene containing monophasic oral contraceptives on hemostasis in Bulgarian women. Expert Opin Pharmacother. 2008 Aug;9(11):1839-44. PMID: 18627323. ***X-2, X-4***

2422. Uchino J, Une Y, Sato Y, et al.; Chemohormonal therapy of unresectable hepatocellular carcinoma. Am J Clin Oncol. 1993 Jun;16(3):206-9. PMID: 8393272. ***X-2, X-4***

2423. Ullmann U, Oberwittle H, Grossmann M, et al.; Repeated oral once daily intake of increasing doses of the novel synthetic genistein product Bonistein in healthy volunteers. Planta Med. 2005 Oct;71(10):891-6. PMID: 16254818. ***X-2, X-4***

2424. Ulstein M, Steier AJ, Hofstad T, et al.; Microflora of cervical and vaginal secretion in women using copper- and norgestrel-releasing IUCDs. Acta Obstet Gynecol Scand. 1987;66(4):321-2. PMID: 3122515. ***X-2, X-3, X-4***

2425. Um SJ, Lee SK, Kim YH, et al.; Clinical features of drug-induced hypersensitivity syndrome in 38 patients. J Investig Allergol Clin Immunol. 2010;20(7):556-62. PMID: 21313995. ***X-2***

2426. Underwood M, Ashby D, Cross P, et al.; Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. BMJ. 2008 Jan 19;336(7636):138-42. PMID: 18056743. ***X-2, X-3, X-4***

2427. Upadhyay R, Torley HI, McKinlay AW, et al.; Iron deficiency anaemia in patients with rheumatic disease receiving non-steroidal anti-inflammatory drugs: the role of upper gastrointestinal lesions. Ann Rheum Dis. 1990 Jun;49(6):359-62. PMID: 2383058. ***X-2, X-3, X-4***

2428. Uppalapati SS, Boylan JD, Stoltzfus J; Risk factors involved in patients with bleeding peptic ulcers: a case-control study. Dig Dis Sci. 2009 Mar;54(3):593-8. PMID: 18648934. ***X-2, X-3, X-4***

2429. Ursin G, Ross RK, Sullivan-Halley J, et al.; Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res Treat. 1998 Jul;50(2):175-84. PMID: 9822222. ***X-4***

2430. Usichenko TI, Edinger H, Witstruck T, et al.; Millimetre wave therapy for pain relief after total knee arthroplasty: a randomised controlled trial. Eur J Pain. 2008 Jul;12(5):617-23. PMID: 18042413. ***X-2, X-3, X-4***

2431. Utz JP, Limper AH, Kalra S, et al.; Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003 Jul;124(1):177-85. PMID: 12853521. ***X-2, X-3, X-4***

2432. Vaisbich MH, Fujimura MD, Koch VH; Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol. 2004 Aug;19(8):858-63. PMID: 15206026. ***X-2, X-3, X-4***

2433. Valkhoff VE, van Soest EM, Sturkenboom MC, et al.; Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther. 2010 Jun;31(11):1218-28. PMID: 20222917. ***X-3, X-4***

2434. Vallette S, Serri K, Rivera J, et al.; Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12(3):153-7. PMID: 18594989. ***X-2***

2435. Vallette S, Serri K, Serri O; Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? Expert Rev Cardiovasc Ther. 2010 Jan;8(1):49-54. PMID: 20014934. ***X-1***

2436. Vally H, Taylor ML, Thompson PJ; The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax. 2002 Jul;57(7):569-74. PMID: 12096197. ***X-4***

2437. van Amerongen D; Removal rates of subdermal levonorgestrel implants. J Reprod Med. 1994 Nov;39(11):873-6. PMID: 7853277. ***X-2, X-3, X-4***

2438. van den Berg AA, Honjol NM, Prabhu NV, et al.; Analgesics and ENT surgery. A clinical comparison of the intraoperative, recovery and postoperative effects of buprenorphine, diclofenac, fentanyl, morphine, nalbuphine, pethidine and placebo given intravenously with induction of anaesthesia. Br J Clin Pharmacol. 1994 Dec;38(6):533-43. PMID: 7888292. ***X-2, X-3, X-4***

2439. van den Hondel KE, Eijgelsheim M, Ruiter R, et al.; Effect of short-term NSAID use on echocardiographic parameters in elderly people: a population-based cohort study. Heart. 2011 Apr;97(7):540-3. PMID: 21097821. ***X-4***

2440. Van den Ouweland FA, Gribnau FW, Meyboom RH; Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly. Age Ageing. 1988 Jan;17(1):8-16. PMID: 3364313. ***X-2***

2441. van der Heijden BJ, Carlus C, Narcy F, et al.; Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin. Am J Obstet Gynecol. 1994 Sep;171(3):617-23. PMID: 8092206. ***X-2, X-4***

2442. van der Heijden PG, van Puijenbroek EP, van Buuren S, et al.; On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med. 2002 Jul 30;21(14):2027-44. PMID: 12111885. ***X-1***

2443. van der Hooft CS, Jong GW, Dieleman JP, et al.; Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria--a population-based cohort study. Br J Clin Pharmacol. 2005 Aug;60(2):137-44. PMID: 16042666. ***X-2, X-3, X-4***

2444. van der Klauw MM, Stricker BH, Herings RM, et al.; A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol. 1993 Apr;35(4):400-8. PMID: 8097922. ***X-2, X-4***

2445. Van der Linden MW, Gaugris S, Kuipers EJ, et al.; Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Curr Med Res Opin. 2009 Jan;25(1):195-204. PMID: 19210152. ***X-4***

2446. van der Linden MW, Gaugris S, Kuipers EJ, et al.; COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.

Pharmacoepidemiol Drug Saf. 2009 Oct;18(10):880-90. PMID: 19593747. ***X-4***

2447. van der Loo B, Braun J, Koppensteiner R; On-treatment function testing of platelets and long-term outcome of patients with peripheral arterial disease undergoing transluminal angioplasty. Eur J Vasc Endovasc Surg. 2011 Dec;42(6):809-16. PMID: 21917489. ***X-2, X-3, X-4***

2448. van der Mooren MJ, Demacker PN, Thomas CM, et al.; A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol Reprod Biol. 1993 Dec 15;52(2):117-23. PMID: 8157140. ***X-2, X-4***

2449. van der Mooren MJ, Hanselaar AG, Borm GF, et al.; Changes in the withdrawal bleeding pattern and endometrial histology during 17 beta-estradiol-dydrogesterone therapy in postmenopausal women: a 2 year prospective study. Maturitas. 1994 Dec;20(2-3):175-80. PMID: 7715470. ***X-2, X-4***

2450. van der Steen WJ, Ho VK; Drugs versus diets: disillusions with Dutch health care. Acta Biotheor. 2001;49(2):125-40. PMID: 11450808. ***X-1***

2451. van der Velde G, Hogg-Johnson S, Bayoumi AM, et al.; Identifying the best treatment among common nonsurgical neck pain treatments: a decision analysis. Spine (Phila Pa 1976). 2008 Feb 15;33(4 Suppl):S184-91. PMID: 18204391. ***X-3, X-4***

2452. van der Velden T, Ping C; The introduction of Norplant in Cambodia through the private sector. Asia Pac J Public Health. 2002;14(2):69-74. PMID: 12862410. ***X-2, X-3, X-4***

2453. Van Deun A, Maug AK, Salim MA, et al.; Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92. PMID: 20442432. ***X-2, X-3, X-4***

2454. Van Dierendonck B, Ladipo OA, Ekwempu CC, et al.; A multicenter clinical trial in Nigeria with Multiload-Cu250 (MLCu250) and Multiload-Cu375 (MLCu375) intrauterine devices. Adv Contracept. 1992 Dec;8(4):327-30. PMID: 1290334. ***X-3, X-4***

2455. van Dijk KN, ter Huurne K, de Vries CS, et al.; Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci. 2002 Jun;24(3):100-3. PMID: 12136741. ***X-3, X-4***

2456. Van Dis ML, Parks ET; Prevalence of oral lichen planus in patients with diabetes mellitus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Jun;79(6):696-700. PMID: 7621025. ***X-2***

2457. van Dongen H, van Aken J, Lard LR, et al.; Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007 May;56(5):1424-32. PMID: 17469099. ***X-2, X-3, X-4***

2458. van Eijkeren MA, Christiaens GC, Geuze HJ, et al.; Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol. 1992 May;166(5):1419-28. PMID: 1595797. ***X-2, X-3, X-4***

2459. van Gelder MM, Roeleveld N, Nordeng H; Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. PLoS One. 2011;6(7):e22174. PMID: 21789231. ***X-4***

2460. van Haselen RA, Fisher PA; A randomized controlled trial comparing topical piroxicam gel with a homeopathic gel in osteoarthritis of the knee. Rheumatology (Oxford). 2000 Jul;39(7):714-9. PMID: 10908688. ***X-2, X-4***

2461. van Jaarsveld CH, Jahangier ZN, Jacobs JW, et al.; Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatology (Oxford). 2000 Dec;39(12):1374-82. PMID: 11136881. ***X-2***

2462. van Kets H, Vrijens M, Van Trappen Y, et al.; The frameless GyneFix intrauterine implant: a major improvement in efficacy, expulsion and tolerance. Adv Contracept. 1995 Jun;11(2):131-42. PMID: 7491854. ***X-1, X-2, X-3, X-4***

2463. van Kets HE, Thiery M, van der Pas H, et al.; Long-term experience with Multiload intrauterine devices. Adv Contracept. 1989 Sep;5(3):179-88. PMID: 2633607. ***X-1, X-4***

2464. Van Kets HE, Van der Pas H, Delbarge W, et al.; A randomized comparative study of the TCu380A and Cu-Safe 300 IUDs. Adv Contracept. 1995 Jun;11(2):123-9. PMID: 7491853. ***X-2, X-4***

2465. Van Lancker P, Vandekerckhove B, Cooman F; The analgesic effect of preoperative administration of propacetamol, tenoxicam or a mixture of both in arthroscopic, outpatient knee surgery. Acta Anaesthesiol Belg. 1999;50(2):65-9. PMID: 10418644. ***X-2, X-3, X-4***

2466. van Lumig PP, Driessen RJ, Roelofs-Thijssen MA, et al.; Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab. Br J Dermatol. 2011 Aug;165(2):375-82. PMID: 21428975. ***X-2, X-3, X-4***

2467. Van Marter LJ, Leviton A, Allred EN, et al.; Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics. 1996 May;97(5):658-63. PMID: 8628603. ***X-2***

2468. van Oijen MG, Dieleman JP, Laheij RJ, et al.; Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol. 2008 Mar;6(3):309-13. PMID: 18242146. ***X-4***

2469. van Oijen MG, Koetsier MI, Laheij RJ, et al.; Genetic polymorphisms in UDP-glucuronosyltransferase 1A6 are not associated with NSAIDs-related peptic ulcer haemorrhage. Drug Metab Lett. 2009 Aug;3(3):199-204. PMID: 19799547. ***X-2, X-3, X-4***

2470. van Oijen MG, Laheij RJ, Koetsier M, et al.; Effect of a specific cyclooxygenase-gene polymorphism (A-842G/C50T) on the occurrence of peptic ulcer hemorrhage. Dig Dis Sci. 2006 Dec;51(12):2348-52. PMID: 17078001. ***X-2, X-3, X-4***

2471. van Overmeire B, Brus F, van Acker KJ, et al.; Aspirin versus indomethacin treatment of patent ductus arteriosus in preterm infants with respiratory distress syndrome. Pediatr Res. 1995 Dec;38(6):886-91. PMID: 8618789. ***X-2, X-3, X-4***

2472. Van Overmeire B, Slootmaekers V, De Loor J, et al.; The addition of indomethacin to betamimetics for tocolysis: any benefit for the neonate? Eur J Obstet Gynecol Reprod Biol. 1998 Mar;77(1):41-5. PMID: 9550199. ***X-2, X-4***

2473. Van Overmeire B, Smets K, Lecoutere D, et al.; A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000 Sep 7;343(10):674-81. PMID: 10974130. ***X-2, X-4***

2474. Van Overmeire B, Van de Broek H, Van Laer P, et al.; Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr. 2001 Feb;138(2):205-11. PMID: 11174617. ***X-2, X-4***

2475. van Puijenbroek EP, Egberts AC, Heerdink ER, et al.; Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2000 Dec;56(9-10):733-8. PMID: 11214785. ***X-3, X-4***

2476. van Puijenbroek EP, Egberts AC, Meyboom RH, et al.; Different risks for NSAID-induced anaphylaxis. Ann Pharmacother. 2002 Jan;36(1):24-9. PMID: 11816253. ***X-4***

2477. van Rooijen M, Silveira A, Hamsten A, et al.; Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol. 2004 Feb;190(2):332-7. PMID: 14981370. ***X-2***

2478. Van Roon EN, Jansen TL, Mourad L, et al.; Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol. 2004 Jun;57(6):790-7. PMID: 15151525. ***X-2, X-4***

2479. van Soest EM, Sturkenboom MC, Dieleman JP, et al.; Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007 Jul 15;26(2):265-75. PMID: 17593072. ***X-4***

2480. van Soest EM, Valkhoff VE, Mazzaglia G, et al.; Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011 Dec;60(12):1650-9. PMID: 21636644. ***X-4***

2481. van Staa TP, Abenhaim L, Leufkens H; A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. J Clin Epidemiol. 1994 Feb;47(2):183-9. PMID: 8113827. ***X-2, X-3, X-4***

2482. van Staa TP, Leufkens HG, Cooper C; Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone. 2000 Oct;27(4):563-8. PMID: 11033453. ***X-4***

2483. van Staa TP, Rietbrock S, Setakis E, et al.; Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med. 2008 Nov;264(5):481-92. PMID: 18624902. ***X-4***

2484. van Staa TP, Smeeth L, Persson I, et al.; What is the harm-benefit ratio of Cox-2 inhibitors? Int J Epidemiol. 2008 Apr;37(2):405-13. PMID: 18263647. ***X-4***

2485. Van Staa TP, Travis S, Leufkens HG, et al.; 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004 Jun;126(7):1733-9. PMID: 15188168. ***X-4***

2486. van Vlijmen EF, Brouwer JL, Veeger NJ, et al.; Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med. 2007 Feb 12;167(3):282-9. PMID: 17296885. ***X-2***

2487. van Vlijmen EF, Veeger NJ, Middeldorp S, et al.; Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood. 2011 Aug 25;118(8):2055-61; quiz 375. PMID: 21659542. ***X-2***

2488. Van Wyck DB, Mangione A, Morrison J, et al.; Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009 Dec;49(12):2719-28. PMID: 19682342. ***X-2, X-4***

2489. Vandermeulen EP, Van Aken H, Scholtes JL, et al.; Intravenous administration of tenoxicam 40 mg for post-operative analgesia: a double-blind, placebo-controlled multicentre study. Eur J Anaesthesiol. 1997 May;14(3):250-7. PMID: 9202910. ***X-2, X-3, X-4***

2490. Vandraas KF, Spigset O, Mahic M, et al.; Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol. 2010 Aug;66(8):823-9. PMID: 20405110. ***X-4***

2491. Vanek T, Jares M, Fajt R, et al.; Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). Eur J Cardiothorac Surg. 2005 Oct;28(4):563-8. PMID: 16125959. ***X-2, X-4***

2492. Vanky E, Salvesen KA, Heimstad R, et al.; Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004 Aug;19(8):1734-40. PMID: 15178665. ***X-2, X-4***

2493. Vargas E, Terleira A, Hernando F, et al.; Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med. 2003 Mar;31(3):694-8. PMID: 12626971. ***X-2, X-4***

2494. Vargyas JM, Campeau JD, Mishell DR, Jr.; Treatment of menorrhagia with meclofenamate sodium. Am J Obstet Gynecol. 1987 Oct;157(4 Pt 1):944-50. PMID: 3314521. ***X-2, X-3, X-4***

2495. Varila E, Wahlstrom T, Rauramo I; A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril. 2001 Nov;76(5):969-73. PMID: 11704119. ***X-2, X-3, X-4***

2496. Vasisht KP, Chen SC, Peng Y, et al.; Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec;12(12):1079-83. PMID: 20977579. ***X-2, X-3***

2497. Veehof LJ, Stewart RE, Meyboom-de Jong B, et al.; Adverse drug reactions and polypharmacy in the elderly in general practice. Eur J Clin Pharmacol. 1999 Sep;55(7):533-6. PMID: 10501824. ***X-7***

2498. Vekemans M, Delvigne A, Paesmans M; Continuation rates with a levonorgestrel-releasing contraceptive implant (Norplant). A prospective study in Belgium. Contraception. 1997 Nov;56(5):291-9. PMID: 9437557. ***X-2, X-3, X-4***

2499. Veldhuis HM, Vos AG, Lagro-Janssen AL; Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract. 2004 Sep;10(3):82-7. PMID: 15534571. ***X-2, X-4***

2500. Velentgas P, West W, Cannuscio CC, et al.; Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf. 2006 Sep;15(9):641-52. PMID: 16392153. ***X-4***

2501. Velosa JA, Torres VE; Benefits and risks of nonsteroidal antiinflammatory drugs in steroid-resistant nephrotic syndrome. Am J Kidney Dis. 1986 Nov;8(5):345-50. PMID: 3788972. ***X-2***

2502. Velten FW, Bayerl C, Baenkler HW, et al.; Functional eicosanoid test and typing (FET) in acetylsalicylic acid intolerant patients with urticaria. J Physiol Pharmacol. 2006 Dec;57 Suppl 12:35-46. PMID: 17244953. ***X-2, X-3, X-4***

2503. Venerito M, Treiber G, Wex T, et al.; Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1225-33. PMID: 16611284. ***X-2, X-4***

2504. Venn A, Bruinsma F, Werther G, et al.; Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet. 2004 Oct 23-29;364(9444):1513-8. PMID: 15500896. ***X-2***

2505. Ventura MT, Cenci L, Giuliano G, et al.; Retrospective study of adverse reactions to non steroid anti-inflammatory drugs (NSAIDs): predictive value of controlled challenge with alternative drugs. Immunopharmacol Immunotoxicol. 1999 Aug;21(3):455-68. PMID: 10466074. ***X-4***

2506. Venturoli S, Marescalchi O, Colombo FM, et al.; A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999 Apr;84(4):1304-10. PMID: 10199771. ***X-2, X-3, X-4***

2507. Vercellini P, Aimi G, Panazza S, et al.; A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril. 1999 Sep;72(3):505-8. PMID: 10519624. ***X-2, X-4***

2508. Vercellini P, Frontino G, De Giorgi O, et al.; Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003 Sep;80(3):560-3. PMID: 12969698. ***X-2, X-3, X-4***

2509. Verhamme KM, Dieleman JP, Van Wijk MA, et al.; Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med. 2005 Jul 11;165(13):1547-51. PMID: 16009872. ***X-6***

2510. Verhelst J, Abs R, Maiter D, et al.; Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22. PMID: 10404830. ***X-2***

2511. Vermillion ST, Newman RB; Recent indomethacin tocolysis is not associated with neonatal complications in

preterm infants. Am J Obstet Gynecol. 1999 Nov;181(5 Pt 1):1083-6. PMID: 10561622. ***X-2, X-4***

2512. Verrico MM, Weber RJ, McKaveney TP, et al.; Adverse Drug Events Involving COX-2 Inhibitors. Ann Pharmacother. 2003 Sep;37(9):1203-13. PMID: 12921500. ***X-2, X-4***

2513. Vestergaard P, Rejnmark L, Mosekilde L; Osteoarthritis and risk of fractures. Calcif Tissue Int. 2009 Apr;84(4):249-56. PMID: 19234808. ***X-3, X-4***

2514. Vidal X, Ibanez L, Vendrell L, et al.; Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf. 2008;31(2):159-68. PMID: 18217791. ***X-4***

2515. Viegas OA, Singh K, Koh S, et al.; The effects of Norplant on clinical chemistry in Singaporean acceptors after 1 year of use: I. Haemostatic changes. Contraception. 1988 Sep;38(3):313-23. PMID: 3139360. ***X-2, X-4***

2516. Vilar L, Canadas V, Arruda MJ, et al.; Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes. Arq Bras Endocrinol Metabol. 2010 Mar;54(3):311-8. PMID: 20520962. ***X-2, X-4***

2517. Villanacci V, Casella G, Bassotti G; The spectrum of drug-related colitides: important entities, though frequently overlooked. Dig Liver Dis. 2011 Jul;43(7):523-8. PMID: 21324756. ***X-8***

2518. Viola AS, Castro S, Bahamondes MV, et al.; A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate. Contraception. 2011 Nov;84(5):e31-7. PMID: 22018135. ***X-2***

2519. Viola AS, Castro S, Marchi NM, et al.; Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception. 2011 Aug;84(2):122-7. PMID: 21757052. ***X-2***

2520. Visser LE, van Schaik RH, van Vliet M, et al.; Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther. 2005 Jun;77(6):479-85. PMID: 15961979. ***X-2***

2521. Viswanathan P, Chaudhuri A, Bhatia R, et al.; Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007 Sep;13(5):444-50. PMID: 17872344. ***X-2, X-3, X-4***

2522. Vitale MG, Choe JC, Hwang MW, et al.; Use of ketorolac tromethamine in children undergoing scoliosis surgery. an analysis of complications. Spine J. 2003 Jan-Feb;3(1):55-62. PMID: 14589246. ***X-2***

2523. Vlajkovic G, Sindjelic R, Stefanovic I; Ketorolac as a pre-emptive analgesic in retinal detachment surgery: a prospective, randomized clinical trial. Int J Clin Pharmacol Ther. 2007 May;45(5):259-63. PMID: 17542347. ***X-2, X-4***

2524. Voaklander DC, Kelly KD, Rowe BH, et al.; Pain, medication, and injury in older farmers. Am J Ind Med. 2006 May;49(5):374-82. PMID: 16526061. ***X-2, X-3, X-4***

2525. Vogel RI, Gross JI; The effects of nonsteroidal anti-inflammatory analgesics on pain after periodontal surgery. J Am Dent Assoc. 1984 Nov;109(5):731-4. PMID: 6333443. ***X-2, X-4***

2526. Vogel U, Christensen J, Wallin H, et al.; Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008 Mar 1;639(1-2):89-100. PMID: 18164040. ***X-2, X-3, X-4***

2527. Vogel U, Segel S, Dethlefsen C, et al.; PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes. BMC Med Genet. 2009;10:52. PMID: 19500413. ***X-4***

2528. Vogel U, Segel S, Dethlefsen C, et al.; Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis. 2010 Mar;209(1):155-62. PMID: 19748095. ***X-3, X-4***

2529. Voke J, Keidan J, Pavord S, et al.; The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol. 2007 Nov;139(4):545-58. PMID: 17916101. ***X-2, X-4***

2530. Volpe A, Silferi M, Genazzani AD, et al.; Contraception in older woman. Contraception. 1993 Mar;47(3):229-39. PMID: 8462314. ***X-2***

2531. von Holst T, Lang E, Winkler U, et al.; Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas. 2002 Dec 10;43(4):265-75. PMID: 12468135. ***X-2, X-4***

2532. Von Korff M, Galer BS, Stang P; Chronic use of symptomatic headache medications. Pain. 1995 Aug;62(2):179-86. PMID: 8545143. ***X-2, X-3, X-4***

2533. Vonbach P, Reich R, Moll F, et al.; Risk factors for gastrointestinal bleeding: a hospital-based case-control study. Swiss Med Wkly. 2007 Dec 22;137(49-50):705-10. PMID: 18197486. ***X-2, X-4***

2534. Vonkeman HE, Braakman-Jansen LM, Klok RM, et al.; Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis

linked to a case-control study. Arthritis Res Ther. 2008;10(6):R144. PMID: 19077318. ***X-4***

2535. Vonkeman HE, Fernandes RW, van der Palen J, et al.; Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther. 2007;9(3):R52. PMID: 17521422. ***X-3, X-4***

2536. Vonkeman HE, van de Laar MA, van der Palen J, et al.; Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin Ther. 2006 Oct;28(10):1670-6. PMID: 17157122. ***X-2, X-3, X-4***

2537. Voskuyl AE, Van de Laar MA, Moens HJ, et al.; Extra-articular manifestations of rheumatoid arthritis: risk factors for serious gastrointestinal events. Ann Rheum Dis. 1993 Nov;52(11):771-5. PMID: 8250607. ***X-4***

2538. Voutilainen M, Sokka T, Juhola M, et al.; Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer. Scand J Gastroenterol. 1998 Aug;33(8):811-6. PMID: 9754727. ***X-2, X-3***

2539. Vree ML, Schmidt J; A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany. Eur J Contracept Reprod Health Care. 2001 Jun;6(2):108-14. PMID: 11518448. ***X-4***

2540. Vreeburg EM, de Bruijne HW, Snel P, et al.; Previous use of non-steroidal anti-inflammatory drugs and anticoagulants: the influence on clinical outcome of bleeding gastroduodenal ulcers. Eur J Gastroenterol Hepatol. 1997 Jan;9(1):41-4. PMID: 9031897. ***X-2***

2541. Vuorma S, Teperi J, Aalto AM, et al.; A randomized trial among women with heavy menstruation -- impact of a decision aid on treatment outcomes and costs. Health Expect. 2004 Dec;7(4):327-37. PMID: 15544685. ***X-2, X-3***

2542. Wadelius M, Stjernberg E, Wiholm BE, et al.; Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics. 2000 Feb;10(1):35-41. PMID: 10739170. ***X-2, X-3, X-4***

2543. Wahl PM, Rodgers K, Schneeweiss S, et al.; Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):596-603. PMID: 20140892. ***X-2, X-3, X-4***

2544. Wahn U, Bos JD, Goodfield M, et al.; Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002 Jul;110(1 Pt 1):e2. PMID: 12093983. ***X-2, X-3, X-4***

2545. Waikakul S, Waikakul W; A post marketing survey on the side-effects of loxoprofen. J Med Assoc Thai. 1999 Jul;82(7):721-6. PMID: 10511775. ***X-2, X-4***

2546. Walker AM, Szneke P, Bianchi LA, et al.; 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol. 1997 May;92(5):816-20. PMID: 9149192. ***X-4***

2547. Walker PC, Alrawi A, Mitchell JF, et al.; Medication use as a risk factor for falls among hospitalized elderly patients. Am J Health Syst Pharm. 2005 Dec 1;62(23):2495-9. PMID: 16303905. ***X-2***

2548. Walker SL, Kennedy F, Niamh N, et al.; Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol Drug Saf. 2008 Nov;17(11):1108-12. PMID: 18821716. ***X-2, X-4***

2549. Wallander MA, Johansson S, Ruigomez A, et al.; Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality. Fam Pract. 2007 Oct;24(5):403-11. PMID: 17728288. ***X-3, X-4***

2550. Wallenstein EJ, Fife D; Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf. 2001;24(3):233-7. PMID: 11347725. ***X-3, X-4***

2551. Waller PC, Ramsay LE; Arthritis and drug therapy in the hypertension clinic. Biomed Pharmacother. 1988;42(3):207-11. PMID: 3052606. ***X-2, X-3, X-4***

2552. Wallerstedt SM, Gleerup H, Sundstrom A, et al.; Risk of clinically relevant bleeding in warfarin-treated patients--influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009 May;18(5):412-6. PMID: 19301238. ***X-2, X-4***

2553. Walling M; A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol. Contraception. 1992 Oct;46(4):313-26. PMID: 1486770. ***X-2, X-4***

2554. Walsh JS, Eastell R, Peel NF; Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab. 2008 Apr;93(4):1317-23. PMID: 18230659. ***X-2***

2555. Walsh JS, Eastell R, Peel NF; Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density. Fertil Steril. 2010 Feb;93(3):697-701. PMID: 19013564. ***X-2***

2556. Walsh T, Grimes D, Frezieres R, et al.; Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet. 1998 Apr 4;351(9108):1005-8. PMID: 9546505. ***X-3, X-4***

2557. Walter RB, Milano F, Brasky TM, et al.; Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol. 2011 Jun 10;29(17):2424-31. PMID: 21555699. ***X-4***

2558. Wan LS, Stiber A, Lam LY; The levonorgestrel two-rod implant for long-acting contraception: 10 years of clinical experience. Obstet Gynecol. 2003 Jul;102(1):24-6. PMID: 12850601. ***X-2, X-4***

2559. Wang J, Donnan PT, MacDonald TM; An approximate Bayesian risk-analysis for the gastro-intestinal safety of ibuprofen. Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):695-701. PMID: 12512246. ***X-4, X-8***

2560. Wang J, Mullins CD, Mamdani M, et al.; New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study. Ann Pharmacother. 2007 Jun;41(6):937-43. PMID: 17488830. ***X-4***

2561. Wang ML, Miao F, Tang YH, et al.; Special diaphragm-like strictures of small bowel unrelated to non-steroidal anti-inflammatory drugs. World J Gastroenterol. 2011 Aug 21;17(31):3596-604. PMID: 21987606. ***X-2***

2562. Wang SL, Wu SC, Xin XM, et al.; Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study. Adv Contracept. 1992 Jun;8(2):105-14. PMID: 1519493. ***X-2, X-3, X-4***

2563. Wang YP, Shi B, Chen YX, et al.; Drug-induced liver disease: an 8-year study of patients from one gastroenterological department. J Dig Dis. 2009 Aug;10(3):195-200. PMID: 19659787. ***X-2, X-4***

2564. Ward MM, Kuzis S; Medication toxicity among patients with ankylosing spondylitis. Arthritis Rheum. 2002 Jun 15;47(3):234-41. PMID: 12115151. ***X-2, X-4***

2565. Warner JJ, Weideman RA, Kelly KC, et al.; The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. J Cardiovasc Pharmacol Ther. 2008 Dec;13(4):252-60. PMID: 18787084. ***X-2, X-4***

2566. Watson DJ, Bolognese JA, Yu C, et al.; Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004 Dec;20(12):1899-908. PMID: 15701208. ***X-4***

2567. Watson MG, Shenoi PM; Drug-induced epistaxis? J R Soc Med. 1990 Mar;83(3):162-4. PMID: 2325058. ***X-2***

2568. Weale AE, Warwick DJ, Durant N, et al.; Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement? Ann R Coll Surg Engl. 1995 Jan;77(1):35-7. PMID: 7717643. ***X-2, X-4***

2569. Weaver GA, Harper RL, Storey JA, et al.; Nonsteroidal antiinflammatory drugs are associated with gastric outlet obstruction. J Clin Gastroenterol. 1995 Apr;20(3):196-8. PMID: 7797825. ***X-2, X-4***

2570. Weber-Diehl F, Unger R, Lachnit U; Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial. Contraception. 1992 Jul;46(1):19-27. PMID: 1424620. ***X-4***

2571. Webster J, Piscitelli G, Polli A, et al.; Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. Clin Endocrinol (Oxf). 1992 Dec;37(6):534-41. PMID: 1286524. ***X-2***

2572. Webster J, Piscitelli G, Polli A, et al.; The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol (Oxf). 1993 Sep;39(3):323-9. PMID: 7900937. ***X-2***

2573. Weckx LL, Ruiz JE, Duperly J, et al.; Efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac. J Int Med Res. 2002 Mar-Apr;30(2):185-94. PMID: 12025527. ***X-2, X-4***

2574. Weil J, Colin-Jones D, Langman M, et al.; Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995 Apr 1;310(6983):827-30. PMID: 7711618. ***X-2, X-3, X-4***

2575. Weil J, Langman MJ, Wainwright P, et al.; Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut. 2000 Jan;46(1):27-31. PMID: 10601050. ***X-2, X-4***

2576. Weinbroum AA; Superiority of postoperative epidural over intravenous patient-controlled analgesia in orthopedic oncologic patients. Surgery. 2005 Nov;138(5):869-76. PMID: 16291387. ***X-2, X-3, X-4***

2577. Weir MA, Gomes T, Mamdani M, et al.; Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. Nephrol Dial Transplant. 2011 Jun;26(6):1888-94. PMID: 20974644. ***X-4, X-7***

2578. Weisberg F, Bouchard C, Moreau M, et al.; Preference for and satisfaction of Canadian women with the

transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. J Obstet Gynaecol Can. 2005 Apr;27(4):350-9. PMID: 15937609. ***X-2, X-3, X-4***

2579. Wells M, Sturdee DW, Barlow DH, et al.; Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. BMJ. 2002 Aug 3;325(7358):239. PMID: 12153918. ***X-2, X-4***

2580. Wemme H, Pohlenz J, Schonberger W; Effect of oestrogen/gestagen replacement therapy on liver enzymes in patients with Ullrich-Turner syndrome. Eur J Pediatr. 1995 Oct;154(10):807-10. PMID: 8529677. ***X-2***

2581. Wen SW, Yang T, Krewski D, et al.; Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population. J Perinatol. 2008 May;28(5):324-9. PMID: 18288118. ***X-4***

2582. Wen YK; Impact of acute kidney injury on metformin-associated lactic acidosis. Int Urol Nephrol. 2009 Dec;41(4):967-72. PMID: 19280360. ***X-2***

2583. Werler MM, Bosco JL, Shapira SK; Maternal vasoactive exposures, amniotic bands, and terminal transverse limb defects. Birth Defects Res A Clin Mol Teratol. 2009 Jan;85(1):52-7. PMID: 19067400. ***X-2, X-3, X-4***

2584. Wernli KJ, Hampton JM, Trentham-Dietz A, et al.; Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):131-7. PMID: 21254283. ***X-4***

2585. Wessinger S, Kaplan M, Choi L, et al.; Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006 Apr 1;23(7):937-44. PMID: 16573796. ***X-2, X-3, X-4***

2586. Westerlund T, Allebeck P, Marklund B, et al.; Evaluation of a model for counseling patients with dyspepsia in Swedish community pharmacies. Am J Health Syst Pharm. 2003 Jul 1;60(13):1336-41. PMID: 12901035. ***X-2, X-3, X-4***

2587. Westhoff C, Truman C, Kalmuss D, et al.; Depressive symptoms and Depo-Provera. Contraception. 1998 Apr;57(4):237-40. PMID: 9649914. ***X-2, X-4***

2588. Westhoff C, Truman C, Kalmuss D, et al.; Depressive symptoms and Norplant contraceptive implants. Contraception. 1998 Apr;57(4):241-5. PMID: 9649915. ***X-2, X-4***

2589. Wetmore CM, Ichikawa L, LaCroix AZ, et al.; Association between caffeine intake and bone mass among young women: potential effect modification by depot medroxyprogesterone acetate use. Osteoporos Int. 2008 Apr;19(4):519-27. PMID: 18004611. ***X-2, X-4***

2590. Wharam PC, Speedy DB, Noakes TD, et al.; NSAID use increases the risk of developing hyponatremia during an Ironman triathlon. Med Sci Sports Exerc. 2006 Apr;38(4):618-22. PMID: 16679974. ***X-2***

2591. Whelan CT, Kaboli P, Zhang Q, et al.; Upper gastrointestinal hemorrhage: have new therapeutics made a difference? J Hosp Med. 2009 Sep;4(7):E6-10. PMID: 19753582. ***X-2***

2592. White E, Malone KE, Weiss NS, et al.; Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst. 1994 Apr 6;86(7):505-14. PMID: 8133534. ***X-4***

2593. Wiegratz I, Stahlberg S, Manthey T, et al.; Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception. 2011 Aug;84(2):133-43. PMID: 21757054. ***X-2***

2594. Wiegratz I, Stahlberg S, Manthey T, et al.; Effects of combined oral contraceptive ethinylestradiol (30 microg) and dienogest (2 mg) on carbohydrate metabolism during 1 year of conventional or extended-cycle use. Horm Metab Res. 2010 May;42(5):358-63. PMID: 20213585. ***X-2, X-4***

2595. Wierod FS, Frandsen NJ, Jacobsen JD, et al.; Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scand J Urol Nephrol. 1998 Apr;32(2):120-2. PMID: 9606784. ***X-2***

2596. Wijnands M, van Riel P, van 't Hof M, et al.; Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study. J Rheumatol. 1991 Feb;18(2):184-7. PMID: 2023212. ***X-2, X-3, X-4***

2597. Wilcox CM, Alexander LN, Cotsonis GA, et al.; Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci. 1997 May;42(5):990-7. PMID: 9149053. ***X-4***

2598. Wilcox CM, Clark WS; Features associated with painless peptic ulcer bleeding. Am J Gastroenterol. 1997 Aug;92(8):1289-92. PMID: 9260791. ***X-2, X-4***

2599. Wilcox CM, Shalek KA, Cotsonis G; Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med. 1994 Jan 10;154(1):42-6. PMID: 8267488. ***X-2, X-3***

2600. Wildemeersch D, Janssens D, Andrade A; The Femilis LNG-IUS: contraceptive performance-an interim analysis. Eur J Contracept Reprod Health Care. 2009 Apr;14(2):103-10. PMID: 19340705. ***X-2***

2601. Wildemeersch D, Janssens D, Vrijens M, et al.; Ease of insertion, contraceptive efficacy and safety of new

T-shaped levonorgestrel-releasing intrauterine systems. Contraception. 2005 Jun;71(6):465-9. PMID: 15914138. ***X-2***

2602. Wildemeersch D, Rowe PJ; Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system. Contraception. 2005 Jun;71(6):470-3. PMID: 15914139. ***X-2, X-3, X-4***

2603. Wildemeersch D, Schacht E; Contraception with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care. 2000 Dec;5(4):234-40. PMID: 11245550. ***X-2, X-4***

2604. Wildemeersch D, Schacht E, Wildemeersch P; Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care. 2001 Dec;6(4):192-8. PMID: 11848648. ***X-2, X-4***

2605. Wildemeersch D, Schacht E, Wildemeersch P; Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women. Maturitas. 2003 Mar 28;44(3):237-45. PMID: 12648887. ***X-2, X-3***

2606. Wilder-Smith CH, Hill L, Dyer RA, et al.; Postoperative sensitization and pain after cesarean delivery and the effects of single im doses of tramadol and diclofenac alone and in combination. Anesth Analg. 2003 Aug;97(2):526-33, table of contents. PMID: 12873948. ***X-2, X-3, X-4***

2607. Wildner-Christensen M, Hansen JM, De Muckadell OB; Risk factors for dyspepsia in a general population: non-steroidal anti-inflammatory drugs, cigarette smoking and unemployment are more important than Helicobacter pylori infection. Scand J Gastroenterol. 2006 Feb;41(2):149-54. PMID: 16484119. ***X-4***

2608. Wile DJ, Toth C; Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010 Jan;33(1):156-61. PMID: 19846797. ***X-2***

2609. Wilkinson SM, Smith AG, Davis MJ, et al.; Suspected cutaneous drug toxicity in rheumatoid arthritis--an evaluation. Br J Rheumatol. 1993 Sep;32(9):798-803. PMID: 8103699. ***X-2, X-4***

2610. Williams AN, Simon RA, Woessner KM, et al.; The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol. 2007 Aug;120(2):273-7. PMID: 17481713. ***X-2, X-4***

2611. Williams D, O'Kelly P, Kelly A, et al.; Lack of symptom benefit following presumptive Helicobacter pylori eradication therapy in primary care. Aliment Pharmacol Ther. 2001 Nov;15(11):1769-75. PMID: 11683691. ***X-3, X-4***

2612. Williams HJ, Ward JR, Egger MJ, et al.; Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993 Sep;36(9):1196-206. PMID: 8216413. ***X-2, X-4***

2613. Willison DJ, Gaebel KA, Borden EK, et al.; Experience in the development of a postmarketing surveillance network: the pharmacy medication monitoring program. Ann Pharmacother. 1995 Dec;29(12):1208-13. PMID: 8672822. ***X-2, X-3, X-4***

2614. Wills BK, Bryant SM, Buckley P, et al.; Can acute overdose of metformin lead to lactic acidosis? Am J Emerg Med. 2010 Oct;28(8):857-61. PMID: 20887905. ***X-2***

2615. Wilson J; A randomised trial and a comparative study of the copper 7 200 and the multiload copper 250 intrauterine devices. Aust N Z J Obstet Gynaecol. 1982 Feb;22(1):34-7. PMID: 7049154. ***X-2, X-3, X-4***

2616. Wilson JA, Romagnuolo J, Byrne TK, et al.; Predictors of endoscopic findings after Roux-en-Y gastric bypass. Am J Gastroenterol. 2006 Oct;101(10):2194-9. PMID: 17032183. ***X-2, X-3***

2617. Wilson JC; A prospective New Zealand study of fertility after removal of copper intrauterine contraceptive devices for conception and because of complications: a four-year study. Am J Obstet Gynecol. 1989 Feb;160(2):391-6. PMID: 2916624. ***X-2, X-4***

2618. Wilson JC; A New Zealand randomized comparative study of three IUDs (Nova-T, MLCu375, MLAgCu250): 1-, 2- and 3-year results. Adv Contracept. 1992 Jun;8(2):153-9. PMID: 1519497. ***X-2, X-3, X-4***

2619. Wilson RG, Smith AN, Macintyre IM; Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. Br J Surg. 1990 Oct;77(10):1103-4. PMID: 2121310. ***X-2***

2620. Wilting I, Movig KL, Moolenaar M, et al.; Drug-drug interactions as a determinant of elevated lithium serum levels in daily clinical practice. Bipolar Disord. 2005 Jun;7(3):274-80. PMID: 15898965. ***X-2, X-4***

2621. Wingrave SJ; Progestogen effects and their relationship to lipoprotein changes. A report from the Oral Contraception Study of the Royal College of General Practitioners. Acta Obstet Gynecol Scand Suppl. 1982;105:33-6. PMID: 6805242. ***X-4***

2622. Winkelmayer WC, Waikar SS, Mogun H, et al.; Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med. 2008 Dec;121(12):1092-8. PMID: 19028206. ***X-7***

2623. Winkler UH; The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol. 2001 Dec 1;99(2):238-43. PMID: 11788179. ***X-2, X-3***

2624. Winkler UH, Holscher T, Schulte H, et al.; Ethinylestradiol 20 versus 30 micrograms combined with 150 micrograms desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. Gynecol Endocrinol. 1996 Aug;10(4):265-71. PMID: 8908527. ***X-2, X-4***

2625. Witjaksono J, Lau TM, Affandi B, et al.; Oestrogen treatment for increased bleeding in Norplant users: preliminary results. Hum Reprod. 1996 Oct;11 Suppl 2:109-14. PMID: 8982752. ***X-2, X-3, X-4***

2626. Wittpenn JR, Silverstein S, Heier J, et al.; A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008 Oct;146(4):554-60. PMID: 18599019. ***X-2, X-3, X-4***

2627. Wohrl S, Vigl K, Stingl G; Patients with drug reactions -- is it worth testing? Allergy. 2006 Aug;61(8):928-34. PMID: 16867044. ***X-2, X-3, X-4***

2628. Wolfe BM, Koval JJ, Nisker JA; Impact on postmenopausal symptoms of adding continuous C-21 versus C-19 progestin to estrogen. Maturitas. 1999 Oct 24;33(2):153-61. PMID: 10597880. ***X-2, X-4***

2629. Wolfe F, Anderson J, Burke TA, et al.; Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol. 2002 Mar;29(3):467-73. PMID: 11908558. ***X-4***

2630. Wolfe F, Hawley DJ; The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol. 2000 Jul;27(7):1668-73. PMID: 10914849. ***X-4***

2631. Wolfe F, Michaud K, Stephenson B, et al.; Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate. J Rheumatol. 2003 Aug;30(8):1725-32. PMID: 12913927. ***X-2, X-3, X-4***

2632. Wolkenstein P, Chosidow O, Flechet ML, et al.; Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996 Oct;35(4):234-6. PMID: 8957644. ***X-2, X-3, X-4***

2633. Wollter-Svensson LO, Stadberg E, Andersson K, et al.; Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism. Maturitas. 1995 Nov;22(3):199-205. PMID: 8746877. ***X-2, X-4***

2634. Womack JA, Scherzer R, Cole SR, et al.; Hormonal contraception and metabolic outcomes in women with or at risk for HIV infection. J Acquir Immune Defic Syndr. 2009 Dec;52(5):581-7. PMID: 19950431. ***X-2, X-3***

2635. Wong A, Sibbald A, Ferrero F, et al.; Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study. Clin Pediatr (Phila). 2001 Jun;40(6):313-24. PMID: 11824173. ***X-2, X-3, X-4***

2636. Wood SL, Jarrell JJ, Swaby C, et al.; Endocrine disruptors and spontaneous premature labor: a case control study. Environ Health. 2007;6:35. PMID: 18005447. ***X-2, X-3, X-4***

2637. Woods ER, Grace E, Havens KK, et al.; Contraceptive compliance with a levonorgestrel triphasic and a norethindrone monophasic oral contraceptive in adolescent patients. Am J Obstet Gynecol. 1992 Mar;166(3):901-7. PMID: 1550161. ***X-2, X-4***

2638. Woutersz TB, Korba VD; Five-year, multicenter study of a triphasic, low-dose, combination oral contraceptive. Int J Fertil. 1988 Nov-Dec;33(6):406-10. PMID: 2906915. ***X-4***

2639. Wright RL, Frost CJ, Turok DK; A qualitative exploration of emergency contraception users' willingness to select the copper IUD. Contraception. 2012 Jan;85(1):32-5. PMID: 22067808. ***X-2, X-3, X-4***

2640. Wroblewski M, Ostberg H; Ulcer disease among geriatric inpatients with positive faecal occult blood test and/or iron deficiency anaemia. A prospective study. Scand J Gastroenterol. 1990 May;25(5):489-95. PMID: 2359977. ***X-2***

2641. Wu CJ, Hsu PI, Lo GH, et al.; Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection. J Chin Med Assoc. 2004 Apr;67(4):161-7. PMID: 15244013. ***X-2, X-3, X-4***

2642. Wu CS, Wang SH, Chen PC, et al.; Does famotidine have similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy? Int J Clin Pract. 1998 Oct;52(7):472-4. PMID: 10622088. ***X-2, X-3, X-4***

2643. Wu CY, Poon SK, Chen GH, et al.; Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand J Gastroenterol. 1999 Mar;34(3):234-7. PMID: 10232865. ***X-2, X-4***

2644. Wu CY, Wu MS, Chen CJ, et al.; The interaction of H. pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer. J Clin Gastroenterol. 2005 Jan;39(1):50-5. PMID: 15599211. ***X-2***

2645. Wu S, Godfrey EM, Wojdyla D, et al.; Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial. BJOG. 2010 Sep;117(10):1205-10. PMID: 20618314. ***X-4***

2646. Wurnig C, Eyb R, Auersperg V; Indomethacin for prevention of ectopic ossification in cementless hip arthroplasties. A prospective 1-year study of 100 cases. Acta Orthop Scand. 1992 Dec;63(6):628-30. PMID: 1471510. ***X-2, X-4***

2647. Wysenbeek AJ, Klein Z, Nakar S, et al.; Assessment of cognitive function in elderly patients treated with naproxen. A prospective study. Clin Exp Rheumatol. 1988 Oct-Dec;6(4):399-400. PMID: 3229030. ***X-2, X-4***

2648. Wysowski DK, Green L; Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System. Obstet Gynecol. 1995 Apr;85(4):538-42. PMID: 7898829. ***X-2, X-4***

2649. Xia HH, Phung N, Kalantar JS, et al.; Demographic and endoscopic characteristics of patients with Helicobacter pylori positive and negative peptic ulcer disease. Med J Aust. 2000 Nov 20;173(10):515-9. PMID: 11194733. ***X-2, X-3, X-4***

2650. Xiang AH, Kawakubo M, Kjos SL, et al.; Long-acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus. Diabetes Care. 2006 Mar;29(3):613-7. PMID: 16505515. ***X-2***

2651. Xiao B, Wu SC, Chong J, et al.; Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003 Apr;79(4):963-9. PMID: 12749438. ***X-2, X-3***

2652. Yamada A, Sugimoto T, Kondo S, et al.; Assessment of the risk factors for colonic diverticular hemorrhage. Dis Colon Rectum. 2008 Jan;51(1):116-20. PMID: 18085336. ***X-4***

2653. Yamamoto T, Mishina Y, Ebato T, et al.; Prevalence of erosive esophagitis among Japanese patients taking low-dose aspirin. J Gastroenterol Hepatol. 2010 Apr;25(4):792-4. PMID: 20074160. ***X-4***

2654. Yamamoto T, Umegae S, Matsumoto K; High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy. Dig Liver Dis. 2011 May;43(5):386-90. PMID: 21195041. ***X-2, X-3, X-4***

2655. Yanagi RM, Wilson A, Newfeld EA, et al.; Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics. 1981 May;67(5):647-52. PMID: 7019841. ***X-2, X-3, X-4***

2656. Yanchick J, Magelli M, Bodie J, et al.; Time to significant pain reduction following DETP application vs placebo for acute soft tissue injuries. Curr Med Res Opin. 2010 Aug;26(8):1993-2002. PMID: 20575621. ***X-2, X-4***

2657. Yang CP, Cherng CH, Wong CS, et al.; Effects of intravenous ketorolac and fentanyl combined with midazolam on analgesia and side effects during extracorporeal shock wave lithotripsy. Acta Anaesthesiol Sin. 2002 Mar;40(1):9-12. PMID: 11989050. ***X-2, X-4***

2658. Yang MS, Lee SH, Kim TW, et al.; Epidemiologic and clinical features of anaphylaxis in Korea. Ann Allergy Asthma Immunol. 2008 Jan;100(1):31-6. PMID: 18254479. ***X-4***

2659. Yang YX, Hennessy S, Propert K, et al.; Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007 Sep;133(3):748-54. PMID: 17678926. ***X-4***

2660. Yaniv E, Shvero J, Hadar T; Hemostatic effect of tranexamic acid in elective nasal surgery. Am J Rhinol. 2006 Mar-Apr;20(2):227-9. PMID: 16686395. ***X-2, X-3, X-4***

2661. Yasmin E, Glanville J, Barth J, et al.; Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011 May;156(1):67-71. PMID: 21277073. ***X-2, X-3***

2662. Ye Z, Thomas DB, Ray RM; Combined oral contraceptives and risk of cervical carcinoma in situ. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol. 1995 Feb;24(1):19-26. PMID: 7797343. ***X-4***

2663. Yeh TF, Goldbarg H, Pildes RS; Follow-up of premature infants treated with indomethacin. J Pediatr. 1981 Aug;99(2):336. PMID: 7252709. ***X-1, X-2***

2664. Yeh TF, Goldbarg HR, Henek T, et al.; Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one-year follow-up. Am J Dis Child. 1982 Sep;136(9):803-7. PMID: 7114004. ***X-2, X-3, X-4***

2665. Yeomans N, Lanas A, Labenz J, et al.; Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008 Oct;103(10):2465-73. PMID: 18637091. ***X-2, X-3, X-4***

2666. Yeomans N, Wilson I, Langstrom G, et al.; Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol. 2001;30(6):328-34. PMID: 11846050. ***X-2, X-4***

2667. Yigit N, Kacar M, Yigit H, et al.; The effects of copper contraceptive intrauterine device on the uterine blood flow: A prospective transvaginal Doppler study. J

Clin Ultrasound. 2009 Sep;37(7):380-4. PMID: 19455700. ***X-2, X-3***

2668. Yilmaz H, Gurel S, Ozdemir O; Turkish patients with osteoarthritis: their awareness of the side effects of NSAIDs. Turk J Gastroenterol. 2005 Jun;16(2):89-92. PMID: 16252199. ***X-4***

2669. Yilmaz S, Bayan K, Dursun M, et al.; Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study. Dig Dis Sci. 2007 Jan;52(1):110-8. PMID: 17151802. ***X-2, X-3, X-4***

2670. Yki-Jarvinen H, Ryysy L, Nikkila K, et al.; Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999 Mar 2;130(5):389-96. PMID: 10068412. ***X-2, X-4***

2671. Ylikorkala O, Wahlstrom T, Caubel P, et al.; Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate. Acta Obstet Gynecol Scand. 2002 Jul;81(7):654-60. PMID: 12190841. ***X-2, X-4***

2672. Yoon NM, Cavaghan MK, Brunelle RL, et al.; Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009 Jul;31(7):1511-23. PMID: 19695400. ***X-2, X-3, X-4***

2673. Yoong WC, Tuck SM, Yardumian A; Red cell deformability in oral contraceptive pill users with sickle cell anaemia. Br J Haematol. 1999 Mar;104(4):868-70. PMID: 10192452. ***X-2, X-4***

2674. Younossi ZM, Strum WB, Schatz RA, et al.; Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Dig Dis Sci. 1997 Jan;42(1):79-82. PMID: 9009119. ***X-2, X-4***

2675. Yu JO, Gundel RE; Use of Acular LS in the pain management of keratoconus: a pilot study. Optom Vis Sci. 2010 Feb;87(2):125-30. PMID: 19996813. ***X-2, X-4***

2676. Zabinski RA, Burke TA, Johnson J, et al.; An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics. 2001;19 Suppl 1:49-58. PMID: 11280105. ***X-2, X-4***

2677. Zackova M, Taddei S, Calo P, et al.; Ketorolac vs tramadol in the treatment of postoperative pain during maxillofacial surgery. Minerva Anestesiol. 2001 Sep;67(9):641-6. PMID: 11731754. ***X-2, X-3, X-4***

2678. Zalel Y, Shulman A, Lidor A, et al.; The local progestational effect of the levonorgestrel-releasing intrauterine system: a sonographic and Doppler flow study. Hum Reprod. 2002 Nov;17(11):2878-80. PMID: 12407042. ***X-2, X-4***

2679. Zalev AH, Gardiner GW, Warren RE; NSAID injury to the small intestine. Abdom Imaging. 1998 Jan-Feb;23(1):40-4. PMID: 9437061. ***X-2***

2680. Zancan A, Locatelli C, Ramella F, et al.; A new model of pharmacovigilance? A pilot study. Biomed Pharmacother. 2009 Jul;63(6):451-5. PMID: 18790597. ***X-2, X-3, X-4***

2681. Zandbelt MM, Houbiers JG, van den Hoogen FH, et al.; Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis. J Rheumatol. 2006 Sep;33(9):1726-33. PMID: 16960935. ***X-2, X-4***

2682. Zanettini R, Antonini A, Gatto G, et al.; Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007 Jan 4;356(1):39-46. PMID: 17202454. ***X-2***

2683. Zanettini R, Antonini A, Gatto G, et al.; Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther. 2011 Dec;29(6):404-10. PMID: 20553285. ***X-2***

2684. Zapata-Colindres JC, Zepeda-Gomez S, Montano-Loza A, et al.; The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease. Can J Gastroenterol. 2006 Apr;20(4):277-80. PMID: 16609757. ***X-2***

2685. Zaporozhan VN, Khait OV, Tumasyan KP; Norcolut with immune modulators in the complex treatment for hyperplastic uterine processes. Clin Exp Obstet Gynecol. 1993;20(1):13-9. PMID: 8462182. ***X-2, X-4***

2686. Zaraa I, Jones M, Trojjet S, et al.; Severe adverse cutaneous drug eruptions: epidemiological and clinical features. Int J Dermatol. 2011 Jul;50(7):877-80. PMID: 21699528. ***X-2***

2687. Zecca E, Romagnoli C, De Carolis MP, et al.; Does Ibuprofen increase neonatal hyperbilirubinemia? Pediatrics. 2009 Aug;124(2):480-4. PMID: 19620202. ***X-2, X-4***

2688. Zeidler H; Epidemiology and NSAID induced gastropathy. J Rheumatol Suppl. 1991 Mar;28:2-5. PMID: 2038013. ***X-1***

2689. Zembowicz A, Mastalerz L, Setkowicz M, et al.; Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol. 2003 Dec;139(12):1577-82. PMID: 14676074. ***X-2, X-3, X-4***

2690. Zerr DM, Alexander ER, Duchin JS, et al.; A case-control study of necrotizing fasciitis during primary varicella. Pediatrics. 1999 Apr;103(4 Pt 1):783-90. PMID: 10103303. ***X-2, X-4***

2691. Zhang J; Factors associated with copper T IUD removal for bleeding/pain: a multivariate analysis. Contraception. 1993 Jul;48(1):13-21. PMID: 8403901. ***X-2, X-4***

2692. Zhang Y, Coogan PF, Palmer JR, et al.; Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs. Cancer Detect Prev. 2006;30(1):99-101. PMID: 16495019. ***X-4***

2693. Zhao S, Choksuchat C, Zhao Y, et al.; Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant. Contraception. 2009 Jun;79(6):469-78. PMID: 19442784. ***X-2, X-4***

2694. Zhao SZ, Burke TA, Whelton A, et al.; Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27. PMID: 12416791. ***X-4***

2695. Ziaei S, Ninavaei M, Faghihzadeh S; Urinary tract infection in the users of depot-medroxyprogesterone acetate. Acta Obstet Gynecol Scand. 2004 Oct;83(10):909-11. PMID: 15453884. ***X-2***

2696. Zichella L, Sbrignadello C, Tomassini A, et al.; Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene. Adv Contracept. 1999;15(3):191-200. PMID: 11019950. *X-2, X-4*

2697. Zimmerman J, Arnon R, Beeri R, et al.; Seasonal fluctuations in acute upper gastrointestinal bleeding: lack of effect of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 1992 Nov;87(11):1587-90. PMID: 1442678. ***X-2, X-3, X-4***

2698. Zimmerman J, Arnon R, Ligumski M, et al.; Acute upper gastrointestinal bleeding in Jerusalem 1988-91: causes, characteristics and relation to nonsteroidal anti-inflammatory drugs. Isr J Med Sci. 1993 May;29(5):292-7. PMID: 8314690. ***X-2, X-4***

2699. Zimmerman J, Meroz Y, Siguencia J, et al.; Upper gastrointestinal hemorrhage. Comparison of the causes and prognosis in primary and secondary bleeders. Scand J Gastroenterol. 1994 Sep;29(9):795-8. PMID: 7824858. ***X-2, X-3, X-4***

2700. Zimmermann T, Dietrich H, Wisser KH, et al.; The efficacy and tolerability of Valette: a postmarketing surveillance study. Eur J Contracept Reprod Health Care. 1999 Sep;4(3):155-64. PMID: 10574641. ***X-4***

2701. Zimran A, Kramer M, Plaskin M, et al.; Incidence of hyperkalaemia induced by indomethacin in a hospital population. Br Med J (Clin Res Ed). 1985 Jul 13;291(6488):107-8. PMID: 3926071. ***X-1***

2702. Zizic TM, Sutton JD, Stevens MB; A long-term evaluation of the treatment of osteoarthritis. Am J Med. 1986 Nov 28;81(5B):29-35. PMID: 3538868. ***X-2, X-3, X-4***

2703. Zochling J, Bohl-Buhler MH, Baraliakos X, et al.; Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey. Clin Rheumatol. 2006 Nov;25(6):794-800. PMID: 16528455. ***X-2***

2704. Zweifel SA, Engelbert M, Khan S, et al.; Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina. 2009 Nov-Dec;29(10):1527-31. PMID: 19898185. ***X-2, X-3, X-4***

2705. Zziwambazza W, Merkle CJ, Moore IM, et al.; The effects of norepinephrine infusion on the circulating lymphocyte counts of post-open heart surgery patients. Biol Res Nurs. 2000 Jan;1(3):199-209. PMID: 11232215. ***X-2, X-4***

Appendix M. Labeled Indications for Drugs Included in Review

Generic Name, Route of Administration	Brand Name(s) (approval date)[1]	Labeled Indications[1]
Intrauterine Device		
Levonorgestrel-releasing intrauterine system (52 mg, releasing ~0.02 mg/day) (LNG-IUS; intrauterine device)	Mirena®[2] (December 6, 2000)	• Intrauterine contraception for up to 5 years. • Treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception as their method of contraception. Mirena [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2009. Daily Med (Mirena) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92231d6f-f4d8-43b0-aa95-f7cec1cc18c5
Contraceptive vaginal ring (etonogestrel/ethinyl estradiol vaginal ring, delivers 0.120 mg/0.015 mg per day)	NuvaRing®[2] (October 3, 2001)	• Prevention of pregnancy. NuvaRing [package insert]. Whitehouse Station, NJ: Merck & Co; 2012. DailyMed (NuvaRing) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=017343fb-86c4-45ab-9c47-52cc5b9f3a02
Antifibrinolytic Agents		
Tranexamic acid (650 mg) (oral)	Lysteda®[2] (November 13, 2009)	• Treatment of cyclic heavy menstrual bleeding. Lysteda [package insert]. Parsippany, NJ: Ferring Pharmaceutical; 2011. DailyMed (Lysteda) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84a65305-65d7-e7fd-66f3-dda8d8f920b1
Combined Oral Contraceptive Agents (COCs)		
Estradiol valerate and dienogest (oral) 28 tablets in the following order: 2 tablets of 3 mg EV; 5 tablets of 2 mg EV and 2 mg D; 17 tablets of 2 mg EV and 3 mg D; 2 tablets of 1 mg EV; and 2 inert tablets.	Natazia®[2] (May 6, 2010)	• Prevent pregnancy. • Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception. Natazia [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2012. DailyMed (Natazia) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02c91fba-9c47-43ef-ac78-e82369798834

Generic Name, Route of Administration	Brand Name(s) (approval date)[1]	Labeled Indications[1]
Ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg) (oral) 28 tablets: 21 tablets of 0.030 mg EE and 0.15 mg L; and 7 inert tablets.	Nordette-28®[2] (July 21, 1982) Levora®[3] (December 13, 1993) Portia-28®[3] (May 23, 2002) Altavera®[3] (August 2, 2010) Marlissa®[3] (February 29, 2012)	• Prevention of pregnancy. Nordette [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2010. DailyMed (Nordette) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef68258d-9d09-43c9-af87-bfa4b3b0ee01
Ethinyl estradiol (0.020 mg) and norethindrone acetate (1 mg) (oral) 21 tablets of 0.020 mg EE and 1 mg N. Also available as 28-day regimen with additional 7 tablets containing 75 mg ferrous fumarate (Loestrin Fe 1/20).	Loestrin 21 1/20®[3] (October 1, 1976) Microgestin 1/20®[3] (February 5, 2001) Junel 1/20®[3] (May 30, 2003) Minestrin 1/20®[4]	Loestrin: • For the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Minestrin: • For the control of contraception. Loestrin [package insert]. Pomona, NY: Barr harmaceuticals; 2009. DailyMed (Loestrin) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f40605cf-9933-40d9-915a-ea6dbc0f169f Minestrin 1/20 [package insert]. Fajardo, Puerto Rico: Warner Chilcott; 2006.

Generic Name, Route of Administration	Brand Name(s) (approval date)[1]	Labeled Indications[1]
Norgestimate ethinyl estradiol, triphasic (oral) 28 tablets: 7 tablets of 0.180 mg N and 0.035 mg EE; 7 tablets of 0.215 mg N and 0.035 mg EE; 7 tablets of 0.250 mg N and 0.035 mg EE; and 7 inert tablets.	Ortho Tri-Cyclen®[2] (July 3, 1992) Tri-Sprintec®[3] (December 29, 2003) Tri-Previfem®[3] (March 26, 2004) *LexiComp[5] lists additional brand names. Only those detailed here are listed by the FDA as therapeutic equivalents.* TriNessa *is not listed in Drugs@FDA, but it does appear to be available in the US (drugstore.com).*	Ortho Tri-Cyclen[2] and Tri-Previfem[3]: • Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. • Treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. [The drug] should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. Tri-Sprintec[3] labeling differs slightly on second indication: • Treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire contraception, have achieved menarche and are unresponsive to topical anti-acne medications. Ortho Tri-Cyclen [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals; 2010. DailyMed (Ortho Tri-Cyclen) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=384e7a40-dcbd-4908-bf5e-65abc9932973 Tri-Sprintec [package insert]. Pomona, NY: Barr Laboratories; 2009. DailyMed (Tri-Sprintec) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=843cbef6-cbfb-4a44-bb80-22930753e4c0 Tri-Previfem [package insert]. Huntsville, AL: Qualitest Pharmaceuticals; 2011. DailyMed (Tri-Previfem) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd15dbd7-75b7-416e-af55-1e90c2bab051
Progestogens		
Dydrogesterone (10 mg) (oral)	Gynorest International brand names[5]: Dabroston; Dufaston; Duphaston; Terolut *NOTE: Dydrogesterone is not currently available in the United States; the FDA lists the marketing status of dydrogesterone (Gynorest) as discontinued. The drug is available in other countries.*	Reported use[5]: Treatment of progesterone deficiencies; counteract unopposed estrogen in hormone replacement therapy.

Generic Name, Route of Administration	Brand Name(s) (approval date)[1]	Labeled Indications[1]
Medroxyprogesterone acetate (400 mg/mL) (injectable suspension)	Depo-Provera CI®[2] (October 29, 1992) Depo-subQ Provera 104®[2] (December 17, 2004)	Depo-Provera CI: • Prevention of pregnancy. Depo-subQ Provera 104: • Prevention of pregnancy in women of child bearing potential. • Management of endometriosis-associated pain. Depo-Provera CI [package insert]. New York City, NY: Parmacia and Upjohn; 2011. DailyMed (Depo-Provera) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=199cf13e-0859-4a73-9b45-e700d0cd1049 Depo-subQ Provera 104 [package insert]. New York City, NY: Pharmacia and Upjohn; 2011. DailyMed (Depo-subQ Provera) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=390087a6-f3c3-4f0b-a930-79acf412f153
Medroxyprogesterone acetate (2.5 mg, 5 mg, or 10 mg) (oral)	Provera®[2] (June 18, 1959)	• Treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. • Reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. Provera [package insert]. New York City, NY: Pharmacia and Upjohn; 2009. DailyMed (Provera) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a586be28-96af-4fed-a13f-9b94fd4c7405
Norethisterone [norethindrone] (5 mg) (oral)	Aygestin®[2] (April 21, 1982)	• Treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Aygestin [package insert]. Pomona, NY: Duramed Pharmaceuticals; 2010. DailyMed (Aygestin) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69f5bc4b-758d-471b-ad8d-17c94f8e0963
Progesterone (4% [45 mg] or 8% [90 mg]) (vaginal gel)	Crinone®[2] (July 31, 1997)	• Progesterone supplementation or replacement as part of an Assisted Reproductive Technology ("ART") treatment for infertile women with progesterone deficiency. • Secondary amenorrhea. Crinone [package insert]. Morristown, NJ: Watson Pharma; 2011. DailyMed (Crinone) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c8ffbd2-6b7a-42c7-b29e-e4de69dad9e6

Generic Name, Route of Administration	Brand Name(s) (approval date)[1]	Labeled Indications[1]
Progesterone (0.065 mg/day, according to multiple sources) (coil/intrauterine insert)	Progestasert (February 4, 1976) *NOTE: The FDA lists the marketing status of Progestasert as discontinued as of June 1, 2001.*	• Prevention of pregnancy.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)		
Flurbiprofen (50 mg or 100 mg) (oral)	Ansaid®[2] (October 31, 1988)	• For relief of the signs and symptoms of rheumatoid arthritis. • For relief of the signs and symptoms of osteoarthritis. Ansaid [package insert]. New York City, NY: Pfizer / Pharmacia & Upjohn Co.; 2010. DailyMed (flurbiprofen) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f56be63c-88e4-4b78-b12d-d80e3e8b3893
Meclofenamate sodium (50 mg or 100 mg) (oral)	Meclomen (June 25, 1980) *NOTE: The FDA lists the marketing status of Meclomen as discontinued. The drug is available in the US as generic.*	• For the relief of mild to moderate pain. • For the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. • For relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis. Meclofenamate sodium [package insert]. Morgantown, WV: Mylan Pharmaceuticals; 2006. DailyMed (meclofenamate sodium) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96f19af4-de8f-4fd7-90d8-55fe6ebdd81d
Mefenamic acid (250 mg) (oral)	Ponstel®[2] (March 28, 1967)	• For relief of mild to moderate pain in patients ≥14 years of age, when therapy will not exceed one week (7 days). • For treatment of primary dysmenorrhea. Ponstel [package insert]. Atlanta, GA: Sciele Pharma; 2008. DailyMed (Ponstel) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d77e13db-d1b1-4dbf-9de8-80827018cf43

Generic Name, Route of Administration	Brand Name(s) (approval date)[1]	Labeled Indications[1]
Naproxen sodium (oral) Naprosyn as 250 mg, 375 mg, or 500 mg tablets; Anaprox as 275 mg tablets; Anaprox DS as 550 mg tablets; others available.	Naprosyn®[2] (March 11, 1976) Anaprox DS®[2] (September 4, 1980) Anaprox®[3] (September 4, 1980) Naprosyn Suspension®[2] (March 23, 1987) EC-Naprosyn®[2] (October 14, 1994) *Also various OTC brands*	Naprosyn, EC-Naprosyn, Anaprox, Anaprox DS, and Naprosyn Suspension is indicated: • For the relief of the signs and symptoms of rheumatoid arthritis. • For the relief of the signs and symptoms of osteoarthritis. • For the relief of the signs and symptoms of ankylosing spondylitis. • For the relief of the signs and symptoms of juvenile arthritis. Naprosyn, Anaprox, Anaprox DS, and Naprosyn Suspension is also indicated: • For relief of the signs and symptoms of tendonitis. • For relief of the signs and symptoms of bursitis. • For relief of the signs and symptoms of acute gout. • For the management of pain. • For the management of primary dysmenorrheal. EC-Naprosyn / Naprosyn / Anaprox / Anaprox DS / Naprosyn [package insert]. Nutley, NJ: Roche Pharmaceuticals; 1999-200X. DailyMed (Naprosyn) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68848217-03c9-4377-9be6-6f567e629129
Other Drugs		
Cabergoline (0.5 mg) (oral)	Dostinex (December 23, 1996) *NOTE: The FDA lists the marketing status of Dostinex as discontinued. The drug is available in the US as generic.*	• Treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Cabergoline [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2011. DailyMed (cabergoline) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e497366b-a124-4d7f-bd45-a883c392d4bb
Etamsylate [ethamsylate] (250 mg or 500 mg) (oral)	International brand names[5]: Altodor; Dicinone; Dicynene; Dicynone; Eselin; Ethamsyl; Hemo 141; Hemoced; Impedil *NOTE: Etamsylate is not currently available in the United States. The drug is available in other countries.*	Reported use[5]: Prevention and treatment of capillary hemorrhages; treatment of menorrhagia or metrorrhagia.
Exenatide (0.25 mg/mL as either 0.005 mg or 0.01 mg per dose) (injection)	Byetta®[2] (April 28, 2005)	• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2011. DailyMed (Byetta) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=751747da-7c1f-41ad-b1a6-a6d920f70599

Generic Name, Route of Administration	Brand Name(s) (approval date)[1]	Labeled Indications[1]
Metformin hydrochloride (oral) Glucophage as 500 mg, 850 mg, or 1000 mg tablets; Glucophage XR as 500 mg or 750 mg tablets; Fortamet and Glumetza as 500 mg or 1000 mg tablets.	Glucophage®[2] (March 3, 1995) Glucophage XR®[2] (October 13, 2000) Fortamet®[2] (April 28, 2004) Glumetza®[2] (June 3, 2005)	• As an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009. DailyMed (Glucophage) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a0166c7-7097-4e4a-9036-6c9a60d08fc6
N-acetyl-cysteine (oral; also available as solution for inhalation, IV injection, or ocular solution)	Mucomyst (September 14, 1963; marketing discontinued) Acetadote®[2] (injectable, IV) (January 23, 2004) Acetylcysteine is also available in tablet form as a dietary supplement under various brand names.	• Prevent or lessen hepatic injury after ingestion of acetaminophen (acute poisoning or repeated supratherapeutic ingestion). • Adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in conditions such as: chronic broncopulmonary disease; acute bronchopulmonary disease; pulmonary complications of cystic fibrosis; tracheostomy care; pulmonary complications associated with surgery; during anesthesia, post-traumatic chest conditions; atelectasis due to mucous obstruction; and diagnostic bronchial studies. Acetadote [package insert]. Nashville, TN: Cumberland Pharmaceuticals; 2011. Acetylcysteine solution [package insert]. Lake Forest, IL: Hospira, Inc.; 2004. DailyMed (Acetadote) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39 DailyMed (acetylcysteine solution) http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586

Notes:

[1] US-based information; brand names, therapeutic equivalency, dates of approval, and indications per FDA website (Drugs@FDA) and individual package inserts, unless otherwise noted; last accessed September 4, 2012.

[2] Listed by FDA as the Reference Listed Drug (RLD): an approved drug product to which new generic versions are compared to show that they are bioequivalent.

[3] Listed by FDA as therapeutic equivalent to RLD.

[4] Canadian brand name and approval information.

[5] Lexi-Comp OnlineTM, Lexi-Drugs International OnlineTM, Hudson, Ohio: Lexi-Comp, Inc.; September 4, 2012.

Appendix N. Harms from Package Inserts for Drugs Included in Review

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
Levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena®)	*Warnings and Precautions:* • If pregnancy should occur with Mirena in place, remove Mirena. • There is increased risk of ectopic pregnancy including loss of fertility, pregnancy loss, septic abortion (including septicemia, shock and death) and premature labor and delivery. • Group A streptococcal infection has been reported; strict aseptic technique is essential during insertion. • Before using Mirena, consider the risks of pelvic inflammatory disease (PID). • Bleeding patterns become altered, may remain irregular and amenorrhea may ensue. • Perforation may occur during insertion. Risk is increased in women with fixed retroverted uteri, during lactation, and postpartum. • Embedment in the myometrium and partial or complete expulsion may occur. • Persistent enlarged ovarian follicles should be evaluated. *Serious:* • Ectopic pregnancy - Incidence in clinical trials excluding women with risk factors for ectopic was 0.1% per year. • Intrauterine pregnancy - "As of September 2006, 390 live births out of an estimated 9.9 million Mirena users had been reported." • Group A streptococcal sepsis (GAS) – "As of September 2006, 9 cases of Group A streptococcal sepsis (GAS) out of an estimated 9.9 million Mirena users had been reported." • Pelvic Inflammatory Disease • Embedment • Perforation • Breast cancer – "Spontaneous reports of breast cancer have been received during postmarketing experience with Mirena… Two observational studies have not provided evidence of an increased risk of breast cancer during the use of Mirena." *Most common (≥5% users):* • Uterine/vaginal bleeding alterations (51.9%) • Amenorrhea (23.9%) • Intermenstrual bleeding and spotting (23.4%)	"The data provided reflect the experience with the use of Mirena in the adequate and well-controlled studies for contraception (n=2,339) and heavy menstrual bleeding (n=80). For the contraception indication, Mirena was compared to a copper IUD (n=1,855), to another formulation of levonorgestrel intrauterine system (n=390) and to a combined oral contraceptive (n=94) in women 18 to 35 years old. The data cover more than 92,000 woman-months of exposure. For the treatment of heavy menstrual bleeding indication (n=80), the subjects included women aged 26 to 50 with confirmed heavy bleeding and exposed for a median of 183 treatment days of Mirena (range 7 to 295 days). The frequencies of reported adverse drug reactions represent crude incidences. The adverse reactions seen across the 2 indications overlapped, and are reported using the frequencies from the contraception studies." Mirena [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2009.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Abdominal/pelvic pain (12.8%) • Ovarian cysts (12%) • Headache/migraine (7.7%) • Acne (7.2%) • Depressed/altered mood (6.4%) • Menorrhagia (6.3%) • Breast tenderness/pain (4.9%) • Vaginal discharge (4.9%) • IUD expulsion (4.9%) *Other (<5% users):* • Nausea • Nervousness • Vulvovaginitis • Dysmenorrhea • Back pain • Weight increase • Decreased libido • Cervicitis/Papanicolaou smear normal/class II • Hypertension • Dyspareunia • Anemia • Alopecia • Skin disorders including eczema • Pruritus • Rash and urticaria • Abdominal distention • Hirsutism • Edema *Postmarketing reports of:* • Device breakage • Angioedema	
Contraceptive vaginal ring (NuvaRing®)	*Warning:* Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, particularly in women over 35 years of age and with the number of cigarettes smoked. For this reason, COCs should not be used by women	NuvaRing [package insert]. Whitehouse Station, NJ: Merck & Co; 2012.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	who are over 35 years of age and smoke. *Most common (reported by 5-14% of women in clinical trials:* • Vaginitis • Headache • Upper respiratory infection • Vaginal secretion • Sinusitis • Weight gain • Nausea *Adverse events leading to discontinuation in 1-2.5% of women using NuvaRing in trials:* • Device-related events (foreign body sensation, coital problems, device explusion) • Vaginal symptoms (discomfort/vaginitis/vaginal secretion) • Headache • Emotional lability • Weight gain Also any adverse reactions that are associated with the use of combination hormonal contraceptives are also likely to apply to combination vaginal hormonal contraceptives, such as NuvaRing.	
Tranexamic acid (oral; Lysteda®)	*Warnings and Precautions:* • The risk of thrombotic and thromboembolic events may increase further when hormonal contraceptives are administered with Lysteda, especially in women who are obese or smoke cigarettes. Women using hormonal contraception should use Lysteda only if there is a strong medical need and the benefit of treatment will outweigh the potential increased risk of a thrombotic event. Do not use Lysteda in women who are taking more than the approved dose of a hormonal contraceptive. • Concomitant use of Lysteda with Factor IX complex concentrates, anti-inhibitor coagulant concentrates, or all-trans retinoic acid (oral tretinoin) may increase the risk of thrombosis. • Visual or ocular adverse effects may occur with Lysteda. Immediately discontinue use if visual or ocular symptoms occur. • Cerebral edema and cerebral infarction may be caused by use of Lysteda in women with subarachnoid hemorrhage. • Ligneous conjunctivitis has been reported in patients taking	"Lysteda safety derived from two randomized, double-blind, placebo-controlled studies on treatment of heavy menstrual bleeding. Long-term safety was studied in two open label studies." "In one study, subjects with physician-diagnosed heavy menstrual bleeding (not using the alkaline hematin methodology) were treated with 3900 mg/day for up to 5 days during each menstrual period for up to 27 menstrual cycles. A total of 781 subjects were enrolled and 239 completed the study through 27 menstrual cycles. A total of 12.4% of the subjects withdrew due to adverse events. Women using hormonal contraception were excluded from the study… A long-term open-label extension study of subjects from the two short-term efficacy studies was also conducted in which subjects were treated with 3900 mg/day for up to 5 days during each menstrual

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	tranexamic acid. *From RCTs for HMB:* G1: lysteda group (N=232) G2: placebo group (N=139) Total number of adverse events G1: 1500 G1: 923 Headache, including tension headache G1: 117 (50.4%) G2: 65 (46.8%) Nasal and sinus symptoms, including nasal, respiratory tract and sinus congestion, sinusitis, acute sinusitis, sinus headache, allergic sinusitis, and sinus pain, and multiple allergies and seasonal allergies G1: 59 (25.4%) G2: 24 (17.3%) Back pain G1: 48 (20.7%) G2: 21 (15.1%) Abdominal pain, including abdominal tenderness and discomfort G1:46 (19.8%) G2: 25 (18.0%) Musculoskeletal pain, including musculoskeletal discomfort and myalgia G1: 26 (11.2%) G2: 4 (2.9%) Arthralgia, including joint stiffness and swelling G1: 16 (6.9%) G2: 7 (5.0%) Muscle cramps and spasms G1: 15 (6.5%) G2: 8 (5.8%) Migraine G1: 14 (6.0%) G2: 8 (5.8%) Anemia G1: 13 (5.6%) G2: 5 (3.6%) Fatigue G1: 12 (5.2%) G2: 6 (4.3%) *Postmarketing reports in patients receiving tranexamic acid for various*	period for up to 9 menstrual cycles. A total of 288 subjects were enrolled and 196 subjects completed the study through 9 menstrual cycles. A total of 2.1% of the subjects withdrew due to adverse events… The types and severity of adverse events in these two long-term open-label trials were similar to those observed in the double-blind, placebo-controlled studies although the percentage of subjects reporting them was greater in the 27-month study, most likely because of the longer study duration." Lysteda [package insert]. Parsippany, NJ: Ferring Pharmaceutical; 2011.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	indications: • Nausea, vomiting, and diarrhea • Allergic skin reactions • Anaphylactic shock and anaphylactoid reactions • Thrombotic events (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery and vein obstruction) – including venous and arterial thrombotic events in women who have used Lysteda concomitantly with combined hormonal contraceptives • Impaired color vision and other visual disturbances • Dizziness	
0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel (oral; Nordette-28®, others)	*Warning:* Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke. *Reported in patients taking oral contraceptives and believed to be drug-related:* • Nausea • Vomiting • Gastrointestinal symptoms (such as abdominal pain, cramps and bloating) • Breakthrough bleeding • Spotting • Change in menstrual flow • Amenorrhea • Temporary infertility after discontinuation of treatment • Edema/fluid retention • Melasma/chloasma which may persist • Breast changes: tenderness, pain, enlargement, secretion • Change in weight or appetite (increase or decrease) • Change in cervical erosion and secretion • Diminution in lactation when given immediately postpartum • Cholestatic jaundice • Rash (allergic) • Mood changes, including depression • Vaginitis, including candidiasis • Change in corneal curvature (steepening)	"The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six. The risk is very low under the age of 30." "Case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep-vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease. Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization. The approximate incidence of deep-vein thrombosis and pulmonary embolism in users of low dose (<50µg ethinyl estradiol) combination oral contraceptives is up to 4 per 10,000 woman-years compared to 0.5 to 3 per 10,000 woman-years for non-users. However, the incidence is substantially less than that associated with pregnancy (6 per 10,000 woman-years). The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped." "In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension. The relative risk of hemorrhagic stroke is reported to be 1.2 for nonsmokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Intolerance to contact lenses • Mesenteric thrombosis • Decrease in serum folate levels • Exacerbation of systemic lupus erythematosus • Exacerbation of porphyria • Exacerbation of chorea • Aggravation of varicose veins • Anaphylactic/anaphylactoid reactions, including urticaria, angioedema, and severe reactions with respiratory and circulatory symptoms. *Reported in patients taking oral contraceptives, with association neither confirmed nor refuted:* • Congenital anomalies • Premenstrual syndrome • Cataracts • Optic neuritis, which may lead to partial or complete loss of vision • Cystitis-like syndrome • Nervousness • Dizziness • Hirsutism • Loss of scalp hair • Erythema multiforme • Erythema nodosum • Hemorrhagic eruption • Impaired renal function • Hemolytic uremic syndrome • Budd-Chiari syndrome • Acne • Changes in libido • Colitis • Sickle-cell disease • Cerebral-vascular disease with mitral valve prolapse • Lupus-like syndromes • Pancreatitis • Dysmenorrhea	normotensive users, and 25.7 for users with severe hypertension. The attributable risk is also greater in older women." Nordette [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2010.
estradiol valerate and dienogest (oral; Natazia®)	*Warning:* Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age and with the number of cigarettes smoked. For this reason, COCs should not be used by women	"A total of 2,131 women, 18 to 54 years of age, who took at least one dose of Natazia were enrolled in four clinical phase 3 trials. A total of 1,867 subjects were included in two clinical phase 3 studies with a treatment duration up to 28 cycles with Natazia as an

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	who are over 35 years of age and smoke. *Serious:* • Serious cardiovascular events and stroke • Vascular events • Liver disease *Including reports from clinical trials of:* • Myocardial infarction (2 cases) • Ruptured ovarian cyst (2 cases) • Deep vein thrombosis • Focal nodular hyperplasia of the liver • Uterine leiomyoma • Acute cholecystitis • Chronic acalculous cholecystitis *Commonly reported:* • Irregular uterine bleeding • Nausea • Breast tenderness • Headache *Common (≥2%):* • Headache (including migraines) (12.7%) • Breast pain, discomfort or tenderness (7.0%) • Menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%) • Nausea or vomiting (6.0%) • Acne (3.9%) • Mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) • Increased weight (2.9%) *Led to study discontinuation:* 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were: • Menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%)	oral contraceptive and 264 subjects in the two phase 3 clinical trials with a treatment duration of 7 cycles evaluating Natazia in the treatment of heavy, prolonged, and/or frequent menstrual bleeding in women without organic pathology." Natazia [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2012.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%) • Acne (1.1%), headache (including migraines) (1.1%) • Weight increased (0.7 %) *Postmarketing experience:* • Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension • Hepatobiliary disorders: Gallbladder disease, hepatitis • Immune system disorders: Hypersensitivity • Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia • Nervous system disorders: Dizziness • Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme • Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain) • Infections and infestations: Vulvovaginal candidiasis	
0.20mg ethinyl estradiol and 1mg norethindrone acetate (oral; Loestrin 21 1/20®, others)	*Warning:* Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke. *Increased risk of serious adverse reactions:* • Thrombophlebitis • Arterial thromboembolism • Pulmonary embolism • Myocardial infarction • Cerebral hemorrhage • Cerebral thrombosis • Hypertension • Gallbladder disease • Hepatic adenomas or benign liver tumors *Evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed:*	Loestrin [package insert]. Pomona, NY: Barr Pharmaceuticals; 2009. NOTE: package insert includes 89 references, many of which are related to adverse effects.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Mesenteric thrombosis • Retinal thrombosis *Reported in patients receiving oral contraceptives and are believed to be drug-related:* • Nausea • Vomiting • Gastrointestinal symptoms (such as abdominal cramps and bloating) • Breakthrough bleeding • Spotting • Change in menstrual flow • Amenorrhea • Temporary infertility after discontinuation of treatment • Edema • Melasma which may persist • Breast changes: tenderness, enlargement, secretion • Change in weight (increase or decrease) • Change in cervical erosion and secretion • Diminution in lactation when given immediately postpartum • Cholestatic jaundice • Migraine • Rash (allergic) • Mental depression • Reduced tolerance to carbohydrates • Vaginal candidiasis • Change in corneal curvature (steepening) • Intolerance to contact lenses *Reported in users of oral contraceptives and the association has been neither confirmed nor refuted:* • Pre-menstrual syndrome • Cataracts • Changes in appetite • Cystitis-like syndrome • Headache • Nervousness • Dizziness • Hirsutism • Loss of scalp hair • Erythema multiforme	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Erythema nodosum • Hemorrhagic eruption • Vaginitis • Porphyria • Impaired renal function • Hemolytic uremic syndrome • Budd-Chiari syndrome • Acne • Changes in libido • Colitis	
norgestimate ethinyl estradiol, triphasic (oral; Ortho Tri Cyclen®, others)	*Warning:* Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke. *An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives:* • Thrombophlebitis and venous thrombosis with or without embolism • Arterial thromboembolism • Pulmonary embolism • Myocardial infarction • Cerebral hemorrhage • Cerebral thrombosis • Hypertension • Gallbladder disease • Hepatic adenomas or benign liver tumors *There is evidence of an association between the following conditions and the use of oral contraceptives:* • Mesenteric thrombosis • Retinal thrombosis *The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:* • Nausea • Vomiting • Gastrointestinal symptoms (such as abdominal cramps and bloating) • Breakthrough bleeding	Ortho Tri-cyclen [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals; 2010. NOTE: package insert includes 101 references, many of which are related to adverse effects.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Spotting • Change in menstrual flow • Amenorrhea • Temporary infertility after discontinuation of treatment • Edema • Melasma which may persist • Breast changes: Tenderness, enlargement, secretion • Change in weight (increase or decrease) • Change in cervical erosion and secretion • Diminution in lactation when given immediately postpartum • Cholestatic jaundice • Migraine • Allergic reaction, including rash, urticaria, angioedema • Mental depression • Reduced tolerance to carbohydrates • Vaginal candidiasis • Change in corneal curvature (steepening) • Intolerance to contact lenses *The following adverse reactions have been reported in users of oral contraceptives and a causal association has been neither confirmed nor refuted:* • Pre-menstrual syndrome • Cataracts • Changes in appetite • Cystitis-like syndrome • Headache • Nervousness • Dizziness • Hirsutism • Loss of scalp hair • Erythema multiforme • Erythema nodosum • Hemorrhagic eruption • Vaginitis • Porphyria • Impaired renal function • Hemolytic uremic syndrome • Acne • Changes in libido	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Colitis • Budd-Chiari Syndrome	
Dydrogesterone (oral; Gynorest) NOTE: marketing discontinued in US; labels are not available.	As for progestogens in general. Porphyria • The Drug Database for Acute Porphyria, compiled by the Norwegian Porphyria Centre (NAPOS) and the Porphyria Centre Sweden, classifies dydrogesterone as porphyrinogenic; it should be prescribed only for compelling reasons and precautions should be taken in all patients. (The Drug Database for Acute Porphyria. Available at: http://www.drugs-porphyria.org (accessed 04/10/11)) Pregnancy • Anomalies (non-virilising) of the genito-urinary tract were found in a 4-month-old baby whose mother had taken dydrogesterone 20 mg daily from the eighth to twentieth week of pregnancy and 10 mg daily from then until term.1 She had also been given hydroxyprogesterone caproate 250 mg by intramuscular injection weekly from the eighth to the twentieth week. (Roberts IF, West RJ. Teratogenesis and maternal progesterone. Lancet 1977; ii: 982. (PubMed id:72325))	Dydrogesterone. In: Micromedex® Healthcare Series. Thomson Reuters (Healthcare) Inc. http://www.thomsonhc.com (accessed March 31, 2012). Martindale: The Complete Drug Reference. Pharmaceutical Press. Electronic version, Thomson Reuters (Healthcare) Inc. http://www.thomsonhc.com (accessed March 31, 2012).
Medroxyprogesterone acetate (injectable; Depo-Provera CI®, others)	*Warnings:* • Intrauterine exposure: "Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and genital abnormalities in male and female fetuses. The risk of hypospadias (5 to 8 per 1,000 male births in the general population) may be approximately doubled with exposure to these drugs. There are insufficient data to quantify the risk to exposed female fetuses, but insofar as some of these drugs induce mild virilization of the external genitalia of the female fetus, and because of the increased association of hypospadias in the male fetus, it is prudent to avoid the use of these drugs during the first trimester of pregnancy." • Thromboembolic disorders • Ocular disorders • Lactation *Reported:* • Breakthrough bleeding • Spotting • Change in menstrual flow • Amenorrhea	Depo-Provera CI [package insert]. New York, NY: Pharmacia and Upjohn Company; 2011.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Headache • Nervousness • Dizziness • Edema • Change in weight (increase or decrease) • Changes in cervical erosion and cervical secretions • Cholestatic jaundice, including neonatal jaundice • Breast tenderness and galactorrhea • Skin sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash • Acne, alopecia and hirsutism • Rash (allergic) with and without pruritis • Anaphylactoid reactions and anaphylaxis • Mental depression • Pyrexia • Fatigue • Insomnia • Nausea • Somnolence In a few instances there have been undesirable sequelae at the site of injection, such as residual lump, change in color of skin, or sterile abscess. *The following adverse reactions have been observed in patients receiving estrogen-progestin combination drugs:* • Rise in blood pressure in susceptible individuals • Premenstrual syndrome • Changes in libido • Changes in appetite • Cystitis-like syndrome • Headache • Nervousness • Fatigue • Backache • Hirsutism • Loss of scalp hair • Erythema multiforma • Erythema nodosum • Hemorrhagic eruption	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Itching • Dizziness *The following laboratory results may be altered by the use of estrogen-progestin combination drugs:* • Increased sulfobromophthalein retention and other hepatic function tests • Coagulation tests: increase in prothrombin factors VII, VIII, IX, and X • Metyrapone test • Pregnanediol determinations • Thyroid function: increase in PBI, and butanol extractable protein bound iodine and decrease in T3 uptake values	
Medroxyprogesterone acetate (oral; Provera®)	*Warnings:* • Cardiovascular disorders • Stroke • Coronary heart disease • Venous thromboembolism • Malignant neoplasms (breast cancer, endometrial cancer, ovarian cancer) • Dementia • Visual abnormalities *The following adverse reactions have been reported in women taking progestins, including PROVERA tablets, without concomitant estrogens treatment:* • Genitourinary system: Abnormal uterine bleeding (irregular, increase, decrease), change in menstrual flow, breakthrough bleeding, spotting, amenorrhea, changes in cervical erosion and cervical secretions. • Breasts: Breast tenderness, mastodynia or galactorrhea has been reported. • Cardiovascular: Thromboembolic disorders including thrombophlebitis and pulmonary embolism have been reported. • Gastrointestinal: Nausea, cholestatic jaundice. • Skin: Sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash have occurred. Acne, alopecia and hirsutism have been reported. • Eyes: Neuro-ocular lesions, e.g., retinal thrombosis and optic neuritis. • Central nervous system: Mental depression, insomnia, somnolence, dizziness, headache, nervousness.	Provera [package insert]. New York, NY: Pharmacia and Upjohn Company; 2009.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Miscellaneous: Hypersensitivity reactions (e.g., anaphylaxis & anaphylactoid reactions, angioedema), rash (allergic) with and without pruritus, change in weight (increase or decrease), pyrexia, edema/fluid retention, fatigue, decreased glucose tolerance. *The following additional adverse reactions have been reported with estrogen and/or progestin therapy:* • Genitourinary system: Abnormal uterine bleeding/spotting, or flow; breakthrough bleeding; spotting; dysmenorrheal/pelvic pain, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; ovarian cancer; endometrial hyperplasia; endometrial cancer. • Breasts: Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer. • Cardiovascular: Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; myocardial infarction; stroke; increase in blood pressure. • Gastrointestinal: Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice; increased incidence of gallbladder disease; pancreatitis, enlargement of hepatic hemangiomas. • Skin: Chloasma or melasma that may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; pruritus, rash. • Eyes: Retinal vascular thrombosis, intolerance to contact lenses. • Central nervous system: Headache; migraine; dizziness; mental depression; chorea; nervousness; mood disturbances; irritability; exacerbation of epilepsy, dementia. • Miscellaneous: Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthalgias; leg cramps; changes in libido; urticaria, angioedema, anaphylactoid/anaplylactic reactions; hypocalcemia; exacerbation of asthma; increased triglycerides.	
Norethisterone [norethindrone] (oral; Aygestin®)	*Warnings:* • Cardiovascular disorders • Visual anomalies *The following adverse reactions have been observed in women taking progestins:* • Breakthrough bleeding • Spotting	Aygestin [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2010.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Change in menstrual flow • Amenorrhea • Edema • Changes in weight (decreases, increases) • Changes in the cervical squamo-columnar junction and cervical secretions • Cholestatic jaundice • Rash (allergic) with and without pruritus • Melasma or chloasma • Clinical depression • Acne • Breast enlargement/tenderness • Headache/migraine • Urticaria • Abnormalities of liver tests (i.e., AST, ALT, Bilirubin) • Decreased HDL cholesterol and increased LDL/HDL ratio • Mood swings • Nausea • Insomnia • Anaphylactic/anaphylactoid reactions • Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism) • Optic neuritis (which may lead to partial or complete loss of vision)	
Progesterone (vaginal gel; Crinone®)	*Warnings:* The physician should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular disorders, pulmonary embolism, and retinal thrombosis). *In one clinical study for assisted reproductive technology, AEs associated with treatment, occurring in 5% or more of women:* • Bloating 7% • Cramps NOS 15% • Pain 8% • Dizziness 5% • Headache 13% • Nausea 7% • Breast Pain 13% • Moniliasis Genital 5% • Vaginal Discharge 7%	Crinone [package insert]. Livingston, NJ: Columbia Laboratories; 2009.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Pruritus Genital 5% *In a second clinical study for assisted reproductive technology (ART), AEs associated with treatment, occurring in ≥5% of women:* • Abdominal Pain 12% • Perineal Pain Female 17% • Headache 17% • Constipation 27% • Diarrhea 8% • Nausea 22% • Vomiting 5% • Arthralgia 8% • Depression 11% • Libido Decreased 10% • Nervousness 16% • Somnolence 27% • Breast Enlargement 40% • Dyspareunia 6% • Nocturia 13% *In three clinical studies for secondary amenorrhea taking (either 4%, 8%) Crinone along with estrogen, AEs associated with treatment, occurring in 5% or more of women:* • Abdominal Pain 5%, 9% • Appetite Increased 5%, 8% • Bloating 13%, 12% • Cramps NOS 19%, 26% • Fatigue 21%, 22% • Headache 19%, 15% • Nausea 8%, 6% • Back Pain 8%, 3% • Myalgia 8%, 0% • Depression 19%, 15% • Emotional Lability 23%, 22% • Sleep Disorder 18%, 18% • Vaginal Discharge 11%, 3% • Upper Respiratory Tract Infection 5%, 8% • Pruitis genital 2%, 6% *Reported in women at a frequency <5% in Crinone ART and secondary*	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	amenorrhea studies and not listed above include: • Mouth dry • Sweating increased • Abnormal crying • Allergic reaction • Allergy • Appetite decreased • Asthenia • Edema • Face edema • Fever • Hot flushes • Influenza-like symptoms • Water retention • Xerophthalmia • Syncope • Migraine • Tremor • Dyspepsia • Eructation • Flatulence • Gastritis • Toothache • Thirst • Cramps legs • Leg pain • Skeletal pain • Benign cyst • Purpura • Aggressive reactions • Forgetfulness • Insomnia • Anemia • Dysmenorrheal • Premenstrual tension • Vaginal dryness • Infection • Pharyngitis • Sinusitis • Urinary tract infection	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Asthma • Dyspnea • Hyperventilation • Rhinitis • Acne • Pruritus • Rash • Seborrhea • Skin discoloration • Skin disorder • Urticaria • Cystitis • Dysuria • Micturition frequency • Conjunctivitis	
Progesterone (coil; Progestasert) NOTE: marketing discontinued in US; labels are not available.	See progesterone in general. *Common:* • Abdominal pain (vaginal insert, 12%) • Constipation (vaginal insert, 2% to 3%) • Nausea (vaginal insert; 7% to 8%) • Swollen abdomen (vaginal insert, 4%) • Post-oocyte retrieval (vaginal insert, 25% to 28%) • Fatigue (vaginal insert, 2% to 3%)	Progesterone. In: Micromedex® Healthcare Series. Thomson Reuters (Healthcare) Inc. http://www.thomsonhc.com (accessed March 31, 2012). "Progesterone." In: DrugPoints® System. Thomson Reuters (Healthcare) Inc. http://www.thomsonhc.com (accessed March 31, 2012).
Flurbiprofen (oral; Ansaid®)	*Reported adverse events in patients receiving Ansaid or other NSAIDs* *Warnings and Precautions:* • Cardiovascular thrombotic events, myocardial infarction, and stroke • Hypertension • Congestive heart failure and edema • Gastrointestinal effects, including risk of ulceration, bleeding, and perforation • Renal effects • Advanced renal disease • Anaphylactoid reactions • Skin reactions • Hepatic effects; borderline elevations of liver tests can occur in up to 15% of patients taking NSAIDs including flurbiprofen • Hematological effects	Ansaid [package insert]. New York City, NY: Pharmacia & Upjohn Co.; 2010.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Vision changes (blurred and/pr diminished vision) • Cross reactivity in patients with aspirin-sensitive asthma *Incidence ≥1% from clinical trials:* • Edema • Abdominal pain • Constipation • Diarrhea • Dyspepsia/ heartburn • Elevated liver enzymes • Flatulence • GI bleeding • Nausea • Vomiting • Body weight changes • Headache • Nervousness and other manifestations of CNS stimulation (e.g., anxiety, insomnia, increased reflexes, tremor) • Symptoms associated with CNS inhibition (e.g., amnesia, asthenia, depression, malaise, somnolence) • Rash, • Changes in vision • Dizziness/ vertigo • Tinnitus • Signs and symptoms suggesting urinary tract infection *Incidence <1% from clinical trials, postmarketing surveillance, or literature, with probable causal relationship:* • Anaphylactic reaction • Chills • Fever • Congestive heart failure • Hypertension • Vascular diseases • Vasodilation • Bloody diarrhea • Esophageal disease • Gastric / peptic ulcer disease • Gastritis • Jaundice (cholestatic and noncholestatic)	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Hematemesis • Hepatitis • Stomatitis / glossitis • Aplastic anemia (including agranulocytosis or pancytopenia) • Decrease in hemoglobin and hematocrit • Ecchymosis / purpura • Eosinophilia • Hemolytic anemia • Iron deficiency anemia • Leucopenia • Thrombocytopenia • Hyperuricemia • Ataxia • Cerebrovascular ischemia • Confusion • Paresthesia • Twitching • Asthma • Epistaxis • Angioedema • Eczema • Exfoliative dermatitis • Photosensitivity • Pruritus • Toxic epidermal necrolysis • Urticaria • Conjunctivitis • Parosmia • Hematuria • Interstitial nephritis • Renal failure *Incidence <1% from clinical trials, postmarketing surveillance, or literature, with causal relationship unknown:* • Angina pectoris • Arrhythmias • Myocardial infarction • Appetite changes • Cholecystitis • Colitis	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Dry mouth • Exacerbation of inflammatory bowel disease • Periodontal abscess • Small intestine inflammation with loss of blood and protein • Lymphadenopathy • Hyperkalemia • Convulsion • Cerebrovascular accident • Emotional lability • Hypertonia • Meningitis • Myasthenia • Subarachnoid hemorrhage • Bronchitis • Dyspnea • Hyperventilation • Laryngitis • Pulmonary embolism • Pulmonary infarct • Alopecia • Dry skin • Herpes simplex / zoster • Nail disorder • Sweating • Changes in taste • Corneal opacity • Ear disease • Glaucoma • Retinal hemorrhage • Retrobulbar neuritis • Transient hearing loss • Menstrual disturbances • Prostate disease • Vaginal and uterine hemorrhage • Vulvovaginitis	
Meclofenamate sodium (oral; Mecolmen®)	*Warnings:* • Risk of GI ulceration, bleeding and perforation with NSAID therapy *Reported incidence greater than 1%:* • Diarrhea (10% to 33%)	Meclofenamate sodium [package insert]. Morgantown, WV: Mylan Pharmaceuticals; 2006. "[A]dverse reactions were observed in clinical trials and included observations from more than 2,700

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Nausea with or without vomiting (11%) • Other gastrointestinal disorders (10%) • Anorexia • Constipation • Stomatitis • Peptic ulcer • Edema • Urticaria • Pruritus • Tinnitus *Reported incidence between 3% and 9%%:* • Abdominal pain • Pyrosis • Flatulence • Rash • Headache • Dizziness *Reported incidence less than 1%, probably causally related:* • Bleeding and/or perforation with or without obvious ulcer formation • Colitis • Cholestatic jaundice • Renal failure • Neutropenia • Thrombocytopenic purpura • Leucopenia • Agranulocytosis • Hemolytic anemia • Eosinophilia • Decrease in hemoglobin and/or hematocrit • Erythema multiforme • Stevens-Johnson Syndrome • Exfoliative dermatitis • Alteration of liver function tests • Lupus and serum sickness-like symptoms *Reported incidence less than 1%, causal relationship unknown:* • Palpitations • Malaise	patients, 594 of whom were treated for one year and 248 for at least two years." "In approximately 4% of the patients in controlled studies, diarrhea was severe enough to require discontinuation of meclofenamate sodium."

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Fatigue • Paresthesia • Insomnia • Depression • Blurred vision • Taste disturbances • Decreased visual acuity • Temporary loss of vision • Reversible loss of color vision • Retinal changes including macular fibrosis • Macular and perimacular edema • Conjunctivitis • Iritis • Nocturia • Paralytic ileus • Erythema nodosum • Hair loss	
Mefenamic acid (oral; Ponstel®)	*Warnings and precautions:* • Cardiovascular risk, including thrombotic events, hypertension, and congestive heart failure and edema • Gastrointestinal risk *Most frequently reported, occurring in approximately 1-10% of patients:* • Abdominal pain • Constipation • Diarrhea • Dyspepsia • Flatulence • Gross bleeding / perforation • Heartburn • Nausea • GI ulcers (gastric / duodenal) • Vomiting • Abnormal renal function • Anemia • Dizziness • Edema • Elevated liver enzymes • Headaches • Increased bleeding time	Ponstel [package insert]. Atlanta, GA: Shionogi Pharma; 2010.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Pruritus • Rashes • Tinnitus *Additional adverse experiences reported occasionally include:* • Fever • Infection • Sepsis • Congestive heart failure • Hypertension • Tachycardia • Syncope • Dry mouth • Esophagitis • Gastric/peptic ulcers • Gastritis • Gastrointestinal bleeding • Glossitis • Hematemesis • Hepatitis • Jaundice • Ecchymosis • Eosinophilia • Leucopenia • Melena • Purpura • Rectal bleeding • Stomatitis • Thrombocytopenia • Weight changes • Anxiety • Asthenia • Confusion • Depression • Dream abnormalities • Drowsiness • Insomnia • Malaise • Nervousness • Paresthesia	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Somnolence • Tremors • Vertigo • Asthma • Dyspnea • Alopecia • Photosensitivity • Pruritus • Sweat • Blurred vision • Cystitis • Dysuria • Hematuria • Interstitial nephritis • Pliguria/polyuria • Proteinuria • Renal failure *Other adverse reactions, which occur rarely:* • Anaphylactoid reactions • Appetite changes • Death • Arrhythmia • Hypotension • Myocardial infarction • Palpitations • Vasculitis • Eructation • Liver failure • Pancreatitis • Agranulocytosis • Hemolytic anemia • Aplastic anemia • Lymphadenopathy • Pancytopenia • Hyperglycemia • Convulsions • Coma • Hallucinations • Meningitis	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Respiratory depression • Pneumonia • Angioedema • Toxic epidermal necrosis • Erythema multiforme • Exfoliative dermatitis • Stevens-Johnson Syndrome • Urticaria • Conjunctivitis • Hearing impairment	
Naproxen (oral; EC-Naprosyn®, Naprosyn®, Anaprox®, Anaprox DS®, Naprosyn®, others)	*Incidence 3-9% of patients in clinical trials with naproxen:* • Heartburn • Abdominal pain • Nausea • Constipation • Headache • Dizziness • Drowsiness • Pruritus • Skin eruptions • Ecchymoses • Tinnitus • Edema • Dyspnea *Incidence <3% of patients in clinical trials with naproxen:* • Diarrhea • Dyspepsia • Stomatitis • Lightheadedness • Vertigo • Sweating • Purpura • Visual disturbances • Hearing disturbances • Palpitations • Thirst *Incidence <1% of patients in clinical trials with naproxen:* • Gastrointestinal bleeding	"Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed [here]. In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea." EC-Naprosyn / Naprosyn / Anaprox / Anaprox DS / Naprosyn [package insert]. Nutley, NJ: Roche Pharmaceuticals; 1999-200X.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Jaundice • Melena • Thrombocytopenia • Agranulocytosis • Inability to concentrate • Skin rashes *Incidence <1% of patients in taking naproxen, from postmarketing reports:* • Anaphylactoid reactions • Angioneurotic edema • Menstrual disorders • Pyrexia (chills and fever) • Congestive heart failure • Vasculitis • Hypertension • Pulmonary edema • Perforation • Hematemesis • Colitis • Exacerbation of inflammatory bowel disease (ulcerative colitis, Crohn's disease) • Nonpeptic gastrointestinal ulceration • Ulcerative stomatitis • Esophagitis, peptic ulceration • Abnormal liver function tests • Hepatitis (some cases have been fatal) • Eosinophilia • Leucopenia • Granulocytopenia • Hemolytic anemia • Aplastic anemia • Hyperglycemia • Hypoglycemia • Depression • Dream abnormalities • Insomnia • Malaise • Myalgia • Muscle weakness	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Aseptic meningitis • Cognitive dysfunction • Convulsions • Eosinophilic pneumonitis • Asthma • Alopecia • Urticaria • Toxic epidermal necrolysis • Erythema multiforme • Erythema nodosum • Fixed drug eruption • Lichen planus • Pustular reaction • Systemic lupus erythematoses • Bullous reactions, including Stevens-Johnson Syndrome • Photosensitive dermatitis • Photosensitivity reactions, including rare cases resembling porphyria cutanea tarda (pseudoporphyria) or epidermolysis bullosa. If skin fragility, blistering or other symptoms suggestive of pseudoporphyria occur, treatment should be discontinued and the patient monitored. • Hearing impairment • Corneal opacity • Papillitis • Retrobulbar optic neuritis • Papilledema • Glomerular nephritis • Hematuria • Hyperkalemia • Interstitial nephritis • Nephrotic Syndrome • Renal disease • Renal failure • Renal papillary necrosis • Raised serum creatinine • Infertility in women	
Cabergoline (oral)	*Incidence during 4-week RCT (% in cabergoline group, % in placebo group):* • Nausea (27, 20) • Constipation (10, 0) • Abdominal pain (5, 5)	Cabergoline [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2011.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Dyspepsia (2, 0) • Vomiting (2, 0) • Headache (26, 25) • Dizziness (15, 5) • Paresthesia (1, 0) • Vertigo (1, 0) • Asthenia (9, 10) • Fatigue (7, 0) • Hot flashes (1, 5) • Somnolence (5, 5) • Depression (3, 5) • Nervousness (2, 0) • Postural hypotension (4, 0) • Breast pain (1, 0) • Dysmenorrhea (1, 0) • Abnormal vision (1, 0) *Incidence during 8-week trial (% in cabergoline group, % in bromocriptine group):* • Nausea (29, 43) • Constipation (7, 9) • Abdominal pain (5, 8) • Dyspepsia (5, 7) • Vomiting (4, 7) • Dry mouth (2, 1) • Diarrhea (2, 3) • Flatulence (2, 1) • Throat irritation (1, 0) • Toothache (1, 0) • Headache (26, 27) • Dizziness (17, 18) • Vertigo (4, 4) • Paresthesia (2, 3) • Asthenia (6, 6) • Fatigue (5, 8) • Syncope (1, 1) • Influenza-like symptoms (1, 0) • Malaise (1, 0) • Periorbital edema (1, 1) • Peripheral edema (1, 1)	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Depression (3, 2) • Somnolence (2, 2) • Anorexia (1, 1) • Anxiety (1, 1) • Insomnia (1, 1) • Impaired concentration (1, 1) • Nervousness (1, 2) • Hot flashes (3, 1) • Hypotension (1, 2) • Dependent edema (1, 1) • Palpitation (1, 2) • Breast pain (2, 3) • Dysmenorrhea (1, 1) • Acne (1, 0) • Pruritus (1, 1) • Pain (2, 3) • Arthralgia (1, 0) • Rhinitis (1, 4) • Abnormal vision (1, 1) *Reported at an incidence of < 1% in the overall clinical studies:* • Facial edema • Influenza-like symptoms • Malaise • Hypotension • Syncope • Palpitations • Dry mouth • Flatulence • Diarrhea • Anorexia • Weight loss • Weight gain • Somnolence • Nervousness • Paresthesia • Insomnia • Anxiety • Nasal stuffiness • Epistaxis	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Acne • Pruritus • Abnormal vision • Dysmenorrhea • Increased libido *Postmarketing surveillance data:* • Cardiac valvulopathy • Extracardiac fibrotic reactions • Hypersexuality • Increased libido • Pathological gambling • Cases of alopecia • Aggression and psychotic disorder	
Etamsylate [ethamsylate] (oral) NOTE: not available in US; labels are not available.	*Precautions:* • Patients with asthma, allergies, or a history of allergic-type reactions to medications (potential for allergic phenomena; tablets/ampules contain sodium sulfite) • Patients with or a history of thromboembolism (eg, ischemic stroke, pulmonary embolism, deep-vein thrombosis) • Renal impairment (most of a dose is excreted unchanged) *Adverse reactions:* • Thromboembolic disorder • Rash • Acute intermittent porphyria • Gastrointestinal tract findings: nausea, abdominal discomfort, bitter taste, and other nonspecific gastrointestinal disturbances have been reported occasionally during oral therapy • Backache (causality uncertain) • Headache (causality is questionable)	Ethamsylate. In: Micromedex® Healthcare Series. Thomson Reuters (Healthcare) Inc. http://www.thomsonhc.com (accessed March 31, 2012). DRUGDEX® System. Thomson Reuters (Healthcare) Inc. http://www.thomsonhc.com (accessed March 31, 2012).
Exenatide (injection; Byetta®, others)	Hypoglycemia is a common adverse effect. *Treatment-emergent ARs ≥2% incidence and greater incidence with BYETTA treatment used with metformin and/or a sulfonylurea, excluding hypoglycemia:* • Nausea • Vomiting • Diarrhea	Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2011.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Feeling jittery • Dizziness • Headache • Dyspepsia • Asthenia • Gastroesophageal reflux disease • Hyperhidrosis *Treatment-emergent ARs ≥2% incidence and greater incidence with BYETTA treatment used with thiazolidinedione, with or without metformin, excluding hypoglycemia:* • Nausea • Vomiting • Dyspepsia • Diarrhea • Gastroesophageal reflux disease *Treatment-emergent ARs ≥2% incidence and greater incidence with BYETTA treatment used with insulin glargine, with or without oral antihyperglycemic medications, excluding hypoglycemia:* • Nausea • Vomiting • Diarrhea • Headache • Constipation • Dyspepsia • Asthenia • Abdominal distension • Decreased appetite • Flatulence • Gastroesophageal reflux disease *Postmarketing experience:* • Injection-site reactions • Generalized pruritus and/or urticaria • Macular or papular rash • Angioedema • Anaphylactic reaction • International normalized ratio (INR) increased with concomitant warfarin use sometimes associated with bleeding	

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Nausea, vomiting, and/or diarrhea resulting in dehydration • Abdominal distension • Abdominal pain • Eructation • Constipation • Flatulence • Acute pancreatitis • Hemorrhagic and necrotizing pancreatitis sometimes resulting in death • Dysgeusia • Somnolence • Altered renal function, including increased serum creatinine • Renal impairment • Worsened chronic renal failure or acute renal failure (sometimes requiring hemodialysis) • Kidney transplant and kidney transplant dysfunction • Alopecia	
Metformin (oral; Glucophage®, others)	*Warning:* • Lactic acidosis (boxed warning) *Most common (>5%) in placebo-controlled study of monotherapy:* • Diarrhea • Nausea/vomiting • Flatulence • Asthenia • Indigestion • Abdominal discomfort • Headache *Also reported (≥1.0% to ≤5%):* • Abnormal stools • Hypoglycemia • Myalgia • Lightheaded • Dyspnea • Nail disorder • Rash • Sweating increased • Taste disorder • Chest discomfort • Chills	Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	• Flu Syndrome • Flushing • Palpitation	
N-acetyl-cysteine	*Warning:* After proper administration of acetylcysteine, an increased volume of liquified bronchial secretions may occur. When cough is inadequate, the open airway must be maintained by mechanical suction if necessary. When there is a mechanical block due to foreign body or local accumulation, the airway should be cleared by endotracheal aspiration, with or without bronchoscopy. Asthmatics under treatment with acetylcysteine should be watched carefully. Most patients with bronchospasm are quickly relieved by the use of a bronchodilator given by nebulization. If bronchospasm progresses, this medication should be discontinued immediately. *Adverse reactions from intravenous include:* • Tachycardia not otherwise specified • Nausea • Vomiting not otherwise specified • Anaphylactoid reaction • Pharyngitis • Rhinorrhea • Rhonchi • Throat tightness • Pruritus • Rash not otherwise specified • Flushing *Adverse reactions from solution include:* • Stomatitis • Nausea • Vomiting • Fever • Rhinorrhea • Drowsiness • Clamminess • Chest tightness • Bronchoconstrictiong • Acquired sensitization to acetylcysteine (rare)	Acetadote [package insert]. Nashville, TN: Cumberland Pharmaceuticals; 2011. Aceytlcysteine solution [package insert]. Lake Forest, IL: Hospira, Inc.; 2004.

Drug (Route; Brand Name)	Adverse Reactions / Effects	Notes and References
	Adverse reactions from other oral preparations (e.g., tablets) are not listed in package inserts. *Adverse reactions reported in postmarketing safety study of IV formulation include:* • Urticaria/facial flushing (6.1%) • Pruritus (4.3%) • Respiratory symptoms (1.9%) • Edema (1.6%) • Hypotension (0.1%) • Anaphylaxis (0.1%)	

Appendix O. Systematic Reviews[a]

Review Title Author, Year	Review Type Intervention	Findings
Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: A systematic review. Naoulou et al., 2012[1]	Systematic review of 10 studies (5 double-blind RCTs; 2 RCTs; 1 prospective cohort; 1 comparative; 1 observational study) Tranexamic acid	"Available evidence indicates that tranexamic acid therapy in women with idiopathic menorrhagia resulted in 34–54% reduction in menstrual blood loss. Following tranexamic acid treatment, patient's quality-of-life parameters improved by 46–83%, compared with 15–45% for norethisterone treatment. When compared with placebo, tranexamic acid use significantly decreased the blood loss by 70% in women with menorrhagia secondary to an intrauterine device ($p<0.001$). Limited evidence indicated potential benefit in fibroid patients with menorrhagia. No thromboembolic event was reported in all studies analyzed."
Tranexamic acid therapy for heavy menstrual bleeding. Lumsden and Wedisinghe, 2011[2]	Systematic review Tranexamic acid	"Although several treatment options are available for HMB, tranexamic acid is particularly useful in women who either desire immediate pregnancy or for whom hormonal treatment is inappropriate. Tranexamic acid is a well-tolerated, cost-effective drug that reduces menstrual blood loss in the range of 34-59%. It improves the health-related quality of life in women in HMB."
Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Fraser et al., 2011[3]	Pooled analysis of 2 RCTs (421 women in ITT population) Estradiol valerate / dienogest	Mean blood loss reduced in women with heavy and/or prolonged menstrual bleeding, and the effect is seen at the first withdrawal bleed after initiation of treatment. The effect is consistent across a larger and more diverse population of women. "Although not directly comparable, the median decrease in MBL achieved by treatment cycle 7 with E2V/DNG treatment (88%) appears to approach that achieved with the LNG-IUS (median 95% and 96% reduction) over six cycles in two studies that also used the alkaline haematin method to objectively assess blood loss in women with heavy menstrual bleeding."
Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. Blumenthal et al., 2011[4]	Review LNG-IUS	"Treating heavy menstrual bleeding with the LNG-IUS was found to be cost-effective in various countries and settings. Moreover, irrespective of the measuring instrument used, health-related quality-of-life outcomes were found to be improved to a degree similar to that achieved with endometrial ablation or hysterectomy. In some cases, the LNG-IUS appeared to be more effective and less costly than the surgical options."
Systematic review highlights difficulty interpreting diverse clinical outcomes in abnormal uterine bleeding trials. Rahn et al., 2011[5]	Systematic review Includes medical and surgical interventions	" Many interventions for abnormal uterine bleeding (AUB) are tested in clinical trials, but the large number and diversity of outcomes reported limit the ability to compare treatments across trials… There is a dearth of standardized outcome measures in AUB that identify symptoms of importance to patients. Further research is required to develop validated measures that capture patient-based outcomes, are responsive to change, yet feasible to use in future trials."

Review Title Author, Year	Review Type Intervention	Findings
Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Marret et al., 2010[6]	Clinical practice guidelines	"In idiopathic AUB, the first-line treatment is medical, with efficacy ranked as follows: levonorgestrel IUD, tranexamic acid, oral contraceptives, either estrogens and progestins or synthetic progestins only, 21 days a month, or NSAIDs. When hormone treatment is contraindicated or immediate pregnancy is desired, tranexamic acid is indicated. Iron must be included for patients with iron-deficiency anemia. For women who do not wish to become pregnant in the future and who have idiopathic AUB, the long-term efficacy of conservative surgical treatment is greater than that of oral medical treatment. Placement of a levonorgestrel IUD (or administration of tranexamic acid by default) is recommended for women with idiopathic AUB. If this fails, a conservative surgical technique must be proposed…"
Chinese Herbal Medicine for Dysfunctional Uterine Bleeding: a Meta-analysis. Tu et al., 2009[7]	Meta-analysis Chinese herbal medicine (CHM) and conventional Western medicine (CWM)	"Trials of CHM treatments with CWM treatments were compared with CWM treatments alone. Jadad scale and allocation concealment were used to assess the quality of included studies. Four RCTs or quasi-RCTs involving 525 patients were included. The methodological quality was poor in all trials except one trial. No serious adverse events were reported in the included studies. With the lack of trials comparing CHM with no treatment or placebo, it is impossible to accurately evaluate the efficacy of CHM. However, CHM in these studies seem to show an encouraging comparative effectiveness with CWM. More RCTs with a higher quality are required."
The experience of heavy menstrual bleeding: a systematic review and meta-ethnography of qualitative studies. Garside et al., 2008[8]	Systematic review and meta-ethnography	"These provided support for the fourth paper's conceptual framework of a lay model of heavy menstrual bleeding which shows little overlap with the traditional clinical definition. Details of physical, practical and emotional elements of this model were identified. A matrix of uncertainties were identified suggesting reasons why women may or may not seek medical help for heavy menstrual bleeding. Women and healthcare professionals may conspire to privilege blood loss over other symptoms and the disease model of heavy menstrual bleeding is little help to either."
Abnormal uterine bleeding: a review of patient-based outcome measures. Matteson et al., 2009[9]	Systematic review of patient-based outcome measures (983 studies, 80 eligible)	"Fifty different instruments were used to evaluate amount of bleeding, bleeding-related symptoms, or menstrual bleeding-specific quality of life. The quality of each of these instruments was evaluated on eight psychometric properties. The majority of instruments had no documentation of reliability, precision, or feasibility. There was no satisfactory evidence that any one instrument completely addressed all eight psychometric properties."
A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Liu et al., 2007[10]	Systematic review to evaluate the impact of AUB on health-related quality of life and to quantify the economic burden from a societal perspective	"The prevalence of AUB among women of reproductive age ranged from 10% to 30%. The HRQoL scores from the 36-item Short-Form Health Survey Questionnaire (SF-36) suggested that women with AUB have HRQoL below the 25th percentile of that for the general female population within a similar age range. The conservatively estimated annual direct and indirect economic costs of AUB were approximately $1 billion and $12 billion, respectively. These figures do not account for intangible costs and productivity loss due to presenteeism."

Review Title Author, Year	Review Type Intervention	Findings
Current treatment of dysfunctional uterine bleeding. Bongers et al., 2004[11]	Review	"Antifibrinolytic tranexamic acid is the most effective medical therapy to treat dysfunctional uterine bleeding. In general medical therapy is not as effective as endometrial resection in terms of patient satisfaction and health related quality of life. The levonorgestrel releasing intra uterine device is an effective treatment for dysfunctional uterine bleeding. No difference in quality of life was observed in patients treated with a levonorgestrel releasing intra uterine device as compared to hysterectomy."
Quality of life instruments in studies of menorrhagia: a systematic review. Clark et al., 2002[12]	Systematic review Quality of life instruments	"A total of 19 articles, 8 on instrument development and 11 on application, were included in the review. The generic Short Form 36 Health Survey Questionnaire (SF36) was used in 12/19 (63%) studies. Only two studies developed new specific QoL instruments for menorrhagia but they complied with 7/17 (41%) and 10/17 (59%) of the quality criteria. Quality assessment showed that only 7/19 (37%) studies complied with more than half the criteria for face validity whereas 17/19 (90%) studies complied with more than half of the criteria for measurement properties (P = 0.0001)."
ACOG practice bulletin: management of anovulatory bleeding (2001) American College of Obstetricians and Gynecologists[13]		"The treatment of choice for anovulatory uterine bleeding is medical therapy with oral contraceptives. Cyclic progestins also are effective. (Level A evidence)"
The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Stewart et al., 2001[14]	Systematic review (5 controlled trials and 5 case series) LNG-IUS	"Small studies of moderate quality indicate the LNG-IUS is an effective treatment for menorrhagia. Costs may be less than for tranexamic acid in primary and secondary care. Although its use may reduce surgical waiting lists, cost effectiveness assessment requires longer follow up."
Thrombotic risks of oral contraceptives. Rott, 2012[15]	Review Contraceptive vaginal ring	"The venous thromboembolism risk for transdermal COCs like vaginal ring (Nuvaring) or patch (Evra) is as high as for COCs of third or fourth generation." "Second-generation COCs should be first choice when prescribing hormonal contraception"
Contraceptive vaginal rings: a review. Brache and Faundes, 2010[16]	Systematic review	"The incidence of estrogen-related adverse events such as breast tenderness, headache and nausea was similar between the NuvaRing and COC users. The only difference… was the higher incidences of loca events such as leucorrhea, vaginitis, vaginal discomfort and ring-related events (foreign body sensation, coital problems, expulsions)." (In Ring users)
Combined hormonal contraception and bone health: a systematic review. Martins et al., 2006[17]	Systematic review (one vaginal ring cohort study) Contraceptive vaginal ring	"…measured changes in BMD among 105 users of a combined CRV (Nuvaring, 15 µg EE/120 µg etongestrel daily)and 39 nonhormonal contraceptive users aged 18-35 years. Over 24 months, BMD at the spine and femoral neck did not change significantly in the ring group but increases in the control group (NuvaRing vs control, p<0.0001). Because differences in BMD between the two groups were within 1 S.D. of each other, the study authors did not consider them to be clinically relevant."

[a] Does not include systematic reviews published by the Cochrane Collaboration or reviews of interventions (e.g., surgical intervention, medical treatments not used in primary care) or populations (e.g., women with bleeding due to fibroids or systemic disease, post-menopausal women, acute bleeding, etc.) outside the scope of this review.

References

1. Naoulou B, Tsai MC. Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: A systematic review. Acta Obstet Gynecol Scand 2012 May;91(5):529-37. PMID: 22229782.

2. Lumsden MA, Wedisinghe L. Tranexamic acid therapy for heavy menstrual bleeding. Expert Opin Pharmacother 2011 Sep;12(13):2089-95. PMID: 21767224.

3. Fraser IS, Parke S, Mellinger U, et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2011 Aug;16(4):258-69. PMID: 21774563.

4. Blumenthal PD, Dawson L, Hurskainen R. Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet 2011 Mar;112(3):171-8. PMID: 21269626.

5. Rahn DD, Abed H, Sung VW, et al.; Society of Gynecologic Surgeons Systematic Review Group. Systematic review highlights difficulty interpreting diverse clinical outcomes in abnormal uterine bleeding trials. J Clin Epidemiol 2011 Mar;64(3):293-300. PMID: 20705427.

6. Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Bio 2010 Oct;152(2):133-7. PMID: 20688424.

7. Tu X, Huang G, Tan S. Chinese Herbal Medicine for Dysfunctional Uterine Bleeding: a Meta-analysis. Evid Based Complement Alternat Med 2009 Mar;6(1):99-105. PMID: 18955223.

8. Garside R, Britten N, Stein K. The experience of heavy menstrual bleeding: a systematic review and meta-ethnography of qualitative studies. J Adv Nurs 2008 Sep;63(6):550-62. PMID: 18808575.

9. Matteson KA, Boardman LA, Munro MG, et al. Abnormal uterine bleeding: a review of patient-based outcome measures. Fertil Steril 2009 Jul;92(1):205-16. PMID: 18635169.

10. Liu Z, Doan QV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007 May-Jun;10(3):183-94. PMID: 17532811.

11. Bongers MY, Mol BW, Brolmann HA. Current treatment of dysfunctional uterine bleeding. Maturitas 2004 Mar 15;47(3):159-74. PMID: 15036486.

12. Clark TJ, Khan KS, Foon R, et al. Quality of life instruments in studies of menorrhagia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2002 Sep 10;104(2):96-104. PMID: 12206918.

13. ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin No. 14: management of anovulatory bleeding. Int J Gynaecol Obstet 2001 Mar;72(3):263-71. PMID: 11296797.

14. Stewart A, Cummins C, Gold L, et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG 2001 Jan;108(1):74-86. PMID: 11213008.

15. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol 2012 Aug;24(4):235-40. PMID: 22729096.

16. Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception 2010 Nov;82(5):418-27. PMID: 20933115.

17. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception 2006 May;73(5):445-69. PMID: 16627030.

Appendix P. Ongoing Studies

Study Name Study Status Location Trial Identifier	Inclusion / Exclusion Criteria	Interventions / Groups	Sponsor	Start Date Anticipated Completion Date	Estimated Enrollment
Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding **Currently recruiting** United States NCT01391052	**Inclusion Criteria:** Women aged 18-45 years old with heavy periods US **Exclusion Criteria:** Pregnant Currently using hormonal contraception or hormonal therapy History of pelvic inflammatory disease Infected abortion within the last three months Abnormal or cancerous cells of the cervix or uterus Active infection of genital organs Known or suspected breast cancer Active liver disease or tumors Allergy to levonorgestrel or norethindrone Deep vein thrombosis, pulmonary embolism, or history of arterial thromboembolic disease	**Drug**: Norethindrone acetate (Aygestin) pretreatment 5 mg tablets, three times a day for 21 days for 2 menstrual cycles. **Other**: No pretreatment. LNG-IUS is placed without norethindrone acetate pretreatment.	Scott and White Hospital & Clinic	January 2011 January 2013	80
Mirena Observational Program **Currently recruiting** Kazakhstan NCT00883662	**Inclusion Criteria:** Older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications **Exclusion Criteria:** Contraindications to Mirena insertion, according to approved prescribing information.	**Drug**: Levonorgestrel releasing intrauterine device (Mirena, BAY86-5028)	Bayer	June 2009 April 2014	7500
Multicenter Study to Investigate the Bleeding Profile and the Insertion Easiness in Women Inserted With a Second Consecutive MIRENA for Contraception or	**Inclusion Criteria:** Woman currently using MIRENA for contraception or menorrhagia with duration use between 4 years 3 months and 4 years 9 months and willingness to continue with the method. Normal size uterus at insertion (6-10 cm) Clinically normal cervical smear result within 12 preceding months or at screening. Clinically normal breast examination findings. **Exclusion Criteria:**	**Drug**: Mirena (BAY86-5028) Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 µg/24 h) at year 5 visit. **Drug**: Cytotec, single, sublingual dose of 400 µg, 3	Bayer	October 2006 September 2012	204

Study Name Study Status Location Trial Identifier	Inclusion / Exclusion Criteria	Interventions / Groups	Sponsor	Start Date Anticipated Completion Date	Estimated Enrollment
Menorrhagia **Ongoing but not recruiting** Finland, France, Ireland, Sweden NCT00393198	Menopausal symptoms impairing patient's quality of life or current estrogen therapy for menopausal symptoms. Known or suspected pregnancy. Any distortion of the uterine cavity, including congenital or acquired uterine anomalies and fibroids Current or recurrent pelvic inflammatory disease. Abnormal uterine bleeding of unknown origin. Acute cervicitis or vaginitis not responding to treatment. History of, diagnosed or suspected genital or other malignancy (excluding treated squamous cell carcinoma of the skin), and untreated cervical dysplasia. Any active acute liver disease or liver tumor. **Publications:** Heikinheimo O, Inki P, Kunz M, Parmhed S, Anttila AM, Olsson SE, Hurskainen R, Gemzell-Danielsson K. Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. Contraception. 2010 Jun;81(6):481-6. Epub 2010 Mar 1. Gemzell-Danielsson K, Inki P, Boubli L, O'Flynn M, Kunz M, Heikinheimo O. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a multicentre prospective study. Hum Reprod. 2010 Feb;25(2):354-9. Epub 2009 Dec 1.	hours prior to the MIRENA removal and insertion procedure at entry visit **Drug**: Placebo - single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit			
Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Reduce Bleeding in Premenopausal Women With	**Inclusion Criteria:** Women aged 25-40 years in good health History of abnormal uterine bleeding (anovulatory and ovulatory) documented by menorrhagia impact questionnaire (MIQ) and menstrual calendar Ovulatory women will be defined as those who have menstrual cycles of 24 - 35 days and a progesterone value > 3.0 pg/mL between 5 and 9 days after in-home documentation of an LH surge Anovulatory women will be defined as	**Drug**: CDB-2914	Bayer	November 2011 August 2014	50

Study Name Study Status Location Trial Identifier	Inclusion / Exclusion Criteria	Interventions / Groups	Sponsor	Start Date Anticipated Completion Date	Estimated Enrollment
Abnormal Uterine Bleeding: A Pilot Study **Not yet recruiting** United States NCT01493791	those without an in-house LH surge in whom progesterone values 3 and 4 weeks after menses are < 3.0 ng/mL Hemoglobin > 10 g/dL (for those wishing surgery) Willing and able to comply with study requirements Using mechanical (condoms, diaphragms), sterilization or abstinence methods of contraception for the duration of the study Negative urine pregnancy test BMI less than or equal to 33, if a surgical candidate or less than or equal to 35, if not a surgical candidate. Creatinine less than 1.3 mg/dL Liver function tests within 130 percent of upper limit Women who elect surgery must state that they do not desire further fertility. Endometrial biopsy without endometrial hyperplasia or neoplasia Normal cervical cytology screening within the last 12 months **Exclusion Criteria:** Significant abnormalities in the history, physical or laboratory examination Pregnancy or lactation Use of oral, injectable or inhaled glucocorticoids or megesterol within the last year History of malignancy within the past 5 years Vaginal bleeding in context of anatomic abnormality, endometrial neoplasia or hyperplasia, cervical, vaginal, or vulvar neoplasia or preneoplastic pathology Use of estrogen or progesterone-containing compounds Current use of agents known to induce hepatic P450 enzymes Use of imidazoles Current use of GnRH analogs or other compounds that affect menstrual cyclicity Use of herbal medication having estrogenic or antiestrogenic effects within the past 3 months Untreated cervical dysplasia Need for interval use of narcotics Abnormal adnexal/ovarian mass Contradiction to anesthesia, for women planning surgery				

Study Name Study Status Location Trial Identifier	Inclusion / Exclusion Criteria	Interventions / Groups	Sponsor	Start Date Anticipated Completion Date	Estimated Enrollment
	Leiomyomata, polyps or other anatomic causes of vaginal bleeding Previous participation in the study Thrombocytopenia defined as platelets < 150,000 **Publications:** Batista MC, Cartledge TP, Zellmer AW, Merino MJ, Axiotis C, Loriaux DL, Nieman LK. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy. Am J Obstet Gynecol. 1992 Jul;167(1):60-5. Bushnell DM, Martin ML, Moore KA, Richter HE, Rubin A, Patrick DL. Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. Curr Med Res Opin. 2010 Dec;26(12):2745-55. Epub 2010 Nov 3. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med. 1997;48:129-56. Review.				

DNG = dienogest; EV = estradiol valerate; GnRH: gonadotropin-releasing hormone; LNG-IUS = levonorgestrel-releasing intrauterine system; TXA = tranexamic acid. MPA: medroxyprogesterone; DMPA: depot medroxyprogesterone